[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f29QylLt4bpmx7QT74I2lRK3-mgv5JSMsXwCYpXSmU2M":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Mayo Clinic",[4],3203,false,819,141,13282159,326,2065,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Obesity",87,{"name":18,"count":19},"Healthy",85,{"name":21,"count":22},"Breast Cancer",76,{"name":24,"count":25},"Malignant Solid Neoplasm",60,{"name":27,"count":28},"Heart Failure",41,{"name":30,"count":31},"Breast Carcinoma",33,{"name":33,"count":34},"Atrial Fibrillation",29,{"name":36,"count":34},"Hematopoietic and Lymphatic System Neoplasm",[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02104310","A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas","2021-03-26","Fluorine-18-L-dihydroxyphenylalanine",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04197934","WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases","2022-10-30","EGFR\u002FEGFRvIII Inhibitor WSD0922-FU",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03120624","VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer","2023-08-29","Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04323956","Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","2023-10-04","Cyclophosphamide",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03268603","Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)","2024-01-31","Autologous Adipose-derived Mesenchymal Stromal Cells",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT02068794","MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer","2024-03-15","Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT03197506","Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma","2024-07-16","Pembrolizumab",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT03941730","Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer","2024-07-29","Therapeutic Estradiol",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT03179904","TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer","2024-07-30","Anastrozole",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT05232851","A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer","2025-04-09","Liposomal HPV-16 E6\u002FE7 Multipeptide Vaccine PDS0101",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,679,745,803,838,960,1028,1072,1105,1131,1169,1195,1273,1345,1401,1454,1490,1520,1550,1584,1608,1633,1658,1676,1703,1721,1747,1765,1783,1801,1825,1848,1873,1891,1916,1944,1962,1980,2006,2033,2051,2076,2094,2120,2138,2156,2174,2192,2216,2239,2262,2286,2310,2328,2346,2369,2395,2413,2431,2456,2474,2500,2518,2536,2562,2649,2703,2770,2814,2840,2870,2909,2965,3020,3049,3076,3094,3122,3147,3165,3194,3212,3238,3256,3279,3310,3766,4136,4227,4507,4644,4726,4840,4936,4974,5025,5157,5234,5499,5578,5665,5701,5731,5767,5793,5825,5851,5893,5935,6089,6136,6182,6247,6294,6345,6388,6424,6481,6523,6565,6596,6628,6676,6698,6735,6757,6783,6817,6839,6861,6883,6908,6960,7038,7120,7158,7201,7247,7278,7378,7432,7511,7590,7637,7680,7734,7768,7820,7865,7908,7939,7965,8005,8031,8068,8095,8124,8156,8190,8215,8246,8268,8304,8339,8384,8406,8428,8457,8483,8510,8532,8560,8587,8605,8633,8657,8684,8702,8720,8744,8769,8787,8810,8828,8846,8864,8889,8907,8927,8945,8963,8985,9010,9028,9049,9067,9085,9114,9136,9154,9180,9203,9221,9239,9257,9275,9299,9317,9342,9367,9390,9408,9426,9444,9468,9486,9511,9529,9553,9580,9603,9621,9645,9663,9687,9705,9728,9746,9772,9790,9813,9831,9849,9872,9890,9908,9926,9944,9968,9986,10004,10022,10040,10058,10076,10094,10112,10137,10222,10291,10377,10415,10470,10510,10540,10566,10592,10618,10644,10677,10699,10760,10790,10820,10846,10879,10906,10932,10950,10997,11015,11038,11056,11083,11105,11128,11150,11174,11192,11216,11239,11257,11275,11298,11316,11341,11359,11377,11401,11425,11448,11466,11522,11565,11587,11612,11636,11654,11681,11704,11729,11752,11770,11794,11812,11837,11860,11901,11963,11998,12044,12080,12102,12144,12176,12208,12226,12244,12264,12282,12300,12322,12344,12366,12392,12414,12436,12494,12544,12593,12626,12654,12695,12729,12762,12807,12835,12869,12900,12931,12965,12992,13018,13050,13079,13111,13136,13173,13204,13237,13264,13286,13316,13348,13366,13389,13414,13432,13454,13478,13496,13514,13538,13556,13577,13600,13623,13646,13664,13682,13707,13725,13747,13772,13790,13815,13833,13868,13886,13904,13922,13940,13958,13976,13994,14012,14030,14048,14066,14089,14107,14125,14147,14165,14189,14213,14231,14254,14278,14296,14314,14332,14350,14372,14395,14423,14446,14476,14494,14519,14537,14555,14578,14596,14618,14644,14667,14690,14708,14731,14749,14771,14789,14813,14831,14849,14867,14889,14916,14938,14956,14977,15001,15019,15044,15062,15083,15101,15119,15143,15161,15184,15209,15227,15250,15273,15297,15318,15340,15358,15381,15404,15430,15448,15472,15498,15516,15534,15552,15602,15672,15723,15760,15810,15851,15888,15932,15973,16013,16054,16088,16128,16150,16176,16204,16238,16269,16300,16332,16358,16380,16403,16425,16443,16461,16485,16506,16529,16553,16580,16598,16621,16644,16667,16685,16708,16730,16748,16766,16789,16807,16831,16849,16867,16890,16912,16930,16954,16978,16996,17018,17036,17059,17077,17104,17122,17144,17167,17191,17214,17235,17260,17278,17300,17323,17348,17366,17384,17402,17425,17443,17465,17488,17515,17537,17561,17586,17609,17627,17648,17671,17692,17713,17738,17764,17782,17836,17931,17965,18030,18090,18126,18173,18203,18233,18263,18303,18329,18359,18395,18417,18442,18476,18498,18520,18542,18564,18605,18631,18653,18675,18697,18719,18741,18772,18794,18829,18851,18882,18904,18934,18961,18994,19022,19046,19069,19093,19111,19133,19155,19173,19191,19209,19227,19245,19267,19285,19307,19329,19352,19374,19396,19420,19444,19468,19486,19512,19530,19548,19566,19584,19605,19630,19648,19671,19689,19707,19729,19754,19780,19798,19816,19834,19857,19875,19902,19923,19946,19971,19989,20012,20030,20052,20070,20094,20112,20134,20156,20177,20202,20220,20241,20259,20281,20299,20317,20339,20357,20378,20401,20426,20448,20470,20488,20510,20531,20549,20567,20591,20609,20627,20645,20663,20681,20712,20734,20758,20776,20794,20816,20837,20862,20880,20898,20922,20946,20964,20986,21008,21026,21044,21067,21090,21113,21134,21152,21173,21191,21209,21236,21259,21281,21299,21317,21335,21357,21379,21403,21509,21527,21557,21580,21602,21620,21644,21662,21684,21707,21728,21751,21769,21793,21811,21829,21847,21869,21890,21913,21934,21952,21973,21991,22016,22034,22052,22076,22094,22118,22136,22159,22177,22195,22213,22231,22253,22276,22294,22321,22344,22365,22383,22401,22423,22444,22467,22485,22507,22532,22555,22577,22598,22622,22646,22670,22694,22717,22738,22763,22786,22804,22852,22903,22933,22973,23005,23027,23054,23076,23105,23134,23164,23198,23226,23248,23269,23295,23313,23335,23362,23384,23408,23429,23447,23470,23493,23516,23537,23561,23585,23603,23630,23654,23672,23693,23711,23734,23752,23774,23792,23818,23842,23865,23889,23911,23929,23947,23965,23988,24010,24033,24054,24076,24094,24116,24146,24164,24188,24211,24229,24247,24272,24290,24311,24333,24351,24369,24391,24412,24433,24457,24475,24496,24514,24539,24561,24583,24608,24629,24653,24676,24699,24721,24745,24769,24787,24810,24828,24849,24870,24888,24906,24924,24945,24966,24990,25012,25030,25048,25071,25093,25116,25137,25161,25179,25197,25219,25241,25259,25277,25300,25321,25339,25362,25384,25406,25430,25453,25471,25494,25512,25530,25553,25576,25599,25617,25635,25653,25671,25689,25707,25731,25749,25771,25796,25814,25836,25854,25875,25897,25922,25940,25958,25981,25999,26022,26040,26063,26087,26105,26123,26141,26159,26177,26199,26220,26241,26259,26277,26300,26325,26347,26365,26391,26415,26449,26472,26497,26525,26546,26564,26587,26605,26623,26641,26669,26687,26705,26723,26745,26766,26789,26807,26825,26843,26861,26886,26904,26922,26940,26964,26989,27029,27051,27073,27091,27112,27134,27169,27205,27223,27241,27265,27289,27307,27325,27351,27369,27458,27521,27574,27622,27658,27688,27718,27764,27792,27829,27855,27884,27921,27960,27988,28021,28048,28076,28108,28139,28170,28195,28224,28258,28284,28312,28337,28363,28385,28412,28441,28459,28477,28502,28520,28538,28561,28584,28605,28627,28650,28673,28694,28712,28738,28761,28783,28807,28833,28851,28874,28898,28922,28940,28965,28983,29004,29027,29048,29069,29087,29110,29128,29150,29168,29186,29204,29222,29250,29268,29286,29304,29322,29344,29365,29389,29407,29428,29446,29464,29489,29507,29525,29553,29577,29601,29625,29648,29666,29689,29707,29725,29747,29765,29786,29807,29829,29851,29878,29896,29914,29932,29956,29987,30012,30039,30064,30087,30105,30123,30141,30163,30181,30205,30229,30250,30273,30291,30309,30333,30355],{"intervention":72,"totalTrials":97,"cells":98},27,{"EARLY_PHASE1":99,"PHASE1":129,"PHASE2":225,"PHASE3":658,"PHASE4":660,"NA":677},{"trials":100,"activeCount":128},[101,114],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":111},"NCT04581382","Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma","COMPLETED",[89],"2024-10-06","2020-12-14",18,[110],"Melanoma",[112,72,113],"Nivolumab","Therapeutic Exchange Plasma",{"nctId":115,"briefTitle":116,"status":104,"phases":117,"primaryCompletion":118,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":126},"NCT03276832","Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma",[89],"2019-10-15","2017-12-20",7,[122,123,124,125],"Metastatic Melanoma","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7","Stage IV Cutaneous Melanoma AJCC v6 and v7",[127,72],"Imiquimod",0,{"trials":130,"activeCount":224,"soonestReadout":184},[131,166,180,211],{"nctId":132,"briefTitle":133,"status":134,"phases":135,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":155},"NCT03432741","Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer","TERMINATED",[90],"2022-08-26","2022-10-03","2018-03-27",17,[141,142,143,144,145,146,147,148,149,150,151,152,153,154],"Breast Adenocarcinoma","Metastatic Breast Carcinoma","Recurrent Breast Carcinoma","Recurrent Hodgkin Lymphoma","Recurrent Mycosis Fungoides","Recurrent Non-Hodgkin Lymphoma","Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory Breast Carcinoma","Refractory Hodgkin Lymphoma","Refractory Mycosis Fungoides","Refractory Nodal Marginal Zone Lymphoma","Refractory Non-Hodgkin Lymphoma","Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Stage IV Breast Cancer AJCC v6 and v7",[156,157,158,159,160,161,112,162,72,163,164,165],"Belinostat","Carfilzomib","Copanlisib Hydrochloride","Daratumumab","Fludeoxyglucose F-18","Gemcitabine Hydrochloride","Obinutuzumab","Rituximab","Romidepsin","Trastuzumab",{"nctId":167,"briefTitle":168,"status":169,"phases":170,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":178},"NCT03021460","Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","ACTIVE_NOT_RECRUITING",[90],"2026-12-31","2017-01-31",20,[122,175,176,123,124,125,177],"Stage III Cutaneous Melanoma AJCC v7","Stage IIIA Cutaneous Melanoma AJCC v7","Unresectable Melanoma",[179,72],"Ibrutinib",{"nctId":181,"briefTitle":182,"status":169,"phases":183,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":209},"NCT04007744","Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors",[90],"2025-05-08","2027-07-02","2020-02-13",36,[189,190,191,192,193,194,195,196,197,198,199,200,201,202,122,203,204,205,206,207,208,177],"Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Locally Advanced Gastric Adenocarcinoma","Locally Advanced Gastroesophageal Junction Adenocarcinoma","Locally Advanced Urothelial Carcinoma","Metastatic Gastric Adenocarcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Urothelial Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Refractory Lung Non-Small Cell Carcinoma","Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage IV Lung Cancer AJCC v8","Unresectable Malignant Solid Neoplasm",[72,210],"Sonidegib",{"nctId":212,"briefTitle":213,"status":104,"phases":214,"primaryCompletion":215,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":222},"NCT03012230","Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer",[90],"2023-01-06","2023-03-08","2017-12-06",12,[220,154,221],"Metastatic Malignant Neoplasm in the Bone","Triple-Negative Breast Carcinoma",[72,223],"Ruxolitinib Phosphate",2,{"trials":226,"activeCount":370,"soonestReadout":71},[227,242,253,262,277,294,307,324,335,348,364,403,423,454,469,492,518,541,552,571],{"nctId":228,"briefTitle":229,"status":104,"phases":230,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":240},"NCT03106415","Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer",[90,91],"2022-05-19","2017-09-27",23,[141,235,236,237,238,239,154],"Metastatic Triple-Negative Breast Carcinoma","Stage III Breast Cancer AJCC v7","Stage IIIA Breast Cancer AJCC v7","Stage IIIB Breast Cancer AJCC v7","Stage IIIC Breast Cancer AJCC v7",[241,72],"Binimetinib",{"nctId":84,"briefTitle":85,"status":169,"phases":243,"primaryCompletion":86,"completion":244,"start":245,"enrollment":173,"conditions":246,"interventions":252},[90,91],"2026-09-10","2022-06-16",[247,248,249,250,251],"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Human Papillomavirus-Related Carcinoma","Locally Advanced Oropharyngeal Carcinoma","Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8",[87,72],{"nctId":254,"briefTitle":255,"status":134,"phases":256,"primaryCompletion":257,"completion":257,"start":258,"enrollment":120,"conditions":259,"interventions":260},"NCT03325101","Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma",[90,91],"2020-06-14","2017-11-15",[175,176,123,124,125],[72,261],"Therapeutic Autologous Dendritic Cells",{"nctId":263,"briefTitle":264,"status":265,"phases":266,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":275},"NCT05465954","Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma","RECRUITING",[91],"2027-10-15","2028-10-15","2023-01-24",54,[272,273,274],"High Grade Astrocytic Tumor","Recurrent Glioblastoma, IDH-Wildtype","Recurrent Gliosarcoma",[276,72],"Efineptakin alfa",{"nctId":278,"briefTitle":279,"status":265,"phases":280,"primaryCompletion":281,"completion":282,"start":283,"enrollment":187,"conditions":284,"interventions":292},"NCT07301268","GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma",[91],"2029-04-30","2034-04-30","2026-04-01",[285,286,287,288,289,273,274,290,291],"Glioblastoma, IDH-Wildtype","Progressive Astrocytoma, IDH-Mutant, Grade 4","Progressive Glioblastoma","Progressive Gliosarcoma","Recurrent Astrocytoma, IDH-Mutant, Grade 4","Resectable Astrocytoma","Resectable Glioblastoma",[293,72],"Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102",{"nctId":295,"briefTitle":296,"status":104,"phases":297,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":304},"NCT03506360","Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",[91],"2019-11-14","2020-12-10","2018-06-19",13,[303],"Recurrent Plasma Cell Myeloma",[305,306,72],"Dexamethasone","Ixazomib Citrate",{"nctId":308,"briefTitle":309,"status":265,"phases":310,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":321},"NCT07087860","Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers",[91],"2028-08-07","2025-08-01",70,[315,316,317,318,319,320],"Metastatic Bladder Urothelial Carcinoma","Metastatic Renal Pelvis and Ureter Urothelial Carcinoma","Refractory Bladder Urothelial Carcinoma","Refractory Renal Pelvis and Ureter Urothelial Carcinoma","Stage IV Bladder Cancer AJCC v7","Stage IV Renal Pelvis and Ureter Cancer AJCC v7",[322,72,323],"Enfortumab Vedotin","Antibody-Drug Conjugate Therapy",{"nctId":69,"briefTitle":70,"status":169,"phases":325,"primaryCompletion":71,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":333},[91],"2028-06-06","2018-01-15",52,[330,331,332],"Glioblastoma","Gliosarcoma","Supratentorial Glioblastoma",[72,334],"Temozolomide",{"nctId":336,"briefTitle":337,"status":104,"phases":338,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT03211117","Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer",[91],"2018-02-12","2019-03-28","2017-08-14",3,[344],"Thyroid Gland Undifferentiated (Anaplastic) Carcinoma",[346,347,72],"Docetaxel","Doxorubicin Hydrochloride",{"nctId":349,"briefTitle":350,"status":104,"phases":351,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":362},"NCT04828486","Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer",[91],"2024-09-18","2025-08-31","2021-08-17",14,[357,358,359,360,361],"Advanced Hepatocellular Carcinoma","BCLC Stage A Hepatocellular Carcinoma","BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","Metastatic Hepatocellular Carcinoma",[363,72],"Futibatinib",{"nctId":365,"briefTitle":366,"status":169,"phases":367,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":400},"NCT05507541","TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[91],"2027-07-30","2023-04-19",10,[372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399],"Recurrent ALK Positive Large B-Cell Lymphoma","Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent Grade 3b Follicular Lymphoma","Recurrent High Grade B-Cell Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified","Recurrent Intravascular Large B-Cell Lymphoma","Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Recurrent T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma","Refractory ALK Positive Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory Grade 3b Follicular Lymphoma","Refractory High Grade B-Cell Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified","Refractory Intravascular Large B-Cell Lymphoma","Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","Refractory Primary Mediastinal Large B-Cell Lymphoma","Refractory T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma","Recurrent Gray Zone Lymphoma",[401,72,402],"Ontorpacept","Maplirpacept",{"nctId":404,"briefTitle":405,"status":104,"phases":406,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":420},"NCT03035331","Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma",[90,91],"2022-01-25","2022-09-10","2017-08-15",11,[412,413,414,415,416,417,146,384,418,419],"Aggressive Non-Hodgkin Lymphoma","Indolent Non-Hodgkin Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Small Lymphocytic Lymphoma",[421,72,422],"Dendritic Cell Therapy","Pneumococcal 13-valent Conjugate Vaccine",{"nctId":424,"briefTitle":425,"status":104,"phases":426,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":452},"NCT02332980","Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas",[91],"2021-08-10","2022-01-04","2015-02-19",65,[373,432,433,434,435,436,437,417,438,439,440,441,442,443,444,445,446,151,447,448,449,450,451],"Recurrent Chronic Lymphocytic Leukemia","Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Lymphoplasmacytic Lymphoma","Recurrent Nodal Marginal Zone Lymphoma","Recurrent Small Lymphocytic Lymphoma","Recurrent Splenic Marginal Zone Lymphoma","Recurrent Waldenstrom Macroglobulinemia","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Refractory Follicular Lymphoma","Refractory Lymphoplasmacytic Lymphoma","Refractory Small Lymphocytic Lymphoma","Refractory Splenic Marginal Zone Lymphoma","Refractory Waldenstrom Macroglobulinemia","Richter Syndrome","Waldenstrom Macroglobulinemia",[179,453,72],"Idelalisib",{"nctId":455,"briefTitle":456,"status":169,"phases":457,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":467},"NCT04895735","MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and\u002For Metastatic Salivary Gland Cancer",[91],"2025-08-13","2028-02-28","2021-07-23",45,[463,464,465,466],"Metastatic Salivary Gland Carcinoma","Recurrent Salivary Gland Carcinoma","Stage IV Major Salivary Gland Cancer AJCC v8","Adenoid Cystic Carcinoma",[72,468],"Pemetrexed Disodium",{"nctId":470,"briefTitle":471,"status":104,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":491},"NCT03695471","Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides",[91],"2023-06-21","2024-10-08","2020-02-04",9,[478,479,480,481,482,483,484,485,486,487,488,489,490],"Mycosis Fungoides","Sezary Syndrome","Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8",[72],{"nctId":493,"briefTitle":494,"status":265,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":516},"NCT05920798","Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",[90,91],"2028-06-30","2023-09-28",40,[500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515],"Fallopian Tube Carcinosarcoma","Primary Peritoneal Carcinosarcoma","Recurrent Fallopian Tube Carcinoma","Recurrent Fallopian Tube Clear Cell Adenocarcinoma","Recurrent Fallopian Tube Endometrioid Adenocarcinoma","Recurrent Fallopian Tube High Grade Serous Adenocarcinoma","Recurrent Ovarian Carcinoma","Recurrent Ovarian Carcinosarcoma","Recurrent Ovarian Clear Cell Adenocarcinoma","Recurrent Ovarian Endometrioid Adenocarcinoma","Recurrent Ovarian High Grade Serous Adenocarcinoma","Recurrent Primary Peritoneal Carcinoma","Recurrent Primary Peritoneal Clear Cell Adenocarcinoma","Recurrent Primary Peritoneal Endometrioid Adenocarcinoma","Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma","Recurrent Primary Peritoneal Carcinosarcoma",[517,72],"Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine",{"nctId":519,"briefTitle":520,"status":104,"phases":521,"primaryCompletion":522,"completion":523,"start":524,"enrollment":525,"conditions":526,"interventions":535},"NCT02730546","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",[90,91],"2021-07-01","2023-10-31","2016-06-24",31,[527,528,529,530,531,532,533,534],"Gastric Cardia Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Stage IB Gastric Cancer AJCC v7","Stage II Gastric Cancer AJCC v7","Stage IIA Gastric Cancer AJCC v7","Stage IIB Gastric Cancer AJCC v7","Stage IIIA Gastric Cancer AJCC v7","Stage IIIB Gastric Cancer AJCC v7",[536,537,538,539,540,72],"Carboplatin","Fluorouracil","Leucovorin Calcium","Oxaliplatin","Paclitaxel",{"nctId":542,"briefTitle":543,"status":104,"phases":544,"primaryCompletion":545,"completion":546,"start":547,"enrollment":410,"conditions":548,"interventions":550},"NCT02880228","Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant",[91],"2017-07-06","2018-07-29","2016-09-16",[549],"Plasma Cell Myeloma",[305,551,72],"Lenalidomide",{"nctId":553,"briefTitle":554,"status":265,"phases":555,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":566},"NCT06381154","Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer",[91],"2029-12-06","2024-12-06",25,[560,561,562,563,564,565],"Locally Advanced Pancreatic Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Unresectable Pancreatic Adenocarcinoma",[537,567,568,539,72,569,570],"Irinotecan","Leucovorin","Photodynamic Therapy","Verteporfin",{"nctId":572,"briefTitle":573,"status":265,"phases":574,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":655},"NCT05269381","Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",[90,91],"2028-03-31","2022-03-31",132,[579,580,581,582,583,189,190,191,584,192,193,194,585,586,587,588,589,590,591,195,196,592,593,594,595,596,597,598,599,600,601,602,603,604,605,197,606,607,198,199,200,361,201,202,122,608,609,610,235,203,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,206,629,207,630,631,632,633,634,635,636,637,638,221,639,640,641,642,643,644,645,208,177,646,647,648,649,650,141,651,652,653,654],"Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Clinical Stage III Merkel Cell Carcinoma AJCC v8","Clinical Stage IV Merkel Cell Carcinoma AJCC v8","Clinical Stage IVA Gastric Cancer AJCC v8","Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IVB Gastric Cancer AJCC v8","Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Locally Advanced Cervical Carcinoma","Locally Advanced Endometrial Carcinoma","Locally Advanced Head and Neck Squamous Cell Carcinoma","Locally Advanced Hepatocellular Carcinoma","Locally Advanced Lung Non-Small Cell Carcinoma","Locally Advanced Malignant Solid Neoplasm","Locally Advanced Melanoma","Locally Advanced Merkel Cell Carcinoma","Locally Advanced Renal Cell Carcinoma","Locally Advanced Skin Squamous Cell Carcinoma","Locally Advanced Triple-Negative Breast Carcinoma","Locally Advanced Unresectable Breast Carcinoma","Locally Advanced Unresectable Cervical Carcinoma","Locally Advanced Unresectable Gastric Adenocarcinoma","Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma","Locally Advanced Unresectable Renal Cell Carcinoma","Metastatic Cervical Carcinoma","Metastatic Endometrial Carcinoma","Metastatic Merkel Cell Carcinoma","Metastatic Renal Cell Carcinoma","Metastatic Skin Squamous Cell Carcinoma","Skin Squamous Cell Carcinoma","Stage III Cervical Cancer AJCC v8","Stage III Hepatocellular Carcinoma AJCC v8","Stage III Lung Cancer AJCC v8","Stage III Renal Cell Cancer AJCC v8","Stage IIIA Cervical Cancer AJCC v8","Stage IIIA Hepatocellular Carcinoma AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIA Uterine Corpus Cancer AJCC v8","Stage IIIB Cervical Cancer AJCC v8","Stage IIIB Hepatocellular Carcinoma AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIB Uterine Corpus Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IIIC Uterine Corpus Cancer AJCC v8","Stage IIIC1 Uterine Corpus Cancer AJCC v8","Stage IIIC2 Uterine Corpus Cancer AJCC v8","Stage IV Cervical Cancer AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Stage IVA Cervical Cancer AJCC v8","Stage IVA Hepatocellular Carcinoma AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVA Uterine Corpus Cancer AJCC v8","Stage IVB Cervical Cancer AJCC v8","Stage IVB Hepatocellular Carcinoma AJCC v8","Stage IVB Lung Cancer AJCC v8","Stage IVB Uterine Corpus Cancer AJCC v8","Unresectable Cervical Carcinoma","Unresectable Endometrial Carcinoma","Unresectable Gastric Adenocarcinoma","Unresectable Gastroesophageal Junction Adenocarcinoma","Unresectable Head and Neck Squamous Cell Carcinoma","Unresectable Hepatocellular Carcinoma","Unresectable Lung Non-Small Cell Carcinoma","Unresectable Merkel Cell Carcinoma","Unresectable Renal Cell Carcinoma","Unresectable Skin Squamous Cell Carcinoma","Unresectable Triple-Negative Breast Carcinoma","Unresectable Urothelial Carcinoma","Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",[57,656,72,657],"Neoantigen Peptide Vaccine","Sargramostim",{"trials":659,"activeCount":128},[],{"trials":661,"activeCount":676,"soonestReadout":666},[662],{"nctId":663,"briefTitle":664,"status":265,"phases":665,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":675},"NCT06764095","Enfortumab Vedotin and Pembrolizumab With Cystectomy and\u002For Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial",[93],"2034-12-31","2025-01-08",75,[670,671,315,316,672,673,674],"Locally Advanced Bladder Urothelial Carcinoma","Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma","Stage III Bladder Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8","Stage IV Renal Pelvis and Ureter Cancer AJCC v8",[322,72],1,{"trials":678,"activeCount":128},[],{"intervention":680,"totalTrials":681,"cells":682},"Semaglutide",4,{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":701,"PHASE4":703,"NA":743},{"trials":684,"activeCount":128},[],{"trials":686,"activeCount":128},[],{"trials":688,"activeCount":676,"soonestReadout":694},[689],{"nctId":690,"briefTitle":691,"status":692,"phases":693,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":697,"interventions":700},"NCT05371496","Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction","ENROLLING_BY_INVITATION",[91],"2026-08","2022-09-06",81,[698,699,15],"Cardiomyopathy","Heart Failure With Preserved Ejection Fraction (HFpEF)",[680],{"trials":702,"activeCount":128},[],{"trials":704,"activeCount":342,"soonestReadout":737},[705,723,733],{"nctId":706,"briefTitle":707,"status":265,"phases":708,"primaryCompletion":709,"completion":710,"start":711,"enrollment":712,"conditions":713,"interventions":719},"NCT07213466","Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder",[93],"2028-02-01","2029-02-01","2026-01-19",100,[714,715,716,15,717,718],"Bipolar I Disorder","Bipolar II Disorder","Schizo Affective Disorder","Weight Loss","GLP - 1",[720,721,722],"semaglutide","Phentermine-Topiramate","naltrexone and bupropion",{"nctId":724,"briefTitle":725,"status":169,"phases":726,"primaryCompletion":727,"completion":575,"start":728,"enrollment":729,"conditions":730,"interventions":731},"NCT06801015","Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions",[93],"2028-01-31","2025-10-01",30,[15],[680,732],"Tirzepatide",{"nctId":734,"briefTitle":735,"status":265,"phases":736,"primaryCompletion":737,"completion":738,"start":739,"enrollment":740,"conditions":741,"interventions":742},"NCT06814938","A Study of a Novel Precision Medicine Approach For Obesity",[93],"2027-12","2028-11","2025-02-21",135,[15],[680],{"trials":744,"activeCount":128},[],{"intervention":746,"totalTrials":681,"cells":747},"Bupivacaine",{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":765,"NA":801},{"trials":749,"activeCount":128},[],{"trials":751,"activeCount":128},[],{"trials":753,"activeCount":128},[],{"trials":755,"activeCount":676,"soonestReadout":760},[756],{"nctId":757,"briefTitle":758,"status":265,"phases":759,"primaryCompletion":760,"completion":761,"start":369,"enrollment":762,"conditions":763,"interventions":764},"NCT05357690","A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation",[91,92],"2026-04","2026-12",220,[33],[746],{"trials":766,"activeCount":224,"soonestReadout":761},[767,779,792],{"nctId":768,"briefTitle":769,"status":692,"phases":770,"primaryCompletion":171,"completion":771,"start":772,"enrollment":773,"conditions":774,"interventions":777},"NCT05425979","Mepivacaine Versus Bupivacaine Onset Time in Ultrasound-guided Ankle Blocks",[93],"2027-03-30","2024-03-11",50,[775,776],"Ankle Block","Foot Surgery",[778,746],"Mepivacaine",{"nctId":780,"briefTitle":781,"status":104,"phases":782,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":789},"NCT05732532","Steroids in Occipital Nerve Block for Treatment of Headache",[93],"2025-06-01","2023-02-17",120,[787,788],"Headache","Occipital Nerve Block",[746,790,305,791],"Lidocaine","Normal saline",{"nctId":793,"briefTitle":794,"status":169,"phases":795,"primaryCompletion":761,"completion":761,"start":796,"enrollment":797,"conditions":798,"interventions":800},"NCT02381353","Exparel Injection for Postoperative Orbital Pain",[93],"2015-02",88,[799],"Pain, Postoperative",[746],{"trials":802,"activeCount":128},[],{"intervention":322,"totalTrials":342,"cells":804},{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":828,"PHASE4":830,"NA":836},{"trials":806,"activeCount":128},[],{"trials":808,"activeCount":128},[],{"trials":810,"activeCount":224,"soonestReadout":815},[811,824],{"nctId":812,"briefTitle":813,"status":265,"phases":814,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":823},"NCT06104618","Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis",[91],"2026-11-01","2023-12-21",28,[819,820,821,822],"Metastatic Penile Squamous Cell Carcinoma","Stage III Penile Cancer AJCC v8","Stage IV Penile Cancer AJCC v8","Unresectable Penile Squamous Cell Carcinoma",[322],{"nctId":308,"briefTitle":309,"status":265,"phases":825,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":826,"interventions":827},[91],[315,316,317,318,319,320],[322,72,323],{"trials":829,"activeCount":128},[],{"trials":831,"activeCount":676,"soonestReadout":666},[832],{"nctId":663,"briefTitle":664,"status":265,"phases":833,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":834,"interventions":835},[93],[670,671,315,316,672,673,674],[322,72],{"trials":837,"activeCount":128},[],{"intervention":839,"totalTrials":370,"cells":840},"Ketamine",{"EARLY_PHASE1":841,"PHASE1":853,"PHASE2":855,"PHASE3":912,"PHASE4":914,"NA":927},{"trials":842,"activeCount":676,"soonestReadout":761},[843],{"nctId":844,"briefTitle":845,"status":169,"phases":846,"primaryCompletion":761,"completion":761,"start":847,"enrollment":108,"conditions":848,"interventions":852},"NCT03573349","Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:",[89],"2019-01-03",[849,850,851],"Major Depressive Disorder","Treatment Resistant Depression","Bipolar Depression",[839],{"trials":854,"activeCount":128},[],{"trials":856,"activeCount":676,"soonestReadout":861},[857,868,879,890,900],{"nctId":858,"briefTitle":859,"status":265,"phases":860,"primaryCompletion":861,"completion":861,"start":862,"enrollment":729,"conditions":863,"interventions":866},"NCT06668571","Intravenous Ketamine for Treatment-Resistant Depression",[91],"2027-12-31","2025-02-10",[864,865],"Depressive Disorder, Treatment-Resistant","Treatment Resistant Depression (TRD)",[839,867],"Normal Saline",{"nctId":869,"briefTitle":870,"status":104,"phases":871,"primaryCompletion":872,"completion":873,"start":874,"enrollment":218,"conditions":875,"interventions":878},"NCT02094898","Ketamine for Depression and Suicide Risk",[91],"2016-07","2016-08","2014-09",[876,877],"Depression","Suicide",[839],{"nctId":880,"briefTitle":881,"status":104,"phases":882,"primaryCompletion":883,"completion":883,"start":884,"enrollment":885,"conditions":886,"interventions":888},"NCT03448068","Perioperative Ketamine for Pain With Gastric Bypass",[91],"2020-01-09","2018-04-16",34,[887,839],"Laparoscopic Gastric Bypass Surgery",[839,889],"Standard therapy",{"nctId":891,"briefTitle":892,"status":134,"phases":893,"primaryCompletion":796,"completion":796,"start":894,"enrollment":895,"conditions":896,"interventions":899},"NCT01680172","Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer",[91],"2012-08",5,[897,876,898],"Cancer","Anxiety",[839],{"nctId":901,"briefTitle":902,"status":104,"phases":903,"primaryCompletion":904,"completion":904,"start":905,"enrollment":328,"conditions":906,"interventions":910},"NCT02554253","The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction",[91],"2020-12","2015-09",[907,908,909],"Cognitive Disorders","Delirium","Acute Kidney Injury",[839,911],"Propofol",{"trials":913,"activeCount":128},[],{"trials":915,"activeCount":676,"soonestReadout":920},[916],{"nctId":917,"briefTitle":918,"status":169,"phases":919,"primaryCompletion":920,"completion":921,"start":922,"enrollment":923,"conditions":924,"interventions":926},"NCT05268562","Ketamine and Kidney Injury in Cardiac Surgery",[93],"2025-09-05","2026-06","2022-03-02",200,[925],"Cardiac Surgery",[839,911],{"trials":928,"activeCount":128},[929,941,950],{"nctId":930,"briefTitle":931,"status":104,"phases":932,"primaryCompletion":933,"completion":934,"start":935,"enrollment":936,"conditions":937,"interventions":939},"NCT00587665","Low Dose Ketamine as an Adjunct to Fentanyl in Outpatient Tonsillectomy",[94],"2007-10","2007-12","2006-08",122,[938],"Pain",[940],"ketamine",{"nctId":942,"briefTitle":943,"status":104,"phases":944,"primaryCompletion":945,"completion":945,"start":946,"enrollment":19,"conditions":947,"interventions":949},"NCT01065350","A Comparison of Ketofol (Ketamine and Propofol Admixture) Versus Propofol as Induction Agents on Hemodynamic Parameters",[94],"2011-03","2010-12",[948],"Blood Pressure",[911,839],{"nctId":951,"briefTitle":952,"status":104,"phases":953,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":957,"interventions":958},"NCT01367119","Ketamine Anesthesia in Electroconvulsive Therapy",[94],"2012-03","2011-05",38,[876],[839,959],"methohexital",{"intervention":961,"totalTrials":895,"cells":962},"Oxycodone",{"EARLY_PHASE1":963,"PHASE1":974,"PHASE2":976,"PHASE3":986,"PHASE4":988,"NA":1026},{"trials":964,"activeCount":128},[965],{"nctId":966,"briefTitle":967,"status":104,"phases":968,"primaryCompletion":969,"completion":969,"start":970,"enrollment":461,"conditions":971,"interventions":973},"NCT03845881","Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty",[89],"2020-07-28","2019-04-10",[972],"Total Knee Arthroplasty",[961],{"trials":975,"activeCount":128},[],{"trials":977,"activeCount":128},[978],{"nctId":979,"briefTitle":980,"status":104,"phases":981,"primaryCompletion":982,"completion":982,"start":983,"enrollment":355,"conditions":984,"interventions":985},"NCT04223609","Non-intrusive Detection of Temporary Neurologic Impairment By Opioids",[90,91],"2022-04-11","2020-02-28",[18],[961],{"trials":987,"activeCount":128},[],{"trials":989,"activeCount":224,"soonestReadout":1006},[990,1002,1016],{"nctId":991,"briefTitle":992,"status":692,"phases":993,"primaryCompletion":994,"completion":995,"start":996,"enrollment":997,"conditions":998,"interventions":1000},"NCT07153003","Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty",[93],"2030-09-01","2031-09-01","2026-02-02",560,[999],"Post Operative Pain",[961,1001],"Tramadol and Oxycodone",{"nctId":1003,"briefTitle":1004,"status":265,"phases":1005,"primaryCompletion":1006,"completion":760,"start":1007,"enrollment":1008,"conditions":1009,"interventions":1011},"NCT05076110","Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures",[93],"2026-03","2022-04-07",188,[1010],"Hip Arthroscopy",[961,1012,1013,1014,1015],"Ibuprofen","Gabapentin","Acetaminophen","Methocarbamol",{"nctId":1017,"briefTitle":1018,"status":104,"phases":1019,"primaryCompletion":1020,"completion":1021,"start":955,"enrollment":956,"conditions":1022,"interventions":1024},"NCT01500317","Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans",[93],"2011-10","2011-12",[1023],"Effects of 2 Mu-opiates on Gastrointestinal Transit",[1025,961],"Tapentadol",{"trials":1027,"activeCount":128},[],{"intervention":1029,"totalTrials":224,"cells":1030},"Doxycycline",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1037,"PHASE4":1039,"NA":1070},{"trials":1032,"activeCount":128},[],{"trials":1034,"activeCount":128},[],{"trials":1036,"activeCount":128},[],{"trials":1038,"activeCount":128},[],{"trials":1040,"activeCount":224,"soonestReadout":921},[1041,1051],{"nctId":1042,"briefTitle":1043,"status":265,"phases":1044,"primaryCompletion":994,"completion":995,"start":1045,"enrollment":1046,"conditions":1047,"interventions":1049},"NCT07164131","Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams",[93],"2025-09-15",1120,[1048],"Community-acquired Pneumonia",[1029,1050],"Azithromycin",{"nctId":1052,"briefTitle":1053,"status":692,"phases":1054,"primaryCompletion":921,"completion":921,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1067},"NCT04297592","Antibiotic Prophylaxis in High-Risk Arthroplasty Patients",[93],"2020-06-11",4618,[1058,1059,1060,1061,1062,1063,1064,1065,1066],"Infections Joint Prosthetic","Overweight or Obesity","MSSA Colonization","MRSA","Chronic Kidney Diseases","Diabetes","Autoimmune Diseases","Inflammatory Disease","Tobacco Use",[1068,1029,1069],"Cephalexin","Cefadroxil",{"trials":1071,"activeCount":128},[],{"intervention":1073,"totalTrials":224,"cells":1074},"Low-Dose Aspirin",{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1089,"PHASE4":1091,"NA":1103},{"trials":1076,"activeCount":128},[],{"trials":1078,"activeCount":128},[],{"trials":1080,"activeCount":676,"soonestReadout":1085},[1081],{"nctId":1082,"briefTitle":1083,"status":265,"phases":1084,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":25,"conditions":1087,"interventions":1088},"NCT05557877","Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer",[91],"2027-01-30","2023-03-09",[30],[1073],{"trials":1090,"activeCount":128},[],{"trials":1092,"activeCount":676,"soonestReadout":1098},[1093],{"nctId":1094,"briefTitle":1095,"status":1096,"phases":1097,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":558,"conditions":1100,"interventions":1102},"NCT07281547","Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain","NOT_YET_RECRUITING",[93],"2027-06-11","2026-08-12",[1101],"Endometrial Carcinoma",[1073],{"trials":1104,"activeCount":128},[],{"intervention":732,"totalTrials":224,"cells":1106},{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1113,"PHASE4":1115,"NA":1129},{"trials":1108,"activeCount":128},[],{"trials":1110,"activeCount":128},[],{"trials":1112,"activeCount":128},[],{"trials":1114,"activeCount":128},[],{"trials":1116,"activeCount":224,"soonestReadout":1121},[1117,1125],{"nctId":1118,"briefTitle":1119,"status":265,"phases":1120,"primaryCompletion":1121,"completion":1121,"start":760,"enrollment":498,"conditions":1122,"interventions":1124},"NCT07218445","The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity",[93],"2027-09-18",[15,1123],"Menopause Hot Flashes",[732],{"nctId":724,"briefTitle":725,"status":169,"phases":1126,"primaryCompletion":727,"completion":575,"start":728,"enrollment":729,"conditions":1127,"interventions":1128},[93],[15],[680,732],{"trials":1130,"activeCount":128},[],{"intervention":1132,"totalTrials":224,"cells":1133},"Corticosteroid",{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1140,"PHASE4":1142,"NA":1167},{"trials":1135,"activeCount":128},[],{"trials":1137,"activeCount":128},[],{"trials":1139,"activeCount":128},[],{"trials":1141,"activeCount":128},[],{"trials":1143,"activeCount":224,"soonestReadout":1148},[1144,1155],{"nctId":1145,"briefTitle":1146,"status":265,"phases":1147,"primaryCompletion":1148,"completion":1149,"start":1150,"enrollment":1151,"conditions":1152,"interventions":1154},"NCT07223580","A Study Of Corticosteroid On Postoperative Pain After Ureteroscopy For Urinary Calculi",[93],"2027-01-01","2027-12-01","2026-01-23",90,[1153,999],"Ureteroscopy",[1132],{"nctId":1156,"briefTitle":1157,"status":265,"phases":1158,"primaryCompletion":1159,"completion":1160,"start":1161,"enrollment":1162,"conditions":1163,"interventions":1166},"NCT07217405","Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis",[93],"2027-05-01","2027-10-01","2025-12-19",165,[1164,1165],"Osteoarthritis Hand","Osteoarthritis Wrist",[1132],{"trials":1168,"activeCount":128},[],{"intervention":1014,"totalTrials":224,"cells":1170},{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1175,"PHASE3":1177,"PHASE4":1179,"NA":1193},{"trials":1172,"activeCount":128},[],{"trials":1174,"activeCount":128},[],{"trials":1176,"activeCount":128},[],{"trials":1178,"activeCount":128},[],{"trials":1180,"activeCount":224,"soonestReadout":1006},[1181,1185],{"nctId":1003,"briefTitle":1004,"status":265,"phases":1182,"primaryCompletion":1006,"completion":760,"start":1007,"enrollment":1008,"conditions":1183,"interventions":1184},[93],[1010],[961,1012,1013,1014,1015],{"nctId":1186,"briefTitle":1187,"status":692,"phases":1188,"primaryCompletion":737,"completion":737,"start":1189,"enrollment":108,"conditions":1190,"interventions":1192},"NCT05878015","A Study of Intravenous Acetaminophen for Small Bowel Obstruction",[93],"2023-10-11",[1191],"Small Bowel Obstruction",[1014],{"trials":1194,"activeCount":128},[],{"intervention":1196,"totalTrials":1197,"cells":1198},"Liposomal Bupivacaine",6,{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1205,"PHASE4":1207,"NA":1271},{"trials":1200,"activeCount":128},[],{"trials":1202,"activeCount":128},[],{"trials":1204,"activeCount":128},[],{"trials":1206,"activeCount":128},[],{"trials":1208,"activeCount":676,"soonestReadout":1213},[1209,1219,1230,1242,1250,1261],{"nctId":1210,"briefTitle":1211,"status":1096,"phases":1212,"primaryCompletion":1213,"completion":1213,"start":921,"enrollment":1214,"conditions":1215,"interventions":1217},"NCT07570940","A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery",[93],"2030-06",450,[1216,33],"Coronary Artery Disease",[1218],"Liposomal bupivacaine",{"nctId":1220,"briefTitle":1221,"status":104,"phases":1222,"primaryCompletion":1223,"completion":1223,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1228},"NCT05891613","A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction",[93],"2025-10-06","2024-01-24",32,[1227],"Breast Reduction",[1229,1196],"Bupivacaine Hydrochloride",{"nctId":1231,"briefTitle":1232,"status":104,"phases":1233,"primaryCompletion":1234,"completion":1234,"start":1235,"enrollment":1236,"conditions":1237,"interventions":1241},"NCT02444533","EXPAREL® for Pain After Tonsillectomy",[93],"2016-05","2015-05",39,[1238,1239,1240],"Tonsillectomy","Tonsillitis","Post-operative Pain",[1196],{"nctId":1243,"briefTitle":1244,"status":134,"phases":1245,"primaryCompletion":460,"completion":460,"start":1246,"enrollment":817,"conditions":1247,"interventions":1249},"NCT03907033","Liposomal Bupivacaine in Vaginal Hysterectomy",[93],"2019-09-03",[1248],"Vaginal Hysterectomy",[1218,1229],{"nctId":1251,"briefTitle":1252,"status":104,"phases":1253,"primaryCompletion":1254,"completion":1254,"start":1255,"enrollment":1256,"conditions":1257,"interventions":1259},"NCT04258631","Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies",[93],"2023-08-08","2020-07-09",105,[1258],"Malignant Female Reproductive System Neoplasm",[1260,1196],"Hydromorphone",{"nctId":1262,"briefTitle":1263,"status":104,"phases":1264,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1270},"NCT03663283","Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty",[93],"2020-02-14","2018-10-29",104,[1269],"Arthropathy Shoulder",[1196,1229],{"trials":1272,"activeCount":128},[],{"intervention":1274,"totalTrials":1197,"cells":1275},"Ropivacaine",{"EARLY_PHASE1":1276,"PHASE1":1287,"PHASE2":1289,"PHASE3":1291,"PHASE4":1303,"NA":1343},{"trials":1277,"activeCount":128},[1278],{"nctId":1279,"briefTitle":1280,"status":104,"phases":1281,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":498,"conditions":1284,"interventions":1286},"NCT04916691","Ultrasound-guided Erector Spinae Plane Blocks",[89],"2022-08-22","2021-05-15",[1285],"Rib Fractures",[1274],{"trials":1288,"activeCount":128},[],{"trials":1290,"activeCount":128},[],{"trials":1292,"activeCount":128},[1293],{"nctId":1294,"briefTitle":1295,"status":134,"phases":1296,"primaryCompletion":1297,"completion":1298,"start":1299,"enrollment":1300,"conditions":1301,"interventions":1302},"NCT00586976","A Phase II\u002FIII Study of Continuous Local Anesthetic Infusion in Median Sternotomy Following Cardiac Surgery",[91,92],"2007-06","2008-06","2005-07",125,[925],[1274,791],{"trials":1304,"activeCount":676,"soonestReadout":1328},[1305,1314,1324,1333],{"nctId":1306,"briefTitle":1307,"status":134,"phases":1308,"primaryCompletion":1309,"completion":1309,"start":1310,"enrollment":224,"conditions":1311,"interventions":1313},"NCT05820997","Paravertebral Block vs no Block in Open Pancreaticoduodenectomy",[93],"2024-12-04","2023-04-24",[1312],"Pancreaticoduodenectomy",[1274],{"nctId":1315,"briefTitle":1316,"status":104,"phases":1317,"primaryCompletion":1235,"completion":1318,"start":1319,"enrollment":1320,"conditions":1321,"interventions":1323},"NCT01450007","Ropivacaine Block Alone or With Perineural or Systemic Dexamethasone for Pain in Shoulder Surgery",[93],"2015-07","2012-05",130,[1322],"Shoulder Injury",[1274,305,305,791,791],{"nctId":1325,"briefTitle":1326,"status":692,"phases":1327,"primaryCompletion":1328,"completion":1328,"start":1329,"enrollment":773,"conditions":1330,"interventions":1332},"NCT05544721","A Study of Paravertebral Block in Thoracic Outlet Syndrome",[93],"2027-08","2022-10-05",[1331],"Thoracic Outlet Syndrome",[1274],{"nctId":1334,"briefTitle":1335,"status":104,"phases":1336,"primaryCompletion":872,"completion":1337,"start":1338,"enrollment":34,"conditions":1339,"interventions":1341},"NCT02576249","Corticosteroid\u002FRopivacaine Versus Corticosteroid\u002FSaline Injections for Knee Osteoarthritis",[93],"2016-10","2015-10",[1340],"Osteoarthritis",[1274,791,1342],"Methylprednisolone",{"trials":1344,"activeCount":128},[],{"intervention":1346,"totalTrials":342,"cells":1347},"F-18 FDG",{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1379,"PHASE3":1381,"PHASE4":1383,"NA":1399},{"trials":1349,"activeCount":128},[],{"trials":1351,"activeCount":128},[1352,1370],{"nctId":1353,"briefTitle":1354,"status":104,"phases":1355,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":1358,"conditions":1359,"interventions":1368},"NCT01623284","PiB PET Scanning in Speech and Language Based Dementias",[90],"2015-01","2010-03",168,[1360,1361,1362,1363,1364,1365,1366,1367],"PPA","Primary Progressive Aphasia","Aphasia","Non-fluent Aphasia","Semantic Dementia","Apraxia of Speech","Primary Progressive Nonfluent Aphasia","Progressive Aphasia",[1369,1346],"C-11 PiB",{"nctId":1371,"briefTitle":1372,"status":104,"phases":1373,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":28,"conditions":1376,"interventions":1378},"NCT01609335","Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults",[90],"2013-08","2012-07",[1377],"Alzheimer's Disease",[1346,1369],{"trials":1380,"activeCount":128},[],{"trials":1382,"activeCount":128},[],{"trials":1384,"activeCount":676,"soonestReadout":1389},[1385],{"nctId":1386,"briefTitle":1387,"status":692,"phases":1388,"primaryCompletion":1389,"completion":1389,"start":1390,"enrollment":1391,"conditions":1392,"interventions":1396},"NCT00950430","Imaging of Brain Amyloid Plaques in the Aging Population",[93],"2027-06","2008-04",8000,[1377,1393,1394,1395],"Dementia With Lewy Bodies","Frontotemporal Dementia","Vascular Dementia",[1397,1346,1398],"Pittsburgh Compound B","Tau",{"trials":1400,"activeCount":128},[],{"intervention":1402,"totalTrials":342,"cells":1403},"Lisinopril",{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1438,"PHASE4":1440,"NA":1452},{"trials":1405,"activeCount":128},[],{"trials":1407,"activeCount":128},[],{"trials":1409,"activeCount":128},[1410,1425],{"nctId":1411,"briefTitle":1412,"status":1413,"phases":1414,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":128,"conditions":1417,"interventions":1421},"NCT04190433","Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial","WITHDRAWN",[91],"2023-04-18","2020-09-01",[30,1418,1419,1420],"Hematopoietic and Lymphoid Cell Neoplasm","Lymphoma","Sarcoma",[1422,1402,1423,1424],"Carvedilol","Pravastatin","Spironolactone",{"nctId":1426,"briefTitle":1427,"status":104,"phases":1428,"primaryCompletion":1429,"completion":1430,"start":1431,"enrollment":233,"conditions":1432,"interventions":1436},"NCT01880528","Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer",[91],"2013-06-05","2019-01-29","2013-05-31",[1433,1434,1435],"Dyspnea","Non-small Cell Lung Cancer","Small Cell Lung Cancer",[1437],"lisinopril",{"trials":1439,"activeCount":128},[],{"trials":1441,"activeCount":676,"soonestReadout":1446},[1442],{"nctId":1443,"briefTitle":1444,"status":1096,"phases":1445,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":729,"conditions":1449,"interventions":1451},"NCT07594535","The Effect Of Lisinopril On Polycythemia",[93],"2028-07-01","2029-07-01","2026-07-01",[1450],"Polycythemia",[1402],{"trials":1453,"activeCount":128},[],{"intervention":1455,"totalTrials":224,"cells":1456},"Dexmedetomidine",{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1463,"PHASE4":1477,"NA":1488},{"trials":1458,"activeCount":128},[],{"trials":1460,"activeCount":128},[],{"trials":1462,"activeCount":128},[],{"trials":1464,"activeCount":128},[1465],{"nctId":1466,"briefTitle":1467,"status":104,"phases":1468,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":1472,"conditions":1473,"interventions":1476},"NCT02819141","Self-management of Sedative Therapy by Ventilated Patients",[91,92],"2024-10","2024-12","2016-11",161,[1474,898,1475],"Critical Illness","Respiratory Failure",[1455],{"trials":1478,"activeCount":676,"soonestReadout":694},[1479],{"nctId":1480,"briefTitle":1481,"status":265,"phases":1482,"primaryCompletion":694,"completion":694,"start":1483,"enrollment":498,"conditions":1484,"interventions":1487},"NCT04730609","Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery",[93],"2021-09-21",[1485,1486],"Shivering","Dose Finding Study",[1455],{"trials":1489,"activeCount":128},[],{"intervention":778,"totalTrials":224,"cells":1491},{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1512,"NA":1518},{"trials":1493,"activeCount":128},[],{"trials":1495,"activeCount":128},[],{"trials":1497,"activeCount":128},[],{"trials":1499,"activeCount":128},[1500],{"nctId":1501,"briefTitle":1502,"status":104,"phases":1503,"primaryCompletion":1504,"completion":1504,"start":1505,"enrollment":1506,"conditions":1507,"interventions":1510},"NCT03838874","Mepivacaine Versus Low-Dose Bupivacaine For Primary Total Hip and Knee Arthroplasty",[91,92],"2019-10-29","2019-02-25",154,[1508,1509],"Knee Osteoarthritis","Hip Osteoarthritis",[1511,778],"Low-Dose Bupivacaine",{"trials":1513,"activeCount":676,"soonestReadout":171},[1514],{"nctId":768,"briefTitle":769,"status":692,"phases":1515,"primaryCompletion":171,"completion":771,"start":772,"enrollment":773,"conditions":1516,"interventions":1517},[93],[775,776],[778,746],{"trials":1519,"activeCount":128},[],{"intervention":721,"totalTrials":224,"cells":1521},{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1542,"NA":1548},{"trials":1523,"activeCount":128},[],{"trials":1525,"activeCount":128},[],{"trials":1527,"activeCount":128},[],{"trials":1529,"activeCount":128},[1530],{"nctId":1531,"briefTitle":1532,"status":104,"phases":1533,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":1536,"conditions":1537,"interventions":1538},"NCT03374956","Individualized Obesity Pharmacotherapy",[92],"2022-05-26","2017-12-11",193,[15],[721,1539,1540,1541],"Liraglutide","Naltrexone\u002Fbupropion","Phentermine",{"trials":1543,"activeCount":676,"soonestReadout":709},[1544],{"nctId":706,"briefTitle":707,"status":265,"phases":1545,"primaryCompletion":709,"completion":710,"start":711,"enrollment":712,"conditions":1546,"interventions":1547},[93],[714,715,716,15,717,718],[720,721,722],{"trials":1549,"activeCount":128},[],{"intervention":1551,"totalTrials":224,"cells":1552},"Methadone",{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1569,"PHASE4":1571,"NA":1582},{"trials":1554,"activeCount":128},[],{"trials":1556,"activeCount":128},[],{"trials":1558,"activeCount":128},[1559],{"nctId":1560,"briefTitle":1561,"status":134,"phases":1562,"primaryCompletion":1563,"completion":1563,"start":1564,"enrollment":676,"conditions":1565,"interventions":1567},"NCT00573937","Methadone Versus Morphine for Cancer-Related Pain",[91],"2009-04","2007-08",[1566,938],"Neoplasms",[1551,1568],"Morphine",{"trials":1570,"activeCount":128},[],{"trials":1572,"activeCount":676,"soonestReadout":1577},[1573],{"nctId":1574,"briefTitle":1575,"status":265,"phases":1576,"primaryCompletion":1577,"completion":1577,"start":1578,"enrollment":1579,"conditions":1580,"interventions":1581},"NCT06525740","Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery",[93],"2029-09-01","2024-09-03",140,[1258],[1260,1551],{"trials":1583,"activeCount":128},[],{"intervention":1585,"totalTrials":676,"cells":1586},"semaglutide or tirzepatide",{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1593,"PHASE4":1595,"NA":1606},{"trials":1588,"activeCount":128},[],{"trials":1590,"activeCount":128},[],{"trials":1592,"activeCount":128},[],{"trials":1594,"activeCount":128},[],{"trials":1596,"activeCount":676,"soonestReadout":171},[1597],{"nctId":1598,"briefTitle":1599,"status":692,"phases":1600,"primaryCompletion":171,"completion":1601,"start":1602,"enrollment":729,"conditions":1603,"interventions":1605},"NCT07057310","Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women",[93],"2027-03-31","2025-05-01",[15,1604],"Menopause",[1585],{"trials":1607,"activeCount":128},[],{"intervention":1609,"totalTrials":676,"cells":1610},"Itraconazole 200 mg",{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1615,"PHASE3":1617,"PHASE4":1619,"NA":1631},{"trials":1612,"activeCount":128},[],{"trials":1614,"activeCount":128},[],{"trials":1616,"activeCount":128},[],{"trials":1618,"activeCount":128},[],{"trials":1620,"activeCount":676,"soonestReadout":1625},[1621],{"nctId":1622,"briefTitle":1623,"status":265,"phases":1624,"primaryCompletion":1625,"completion":1625,"start":1626,"enrollment":729,"conditions":1627,"interventions":1630},"NCT07283497","Itraconazole Therapy In Bronchiectasis With Airway Mold",[93],"2030-12-31","2026-06-20",[1628,1629],"Bronchiectasis","Fungal Infection of Upper Respiratory Tract",[1609],{"trials":1632,"activeCount":128},[],{"intervention":1634,"totalTrials":676,"cells":1635},"18-F-Flortaucipir",{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1640,"PHASE3":1642,"PHASE4":1644,"NA":1656},{"trials":1637,"activeCount":128},[],{"trials":1639,"activeCount":128},[],{"trials":1641,"activeCount":128},[],{"trials":1643,"activeCount":128},[],{"trials":1645,"activeCount":676,"soonestReadout":1650},[1646],{"nctId":1647,"briefTitle":1648,"status":265,"phases":1649,"primaryCompletion":1650,"completion":1650,"start":1651,"enrollment":1652,"conditions":1653,"interventions":1655},"NCT03821857","Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease",[93],"2030-05","2019-06-27",614,[1654],"Alzheimer Disease",[1634],{"trials":1657,"activeCount":128},[],{"intervention":1050,"totalTrials":676,"cells":1659},{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1666,"PHASE4":1668,"NA":1674},{"trials":1661,"activeCount":128},[],{"trials":1663,"activeCount":128},[],{"trials":1665,"activeCount":128},[],{"trials":1667,"activeCount":128},[],{"trials":1669,"activeCount":676,"soonestReadout":994},[1670],{"nctId":1042,"briefTitle":1043,"status":265,"phases":1671,"primaryCompletion":994,"completion":995,"start":1045,"enrollment":1046,"conditions":1672,"interventions":1673},[93],[1048],[1029,1050],{"trials":1675,"activeCount":128},[],{"intervention":1677,"totalTrials":676,"cells":1678},"Mycophenolate Mofetil (MMF) Maintenance Group",{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1683,"PHASE3":1685,"PHASE4":1687,"NA":1701},{"trials":1680,"activeCount":128},[],{"trials":1682,"activeCount":128},[],{"trials":1684,"activeCount":128},[],{"trials":1686,"activeCount":128},[],{"trials":1688,"activeCount":676,"soonestReadout":1625},[1689],{"nctId":1690,"briefTitle":1691,"status":265,"phases":1692,"primaryCompletion":1625,"completion":1693,"start":1694,"enrollment":1695,"conditions":1696,"interventions":1699},"NCT06568549","Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®\u002FTRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.",[93],"2031-03-31","2025-06-13",350,[1697,1698],"Kidney Transplantation","Mycophenolate Mofetil",[1677,1700],"Mycophenolate Mofetil (MMF) Withdrawal Group",{"trials":1702,"activeCount":128},[],{"intervention":1700,"totalTrials":676,"cells":1704},{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1711,"PHASE4":1713,"NA":1719},{"trials":1706,"activeCount":128},[],{"trials":1708,"activeCount":128},[],{"trials":1710,"activeCount":128},[],{"trials":1712,"activeCount":128},[],{"trials":1714,"activeCount":676,"soonestReadout":1625},[1715],{"nctId":1690,"briefTitle":1691,"status":265,"phases":1716,"primaryCompletion":1625,"completion":1693,"start":1694,"enrollment":1695,"conditions":1717,"interventions":1718},[93],[1697,1698],[1677,1700],{"trials":1720,"activeCount":128},[],{"intervention":1722,"totalTrials":676,"cells":1723},"Vortioxetine",{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1730,"PHASE4":1732,"NA":1745},{"trials":1725,"activeCount":128},[],{"trials":1727,"activeCount":128},[],{"trials":1729,"activeCount":128},[],{"trials":1731,"activeCount":128},[],{"trials":1733,"activeCount":676,"soonestReadout":1738},[1734],{"nctId":1735,"briefTitle":1736,"status":265,"phases":1737,"primaryCompletion":1738,"completion":1625,"start":1739,"enrollment":785,"conditions":1740,"interventions":1742},"NCT07266545","RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)",[93],"2028-12-31","2026-02-17",[1741,851],"Unipolar Depression",[1722,1743,1744],"Bupropion extended release","Cariprazine",{"trials":1746,"activeCount":128},[],{"intervention":1743,"totalTrials":676,"cells":1748},{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1755,"PHASE4":1757,"NA":1763},{"trials":1750,"activeCount":128},[],{"trials":1752,"activeCount":128},[],{"trials":1754,"activeCount":128},[],{"trials":1756,"activeCount":128},[],{"trials":1758,"activeCount":676,"soonestReadout":1738},[1759],{"nctId":1735,"briefTitle":1736,"status":265,"phases":1760,"primaryCompletion":1738,"completion":1625,"start":1739,"enrollment":785,"conditions":1761,"interventions":1762},[93],[1741,851],[1722,1743,1744],{"trials":1764,"activeCount":128},[],{"intervention":1744,"totalTrials":676,"cells":1766},{"EARLY_PHASE1":1767,"PHASE1":1769,"PHASE2":1771,"PHASE3":1773,"PHASE4":1775,"NA":1781},{"trials":1768,"activeCount":128},[],{"trials":1770,"activeCount":128},[],{"trials":1772,"activeCount":128},[],{"trials":1774,"activeCount":128},[],{"trials":1776,"activeCount":676,"soonestReadout":1738},[1777],{"nctId":1735,"briefTitle":1736,"status":265,"phases":1778,"primaryCompletion":1738,"completion":1625,"start":1739,"enrollment":785,"conditions":1779,"interventions":1780},[93],[1741,851],[1722,1743,1744],{"trials":1782,"activeCount":128},[],{"intervention":1001,"totalTrials":676,"cells":1784},{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1789,"PHASE3":1791,"PHASE4":1793,"NA":1799},{"trials":1786,"activeCount":128},[],{"trials":1788,"activeCount":128},[],{"trials":1790,"activeCount":128},[],{"trials":1792,"activeCount":128},[],{"trials":1794,"activeCount":676,"soonestReadout":994},[1795],{"nctId":991,"briefTitle":992,"status":692,"phases":1796,"primaryCompletion":994,"completion":995,"start":996,"enrollment":997,"conditions":1797,"interventions":1798},[93],[999],[961,1001],{"trials":1800,"activeCount":128},[],{"intervention":1802,"totalTrials":676,"cells":1803},"Uroselective alpha-1-adrenergic receptor antagonist",{"EARLY_PHASE1":1804,"PHASE1":1806,"PHASE2":1808,"PHASE3":1810,"PHASE4":1812,"NA":1823},{"trials":1805,"activeCount":128},[],{"trials":1807,"activeCount":128},[],{"trials":1809,"activeCount":128},[],{"trials":1811,"activeCount":128},[],{"trials":1813,"activeCount":676,"soonestReadout":1818},[1814],{"nctId":1815,"briefTitle":1816,"status":265,"phases":1817,"primaryCompletion":1818,"completion":1738,"start":1819,"enrollment":173,"conditions":1820,"interventions":1822},"NCT07174349","Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery",[93],"2027-01-31","2026-04-10",[1821],"Urinary Retention Postoperative",[1802],{"trials":1824,"activeCount":128},[],{"intervention":1826,"totalTrials":676,"cells":1827},"Ketamine Infustion",{"EARLY_PHASE1":1828,"PHASE1":1830,"PHASE2":1832,"PHASE3":1834,"PHASE4":1836,"NA":1846},{"trials":1829,"activeCount":128},[],{"trials":1831,"activeCount":128},[],{"trials":1833,"activeCount":128},[],{"trials":1835,"activeCount":128},[],{"trials":1837,"activeCount":676,"soonestReadout":761},[1838],{"nctId":1839,"briefTitle":1840,"status":692,"phases":1841,"primaryCompletion":761,"completion":761,"start":1842,"enrollment":712,"conditions":1843,"interventions":1845},"NCT04933149","Ketamine Infusion for Neuropathic Pain in Brachial Plexus Injuries",[93],"2021-12-15",[1844],"Brachial Plexus Injury",[1826],{"trials":1847,"activeCount":128},[],{"intervention":1849,"totalTrials":676,"cells":1850},"Dextrose",{"EARLY_PHASE1":1851,"PHASE1":1853,"PHASE2":1855,"PHASE3":1857,"PHASE4":1859,"NA":1871},{"trials":1852,"activeCount":128},[],{"trials":1854,"activeCount":128},[],{"trials":1856,"activeCount":128},[],{"trials":1858,"activeCount":128},[],{"trials":1860,"activeCount":676,"soonestReadout":1865},[1861],{"nctId":1862,"briefTitle":1863,"status":169,"phases":1864,"primaryCompletion":1865,"completion":171,"start":1866,"enrollment":729,"conditions":1867,"interventions":1869},"NCT05264727","Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion",[93],"2025-12-31","2023-05-30",[18,1868,15],"Type 2 Diabetes",[1849,1870],"Clinisol 15%",{"trials":1872,"activeCount":128},[],{"intervention":1870,"totalTrials":676,"cells":1874},{"EARLY_PHASE1":1875,"PHASE1":1877,"PHASE2":1879,"PHASE3":1881,"PHASE4":1883,"NA":1889},{"trials":1876,"activeCount":128},[],{"trials":1878,"activeCount":128},[],{"trials":1880,"activeCount":128},[],{"trials":1882,"activeCount":128},[],{"trials":1884,"activeCount":676,"soonestReadout":1865},[1885],{"nctId":1862,"briefTitle":1863,"status":169,"phases":1886,"primaryCompletion":1865,"completion":171,"start":1866,"enrollment":729,"conditions":1887,"interventions":1888},[93],[18,1868,15],[1849,1870],{"trials":1890,"activeCount":128},[],{"intervention":1892,"totalTrials":676,"cells":1893},"Xylocaine",{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1898,"PHASE3":1900,"PHASE4":1902,"NA":1914},{"trials":1895,"activeCount":128},[],{"trials":1897,"activeCount":128},[],{"trials":1899,"activeCount":128},[],{"trials":1901,"activeCount":128},[],{"trials":1903,"activeCount":676,"soonestReadout":694},[1904],{"nctId":1905,"briefTitle":1906,"status":265,"phases":1907,"primaryCompletion":694,"completion":1908,"start":1909,"enrollment":25,"conditions":1910,"interventions":1912},"NCT05285566","Pain Control for Undergoing Costal Cartilage Harvesting",[93],"2026-09","2022-05-04",[1911],"Nasal Surgery",[1913,1892],"Exparel",{"trials":1915,"activeCount":128},[],{"intervention":1917,"totalTrials":676,"cells":1918},"Atogepant 60 mg",{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1925,"PHASE4":1927,"NA":1942},{"trials":1920,"activeCount":128},[],{"trials":1922,"activeCount":128},[],{"trials":1924,"activeCount":128},[],{"trials":1926,"activeCount":128},[],{"trials":1928,"activeCount":676,"soonestReadout":1933},[1929],{"nctId":1930,"briefTitle":1931,"status":265,"phases":1932,"primaryCompletion":1933,"completion":1934,"start":1935,"enrollment":1936,"conditions":1937,"interventions":1939},"NCT06972056","Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study",[93],"2029-03-01","2029-12-01","2025-07-09",1335,[1938],"Migraine",[1917,1940,1941],"Propranolol 160 mg","Topiramate 100 mg",{"trials":1943,"activeCount":128},[],{"intervention":1940,"totalTrials":676,"cells":1945},{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1950,"PHASE3":1952,"PHASE4":1954,"NA":1960},{"trials":1947,"activeCount":128},[],{"trials":1949,"activeCount":128},[],{"trials":1951,"activeCount":128},[],{"trials":1953,"activeCount":128},[],{"trials":1955,"activeCount":676,"soonestReadout":1933},[1956],{"nctId":1930,"briefTitle":1931,"status":265,"phases":1957,"primaryCompletion":1933,"completion":1934,"start":1935,"enrollment":1936,"conditions":1958,"interventions":1959},[93],[1938],[1917,1940,1941],{"trials":1961,"activeCount":128},[],{"intervention":1941,"totalTrials":676,"cells":1963},{"EARLY_PHASE1":1964,"PHASE1":1966,"PHASE2":1968,"PHASE3":1970,"PHASE4":1972,"NA":1978},{"trials":1965,"activeCount":128},[],{"trials":1967,"activeCount":128},[],{"trials":1969,"activeCount":128},[],{"trials":1971,"activeCount":128},[],{"trials":1973,"activeCount":676,"soonestReadout":1933},[1974],{"nctId":1930,"briefTitle":1931,"status":265,"phases":1975,"primaryCompletion":1933,"completion":1934,"start":1935,"enrollment":1936,"conditions":1976,"interventions":1977},[93],[1938],[1917,1940,1941],{"trials":1979,"activeCount":128},[],{"intervention":1981,"totalTrials":676,"cells":1982},"I-123 Ioflupane solution injection prior to SPECT scan",{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1989,"PHASE4":1991,"NA":2004},{"trials":1984,"activeCount":128},[],{"trials":1986,"activeCount":128},[],{"trials":1988,"activeCount":128},[],{"trials":1990,"activeCount":128},[],{"trials":1992,"activeCount":676,"soonestReadout":761},[1993],{"nctId":1994,"briefTitle":1995,"status":692,"phases":1996,"primaryCompletion":761,"completion":761,"start":1020,"enrollment":1997,"conditions":1998,"interventions":2003},"NCT01453127","DaTSCAN Imaging in Aging and Neurodegenerative Disease",[93],500,[1999,2000,2001,2002],"Dementia","Parkinsonism","Mild Cognitive Impairment","REM Sleep Behavior Disorder",[1981],{"trials":2005,"activeCount":128},[],{"intervention":2007,"totalTrials":676,"cells":2008},"Netarsudil 0.02%\u002Flatanoprost 0.005% fixed dose combination ophthalmic solution",{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2017,"NA":2031},{"trials":2010,"activeCount":128},[],{"trials":2012,"activeCount":128},[],{"trials":2014,"activeCount":128},[],{"trials":2016,"activeCount":128},[],{"trials":2018,"activeCount":676,"soonestReadout":2023},[2019],{"nctId":2020,"briefTitle":2021,"status":265,"phases":2022,"primaryCompletion":2023,"completion":2024,"start":2025,"enrollment":729,"conditions":2026,"interventions":2029},"NCT07325240","24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients",[93],"2027-07","2027-10","2025-11-21",[2027,2028],"Open Angle Glaucoma","Ocular Hypertension",[2007,2030],"Latanoprost 0.005% Ophthalmic Solution",{"trials":2032,"activeCount":128},[],{"intervention":2030,"totalTrials":676,"cells":2034},{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2039,"PHASE3":2041,"PHASE4":2043,"NA":2049},{"trials":2036,"activeCount":128},[],{"trials":2038,"activeCount":128},[],{"trials":2040,"activeCount":128},[],{"trials":2042,"activeCount":128},[],{"trials":2044,"activeCount":676,"soonestReadout":2023},[2045],{"nctId":2020,"briefTitle":2021,"status":265,"phases":2046,"primaryCompletion":2023,"completion":2024,"start":2025,"enrollment":729,"conditions":2047,"interventions":2048},[93],[2027,2028],[2007,2030],{"trials":2050,"activeCount":128},[],{"intervention":2052,"totalTrials":676,"cells":2053},"Methadone,",{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2058,"PHASE3":2060,"PHASE4":2062,"NA":2074},{"trials":2055,"activeCount":128},[],{"trials":2057,"activeCount":128},[],{"trials":2059,"activeCount":128},[],{"trials":2061,"activeCount":128},[],{"trials":2063,"activeCount":676,"soonestReadout":2068},[2064],{"nctId":2065,"briefTitle":2066,"status":265,"phases":2067,"primaryCompletion":2068,"completion":694,"start":2069,"enrollment":712,"conditions":2070,"interventions":2072},"NCT07221617","Oral Methadone in Cardiac Surgery",[93],"2026-06-30","2026-01-13",[799,2071,925],"Anesthesia",[2052,2073],"Methadone, intravenously",{"trials":2075,"activeCount":128},[],{"intervention":2073,"totalTrials":676,"cells":2077},{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2084,"PHASE4":2086,"NA":2092},{"trials":2079,"activeCount":128},[],{"trials":2081,"activeCount":128},[],{"trials":2083,"activeCount":128},[],{"trials":2085,"activeCount":128},[],{"trials":2087,"activeCount":676,"soonestReadout":2068},[2088],{"nctId":2065,"briefTitle":2066,"status":265,"phases":2089,"primaryCompletion":2068,"completion":694,"start":2069,"enrollment":712,"conditions":2090,"interventions":2091},[93],[799,2071,925],[2052,2073],{"trials":2093,"activeCount":128},[],{"intervention":2095,"totalTrials":676,"cells":2096},"Sodium bicarbonate",{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2103,"PHASE4":2105,"NA":2118},{"trials":2098,"activeCount":128},[],{"trials":2100,"activeCount":128},[],{"trials":2102,"activeCount":128},[],{"trials":2104,"activeCount":128},[],{"trials":2106,"activeCount":676,"soonestReadout":2111},[2107],{"nctId":2108,"briefTitle":2109,"status":1096,"phases":2110,"primaryCompletion":2111,"completion":1328,"start":2112,"enrollment":2113,"conditions":2114,"interventions":2116},"NCT07424625","A Study of Tris-Hydroxymethyl Aminomethane (THAM) Versus Sodium Bicarbonate in Cardiac Surgical Patients",[93],"2027-02","2026-05",250,[2115],"Metabolic Acidosis",[2095,2117],"Tris-hydroxymethyl Aminomethane",{"trials":2119,"activeCount":128},[],{"intervention":2117,"totalTrials":676,"cells":2121},{"EARLY_PHASE1":2122,"PHASE1":2124,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2136},{"trials":2123,"activeCount":128},[],{"trials":2125,"activeCount":128},[],{"trials":2127,"activeCount":128},[],{"trials":2129,"activeCount":128},[],{"trials":2131,"activeCount":676,"soonestReadout":2111},[2132],{"nctId":2108,"briefTitle":2109,"status":1096,"phases":2133,"primaryCompletion":2111,"completion":1328,"start":2112,"enrollment":2113,"conditions":2134,"interventions":2135},[93],[2115],[2095,2117],{"trials":2137,"activeCount":128},[],{"intervention":722,"totalTrials":676,"cells":2139},{"EARLY_PHASE1":2140,"PHASE1":2142,"PHASE2":2144,"PHASE3":2146,"PHASE4":2148,"NA":2154},{"trials":2141,"activeCount":128},[],{"trials":2143,"activeCount":128},[],{"trials":2145,"activeCount":128},[],{"trials":2147,"activeCount":128},[],{"trials":2149,"activeCount":676,"soonestReadout":709},[2150],{"nctId":706,"briefTitle":707,"status":265,"phases":2151,"primaryCompletion":709,"completion":710,"start":711,"enrollment":712,"conditions":2152,"interventions":2153},[93],[714,715,716,15,717,718],[720,721,722],{"trials":2155,"activeCount":128},[],{"intervention":1012,"totalTrials":676,"cells":2157},{"EARLY_PHASE1":2158,"PHASE1":2160,"PHASE2":2162,"PHASE3":2164,"PHASE4":2166,"NA":2172},{"trials":2159,"activeCount":128},[],{"trials":2161,"activeCount":128},[],{"trials":2163,"activeCount":128},[],{"trials":2165,"activeCount":128},[],{"trials":2167,"activeCount":676,"soonestReadout":1006},[2168],{"nctId":1003,"briefTitle":1004,"status":265,"phases":2169,"primaryCompletion":1006,"completion":760,"start":1007,"enrollment":1008,"conditions":2170,"interventions":2171},[93],[1010],[961,1012,1013,1014,1015],{"trials":2173,"activeCount":128},[],{"intervention":1015,"totalTrials":676,"cells":2175},{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2182,"PHASE4":2184,"NA":2190},{"trials":2177,"activeCount":128},[],{"trials":2179,"activeCount":128},[],{"trials":2181,"activeCount":128},[],{"trials":2183,"activeCount":128},[],{"trials":2185,"activeCount":676,"soonestReadout":1006},[2186],{"nctId":1003,"briefTitle":1004,"status":265,"phases":2187,"primaryCompletion":1006,"completion":760,"start":1007,"enrollment":1008,"conditions":2188,"interventions":2189},[93],[1010],[961,1012,1013,1014,1015],{"trials":2191,"activeCount":128},[],{"intervention":2193,"totalTrials":676,"cells":2194},"Low Sodium Oxybate",{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2199,"PHASE3":2201,"PHASE4":2203,"NA":2214},{"trials":2196,"activeCount":128},[],{"trials":2198,"activeCount":128},[],{"trials":2200,"activeCount":128},[],{"trials":2202,"activeCount":128},[],{"trials":2204,"activeCount":676,"soonestReadout":2209},[2205],{"nctId":2206,"briefTitle":2207,"status":265,"phases":2208,"primaryCompletion":2209,"completion":1389,"start":2210,"enrollment":729,"conditions":2211,"interventions":2213},"NCT05837091","Low Sodium Oxybate in Patients With Idiopathic Hypersomnia",[93],"2027-01-29","2024-02-14",[2212],"Idiopathic Hypersomnia",[2193],{"trials":2215,"activeCount":128},[],{"intervention":2217,"totalTrials":676,"cells":2218},"Zavegepant",{"EARLY_PHASE1":2219,"PHASE1":2221,"PHASE2":2223,"PHASE3":2225,"PHASE4":2227,"NA":2237},{"trials":2220,"activeCount":128},[],{"trials":2222,"activeCount":128},[],{"trials":2224,"activeCount":128},[],{"trials":2226,"activeCount":128},[],{"trials":2228,"activeCount":676,"soonestReadout":2233},[2229],{"nctId":2230,"briefTitle":2231,"status":265,"phases":2232,"primaryCompletion":2233,"completion":2233,"start":2234,"enrollment":923,"conditions":2235,"interventions":2236},"NCT06401642","Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications",[93],"2027-03","2024-03-22",[1938],[2217],{"trials":2238,"activeCount":128},[],{"intervention":2240,"totalTrials":676,"cells":2241},"Bimekizumab",{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2246,"PHASE3":2248,"PHASE4":2250,"NA":2260},{"trials":2243,"activeCount":128},[],{"trials":2245,"activeCount":128},[],{"trials":2247,"activeCount":128},[],{"trials":2249,"activeCount":128},[],{"trials":2251,"activeCount":676,"soonestReadout":2256},[2252],{"nctId":2253,"briefTitle":2254,"status":1096,"phases":2255,"primaryCompletion":2256,"completion":1149,"start":1448,"enrollment":218,"conditions":2257,"interventions":2259},"NCT07497620","Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP",[93],"2027-08-01",[2258],"Pityriasis Rubra Pilaris",[2240],{"trials":2261,"activeCount":128},[],{"intervention":2263,"totalTrials":676,"cells":2264},"AV-1451",{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2271,"PHASE4":2273,"NA":2284},{"trials":2266,"activeCount":128},[],{"trials":2268,"activeCount":128},[],{"trials":2270,"activeCount":128},[],{"trials":2272,"activeCount":128},[],{"trials":2274,"activeCount":676,"soonestReadout":2279},[2275],{"nctId":2276,"briefTitle":2277,"status":265,"phases":2278,"primaryCompletion":2279,"completion":2279,"start":2280,"enrollment":773,"conditions":2281,"interventions":2283},"NCT01818661","Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech",[93],"2028-06","2018-07-01",[1360,1363,1365,2282,1361],"Primary Progressive Non-fluent Aphasia",[2263],{"trials":2285,"activeCount":128},[],{"intervention":2287,"totalTrials":676,"cells":2288},"Oral Tranexamic Acid",{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2295,"PHASE4":2297,"NA":2308},{"trials":2290,"activeCount":128},[],{"trials":2292,"activeCount":128},[],{"trials":2294,"activeCount":128},[],{"trials":2296,"activeCount":128},[],{"trials":2298,"activeCount":676,"soonestReadout":921},[2299],{"nctId":2300,"briefTitle":2301,"status":1096,"phases":2302,"primaryCompletion":921,"completion":921,"start":2303,"enrollment":2304,"conditions":2305,"interventions":2307},"NCT06832878","Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty",[93],"2026-06-01",101,[2306],"Arthroplasty",[2287],{"trials":2309,"activeCount":128},[],{"intervention":1068,"totalTrials":676,"cells":2311},{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2318,"PHASE4":2320,"NA":2326},{"trials":2313,"activeCount":128},[],{"trials":2315,"activeCount":128},[],{"trials":2317,"activeCount":128},[],{"trials":2319,"activeCount":128},[],{"trials":2321,"activeCount":676,"soonestReadout":921},[2322],{"nctId":1052,"briefTitle":1053,"status":692,"phases":2323,"primaryCompletion":921,"completion":921,"start":1055,"enrollment":1056,"conditions":2324,"interventions":2325},[93],[1058,1059,1060,1061,1062,1063,1064,1065,1066],[1068,1029,1069],{"trials":2327,"activeCount":128},[],{"intervention":1069,"totalTrials":676,"cells":2329},{"EARLY_PHASE1":2330,"PHASE1":2332,"PHASE2":2334,"PHASE3":2336,"PHASE4":2338,"NA":2344},{"trials":2331,"activeCount":128},[],{"trials":2333,"activeCount":128},[],{"trials":2335,"activeCount":128},[],{"trials":2337,"activeCount":128},[],{"trials":2339,"activeCount":676,"soonestReadout":921},[2340],{"nctId":1052,"briefTitle":1053,"status":692,"phases":2341,"primaryCompletion":921,"completion":921,"start":1055,"enrollment":1056,"conditions":2342,"interventions":2343},[93],[1058,1059,1060,1061,1062,1063,1064,1065,1066],[1068,1029,1069],{"trials":2345,"activeCount":128},[],{"intervention":2347,"totalTrials":676,"cells":2348},"meta-iodobenzylguanidine",{"EARLY_PHASE1":2349,"PHASE1":2351,"PHASE2":2353,"PHASE3":2355,"PHASE4":2357,"NA":2367},{"trials":2350,"activeCount":128},[],{"trials":2352,"activeCount":128},[],{"trials":2354,"activeCount":128},[],{"trials":2356,"activeCount":128},[],{"trials":2358,"activeCount":676,"soonestReadout":1908},[2359],{"nctId":2360,"briefTitle":2361,"status":692,"phases":2362,"primaryCompletion":1908,"completion":1908,"start":2363,"enrollment":773,"conditions":2364,"interventions":2366},"NCT05514106","MIBG in Aging and Neurologic Disorders",[93],"2023-05-08",[2365,1999,2000,2001,2002],"Lewy Body Disease",[2347],{"trials":2368,"activeCount":128},[],{"intervention":2370,"totalTrials":676,"cells":2371},"Dexamethasone IV",{"EARLY_PHASE1":2372,"PHASE1":2374,"PHASE2":2376,"PHASE3":2378,"PHASE4":2380,"NA":2393},{"trials":2373,"activeCount":128},[],{"trials":2375,"activeCount":128},[],{"trials":2377,"activeCount":128},[],{"trials":2379,"activeCount":128},[],{"trials":2381,"activeCount":676,"soonestReadout":1148},[2382],{"nctId":2383,"briefTitle":2384,"status":692,"phases":2385,"primaryCompletion":1148,"completion":1148,"start":2386,"enrollment":2387,"conditions":2388,"interventions":2390},"NCT06715709","How Many Dexamethasone Doses Should Be Given Perioperatively?",[93],"2025-03-25",339,[2389],"Arthropathy of Knee",[2370,2391,2392],"Dexamethasone IV+Oral","Dexamethasone IV+Oral 2 Day",{"trials":2394,"activeCount":128},[],{"intervention":2391,"totalTrials":676,"cells":2396},{"EARLY_PHASE1":2397,"PHASE1":2399,"PHASE2":2401,"PHASE3":2403,"PHASE4":2405,"NA":2411},{"trials":2398,"activeCount":128},[],{"trials":2400,"activeCount":128},[],{"trials":2402,"activeCount":128},[],{"trials":2404,"activeCount":128},[],{"trials":2406,"activeCount":676,"soonestReadout":1148},[2407],{"nctId":2383,"briefTitle":2384,"status":692,"phases":2408,"primaryCompletion":1148,"completion":1148,"start":2386,"enrollment":2387,"conditions":2409,"interventions":2410},[93],[2389],[2370,2391,2392],{"trials":2412,"activeCount":128},[],{"intervention":2392,"totalTrials":676,"cells":2414},{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2419,"PHASE3":2421,"PHASE4":2423,"NA":2429},{"trials":2416,"activeCount":128},[],{"trials":2418,"activeCount":128},[],{"trials":2420,"activeCount":128},[],{"trials":2422,"activeCount":128},[],{"trials":2424,"activeCount":676,"soonestReadout":1148},[2425],{"nctId":2383,"briefTitle":2384,"status":692,"phases":2426,"primaryCompletion":1148,"completion":1148,"start":2386,"enrollment":2387,"conditions":2427,"interventions":2428},[93],[2389],[2370,2391,2392],{"trials":2430,"activeCount":128},[],{"intervention":2432,"totalTrials":676,"cells":2433},"Triamcinolone Acetonide Low Dose",{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2438,"PHASE3":2440,"PHASE4":2442,"NA":2454},{"trials":2435,"activeCount":128},[],{"trials":2437,"activeCount":128},[],{"trials":2439,"activeCount":128},[],{"trials":2441,"activeCount":128},[],{"trials":2443,"activeCount":676,"soonestReadout":2448},[2444],{"nctId":2445,"briefTitle":2446,"status":265,"phases":2447,"primaryCompletion":2448,"completion":2448,"start":2449,"enrollment":498,"conditions":2450,"interventions":2452},"NCT06782529","Knee Injections for Obese Patients With Knee Arthritis",[93],"2027-01-24","2025-01-24",[2451],"Osteoarthritis of Knee",[2432,2453],"Triamcinolone Acetonide Standard Dose",{"trials":2455,"activeCount":128},[],{"intervention":2453,"totalTrials":676,"cells":2457},{"EARLY_PHASE1":2458,"PHASE1":2460,"PHASE2":2462,"PHASE3":2464,"PHASE4":2466,"NA":2472},{"trials":2459,"activeCount":128},[],{"trials":2461,"activeCount":128},[],{"trials":2463,"activeCount":128},[],{"trials":2465,"activeCount":128},[],{"trials":2467,"activeCount":676,"soonestReadout":2448},[2468],{"nctId":2445,"briefTitle":2446,"status":265,"phases":2469,"primaryCompletion":2448,"completion":2448,"start":2449,"enrollment":498,"conditions":2470,"interventions":2471},[93],[2451],[2432,2453],{"trials":2473,"activeCount":128},[],{"intervention":2475,"totalTrials":676,"cells":2476},"Mavyret",{"EARLY_PHASE1":2477,"PHASE1":2479,"PHASE2":2481,"PHASE3":2483,"PHASE4":2485,"NA":2498},{"trials":2478,"activeCount":128},[],{"trials":2480,"activeCount":128},[],{"trials":2482,"activeCount":128},[],{"trials":2484,"activeCount":128},[],{"trials":2486,"activeCount":676,"soonestReadout":2491},[2487],{"nctId":2488,"briefTitle":2489,"status":169,"phases":2490,"primaryCompletion":2491,"completion":815,"start":2492,"enrollment":923,"conditions":2493,"interventions":2497},"NCT04508907","A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients",[93],"2025-11-01","2020-09-10",[2494,2495,2496],"Hepatitis C","Kidney Transplant; Complications","Heart Transplant Infection",[2475],{"trials":2499,"activeCount":128},[],{"intervention":1397,"totalTrials":676,"cells":2501},{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2506,"PHASE3":2508,"PHASE4":2510,"NA":2516},{"trials":2503,"activeCount":128},[],{"trials":2505,"activeCount":128},[],{"trials":2507,"activeCount":128},[],{"trials":2509,"activeCount":128},[],{"trials":2511,"activeCount":676,"soonestReadout":1389},[2512],{"nctId":1386,"briefTitle":1387,"status":692,"phases":2513,"primaryCompletion":1389,"completion":1389,"start":1390,"enrollment":1391,"conditions":2514,"interventions":2515},[93],[1377,1393,1394,1395],[1397,1346,1398],{"trials":2517,"activeCount":128},[],{"intervention":1398,"totalTrials":676,"cells":2519},{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2526,"PHASE4":2528,"NA":2534},{"trials":2521,"activeCount":128},[],{"trials":2523,"activeCount":128},[],{"trials":2525,"activeCount":128},[],{"trials":2527,"activeCount":128},[],{"trials":2529,"activeCount":676,"soonestReadout":1389},[2530],{"nctId":1386,"briefTitle":1387,"status":692,"phases":2531,"primaryCompletion":1389,"completion":1389,"start":1390,"enrollment":1391,"conditions":2532,"interventions":2533},[93],[1377,1393,1394,1395],[1397,1346,1398],{"trials":2535,"activeCount":128},[],{"intervention":2537,"totalTrials":676,"cells":2538},"Secretin (human synthetic) - ChiRhoClin",{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2543,"PHASE3":2545,"PHASE4":2547,"NA":2560},{"trials":2540,"activeCount":128},[],{"trials":2542,"activeCount":128},[],{"trials":2544,"activeCount":128},[],{"trials":2546,"activeCount":128},[],{"trials":2548,"activeCount":676,"soonestReadout":2233},[2549],{"nctId":2550,"briefTitle":2551,"status":265,"phases":2552,"primaryCompletion":2233,"completion":2553,"start":2554,"enrollment":2555,"conditions":2556,"interventions":2559},"NCT07285863","A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects",[93],"2028-03","2026-03-11",24,[2557,2558],"Exocrine Pancreatic Insufficiency","Chronic Pancreatitis",[2537],{"trials":2561,"activeCount":128},[],{"intervention":790,"totalTrials":2563,"cells":2564},8,{"EARLY_PHASE1":2565,"PHASE1":2567,"PHASE2":2587,"PHASE3":2589,"PHASE4":2600,"NA":2636},{"trials":2566,"activeCount":128},[],{"trials":2568,"activeCount":128},[2569,2578],{"nctId":2570,"briefTitle":2571,"status":104,"phases":2572,"primaryCompletion":905,"completion":905,"start":2573,"enrollment":31,"conditions":2574,"interventions":2576},"NCT02158039","Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms",[90],"2004-06",[2575],"Neoplasms, Cystic, Mucinous, and Serous",[2577,790],"Ethanol",{"nctId":2579,"briefTitle":2580,"status":1413,"phases":2581,"primaryCompletion":872,"completion":872,"start":872,"enrollment":128,"conditions":2582,"interventions":2584},"NCT02684786","A Study of Stellate Ganglion Block and \u002F or Reserpine in Group 2 Pulmonary Hypertension",[90],[2583],"Pulmonary Artery Hypertension",[2585,2586],"reserpine","lidocaine",{"trials":2588,"activeCount":128},[],{"trials":2590,"activeCount":128},[2591],{"nctId":2592,"briefTitle":2593,"status":104,"phases":2594,"primaryCompletion":2595,"completion":2595,"start":2596,"enrollment":1225,"conditions":2597,"interventions":2599},"NCT04648891","Spasmodic Dysphonia Pain",[91,92],"2023-07-01","2021-08-01",[2598],"Spasmodic Dysphonia",[790],{"trials":2601,"activeCount":676,"soonestReadout":761},[2602,2612,2616,2628],{"nctId":2603,"briefTitle":2604,"status":104,"phases":2605,"primaryCompletion":2606,"completion":2606,"start":2607,"enrollment":2608,"conditions":2609,"interventions":2611},"NCT02623803","Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies",[93],"2018-02","2016-01",48,[2610],"Pancreatectomy",[790],{"nctId":780,"briefTitle":781,"status":104,"phases":2613,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":2614,"interventions":2615},[93],[787,788],[746,790,305,791],{"nctId":2617,"briefTitle":2618,"status":104,"phases":2619,"primaryCompletion":2620,"completion":2620,"start":2621,"enrollment":313,"conditions":2622,"interventions":2624},"NCT00915473","Greater Occipital Nerve Block for Migraine Prophylaxis",[93],"2013-01","2009-06",[2623],"Migraine Headache",[2625,2626,2627,2586],"bupivicaine","normal saline","methylprednisolone",{"nctId":2629,"briefTitle":2630,"status":265,"phases":2631,"primaryCompletion":761,"completion":761,"start":2632,"enrollment":173,"conditions":2633,"interventions":2635},"NCT06045936","A Study of Contralateral Limb Block",[93],"2024-06-18",[2634],"Limb Pain, Phantom",[790],{"trials":2637,"activeCount":128},[2638],{"nctId":2639,"briefTitle":2640,"status":104,"phases":2641,"primaryCompletion":2642,"completion":2642,"start":2643,"enrollment":2644,"conditions":2645,"interventions":2647},"NCT00587483","Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation",[94],"2010-01","2007-11",342,[2646],"Other Intraoperative Cardiac Functional Disturbances During Cardiac Surgery",[790,2648],"Amiodarone",{"intervention":1260,"totalTrials":895,"cells":2650},{"EARLY_PHASE1":2651,"PHASE1":2653,"PHASE2":2655,"PHASE3":2657,"PHASE4":2659,"NA":2691},{"trials":2652,"activeCount":128},[],{"trials":2654,"activeCount":128},[],{"trials":2656,"activeCount":128},[],{"trials":2658,"activeCount":128},[],{"trials":2660,"activeCount":676,"soonestReadout":1577},[2661,2673,2683,2687],{"nctId":2662,"briefTitle":2663,"status":104,"phases":2664,"primaryCompletion":2665,"completion":2666,"start":2667,"enrollment":2668,"conditions":2669,"interventions":2672},"NCT02009722","Intrathecal Opioids for Pain Control After Cesarean Delivery: Determining the Optimal Dose",[93],"2014-12","2015-04","2014-01",84,[2670,2671],"Analgesia, Obstetrical","Cesarean Section",[1568,1260],{"nctId":2674,"briefTitle":2675,"status":104,"phases":2676,"primaryCompletion":784,"completion":784,"start":2677,"enrollment":2678,"conditions":2679,"interventions":2682},"NCT04752033","Intrathecal Opioids for Colorectal Resection",[93],"2021-03-10",80,[2680,799,2681],"Colorectal Surgery","Analgesic, Opioid",[1568,1260],{"nctId":1574,"briefTitle":1575,"status":265,"phases":2684,"primaryCompletion":1577,"completion":1577,"start":1578,"enrollment":1579,"conditions":2685,"interventions":2686},[93],[1258],[1260,1551],{"nctId":1251,"briefTitle":1252,"status":104,"phases":2688,"primaryCompletion":1254,"completion":1254,"start":1255,"enrollment":1256,"conditions":2689,"interventions":2690},[93],[1258],[1260,1196],{"trials":2692,"activeCount":128},[2693],{"nctId":2694,"briefTitle":2695,"status":104,"phases":2696,"primaryCompletion":2697,"completion":2698,"start":1234,"enrollment":2699,"conditions":2700,"interventions":2702},"NCT02789410","Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery",[94],"2017-09","2018-03-15",134,[2670,2701],"Obstetric Surgical Procedures",[1568,1260],{"intervention":1013,"totalTrials":895,"cells":2704},{"EARLY_PHASE1":2705,"PHASE1":2707,"PHASE2":2709,"PHASE3":2711,"PHASE4":2713,"NA":2750},{"trials":2706,"activeCount":128},[],{"trials":2708,"activeCount":128},[],{"trials":2710,"activeCount":128},[],{"trials":2712,"activeCount":128},[],{"trials":2714,"activeCount":676,"soonestReadout":1006},[2715,2726,2737,2746],{"nctId":2716,"briefTitle":2717,"status":104,"phases":2718,"primaryCompletion":2719,"completion":2719,"start":796,"enrollment":2720,"conditions":2721,"interventions":2723},"NCT02351934","Early Diuresis Following Colorectal Surgery",[93],"2016-04",123,[2722],"Colorectal Disorders",[2724,2725,1013],"Furosemide","Celecoxib",{"nctId":2727,"briefTitle":2728,"status":104,"phases":2729,"primaryCompletion":2730,"completion":2730,"start":2731,"enrollment":797,"conditions":2732,"interventions":2734},"NCT03012815","Gabapentin for Alcohol Withdrawal Syndrome",[93],"2021-03-01","2017-02-01",[2733],"Alcohol Withdrawal Syndrome",[1013,2735,2736],"Benzodiazepines","Divalproex Sodium",{"nctId":2738,"briefTitle":2739,"status":104,"phases":2740,"primaryCompletion":2741,"completion":2741,"start":2665,"enrollment":2742,"conditions":2743,"interventions":2745},"NCT02330094","Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage",[93],"2017-09-01",16,[2744],"Aneurysmal Subarachnoid Hemorrhage",[1013],{"nctId":1003,"briefTitle":1004,"status":265,"phases":2747,"primaryCompletion":1006,"completion":760,"start":1007,"enrollment":1008,"conditions":2748,"interventions":2749},[93],[1010],[961,1012,1013,1014,1015],{"trials":2751,"activeCount":128},[2752],{"nctId":2753,"briefTitle":2754,"status":104,"phases":2755,"primaryCompletion":2756,"completion":2757,"start":2758,"enrollment":797,"conditions":2759,"interventions":2762},"NCT00667121","Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline",[],"2014-05-12","2014-05-27","2011-03-16",[21,876,2760,2761],"Hot Flashes","Psychosocial Effects of Cancer and Its Treatment",[2763,2764,2765,2766,2767,2768,2769],"citalopram hydrobromide","escitalopram oxalate","gabapentin","sertraline hydrochloride","tamoxifen citrate","venlafaxine","molecular genetic technique",{"intervention":2771,"totalTrials":342,"cells":2772},"Fentanyl",{"EARLY_PHASE1":2773,"PHASE1":2775,"PHASE2":2777,"PHASE3":2779,"PHASE4":2781,"NA":2805},{"trials":2774,"activeCount":128},[],{"trials":2776,"activeCount":128},[],{"trials":2778,"activeCount":128},[],{"trials":2780,"activeCount":128},[],{"trials":2782,"activeCount":676,"soonestReadout":2798},[2783,2794],{"nctId":2784,"briefTitle":2785,"status":134,"phases":2786,"primaryCompletion":945,"completion":945,"start":2787,"enrollment":301,"conditions":2788,"interventions":2792},"NCT01195103","Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery",[93],"2011-02",[2789,2790,2791],"Procedural Sedation","Regional Anesthesia Block","Orthopedic Surgery",[2793,2793,2771],"Fospropofol disodium",{"nctId":2795,"briefTitle":2796,"status":265,"phases":2797,"primaryCompletion":2798,"completion":2303,"start":2799,"enrollment":2800,"conditions":2801,"interventions":2804},"NCT05856136","A Study to Investigate of the Effects of Opioid Exposure on the Ability of the Diaphragm Muscle",[93],"2025-12-08","2023-06-19",69,[2802,2803],"Respiratory Function Loss","Respiratory Complication",[2771],{"trials":2806,"activeCount":128},[2807],{"nctId":2808,"briefTitle":2809,"status":104,"phases":2810,"primaryCompletion":2811,"completion":2811,"start":1375,"enrollment":817,"conditions":2812,"interventions":2813},"NCT02421341","Mechanisms of Altered Ventilatory Control in Heart Failure",[94],"2019-06-21",[27],[2771],{"intervention":911,"totalTrials":342,"cells":2815},{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2826,"PHASE4":2828,"NA":2834},{"trials":2817,"activeCount":128},[],{"trials":2819,"activeCount":128},[],{"trials":2821,"activeCount":128},[2822],{"nctId":901,"briefTitle":902,"status":104,"phases":2823,"primaryCompletion":904,"completion":904,"start":905,"enrollment":328,"conditions":2824,"interventions":2825},[91],[907,908,909],[839,911],{"trials":2827,"activeCount":128},[],{"trials":2829,"activeCount":676,"soonestReadout":920},[2830],{"nctId":917,"briefTitle":918,"status":169,"phases":2831,"primaryCompletion":920,"completion":921,"start":922,"enrollment":923,"conditions":2832,"interventions":2833},[93],[925],[839,911],{"trials":2835,"activeCount":128},[2836],{"nctId":942,"briefTitle":943,"status":104,"phases":2837,"primaryCompletion":945,"completion":945,"start":946,"enrollment":19,"conditions":2838,"interventions":2839},[94],[948],[911,839],{"intervention":1913,"totalTrials":224,"cells":2841},{"EARLY_PHASE1":2842,"PHASE1":2844,"PHASE2":2846,"PHASE3":2848,"PHASE4":2850,"NA":2856},{"trials":2843,"activeCount":128},[],{"trials":2845,"activeCount":128},[],{"trials":2847,"activeCount":128},[],{"trials":2849,"activeCount":128},[],{"trials":2851,"activeCount":676,"soonestReadout":694},[2852],{"nctId":1905,"briefTitle":1906,"status":265,"phases":2853,"primaryCompletion":694,"completion":1908,"start":1909,"enrollment":25,"conditions":2854,"interventions":2855},[93],[1911],[1913,1892],{"trials":2857,"activeCount":128},[2858],{"nctId":2859,"briefTitle":2860,"status":104,"phases":2861,"primaryCompletion":2862,"completion":2862,"start":2863,"enrollment":2864,"conditions":2865,"interventions":2867},"NCT02356198","Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery",[94],"2017-10","2015-03",209,[2866],"Conditions Requiring Colorectal Surgery",[2868,2869],"EXPAREL","Intrathecal hydromorphone",{"intervention":2871,"totalTrials":342,"cells":2872},"Dronabinol",{"EARLY_PHASE1":2873,"PHASE1":2875,"PHASE2":2877,"PHASE3":2887,"PHASE4":2905,"NA":2907},{"trials":2874,"activeCount":128},[],{"trials":2876,"activeCount":128},[],{"trials":2878,"activeCount":128},[2879],{"nctId":2880,"briefTitle":2881,"status":104,"phases":2882,"primaryCompletion":1021,"completion":1021,"start":2883,"enrollment":187,"conditions":2884,"interventions":2886},"NCT01253408","Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)",[91],"2009-09",[2885],"Irritable Bowel Syndrome",[2871],{"trials":2888,"activeCount":224,"soonestReadout":737},[2889,2898],{"nctId":2890,"briefTitle":2891,"status":1096,"phases":2892,"primaryCompletion":2893,"completion":2893,"start":760,"enrollment":2894,"conditions":2895,"interventions":2897},"NCT07570953","A Study Of Synthetic THC And Sleep",[91,92],"2028-04",72,[2896],"Obstructive Sleep Apnea",[2871],{"nctId":2899,"briefTitle":2900,"status":1096,"phases":2901,"primaryCompletion":737,"completion":737,"start":2902,"enrollment":773,"conditions":2903,"interventions":2904},"NCT07231965","Synthetic THC And Blood Pressure",[91,92],"2026-07",[948],[2871],{"trials":2906,"activeCount":128},[],{"trials":2908,"activeCount":128},[],{"intervention":2910,"totalTrials":681,"cells":2911},"Ketorolac",{"EARLY_PHASE1":2912,"PHASE1":2914,"PHASE2":2916,"PHASE3":2918,"PHASE4":2930,"NA":2963},{"trials":2913,"activeCount":128},[],{"trials":2915,"activeCount":128},[],{"trials":2917,"activeCount":128},[],{"trials":2919,"activeCount":676,"soonestReadout":171},[2920],{"nctId":2921,"briefTitle":2922,"status":265,"phases":2923,"primaryCompletion":171,"completion":171,"start":2924,"enrollment":2925,"conditions":2926,"interventions":2928},"NCT05992883","NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis",[92],"2023-07-28",240,[2927],"Thumb Osteoarthritis",[2910,2929],"Triamcinolone",{"trials":2931,"activeCount":128},[2932,2942,2954],{"nctId":2933,"briefTitle":2934,"status":104,"phases":2935,"primaryCompletion":2936,"completion":2936,"start":2937,"enrollment":139,"conditions":2938,"interventions":2941},"NCT00765128","Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy",[93],"2010-11","2008-10",[2939,2940],"Renal Calculus","Kidney Stones",[2910],{"nctId":2943,"briefTitle":2944,"status":104,"phases":2945,"primaryCompletion":2946,"completion":2946,"start":874,"enrollment":1162,"conditions":2947,"interventions":2949},"NCT02242201","Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular",[93],"2016-09",[2948],"Total Hip Arthroplasty",[2950,2951,2952,2953,2910],"PNB Bupivacaine","PAI Ropivacaine","PAI liposomal bupivacaine","Epinephrine",{"nctId":2955,"briefTitle":2956,"status":104,"phases":2957,"primaryCompletion":2936,"completion":2936,"start":2937,"enrollment":2958,"conditions":2959,"interventions":2962},"NCT00765232","Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy",[93],111,[2960,2961],"Nephrectomy","Laparoscopic Donor Nephrectomy",[2910],{"trials":2964,"activeCount":128},[],{"intervention":2966,"totalTrials":681,"cells":2967},"Tadalafil",{"EARLY_PHASE1":2968,"PHASE1":2970,"PHASE2":2972,"PHASE3":3005,"PHASE4":3016,"NA":3018},{"trials":2969,"activeCount":128},[],{"trials":2971,"activeCount":128},[],{"trials":2973,"activeCount":128},[2974,2986,2995],{"nctId":2975,"briefTitle":2976,"status":104,"phases":2977,"primaryCompletion":1374,"completion":2978,"start":2979,"enrollment":2980,"conditions":2981,"interventions":2983},"NCT01544998","Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure",[90,91],"2014-08","2012-02",43,[2982],"Congestive Heart Failure",[2984,2966,2985],"Nesiritide","Saline load",{"nctId":2987,"briefTitle":2988,"status":104,"phases":2989,"primaryCompletion":2990,"completion":2990,"start":2991,"enrollment":173,"conditions":2992,"interventions":2994},"NCT01970176","Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)",[90,91],"2019-09","2014-01-09",[698,2993],"Renal Impairment",[2966],{"nctId":2996,"briefTitle":2997,"status":104,"phases":2998,"primaryCompletion":2999,"completion":3000,"start":3001,"enrollment":3002,"conditions":3003,"interventions":3004},"NCT02058095","Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)",[90,91],"2019-06","2019-12","2014-03",22,[698,2993],[2966],{"trials":3006,"activeCount":676,"soonestReadout":3011},[3007],{"nctId":3008,"briefTitle":3009,"status":265,"phases":3010,"primaryCompletion":3011,"completion":3011,"start":3012,"enrollment":2678,"conditions":3013,"interventions":3015},"NCT05206955","Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology",[92],"2026-11","2022-09-16",[3014],"Fontan Palliation",[2966],{"trials":3017,"activeCount":128},[],{"trials":3019,"activeCount":128},[],{"intervention":2929,"totalTrials":224,"cells":3021},{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3026,"PHASE3":3039,"PHASE4":3045,"NA":3047},{"trials":3023,"activeCount":128},[],{"trials":3025,"activeCount":128},[],{"trials":3027,"activeCount":128},[3028],{"nctId":3029,"briefTitle":3030,"status":104,"phases":3031,"primaryCompletion":3032,"completion":3032,"start":3033,"enrollment":3034,"conditions":3035,"interventions":3037},"NCT01906944","Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain",[91],"2019-08-18","2012-01",62,[3036],"Abdominal Pain",[3038,2929],"Bupivacaine 0.25%",{"trials":3040,"activeCount":676,"soonestReadout":171},[3041],{"nctId":2921,"briefTitle":2922,"status":265,"phases":3042,"primaryCompletion":171,"completion":171,"start":2924,"enrollment":2925,"conditions":3043,"interventions":3044},[92],[2927],[2910,2929],{"trials":3046,"activeCount":128},[],{"trials":3048,"activeCount":128},[],{"intervention":3050,"totalTrials":676,"cells":3051},"Non-invasive vagus nerve stimulator plus nicotine replacement patches",{"EARLY_PHASE1":3052,"PHASE1":3054,"PHASE2":3056,"PHASE3":3058,"PHASE4":3072,"NA":3074},{"trials":3053,"activeCount":128},[],{"trials":3055,"activeCount":128},[],{"trials":3057,"activeCount":128},[],{"trials":3059,"activeCount":676,"soonestReadout":3064},[3060],{"nctId":3061,"briefTitle":3062,"status":1096,"phases":3063,"primaryCompletion":3064,"completion":3065,"start":3066,"enrollment":3067,"conditions":3068,"interventions":3070},"NCT07487818","A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation",[91,92],"2027-01-15","2027-05-31","2026-04-15",150,[3069],"Smoking Cessation",[3050,3071],"nicotine replacement patches",{"trials":3073,"activeCount":128},[],{"trials":3075,"activeCount":128},[],{"intervention":3071,"totalTrials":676,"cells":3077},{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3082,"PHASE3":3084,"PHASE4":3090,"NA":3092},{"trials":3079,"activeCount":128},[],{"trials":3081,"activeCount":128},[],{"trials":3083,"activeCount":128},[],{"trials":3085,"activeCount":676,"soonestReadout":3064},[3086],{"nctId":3061,"briefTitle":3062,"status":1096,"phases":3087,"primaryCompletion":3064,"completion":3065,"start":3066,"enrollment":3067,"conditions":3088,"interventions":3089},[91,92],[3069],[3050,3071],{"trials":3091,"activeCount":128},[],{"trials":3093,"activeCount":128},[],{"intervention":3095,"totalTrials":676,"cells":3096},"Pafolacianine Sodium",{"EARLY_PHASE1":3097,"PHASE1":3099,"PHASE2":3101,"PHASE3":3103,"PHASE4":3118,"NA":3120},{"trials":3098,"activeCount":128},[],{"trials":3100,"activeCount":128},[],{"trials":3102,"activeCount":128},[],{"trials":3104,"activeCount":676,"soonestReadout":1159},[3105],{"nctId":3106,"briefTitle":3107,"status":265,"phases":3108,"primaryCompletion":1159,"completion":1159,"start":3109,"enrollment":173,"conditions":3110,"interventions":3117},"NCT06915727","An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors",[92],"2025-04-15",[3111,3112,3113,3114,3115,3116],"Childhood Malignant Solid Neoplasm","Childhood Malignant Thoracic Neoplasm","Malignant Abdominal Neoplasm","Malignant Neck Neoplasm","Malignant Pelvic Neoplasm","Metastatic Childhood Malignant Solid Neoplasm",[3095],{"trials":3119,"activeCount":128},[],{"trials":3121,"activeCount":128},[],{"intervention":3123,"totalTrials":676,"cells":3124},"Sevoflurane",{"EARLY_PHASE1":3125,"PHASE1":3127,"PHASE2":3129,"PHASE3":3131,"PHASE4":3143,"NA":3145},{"trials":3126,"activeCount":128},[],{"trials":3128,"activeCount":128},[],{"trials":3130,"activeCount":128},[],{"trials":3132,"activeCount":676,"soonestReadout":815},[3133],{"nctId":3134,"briefTitle":3135,"status":265,"phases":3136,"primaryCompletion":815,"completion":815,"start":3137,"enrollment":3138,"conditions":3139,"interventions":3141},"NCT06624592","Sevoflurane\u002FDexmedetomidine vs. Isoflurane for Pediatric Emergence Delirium",[92],"2024-12-20",400,[3140],"Delirium on Emergence",[3123,3142],"Isoflurane",{"trials":3144,"activeCount":128},[],{"trials":3146,"activeCount":128},[],{"intervention":3142,"totalTrials":676,"cells":3148},{"EARLY_PHASE1":3149,"PHASE1":3151,"PHASE2":3153,"PHASE3":3155,"PHASE4":3161,"NA":3163},{"trials":3150,"activeCount":128},[],{"trials":3152,"activeCount":128},[],{"trials":3154,"activeCount":128},[],{"trials":3156,"activeCount":676,"soonestReadout":815},[3157],{"nctId":3134,"briefTitle":3135,"status":265,"phases":3158,"primaryCompletion":815,"completion":815,"start":3137,"enrollment":3138,"conditions":3159,"interventions":3160},[92],[3140],[3123,3142],{"trials":3162,"activeCount":128},[],{"trials":3164,"activeCount":128},[],{"intervention":3166,"totalTrials":676,"cells":3167},"High-dose corticosteroids",{"EARLY_PHASE1":3168,"PHASE1":3170,"PHASE2":3172,"PHASE3":3174,"PHASE4":3190,"NA":3192},{"trials":3169,"activeCount":128},[],{"trials":3171,"activeCount":128},[],{"trials":3173,"activeCount":128},[],{"trials":3175,"activeCount":676,"soonestReadout":3180},[3176],{"nctId":3177,"briefTitle":3178,"status":265,"phases":3179,"primaryCompletion":3180,"completion":3181,"start":3182,"enrollment":3183,"conditions":3184,"interventions":3188},"NCT07100990","Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)",[92],"2029-04-01","2031-04-30","2025-07-11",382,[3185,3186,3187],"Optic Neuritis","Myelitis","Myelitis, Transverse",[3166,3189],"High-dose corticosteroids (HDCS) and PLEX",{"trials":3191,"activeCount":128},[],{"trials":3193,"activeCount":128},[],{"intervention":3189,"totalTrials":676,"cells":3195},{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3200,"PHASE3":3202,"PHASE4":3208,"NA":3210},{"trials":3197,"activeCount":128},[],{"trials":3199,"activeCount":128},[],{"trials":3201,"activeCount":128},[],{"trials":3203,"activeCount":676,"soonestReadout":3180},[3204],{"nctId":3177,"briefTitle":3178,"status":265,"phases":3205,"primaryCompletion":3180,"completion":3181,"start":3182,"enrollment":3183,"conditions":3206,"interventions":3207},[92],[3185,3186,3187],[3166,3189],{"trials":3209,"activeCount":128},[],{"trials":3211,"activeCount":128},[],{"intervention":3213,"totalTrials":676,"cells":3214},"Losartan",{"EARLY_PHASE1":3215,"PHASE1":3217,"PHASE2":3219,"PHASE3":3221,"PHASE4":3234,"NA":3236},{"trials":3216,"activeCount":128},[],{"trials":3218,"activeCount":128},[],{"trials":3220,"activeCount":128},[],{"trials":3222,"activeCount":676,"soonestReadout":3227},[3223],{"nctId":3224,"briefTitle":3225,"status":265,"phases":3226,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":785,"conditions":3229,"interventions":3232},"NCT06150560","A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)",[92],"2028-06-01","2024-04-01",[3230,3231],"Coarctation of Aorta","High Blood Pressure",[3213,3233],"Amlodipine",{"trials":3235,"activeCount":128},[],{"trials":3237,"activeCount":128},[],{"intervention":3233,"totalTrials":676,"cells":3239},{"EARLY_PHASE1":3240,"PHASE1":3242,"PHASE2":3244,"PHASE3":3246,"PHASE4":3252,"NA":3254},{"trials":3241,"activeCount":128},[],{"trials":3243,"activeCount":128},[],{"trials":3245,"activeCount":128},[],{"trials":3247,"activeCount":676,"soonestReadout":3227},[3248],{"nctId":3224,"briefTitle":3225,"status":265,"phases":3249,"primaryCompletion":3227,"completion":3227,"start":3228,"enrollment":785,"conditions":3250,"interventions":3251},[92],[3230,3231],[3213,3233],{"trials":3253,"activeCount":128},[],{"trials":3255,"activeCount":128},[],{"intervention":3257,"totalTrials":676,"cells":3258},"Entresto Pill",{"EARLY_PHASE1":3259,"PHASE1":3261,"PHASE2":3263,"PHASE3":3265,"PHASE4":3275,"NA":3277},{"trials":3260,"activeCount":128},[],{"trials":3262,"activeCount":128},[],{"trials":3264,"activeCount":128},[],{"trials":3266,"activeCount":676,"soonestReadout":761},[3267],{"nctId":3268,"briefTitle":3269,"status":265,"phases":3270,"primaryCompletion":761,"completion":761,"start":3271,"enrollment":461,"conditions":3272,"interventions":3274},"NCT06693674","Effect of Sacubitril-Valsartan on Cardiac Structure and Function",[92],"2025-02-03",[3273],"Congenital Heart Disease",[3257],{"trials":3276,"activeCount":128},[],{"trials":3278,"activeCount":128},[],{"intervention":3280,"totalTrials":676,"cells":3281},"Antiandrogen Therapy",{"EARLY_PHASE1":3282,"PHASE1":3284,"PHASE2":3286,"PHASE3":3288,"PHASE4":3306,"NA":3308},{"trials":3283,"activeCount":128},[],{"trials":3285,"activeCount":128},[],{"trials":3287,"activeCount":128},[],{"trials":3289,"activeCount":676,"soonestReadout":3294},[3290],{"nctId":3291,"briefTitle":3292,"status":265,"phases":3293,"primaryCompletion":3294,"completion":3294,"start":3295,"enrollment":3296,"conditions":3297,"interventions":3305},"NCT06205316","SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma",[92],"2030-01-22","2024-01-22",118,[3298,3299,3300,3301,3302,3303,3304],"Biochemically Recurrent Prostate Carcinoma","Oligometastatic Prostate Carcinoma","Recurrent Prostate Adenocarcinoma","Stage IIB Prostate Cancer AJCC v8","Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8",[3280],{"trials":3307,"activeCount":128},[],{"trials":3309,"activeCount":128},[],{"intervention":57,"totalTrials":31,"cells":3311},{"EARLY_PHASE1":3312,"PHASE1":3328,"PHASE2":3503,"PHASE3":3760,"PHASE4":3762,"NA":3764},{"trials":3313,"activeCount":128},[3314],{"nctId":3315,"briefTitle":3316,"status":104,"phases":3317,"primaryCompletion":3318,"completion":3318,"start":3319,"enrollment":817,"conditions":3320,"interventions":3322},"NCT00662233","Combination Chemotherapy in Treating Patients With Sarcoma",[89],"2013-10-21","1991-10",[3321,1420],"Ovarian Cancer",[3323,3324,3325,3326,3327],"cyclophosphamide","doxorubicin hydrochloride","etoposide","ifosfamide","vincristine sulfate",{"trials":3329,"activeCount":1197,"soonestReadout":56},[3330,3356,3389,3406,3429,3453,3462,3471,3484],{"nctId":3331,"briefTitle":3332,"status":134,"phases":3333,"primaryCompletion":3334,"completion":3335,"start":3336,"enrollment":681,"conditions":3337,"interventions":3353},"NCT02650635","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",[90],"2016-09-26","2017-06-01","2016-02-05",[3338,561,143,3339,3340,3341,3342,3343,3344,3345,3346,3347,3348,3349,3350,3351,3352],"Colorectal Adenocarcinoma","Recurrent Colorectal Carcinoma","Recurrent Melanoma of the Skin","Recurrent Non-Small Cell Lung Carcinoma","Recurrent Pancreatic Carcinoma","Recurrent Renal Cell Carcinoma","Solid Neoplasm","Stage IV Breast Cancer","Stage IV Non-Small Cell Lung Cancer","Stage IV Renal Cell Cancer","Stage IV Skin Melanoma","Stage IVA Colorectal Cancer","Stage IVA Pancreatic Cancer","Stage IVB Colorectal Cancer","Stage IVB Pancreatic Cancer",[57,3354,3355],"Pegfilgrastim","TLR8 Agonist VTX-2337",{"nctId":3357,"briefTitle":3358,"status":104,"phases":3359,"primaryCompletion":3360,"completion":3361,"start":3362,"enrollment":2555,"conditions":3363,"interventions":3387},"NCT01606241","Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[90],"2014-09-25","2018-03-09","2012-07-24",[143,502,506,511,3364,3365,3366,3367,3368,3369,3370,3371,3372,3373,3374,3375,3376,3377,3378,3379,3380,3381,3382,3383,3384,3385,3386],"Stage IIA Breast Cancer","Stage IIA Fallopian Tube Cancer","Stage IIA Ovarian Cancer","Stage IIB Breast Cancer","Stage IIB Fallopian Tube Cancer","Stage IIB Ovarian Cancer","Stage IIC Fallopian Tube Cancer","Stage IIC Ovarian Cancer","Stage IIIA Breast Cancer","Stage IIIA Fallopian Tube Cancer","Stage IIIA Ovarian Cancer","Stage IIIA Primary Peritoneal Cancer","Stage IIIB Breast Cancer","Stage IIIB Fallopian Tube Cancer","Stage IIIB Ovarian Cancer","Stage IIIB Primary Peritoneal Cancer","Stage IIIC Breast Cancer","Stage IIIC Fallopian Tube Cancer","Stage IIIC Ovarian Cancer","Stage IIIC Primary Peritoneal Cancer","Stage IV Fallopian Tube Cancer","Stage IV Ovarian Cancer","Stage IV Primary Peritoneal Cancer",[57,3388],"Multi-epitope Folate Receptor Alpha Peptide Vaccine",{"nctId":3390,"briefTitle":3391,"status":265,"phases":3392,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":97,"conditions":3395,"interventions":3402},"NCT06191887","B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies",[90],"2040-12-31","2024-03-18",[3396,432,414,415,416,417,439,3397,443,3398,445,3399,3400,447,3401],"B-Cell Non-Hodgkin Lymphoma","Recurrent Transformed Chronic Lymphocytic Leukemia","Refractory Diffuse Large B-Cell Lymphoma","Refractory Mantle Cell Lymphoma","Refractory Marginal Zone Lymphoma","Refractory Transformed Chronic Lymphocytic Leukemia",[3403,3404,57,3405],"Autologous BAFFR-targeting CAR T Cells","Bendamustine","Fludarabine",{"nctId":54,"briefTitle":55,"status":169,"phases":3407,"primaryCompletion":56,"completion":3408,"start":3409,"enrollment":773,"conditions":3410,"interventions":3424},[90],"2028-05-16","2020-06-15",[3411,3412,3413,3414,3415,3416,3417,3418,3419,3420,3421,3422,3423,413],"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage II Follicular Lymphoma","Ann Arbor Stage II Marginal Zone Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Follicular Lymphoma","Ann Arbor Stage III Marginal Zone Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Follicular Lymphoma","Ann Arbor Stage IV Marginal Zone Lymphoma","Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 and\u002For BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",[57,347,3425,3354,3426,3427,163,3428],"Parsaclisib","Polatuzumab Vedotin","Prednisone","Vincristine Sulfate",{"nctId":3430,"briefTitle":3431,"status":265,"phases":3432,"primaryCompletion":1738,"completion":3433,"start":3434,"enrollment":3435,"conditions":3436,"interventions":3449},"NCT03017820","A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma",[90],"2032-04-01","2017-04-04",99,[3396,3437,3438,3439,3440,3441,3442,145,303,147,418,3443,3444,3445,150,3446,3447,153,3448],"Histiocytic and Dendritic Cell Neoplasm","Myelodysplastic Syndrome","Previously Treated Myelodysplastic Syndrome","Recurrent Adult Acute Myeloid Leukemia","Recurrent Anaplastic Large Cell Lymphoma","Recurrent Angioimmunoblastic T-Cell Lymphoma","Refractory Acute Myeloid Leukemia","Refractory Anaplastic Large Cell Lymphoma","Refractory Angioimmunoblastic T-Cell Lymphoma","Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified","Refractory Plasma Cell Myeloma","Refractory T-Cell Non-Hodgkin Lymphoma",[57,52,3450,3451,3452,112],"Cemiplimab","Ruxolitinib","ipilimumab",{"nctId":3454,"briefTitle":3455,"status":265,"phases":3456,"primaryCompletion":3457,"completion":3458,"start":137,"enrollment":558,"conditions":3459,"interventions":3460},"NCT04892277","CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed\u002FRefractory B Cell Malignancies",[90],"2028-03-27","2040-03-27",[373,432,439,3397,442,443,447,3401],[3461,3404,57,3405],"Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19\u002F1563",{"nctId":3463,"briefTitle":3464,"status":169,"phases":3465,"primaryCompletion":3466,"completion":3466,"start":3467,"enrollment":895,"conditions":3468,"interventions":3469},"NCT05411497","Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma",[90],"2027-08-18","2022-06-20",[303,3447],[3470,57],"Autologous MUC1-activated T-cells",{"nctId":3472,"briefTitle":3473,"status":104,"phases":3474,"primaryCompletion":3475,"completion":3476,"start":3477,"enrollment":2608,"conditions":3478,"interventions":3480},"NCT00652691","Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer",[90],"2002-06-05","2016-05-04","1998-08",[3321,3479],"Peritoneal Cavity Cancer",[3481,3482,3323,3483],"filgrastim","carboplatin","topotecan hydrochloride",{"nctId":3485,"briefTitle":3486,"status":265,"phases":3487,"primaryCompletion":3488,"completion":3488,"start":3489,"enrollment":218,"conditions":3490,"interventions":3502},"NCT06483048","MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer",[90],"2028-09-30","2024-09-20",[3491,3492,3493,502,3494,3495,506,507,3496,3497,511,515,3498,3499,3500,3501],"Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Ovarian Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma","Recurrent Fallopian Tube Carcinosarcoma","Recurrent Female Reproductive System Carcinoma","Recurrent Platinum-Resistant Fallopian Tube Carcinoma","Recurrent Platinum-Resistant Ovarian Carcinoma","Refractory Fallopian Tube Carcinoma","Refractory Female Reproductive System Carcinoma","Refractory Ovarian Carcinoma","Refractory Primary Peritoneal Carcinoma",[3470,3404,57],{"trials":3504,"activeCount":342,"soonestReadout":575},[3505,3515,3527,3540,3555,3565,3586,3600,3609,3626,3637,3646,3656,3667,3681,3695,3704,3713,3722,3729,3737,3746,3750],{"nctId":3506,"briefTitle":3507,"status":104,"phases":3508,"primaryCompletion":945,"completion":3509,"start":1357,"enrollment":224,"conditions":3510,"interventions":3512},"NCT01072773","Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis",[91],"2012-06",[3511],"Primary Systemic Amyloidosis",[3513,3323,3514],"bortezomib","dexamethasone",{"nctId":3516,"briefTitle":3517,"status":104,"phases":3518,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":3002,"conditions":3521,"interventions":3524},"NCT00445900","Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia",[91],"2006-10","2004-10",[3522,3523],"Chronic Myeloproliferative Disorders","Secondary Myelofibrosis",[3323,3525,3526],"prednisone","thalidomide",{"nctId":3528,"briefTitle":3529,"status":104,"phases":3530,"primaryCompletion":3531,"completion":3532,"start":3533,"enrollment":342,"conditions":3534,"interventions":3538},"NCT01706666","Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant",[91],"2014-07-10","2016-05-17","2012-12-07",[3535,3536,3537],"Stage I Multiple Myeloma","Stage II Multiple Myeloma","Stage III Multiple Myeloma",[3513,3323,3539,3514],"lenalidomide",{"nctId":3541,"briefTitle":3542,"status":104,"phases":3543,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":3548,"interventions":3550},"NCT00816595","Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[91],"2013-07","2016-11-29","2009-02",68,[3549,1419],"Leukemia",[3551,3552,3553,3323,3554],"bevacizumab","pegfilgrastim","rituximab","pentostatin",{"nctId":3556,"briefTitle":3557,"status":104,"phases":3558,"primaryCompletion":3001,"completion":3559,"start":1357,"enrollment":3560,"conditions":3561,"interventions":3563},"NCT01057225","Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma",[90,91],"2017-09-05",64,[3562,3535,3536,3537],"Multiple Myeloma",[3564,3323,3526,3514],"carfilzomib",{"nctId":3566,"briefTitle":3567,"status":104,"phases":3568,"primaryCompletion":3569,"completion":3570,"start":1357,"enrollment":3571,"conditions":3572,"interventions":3583},"NCT01024010","Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[91],"2013-05","2017-09-28",82,[3573,3574,3575,3576,3577,3578,3579,3580,3581,3582],"Chronic Lymphocytic Leukemia","Stage 0 Chronic Lymphocytic Leukemia","Stage I Chronic Lymphocytic Leukemia","Stage I Small Lymphocytic Lymphoma","Stage II Chronic Lymphocytic Leukemia","Stage II Small Lymphocytic Lymphoma","Stage III Chronic Lymphocytic Leukemia","Stage III Small Lymphocytic Lymphoma","Stage IV Chronic Lymphocytic Leukemia","Stage IV Small Lymphocytic Lymphoma",[57,3584,3585],"Ofatumumab","Pentostatin",{"nctId":3587,"briefTitle":3588,"status":104,"phases":3589,"primaryCompletion":1563,"completion":3590,"start":3591,"enrollment":936,"conditions":3592,"interventions":3594},"NCT00436566","Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery",[91],"2019-07-22","2007-03-16",[21,3593],"Cardiac Toxicity",[3595,3323,3324,3596,3597,3598,3599],"trastuzumab","lapatinib ditosylate","paclitaxel","gene expression analysis","reverse transcriptase-polymerase chain reaction",{"nctId":3601,"briefTitle":3602,"status":104,"phases":3603,"primaryCompletion":3604,"completion":3605,"start":3606,"enrollment":2608,"conditions":3607,"interventions":3608},"NCT00450814","Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma",[90,91],"2018-07-10","2019-11-20","2006-11-30",[303,3447],[57,67],{"nctId":3610,"briefTitle":3611,"status":1413,"phases":3612,"primaryCompletion":905,"completion":2697,"start":3613,"enrollment":128,"conditions":3614,"interventions":3620},"NCT01670084","Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia",[91],"2012-12",[3615,3616,3617,3618,3619],"B-cell Adult Acute Lymphoblastic Leukemia","Blastic Phase Chronic Myelogenous Leukemia","Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia","Untreated Adult Acute Lymphoblastic Leukemia",[3621,3553,3323,3324,3327,3622,3623,3525,3624,3514,3625],"nilotinib","methotrexate","cytarabine","mesna","leucovorin calcium",{"nctId":3627,"briefTitle":3628,"status":104,"phases":3629,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":3634,"interventions":3635},"NCT00670358","Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma",[90,91],"2021-05-07","2024-10-04","2008-08-25",138,[1419],[3552,3553,3323,3324,3539,3525,3327,3636],"polymorphism analysis",{"nctId":3638,"briefTitle":3639,"status":104,"phases":3640,"primaryCompletion":3641,"completion":3642,"start":3643,"enrollment":187,"conditions":3644,"interventions":3645},"NCT00784927","Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma",[91],"2013-10","2016-02","2008-11",[1419],[3553,3323,3514,3539],{"nctId":3647,"briefTitle":3648,"status":104,"phases":3649,"primaryCompletion":3650,"completion":3651,"start":3652,"enrollment":16,"conditions":3653,"interventions":3655},"NCT01864018","Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis",[90,91],"2021-04-30","2023-09-09","2013-08-20",[3654,549],"Amyloidosis",[57,305,306],{"nctId":3657,"briefTitle":3658,"status":104,"phases":3659,"primaryCompletion":3660,"completion":3661,"start":3662,"enrollment":3663,"conditions":3664,"interventions":3666},"NCT00478218","Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma",[91],"2008-09","2011-04","2006-07",53,[3665],"Multiple Myeloma and Plasma Cell Neoplasm",[3323,3514,3539],{"nctId":3668,"briefTitle":3669,"status":104,"phases":3670,"primaryCompletion":3671,"completion":3672,"start":3673,"enrollment":3674,"conditions":3675,"interventions":3679},"NCT00711828","Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma",[91],"2013-11","2018-04-06","2008-08",21,[3676,3677,434,435,416,439,443,3678,451],"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Nodal Marginal Zone Lymphoma","Splenic Marginal Zone Lymphoma",[3680,163,57,305],"Bortezomib",{"nctId":3682,"briefTitle":3683,"status":265,"phases":3684,"primaryCompletion":3685,"completion":3685,"start":3686,"enrollment":3687,"conditions":3688,"interventions":3691},"NCT06940297","Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma",[91],"2031-08-15","2025-06-23",44,[3689,3690],"Recurrent Multiple Myeloma","Refractory Multiple Myeloma",[3692,57,3693,3405,3694],"Ciltacabtagene Autoleucel","Dasatinib","Quercetin",{"nctId":3696,"briefTitle":3697,"status":104,"phases":3698,"primaryCompletion":3699,"completion":3700,"start":3701,"enrollment":1162,"conditions":3702,"interventions":3703},"NCT01415882","Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib",[91],"2023-04-21","2025-04-30","2012-01-31",[303,3447],[57,159,305,306],{"nctId":3705,"briefTitle":3706,"status":104,"phases":3707,"primaryCompletion":3708,"completion":3709,"start":3671,"enrollment":558,"conditions":3710,"interventions":3711},"NCT01955434","SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma",[91],"2016-06-09","2016-12-27",[303,3447],[57,3712],"Smac Mimetic LCL161",{"nctId":3714,"briefTitle":3715,"status":104,"phases":3716,"primaryCompletion":3717,"completion":2936,"start":3718,"enrollment":3719,"conditions":3720,"interventions":3721},"NCT00609167","Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma",[91],"2009-01","2006-12",63,[3665],[3513,3323,3514],{"nctId":3723,"briefTitle":3724,"status":104,"phases":3725,"primaryCompletion":3546,"completion":3509,"start":934,"enrollment":3726,"conditions":3727,"interventions":3728},"NCT00564889","Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis",[91],35,[3665],[3323,3514,3539],{"nctId":3730,"briefTitle":3731,"status":104,"phases":3732,"primaryCompletion":946,"completion":3733,"start":3734,"enrollment":461,"conditions":3735,"interventions":3736},"NCT00602836","Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[91],"2017-09-12","2008-02",[3549,1419],[163,57,551,3585],{"nctId":3738,"briefTitle":3739,"status":1096,"phases":3740,"primaryCompletion":3227,"completion":3741,"start":2303,"enrollment":2894,"conditions":3742,"interventions":3743},"NCT07349771","Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial",[91],"2033-06-01",[36],[3744,57,1698,3745],"Axatilimab","Tacrolimus",{"nctId":572,"briefTitle":573,"status":265,"phases":3747,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":3748,"interventions":3749},[90,91],[579,580,581,582,583,189,190,191,584,192,193,194,585,586,587,588,589,590,591,195,196,592,593,594,595,596,597,598,599,600,601,602,603,604,605,197,606,607,198,199,200,361,201,202,122,608,609,610,235,203,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,206,629,207,630,631,632,633,634,635,636,637,638,221,639,640,641,642,643,644,645,208,177,646,647,648,649,650,141,651,652,653,654],[57,656,72,657],{"nctId":3751,"briefTitle":3752,"status":104,"phases":3753,"primaryCompletion":3754,"completion":3755,"start":3756,"enrollment":773,"conditions":3757,"interventions":3758},"NCT00002630","High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse",[91],"1999-02","2001-05","1993-06",[3665],[3481,3323,3759],"melphalan",{"trials":3761,"activeCount":128},[],{"trials":3763,"activeCount":128},[],{"trials":3765,"activeCount":128},[],{"intervention":305,"totalTrials":3767,"cells":3768},46,{"EARLY_PHASE1":3769,"PHASE1":3791,"PHASE2":3873,"PHASE3":4106,"PHASE4":4116,"NA":4134},{"trials":3770,"activeCount":128},[3771,3780],{"nctId":3772,"briefTitle":3773,"status":104,"phases":3774,"primaryCompletion":3775,"completion":3775,"start":2665,"enrollment":2980,"conditions":3776,"interventions":3778},"NCT02318433","Intra-Articular Dexamethasone to Prevent Post-Traumatic Osteoarthritis: A Pilot Study",[89],"2019-07-19",[3777,1340],"Distal Radius Fracture",[305,3779],"Saline",{"nctId":3781,"briefTitle":3782,"status":104,"phases":3783,"primaryCompletion":3784,"completion":3785,"start":3786,"enrollment":3674,"conditions":3787,"interventions":3790},"NCT02921893","Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome",[89],"2022-04-21","2024-05-13","2016-10-31",[3788,3789],"Plasmacytoma","POEMS Syndrome",[305,306,551],{"trials":3792,"activeCount":676,"soonestReadout":3824},[3793,3801,3809,3820,3828,3838,3846,3862],{"nctId":3794,"briefTitle":3795,"status":134,"phases":3796,"primaryCompletion":3394,"completion":3394,"start":3797,"enrollment":895,"conditions":3798,"interventions":3799},"NCT04892264","Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma",[90],"2021-06-03",[549,303,3447],[3800,159,305,551],"Belantamab Mafodotin",{"nctId":3802,"briefTitle":3803,"status":134,"phases":3804,"primaryCompletion":3805,"completion":3805,"start":3806,"enrollment":108,"conditions":3807,"interventions":3808},"NCT03015792","Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant",[90],"2022-10-18","2017-03-10",[303,3447],[305,179,551],{"nctId":3810,"briefTitle":3811,"status":104,"phases":3812,"primaryCompletion":3813,"completion":3814,"start":3815,"enrollment":2563,"conditions":3816,"interventions":3818},"NCT03399539","Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma",[90],"2021-12-20","2024-02-23","2018-05-02",[303,3817],"T(11;14)",[305,306,3819],"Venetoclax",{"nctId":3821,"briefTitle":3822,"status":265,"phases":3823,"primaryCompletion":3824,"completion":3824,"start":3825,"enrollment":712,"conditions":3826,"interventions":3827},"NCT06042725","MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma",[90],"2028-12-01","2024-03-04",[3562],[159,305,551,3819],{"nctId":3829,"briefTitle":3830,"status":104,"phases":3831,"primaryCompletion":3832,"completion":3833,"start":3834,"enrollment":370,"conditions":3835,"interventions":3836},"NCT02697344","Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma",[90],"2018-10-26","2023-12-20","2016-04-14",[303],[305,551,3837],"R-(-)-Gossypol Acetic Acid",{"nctId":3839,"briefTitle":3840,"status":134,"phases":3841,"primaryCompletion":3842,"completion":3842,"start":3673,"enrollment":301,"conditions":3843,"interventions":3844},"NCT00687674","Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",[90],"2011-11",[3665],[3514,3845,551],"sorafenib tosylate",{"nctId":3847,"briefTitle":3848,"status":104,"phases":3849,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":34,"conditions":3853,"interventions":3860},"NCT01722305","Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma",[90],"2016-06-03","2019-07-15","2013-04-08",[3854,3855,3856,3857,3858,3859],"B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma","Central Nervous System Lymphoma","Intraocular Lymphoma","Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","Recurrent Adult Diffuse Large Cell Lymphoma","Retinal Lymphoma",[305,3861],"Pomalidomide",{"nctId":3863,"briefTitle":3864,"status":104,"phases":3865,"primaryCompletion":3866,"completion":3867,"start":2719,"enrollment":355,"conditions":3868,"interventions":3871},"NCT02492750","Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma",[90],"2019-06-05","2019-09-13",[3869,549,3870],"Indolent Plasma Cell Myeloma","Smoldering Plasma Cell Myeloma",[3872,305,551],"Anakinra",{"trials":3874,"activeCount":1197,"soonestReadout":4070},[3875,3879,3883,3890,3894,3903,3907,3918,3922,3930,3939,3949,3953,3957,3967,3976,3980,3984,3992,4001,4012,4018,4022,4026,4036,4040,4049,4058,4066,4076,4094,4102],{"nctId":3506,"briefTitle":3507,"status":104,"phases":3876,"primaryCompletion":945,"completion":3509,"start":1357,"enrollment":224,"conditions":3877,"interventions":3878},[91],[3511],[3513,3323,3514],{"nctId":3528,"briefTitle":3529,"status":104,"phases":3880,"primaryCompletion":3531,"completion":3532,"start":3533,"enrollment":342,"conditions":3881,"interventions":3882},[91],[3535,3536,3537],[3513,3323,3539,3514],{"nctId":3884,"briefTitle":3885,"status":1413,"phases":3886,"primaryCompletion":874,"completion":3887,"start":1374,"enrollment":128,"conditions":3888,"interventions":3889},"NCT01812720","Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant",[91],"2014-10",[3690,3535,3536,3537],[3564,3514],{"nctId":3556,"briefTitle":3557,"status":104,"phases":3891,"primaryCompletion":3001,"completion":3559,"start":1357,"enrollment":3560,"conditions":3892,"interventions":3893},[90,91],[3562,3535,3536,3537],[3564,3323,3526,3514],{"nctId":3895,"briefTitle":3896,"status":104,"phases":3897,"primaryCompletion":409,"completion":3898,"start":3899,"enrollment":773,"conditions":3900,"interventions":3901},"NCT01212952","Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",[90,91],"2018-03-22","2011-09",[3690],[3902,3513,3514],"pomalidomide",{"nctId":295,"briefTitle":296,"status":104,"phases":3904,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":3905,"interventions":3906},[91],[303],[305,306,72],{"nctId":3908,"briefTitle":3909,"status":169,"phases":3910,"primaryCompletion":3911,"completion":3912,"start":3913,"enrollment":3914,"conditions":3915,"interventions":3916},"NCT05392946","Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study",[90,91],"2026-09-29","2028-09-29","2022-08-11",49,[549],[3680,159,305,3917],"Iberdomide",{"nctId":3610,"briefTitle":3611,"status":1413,"phases":3919,"primaryCompletion":905,"completion":2697,"start":3613,"enrollment":128,"conditions":3920,"interventions":3921},[91],[3615,3616,3617,3618,3619],[3621,3553,3323,3324,3327,3622,3623,3525,3624,3514,3625],{"nctId":3923,"briefTitle":3924,"status":1413,"phases":3925,"primaryCompletion":3926,"completion":3926,"start":2698,"enrollment":128,"conditions":3927,"interventions":3929},"NCT03130348","Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis",[91],"2022-04",[3654,3928],"Immunoglobulin Light Chain Deposition",[3680,305,179],{"nctId":3931,"briefTitle":3932,"status":104,"phases":3933,"primaryCompletion":3934,"completion":3934,"start":3935,"enrollment":139,"conditions":3936,"interventions":3938},"NCT02547662","Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia",[91],"2020-10-30","2015-12-24",[3937,549,3788],"Plasma Cell Leukemia",[305,306,3861],{"nctId":3940,"briefTitle":3941,"status":265,"phases":3942,"primaryCompletion":3943,"completion":3943,"start":3944,"enrollment":3945,"conditions":3946,"interventions":3947},"NCT06785415","Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma",[90,91],"2031-04-01","2025-03-18",37,[3689],[159,305,3948,3917],"Elotuzumab",{"nctId":3638,"briefTitle":3639,"status":104,"phases":3950,"primaryCompletion":3641,"completion":3642,"start":3643,"enrollment":187,"conditions":3951,"interventions":3952},[91],[1419],[3553,3323,3514,3539],{"nctId":3647,"briefTitle":3648,"status":104,"phases":3954,"primaryCompletion":3650,"completion":3651,"start":3652,"enrollment":16,"conditions":3955,"interventions":3956},[90,91],[3654,549],[57,305,306],{"nctId":3958,"briefTitle":3959,"status":169,"phases":3960,"primaryCompletion":3961,"completion":3962,"start":3963,"enrollment":1236,"conditions":3964,"interventions":3965},"NCT04764942","Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial",[90,91],"2026-05-06","2027-12-17","2021-05-06",[3689,3690],[157,305,3861,3966],"Selinexor",{"nctId":3968,"briefTitle":3969,"status":104,"phases":3970,"primaryCompletion":3971,"completion":3972,"start":2643,"enrollment":3973,"conditions":3974,"interventions":3975},"NCT00558896","CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis",[91],"2012-09","2017-10-25",378,[3665],[3514,3902],{"nctId":3657,"briefTitle":3658,"status":104,"phases":3977,"primaryCompletion":3660,"completion":3661,"start":3662,"enrollment":3663,"conditions":3978,"interventions":3979},[91],[3665],[3323,3514,3539],{"nctId":3668,"briefTitle":3669,"status":104,"phases":3981,"primaryCompletion":3671,"completion":3672,"start":3673,"enrollment":3674,"conditions":3982,"interventions":3983},[91],[3676,3677,434,435,416,439,443,3678,451],[3680,163,57,305],{"nctId":3985,"briefTitle":3986,"status":104,"phases":3987,"primaryCompletion":3988,"completion":3988,"start":3989,"enrollment":2678,"conditions":3990,"interventions":3991},"NCT03012880","Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma",[91],"2022-12-15","2017-04-20",[549],[159,305,306,551],{"nctId":3993,"briefTitle":3994,"status":134,"phases":3995,"primaryCompletion":3996,"completion":3997,"start":3998,"enrollment":139,"conditions":3999,"interventions":4000},"NCT05288062","Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma",[91],"2024-02-25","2024-07-25","2022-06-15",[549,303,3447,3870],[305,551,3861],{"nctId":4002,"briefTitle":4003,"status":104,"phases":4004,"primaryCompletion":4005,"completion":4006,"start":4007,"enrollment":31,"conditions":4008,"interventions":4010},"NCT02633059","Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",[90,91],"2021-01-31","2022-11-01","2015-12-30",[4009,303],"Loss of Chromosome 17p",[305,4011,306],"Idasanutlin",{"nctId":4013,"briefTitle":4014,"status":104,"phases":4015,"primaryCompletion":1471,"completion":1471,"start":3001,"enrollment":476,"conditions":4016,"interventions":4017},"NCT01794039","Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide",[91],[303,3447],[305,551,3861],{"nctId":3696,"briefTitle":3697,"status":104,"phases":4019,"primaryCompletion":3699,"completion":3700,"start":3701,"enrollment":1162,"conditions":4020,"interventions":4021},[91],[303,3447],[57,159,305,306],{"nctId":3714,"briefTitle":3715,"status":104,"phases":4023,"primaryCompletion":3717,"completion":2936,"start":3718,"enrollment":3719,"conditions":4024,"interventions":4025},[91],[3665],[3513,3323,3514],{"nctId":4027,"briefTitle":4028,"status":104,"phases":4029,"primaryCompletion":4030,"completion":4031,"start":4032,"enrollment":313,"conditions":4033,"interventions":4034},"NCT01049945","Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",[90,91],"2012-11","2015-09-16","2010-02",[3690],[4035,3539,3514],"bendamustine hydrochloride",{"nctId":3723,"briefTitle":3724,"status":104,"phases":4037,"primaryCompletion":3546,"completion":3509,"start":934,"enrollment":3726,"conditions":4038,"interventions":4039},[91],[3665],[3323,3514,3539],{"nctId":4041,"briefTitle":4042,"status":104,"phases":4043,"primaryCompletion":4044,"completion":4045,"start":4046,"enrollment":1236,"conditions":4047,"interventions":4048},"NCT00772915","Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma",[91],"2011-03-22","2018-06-27","2008-12-03",[3665],[3514,3539],{"nctId":4050,"briefTitle":4051,"status":104,"phases":4052,"primaryCompletion":4053,"completion":4054,"start":4055,"enrollment":3945,"conditions":4056,"interventions":4057},"NCT03713294","Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma",[91],"2024-02-20","2024-11-14","2019-01-14",[3447],[305,3948,3861],{"nctId":4059,"briefTitle":4060,"status":265,"phases":4061,"primaryCompletion":761,"completion":761,"start":4062,"enrollment":2555,"conditions":4063,"interventions":4065},"NCT05334316","Individualizing Corticosteroid Use in Pneumonia",[91],"2024-11-06",[4064],"Pneumonia",[305],{"nctId":4067,"briefTitle":4068,"status":169,"phases":4069,"primaryCompletion":4070,"completion":4071,"start":4072,"enrollment":139,"conditions":4073,"interventions":4075},"NCT05497804","Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial",[91],"2026-02-12","2028-09-04","2022-09-22",[4074,3562],"ISS Stage III Plasma Cell Myeloma",[157,159,305,551],{"nctId":4077,"briefTitle":4078,"status":265,"phases":4079,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":2678,"conditions":4083,"interventions":4088},"NCT03418038","Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia",[91],"2031-02-22","2033-11-02","2018-03-23",[4084,3422,414,144,4085,3398,4086,4087],"Clonal Cytopenia of Undetermined Significance","Recurrent Lymphoma","Refractory Lymphoma","Chronic Myelomonocytic Leukemia",[536,4089,4090,305,4091,161,4092,539,163,4093],"Cisplatin","Cytarabine","Etoposide","Ifosfamide","Decitabine",{"nctId":4095,"briefTitle":4096,"status":104,"phases":4097,"primaryCompletion":4098,"completion":4098,"start":4099,"enrollment":2563,"conditions":4100,"interventions":4101},"NCT03202628","Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma",[91],"2021-04-13","2017-07-24",[303,3447],[305,306,3861],{"nctId":542,"briefTitle":543,"status":104,"phases":4103,"primaryCompletion":545,"completion":546,"start":547,"enrollment":410,"conditions":4104,"interventions":4105},[91],[549],[305,551,72],{"trials":4107,"activeCount":128},[4108],{"nctId":4109,"briefTitle":4110,"status":104,"phases":4111,"primaryCompletion":1375,"completion":2665,"start":4112,"enrollment":4113,"conditions":4114,"interventions":4115},"NCT00477971","Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis",[92],"2005-10",89,[3665],[3481,3514,3759],{"trials":4117,"activeCount":128},[4118,4122,4130],{"nctId":780,"briefTitle":781,"status":104,"phases":4119,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":4120,"interventions":4121},[93],[787,788],[746,790,305,791],{"nctId":4123,"briefTitle":4124,"status":104,"phases":4125,"primaryCompletion":4126,"completion":4126,"start":2719,"enrollment":1320,"conditions":4127,"interventions":4129},"NCT02739035","MUA to Treat Postoperative Stiffness After Total Knee Arthroplasty",[93],"2022-12",[4128],"Stiffness Following Total Knee Arthroplasty",[305,2725],{"nctId":1315,"briefTitle":1316,"status":104,"phases":4131,"primaryCompletion":1235,"completion":1318,"start":1319,"enrollment":1320,"conditions":4132,"interventions":4133},[93],[1322],[1274,305,305,791,791],{"trials":4135,"activeCount":128},[],{"intervention":159,"totalTrials":301,"cells":4137},{"EARLY_PHASE1":4138,"PHASE1":4140,"PHASE2":4154,"PHASE3":4221,"PHASE4":4223,"NA":4225},{"trials":4139,"activeCount":128},[],{"trials":4141,"activeCount":676,"soonestReadout":3824},[4142,4146,4150],{"nctId":3794,"briefTitle":3795,"status":134,"phases":4143,"primaryCompletion":3394,"completion":3394,"start":3797,"enrollment":895,"conditions":4144,"interventions":4145},[90],[549,303,3447],[3800,159,305,551],{"nctId":132,"briefTitle":133,"status":134,"phases":4147,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":4148,"interventions":4149},[90],[141,142,143,144,145,146,147,148,149,150,151,152,153,154],[156,157,158,159,160,161,112,162,72,163,164,165],{"nctId":3821,"briefTitle":3822,"status":265,"phases":4151,"primaryCompletion":3824,"completion":3824,"start":3825,"enrollment":712,"conditions":4152,"interventions":4153},[90],[3562],[159,305,551,3819],{"trials":4155,"activeCount":1197,"soonestReadout":4070},[4156,4166,4170,4178,4182,4186,4190,4198,4202,4212],{"nctId":4157,"briefTitle":4158,"status":134,"phases":4159,"primaryCompletion":4160,"completion":4161,"start":4162,"enrollment":2563,"conditions":4163,"interventions":4165},"NCT04230304","Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study",[91],"2023-05-01","2025-02-13","2020-11-11",[432,4164,439,443,447],"Recurrent Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[159,179],{"nctId":3908,"briefTitle":3909,"status":169,"phases":4167,"primaryCompletion":3911,"completion":3912,"start":3913,"enrollment":3914,"conditions":4168,"interventions":4169},[90,91],[549],[3680,159,305,3917],{"nctId":4171,"briefTitle":4172,"status":265,"phases":4173,"primaryCompletion":694,"completion":694,"start":4174,"enrollment":498,"conditions":4175,"interventions":4177},"NCT05654506","Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits",[91],"2023-08-17",[4176],"Proliferative Glomerulonephritis With Monoclonal IgG Deposits",[159],{"nctId":3940,"briefTitle":3941,"status":265,"phases":4179,"primaryCompletion":3943,"completion":3943,"start":3944,"enrollment":3945,"conditions":4180,"interventions":4181},[90,91],[3689],[159,305,3948,3917],{"nctId":3985,"briefTitle":3986,"status":104,"phases":4183,"primaryCompletion":3988,"completion":3988,"start":3989,"enrollment":2678,"conditions":4184,"interventions":4185},[91],[549],[159,305,306,551],{"nctId":3696,"briefTitle":3697,"status":104,"phases":4187,"primaryCompletion":3699,"completion":3700,"start":3701,"enrollment":1162,"conditions":4188,"interventions":4189},[91],[303,3447],[57,159,305,306],{"nctId":4191,"briefTitle":4192,"status":169,"phases":4193,"primaryCompletion":1908,"completion":1908,"start":4194,"enrollment":218,"conditions":4195,"interventions":4197},"NCT04868838","Daratumumab to Treat Active Lupus Nephritis",[91],"2021-04-20",[4196],"Lupus Nephritis",[159],{"nctId":4067,"briefTitle":4068,"status":169,"phases":4199,"primaryCompletion":4070,"completion":4071,"start":4072,"enrollment":139,"conditions":4200,"interventions":4201},[91],[4074,3562],[157,159,305,551],{"nctId":4203,"briefTitle":4204,"status":265,"phases":4205,"primaryCompletion":4206,"completion":4206,"start":4207,"enrollment":4208,"conditions":4209,"interventions":4211},"NCT05898646","Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial",[91],"2026-11-30","2023-07-17",96,[4210],"AL Amyloidosis",[159],{"nctId":4213,"briefTitle":4214,"status":104,"phases":4215,"primaryCompletion":4216,"completion":4217,"start":4218,"enrollment":3914,"conditions":4219,"interventions":4220},"NCT03477539","Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma",[91],"2022-05-11","2025-03-24","2018-04-09",[549],[159,551],{"trials":4222,"activeCount":128},[],{"trials":4224,"activeCount":128},[],{"trials":4226,"activeCount":128},[],{"intervention":4089,"totalTrials":173,"cells":4228},{"EARLY_PHASE1":4229,"PHASE1":4272,"PHASE2":4330,"PHASE3":4470,"PHASE4":4483,"NA":4485},{"trials":4230,"activeCount":128},[4231,4242],{"nctId":4232,"briefTitle":4233,"status":104,"phases":4234,"primaryCompletion":4235,"completion":3972,"start":3660,"enrollment":729,"conditions":4236,"interventions":4238},"NCT00757549","3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx",[89],"2011-08",[4237],"Head and Neck Cancer",[4239,4240,4241],"cetuximab","cisplatin","TdT-mediated dUTP nick end labeling assay",{"nctId":4243,"briefTitle":4244,"status":134,"phases":4245,"primaryCompletion":3825,"completion":4246,"start":4247,"enrollment":224,"conditions":4248,"interventions":4268},"NCT04213794","Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients",[89],"2024-10-03","2019-11-08",[3113,3115,4249,4250,502,4251,4252,4253,506,511,4254,4255,4256,4257,4258,3498,4259,4260,4261,3500,3501,4262,4263,4264,4265,4266,4267],"Recurrent Colon Carcinoma","Recurrent Desmoplastic Small Round Cell Tumor","Recurrent Gastric Carcinoma","Recurrent Liposarcoma","Recurrent Malignant Mesothelioma","Recurrent Rectal Carcinoma","Recurrent Rhabdomyosarcoma","Recurrent Sarcoma","Refractory Colon Carcinoma","Refractory Desmoplastic Small Round Cell Tumor","Refractory Gastric Carcinoma","Refractory Liposarcoma","Refractory Malignant Mesothelioma","Refractory Rectal Carcinoma","Refractory Rhabdomyosarcoma","Refractory Sarcoma","Resectable Liposarcoma","Resectable Malignant Mesothelioma","Resectable Sarcoma",[4089,4269,4270,4271],"Doxorubicin","Hyperthermic Intraperitoneal Chemotherapy","Sodium Thiosulfate",{"trials":4273,"activeCount":128},[4274,4284,4296,4308],{"nctId":4275,"briefTitle":4276,"status":104,"phases":4277,"primaryCompletion":4278,"completion":4278,"start":4279,"enrollment":676,"conditions":4280,"interventions":4282},"NCT01888302","Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery",[90],"2016-06","2013-09",[4281],"Hepatic Complication",[4089,161,4283],"Sirolimus",{"nctId":4285,"briefTitle":4286,"status":104,"phases":4287,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":2608,"conditions":4290,"interventions":4294},"NCT00003690","Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors",[90],"2003-09","1998-12",[21,4291,4292,4293],"Melanoma (Skin)","Prostate Cancer","Unspecified Adult Solid Tumor, Protocol Specific",[4295,3482,4240],"alvocidib",{"nctId":4297,"briefTitle":4298,"status":104,"phases":4299,"primaryCompletion":4300,"completion":4300,"start":2883,"enrollment":956,"conditions":4301,"interventions":4305},"NCT00949949","Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy",[90],"2014-07",[4302,4303,4304,4293],"Cholangiocarcinoma of the Gallbladder","Localized Gallbladder Cancer","Unresectable Gallbladder Cancer",[4306,4307,4240],"everolimus","gemcitabine hydrochloride",{"nctId":4309,"briefTitle":4310,"status":1413,"phases":4311,"primaryCompletion":4312,"completion":4312,"start":4313,"enrollment":128,"conditions":4314,"interventions":4328},"NCT02856568","Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma",[90],"2021-10","2017-05-01",[4315,4316,4317,4318,4319,4320,4321,4322,4323,4324,4325,4326,4327],"Non-Resectable Cholangiocarcinoma","Recurrent Cholangiocarcinoma","Stage III Extrahepatic Bile Duct Cancer","Stage III Intrahepatic Cholangiocarcinoma","Stage IIIA Hilar Cholangiocarcinoma","Stage IIIB Hilar Cholangiocarcinoma","Stage IVA Extrahepatic Bile Duct Cancer","Stage IVA Hilar Cholangiocarcinoma","Stage IVA Intrahepatic Cholangiocarcinoma","Stage IVB Extrahepatic Bile Duct Cancer","Stage IVB Hilar Cholangiocarcinoma","Stage IVB Intrahepatic Cholangiocarcinoma","Unresectable Extrahepatic Bile Duct Carcinoma",[4089,161,4329],"Ricolinostat",{"trials":4331,"activeCount":1197,"soonestReadout":4336},[4332,4346,4355,4376,4386,4395,4407,4423,4427,4438,4460],{"nctId":4333,"briefTitle":4334,"status":692,"phases":4335,"primaryCompletion":4336,"completion":4337,"start":4338,"enrollment":2742,"conditions":4339,"interventions":4345},"NCT07139951","Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence",[91],"2027-05-03","2031-11-03","2025-12-03",[4340,4341,4342,4343,190,191,4344,528],"Clinical Stage I Gastric Cancer AJCC v8","Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage II Gastric Cancer AJCC v8","Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","Gastric Adenocarcinoma",[4089,4270,540],{"nctId":4347,"briefTitle":4348,"status":265,"phases":4349,"primaryCompletion":4350,"completion":4350,"start":4351,"enrollment":498,"conditions":4352,"interventions":4354},"NCT05753306","Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study",[91],"2030-03-25","2023-04-20",[4344,528,4353],"Metastatic Malignant Neoplasm in the Peritoneum",[4089,540,4270],{"nctId":4356,"briefTitle":4357,"status":104,"phases":4358,"primaryCompletion":298,"completion":4359,"start":4360,"enrollment":224,"conditions":4361,"interventions":4373},"NCT03617913","Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer",[91],"2020-07-27","2018-09-19",[4362,4363,4364,4365,4366,672,4367,4368,4369,4370,4371,4372],"Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall","Stage II Bladder Cancer AJCC v8","Stage II Renal Pelvis Cancer AJCC v8","Stage II Ureter Cancer AJCC v8","Stage II Urethral Cancer AJCC v8","Stage III Renal Pelvis Cancer AJCC v8","Stage III Ureter Cancer AJCC v8","Stage III Urethral Cancer AJCC v8","Stage IIIA Bladder Cancer AJCC v8","Stage IIIB Bladder Cancer AJCC v8","Urethral Urothelial Carcinoma",[4374,4089,537,4375],"Avelumab","Mitomycin",{"nctId":4377,"briefTitle":4378,"status":265,"phases":4379,"primaryCompletion":4380,"completion":4380,"start":4381,"enrollment":498,"conditions":4382,"interventions":4384},"NCT04858009","Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis",[91],"2029-07","2024-02-15",[4383,564,4353],"Metastatic Pancreatic Carcinoma",[4089,4270,4385],"Nab-paclitaxel",{"nctId":4387,"briefTitle":4388,"status":104,"phases":4389,"primaryCompletion":4390,"completion":4391,"start":3319,"enrollment":3726,"conditions":4392,"interventions":4394},"NCT00002876","Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas",[91],"1998-04","2005-01",[4393],"Brain and Central Nervous System Tumors",[4240,3325],{"nctId":4396,"briefTitle":4397,"status":104,"phases":4398,"primaryCompletion":4399,"start":4400,"enrollment":1236,"conditions":4401,"interventions":4403},"NCT00652860","Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery",[91],"2006-11","2001-08",[4402,1420],"Metastatic Cancer",[4404,4405,4240,3324,3326,4406],"aerosol sargramostim","sargramostim","mitomycin C",{"nctId":4408,"briefTitle":4409,"status":265,"phases":4410,"primaryCompletion":4411,"completion":4412,"start":4413,"enrollment":4414,"conditions":4415,"interventions":4422},"NCT05541016","De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA",[91],"2028-08-01","2029-08-01","2023-02-21",455,[4416,4417,247,4418,4419,4420,4421],"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma","Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8",[4089,346],{"nctId":4077,"briefTitle":4078,"status":265,"phases":4424,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":2678,"conditions":4425,"interventions":4426},[91],[4084,3422,414,144,4085,3398,4086,4087],[536,4089,4090,305,4091,161,4092,539,163,4093],{"nctId":4428,"briefTitle":4429,"status":104,"phases":4430,"primaryCompletion":4431,"completion":4431,"start":4432,"enrollment":173,"conditions":4433,"interventions":4436},"NCT03132532","Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",[91],"2023-12-23","2017-07-31",[4434,4435,614,645],"Recurrent Lung Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8",[536,4089,4091,540,4437],"Pemetrexed",{"nctId":4439,"briefTitle":4440,"status":169,"phases":4441,"primaryCompletion":4442,"completion":4443,"start":4444,"enrollment":4445,"conditions":4446,"interventions":4459},"NCT05075980","Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study",[91],"2027-11-15","2035-11-15","2022-02-16",174,[4447,4448,4449,4450,4451,4452,4453,4454,4455,4456,4457,4458],"Head and Neck Carcinoma","Head and Neck Carcinoma of Unknown Primary","Hypopharyngeal Carcinoma","Laryngeal Carcinoma","Metastatic Malignant Neoplasm in the Lymph Nodes","Nasal Cavity Carcinoma","Oral Cavity Carcinoma","Oropharyngeal Carcinoma","Paranasal Sinus Carcinoma","Salivary Gland Carcinoma","Cutaneous Squamous Cell Carcinoma of the Head and Neck","Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck",[4089],{"nctId":4461,"briefTitle":4462,"status":104,"phases":4463,"primaryCompletion":4464,"completion":4464,"start":4465,"conditions":4466,"interventions":4469},"NCT00002472","Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors",[91],"2005-08","1991-03",[4393,4467,4468],"Pediatric Germ Cell Tumor","Extragonadal Germ Cell Tumor",[4240,3325],{"trials":4471,"activeCount":128},[4472],{"nctId":4473,"briefTitle":4474,"status":104,"phases":4475,"primaryCompletion":4476,"completion":4477,"start":4478,"enrollment":4479,"conditions":4480,"interventions":4482},"NCT02908477","Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer",[92],"2022-08-20","2024-11-15","2016-10-03",228,[4481],"Oropharynx Cancer",[346,4089],{"trials":4484,"activeCount":128},[],{"trials":4486,"activeCount":128},[4487,4498],{"nctId":4488,"briefTitle":4489,"status":1413,"phases":4490,"primaryCompletion":3559,"completion":3559,"start":1471,"enrollment":128,"conditions":4491,"interventions":4496},"NCT02944357","Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery",[94],[4492,4493,4494,4495],"Infiltrating Bladder Urothelial Carcinoma","Stage II Bladder Urothelial Carcinoma","Stage III Bladder Urothelial Carcinoma","Stage IV Bladder Urothelial Carcinoma",[4089,161,4497],"Tumor Cell-Derived Vaccine Therapy",{"nctId":4499,"briefTitle":4500,"status":104,"phases":4501,"primaryCompletion":4502,"completion":4503,"start":4504,"enrollment":25,"conditions":4505,"interventions":4506},"NCT00645632","Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade Osteosarcoma",[94],"1995-01","2008-01","1990-11",[1420],[4240,3324,3326,3622],{"intervention":112,"totalTrials":410,"cells":4508},{"EARLY_PHASE1":4509,"PHASE1":4515,"PHASE2":4570,"PHASE3":4638,"PHASE4":4640,"NA":4642},{"trials":4510,"activeCount":128},[4511],{"nctId":102,"briefTitle":103,"status":104,"phases":4512,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":4513,"interventions":4514},[89],[110],[112,72,113],{"trials":4516,"activeCount":224,"soonestReadout":4562},[4517,4530,4534,4545,4549,4558],{"nctId":4518,"briefTitle":4519,"status":104,"phases":4520,"primaryCompletion":4521,"completion":4522,"start":4523,"enrollment":342,"conditions":4524,"interventions":4529},"NCT03798314","Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma",[90],"2020-12-30","2021-09-15","2019-01-30",[4525,4526,4527,4528],"Recurrent Nervous System Lymphoma","Recurrent Primary Vitreoretinal DLBCL","Refractory Nervous System Lymphoma","Refractory Primary Vitreoretinal DLBCL",[112,3861],{"nctId":132,"briefTitle":133,"status":134,"phases":4531,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":4532,"interventions":4533},[90],[141,142,143,144,145,146,147,148,149,150,151,152,153,154],[156,157,158,159,160,161,112,162,72,163,164,165],{"nctId":4535,"briefTitle":4536,"status":1413,"phases":4537,"primaryCompletion":4538,"completion":4538,"start":4539,"enrollment":128,"conditions":4540,"interventions":4543},"NCT05717140","Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung",[90],"2026-01-28","2025-10-28",[192,4541,122,4542,177],"Metastatic Malignant Neoplasm in the Lung","Recurrent Melanoma",[4544,112],"Aerosol Sargramostim",{"nctId":3430,"briefTitle":3431,"status":265,"phases":4546,"primaryCompletion":1738,"completion":3433,"start":3434,"enrollment":3435,"conditions":4547,"interventions":4548},[90],[3396,3437,3438,3439,3440,3441,3442,145,303,147,418,3443,3444,3445,150,3446,3447,153,3448],[57,52,3450,3451,3452,112],{"nctId":4550,"briefTitle":4551,"status":134,"phases":4552,"primaryCompletion":4553,"completion":4553,"start":4554,"enrollment":1197,"conditions":4555,"interventions":4556},"NCT04967196","Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma",[90],"2024-04-17","2021-09-16",[189,192,122,177],[4557,112],"Ipilimumab",{"nctId":4559,"briefTitle":4560,"status":265,"phases":4561,"primaryCompletion":4562,"completion":4563,"start":4564,"enrollment":4565,"conditions":4566,"interventions":4568},"NCT05802056","Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis",[90],"2027-04-15","2030-04-15","2023-11-29",15,[193,4344,528,4567,4353],"Metastatic Gastric Carcinoma",[4569,537,538,112,539],"Aldesleukin",{"trials":4571,"activeCount":342,"soonestReadout":171},[4572,4592,4602,4628],{"nctId":4573,"briefTitle":4574,"status":134,"phases":4575,"primaryCompletion":4576,"completion":4576,"start":4577,"enrollment":218,"conditions":4578,"interventions":4591},"NCT03075553","Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma",[91],"2019-05-29","2017-05-17",[4579,4580,4581,4582,4583,4584,3441,4585,4586,145,4587,3444,4588,4589,150,4590,3446],"Blastic Plasmacytoid Dendritic Cell Neoplasm","Hepatosplenic T-Cell Lymphoma","HTLV-1 Infection","NK-Cell Lymphoma, Unclassifiable","Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative","Recurrent Adult T-Cell Leukemia\u002FLymphoma","Recurrent Angioimmunoblastic T-cell Lymphoma","Recurrent Enteropathy-Associated T-Cell Lymphoma","Refractory Adult T-Cell Leukemia\u002FLymphoma","Refractory Angioimmunoblastic T-cell Lymphoma","Refractory Enteropathy-Associated T-Cell Lymphoma","Refractory Nasal Type Extranodal NK\u002FT-Cell Lymphoma",[112],{"nctId":4593,"briefTitle":4594,"status":265,"phases":4595,"primaryCompletion":3824,"completion":3824,"start":4596,"enrollment":2980,"conditions":4597,"interventions":4599},"NCT07226856","BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma",[91],"2025-12-12",[561,4598,564],"Recurrent Pancreatic Adenocarcinoma",[4600,4601,4385,112],"Gemcitabine","Imzokitug",{"nctId":4603,"briefTitle":4604,"status":265,"phases":4605,"primaryCompletion":171,"completion":171,"start":4606,"enrollment":773,"conditions":4607,"interventions":4627},"NCT06265285","Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",[91],"2024-04-30",[4608,4609,4610,4611,4612,189,4613,192,4614,4615,528,4616,197,4617,24,4618,4619,4620,200,203,4621,204,4622,615,4623,206,630,4624,4625,4626,650],"Advanced Esophageal Squamous Cell Carcinoma","Advanced Renal Cell Carcinoma","Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage IIB Cutaneous Melanoma AJCC v8","Clinical Stage IIC Cutaneous Melanoma AJCC v8","Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8","Esophageal Carcinoma","Hepatocellular Carcinoma","Lung Non-Small Cell Carcinoma","Metastatic Colorectal Carcinoma","Metastatic Cutaneous Melanoma","Metastatic Esophageal Squamous Cell Carcinoma","Recurrent Esophageal Squamous Cell Carcinoma","Renal Cell Carcinoma","Stage IV Colorectal Cancer AJCC v8","Unresectable Cutaneous Melanoma","Unresectable Esophageal Squamous Cell Carcinoma","Urothelial Carcinoma",[112],{"nctId":4629,"briefTitle":4630,"status":1096,"phases":4631,"primaryCompletion":4632,"completion":4632,"start":4633,"enrollment":108,"conditions":4634,"interventions":4637},"NCT07510334","VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma",[91],"2033-08-01","2026-05-01",[4635,4636,615,630],"Advanced Clear Cell Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma",[4557,112,52],{"trials":4639,"activeCount":128},[],{"trials":4641,"activeCount":128},[],{"trials":4643,"activeCount":128},[],{"intervention":4645,"totalTrials":1197,"cells":4646},"Durvalumab",{"EARLY_PHASE1":4647,"PHASE1":4649,"PHASE2":4674,"PHASE3":4720,"PHASE4":4722,"NA":4724},{"trials":4648,"activeCount":128},[],{"trials":4650,"activeCount":676,"soonestReadout":4206},[4651,4665],{"nctId":4652,"briefTitle":4653,"status":265,"phases":4654,"primaryCompletion":4206,"completion":4655,"start":4656,"enrollment":2742,"conditions":4657,"interventions":4663},"NCT06058663","Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma",[90],"2028-11-30","2024-06-06",[4658,4659,4660,4661,4662],"Locally Advanced Intrahepatic Cholangiocarcinoma","Oligometastatic Intrahepatic Cholangiocarcinoma","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Unresectable Intrahepatic Cholangiocarcinoma",[4645,4664],"Tremelimumab",{"nctId":4666,"briefTitle":4667,"status":134,"phases":4668,"primaryCompletion":4669,"completion":4670,"start":4671,"enrollment":681,"conditions":4672,"interventions":4673},"NCT05443971","Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen",[90],"2025-06-28","2025-12-17","2024-01-08",[4617,614],[4645],{"trials":4675,"activeCount":681,"soonestReadout":4700},[4676,4687,4696,4710],{"nctId":4677,"briefTitle":4678,"status":265,"phases":4679,"primaryCompletion":4680,"completion":4680,"start":4681,"enrollment":3435,"conditions":4682,"interventions":4686},"NCT06078709","Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma",[91],"2027-05-30","2023-11-20",[4683,4341,4684,4343,4685,191],"Clinical Stage I Esophageal Adenocarcinoma AJCC v8","Clinical Stage II Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Esophageal Adenocarcinoma AJCC v8",[537,538,539,346,4645],{"nctId":4688,"briefTitle":4689,"status":265,"phases":4690,"primaryCompletion":4691,"completion":4691,"start":4692,"enrollment":97,"conditions":4693,"interventions":4694},"NCT05388006","Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[91],"2027-02-22","2023-01-05",[3573,450,419],[4695,4645,3819],"Acalabrutinib",{"nctId":4697,"briefTitle":4698,"status":169,"phases":4699,"primaryCompletion":4700,"completion":4701,"start":4702,"enrollment":34,"conditions":4703,"interventions":4708},"NCT04607954","Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer",[91],"2026-09-01","2031-05-01","2020-12-04",[4704,4705,4706,4707],"Platinum-Resistant Lung Small Cell Carcinoma","Platinum-Sensitive Lung Small Cell Carcinoma","Recurrent Extensive Stage Lung Small Cell Carcinoma","Refractory Extensive Stage Lung Small Cell Carcinoma",[4645,4709],"Lurbinectedin",{"nctId":4711,"briefTitle":4712,"status":265,"phases":4713,"primaryCompletion":4714,"completion":4714,"start":4715,"enrollment":19,"conditions":4716,"interventions":4717},"NCT03942328","Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer",[90,91],"2029-08-31","2019-09-19",[613,4660,629,4661,644,4662],[4718,4719,422,261,4645],"Atezolizumab","Bevacizumab",{"trials":4721,"activeCount":128},[],{"trials":4723,"activeCount":128},[],{"trials":4725,"activeCount":128},[],{"intervention":334,"totalTrials":410,"cells":4727},{"EARLY_PHASE1":4728,"PHASE1":4751,"PHASE2":4770,"PHASE3":4824,"PHASE4":4826,"NA":4838},{"trials":4729,"activeCount":676,"soonestReadout":4744},[4730,4740],{"nctId":4731,"briefTitle":4732,"status":104,"phases":4733,"primaryCompletion":4734,"completion":4734,"start":4735,"enrollment":3674,"conditions":4736,"interventions":4738},"NCT01957956","Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma",[89],"2016-11-16","2013-11-11",[4737,330,331],"Giant Cell Glioblastoma",[4739,334],"Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine",{"nctId":4741,"briefTitle":4742,"status":265,"phases":4743,"primaryCompletion":4744,"completion":4744,"start":4745,"enrollment":370,"conditions":4746,"interventions":4748},"NCT07025226","Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and\u002For Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease",[89],"2027-09-01","2025-08-12",[4747],"Glioma",[3693,4749,4750,3694,334],"Fisetin","Fluorodopa F 18",{"trials":4752,"activeCount":676,"soonestReadout":4757},[4753,4762],{"nctId":4754,"briefTitle":4755,"status":265,"phases":4756,"primaryCompletion":4757,"completion":4757,"start":4758,"enrollment":817,"conditions":4759,"interventions":4761},"NCT05030298","Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial",[90],"2027-09-15","2023-05-23",[4760],"Malignant Glioma",[334],{"nctId":4763,"briefTitle":4764,"status":1413,"phases":4765,"primaryCompletion":2642,"start":4503,"enrollment":128,"conditions":4766,"interventions":4767},"NCT00601614","Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery",[90],[4293],[4768,4769],"temozolomide","vandetanib",{"trials":4771,"activeCount":224,"soonestReadout":71},[4772,4780,4789,4800,4804,4814],{"nctId":4773,"briefTitle":4774,"status":104,"phases":4775,"primaryCompletion":4776,"completion":4777,"start":340,"enrollment":2980,"conditions":4778,"interventions":4779},"NCT03778294","18F-DOPA-PET\u002FMRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy",[91],"2022-06-30","2023-11-26",[330,4760],[334],{"nctId":4781,"briefTitle":4782,"status":134,"phases":4783,"primaryCompletion":4784,"completion":4785,"start":4786,"enrollment":218,"conditions":4787,"interventions":4788},"NCT00568451","Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma",[91],"2009-05","2012-04","2006-06",[4291],[3482,3597,4768],{"nctId":4790,"briefTitle":4791,"status":104,"phases":4792,"primaryCompletion":4793,"completion":4794,"start":4795,"enrollment":4796,"conditions":4797,"interventions":4798},"NCT01991977","18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy",[91],"2019-07-01","2024-07-15","2013-12",91,[4760],[4799,334],"Fluorine F 18 Fluorodopa",{"nctId":69,"briefTitle":70,"status":169,"phases":4801,"primaryCompletion":71,"completion":326,"start":327,"enrollment":328,"conditions":4802,"interventions":4803},[91],[330,331,332],[72,334],{"nctId":4805,"briefTitle":4806,"status":104,"phases":4807,"primaryCompletion":4808,"completion":4809,"start":4810,"enrollment":558,"conditions":4811,"interventions":4813},"NCT01328535","Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery",[91],"2013-06-22","2018-07-11","2011-01",[4542,4812],"Stage IV Melanoma",[4768],{"nctId":4815,"briefTitle":4816,"status":169,"phases":4817,"primaryCompletion":4818,"completion":4819,"start":4820,"enrollment":4821,"conditions":4822,"interventions":4823},"NCT05781321","Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study",[91],"2026-07-02","2028-07-02","2023-03-23",170,[330],[4750,334],{"trials":4825,"activeCount":128},[],{"trials":4827,"activeCount":128},[4828],{"nctId":4829,"briefTitle":4830,"status":104,"phases":4831,"primaryCompletion":4832,"completion":4832,"start":4833,"enrollment":729,"conditions":4834,"interventions":4837},"NCT06625047","Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy",[93],"2025-11-12","2024-10-07",[4835,330,4747,4836],"Astrocytoma, IDH-Mutant","Oligodendroglioma, IDH-Mutant and 1p\u002F19q-Codeleted",[334],{"trials":4839,"activeCount":128},[],{"intervention":537,"totalTrials":370,"cells":4841},{"EARLY_PHASE1":4842,"PHASE1":4844,"PHASE2":4891,"PHASE3":4922,"PHASE4":4932,"NA":4934},{"trials":4843,"activeCount":128},[],{"trials":4845,"activeCount":676,"soonestReadout":4562},[4846,4867,4876,4880],{"nctId":4847,"briefTitle":4848,"status":104,"phases":4849,"primaryCompletion":2936,"completion":4850,"start":1298,"enrollment":120,"conditions":4851,"interventions":4864},"NCT00654160","Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer",[90],"2012-12-03",[4852,4853,4854,4855,4856,4857,4858,4859,4860,4861,4862,4863],"Anal Cancer","Carcinoma of the Appendix","Colorectal Cancer","Esophageal Cancer","Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Gastric Cancer","Gastrointestinal Carcinoid Tumor","Gastrointestinal Stromal Tumor","Liver Cancer","Pancreatic Cancer","Small Intestine Cancer",[4865,4866,3625],"fluorouracil","irinotecan hydrochloride",{"nctId":4868,"briefTitle":4869,"status":104,"phases":4870,"primaryCompletion":4871,"completion":4871,"start":4872,"conditions":4873,"interventions":4874},"NCT00005068","Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors",[90],"2003-06","2000-01",[4293],[4865,4866,3625,4875],"oxaliplatin",{"nctId":4559,"briefTitle":4560,"status":265,"phases":4877,"primaryCompletion":4562,"completion":4563,"start":4564,"enrollment":4565,"conditions":4878,"interventions":4879},[90],[193,4344,528,4567,4353],[4569,537,538,112,539],{"nctId":4881,"briefTitle":4882,"status":104,"phases":4883,"primaryCompletion":4884,"completion":4884,"start":4885,"enrollment":676,"conditions":4886,"interventions":4890},"NCT01893294","Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer",[90],"2015-10-30","2013-04",[4887,4888,4889],"Duct Cell Adenocarcinoma of the Pancreas","Stage III Pancreatic Cancer","Stage IV Pancreatic Cancer",[4307,4865],{"trials":4892,"activeCount":342,"soonestReadout":4680},[4893,4897,4901,4905,4918],{"nctId":4677,"briefTitle":4678,"status":265,"phases":4894,"primaryCompletion":4680,"completion":4680,"start":4681,"enrollment":3435,"conditions":4895,"interventions":4896},[91],[4683,4341,4684,4343,4685,191],[537,538,539,346,4645],{"nctId":4356,"briefTitle":4357,"status":104,"phases":4898,"primaryCompletion":298,"completion":4359,"start":4360,"enrollment":224,"conditions":4899,"interventions":4900},[91],[4362,4363,4364,4365,4366,672,4367,4368,4369,4370,4371,4372],[4374,4089,537,4375],{"nctId":519,"briefTitle":520,"status":104,"phases":4902,"primaryCompletion":522,"completion":523,"start":524,"enrollment":525,"conditions":4903,"interventions":4904},[90,91],[527,528,529,530,531,532,533,534],[536,537,538,539,540,72],{"nctId":4906,"briefTitle":4907,"status":265,"phases":4908,"primaryCompletion":4909,"completion":4910,"start":4911,"enrollment":25,"conditions":4912,"interventions":4914},"NCT07456852","Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy",[90,91],"2028-04-30","2030-04-30","2026-04-30",[4913],"Malignant Digestive System Neoplasm",[4915,4916,537,4917],"Capecitabine","Diltiazem Hydrochloride","Isosorbide Mononitrate",{"nctId":553,"briefTitle":554,"status":265,"phases":4919,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":4920,"interventions":4921},[91],[560,561,562,563,564,565],[537,567,568,539,72,569,570],{"trials":4923,"activeCount":128},[4924],{"nctId":4925,"briefTitle":4926,"status":104,"phases":4927,"primaryCompletion":4464,"completion":4928,"start":4929,"enrollment":712,"conditions":4930,"interventions":4931},"NCT00003049","Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas",[92],"2007-07","1997-05",[4862],[4865,3625],{"trials":4933,"activeCount":128},[],{"trials":4935,"activeCount":128},[],{"intervention":539,"totalTrials":1197,"cells":4937},{"EARLY_PHASE1":4938,"PHASE1":4940,"PHASE2":4950,"PHASE3":4968,"PHASE4":4970,"NA":4972},{"trials":4939,"activeCount":128},[],{"trials":4941,"activeCount":676,"soonestReadout":4562},[4942,4946],{"nctId":4868,"briefTitle":4869,"status":104,"phases":4943,"primaryCompletion":4871,"completion":4871,"start":4872,"conditions":4944,"interventions":4945},[90],[4293],[4865,4866,3625,4875],{"nctId":4559,"briefTitle":4560,"status":265,"phases":4947,"primaryCompletion":4562,"completion":4563,"start":4564,"enrollment":4565,"conditions":4948,"interventions":4949},[90],[193,4344,528,4567,4353],[4569,537,538,112,539],{"trials":4951,"activeCount":342,"soonestReadout":4680},[4952,4956,4960,4964],{"nctId":4677,"briefTitle":4678,"status":265,"phases":4953,"primaryCompletion":4680,"completion":4680,"start":4681,"enrollment":3435,"conditions":4954,"interventions":4955},[91],[4683,4341,4684,4343,4685,191],[537,538,539,346,4645],{"nctId":4077,"briefTitle":4078,"status":265,"phases":4957,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":2678,"conditions":4958,"interventions":4959},[91],[4084,3422,414,144,4085,3398,4086,4087],[536,4089,4090,305,4091,161,4092,539,163,4093],{"nctId":519,"briefTitle":520,"status":104,"phases":4961,"primaryCompletion":522,"completion":523,"start":524,"enrollment":525,"conditions":4962,"interventions":4963},[90,91],[527,528,529,530,531,532,533,534],[536,537,538,539,540,72],{"nctId":553,"briefTitle":554,"status":265,"phases":4965,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":4966,"interventions":4967},[91],[560,561,562,563,564,565],[537,567,568,539,72,569,570],{"trials":4969,"activeCount":128},[],{"trials":4971,"activeCount":128},[],{"trials":4973,"activeCount":128},[],{"intervention":52,"totalTrials":681,"cells":4975},{"EARLY_PHASE1":4976,"PHASE1":4978,"PHASE2":5013,"PHASE3":5019,"PHASE4":5021,"NA":5023},{"trials":4977,"activeCount":128},[],{"trials":4979,"activeCount":342,"soonestReadout":51},[4980,4993,4997],{"nctId":4981,"briefTitle":4982,"status":265,"phases":4983,"primaryCompletion":1738,"completion":3433,"start":4984,"enrollment":3674,"conditions":4985,"interventions":4992},"NCT06508463","Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma",[90],"2024-01-05",[4986,4987,4988,4989,478,4990,4991],"Peripheral T Cell Lymphoma","Relapsed Peripheral T-Cell Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified","Anaplastic Large Cell Lymphoma","Relapsed Anaplastic Large Cell Lymphoma","Relapsed Mycosis Fungoides",[52,3450],{"nctId":3430,"briefTitle":3431,"status":265,"phases":4994,"primaryCompletion":1738,"completion":3433,"start":3434,"enrollment":3435,"conditions":4995,"interventions":4996},[90],[3396,3437,3438,3439,3440,3441,3442,145,303,147,418,3443,3444,3445,150,3446,3447,153,3448],[57,52,3450,3451,3452,112],{"nctId":49,"briefTitle":50,"status":169,"phases":4998,"primaryCompletion":51,"completion":4999,"start":5000,"enrollment":885,"conditions":5001,"interventions":5011},[90],"2028-01-01","2017-09-15",[607,5002,5003,5004,5005,5006,5007,5008,5009,5010],"Recurrent Endometrial Adenocarcinoma","Recurrent Endometrial Carcinoma","Recurrent Endometrial Clear Cell Adenocarcinoma","Recurrent Endometrial Endometrioid Adenocarcinoma","Recurrent Endometrial Mixed Cell Adenocarcinoma","Recurrent Endometrial Serous Adenocarcinoma","Recurrent Endometrial Undifferentiated Carcinoma","Recurrent Uterine Corpus Carcinosarcoma","Stage IV Uterine Corpus Cancer AJCC v7",[52,223,5012],"Technetium Tc-99m Sodium Pertechnetate",{"trials":5014,"activeCount":676,"soonestReadout":4632},[5015],{"nctId":4629,"briefTitle":4630,"status":1096,"phases":5016,"primaryCompletion":4632,"completion":4632,"start":4633,"enrollment":108,"conditions":5017,"interventions":5018},[91],[4635,4636,615,630],[4557,112,52],{"trials":5020,"activeCount":128},[],{"trials":5022,"activeCount":128},[],{"trials":5024,"activeCount":128},[],{"intervention":3427,"totalTrials":301,"cells":5026},{"EARLY_PHASE1":5027,"PHASE1":5038,"PHASE2":5044,"PHASE3":5133,"PHASE4":5135,"NA":5148},{"trials":5028,"activeCount":128},[5029],{"nctId":5030,"briefTitle":5031,"status":104,"phases":5032,"primaryCompletion":5033,"completion":3643,"start":5034,"enrollment":3002,"conditions":5035,"interventions":5037},"NCT00486421","Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura",[89],"2008-05","2007-01",[5036],"Nonneoplastic Condition",[163,3427],{"trials":5039,"activeCount":676,"soonestReadout":56},[5040],{"nctId":54,"briefTitle":55,"status":169,"phases":5041,"primaryCompletion":56,"completion":3408,"start":3409,"enrollment":773,"conditions":5042,"interventions":5043},[90],[3411,3412,3413,3414,3415,3416,3417,3418,3419,3420,3421,3422,3423,413],[57,347,3425,3354,3426,3427,163,3428],{"trials":5045,"activeCount":342,"soonestReadout":5058},[5046,5054,5066,5076,5080,5084,5088,5100,5111],{"nctId":5047,"briefTitle":5048,"status":104,"phases":5049,"primaryCompletion":1390,"completion":5050,"start":5051,"enrollment":31,"conditions":5052,"interventions":5053},"NCT00477750","Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma",[90,91],"2013-08-05","2005-06",[3665],[3539,3759,3525],{"nctId":5055,"briefTitle":5056,"status":169,"phases":5057,"primaryCompletion":5058,"completion":5058,"start":5059,"enrollment":2563,"conditions":5060,"interventions":5064},"NCT05689021","CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations",[91],"2026-07-31","2024-03-05",[5061,5062,5063],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8",[5065,3427],"Abiraterone Acetate\u002FNiraparib",{"nctId":5067,"briefTitle":5068,"status":1413,"phases":5069,"primaryCompletion":5070,"completion":5070,"start":5071,"enrollment":128,"conditions":5072,"interventions":5074},"NCT01893658","Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)",[91],"2018-09-28","2018-06-01",[5073],"Acute Interstitial Nephritis",[5075,3427],"Omalizumab",{"nctId":3516,"briefTitle":3517,"status":104,"phases":5077,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":3002,"conditions":5078,"interventions":5079},[91],[3522,3523],[3323,3525,3526],{"nctId":3610,"briefTitle":3611,"status":1413,"phases":5081,"primaryCompletion":905,"completion":2697,"start":3613,"enrollment":128,"conditions":5082,"interventions":5083},[91],[3615,3616,3617,3618,3619],[3621,3553,3323,3324,3327,3622,3623,3525,3624,3514,3625],{"nctId":3627,"briefTitle":3628,"status":104,"phases":5085,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":5086,"interventions":5087},[90,91],[1419],[3552,3553,3323,3324,3539,3525,3327,3636],{"nctId":5089,"briefTitle":5090,"status":265,"phases":5091,"primaryCompletion":5092,"completion":5093,"start":5094,"enrollment":2742,"conditions":5095,"interventions":5097},"NCT06676579","Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)",[91],"2028-03-02","2029-03-02","2025-06-09",[5096],"IgA Nephropathy (IgAN)",[5098,3427,1342,5099],"Avacopan","Prednisolone",{"nctId":5101,"briefTitle":5102,"status":104,"phases":5103,"primaryCompletion":1299,"completion":3662,"start":5104,"enrollment":498,"conditions":5105,"interventions":5108},"NCT00004482","Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis",[91],"1999-12",[5106,5107],"Myocarditis","Giant Cell Myocarditis",[5109,2627,5110,3525],"Cyclosporine","Muromonab-CD3",{"nctId":5112,"briefTitle":5113,"status":265,"phases":5114,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":5117,"conditions":5118,"interventions":5122},"NCT06378866","Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial",[91],"2031-02-28","2024-06-03",532,[5119,5120,5121,3298],"Recurrent Castration-Sensitive Prostate Carcinoma","Recurrent Prostate Cancer","Castration-resistant Prostate Cancer",[5123,5124,5125,5126,5127,5128,5129,5130,3427,5131,5132],"Abiraterone","Apalutamide","Darolutamide","Degarelix","Enzalutamide","Goserelin","Histrelin","Leuprolide","Relugolix","Triptorelin",{"trials":5134,"activeCount":128},[],{"trials":5136,"activeCount":128},[5137],{"nctId":5138,"briefTitle":5139,"status":104,"phases":5140,"primaryCompletion":2643,"completion":5141,"start":5142,"enrollment":1162,"conditions":5143,"interventions":5145},"NCT00275535","The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients",[93],"2008-12","2001-04",[5144],"Kidney Diseases",[5146,5147,3427,3745,4283],"Anti-thymocyte globulin","Mycophenolate mofetil",{"trials":5149,"activeCount":128},[5150],{"nctId":5151,"briefTitle":5152,"status":134,"phases":5153,"primaryCompletion":3613,"completion":3613,"start":3546,"enrollment":224,"conditions":5154,"interventions":5156},"NCT00934791","Polycystic Liver Disease in Kidney Transplant",[94],[5155],"Polycystic Liver Disease",[3745,4283,1698,3427],{"intervention":5158,"totalTrials":1197,"cells":5159},"Chemotherapy",{"EARLY_PHASE1":5160,"PHASE1":5162,"PHASE2":5187,"PHASE3":5209,"PHASE4":5211,"NA":5213},{"trials":5161,"activeCount":128},[],{"trials":5163,"activeCount":676,"soonestReadout":5168},[5164,5176],{"nctId":5165,"briefTitle":5166,"status":265,"phases":5167,"primaryCompletion":5168,"completion":5168,"start":1150,"enrollment":2555,"conditions":5169,"interventions":5175},"NCT06997094","Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer",[90],"2027-11-08",[5170,5171,5172,5173,5174],"Human Papillomavirus-Negative Neck Squamous Cell Carcinoma","Resectable Head and Neck Squamous Cell Carcinoma","Resectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma","HPV-Negative Squamous Cell Carcinoma","Resectable Head and Neck Squamous-cell Carcinoma",[5158,4093],{"nctId":5177,"briefTitle":5178,"status":134,"phases":5179,"primaryCompletion":5180,"completion":5181,"start":5182,"enrollment":2742,"conditions":5183,"interventions":5185},"NCT02671890","Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer",[90],"2024-05-08","2024-11-11","2016-02-25",[561,5184,564],"Refractory Malignant Solid Neoplasm",[5158,5186,161],"Disulfiram",{"trials":5188,"activeCount":676,"soonestReadout":5193},[5189,5200],{"nctId":5190,"briefTitle":5191,"status":265,"phases":5192,"primaryCompletion":5193,"completion":5194,"start":5195,"enrollment":785,"conditions":5196,"interventions":5199},"NCT06635980","Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer",[91],"2031-10-21","2034-10-21","2025-05-14",[5197,5198,579,30,221],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8",[5158],{"nctId":5201,"briefTitle":5202,"status":134,"phases":5203,"primaryCompletion":5204,"completion":5204,"start":5205,"enrollment":342,"conditions":5206,"interventions":5208},"NCT04975516","Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer",[91],"2025-11-15","2023-07-18",[561,564,4598,5207],"Oligometastatic Pancreatic Ductal Adenocarcinoma",[5158],{"trials":5210,"activeCount":128},[],{"trials":5212,"activeCount":128},[],{"trials":5214,"activeCount":224,"soonestReadout":5229},[5215,5225],{"nctId":5216,"briefTitle":5217,"status":265,"phases":5218,"primaryCompletion":5219,"completion":5219,"start":5220,"enrollment":9,"conditions":5221,"interventions":5224},"NCT07188532","Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial",[94],"2029-12-31","2025-11-24",[5222,5223],"Ewing Sarcoma","Round Cell Sarcoma With EWSR1-non-ETS Fusion",[5158],{"nctId":5226,"briefTitle":5227,"status":265,"phases":5228,"primaryCompletion":5229,"completion":5229,"start":5230,"enrollment":785,"conditions":5231,"interventions":5233},"NCT07074756","A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma",[94],"2028-08-31","2025-09-12",[4747,5232],"Recurrent Glioma",[5158],{"intervention":163,"totalTrials":34,"cells":5235},{"EARLY_PHASE1":5236,"PHASE1":5250,"PHASE2":5300,"PHASE3":5458,"PHASE4":5495,"NA":5497},{"trials":5237,"activeCount":128},[5238,5242],{"nctId":5030,"briefTitle":5031,"status":104,"phases":5239,"primaryCompletion":5033,"completion":3643,"start":5034,"enrollment":3002,"conditions":5240,"interventions":5241},[89],[5036],[163,3427],{"nctId":5243,"briefTitle":5244,"status":104,"phases":5245,"primaryCompletion":5246,"completion":4785,"start":3519,"enrollment":173,"conditions":5247,"interventions":5249},"NCT00405340","Rituximab in the Treatment of Idiopathic Membranous Nephropathy",[89],"2010-07",[5248],"Membranous Nephropathy",[163],{"trials":5251,"activeCount":676,"soonestReadout":56},[5252,5256,5267,5275,5284,5288],{"nctId":132,"briefTitle":133,"status":134,"phases":5253,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":5254,"interventions":5255},[90],[141,142,143,144,145,146,147,148,149,150,151,152,153,154],[156,157,158,159,160,161,112,162,72,163,164,165],{"nctId":5257,"briefTitle":5258,"status":104,"phases":5259,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":729,"conditions":5263,"interventions":5264},"NCT00477815","Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma",[90],"2011-07-28","2018-05-07","2005-05-31",[3665],[3553,3759,5265,657,5266],"Stem Cell","111In Zevalin",{"nctId":5268,"briefTitle":5269,"status":104,"phases":5270,"primaryCompletion":4871,"completion":4871,"start":5271,"conditions":5272,"interventions":5273},"NCT00004260","Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",[90],"1999-10",[1419],[5274,3553],"recombinant interleukin-12",{"nctId":5276,"briefTitle":5277,"status":104,"phases":5278,"primaryCompletion":5279,"completion":5279,"start":5280,"enrollment":370,"conditions":5281,"interventions":5283},"NCT00275613","Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis",[90],"2009-03","2005-11",[5282],"Glomerulonephritis, Membranoproliferative",[163],{"nctId":54,"briefTitle":55,"status":169,"phases":5285,"primaryCompletion":56,"completion":3408,"start":3409,"enrollment":773,"conditions":5286,"interventions":5287},[90],[3411,3412,3413,3414,3415,3416,3417,3418,3419,3420,3421,3422,3423,413],[57,347,3425,3354,3426,3427,163,3428],{"nctId":5289,"briefTitle":5290,"status":104,"phases":5291,"primaryCompletion":5292,"completion":5292,"start":2719,"enrollment":1197,"conditions":5293,"interventions":5299},"NCT02705638","Treatment of IgG4-Related Disease With Revlimid and Rituximab",[90],"2019-04",[5294,5295,5296,5297,5298],"Immunoglobulin G Subclass 4 Related Disease","IgG4-related Disease","Autoimmune Pancreatitis","IgG4-related Sclerosing Cholangitis","Retroperitoneal Fibrosis",[163,551],{"trials":5301,"activeCount":224,"soonestReadout":5381},[5302,5310,5331,5335,5339,5343,5347,5356,5366,5373,5377,5401,5409,5413,5427,5431,5439,5450],{"nctId":5303,"briefTitle":5304,"status":104,"phases":5305,"primaryCompletion":5306,"completion":5306,"start":3641,"enrollment":476,"conditions":5307,"interventions":5309},"NCT01573533","A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS",[91],"2018-11-15",[5308],"Primary Focal Segmental Glomerulosclerosis",[163],{"nctId":5311,"briefTitle":5312,"status":1413,"phases":5313,"primaryCompletion":5314,"start":1337,"enrollment":128,"conditions":5315,"interventions":5329},"NCT02281279","Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",[90,91],"2020-10",[3615,5316,3856,5317,5318,5319,3858,5320,5321,5322,5323,5324,434,435,436,416,417,439,5325,5326,3678,5327,5328],"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Nodal Marginal Zone B-cell Lymphoma","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Refractory Hairy Cell Leukemia","Small Intestine Lymphoma","Testicular Lymphoma","Waldenström Macroglobulinemia",[3553,3539,5330],"romidepsin",{"nctId":3541,"briefTitle":3542,"status":104,"phases":5332,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":5333,"interventions":5334},[91],[3549,1419],[3551,3552,3553,3323,3554],{"nctId":3610,"briefTitle":3611,"status":1413,"phases":5336,"primaryCompletion":905,"completion":2697,"start":3613,"enrollment":128,"conditions":5337,"interventions":5338},[91],[3615,3616,3617,3618,3619],[3621,3553,3323,3324,3327,3622,3623,3525,3624,3514,3625],{"nctId":3627,"briefTitle":3628,"status":104,"phases":5340,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":5341,"interventions":5342},[90,91],[1419],[3552,3553,3323,3324,3539,3525,3327,3636],{"nctId":3638,"briefTitle":3639,"status":104,"phases":5344,"primaryCompletion":3641,"completion":3642,"start":3643,"enrollment":187,"conditions":5345,"interventions":5346},[91],[1419],[3553,3323,3514,3539],{"nctId":5348,"briefTitle":5349,"status":104,"phases":5350,"primaryCompletion":5351,"completion":3842,"start":5352,"enrollment":729,"conditions":5353,"interventions":5354},"NCT00436904","Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia",[91],"2008-07","2004-12",[3549],[5355,163],"Alemtuzumab",{"nctId":5357,"briefTitle":5358,"status":104,"phases":5359,"primaryCompletion":5360,"completion":5361,"start":3520,"enrollment":956,"conditions":5362,"interventions":5364},"NCT00438880","Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",[90,91],"2010-10","2014-11",[5363,3676,3677,3858,434,435,436,416,417,439,3678,451],"Adult Non-Hodgkin Lymphoma",[5365,163],"Agatolimod Sodium",{"nctId":5367,"briefTitle":5368,"status":134,"phases":5369,"primaryCompletion":3717,"completion":2787,"start":4391,"enrollment":3674,"conditions":5370,"interventions":5372},"NCT00588822","Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance",[91],[5371],"Precancerous Condition",[163],{"nctId":3668,"briefTitle":3669,"status":104,"phases":5374,"primaryCompletion":3671,"completion":3672,"start":3673,"enrollment":3674,"conditions":5375,"interventions":5376},[91],[3676,3677,434,435,416,439,443,3678,451],[3680,163,57,305],{"nctId":5378,"briefTitle":5379,"status":265,"phases":5380,"primaryCompletion":5381,"completion":5381,"start":5382,"enrollment":28,"conditions":5383,"interventions":5398},"NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy",[91],"2027-03-03","2025-04-02",[5384,5385,5386,5387,374,5388,375,376,377,5389,381,382,383,5390,385,5391,5392,5393,5394,387,5395,388,389,390,5396,394,395,396,397,398,5397],"Large B-Cell Lymphoma With IRF4 Rearrangement","Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma","Recurrent ALK-Positive Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","Recurrent Primary Mediastinal Large B-Cell Lymphoma","Recurrent Transformed Non-Hodgkin Lymphoma","Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","Refractory ALK-Positive Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","Refractory Transformed Non-Hodgkin Lymphoma",[5399,5400,163],"Chimeric Antigen Receptor T-Cell Therapy","Golcadomide",{"nctId":5402,"briefTitle":5403,"status":104,"phases":5404,"primaryCompletion":3569,"completion":5405,"start":5351,"enrollment":28,"conditions":5406,"interventions":5407},"NCT00669318","Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[91],"2014-05",[3549,1419],[5408,3553,3554,4405],"alemtuzumab",{"nctId":3730,"briefTitle":3731,"status":104,"phases":5410,"primaryCompletion":946,"completion":3733,"start":3734,"enrollment":461,"conditions":5411,"interventions":5412},[91],[3549,1419],[163,57,551,3585],{"nctId":5414,"briefTitle":5415,"status":104,"phases":5416,"primaryCompletion":5417,"completion":5418,"start":4810,"enrollment":3002,"conditions":5419,"interventions":5421},"NCT01269385","Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia",[90,91],"2014-06","2015-06",[5420,443,3574,3575,3577],"B-cell Chronic Lymphocytic Leukemia",[5408,3553,5422,5423,5424,5425,3636,5426],"PGG beta-glucan","DNA analysis","fluorescence in situ hybridization","polymerase chain reaction","mutation analysis",{"nctId":4077,"briefTitle":4078,"status":265,"phases":5428,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":2678,"conditions":5429,"interventions":5430},[91],[4084,3422,414,144,4085,3398,4086,4087],[536,4089,4090,305,4091,161,4092,539,163,4093],{"nctId":5432,"briefTitle":5433,"status":104,"phases":5434,"primaryCompletion":5435,"completion":5435,"start":5361,"enrollment":410,"conditions":5436,"interventions":5438},"NCT02197767","Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis",[91],"2017-04",[5437],"Fibrillary Glomerulonephritis",[3553],{"nctId":5440,"briefTitle":5441,"status":134,"phases":5442,"primaryCompletion":5443,"completion":5443,"start":5444,"enrollment":1197,"conditions":5445,"interventions":5449},"NCT05376319","PR3-AAV Resilient Remission or PRRR",[91],"2024-05-07","2023-06-30",[5446,5447,5448],"Granulomatosis With Polyangiitis","Microscopic Polyangiitis","ANCA Associated Vasculitis",[162,163],{"nctId":5451,"briefTitle":5452,"status":104,"phases":5453,"primaryCompletion":5454,"completion":5455,"start":4503,"enrollment":31,"conditions":5456,"interventions":5457},"NCT00562328","Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia",[91],"2010-02-05","2014-12-18",[3549],[5355,163,657],{"trials":5459,"activeCount":128},[5460,5468,5476],{"nctId":5461,"briefTitle":5462,"status":104,"phases":5463,"primaryCompletion":5464,"completion":5464,"start":3842,"enrollment":1320,"conditions":5465,"interventions":5467},"NCT01180036","MEmbranous Nephropathy Trial Of Rituximab",[91,92],"2017-10-01",[5466],"Idiopathic Membranous Nephropathy",[163,5109],{"nctId":5469,"briefTitle":5470,"status":104,"phases":5471,"primaryCompletion":5472,"completion":5472,"start":5473,"enrollment":4565,"conditions":5474,"interventions":5475},"NCT00425217","Rituximab in Membranous Nephropathy",[91,92],"2007-04","2004-08",[5248],[163],{"nctId":5477,"briefTitle":5478,"status":134,"phases":5479,"primaryCompletion":5480,"completion":5481,"start":5482,"enrollment":173,"conditions":5483,"interventions":5494},"NCT02320292","Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma",[92],"2021-02-28","2023-11-09","2015-02-11",[5484,5485,5486,5487,5488,5489,5490,5491,5492,5493],"Ann Arbor Stage I Grade 1 Follicular Lymphoma","Ann Arbor Stage I Grade 2 Follicular Lymphoma","Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma","Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma","Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma","Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma","Ann Arbor Stage III Grade 1 Follicular Lymphoma","Ann Arbor Stage III Grade 2 Follicular Lymphoma","Ann Arbor Stage IV Grade 1 Follicular Lymphoma","Ann Arbor Stage IV Grade 2 Follicular Lymphoma",[163],{"trials":5496,"activeCount":128},[],{"trials":5498,"activeCount":128},[],{"intervention":346,"totalTrials":2563,"cells":5500},{"EARLY_PHASE1":5501,"PHASE1":5503,"PHASE2":5505,"PHASE3":5568,"PHASE4":5574,"NA":5576},{"trials":5502,"activeCount":128},[],{"trials":5504,"activeCount":128},[],{"trials":5506,"activeCount":342,"soonestReadout":171},[5507,5511,5523,5538,5542,5554,5558],{"nctId":4677,"briefTitle":4678,"status":265,"phases":5508,"primaryCompletion":4680,"completion":4680,"start":4681,"enrollment":3435,"conditions":5509,"interventions":5510},[91],[4683,4341,4684,4343,4685,191],[537,538,539,346,4645],{"nctId":5512,"briefTitle":5513,"status":104,"phases":5514,"primaryCompletion":5515,"completion":5515,"start":5516,"enrollment":5517,"conditions":5518,"interventions":5519},"NCT00645866","Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer",[91],"2006-03","2003-04",47,[21],[5520,5521,5522],"capecitabine","docetaxel","epirubicin hydrochloride",{"nctId":5524,"briefTitle":5525,"status":104,"phases":5526,"primaryCompletion":5527,"completion":5528,"start":5529,"enrollment":696,"conditions":5530,"interventions":5537},"NCT01932697","Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer",[91],"2016-10-20","2021-12-28","2013-09-04",[5531,5532,5533,5534,5535,5536],"Human Papillomavirus Infection","Stage I Oropharyngeal Squamous Cell Carcinoma","Stage II Oropharyngeal Squamous Cell Carcinoma","Stage III Oropharyngeal Squamous Cell Carcinoma","Stage IVA Oropharyngeal Squamous Cell Carcinoma","Stage IVB Oropharyngeal Squamous Cell Carcinoma",[346],{"nctId":336,"briefTitle":337,"status":104,"phases":5539,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":5540,"interventions":5541},[91],[344],[346,347,72],{"nctId":5543,"briefTitle":5544,"status":265,"phases":5545,"primaryCompletion":171,"completion":171,"start":5546,"enrollment":498,"conditions":5547,"interventions":5552},"NCT06704191","In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial",[90,91],"2025-04-21",[5548,5549,5550,5551],"Non-Muscle Invasive Bladder Carcinoma","Stage 0a Bladder Cancer AJCC v8","Stage I Bladder Cancer AJCC v8","Stage 0is Bladder Cancer AJCC v8",[5553,346,4600,4375],"BCG Solution",{"nctId":4408,"briefTitle":4409,"status":265,"phases":5555,"primaryCompletion":4411,"completion":4412,"start":4413,"enrollment":4414,"conditions":5556,"interventions":5557},[91],[4416,4417,247,4418,4419,4420,4421],[4089,346],{"nctId":5559,"briefTitle":5560,"status":134,"phases":5561,"primaryCompletion":5562,"completion":5562,"start":5563,"enrollment":370,"conditions":5564,"interventions":5566},"NCT04396535","Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer",[91],"2023-12-31","2020-10-23",[5565,614,618,622,624,207,633,637],"Advanced Lung Non-Small Cell Carcinoma",[5567,346],"Bintrafusp Alfa",{"trials":5569,"activeCount":128},[5570],{"nctId":4473,"briefTitle":4474,"status":104,"phases":5571,"primaryCompletion":4476,"completion":4477,"start":4478,"enrollment":4479,"conditions":5572,"interventions":5573},[92],[4481],[346,4089],{"trials":5575,"activeCount":128},[],{"trials":5577,"activeCount":128},[],{"intervention":540,"totalTrials":476,"cells":5579},{"EARLY_PHASE1":5580,"PHASE1":5582,"PHASE2":5584,"PHASE3":5659,"PHASE4":5661,"NA":5663},{"trials":5581,"activeCount":128},[],{"trials":5583,"activeCount":128},[],{"trials":5585,"activeCount":342,"soonestReadout":81},[5586,5590,5594,5623,5636,5640,5644,5648,5652],{"nctId":4333,"briefTitle":4334,"status":692,"phases":5587,"primaryCompletion":4336,"completion":4337,"start":4338,"enrollment":2742,"conditions":5588,"interventions":5589},[91],[4340,4341,4342,4343,190,191,4344,528],[4089,4270,540],{"nctId":4781,"briefTitle":4782,"status":134,"phases":5591,"primaryCompletion":4784,"completion":4785,"start":4786,"enrollment":218,"conditions":5592,"interventions":5593},[91],[4291],[3482,3597,4768],{"nctId":5595,"briefTitle":5596,"status":134,"phases":5597,"primaryCompletion":5598,"completion":5598,"start":5599,"enrollment":139,"conditions":5600,"interventions":5620},"NCT02364713","MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer",[91],"2022-01-13","2015-03-13",[500,5601,5602,5603,5604,5605,5606,5607,5608,5609,5610,5611,5612,5613,5614,3491,3492,3493,501,5615,5616,5617,5618,5619,502,506,511],"Fallopian Tube Clear Cell Adenocarcinoma","Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube Mucinous Adenocarcinoma","Fallopian Tube Serous Adenocarcinoma","Fallopian Tube Transitional Cell Carcinoma","Fallopian Tube Undifferentiated Carcinoma","Ovarian Carcinosarcoma","Ovarian Clear Cell Adenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian Mucinous Adenocarcinoma","Ovarian Seromucinous Carcinoma","Ovarian Serous Adenocarcinoma","Ovarian Transitional Cell Carcinoma","Ovarian Undifferentiated Carcinoma","Primary Peritoneal Clear Cell Adenocarcinoma","Primary Peritoneal Endometrioid Adenocarcinoma","Primary Peritoneal Serous Adenocarcinoma","Primary Peritoneal Transitional Cell Carcinoma","Primary Peritoneal Undifferentiated Carcinoma",[4719,161,67,540,5621,5622],"Pegylated Liposomal Doxorubicin Hydrochloride","Topotecan Hydrochloride",{"nctId":79,"briefTitle":80,"status":169,"phases":5624,"primaryCompletion":81,"completion":5625,"start":5626,"enrollment":139,"conditions":5627,"interventions":5631},[91],"2026-06-13","2017-08-03",[5628,5629,579,583,5630],"Advanced Breast Carcinoma","HER2-Positive Breast Carcinoma","HER2-positive Breast Cancer",[82,5632,5633,5634,5635,540,165],"Denifanstat","Exemestane","Fulvestrant","Letrozole",{"nctId":3587,"briefTitle":3588,"status":104,"phases":5637,"primaryCompletion":1563,"completion":3590,"start":3591,"enrollment":936,"conditions":5638,"interventions":5639},[91],[21,3593],[3595,3323,3324,3596,3597,3598,3599],{"nctId":4347,"briefTitle":4348,"status":265,"phases":5641,"primaryCompletion":4350,"completion":4350,"start":4351,"enrollment":498,"conditions":5642,"interventions":5643},[91],[4344,528,4353],[4089,540,4270],{"nctId":519,"briefTitle":520,"status":104,"phases":5645,"primaryCompletion":522,"completion":523,"start":524,"enrollment":525,"conditions":5646,"interventions":5647},[90,91],[527,528,529,530,531,532,533,534],[536,537,538,539,540,72],{"nctId":4428,"briefTitle":4429,"status":104,"phases":5649,"primaryCompletion":4431,"completion":4431,"start":4432,"enrollment":173,"conditions":5650,"interventions":5651},[91],[4434,4435,614,645],[536,4089,4091,540,4437],{"nctId":5653,"briefTitle":5654,"status":104,"phases":5655,"primaryCompletion":1310,"completion":1310,"start":5656,"enrollment":301,"conditions":5657,"interventions":5658},"NCT02312245","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[91],"2015-07-21",[502,506,511],[4719,161,540,5621,5622],{"trials":5660,"activeCount":128},[],{"trials":5662,"activeCount":128},[],{"trials":5664,"activeCount":128},[],{"intervention":3693,"totalTrials":681,"cells":5666},{"EARLY_PHASE1":5667,"PHASE1":5673,"PHASE2":5682,"PHASE3":5695,"PHASE4":5697,"NA":5699},{"trials":5668,"activeCount":676,"soonestReadout":4744},[5669],{"nctId":4741,"briefTitle":4742,"status":265,"phases":5670,"primaryCompletion":4744,"completion":4744,"start":4745,"enrollment":370,"conditions":5671,"interventions":5672},[89],[4747],[3693,4749,4750,3694,334],{"trials":5674,"activeCount":128},[5675],{"nctId":5676,"briefTitle":5677,"status":104,"phases":5678,"primaryCompletion":5455,"completion":5455,"start":3673,"enrollment":97,"conditions":5679,"interventions":5680},"NCT00662636","Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery",[90],[4293],[5681,3596],"dasatinib",{"trials":5683,"activeCount":224,"soonestReadout":921},[5684,5691],{"nctId":5685,"briefTitle":5686,"status":169,"phases":5687,"primaryCompletion":921,"completion":921,"start":5688,"enrollment":173,"conditions":5689,"interventions":5690},"NCT04785300","ALSENLITE: Senolytics for Alzheimer's Disease",[90,91],"2022-07-06",[2001,1654],[3693,3694],{"nctId":3682,"briefTitle":3683,"status":265,"phases":5692,"primaryCompletion":3685,"completion":3685,"start":3686,"enrollment":3687,"conditions":5693,"interventions":5694},[91],[3689,3690],[3692,57,3693,3405,3694],{"trials":5696,"activeCount":128},[],{"trials":5698,"activeCount":128},[],{"trials":5700,"activeCount":128},[],{"intervention":4270,"totalTrials":681,"cells":5702},{"EARLY_PHASE1":5703,"PHASE1":5709,"PHASE2":5711,"PHASE3":5725,"PHASE4":5727,"NA":5729},{"trials":5704,"activeCount":128},[5705],{"nctId":4243,"briefTitle":4244,"status":134,"phases":5706,"primaryCompletion":3825,"completion":4246,"start":4247,"enrollment":224,"conditions":5707,"interventions":5708},[89],[3113,3115,4249,4250,502,4251,4252,4253,506,511,4254,4255,4256,4257,4258,3498,4259,4260,4261,3500,3501,4262,4263,4264,4265,4266,4267],[4089,4269,4270,4271],{"trials":5710,"activeCount":128},[],{"trials":5712,"activeCount":342,"soonestReadout":4336},[5713,5717,5721],{"nctId":4333,"briefTitle":4334,"status":692,"phases":5714,"primaryCompletion":4336,"completion":4337,"start":4338,"enrollment":2742,"conditions":5715,"interventions":5716},[91],[4340,4341,4342,4343,190,191,4344,528],[4089,4270,540],{"nctId":4347,"briefTitle":4348,"status":265,"phases":5718,"primaryCompletion":4350,"completion":4350,"start":4351,"enrollment":498,"conditions":5719,"interventions":5720},[91],[4344,528,4353],[4089,540,4270],{"nctId":4377,"briefTitle":4378,"status":265,"phases":5722,"primaryCompletion":4380,"completion":4380,"start":4381,"enrollment":498,"conditions":5723,"interventions":5724},[91],[4383,564,4353],[4089,4270,4385],{"trials":5726,"activeCount":128},[],{"trials":5728,"activeCount":128},[],{"trials":5730,"activeCount":128},[],{"intervention":3819,"totalTrials":681,"cells":5732},{"EARLY_PHASE1":5733,"PHASE1":5735,"PHASE2":5745,"PHASE3":5761,"PHASE4":5763,"NA":5765},{"trials":5734,"activeCount":128},[],{"trials":5736,"activeCount":676,"soonestReadout":3824},[5737,5741],{"nctId":3810,"briefTitle":3811,"status":104,"phases":5738,"primaryCompletion":3813,"completion":3814,"start":3815,"enrollment":2563,"conditions":5739,"interventions":5740},[90],[303,3817],[305,306,3819],{"nctId":3821,"briefTitle":3822,"status":265,"phases":5742,"primaryCompletion":3824,"completion":3824,"start":3825,"enrollment":712,"conditions":5743,"interventions":5744},[90],[3562],[159,305,551,3819],{"trials":5746,"activeCount":224,"soonestReadout":5755},[5747,5751],{"nctId":4688,"briefTitle":4689,"status":265,"phases":5748,"primaryCompletion":4691,"completion":4691,"start":4692,"enrollment":97,"conditions":5749,"interventions":5750},[91],[3573,450,419],[4695,4645,3819],{"nctId":5752,"briefTitle":5753,"status":169,"phases":5754,"primaryCompletion":5755,"completion":5756,"start":5757,"enrollment":2894,"conditions":5758,"interventions":5759},"NCT05677919","Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia",[91],"2026-11-11","2030-09-03","2023-01-31",[3573,419],[5760,3819],"Pirtobrutinib",{"trials":5762,"activeCount":128},[],{"trials":5764,"activeCount":128},[],{"trials":5766,"activeCount":128},[],{"intervention":3694,"totalTrials":342,"cells":5768},{"EARLY_PHASE1":5769,"PHASE1":5775,"PHASE2":5777,"PHASE3":5787,"PHASE4":5789,"NA":5791},{"trials":5770,"activeCount":676,"soonestReadout":4744},[5771],{"nctId":4741,"briefTitle":4742,"status":265,"phases":5772,"primaryCompletion":4744,"completion":4744,"start":4745,"enrollment":370,"conditions":5773,"interventions":5774},[89],[4747],[3693,4749,4750,3694,334],{"trials":5776,"activeCount":128},[],{"trials":5778,"activeCount":224,"soonestReadout":921},[5779,5783],{"nctId":5685,"briefTitle":5686,"status":169,"phases":5780,"primaryCompletion":921,"completion":921,"start":5688,"enrollment":173,"conditions":5781,"interventions":5782},[90,91],[2001,1654],[3693,3694],{"nctId":3682,"briefTitle":3683,"status":265,"phases":5784,"primaryCompletion":3685,"completion":3685,"start":3686,"enrollment":3687,"conditions":5785,"interventions":5786},[91],[3689,3690],[3692,57,3693,3405,3694],{"trials":5788,"activeCount":128},[],{"trials":5790,"activeCount":128},[],{"trials":5792,"activeCount":128},[],{"intervention":3450,"totalTrials":342,"cells":5794},{"EARLY_PHASE1":5795,"PHASE1":5797,"PHASE2":5807,"PHASE3":5819,"PHASE4":5821,"NA":5823},{"trials":5796,"activeCount":128},[],{"trials":5798,"activeCount":224,"soonestReadout":1738},[5799,5803],{"nctId":4981,"briefTitle":4982,"status":265,"phases":5800,"primaryCompletion":1738,"completion":3433,"start":4984,"enrollment":3674,"conditions":5801,"interventions":5802},[90],[4986,4987,4988,4989,478,4990,4991],[52,3450],{"nctId":3430,"briefTitle":3431,"status":265,"phases":5804,"primaryCompletion":1738,"completion":3433,"start":3434,"enrollment":3435,"conditions":5805,"interventions":5806},[90],[3396,3437,3438,3439,3440,3441,3442,145,303,147,418,3443,3444,3445,150,3446,3447,153,3448],[57,52,3450,3451,3452,112],{"trials":5808,"activeCount":676,"soonestReadout":5813},[5809],{"nctId":5810,"briefTitle":5811,"status":265,"phases":5812,"primaryCompletion":5813,"completion":5813,"start":5814,"enrollment":25,"conditions":5815,"interventions":5817},"NCT06918132","Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer",[91],"2027-04-29","2025-04-29",[4617,5816,4435,618,622],"Stage IB Lung Cancer AJCC v8",[3450,5818],"Fianlimab",{"trials":5820,"activeCount":128},[],{"trials":5822,"activeCount":128},[],{"trials":5824,"activeCount":128},[],{"intervention":3405,"totalTrials":342,"cells":5826},{"EARLY_PHASE1":5827,"PHASE1":5829,"PHASE2":5839,"PHASE3":5845,"PHASE4":5847,"NA":5849},{"trials":5828,"activeCount":128},[],{"trials":5830,"activeCount":224,"soonestReadout":3457},[5831,5835],{"nctId":3390,"briefTitle":3391,"status":265,"phases":5832,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":97,"conditions":5833,"interventions":5834},[90],[3396,432,414,415,416,417,439,3397,443,3398,445,3399,3400,447,3401],[3403,3404,57,3405],{"nctId":3454,"briefTitle":3455,"status":265,"phases":5836,"primaryCompletion":3457,"completion":3458,"start":137,"enrollment":558,"conditions":5837,"interventions":5838},[90],[373,432,439,3397,442,443,447,3401],[3461,3404,57,3405],{"trials":5840,"activeCount":676,"soonestReadout":3685},[5841],{"nctId":3682,"briefTitle":3683,"status":265,"phases":5842,"primaryCompletion":3685,"completion":3685,"start":3686,"enrollment":3687,"conditions":5843,"interventions":5844},[91],[3689,3690],[3692,57,3693,3405,3694],{"trials":5846,"activeCount":128},[],{"trials":5848,"activeCount":128},[],{"trials":5850,"activeCount":128},[],{"intervention":4750,"totalTrials":681,"cells":5852},{"EARLY_PHASE1":5853,"PHASE1":5859,"PHASE2":5861,"PHASE3":5876,"PHASE4":5878,"NA":5880},{"trials":5854,"activeCount":676,"soonestReadout":4744},[5855],{"nctId":4741,"briefTitle":4742,"status":265,"phases":5856,"primaryCompletion":4744,"completion":4744,"start":4745,"enrollment":370,"conditions":5857,"interventions":5858},[89],[4747],[3693,4749,4750,3694,334],{"trials":5860,"activeCount":128},[],{"trials":5862,"activeCount":224,"soonestReadout":4818},[5863,5872],{"nctId":5864,"briefTitle":5865,"status":265,"phases":5866,"primaryCompletion":5867,"completion":5867,"start":5868,"enrollment":5517,"conditions":5869,"interventions":5871},"NCT06667726","An Investigational Scan (18F-DOPA PET\u002FCT) for Improving the Clinical Management of Brain Tumors",[91],"2028-05-31","2026-03-24",[5870],"Malignant Brain Neoplasm",[4750],{"nctId":4815,"briefTitle":4816,"status":169,"phases":5873,"primaryCompletion":4818,"completion":4819,"start":4820,"enrollment":4821,"conditions":5874,"interventions":5875},[91],[330],[4750,334],{"trials":5877,"activeCount":128},[],{"trials":5879,"activeCount":128},[],{"trials":5881,"activeCount":128},[5882],{"nctId":5883,"briefTitle":5884,"status":104,"phases":5885,"primaryCompletion":5886,"completion":5886,"start":5887,"enrollment":476,"conditions":5888,"interventions":5892},"NCT05560009","An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography\u002FMagnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas",[],"2024-07-09","2022-11-10",[5889,5890,5891],"Recurrent Soft Tissue Sarcoma","Resectable Soft Tissue Sarcoma","Soft Tissue Sarcoma",[4750],{"intervention":3625,"totalTrials":120,"cells":5894},{"EARLY_PHASE1":5895,"PHASE1":5897,"PHASE2":5911,"PHASE3":5925,"PHASE4":5931,"NA":5933},{"trials":5896,"activeCount":128},[],{"trials":5898,"activeCount":676,"soonestReadout":4562},[5899,5903,5907],{"nctId":4847,"briefTitle":4848,"status":104,"phases":5900,"primaryCompletion":2936,"completion":4850,"start":1298,"enrollment":120,"conditions":5901,"interventions":5902},[90],[4852,4853,4854,4855,4856,4857,4858,4859,4860,4861,4862,4863],[4865,4866,3625],{"nctId":4868,"briefTitle":4869,"status":104,"phases":5904,"primaryCompletion":4871,"completion":4871,"start":4872,"conditions":5905,"interventions":5906},[90],[4293],[4865,4866,3625,4875],{"nctId":4559,"briefTitle":4560,"status":265,"phases":5908,"primaryCompletion":4562,"completion":4563,"start":4564,"enrollment":4565,"conditions":5909,"interventions":5910},[90],[193,4344,528,4567,4353],[4569,537,538,112,539],{"trials":5912,"activeCount":676,"soonestReadout":4680},[5913,5917,5921],{"nctId":4677,"briefTitle":4678,"status":265,"phases":5914,"primaryCompletion":4680,"completion":4680,"start":4681,"enrollment":3435,"conditions":5915,"interventions":5916},[91],[4683,4341,4684,4343,4685,191],[537,538,539,346,4645],{"nctId":3610,"briefTitle":3611,"status":1413,"phases":5918,"primaryCompletion":905,"completion":2697,"start":3613,"enrollment":128,"conditions":5919,"interventions":5920},[91],[3615,3616,3617,3618,3619],[3621,3553,3323,3324,3327,3622,3623,3525,3624,3514,3625],{"nctId":519,"briefTitle":520,"status":104,"phases":5922,"primaryCompletion":522,"completion":523,"start":524,"enrollment":525,"conditions":5923,"interventions":5924},[90,91],[527,528,529,530,531,532,533,534],[536,537,538,539,540,72],{"trials":5926,"activeCount":128},[5927],{"nctId":4925,"briefTitle":4926,"status":104,"phases":5928,"primaryCompletion":4464,"completion":4928,"start":4929,"enrollment":712,"conditions":5929,"interventions":5930},[92],[4862],[4865,3625],{"trials":5932,"activeCount":128},[],{"trials":5934,"activeCount":128},[],{"intervention":551,"totalTrials":817,"cells":5936},{"EARLY_PHASE1":5937,"PHASE1":5943,"PHASE2":5973,"PHASE3":6083,"PHASE4":6085,"NA":6087},{"trials":5938,"activeCount":128},[5939],{"nctId":3781,"briefTitle":3782,"status":104,"phases":5940,"primaryCompletion":3784,"completion":3785,"start":3786,"enrollment":3674,"conditions":5941,"interventions":5942},[89],[3788,3789],[305,306,551],{"trials":5944,"activeCount":676,"soonestReadout":3824},[5945,5949,5953,5957,5961,5965,5969],{"nctId":3794,"briefTitle":3795,"status":134,"phases":5946,"primaryCompletion":3394,"completion":3394,"start":3797,"enrollment":895,"conditions":5947,"interventions":5948},[90],[549,303,3447],[3800,159,305,551],{"nctId":3802,"briefTitle":3803,"status":134,"phases":5950,"primaryCompletion":3805,"completion":3805,"start":3806,"enrollment":108,"conditions":5951,"interventions":5952},[90],[303,3447],[305,179,551],{"nctId":3821,"briefTitle":3822,"status":265,"phases":5954,"primaryCompletion":3824,"completion":3824,"start":3825,"enrollment":712,"conditions":5955,"interventions":5956},[90],[3562],[159,305,551,3819],{"nctId":3829,"briefTitle":3830,"status":104,"phases":5958,"primaryCompletion":3832,"completion":3833,"start":3834,"enrollment":370,"conditions":5959,"interventions":5960},[90],[303],[305,551,3837],{"nctId":3839,"briefTitle":3840,"status":134,"phases":5962,"primaryCompletion":3842,"completion":3842,"start":3673,"enrollment":301,"conditions":5963,"interventions":5964},[90],[3665],[3514,3845,551],{"nctId":3863,"briefTitle":3864,"status":104,"phases":5966,"primaryCompletion":3866,"completion":3867,"start":2719,"enrollment":355,"conditions":5967,"interventions":5968},[90],[3869,549,3870],[3872,305,551],{"nctId":5289,"briefTitle":5290,"status":104,"phases":5970,"primaryCompletion":5292,"completion":5292,"start":2719,"enrollment":1197,"conditions":5971,"interventions":5972},[90],[5294,5295,5296,5297,5298],[163,551],{"trials":5974,"activeCount":676,"soonestReadout":4070},[5975,5979,5997,6001,6005,6009,6013,6021,6025,6029,6033,6037,6041,6045,6049,6053,6061,6065,6075,6079],{"nctId":5047,"briefTitle":5048,"status":104,"phases":5976,"primaryCompletion":1390,"completion":5050,"start":5051,"enrollment":31,"conditions":5977,"interventions":5978},[90,91],[3665],[3539,3759,3525],{"nctId":5980,"briefTitle":5981,"status":104,"phases":5982,"primaryCompletion":5983,"completion":186,"start":5984,"enrollment":5985,"conditions":5986,"interventions":5995},"NCT01075321","Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma",[90,91],"2015-02-28","2011-01-10",58,[5987,4989,5988,5316,5989,5317,5990,5991,5319,3858,5992,5993,434,435,436,416,5994,3678,451],"Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Hepatosplenic T-cell Lymphoma","Peripheral T-cell Lymphoma","Post-transplant Lymphoproliferative Disorder","Recurrent Adult Hodgkin Lymphoma","Recurrent Adult T-cell Leukemia\u002FLymphoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome",[4306,3539,3636,5996,5424],"microarray analysis",{"nctId":3528,"briefTitle":3529,"status":104,"phases":5998,"primaryCompletion":3531,"completion":3532,"start":3533,"enrollment":342,"conditions":5999,"interventions":6000},[91],[3535,3536,3537],[3513,3323,3539,3514],{"nctId":5311,"briefTitle":5312,"status":1413,"phases":6002,"primaryCompletion":5314,"start":1337,"enrollment":128,"conditions":6003,"interventions":6004},[90,91],[3615,5316,3856,5317,5318,5319,3858,5320,5321,5322,5323,5324,434,435,436,416,417,439,5325,5326,3678,5327,5328],[3553,3539,5330],{"nctId":3627,"briefTitle":3628,"status":104,"phases":6006,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":6007,"interventions":6008},[90,91],[1419],[3552,3553,3323,3324,3539,3525,3327,3636],{"nctId":3638,"briefTitle":3639,"status":104,"phases":6010,"primaryCompletion":3641,"completion":3642,"start":3643,"enrollment":187,"conditions":6011,"interventions":6012},[91],[1419],[3553,3323,3514,3539],{"nctId":6014,"briefTitle":6015,"status":134,"phases":6016,"primaryCompletion":6017,"completion":6017,"start":6018,"enrollment":895,"conditions":6019,"interventions":6020},"NCT01003769","Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia",[90,91],"2018-12-14","2015-07-09",[432],[551,3837],{"nctId":3657,"briefTitle":3658,"status":104,"phases":6022,"primaryCompletion":3660,"completion":3661,"start":3662,"enrollment":3663,"conditions":6023,"interventions":6024},[91],[3665],[3323,3514,3539],{"nctId":3985,"briefTitle":3986,"status":104,"phases":6026,"primaryCompletion":3988,"completion":3988,"start":3989,"enrollment":2678,"conditions":6027,"interventions":6028},[91],[549],[159,305,306,551],{"nctId":3993,"briefTitle":3994,"status":134,"phases":6030,"primaryCompletion":3996,"completion":3997,"start":3998,"enrollment":139,"conditions":6031,"interventions":6032},[91],[549,303,3447,3870],[305,551,3861],{"nctId":4013,"briefTitle":4014,"status":104,"phases":6034,"primaryCompletion":1471,"completion":1471,"start":3001,"enrollment":476,"conditions":6035,"interventions":6036},[91],[303,3447],[305,551,3861],{"nctId":4027,"briefTitle":4028,"status":104,"phases":6038,"primaryCompletion":4030,"completion":4031,"start":4032,"enrollment":313,"conditions":6039,"interventions":6040},[90,91],[3690],[4035,3539,3514],{"nctId":3723,"briefTitle":3724,"status":104,"phases":6042,"primaryCompletion":3546,"completion":3509,"start":934,"enrollment":3726,"conditions":6043,"interventions":6044},[91],[3665],[3323,3514,3539],{"nctId":3730,"briefTitle":3731,"status":104,"phases":6046,"primaryCompletion":946,"completion":3733,"start":3734,"enrollment":461,"conditions":6047,"interventions":6048},[91],[3549,1419],[163,57,551,3585],{"nctId":4041,"briefTitle":4042,"status":104,"phases":6050,"primaryCompletion":4044,"completion":4045,"start":4046,"enrollment":1236,"conditions":6051,"interventions":6052},[91],[3665],[3514,3539],{"nctId":6054,"briefTitle":6055,"status":104,"phases":6056,"primaryCompletion":327,"completion":6057,"start":6058,"enrollment":817,"conditions":6059,"interventions":6060},"NCT02086552","Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma",[91],"2021-08-13","2014-01-17",[303,3447],[551,210],{"nctId":4067,"briefTitle":4068,"status":169,"phases":6062,"primaryCompletion":4070,"completion":4071,"start":4072,"enrollment":139,"conditions":6063,"interventions":6064},[91],[4074,3562],[157,159,305,551],{"nctId":6066,"briefTitle":6067,"status":134,"phases":6068,"primaryCompletion":6069,"completion":6070,"start":6071,"enrollment":218,"conditions":6072,"interventions":6074},"NCT02309515","Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis",[91],"2017-04-28","2017-07-21","2015-06-11",[6073,3574,3575,3576],"Monoclonal B-Cell Lymphocytosis",[551,422],{"nctId":542,"briefTitle":543,"status":104,"phases":6076,"primaryCompletion":545,"completion":546,"start":547,"enrollment":410,"conditions":6077,"interventions":6078},[91],[549],[305,551,72],{"nctId":4213,"briefTitle":4214,"status":104,"phases":6080,"primaryCompletion":4216,"completion":4217,"start":4218,"enrollment":3914,"conditions":6081,"interventions":6082},[91],[549],[159,551],{"trials":6084,"activeCount":128},[],{"trials":6086,"activeCount":128},[],{"trials":6088,"activeCount":128},[],{"intervention":157,"totalTrials":1197,"cells":6090},{"EARLY_PHASE1":6091,"PHASE1":6093,"PHASE2":6099,"PHASE3":6130,"PHASE4":6132,"NA":6134},{"trials":6092,"activeCount":128},[],{"trials":6094,"activeCount":128},[6095],{"nctId":132,"briefTitle":133,"status":134,"phases":6096,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":6097,"interventions":6098},[90],[141,142,143,144,145,146,147,148,149,150,151,152,153,154],[156,157,158,159,160,161,112,162,72,163,164,165],{"trials":6100,"activeCount":224,"soonestReadout":4070},[6101,6105,6109,6122,6126],{"nctId":3884,"briefTitle":3885,"status":1413,"phases":6102,"primaryCompletion":874,"completion":3887,"start":1374,"enrollment":128,"conditions":6103,"interventions":6104},[91],[3690,3535,3536,3537],[3564,3514],{"nctId":3556,"briefTitle":3557,"status":104,"phases":6106,"primaryCompletion":3001,"completion":3559,"start":1357,"enrollment":3560,"conditions":6107,"interventions":6108},[90,91],[3562,3535,3536,3537],[3564,3323,3526,3514],{"nctId":6110,"briefTitle":6111,"status":104,"phases":6112,"primaryCompletion":6113,"completion":6114,"start":6115,"enrollment":773,"conditions":6116,"interventions":6120},"NCT01842308","Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma",[90,91],"2017-10-11","2019-10-28","2013-06-04",[6117,6118,6119,3447],"DS Stage I Plasma Cell Myeloma","DS Stage II Plasma Cell Myeloma","DS Stage III Plasma Cell Myeloma",[157,6121],"Melphalan",{"nctId":3958,"briefTitle":3959,"status":169,"phases":6123,"primaryCompletion":3961,"completion":3962,"start":3963,"enrollment":1236,"conditions":6124,"interventions":6125},[90,91],[3689,3690],[157,305,3861,3966],{"nctId":4067,"briefTitle":4068,"status":169,"phases":6127,"primaryCompletion":4070,"completion":4071,"start":4072,"enrollment":139,"conditions":6128,"interventions":6129},[91],[4074,3562],[157,159,305,551],{"trials":6131,"activeCount":128},[],{"trials":6133,"activeCount":128},[],{"trials":6135,"activeCount":128},[],{"intervention":162,"totalTrials":895,"cells":6137},{"EARLY_PHASE1":6138,"PHASE1":6140,"PHASE2":6146,"PHASE3":6176,"PHASE4":6178,"NA":6180},{"trials":6139,"activeCount":128},[],{"trials":6141,"activeCount":128},[6142],{"nctId":132,"briefTitle":133,"status":134,"phases":6143,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":6144,"interventions":6145},[90],[141,142,143,144,145,146,147,148,149,150,151,152,153,154],[156,157,158,159,160,161,112,162,72,163,164,165],{"trials":6147,"activeCount":224,"soonestReadout":761},[6148,6155,6164,6168],{"nctId":6149,"briefTitle":6150,"status":265,"phases":6151,"primaryCompletion":761,"completion":761,"start":6152,"enrollment":173,"conditions":6153,"interventions":6154},"NCT06295770","Obinutuzumab in Treatment of Fibrillary Glomerulonephritis",[91],"2024-06-24",[5437],[162],{"nctId":6156,"briefTitle":6157,"status":265,"phases":6158,"primaryCompletion":6159,"completion":6160,"start":6161,"enrollment":785,"conditions":6162,"interventions":6163},"NCT03516617","Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[91],"2027-03-15","2030-10-16","2018-09-10",[3573,419],[4695,162],{"nctId":5440,"briefTitle":5441,"status":134,"phases":6165,"primaryCompletion":5443,"completion":5443,"start":5444,"enrollment":1197,"conditions":6166,"interventions":6167},[91],[5446,5447,5448],[162,163],{"nctId":6169,"briefTitle":6170,"status":104,"phases":6171,"primaryCompletion":6172,"completion":6172,"start":6173,"enrollment":173,"conditions":6174,"interventions":6175},"NCT04983888","Obinutuzumab in Primary FSGS",[91],"2025-06-16","2021-11-17",[5308],[162],{"trials":6177,"activeCount":128},[],{"trials":6179,"activeCount":128},[],{"trials":6181,"activeCount":128},[],{"intervention":4385,"totalTrials":681,"cells":6183},{"EARLY_PHASE1":6184,"PHASE1":6199,"PHASE2":6231,"PHASE3":6241,"PHASE4":6243,"NA":6245},{"trials":6185,"activeCount":128},[6186],{"nctId":6187,"briefTitle":6188,"status":1413,"phases":6189,"primaryCompletion":6173,"completion":6173,"start":6190,"enrollment":128,"conditions":6191,"interventions":6198},"NCT04249167","Cryoablation, Atezolizumab\u002FNab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer",[89],"2020-01-23",[579,580,581,582,583,6192,235,6193,6194,6195,6196,6197],"Locally Advanced Breast Carcinoma","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8",[4718,4385],{"trials":6200,"activeCount":128},[6201],{"nctId":6202,"briefTitle":6203,"status":104,"phases":6204,"primaryCompletion":6205,"completion":6205,"start":6206,"enrollment":2980,"conditions":6207,"interventions":6230},"NCT02020707","Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers",[90],"2024-07-18","2014-02-24",[6208,6209,6210,6211,6212,192,6213,6214,6215,6216,6217,6218,6219,6220,500,5601,5602,5603,5604,6221,5605,5606,1258,6222,6223,6224,6225,6226,24,5607,5608,5609,6227,5610,5612,5613,5614,3491,3492,3493,6228,501,5615,5617,5618,5619,177,6229],"Cervical Adenocarcinoma","Cervical Adenosarcoma","Cervical Adenosquamous Carcinoma","Cervical Carcinosarcoma","Cervical Squamous Cell Carcinoma","Endometrial Adenosquamous Carcinoma","Endometrial Clear Cell Adenocarcinoma","Endometrial Endometrioid Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma","Endometrial Mucinous Adenocarcinoma","Endometrial Serous Adenocarcinoma","Endometrial Undifferentiated Carcinoma","Fallopian Tube Adenocarcinoma","Fallopian Tube Squamous Cell Carcinoma","Malignant Ovarian Clear Cell Tumor","Malignant Ovarian Endometrioid Tumor","Malignant Ovarian Epithelial Tumor","Malignant Ovarian Mucinous Tumor","Malignant Peritoneal Neoplasm","Ovarian High Grade Serous Adenocarcinoma","Platinum-Sensitive Ovarian Carcinoma","Uterine Corpus Carcinosarcoma",[4719,4385],{"trials":6232,"activeCount":224,"soonestReadout":3824},[6233,6237],{"nctId":4377,"briefTitle":4378,"status":265,"phases":6234,"primaryCompletion":4380,"completion":4380,"start":4381,"enrollment":498,"conditions":6235,"interventions":6236},[91],[4383,564,4353],[4089,4270,4385],{"nctId":4593,"briefTitle":4594,"status":265,"phases":6238,"primaryCompletion":3824,"completion":3824,"start":4596,"enrollment":2980,"conditions":6239,"interventions":6240},[91],[561,4598,564],[4600,4601,4385,112],{"trials":6242,"activeCount":128},[],{"trials":6244,"activeCount":128},[],{"trials":6246,"activeCount":128},[],{"intervention":6248,"totalTrials":681,"cells":6249},"autologous mesenchymal stem cells",{"EARLY_PHASE1":6250,"PHASE1":6252,"PHASE2":6269,"PHASE3":6288,"PHASE4":6290,"NA":6292},{"trials":6251,"activeCount":128},[],{"trials":6253,"activeCount":128},[6254,6262],{"nctId":6255,"briefTitle":6256,"status":104,"phases":6257,"primaryCompletion":3661,"completion":3661,"start":6258,"enrollment":676,"conditions":6259,"interventions":6261},"NCT01142856","Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)",[90],"2010-06",[6260],"Amyotrophic Lateral Sclerosis",[6248],{"nctId":6263,"briefTitle":6264,"status":104,"phases":6265,"primaryCompletion":6266,"completion":6266,"start":1319,"enrollment":97,"conditions":6267,"interventions":6268},"NCT01609283","A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis",[90],"2019-01-31",[6260],[6248],{"trials":6270,"activeCount":224,"soonestReadout":761},[6271,6280],{"nctId":6272,"briefTitle":6273,"status":169,"phases":6274,"primaryCompletion":2233,"completion":2233,"start":6275,"enrollment":729,"conditions":6276,"interventions":6278},"NCT02315027","Mesenchymal Stem Cell Therapy in Multiple System Atrophy",[90,91],"2012-10",[6277],"MSA",[6279,6279,6279,6279,6279],"Autologous Mesenchymal Stem Cells",{"nctId":6281,"briefTitle":6282,"status":169,"phases":6283,"primaryCompletion":761,"completion":761,"start":1842,"enrollment":6284,"conditions":6285,"interventions":6287},"NCT05167721","Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy",[91],71,[6286],"Multiple System Atrophy",[6279],{"trials":6289,"activeCount":128},[],{"trials":6291,"activeCount":128},[],{"trials":6293,"activeCount":128},[],{"intervention":4093,"totalTrials":681,"cells":6295},{"EARLY_PHASE1":6296,"PHASE1":6298,"PHASE2":6320,"PHASE3":6339,"PHASE4":6341,"NA":6343},{"trials":6297,"activeCount":128},[],{"trials":6299,"activeCount":676,"soonestReadout":5168},[6300,6304],{"nctId":5165,"briefTitle":5166,"status":265,"phases":6301,"primaryCompletion":5168,"completion":5168,"start":1150,"enrollment":2555,"conditions":6302,"interventions":6303},[90],[5170,5171,5172,5173,5174],[5158,4093],{"nctId":6305,"briefTitle":6306,"status":104,"phases":6307,"primaryCompletion":6308,"completion":6309,"start":5405,"enrollment":3719,"conditions":6310,"interventions":6318},"NCT02129101","Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies",[90],"2016-12-31","2019-10-25",[4087,6311,6312,3438,6313,6314,3439,6315,3440,6316,6317],"de Novo Myelodysplastic Syndrome","Essential Thrombocythemia","Myelodysplastic\u002FMyeloproliferative Neoplasm","Polycythemia Vera","Primary Myelofibrosis","Recurrent Childhood Acute Myeloid Leukemia","Untreated Adult Acute Myeloid Leukemia",[6319,4093,210],"Azacitidine",{"trials":6321,"activeCount":676,"soonestReadout":4080},[6322,6335],{"nctId":6323,"briefTitle":6324,"status":134,"phases":6325,"primaryCompletion":6326,"completion":6327,"start":4007,"enrollment":676,"conditions":6328,"interventions":6333},"NCT02634827","Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation",[91],"2017-03-18","2018-06-12",[6329,6330,6331,6332,6317],"Acute Myeloid Leukemia With FLT3\u002FITD Mutation","Acute Myeloid Leukemia With Gene Mutations","FLT3 Tyrosine Kinase Domain Point Mutation","Secondary Acute Myeloid Leukemia",[4093,6334],"Midostaurin",{"nctId":4077,"briefTitle":4078,"status":265,"phases":6336,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":2678,"conditions":6337,"interventions":6338},[91],[4084,3422,414,144,4085,3398,4086,4087],[536,4089,4090,305,4091,161,4092,539,163,4093],{"trials":6340,"activeCount":128},[],{"trials":6342,"activeCount":128},[],{"trials":6344,"activeCount":128},[],{"intervention":4557,"totalTrials":681,"cells":6346},{"EARLY_PHASE1":6347,"PHASE1":6349,"PHASE2":6359,"PHASE3":6382,"PHASE4":6384,"NA":6386},{"trials":6348,"activeCount":128},[],{"trials":6350,"activeCount":676,"soonestReadout":1738},[6351,6355],{"nctId":3430,"briefTitle":3431,"status":265,"phases":6352,"primaryCompletion":1738,"completion":3433,"start":3434,"enrollment":3435,"conditions":6353,"interventions":6354},[90],[3396,3437,3438,3439,3440,3441,3442,145,303,147,418,3443,3444,3445,150,3446,3447,153,3448],[57,52,3450,3451,3452,112],{"nctId":4550,"briefTitle":4551,"status":134,"phases":6356,"primaryCompletion":4553,"completion":4553,"start":4554,"enrollment":1197,"conditions":6357,"interventions":6358},[90],[189,192,122,177],[4557,112],{"trials":6360,"activeCount":676,"soonestReadout":4632},[6361,6378],{"nctId":6362,"briefTitle":6363,"status":104,"phases":6364,"primaryCompletion":3661,"completion":6365,"start":2573,"enrollment":6366,"conditions":6367,"interventions":6373},"NCT00170157","Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer",[91],"2013-06",112,[6368,6369,6370,6371,6372],"Prostate Adenocarcinoma","Prostate Carcinoma","Recurrent Prostate Carcinoma","Stage III Prostate Cancer","Stage IV Prostate Cancer",[6374,6375,6376,4557,6377],"Bicalutamide","Flutamide","Goserelin Acetate","Leuprolide Acetate",{"nctId":4629,"briefTitle":4630,"status":1096,"phases":6379,"primaryCompletion":4632,"completion":4632,"start":4633,"enrollment":108,"conditions":6380,"interventions":6381},[91],[4635,4636,615,630],[4557,112,52],{"trials":6383,"activeCount":128},[],{"trials":6385,"activeCount":128},[],{"trials":6387,"activeCount":128},[],{"intervention":4749,"totalTrials":342,"cells":6389},{"EARLY_PHASE1":6390,"PHASE1":6396,"PHASE2":6398,"PHASE3":6418,"PHASE4":6420,"NA":6422},{"trials":6391,"activeCount":676,"soonestReadout":4744},[6392],{"nctId":4741,"briefTitle":4742,"status":265,"phases":6393,"primaryCompletion":4744,"completion":4744,"start":4745,"enrollment":370,"conditions":6394,"interventions":6395},[89],[4747],[3693,4749,4750,3694,334],{"trials":6397,"activeCount":128},[],{"trials":6399,"activeCount":676,"soonestReadout":1908},[6400,6408],{"nctId":6401,"briefTitle":6402,"status":169,"phases":6403,"primaryCompletion":1908,"completion":1908,"start":6404,"enrollment":2678,"conditions":6405,"interventions":6407},"NCT04476953","COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation",[91],"2020-08-03",[6406],"Covid19",[4749],{"nctId":6409,"briefTitle":6410,"status":134,"phases":6411,"primaryCompletion":6412,"completion":6413,"start":6414,"enrollment":173,"conditions":6415,"interventions":6417},"NCT04537299","COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes",[91],"2024-08-31","2024-11-30","2022-04-29",[6406,6416],"SARS-CoV Infection",[4749],{"trials":6419,"activeCount":128},[],{"trials":6421,"activeCount":128},[],{"trials":6423,"activeCount":128},[],{"intervention":517,"totalTrials":342,"cells":6425},{"EARLY_PHASE1":6426,"PHASE1":6445,"PHASE2":6447,"PHASE3":6475,"PHASE4":6477,"NA":6479},{"trials":6427,"activeCount":128},[6428],{"nctId":6429,"briefTitle":6430,"status":104,"phases":6431,"primaryCompletion":6432,"completion":6432,"start":6433,"enrollment":6434,"conditions":6435,"interventions":6444},"NCT02111941","Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer",[89],"2021-07-27","2014-04-14",19,[5601,6436,6437,6438,5605,6439,5609,6440,5611,6441,5613,5617,502,506,511,3381,3382,3383,3384,3385,3386,6442,6443],"Fallopian Tube Endometrioid Tumor","Fallopian Tube Mucinous Neoplasm","Fallopian Tube Serous Neoplasm","Ovarian Clear Cell Cystadenocarcinoma","Ovarian Mucinous Cystadenocarcinoma","Ovarian Serous Cystadenocarcinoma","Undifferentiated Fallopian Tube Carcinoma","Undifferentiated Ovarian Carcinoma",[517],{"trials":6446,"activeCount":128},[],{"trials":6448,"activeCount":224,"soonestReadout":861},[6449,6471],{"nctId":6450,"briefTitle":6451,"status":265,"phases":6452,"primaryCompletion":861,"completion":861,"start":6453,"enrollment":6454,"conditions":6455,"interventions":6468},"NCT06639074","Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial",[91],"2024-11-08",78,[6456,6457,6458,6459,6460,6461,6462,6463,6464,500,5601,5602,6465,6466,6467,501,5615,5616],"Advanced Fallopian Tube Carcinoma","Advanced Fallopian Tube High Grade Serous Adenocarcinoma","Advanced Ovarian Carcinoma","Advanced Ovarian Carcinosarcoma","Advanced Ovarian Clear Cell Adenocarcinoma","Advanced Ovarian Endometrioid Adenocarcinoma","Advanced Ovarian High Grade Serous Adenocarcinoma","Advanced Primary Peritoneal Carcinoma","Advanced Primary Peritoneal High Grade Serous Adenocarcinoma","FIGO Stage III Ovarian Cancer 2014","FIGO Stage IV Ovarian Cancer 2014","Ovarian Mixed Cell Adenocarcinoma",[6469,517,6470],"Diphtheria Toxoid\u002FTetanus Toxoid\u002FAcellular Pertussis Vaccine Adsorbed","Tetanus and Diphtheria Toxoids Adsorbed",{"nctId":493,"briefTitle":494,"status":265,"phases":6472,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":6473,"interventions":6474},[90,91],[500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515],[517,72],{"trials":6476,"activeCount":128},[],{"trials":6478,"activeCount":128},[],{"trials":6480,"activeCount":128},[],{"intervention":6482,"totalTrials":342,"cells":6483},"Pyridostigmine",{"EARLY_PHASE1":6484,"PHASE1":6486,"PHASE2":6488,"PHASE3":6517,"PHASE4":6519,"NA":6521},{"trials":6485,"activeCount":128},[],{"trials":6487,"activeCount":128},[],{"trials":6489,"activeCount":224,"soonestReadout":2112},[6490,6498,6509],{"nctId":6491,"briefTitle":6492,"status":265,"phases":6493,"primaryCompletion":2111,"completion":2111,"start":3519,"enrollment":773,"conditions":6494,"interventions":6496},"NCT00409435","A Study of Pyridostigmine in Postural Tachycardia Syndrome",[91],[6495],"Postural Tachycardia Syndrome",[6497],"pyridostigmine",{"nctId":6499,"briefTitle":6500,"status":104,"phases":6501,"primaryCompletion":5360,"completion":5360,"start":6502,"enrollment":729,"conditions":6503,"interventions":6508},"NCT00276406","Use of Pyridostigmine for Constipation in Diabetics",[90,91],"2006-05",[6504,6505,6506,6507],"Constipation","Diabetes Mellitus","Colonic Transit","Gastric Emptying",[6482],{"nctId":6510,"briefTitle":6511,"status":692,"phases":6512,"primaryCompletion":2112,"completion":2112,"start":3842,"enrollment":729,"conditions":6513,"interventions":6515},"NCT01370512","Droxidopa \u002F Pyridostigmine in Orthostatic Hypotension",[91],[6514],"Orthostatic Hypotension",[6516,6482],"Droxidopa",{"trials":6518,"activeCount":128},[],{"trials":6520,"activeCount":128},[],{"trials":6522,"activeCount":128},[],{"intervention":6524,"totalTrials":342,"cells":6525},"Exendin 9-39",{"EARLY_PHASE1":6526,"PHASE1":6528,"PHASE2":6530,"PHASE3":6559,"PHASE4":6561,"NA":6563},{"trials":6527,"activeCount":128},[],{"trials":6529,"activeCount":128},[],{"trials":6531,"activeCount":224,"soonestReadout":6555},[6532,6542,6551],{"nctId":6533,"briefTitle":6534,"status":104,"phases":6535,"primaryCompletion":6536,"completion":6536,"start":5417,"enrollment":1267,"conditions":6537,"interventions":6540},"NCT02170870","Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus",[91],"2017-11-17",[6538,6539],"Dyspepsia","Diabetes Mellitus With Gastrointestinal Symptoms",[6524,6541],"Microlipid",{"nctId":6543,"briefTitle":6544,"status":1096,"phases":6545,"primaryCompletion":1738,"completion":1933,"start":6546,"enrollment":2678,"conditions":6547,"interventions":6550},"NCT06972407","The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans",[91],"2026-10-01",[6548,6549],"Genetic Predisposition","Type2diabetes",[6524],{"nctId":6552,"briefTitle":6553,"status":265,"phases":6554,"primaryCompletion":6555,"completion":575,"start":2491,"enrollment":25,"conditions":6556,"interventions":6558},"NCT06967558","The Role of Islet GLP-1 in the Pathogenesis of Prediabetes",[91],"2027-10-30",[6557],"PreDiabetes",[6524,3779],{"trials":6560,"activeCount":128},[],{"trials":6562,"activeCount":128},[],{"trials":6564,"activeCount":128},[],{"intervention":4600,"totalTrials":342,"cells":6566},{"EARLY_PHASE1":6567,"PHASE1":6569,"PHASE2":6571,"PHASE3":6590,"PHASE4":6592,"NA":6594},{"trials":6568,"activeCount":128},[],{"trials":6570,"activeCount":128},[],{"trials":6572,"activeCount":224,"soonestReadout":171},[6573,6582,6586],{"nctId":6574,"briefTitle":6575,"status":104,"phases":6576,"primaryCompletion":6577,"completion":6578,"start":4464,"enrollment":773,"conditions":6579,"interventions":6580},"NCT00110084","ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer",[91],"2010-05","2010-08",[21],[4600,6581],"Paclitaxel protein-bound particles for injectable suspension",{"nctId":5543,"briefTitle":5544,"status":265,"phases":6583,"primaryCompletion":171,"completion":171,"start":5546,"enrollment":498,"conditions":6584,"interventions":6585},[90,91],[5548,5549,5550,5551],[5553,346,4600,4375],{"nctId":4593,"briefTitle":4594,"status":265,"phases":6587,"primaryCompletion":3824,"completion":3824,"start":4596,"enrollment":2980,"conditions":6588,"interventions":6589},[91],[561,4598,564],[4600,4601,4385,112],{"trials":6591,"activeCount":128},[],{"trials":6593,"activeCount":128},[],{"trials":6595,"activeCount":128},[],{"intervention":4915,"totalTrials":342,"cells":6597},{"EARLY_PHASE1":6598,"PHASE1":6600,"PHASE2":6602,"PHASE3":6622,"PHASE4":6624,"NA":6626},{"trials":6599,"activeCount":128},[],{"trials":6601,"activeCount":128},[],{"trials":6603,"activeCount":224,"soonestReadout":4909},[6604,6608,6618],{"nctId":5512,"briefTitle":5513,"status":104,"phases":6605,"primaryCompletion":5515,"completion":5515,"start":5516,"enrollment":5517,"conditions":6606,"interventions":6607},[91],[21],[5520,5521,5522],{"nctId":6609,"briefTitle":6610,"status":265,"phases":6611,"primaryCompletion":6612,"completion":6612,"start":728,"enrollment":3726,"conditions":6613,"interventions":6617},"NCT06525766","Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer",[91],"2030-10-15",[583,6614,6615,6616],"Estrogen-receptor-positive Breast Cancer","Metastatic HER2-Negative Breast Carcinoma","Metastatic Breast Cancer",[4915],{"nctId":4906,"briefTitle":4907,"status":265,"phases":6619,"primaryCompletion":4909,"completion":4910,"start":4911,"enrollment":25,"conditions":6620,"interventions":6621},[90,91],[4913],[4915,4916,537,4917],{"trials":6623,"activeCount":128},[],{"trials":6625,"activeCount":128},[],{"trials":6627,"activeCount":128},[],{"intervention":6629,"totalTrials":224,"cells":6630},"Cancer Therapeutic Procedure",{"EARLY_PHASE1":6631,"PHASE1":6633,"PHASE2":6635,"PHASE3":6670,"PHASE4":6672,"NA":6674},{"trials":6632,"activeCount":128},[],{"trials":6634,"activeCount":128},[],{"trials":6636,"activeCount":224,"soonestReadout":6651},[6637,6647],{"nctId":6638,"briefTitle":6639,"status":265,"phases":6640,"primaryCompletion":6641,"completion":6641,"start":6642,"enrollment":956,"conditions":6643,"interventions":6646},"NCT07073794","Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer",[91],"2028-08-27","2025-08-27",[3298,6644,6645,3303,3304],"Locally Advanced Prostate Carcinoma","Metastatic Prostate Carcinoma",[6629,6629],{"nctId":6648,"briefTitle":6649,"status":265,"phases":6650,"primaryCompletion":6651,"completion":6651,"start":6652,"enrollment":97,"conditions":6653,"interventions":6669},"NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas",[91],"2026-12-18","2025-12-18",[3654,6654,6655,6656,30,6657,6658,1101,6659,6660,330,4447,36,4616,6661,6662,24,6663,110,6664,3562,3438,6665,6666,6667,6369,4622,6668,4626],"Basal Cell Carcinoma","Biliary Tract Carcinoma","Bladder Carcinoma","Cervical Carcinoma","Colorectal Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Hodgkin Lymphoma","Lung Carcinoma","Mantle Cell Lymphoma","Merkel Cell Carcinoma","Ovarian Carcinoma","Pancreatic Carcinoma","Primary Peritoneal Carcinoma","Squamous Cell Carcinoma",[6629,6629],{"trials":6671,"activeCount":128},[],{"trials":6673,"activeCount":128},[],{"trials":6675,"activeCount":128},[],{"intervention":3917,"totalTrials":224,"cells":6677},{"EARLY_PHASE1":6678,"PHASE1":6680,"PHASE2":6682,"PHASE3":6692,"PHASE4":6694,"NA":6696},{"trials":6679,"activeCount":128},[],{"trials":6681,"activeCount":128},[],{"trials":6683,"activeCount":224,"soonestReadout":3911},[6684,6688],{"nctId":3908,"briefTitle":3909,"status":169,"phases":6685,"primaryCompletion":3911,"completion":3912,"start":3913,"enrollment":3914,"conditions":6686,"interventions":6687},[90,91],[549],[3680,159,305,3917],{"nctId":3940,"briefTitle":3941,"status":265,"phases":6689,"primaryCompletion":3943,"completion":3943,"start":3944,"enrollment":3945,"conditions":6690,"interventions":6691},[90,91],[3689],[159,305,3948,3917],{"trials":6693,"activeCount":128},[],{"trials":6695,"activeCount":128},[],{"trials":6697,"activeCount":128},[],{"intervention":6699,"totalTrials":224,"cells":6700},"Eflornithine",{"EARLY_PHASE1":6701,"PHASE1":6712,"PHASE2":6714,"PHASE3":6729,"PHASE4":6731,"NA":6733},{"trials":6702,"activeCount":676,"soonestReadout":3064},[6703],{"nctId":6704,"briefTitle":6705,"status":265,"phases":6706,"primaryCompletion":3064,"completion":4757,"start":6707,"enrollment":108,"conditions":6708,"interventions":6710},"NCT05717153","Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma",[89],"2023-10-01",[6709,4760],"Diffuse Glioma",[6699,6711],"Polyamine Transport Inhibitor AMXT-1501 Dicaprate",{"trials":6713,"activeCount":128},[],{"trials":6715,"activeCount":676,"soonestReadout":6720},[6716],{"nctId":6717,"briefTitle":6718,"status":1096,"phases":6719,"primaryCompletion":6720,"completion":6720,"start":6721,"enrollment":31,"conditions":6722,"interventions":6727},"NCT07468136","Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas",[90,91],"2030-10-25","2026-04-24",[6723,6724,6725,6726,285,4760],"Anaplastic Oligodendroglioma","Astrocytoma, IDH-Mutant, Grade 3","Astrocytoma, IDH-Mutant, Grade 4","Diffuse Astrocytoma",[6699,6728],"Retifanlimab",{"trials":6730,"activeCount":128},[],{"trials":6732,"activeCount":128},[],{"trials":6734,"activeCount":128},[],{"intervention":4695,"totalTrials":224,"cells":6736},{"EARLY_PHASE1":6737,"PHASE1":6739,"PHASE2":6741,"PHASE3":6751,"PHASE4":6753,"NA":6755},{"trials":6738,"activeCount":128},[],{"trials":6740,"activeCount":128},[],{"trials":6742,"activeCount":224,"soonestReadout":4691},[6743,6747],{"nctId":4688,"briefTitle":4689,"status":265,"phases":6744,"primaryCompletion":4691,"completion":4691,"start":4692,"enrollment":97,"conditions":6745,"interventions":6746},[91],[3573,450,419],[4695,4645,3819],{"nctId":6156,"briefTitle":6157,"status":265,"phases":6748,"primaryCompletion":6159,"completion":6160,"start":6161,"enrollment":785,"conditions":6749,"interventions":6750},[91],[3573,419],[4695,162],{"trials":6752,"activeCount":128},[],{"trials":6754,"activeCount":128},[],{"trials":6756,"activeCount":128},[],{"intervention":5098,"totalTrials":224,"cells":6758},{"EARLY_PHASE1":6759,"PHASE1":6761,"PHASE2":6771,"PHASE3":6777,"PHASE4":6779,"NA":6781},{"trials":6760,"activeCount":128},[],{"trials":6762,"activeCount":676,"soonestReadout":2553},[6763],{"nctId":6764,"briefTitle":6765,"status":265,"phases":6766,"primaryCompletion":2553,"completion":2553,"start":2112,"enrollment":1197,"conditions":6767,"interventions":6770},"NCT07556484","Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube",[90],[6768,6769],"Diffuse Alveolar Hemorrhage","Antineutrophil Cytoplasmic Antibody Positive Vasculitis",[5098],{"trials":6772,"activeCount":676,"soonestReadout":5092},[6773],{"nctId":5089,"briefTitle":5090,"status":265,"phases":6774,"primaryCompletion":5092,"completion":5093,"start":5094,"enrollment":2742,"conditions":6775,"interventions":6776},[91],[5096],[5098,3427,1342,5099],{"trials":6778,"activeCount":128},[],{"trials":6780,"activeCount":128},[],{"trials":6782,"activeCount":128},[],{"intervention":6784,"totalTrials":224,"cells":6785},"Duloxetine 30 MG",{"EARLY_PHASE1":6786,"PHASE1":6788,"PHASE2":6790,"PHASE3":6811,"PHASE4":6813,"NA":6815},{"trials":6787,"activeCount":128},[],{"trials":6789,"activeCount":128},[],{"trials":6791,"activeCount":224,"soonestReadout":6807},[6792,6803],{"nctId":6793,"briefTitle":6794,"status":265,"phases":6795,"primaryCompletion":761,"completion":761,"start":6796,"enrollment":773,"conditions":6797,"interventions":6799},"NCT05110144","Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough",[91],"2021-11-01",[6798],"Refractory Chronic Cough",[6784,6800,6801,6802],"Duloxetine 60 MG","Amitriptyline 25 MG","Amitriptyline 50 MG",{"nctId":6804,"briefTitle":6805,"status":265,"phases":6806,"primaryCompletion":6807,"completion":6807,"start":6796,"enrollment":558,"conditions":6808,"interventions":6810},"NCT05120934","Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough",[91],"2026-10",[6809],"Interstitial Lung Disease",[6801,6802,6784,6800],{"trials":6812,"activeCount":128},[],{"trials":6814,"activeCount":128},[],{"trials":6816,"activeCount":128},[],{"intervention":6800,"totalTrials":224,"cells":6818},{"EARLY_PHASE1":6819,"PHASE1":6821,"PHASE2":6823,"PHASE3":6833,"PHASE4":6835,"NA":6837},{"trials":6820,"activeCount":128},[],{"trials":6822,"activeCount":128},[],{"trials":6824,"activeCount":224,"soonestReadout":6807},[6825,6829],{"nctId":6793,"briefTitle":6794,"status":265,"phases":6826,"primaryCompletion":761,"completion":761,"start":6796,"enrollment":773,"conditions":6827,"interventions":6828},[91],[6798],[6784,6800,6801,6802],{"nctId":6804,"briefTitle":6805,"status":265,"phases":6830,"primaryCompletion":6807,"completion":6807,"start":6796,"enrollment":558,"conditions":6831,"interventions":6832},[91],[6809],[6801,6802,6784,6800],{"trials":6834,"activeCount":128},[],{"trials":6836,"activeCount":128},[],{"trials":6838,"activeCount":128},[],{"intervention":6801,"totalTrials":224,"cells":6840},{"EARLY_PHASE1":6841,"PHASE1":6843,"PHASE2":6845,"PHASE3":6855,"PHASE4":6857,"NA":6859},{"trials":6842,"activeCount":128},[],{"trials":6844,"activeCount":128},[],{"trials":6846,"activeCount":224,"soonestReadout":6807},[6847,6851],{"nctId":6793,"briefTitle":6794,"status":265,"phases":6848,"primaryCompletion":761,"completion":761,"start":6796,"enrollment":773,"conditions":6849,"interventions":6850},[91],[6798],[6784,6800,6801,6802],{"nctId":6804,"briefTitle":6805,"status":265,"phases":6852,"primaryCompletion":6807,"completion":6807,"start":6796,"enrollment":558,"conditions":6853,"interventions":6854},[91],[6809],[6801,6802,6784,6800],{"trials":6856,"activeCount":128},[],{"trials":6858,"activeCount":128},[],{"trials":6860,"activeCount":128},[],{"intervention":6802,"totalTrials":224,"cells":6862},{"EARLY_PHASE1":6863,"PHASE1":6865,"PHASE2":6867,"PHASE3":6877,"PHASE4":6879,"NA":6881},{"trials":6864,"activeCount":128},[],{"trials":6866,"activeCount":128},[],{"trials":6868,"activeCount":224,"soonestReadout":6807},[6869,6873],{"nctId":6793,"briefTitle":6794,"status":265,"phases":6870,"primaryCompletion":761,"completion":761,"start":6796,"enrollment":773,"conditions":6871,"interventions":6872},[91],[6798],[6784,6800,6801,6802],{"nctId":6804,"briefTitle":6805,"status":265,"phases":6874,"primaryCompletion":6807,"completion":6807,"start":6796,"enrollment":558,"conditions":6875,"interventions":6876},[91],[6809],[6801,6802,6784,6800],{"trials":6878,"activeCount":128},[],{"trials":6880,"activeCount":128},[],{"trials":6882,"activeCount":128},[],{"intervention":5131,"totalTrials":224,"cells":6884},{"EARLY_PHASE1":6885,"PHASE1":6887,"PHASE2":6889,"PHASE3":6902,"PHASE4":6904,"NA":6906},{"trials":6886,"activeCount":128},[],{"trials":6888,"activeCount":128},[],{"trials":6890,"activeCount":224,"soonestReadout":171},[6891,6898],{"nctId":6892,"briefTitle":6893,"status":265,"phases":6894,"primaryCompletion":171,"completion":171,"start":6895,"enrollment":729,"conditions":6896,"interventions":6897},"NCT07025369","Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET\u002FCT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial",[91],"2025-08-25",[6368,3302,3303,3304],[5131],{"nctId":5112,"briefTitle":5113,"status":265,"phases":6899,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":5117,"conditions":6900,"interventions":6901},[91],[5119,5120,5121,3298],[5123,5124,5125,5126,5127,5128,5129,5130,3427,5131,5132],{"trials":6903,"activeCount":128},[],{"trials":6905,"activeCount":128},[],{"trials":6907,"activeCount":128},[],{"intervention":6909,"totalTrials":681,"cells":6910},"Pioglitazone",{"EARLY_PHASE1":6911,"PHASE1":6921,"PHASE2":6923,"PHASE3":6945,"PHASE4":6947,"NA":6949},{"trials":6912,"activeCount":676,"soonestReadout":6917},[6913],{"nctId":6914,"briefTitle":6915,"status":265,"phases":6916,"primaryCompletion":6917,"completion":171,"start":6918,"enrollment":3560,"conditions":6919,"interventions":6920},"NCT03866408","Insulin Regulation of Lipolysis and Lipolysis Proteins",[89],"2026-12-30","2018-11-12",[15],[6909],{"trials":6922,"activeCount":128},[],{"trials":6924,"activeCount":676,"soonestReadout":3065},[6925,6935],{"nctId":6926,"briefTitle":6927,"status":104,"phases":6928,"primaryCompletion":6578,"completion":6578,"start":4464,"enrollment":817,"conditions":6929,"interventions":6932},"NCT00443755","Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance",[91],[1868,6930,6931],"Insulin Resistance","Metabolic Syndrome",[6933,6934],"metformin","pioglitazone",{"nctId":6936,"briefTitle":6937,"status":265,"phases":6938,"primaryCompletion":3065,"completion":3065,"start":6939,"enrollment":498,"conditions":6940,"interventions":6943},"NCT06729996","Pioglitazone Versus Empagliflozin for Chronic Pancreatitis\u002FRecurrent Acute Pancreatitis Associated Diabetes Mellitus",[91],"2025-05-29",[6941,6942,6505],"Pancreatitis, Chronic","Pancreatitis, Acute",[6909,6944],"Empagliflozin",{"trials":6946,"activeCount":128},[],{"trials":6948,"activeCount":128},[],{"trials":6950,"activeCount":128},[6951],{"nctId":6952,"briefTitle":6953,"status":134,"phases":6954,"primaryCompletion":3717,"completion":6955,"start":5515,"enrollment":187,"conditions":6956,"interventions":6958},"NCT00586261","Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function",[94],"2009-07",[6957],"Chronic Kidney Disease",[6909,6959],"Nitroglycerin",{"intervention":791,"totalTrials":370,"cells":6961},{"EARLY_PHASE1":6962,"PHASE1":6964,"PHASE2":6966,"PHASE3":7002,"PHASE4":7018,"NA":7036},{"trials":6963,"activeCount":128},[],{"trials":6965,"activeCount":128},[],{"trials":6967,"activeCount":676,"soonestReadout":861},[6968,6978,6988,6992],{"nctId":6969,"briefTitle":6970,"status":104,"phases":6971,"primaryCompletion":6972,"completion":6972,"start":6973,"enrollment":218,"conditions":6974,"interventions":6976},"NCT02762708","The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes",[91],"2018-01-06","2016-03",[6975,15],"Type 2 Diabetes Mellitus",[6977,867],"Exendin-9,39",{"nctId":6979,"briefTitle":6980,"status":134,"phases":6981,"primaryCompletion":1337,"completion":1337,"start":4300,"enrollment":1236,"conditions":6982,"interventions":6986},"NCT02227329","Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition",[90,91],[6983,6984,6985],"Catheter-related Bloodstream Infection (CRBSI) Nos","Bloodstream Infection Due to Central Venous Catheter","Bloodstream Infection Due to Hickman Catheter",[2577,6987,867],"Heparin Lock",{"nctId":858,"briefTitle":859,"status":265,"phases":6989,"primaryCompletion":861,"completion":861,"start":862,"enrollment":729,"conditions":6990,"interventions":6991},[91],[864,865],[839,867],{"nctId":6993,"briefTitle":6994,"status":134,"phases":6995,"primaryCompletion":6996,"completion":6996,"start":6997,"enrollment":342,"conditions":6998,"interventions":7000},"NCT01978535","Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)",[90,91],"2017-09-08","2014-12-17",[6999],"Postural Orthostatic Tachycardia Syndrome",[7001,791],"Iron",{"trials":7003,"activeCount":128},[7004,7014],{"nctId":7005,"briefTitle":7006,"status":134,"phases":7007,"primaryCompletion":7008,"completion":7008,"start":3642,"enrollment":139,"conditions":7009,"interventions":7011},"NCT02697292","IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy",[92],"2018-12-03",[7010],"Autoimmune Epilepsy",[7012,7013,867],"Intravenous Immunoglobulin","Placebos",{"nctId":1294,"briefTitle":1295,"status":134,"phases":7015,"primaryCompletion":1297,"completion":1298,"start":1299,"enrollment":1300,"conditions":7016,"interventions":7017},[91,92],[925],[1274,791],{"trials":7019,"activeCount":128},[7020,7024,7028,7032],{"nctId":780,"briefTitle":781,"status":104,"phases":7021,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":7022,"interventions":7023},[93],[787,788],[746,790,305,791],{"nctId":2617,"briefTitle":2618,"status":104,"phases":7025,"primaryCompletion":2620,"completion":2620,"start":2621,"enrollment":313,"conditions":7026,"interventions":7027},[93],[2623],[2625,2626,2627,2586],{"nctId":1315,"briefTitle":1316,"status":104,"phases":7029,"primaryCompletion":1235,"completion":1318,"start":1319,"enrollment":1320,"conditions":7030,"interventions":7031},[93],[1322],[1274,305,305,791,791],{"nctId":1334,"briefTitle":1335,"status":104,"phases":7033,"primaryCompletion":872,"completion":1337,"start":1338,"enrollment":34,"conditions":7034,"interventions":7035},[93],[1340],[1274,791,1342],{"trials":7037,"activeCount":128},[],{"intervention":7039,"totalTrials":476,"cells":7040},"Metformin",{"EARLY_PHASE1":7041,"PHASE1":7043,"PHASE2":7060,"PHASE3":7093,"PHASE4":7101,"NA":7118},{"trials":7042,"activeCount":128},[],{"trials":7044,"activeCount":128},[7045,7053],{"nctId":7046,"briefTitle":7047,"status":104,"phases":7048,"primaryCompletion":7049,"completion":7049,"start":3001,"enrollment":3547,"conditions":7050,"interventions":7052},"NCT02086526","Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)",[90],"2016-11-20",[7051],"Polycystic Ovary Syndrome",[7039],{"nctId":7054,"briefTitle":7055,"status":104,"phases":7056,"primaryCompletion":6973,"completion":6973,"start":3641,"enrollment":218,"conditions":7057,"interventions":7059},"NCT01956929","Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.",[90],[6930,7058],"Prediabetic State",[7039],{"trials":7061,"activeCount":676,"soonestReadout":1159},[7062,7069,7073,7082],{"nctId":7063,"briefTitle":7064,"status":265,"phases":7065,"primaryCompletion":1159,"completion":1159,"start":7066,"enrollment":712,"conditions":7067,"interventions":7068},"NCT06377696","Remote Cognitive Assessment and Wearable Device While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy",[91],"2024-05-31",[5870],[7039],{"nctId":6926,"briefTitle":6927,"status":104,"phases":7070,"primaryCompletion":6578,"completion":6578,"start":4464,"enrollment":817,"conditions":7071,"interventions":7072},[91],[1868,6930,6931],[6933,6934],{"nctId":7074,"briefTitle":7075,"status":134,"phases":7076,"primaryCompletion":7077,"completion":7077,"start":6275,"enrollment":1197,"conditions":7078,"interventions":7081},"NCT01717482","Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer",[91],"2019-05-22",[7079,7080],"Lung Neoplasms","Carcinoma, Non-Small-Cell Lung",[7039],{"nctId":7083,"briefTitle":7084,"status":134,"phases":7085,"primaryCompletion":7086,"completion":7086,"start":7087,"enrollment":120,"conditions":7088,"interventions":7092},"NCT03451006","Effect of Metformin on Frailty in 12 Subjects",[91],"2021-12-16","2018-05-24",[7089,7090,7091],"Aging","Inflammation","Frailty",[7039],{"trials":7094,"activeCount":128},[7095],{"nctId":7096,"briefTitle":7097,"status":104,"phases":7098,"primaryCompletion":2999,"completion":2999,"start":3642,"enrollment":885,"conditions":7099,"interventions":7100},"NCT02593097","Metformin for the Prevention of Episodic Migraine (MPEM)",[92],[1938],[7039],{"trials":7102,"activeCount":128},[7103,7110],{"nctId":7104,"briefTitle":7105,"status":1413,"phases":7106,"primaryCompletion":6258,"completion":7107,"start":6258,"enrollment":128,"conditions":7108,"interventions":7109},"NCT00588172","Genetic Variation in OCT1 and Response to Metformin",[93],"2011-06",[1868],[7039],{"nctId":7111,"briefTitle":7112,"status":104,"phases":7113,"primaryCompletion":1375,"completion":3613,"start":7114,"enrollment":956,"conditions":7115,"interventions":7116},"NCT00951899","The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics",[93],"2009-08",[1868],[7117,7039],"Colesevelam",{"trials":7119,"activeCount":128},[],{"intervention":1342,"totalTrials":895,"cells":7121},{"EARLY_PHASE1":7122,"PHASE1":7124,"PHASE2":7126,"PHASE3":7144,"PHASE4":7146,"NA":7156},{"trials":7123,"activeCount":128},[],{"trials":7125,"activeCount":128},[],{"trials":7127,"activeCount":676,"soonestReadout":5092},[7128,7132,7136],{"nctId":5089,"briefTitle":5090,"status":265,"phases":7129,"primaryCompletion":5092,"completion":5093,"start":5094,"enrollment":2742,"conditions":7130,"interventions":7131},[91],[5096],[5098,3427,1342,5099],{"nctId":5101,"briefTitle":5102,"status":104,"phases":7133,"primaryCompletion":1299,"completion":3662,"start":5104,"enrollment":498,"conditions":7134,"interventions":7135},[91],[5106,5107],[5109,2627,5110,3525],{"nctId":7137,"briefTitle":7138,"status":104,"phases":7139,"primaryCompletion":7140,"completion":7140,"start":7141,"enrollment":3687,"conditions":7142,"interventions":7143},"NCT03852537","Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia",[91],"2020-11-17","2019-12-02",[4064],[1342],{"trials":7145,"activeCount":128},[],{"trials":7147,"activeCount":128},[7148,7152],{"nctId":2617,"briefTitle":2618,"status":104,"phases":7149,"primaryCompletion":2620,"completion":2620,"start":2621,"enrollment":313,"conditions":7150,"interventions":7151},[93],[2623],[2625,2626,2627,2586],{"nctId":1334,"briefTitle":1335,"status":104,"phases":7153,"primaryCompletion":872,"completion":1337,"start":1338,"enrollment":34,"conditions":7154,"interventions":7155},[93],[1340],[1274,791,1342],{"trials":7157,"activeCount":128},[],{"intervention":7159,"totalTrials":342,"cells":7160},"Dapagliflozin",{"EARLY_PHASE1":7161,"PHASE1":7163,"PHASE2":7165,"PHASE3":7186,"PHASE4":7188,"NA":7199},{"trials":7162,"activeCount":128},[],{"trials":7164,"activeCount":128},[],{"trials":7166,"activeCount":676,"soonestReadout":2111},[7167,7177],{"nctId":7168,"briefTitle":7169,"status":265,"phases":7170,"primaryCompletion":2111,"completion":2111,"start":7171,"enrollment":97,"conditions":7172,"interventions":7176},"NCT06762964","CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation",[91],"2025-05-16",[7173,7174,7175],"Fontan Circulation","Single Ventricle Heart Disease","HFpEF - Heart Failure With Preserved Ejection Fraction",[7159],{"nctId":7178,"briefTitle":7179,"status":104,"phases":7180,"primaryCompletion":7181,"completion":7181,"start":7182,"enrollment":956,"conditions":7183,"interventions":7185},"NCT04730947","Dapagliflozin (DAPA) Effects in HFpEF",[91],"2022-11-17","2021-02-24",[7184],"Heart Failure With Preserved Ejection Fraction",[7159],{"trials":7187,"activeCount":128},[],{"trials":7189,"activeCount":128},[7190],{"nctId":7191,"briefTitle":7192,"status":104,"phases":7193,"primaryCompletion":667,"completion":667,"start":5443,"enrollment":108,"conditions":7194,"interventions":7197},"NCT06263673","Anti-Diabetic Medications to Fight PD and LBD",[93],[7195,7196],"Lewy Body Dementia","Parkinson Disease",[7198,7159],"Sitagliptin",{"trials":7200,"activeCount":128},[],{"intervention":2725,"totalTrials":342,"cells":7202},{"EARLY_PHASE1":7203,"PHASE1":7205,"PHASE2":7207,"PHASE3":7233,"PHASE4":7235,"NA":7245},{"trials":7204,"activeCount":128},[],{"trials":7206,"activeCount":128},[],{"trials":7208,"activeCount":676,"soonestReadout":496},[7209],{"nctId":7210,"briefTitle":7211,"status":265,"phases":7212,"primaryCompletion":496,"completion":496,"start":1935,"enrollment":558,"conditions":7213,"interventions":7230},"NCT06997068","Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent\u002FMetastatic Head and Neck Cancer in a Rural Midwest United States Population",[91],[7214,7215,7216,4237,7217,4481,7218,7219,7220,7221,7222,7223,7224,7225,7226,7227,7228,7229],"Metastatic Oral Cavity Carcinoma","Recurrent Oral Cavity Carcinoma","Stage IVC Lip and Oral Cavity Cancer AJCC v8","Hypopharynx Cancer","Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Metastatic Hypopharyngeal Carcinoma","Metastatic Laryngeal Carcinoma","Metastatic Malignant Head and Neck Neoplasm","Metastatic Oropharyngeal Carcinoma","Recurrent Hypopharyngeal Carcinoma","Recurrent Laryngeal Carcinoma","Recurrent Malignant Head and Neck Neoplasm","Recurrent Oropharyngeal Carcinoma","Stage IVC Hypopharyngeal Carcinoma AJCC v8","Stage IVC Laryngeal Cancer AJCC v8","Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8",[2725,7231,7232],"Erlotinib Hydrochloride","Methotrexate",{"trials":7234,"activeCount":128},[],{"trials":7236,"activeCount":128},[7237,7241],{"nctId":2716,"briefTitle":2717,"status":104,"phases":7238,"primaryCompletion":2719,"completion":2719,"start":796,"enrollment":2720,"conditions":7239,"interventions":7240},[93],[2722],[2724,2725,1013],{"nctId":4123,"briefTitle":4124,"status":104,"phases":7242,"primaryCompletion":4126,"completion":4126,"start":2719,"enrollment":1320,"conditions":7243,"interventions":7244},[93],[4128],[305,2725],{"trials":7246,"activeCount":128},[],{"intervention":7248,"totalTrials":224,"cells":7249},"Ketamine Hydrochloride",{"EARLY_PHASE1":7250,"PHASE1":7252,"PHASE2":7254,"PHASE3":7263,"PHASE4":7265,"NA":7276},{"trials":7251,"activeCount":128},[],{"trials":7253,"activeCount":128},[],{"trials":7255,"activeCount":676,"soonestReadout":761},[7256],{"nctId":7257,"briefTitle":7258,"status":265,"phases":7259,"primaryCompletion":761,"completion":761,"start":7260,"enrollment":773,"conditions":7261,"interventions":7262},"NCT05803551","A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients",[91],"2025-07-07",[876],[7248],{"trials":7264,"activeCount":128},[],{"trials":7266,"activeCount":128},[7267],{"nctId":7268,"briefTitle":7269,"status":104,"phases":7270,"primaryCompletion":7271,"completion":7272,"start":3335,"enrollment":668,"conditions":7273,"interventions":7275},"NCT03156504","The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.",[93],"2020-02-12","2020-03-12",[7274,714,715,1741],"Major Depression",[7248],{"trials":7277,"activeCount":128},[],{"intervention":3513,"totalTrials":355,"cells":7279},{"EARLY_PHASE1":7280,"PHASE1":7282,"PHASE2":7311,"PHASE3":7372,"PHASE4":7374,"NA":7376},{"trials":7281,"activeCount":128},[],{"trials":7283,"activeCount":128},[7284,7292,7300],{"nctId":7285,"briefTitle":7286,"status":104,"phases":7287,"primaryCompletion":7288,"completion":7289,"start":1374,"enrollment":410,"conditions":7290,"interventions":7291},"NCT01936090","Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma",[90],"2016-02-02","2018-02-16",[6117,6118,6119,3447],[3680,6121],{"nctId":7293,"briefTitle":7294,"status":104,"phases":7295,"primaryCompletion":7296,"completion":7296,"start":7297,"conditions":7298,"interventions":7299},"NCT00006362","PS-341 in Treating Patients With Advanced Cancer",[90],"2003-08","1999-11",[3549,1419,3665,5371,4293],[3513],{"nctId":7301,"briefTitle":7302,"status":104,"phases":7303,"primaryCompletion":7304,"completion":7305,"start":7306,"enrollment":476,"conditions":7307,"interventions":7308},"NCT03829020","Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and\u002For Refractory Multiple Myeloma",[90],"2022-09-21","2023-11-24","2019-04-17",[303,3447],[3680,7309,7310],"Metformin Hydrochloride","Nelfinavir Mesylate",{"trials":7312,"activeCount":676,"soonestReadout":3911},[7313,7320,7324,7328,7335,7339,7343,7347,7356,7360,7364],{"nctId":7314,"briefTitle":7315,"status":104,"phases":7316,"primaryCompletion":7317,"completion":7317,"start":1298,"enrollment":108,"conditions":7318,"interventions":7319},"NCT00722722","The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates",[91],"2014-04",[1697],[3680],{"nctId":3506,"briefTitle":3507,"status":104,"phases":7321,"primaryCompletion":945,"completion":3509,"start":1357,"enrollment":224,"conditions":7322,"interventions":7323},[91],[3511],[3513,3323,3514],{"nctId":3528,"briefTitle":3529,"status":104,"phases":7325,"primaryCompletion":3531,"completion":3532,"start":3533,"enrollment":342,"conditions":7326,"interventions":7327},[91],[3535,3536,3537],[3513,3323,3539,3514],{"nctId":7329,"briefTitle":7330,"status":104,"phases":7331,"primaryCompletion":2643,"completion":2621,"start":7332,"enrollment":773,"conditions":7333,"interventions":7334},"NCT00478075","Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma",[90,91],"2005-09",[3665],[3513],{"nctId":3895,"briefTitle":3896,"status":104,"phases":7336,"primaryCompletion":409,"completion":3898,"start":3899,"enrollment":773,"conditions":7337,"interventions":7338},[90,91],[3690],[3902,3513,3514],{"nctId":3908,"briefTitle":3909,"status":169,"phases":7340,"primaryCompletion":3911,"completion":3912,"start":3913,"enrollment":3914,"conditions":7341,"interventions":7342},[90,91],[549],[3680,159,305,3917],{"nctId":3923,"briefTitle":3924,"status":1413,"phases":7344,"primaryCompletion":3926,"completion":3926,"start":2698,"enrollment":128,"conditions":7345,"interventions":7346},[91],[3654,3928],[3680,305,179],{"nctId":7348,"briefTitle":7349,"status":1413,"phases":7350,"enrollment":128,"conditions":7351,"interventions":7352},"NCT00995059","Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma",[90,91],[3562,3690],[3513,3759,7353,7354,7355],"anti-thymocyte globulin","sirolimus","tacrolimus",{"nctId":3668,"briefTitle":3669,"status":104,"phases":7357,"primaryCompletion":3671,"completion":3672,"start":3673,"enrollment":3674,"conditions":7358,"interventions":7359},[91],[3676,3677,434,435,416,439,443,3678,451],[3680,163,57,305],{"nctId":3714,"briefTitle":3715,"status":104,"phases":7361,"primaryCompletion":3717,"completion":2936,"start":3718,"enrollment":3719,"conditions":7362,"interventions":7363},[91],[3665],[3513,3323,3514],{"nctId":7365,"briefTitle":7366,"status":104,"phases":7367,"primaryCompletion":874,"completion":5361,"start":4032,"enrollment":7368,"conditions":7369,"interventions":7370},"NCT01034553","Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma",[90,91],26,[3690],[7371,3513],"Aurora A kinase inhibitor MLN8237",{"trials":7373,"activeCount":128},[],{"trials":7375,"activeCount":128},[],{"trials":7377,"activeCount":128},[],{"intervention":3861,"totalTrials":370,"cells":7379},{"EARLY_PHASE1":7380,"PHASE1":7382,"PHASE2":7392,"PHASE3":7426,"PHASE4":7428,"NA":7430},{"trials":7381,"activeCount":128},[],{"trials":7383,"activeCount":128},[7384,7388],{"nctId":4518,"briefTitle":4519,"status":104,"phases":7385,"primaryCompletion":4521,"completion":4522,"start":4523,"enrollment":342,"conditions":7386,"interventions":7387},[90],[4525,4526,4527,4528],[112,3861],{"nctId":3847,"briefTitle":3848,"status":104,"phases":7389,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":34,"conditions":7390,"interventions":7391},[90],[3854,3855,3856,3857,3858,3859],[305,3861],{"trials":7393,"activeCount":676,"soonestReadout":3961},[7394,7398,7402,7406,7410,7414,7418,7422],{"nctId":3895,"briefTitle":3896,"status":104,"phases":7395,"primaryCompletion":409,"completion":3898,"start":3899,"enrollment":773,"conditions":7396,"interventions":7397},[90,91],[3690],[3902,3513,3514],{"nctId":3931,"briefTitle":3932,"status":104,"phases":7399,"primaryCompletion":3934,"completion":3934,"start":3935,"enrollment":139,"conditions":7400,"interventions":7401},[91],[3937,549,3788],[305,306,3861],{"nctId":3958,"briefTitle":3959,"status":169,"phases":7403,"primaryCompletion":3961,"completion":3962,"start":3963,"enrollment":1236,"conditions":7404,"interventions":7405},[90,91],[3689,3690],[157,305,3861,3966],{"nctId":3968,"briefTitle":3969,"status":104,"phases":7407,"primaryCompletion":3971,"completion":3972,"start":2643,"enrollment":3973,"conditions":7408,"interventions":7409},[91],[3665],[3514,3902],{"nctId":3993,"briefTitle":3994,"status":134,"phases":7411,"primaryCompletion":3996,"completion":3997,"start":3998,"enrollment":139,"conditions":7412,"interventions":7413},[91],[549,303,3447,3870],[305,551,3861],{"nctId":4013,"briefTitle":4014,"status":104,"phases":7415,"primaryCompletion":1471,"completion":1471,"start":3001,"enrollment":476,"conditions":7416,"interventions":7417},[91],[303,3447],[305,551,3861],{"nctId":4050,"briefTitle":4051,"status":104,"phases":7419,"primaryCompletion":4053,"completion":4054,"start":4055,"enrollment":3945,"conditions":7420,"interventions":7421},[91],[3447],[305,3948,3861],{"nctId":4095,"briefTitle":4096,"status":104,"phases":7423,"primaryCompletion":4098,"completion":4098,"start":4099,"enrollment":2563,"conditions":7424,"interventions":7425},[91],[303,3447],[305,306,3861],{"trials":7427,"activeCount":128},[],{"trials":7429,"activeCount":128},[],{"trials":7431,"activeCount":128},[],{"intervention":4405,"totalTrials":476,"cells":7433},{"EARLY_PHASE1":7434,"PHASE1":7448,"PHASE2":7481,"PHASE3":7505,"PHASE4":7507,"NA":7509},{"trials":7435,"activeCount":128},[7436],{"nctId":7437,"briefTitle":7438,"status":104,"phases":7439,"primaryCompletion":7440,"completion":7440,"start":7441,"enrollment":461,"conditions":7442,"interventions":7443},"NCT00640861","Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer",[89],"2015-04-21","2008-08-28",[21],[7444,7445,7446,7447,4405],"CpG oligodeoxynucleotide","HER-2\u002Fneu peptide vaccine","MUC-1 peptide vaccine","incomplete Freund's adjuvant",{"trials":7449,"activeCount":128},[7450,7458,7462],{"nctId":7451,"briefTitle":7452,"status":104,"phases":7453,"primaryCompletion":7454,"completion":7087,"start":7455,"enrollment":410,"conditions":7456,"interventions":7457},"NCT00568763","Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma",[90],"2010-05-10","2005-11-25",[4291],[4405],{"nctId":5257,"briefTitle":5258,"status":104,"phases":7459,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":729,"conditions":7460,"interventions":7461},[90],[3665],[3553,3759,5265,657,5266],{"nctId":7463,"briefTitle":7464,"status":104,"phases":7465,"primaryCompletion":7466,"completion":7467,"start":7468,"enrollment":1197,"conditions":7469,"interventions":7479},"NCT02444546","Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors",[90],"2018-07-13","2022-11-21","2015-06-21",[7470,7471,7472,4747,7473,7474,7475,7476,7477,7478],"Childhood Astrocytoma","Childhood Atypical Teratoid\u002FRhabdoid Tumor","Diffuse Intrinsic Pontine Glioma","Recurrent Childhood Anaplastic Oligodendroglioma","Recurrent Childhood Brain Neoplasm","Recurrent Childhood Glioblastoma","Recurrent Childhood Medulloblastoma","Recurrent Primitive Neuroectodermal Tumor","Refractory Brain Neoplasm",[657,7480],"Wild-type Reovirus",{"trials":7482,"activeCount":676,"soonestReadout":575},[7483,7489,7493,7497,7501],{"nctId":7484,"briefTitle":7485,"status":104,"phases":7486,"primaryCompletion":4871,"completion":5246,"start":4872,"enrollment":22,"conditions":7487,"interventions":7488},"NCT00602706","Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant",[90,91],[3665],[4405,3759],{"nctId":4396,"briefTitle":4397,"status":104,"phases":7490,"primaryCompletion":4399,"start":4400,"enrollment":1236,"conditions":7491,"interventions":7492},[91],[4402,1420],[4404,4405,4240,3324,3326,4406],{"nctId":5402,"briefTitle":5403,"status":104,"phases":7494,"primaryCompletion":3569,"completion":5405,"start":5351,"enrollment":28,"conditions":7495,"interventions":7496},[91],[3549,1419],[5408,3553,3554,4405],{"nctId":572,"briefTitle":573,"status":265,"phases":7498,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":7499,"interventions":7500},[90,91],[579,580,581,582,583,189,190,191,584,192,193,194,585,586,587,588,589,590,591,195,196,592,593,594,595,596,597,598,599,600,601,602,603,604,605,197,606,607,198,199,200,361,201,202,122,608,609,610,235,203,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,206,629,207,630,631,632,633,634,635,636,637,638,221,639,640,641,642,643,644,645,208,177,646,647,648,649,650,141,651,652,653,654],[57,656,72,657],{"nctId":5451,"briefTitle":5452,"status":104,"phases":7502,"primaryCompletion":5454,"completion":5455,"start":4503,"enrollment":31,"conditions":7503,"interventions":7504},[91],[3549],[5355,163,657],{"trials":7506,"activeCount":128},[],{"trials":7508,"activeCount":128},[],{"trials":7510,"activeCount":128},[],{"intervention":67,"totalTrials":120,"cells":7512},{"EARLY_PHASE1":7513,"PHASE1":7515,"PHASE2":7568,"PHASE3":7584,"PHASE4":7586,"NA":7588},{"trials":7514,"activeCount":128},[],{"trials":7516,"activeCount":128},[7517,7535,7546,7556],{"nctId":7518,"briefTitle":7519,"status":104,"phases":7520,"primaryCompletion":7521,"completion":7522,"start":7523,"enrollment":218,"conditions":7524,"interventions":7534},"NCT01846091","Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer",[90],"2019-09-18","2019-11-26","2013-04-09",[7525,7526,7527,7528,7529,7530,7531,7532,7533,3345,221],"Estrogen Receptor Negative","Estrogen Receptor Positive","Head and Neck Squamous Cell Carcinoma","HER2\u002FNeu Negative","HER2\u002FNeu Positive","Invasive Breast Carcinoma","Progesterone Receptor Negative","Progesterone Receptor Positive","Recurrent Head and Neck Carcinoma",[67],{"nctId":7536,"briefTitle":7537,"status":104,"phases":7538,"primaryCompletion":894,"completion":7539,"start":7540,"enrollment":3945,"conditions":7541,"interventions":7543},"NCT00408590","Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer",[90],"2017-11-07","2004-04-19",[3321,7542],"Primary Peritoneal Cavity Cancer",[7544,7545,3599],"carcinoembryonic antigen-expressing measles virus","oncolytic measles virus encoding thyroidal sodium iodide symporter",{"nctId":7547,"briefTitle":7548,"status":104,"phases":7549,"primaryCompletion":4553,"completion":4553,"start":7550,"enrollment":476,"conditions":7551,"interventions":7555},"NCT02700230","Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery",[90],"2017-03-22",[7552,7553,7554],"Metastatic Malignant Peripheral Nerve Sheath Tumor","Neurofibromatosis Type 1","Recurrent Malignant Peripheral Nerve Sheath Tumor",[67],{"nctId":7557,"briefTitle":7558,"status":104,"phases":7559,"primaryCompletion":7560,"completion":7560,"start":3842,"enrollment":4565,"conditions":7561,"interventions":7567},"NCT01503177","Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma",[90],"2019-04-11",[4253,7562,7563,7564,7565,7566],"Stage IA Malignant Mesothelioma","Stage IB Malignant Mesothelioma","Stage II Malignant Mesothelioma","Stage III Malignant Mesothelioma","Stage IV Malignant Mesothelioma",[7545],{"trials":7569,"activeCount":676,"soonestReadout":66},[7570,7574,7578],{"nctId":5595,"briefTitle":5596,"status":134,"phases":7571,"primaryCompletion":5598,"completion":5598,"start":5599,"enrollment":139,"conditions":7572,"interventions":7573},[91],[500,5601,5602,5603,5604,5605,5606,5607,5608,5609,5610,5611,5612,5613,5614,3491,3492,3493,501,5615,5616,5617,5618,5619,502,506,511],[4719,161,67,540,5621,5622],{"nctId":3601,"briefTitle":3602,"status":104,"phases":7575,"primaryCompletion":3604,"completion":3605,"start":3606,"enrollment":2608,"conditions":7576,"interventions":7577},[90,91],[303,3447],[57,67],{"nctId":64,"briefTitle":65,"status":169,"phases":7579,"primaryCompletion":66,"completion":4700,"start":7580,"enrollment":885,"conditions":7581,"interventions":7583},[90,91],"2014-04-25",[5601,5602,5603,5604,5605,5606,7582,5608,5609,5610,5611,5612,5613,5614,5617,502,506,511],"Malignant Ovarian Brenner Tumor",[67],{"trials":7585,"activeCount":128},[],{"trials":7587,"activeCount":128},[],{"trials":7589,"activeCount":128},[],{"intervention":3482,"totalTrials":120,"cells":7591},{"EARLY_PHASE1":7592,"PHASE1":7594,"PHASE2":7613,"PHASE3":7631,"PHASE4":7633,"NA":7635},{"trials":7593,"activeCount":128},[],{"trials":7595,"activeCount":128},[7596,7600,7609],{"nctId":4285,"briefTitle":4286,"status":104,"phases":7597,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":2608,"conditions":7598,"interventions":7599},[90],[21,4291,4292,4293],[4295,3482,4240],{"nctId":7601,"briefTitle":7602,"status":104,"phases":7603,"primaryCompletion":7604,"completion":7604,"start":7605,"conditions":7606,"interventions":7608},"NCT00002693","Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia",[90],"2006-04","1995-10",[3549,7607],"Neutropenia",[3481,3482,3483],{"nctId":3472,"briefTitle":3473,"status":104,"phases":7610,"primaryCompletion":3475,"completion":3476,"start":3477,"enrollment":2608,"conditions":7611,"interventions":7612},[90],[3321,3479],[3481,3482,3323,3483],{"trials":7614,"activeCount":676,"soonestReadout":4080},[7615,7619,7623,7627],{"nctId":4781,"briefTitle":4782,"status":134,"phases":7616,"primaryCompletion":4784,"completion":4785,"start":4786,"enrollment":218,"conditions":7617,"interventions":7618},[91],[4291],[3482,3597,4768],{"nctId":4077,"briefTitle":4078,"status":265,"phases":7620,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":2678,"conditions":7621,"interventions":7622},[91],[4084,3422,414,144,4085,3398,4086,4087],[536,4089,4090,305,4091,161,4092,539,163,4093],{"nctId":519,"briefTitle":520,"status":104,"phases":7624,"primaryCompletion":522,"completion":523,"start":524,"enrollment":525,"conditions":7625,"interventions":7626},[90,91],[527,528,529,530,531,532,533,534],[536,537,538,539,540,72],{"nctId":4428,"briefTitle":4429,"status":104,"phases":7628,"primaryCompletion":4431,"completion":4431,"start":4432,"enrollment":173,"conditions":7629,"interventions":7630},[91],[4434,4435,614,645],[536,4089,4091,540,4437],{"trials":7632,"activeCount":128},[],{"trials":7634,"activeCount":128},[],{"trials":7636,"activeCount":128},[],{"intervention":4719,"totalTrials":1197,"cells":7638},{"EARLY_PHASE1":7639,"PHASE1":7641,"PHASE2":7647,"PHASE3":7674,"PHASE4":7676,"NA":7678},{"trials":7640,"activeCount":128},[],{"trials":7642,"activeCount":128},[7643],{"nctId":6202,"briefTitle":6203,"status":104,"phases":7644,"primaryCompletion":6205,"completion":6205,"start":6206,"enrollment":2980,"conditions":7645,"interventions":7646},[90],[6208,6209,6210,6211,6212,192,6213,6214,6215,6216,6217,6218,6219,6220,500,5601,5602,5603,5604,6221,5605,5606,1258,6222,6223,6224,6225,6226,24,5607,5608,5609,6227,5610,5612,5613,5614,3491,3492,3493,6228,501,5615,5617,5618,5619,177,6229],[4719,4385],{"trials":7648,"activeCount":676,"soonestReadout":4714},[7649,7653,7662,7666,7670],{"nctId":3541,"briefTitle":3542,"status":104,"phases":7650,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":7651,"interventions":7652},[91],[3549,1419],[3551,3552,3553,3323,3554],{"nctId":7654,"briefTitle":7655,"status":104,"phases":7656,"primaryCompletion":3718,"completion":7657,"start":7604,"enrollment":7658,"conditions":7659,"interventions":7660},"NCT00482495","Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma",[91],"2009-11",42,[3665],[3551,3598,7661],"protein expression analysis",{"nctId":5595,"briefTitle":5596,"status":134,"phases":7663,"primaryCompletion":5598,"completion":5598,"start":5599,"enrollment":139,"conditions":7664,"interventions":7665},[91],[500,5601,5602,5603,5604,5605,5606,5607,5608,5609,5610,5611,5612,5613,5614,3491,3492,3493,501,5615,5616,5617,5618,5619,502,506,511],[4719,161,67,540,5621,5622],{"nctId":4711,"briefTitle":4712,"status":265,"phases":7667,"primaryCompletion":4714,"completion":4714,"start":4715,"enrollment":19,"conditions":7668,"interventions":7669},[90,91],[613,4660,629,4661,644,4662],[4718,4719,422,261,4645],{"nctId":5653,"briefTitle":5654,"status":104,"phases":7671,"primaryCompletion":1310,"completion":1310,"start":5656,"enrollment":301,"conditions":7672,"interventions":7673},[91],[502,506,511],[4719,161,540,5621,5622],{"trials":7675,"activeCount":128},[],{"trials":7677,"activeCount":128},[],{"trials":7679,"activeCount":128},[],{"intervention":5634,"totalTrials":895,"cells":7681},{"EARLY_PHASE1":7682,"PHASE1":7684,"PHASE2":7711,"PHASE3":7728,"PHASE4":7730,"NA":7732},{"trials":7683,"activeCount":128},[],{"trials":7685,"activeCount":128},[7686,7692,7701],{"nctId":7687,"briefTitle":7688,"status":104,"phases":7689,"primaryCompletion":6365,"completion":6365,"start":2621,"enrollment":729,"conditions":7690,"interventions":7691},"NCT01186796","Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women",[90],[18],[5634],{"nctId":7693,"briefTitle":7694,"status":104,"phases":7695,"primaryCompletion":7696,"completion":7696,"start":3001,"enrollment":3034,"conditions":7697,"interventions":7699},"NCT02026973","Impact of Endogenous E2 on SSI and GH Rebound",[90],"2015-11",[7698],"Normal Healthy Volunteers",[5634,82,7700],"Somatostatin",{"nctId":7702,"briefTitle":7703,"status":104,"phases":7704,"primaryCompletion":7705,"completion":7706,"start":7707,"enrollment":370,"conditions":7708,"interventions":7709},"NCT02219789","Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery",[90],"2016-03-28","2018-10-01","2014-12-05",[7526,7532,143,3376,3380,3345],[7710,5634],"Alisertib",{"trials":7712,"activeCount":676,"soonestReadout":81},[7713,7724],{"nctId":7714,"briefTitle":7715,"status":104,"phases":7716,"primaryCompletion":7717,"completion":7718,"start":545,"enrollment":4208,"conditions":7719,"interventions":7723},"NCT02860000","Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",[91],"2022-01-10","2025-02-14",[7720,7528,7530,7721,7722,3372,3376,3380,3345],"Estrogen Receptor Status","Postmenopausal","Stage III Breast Cancer",[7710,5634],{"nctId":79,"briefTitle":80,"status":169,"phases":7725,"primaryCompletion":81,"completion":5625,"start":5626,"enrollment":139,"conditions":7726,"interventions":7727},[91],[5628,5629,579,583,5630],[82,5632,5633,5634,5635,540,165],{"trials":7729,"activeCount":128},[],{"trials":7731,"activeCount":128},[],{"trials":7733,"activeCount":128},[],{"intervention":3325,"totalTrials":895,"cells":7735},{"EARLY_PHASE1":7736,"PHASE1":7742,"PHASE2":7744,"PHASE3":7762,"PHASE4":7764,"NA":7766},{"trials":7737,"activeCount":128},[7738],{"nctId":3315,"briefTitle":3316,"status":104,"phases":7739,"primaryCompletion":3318,"completion":3318,"start":3319,"enrollment":817,"conditions":7740,"interventions":7741},[89],[3321,1420],[3323,3324,3325,3326,3327],{"trials":7743,"activeCount":128},[],{"trials":7745,"activeCount":676,"soonestReadout":4080},[7746,7750,7754,7758],{"nctId":4387,"briefTitle":4388,"status":104,"phases":7747,"primaryCompletion":4390,"completion":4391,"start":3319,"enrollment":3726,"conditions":7748,"interventions":7749},[91],[4393],[4240,3325],{"nctId":4077,"briefTitle":4078,"status":265,"phases":7751,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":2678,"conditions":7752,"interventions":7753},[91],[4084,3422,414,144,4085,3398,4086,4087],[536,4089,4090,305,4091,161,4092,539,163,4093],{"nctId":4428,"briefTitle":4429,"status":104,"phases":7755,"primaryCompletion":4431,"completion":4431,"start":4432,"enrollment":173,"conditions":7756,"interventions":7757},[91],[4434,4435,614,645],[536,4089,4091,540,4437],{"nctId":4461,"briefTitle":4462,"status":104,"phases":7759,"primaryCompletion":4464,"completion":4464,"start":4465,"conditions":7760,"interventions":7761},[91],[4393,4467,4468],[4240,3325],{"trials":7763,"activeCount":128},[],{"trials":7765,"activeCount":128},[],{"trials":7767,"activeCount":128},[],{"intervention":4718,"totalTrials":681,"cells":7769},{"EARLY_PHASE1":7770,"PHASE1":7776,"PHASE2":7793,"PHASE3":7814,"PHASE4":7816,"NA":7818},{"trials":7771,"activeCount":128},[7772],{"nctId":6187,"briefTitle":6188,"status":1413,"phases":7773,"primaryCompletion":6173,"completion":6173,"start":6190,"enrollment":128,"conditions":7774,"interventions":7775},[89],[579,580,581,582,583,6192,235,6193,6194,6195,6196,6197],[4718,4385],{"trials":7777,"activeCount":128},[7778],{"nctId":7779,"briefTitle":7780,"status":134,"phases":7781,"primaryCompletion":7782,"completion":7783,"start":7784,"enrollment":676,"conditions":7785,"interventions":7791},"NCT03455556","Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer",[90],"2019-09-11","2020-01-07","2018-08-10",[7786,7787,7788,7789,7790],"Mesothelin Positive","Stage III Non-Small Cell Lung Cancer AJCC v7","Stage IIIA Non-Small Cell Lung Cancer AJCC v7","Stage IIIB Non-Small Cell Lung Cancer AJCC v7","Stage IV Non-Small Cell Lung Cancer AJCC v7",[7792,4718],"Anetumab Ravtansine",{"trials":7794,"activeCount":676,"soonestReadout":4714},[7795,7810],{"nctId":7796,"briefTitle":7797,"status":104,"phases":7798,"primaryCompletion":3700,"completion":3700,"start":7799,"enrollment":3560,"conditions":7800,"interventions":7806},"NCT03554083","Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma",[91],"2018-10-05",[189,7801,7802,7803,7804,7805],"Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8",[4718,7807,7808,7809],"Cobimetinib","Tiragolumab","Vemurafenib",{"nctId":4711,"briefTitle":4712,"status":265,"phases":7811,"primaryCompletion":4714,"completion":4714,"start":4715,"enrollment":19,"conditions":7812,"interventions":7813},[90,91],[613,4660,629,4661,644,4662],[4718,4719,422,261,4645],{"trials":7815,"activeCount":128},[],{"trials":7817,"activeCount":128},[],{"trials":7819,"activeCount":128},[],{"intervention":6376,"totalTrials":681,"cells":7821},{"EARLY_PHASE1":7822,"PHASE1":7824,"PHASE2":7826,"PHASE3":7859,"PHASE4":7861,"NA":7863},{"trials":7823,"activeCount":128},[],{"trials":7825,"activeCount":128},[],{"trials":7827,"activeCount":676,"soonestReadout":7849},[7828,7837,7845,7855],{"nctId":7829,"briefTitle":7830,"status":104,"phases":7831,"primaryCompletion":3718,"completion":934,"start":7832,"enrollment":712,"conditions":7833,"interventions":7834},"NCT00653757","Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer",[90,91],"2002-03",[4292],[7835,7836],"goserelin acetate","leuprolide acetate",{"nctId":7838,"briefTitle":7839,"status":134,"phases":7840,"primaryCompletion":3509,"completion":1375,"start":6955,"enrollment":2742,"conditions":7841,"interventions":7844},"NCT00937768","Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy",[91],[6368,7842,7843,6371,6372],"Stage IIA Prostate Cancer","Stage IIB Prostate Cancer",[6376,6377],{"nctId":7846,"briefTitle":7847,"status":1096,"phases":7848,"primaryCompletion":7849,"completion":7850,"start":5868,"enrollment":7851,"conditions":7852,"interventions":7854},"NCT07460752","Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients",[91],"2028-09-26","2029-09-26",98,[5197,5198,579,7853],"Locally Advanced Hormone Receptor-Positive Breast Carcinoma",[6376],{"nctId":6362,"briefTitle":6363,"status":104,"phases":7856,"primaryCompletion":3661,"completion":6365,"start":2573,"enrollment":6366,"conditions":7857,"interventions":7858},[91],[6368,6369,6370,6371,6372],[6374,6375,6376,4557,6377],{"trials":7860,"activeCount":128},[],{"trials":7862,"activeCount":128},[],{"trials":7864,"activeCount":128},[],{"intervention":4090,"totalTrials":681,"cells":7866},{"EARLY_PHASE1":7867,"PHASE1":7869,"PHASE2":7871,"PHASE3":7902,"PHASE4":7904,"NA":7906},{"trials":7868,"activeCount":128},[],{"trials":7870,"activeCount":128},[],{"trials":7872,"activeCount":676,"soonestReadout":4080},[7873,7877,7888,7898],{"nctId":3610,"briefTitle":3611,"status":1413,"phases":7874,"primaryCompletion":905,"completion":2697,"start":3613,"enrollment":128,"conditions":7875,"interventions":7876},[91],[3615,3616,3617,3618,3619],[3621,3553,3323,3324,3327,3622,3623,3525,3624,3514,3625],{"nctId":7878,"briefTitle":7879,"status":104,"phases":7880,"primaryCompletion":7881,"completion":7882,"start":7883,"enrollment":342,"conditions":7884,"interventions":7886},"NCT02666950","WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome",[91],"2018-09-25","2018-10-17","2017-05-05",[4087,7885,6313,3439,3440,6317],"Myelodysplastic Syndrome With Isolated Del(5q)",[4090,7887],"WEE1 Inhibitor AZD1775",{"nctId":7889,"briefTitle":7890,"status":104,"phases":7891,"primaryCompletion":4432,"completion":7892,"start":7893,"enrollment":885,"conditions":7894,"interventions":7895},"NCT01806571","Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",[91],"2019-11-30","2015-03-12",[6317],[4090,7896,7897],"Daunorubicin Hydrochloride","Nilotinib",{"nctId":4077,"briefTitle":4078,"status":265,"phases":7899,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":2678,"conditions":7900,"interventions":7901},[91],[4084,3422,414,144,4085,3398,4086,4087],[536,4089,4090,305,4091,161,4092,539,163,4093],{"trials":7903,"activeCount":128},[],{"trials":7905,"activeCount":128},[],{"trials":7907,"activeCount":128},[],{"intervention":261,"totalTrials":342,"cells":7909},{"EARLY_PHASE1":7910,"PHASE1":7912,"PHASE2":7914,"PHASE3":7933,"PHASE4":7935,"NA":7937},{"trials":7911,"activeCount":128},[],{"trials":7913,"activeCount":128},[],{"trials":7915,"activeCount":676,"soonestReadout":4714},[7916,7920,7924],{"nctId":254,"briefTitle":255,"status":134,"phases":7917,"primaryCompletion":257,"completion":257,"start":258,"enrollment":120,"conditions":7918,"interventions":7919},[90,91],[175,176,123,124,125],[72,261],{"nctId":4711,"briefTitle":4712,"status":265,"phases":7921,"primaryCompletion":4714,"completion":4714,"start":4715,"enrollment":19,"conditions":7922,"interventions":7923},[90,91],[613,4660,629,4661,644,4662],[4718,4719,422,261,4645],{"nctId":7925,"briefTitle":7926,"status":134,"phases":7927,"primaryCompletion":7928,"completion":1357,"start":3717,"enrollment":224,"conditions":7929,"interventions":7930},"NCT00814892","Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer",[91],"2009-12",[4292],[7931,7932],"allogeneic tumor cell vaccine","therapeutic autologous dendritic cells",{"trials":7934,"activeCount":128},[],{"trials":7936,"activeCount":128},[],{"trials":7938,"activeCount":128},[],{"intervention":165,"totalTrials":342,"cells":7940},{"EARLY_PHASE1":7941,"PHASE1":7943,"PHASE2":7949,"PHASE3":7959,"PHASE4":7961,"NA":7963},{"trials":7942,"activeCount":128},[],{"trials":7944,"activeCount":128},[7945],{"nctId":132,"briefTitle":133,"status":134,"phases":7946,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":7947,"interventions":7948},[90],[141,142,143,144,145,146,147,148,149,150,151,152,153,154],[156,157,158,159,160,161,112,162,72,163,164,165],{"trials":7950,"activeCount":676,"soonestReadout":81},[7951,7955],{"nctId":79,"briefTitle":80,"status":169,"phases":7952,"primaryCompletion":81,"completion":5625,"start":5626,"enrollment":139,"conditions":7953,"interventions":7954},[91],[5628,5629,579,583,5630],[82,5632,5633,5634,5635,540,165],{"nctId":3587,"briefTitle":3588,"status":104,"phases":7956,"primaryCompletion":1563,"completion":3590,"start":3591,"enrollment":936,"conditions":7957,"interventions":7958},[91],[21,3593],[3595,3323,3324,3596,3597,3598,3599],{"trials":7960,"activeCount":128},[],{"trials":7962,"activeCount":128},[],{"trials":7964,"activeCount":128},[],{"intervention":569,"totalTrials":342,"cells":7966},{"EARLY_PHASE1":7967,"PHASE1":7979,"PHASE2":7981,"PHASE3":7999,"PHASE4":8001,"NA":8003},{"trials":7968,"activeCount":128},[7969],{"nctId":7970,"briefTitle":7971,"status":104,"phases":7972,"primaryCompletion":7973,"completion":7974,"start":7975,"enrollment":410,"conditions":7976,"interventions":7977},"NCT03281811","Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides",[89],"2020-02-25","2020-08-12","2017-11-13",[150],[7978,569],"Aminolevulinic Acid Hydrochloride",{"trials":7980,"activeCount":128},[],{"trials":7982,"activeCount":676,"soonestReadout":556},[7983,7995],{"nctId":7984,"briefTitle":7985,"status":104,"phases":7986,"primaryCompletion":7987,"completion":7987,"start":7988,"enrollment":301,"conditions":7989,"interventions":7994},"NCT03033225","Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study",[91],"2023-09-20","2017-05-31",[7990,7991,4383,7992,562,563,564,7993],"Advanced Pancreatic Carcinoma","Locally Advanced Pancreatic Carcinoma","Pancreatic Neoplasm","Unresectable Pancreatic Carcinoma",[569,570],{"nctId":553,"briefTitle":554,"status":265,"phases":7996,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":7997,"interventions":7998},[91],[560,561,562,563,564,565],[537,567,568,539,72,569,570],{"trials":8000,"activeCount":128},[],{"trials":8002,"activeCount":128},[],{"trials":8004,"activeCount":128},[],{"intervention":422,"totalTrials":342,"cells":8006},{"EARLY_PHASE1":8007,"PHASE1":8009,"PHASE2":8011,"PHASE3":8025,"PHASE4":8027,"NA":8029},{"trials":8008,"activeCount":128},[],{"trials":8010,"activeCount":128},[],{"trials":8012,"activeCount":676,"soonestReadout":4714},[8013,8017,8021],{"nctId":404,"briefTitle":405,"status":104,"phases":8014,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":8015,"interventions":8016},[90,91],[412,413,414,415,416,417,146,384,418,419],[421,72,422],{"nctId":6066,"briefTitle":6067,"status":134,"phases":8018,"primaryCompletion":6069,"completion":6070,"start":6071,"enrollment":218,"conditions":8019,"interventions":8020},[91],[6073,3574,3575,3576],[551,422],{"nctId":4711,"briefTitle":4712,"status":265,"phases":8022,"primaryCompletion":4714,"completion":4714,"start":4715,"enrollment":19,"conditions":8023,"interventions":8024},[90,91],[613,4660,629,4661,644,4662],[4718,4719,422,261,4645],{"trials":8026,"activeCount":128},[],{"trials":8028,"activeCount":128},[],{"trials":8030,"activeCount":128},[],{"intervention":8032,"totalTrials":342,"cells":8033},"pemetrexed disodium",{"EARLY_PHASE1":8034,"PHASE1":8036,"PHASE2":8047,"PHASE3":8062,"PHASE4":8064,"NA":8066},{"trials":8035,"activeCount":128},[],{"trials":8037,"activeCount":128},[8038],{"nctId":8039,"briefTitle":8040,"status":104,"phases":8041,"primaryCompletion":8042,"completion":8042,"start":8043,"enrollment":34,"conditions":8044,"interventions":8045},"NCT00390000","Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors",[90],"2016-08-04","2007-01-25",[4293],[8046,8032],"vatalanib",{"trials":8048,"activeCount":676,"soonestReadout":458},[8049,8053],{"nctId":455,"briefTitle":456,"status":169,"phases":8050,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":8051,"interventions":8052},[91],[463,464,465,466],[72,468],{"nctId":8054,"briefTitle":8055,"status":104,"phases":8056,"primaryCompletion":4503,"completion":8057,"start":4399,"enrollment":6434,"conditions":8058,"interventions":8060},"NCT00407550","Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[91],"2010-05-12",[8059],"Lung Cancer",[8061,8032,8061],"gemcitabine HCL",{"trials":8063,"activeCount":128},[],{"trials":8065,"activeCount":128},[],{"trials":8067,"activeCount":128},[],{"intervention":3800,"totalTrials":224,"cells":8069},{"EARLY_PHASE1":8070,"PHASE1":8072,"PHASE2":8078,"PHASE3":8089,"PHASE4":8091,"NA":8093},{"trials":8071,"activeCount":128},[],{"trials":8073,"activeCount":128},[8074],{"nctId":3794,"briefTitle":3795,"status":134,"phases":8075,"primaryCompletion":3394,"completion":3394,"start":3797,"enrollment":895,"conditions":8076,"interventions":8077},[90],[549,303,3447],[3800,159,305,551],{"trials":8079,"activeCount":676,"soonestReadout":8084},[8080],{"nctId":8081,"briefTitle":8082,"status":265,"phases":8083,"primaryCompletion":8084,"completion":8085,"start":8086,"enrollment":3034,"conditions":8087,"interventions":8088},"NCT05847569","Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma",[91],"2029-06-29","2034-06-29","2024-01-04",[3689,3690],[3800],{"trials":8090,"activeCount":128},[],{"trials":8092,"activeCount":128},[],{"trials":8094,"activeCount":128},[],{"intervention":62,"totalTrials":224,"cells":8096},{"EARLY_PHASE1":8097,"PHASE1":8099,"PHASE2":8110,"PHASE3":8118,"PHASE4":8120,"NA":8122},{"trials":8098,"activeCount":128},[],{"trials":8100,"activeCount":128},[8101],{"nctId":8102,"briefTitle":8103,"status":134,"phases":8104,"primaryCompletion":8105,"completion":8105,"start":7882,"enrollment":676,"conditions":8106,"interventions":8108},"NCT03461458","Autologous, Culture-Expanded Mesenchymal Stromal Cells for Degenerative Disc Disease",[90],"2021-02-06",[8107],"Degenerative Disc Disease",[8109],"Autologous Adipose-Derived Mesenchymal Stromal Cells",{"trials":8111,"activeCount":676,"soonestReadout":61},[8112],{"nctId":59,"briefTitle":60,"status":169,"phases":8113,"primaryCompletion":61,"completion":171,"start":8114,"enrollment":668,"conditions":8115,"interventions":8117},[91],"2017-10-10",[8116,6260],"ALS",[62],{"trials":8119,"activeCount":128},[],{"trials":8121,"activeCount":128},[],{"trials":8123,"activeCount":128},[],{"intervention":8125,"totalTrials":224,"cells":8126},"Deucravacitinib",{"EARLY_PHASE1":8127,"PHASE1":8129,"PHASE2":8131,"PHASE3":8150,"PHASE4":8152,"NA":8154},{"trials":8128,"activeCount":128},[],{"trials":8130,"activeCount":128},[],{"trials":8132,"activeCount":676,"soonestReadout":8137},[8133,8140],{"nctId":8134,"briefTitle":8135,"status":265,"phases":8136,"primaryCompletion":8137,"completion":1448,"start":76,"enrollment":218,"conditions":8138,"interventions":8139},"NCT06444399","Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris",[91],"2025-09-02",[2258],[8125],{"nctId":8141,"briefTitle":8142,"status":104,"phases":8143,"primaryCompletion":8144,"completion":8145,"start":8146,"enrollment":218,"conditions":8147,"interventions":8149},"NCT06091956","A Study of Deucravacitinib to Treat LPP and FFA",[91],"2024-05-21","2024-12-24","2023-11-07",[8148],"Lichen Planopilaris",[8125],{"trials":8151,"activeCount":128},[],{"trials":8153,"activeCount":128},[],{"trials":8155,"activeCount":128},[],{"intervention":8157,"totalTrials":224,"cells":8158},"Definity",{"EARLY_PHASE1":8159,"PHASE1":8161,"PHASE2":8173,"PHASE3":8184,"PHASE4":8186,"NA":8188},{"trials":8160,"activeCount":128},[],{"trials":8162,"activeCount":128},[8163],{"nctId":8164,"briefTitle":8165,"status":104,"phases":8166,"primaryCompletion":8167,"completion":8167,"start":3988,"enrollment":370,"conditions":8168,"interventions":8170},"NCT05613946","Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema",[90],"2024-06-30",[8169],"Lymphedema Arm",[8171,8172,8157],"Lumason","Optison",{"trials":8174,"activeCount":676,"soonestReadout":8179},[8175],{"nctId":8176,"briefTitle":8177,"status":692,"phases":8178,"primaryCompletion":8179,"completion":2893,"start":8180,"enrollment":8181,"conditions":8182,"interventions":8183},"NCT05764642","A Study of Renal Microvessel Imaging for Chronic Kidney Disease",[91],"2028-04-01","2023-08-09",186,[18,1062],[8157],{"trials":8185,"activeCount":128},[],{"trials":8187,"activeCount":128},[],{"trials":8189,"activeCount":128},[],{"intervention":5130,"totalTrials":224,"cells":8191},{"EARLY_PHASE1":8192,"PHASE1":8194,"PHASE2":8203,"PHASE3":8209,"PHASE4":8211,"NA":8213},{"trials":8193,"activeCount":128},[],{"trials":8195,"activeCount":128},[8196],{"nctId":8197,"briefTitle":8198,"status":104,"phases":8199,"primaryCompletion":2620,"completion":2620,"start":6258,"enrollment":1236,"conditions":8200,"interventions":8201},"NCT01160328","Influence of Male Hormones on Regional Fat Metabolism",[90],[15],[5130,8202],"Testosterone",{"trials":8204,"activeCount":676,"soonestReadout":5115},[8205],{"nctId":5112,"briefTitle":5113,"status":265,"phases":8206,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":5117,"conditions":8207,"interventions":8208},[91],[5119,5120,5121,3298],[5123,5124,5125,5126,5127,5128,5129,5130,3427,5131,5132],{"trials":8210,"activeCount":128},[],{"trials":8212,"activeCount":128},[],{"trials":8214,"activeCount":128},[],{"intervention":8216,"totalTrials":224,"cells":8217},"Group 2: Dasatinib",{"EARLY_PHASE1":8218,"PHASE1":8220,"PHASE2":8231,"PHASE3":8240,"PHASE4":8242,"NA":8244},{"trials":8219,"activeCount":128},[],{"trials":8221,"activeCount":128},[8222],{"nctId":8223,"briefTitle":8224,"status":104,"phases":8225,"primaryCompletion":4758,"completion":4758,"start":8226,"enrollment":476,"conditions":8227,"interventions":8229},"NCT02652052","Hematopoietic Stem Cell Transplant Survivors Study",[90],"2016-03-01",[8228],"Stem Cell Transplant",[8230,8216],"Group 2: Quercetin",{"trials":8232,"activeCount":676,"soonestReadout":8237},[8233],{"nctId":8234,"briefTitle":8235,"status":692,"phases":8236,"primaryCompletion":8237,"completion":8237,"start":872,"enrollment":729,"conditions":8238,"interventions":8239},"NCT02848131","Senescence in Chronic Kidney Disease",[91],"2027-04",[6957],[8216,8230],{"trials":8241,"activeCount":128},[],{"trials":8243,"activeCount":128},[],{"trials":8245,"activeCount":128},[],{"intervention":8230,"totalTrials":224,"cells":8247},{"EARLY_PHASE1":8248,"PHASE1":8250,"PHASE2":8256,"PHASE3":8262,"PHASE4":8264,"NA":8266},{"trials":8249,"activeCount":128},[],{"trials":8251,"activeCount":128},[8252],{"nctId":8223,"briefTitle":8224,"status":104,"phases":8253,"primaryCompletion":4758,"completion":4758,"start":8226,"enrollment":476,"conditions":8254,"interventions":8255},[90],[8228],[8230,8216],{"trials":8257,"activeCount":676,"soonestReadout":8237},[8258],{"nctId":8234,"briefTitle":8235,"status":692,"phases":8259,"primaryCompletion":8237,"completion":8237,"start":872,"enrollment":729,"conditions":8260,"interventions":8261},[91],[6957],[8216,8230],{"trials":8263,"activeCount":128},[],{"trials":8265,"activeCount":128},[],{"trials":8267,"activeCount":128},[],{"intervention":8269,"totalTrials":224,"cells":8270},"Midodrine",{"EARLY_PHASE1":8271,"PHASE1":8273,"PHASE2":8284,"PHASE3":8298,"PHASE4":8300,"NA":8302},{"trials":8272,"activeCount":128},[],{"trials":8274,"activeCount":128},[8275],{"nctId":8276,"briefTitle":8277,"status":104,"phases":8278,"primaryCompletion":8279,"completion":8279,"start":8280,"enrollment":370,"conditions":8281,"interventions":8283},"NCT03600870","Midodrine in Hepatopulmonary Syndrome",[90],"2020-12-01","2018-08-02",[8282],"Hepatopulmonary Syndrome (HPS)",[8269],{"trials":8285,"activeCount":676,"soonestReadout":8290},[8286],{"nctId":8287,"briefTitle":8288,"status":265,"phases":8289,"primaryCompletion":8290,"completion":8291,"start":8292,"enrollment":8293,"conditions":8294,"interventions":8297},"NCT06319248","MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial",[91],"2029-03-31","2029-06-30","2024-05-14",308,[8295,8296],"Sepsis","Low Blood Pressure",[8269],{"trials":8299,"activeCount":128},[],{"trials":8301,"activeCount":128},[],{"trials":8303,"activeCount":128},[],{"intervention":8305,"totalTrials":224,"cells":8306},"Fenofibrate",{"EARLY_PHASE1":8307,"PHASE1":8309,"PHASE2":8311,"PHASE3":8333,"PHASE4":8335,"NA":8337},{"trials":8308,"activeCount":128},[],{"trials":8310,"activeCount":128},[],{"trials":8312,"activeCount":676,"soonestReadout":8317},[8313,8324],{"nctId":8314,"briefTitle":8315,"status":265,"phases":8316,"primaryCompletion":8317,"completion":1446,"start":3109,"enrollment":2678,"conditions":8318,"interventions":8323},"NCT06905054","Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation",[91],"2028-03-30",[8319,8320,8321,8322],"Primary Sclerosing Cholangitis","Liver Transplant, Complications","PSC","Biliary Strictures",[8305],{"nctId":8325,"briefTitle":8326,"status":134,"phases":8327,"primaryCompletion":8167,"completion":8328,"start":8329,"enrollment":1197,"conditions":8330,"interventions":8332},"NCT05514119","A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation",[91],"2024-12-01","2022-08-17",[8331],"Liver Transplant",[8305],{"trials":8334,"activeCount":128},[],{"trials":8336,"activeCount":128},[],{"trials":8338,"activeCount":128},[],{"intervention":567,"totalTrials":224,"cells":8340},{"EARLY_PHASE1":8341,"PHASE1":8343,"PHASE2":8345,"PHASE3":8378,"PHASE4":8380,"NA":8382},{"trials":8342,"activeCount":128},[],{"trials":8344,"activeCount":128},[],{"trials":8346,"activeCount":676,"soonestReadout":556},[8347,8374],{"nctId":8348,"briefTitle":8349,"status":104,"phases":8350,"primaryCompletion":6057,"completion":6057,"start":8351,"enrollment":817,"conditions":8352,"interventions":8371},"NCT04072445","Trifluridine\u002FTipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer",[91],"2019-10-18",[8353,8354,8355,8356,8357,8358,8359,8360,8361,8362,8363,8364,8365,8366,8367,8368,8369,8370],"Advanced Bile Duct Carcinoma","Advanced Gallbladder Carcinoma","Refractory Bile Duct Carcinoma","Refractory Gallbladder Carcinoma","Stage III Distal Bile Duct Cancer AJCC v8","Stage III Gallbladder Cancer AJCC v8","Stage III Intrahepatic Bile Duct Cancer AJCC v8","Stage IIIA Distal Bile Duct Cancer AJCC v8","Stage IIIA Gallbladder Cancer AJCC v8","Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8","Stage IIIB Distal Bile Duct Cancer AJCC v8","Stage IIIB Gallbladder Cancer AJCC v8","Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Gallbladder Cancer AJCC v8","Stage IV Intrahepatic Bile Duct Cancer AJCC v8","Stage IVA Gallbladder Cancer AJCC v8","Stage IVB Gallbladder Cancer AJCC v8",[567,8372,8373],"Irinotecan Hydrochloride","Trifluridine and Tipiracil Hydrochloride",{"nctId":553,"briefTitle":554,"status":265,"phases":8375,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":8376,"interventions":8377},[91],[560,561,562,563,564,565],[537,567,568,539,72,569,570],{"trials":8379,"activeCount":128},[],{"trials":8381,"activeCount":128},[],{"trials":8383,"activeCount":128},[],{"intervention":3948,"totalTrials":224,"cells":8385},{"EARLY_PHASE1":8386,"PHASE1":8388,"PHASE2":8390,"PHASE3":8400,"PHASE4":8402,"NA":8404},{"trials":8387,"activeCount":128},[],{"trials":8389,"activeCount":128},[],{"trials":8391,"activeCount":676,"soonestReadout":3943},[8392,8396],{"nctId":3940,"briefTitle":3941,"status":265,"phases":8393,"primaryCompletion":3943,"completion":3943,"start":3944,"enrollment":3945,"conditions":8394,"interventions":8395},[90,91],[3689],[159,305,3948,3917],{"nctId":4050,"briefTitle":4051,"status":104,"phases":8397,"primaryCompletion":4053,"completion":4054,"start":4055,"enrollment":3945,"conditions":8398,"interventions":8399},[91],[3447],[305,3948,3861],{"trials":8401,"activeCount":128},[],{"trials":8403,"activeCount":128},[],{"trials":8405,"activeCount":128},[],{"intervention":4375,"totalTrials":224,"cells":8407},{"EARLY_PHASE1":8408,"PHASE1":8410,"PHASE2":8412,"PHASE3":8422,"PHASE4":8424,"NA":8426},{"trials":8409,"activeCount":128},[],{"trials":8411,"activeCount":128},[],{"trials":8413,"activeCount":676,"soonestReadout":171},[8414,8418],{"nctId":5543,"briefTitle":5544,"status":265,"phases":8415,"primaryCompletion":171,"completion":171,"start":5546,"enrollment":498,"conditions":8416,"interventions":8417},[90,91],[5548,5549,5550,5551],[5553,346,4600,4375],{"nctId":4356,"briefTitle":4357,"status":104,"phases":8419,"primaryCompletion":298,"completion":4359,"start":4360,"enrollment":224,"conditions":8420,"interventions":8421},[91],[4362,4363,4364,4365,4366,672,4367,4368,4369,4370,4371,4372],[4374,4089,537,4375],{"trials":8423,"activeCount":128},[],{"trials":8425,"activeCount":128},[],{"trials":8427,"activeCount":128},[],{"intervention":3966,"totalTrials":224,"cells":8429},{"EARLY_PHASE1":8430,"PHASE1":8432,"PHASE2":8445,"PHASE3":8451,"PHASE4":8453,"NA":8455},{"trials":8431,"activeCount":128},[],{"trials":8433,"activeCount":128},[8434],{"nctId":8435,"briefTitle":8436,"status":104,"phases":8437,"primaryCompletion":8438,"completion":8438,"start":8439,"enrollment":3002,"conditions":8440,"interventions":8443},"NCT04640779","Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic\u002FDendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma",[90],"2025-11-19","2021-02-08",[8441,144,146,303,8442,149,152,3447],"Recurrent Histiocytic and Dendritic Cell Neoplasm","Refractory Histiocytic and Dendritic Cell Neoplasm",[8444,3966],"Choline Salicylate",{"trials":8446,"activeCount":676,"soonestReadout":3961},[8447],{"nctId":3958,"briefTitle":3959,"status":169,"phases":8448,"primaryCompletion":3961,"completion":3962,"start":3963,"enrollment":1236,"conditions":8449,"interventions":8450},[90,91],[3689,3690],[157,305,3861,3966],{"trials":8452,"activeCount":128},[],{"trials":8454,"activeCount":128},[],{"trials":8456,"activeCount":128},[],{"intervention":1424,"totalTrials":224,"cells":8458},{"EARLY_PHASE1":8459,"PHASE1":8461,"PHASE2":8463,"PHASE3":8477,"PHASE4":8479,"NA":8481},{"trials":8460,"activeCount":128},[],{"trials":8462,"activeCount":128},[],{"trials":8464,"activeCount":676,"soonestReadout":8469},[8465,8473],{"nctId":8466,"briefTitle":8467,"status":1096,"phases":8468,"primaryCompletion":8469,"completion":8469,"start":2112,"enrollment":773,"conditions":8470,"interventions":8472},"NCT07483177","HEART: Pilot Randomized Controlled Trial",[90,91],"2028-05",[8471],"Thoracic Aortic Aneurysm",[1424],{"nctId":1411,"briefTitle":1412,"status":1413,"phases":8474,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":128,"conditions":8475,"interventions":8476},[91],[30,1418,1419,1420],[1422,1402,1423,1424],{"trials":8478,"activeCount":128},[],{"trials":8480,"activeCount":128},[],{"trials":8482,"activeCount":128},[],{"intervention":5126,"totalTrials":224,"cells":8484},{"EARLY_PHASE1":8485,"PHASE1":8487,"PHASE2":8498,"PHASE3":8504,"PHASE4":8506,"NA":8508},{"trials":8486,"activeCount":128},[],{"trials":8488,"activeCount":128},[8489],{"nctId":8490,"briefTitle":8491,"status":104,"phases":8492,"primaryCompletion":8493,"completion":8494,"start":3569,"enrollment":2980,"conditions":8495,"interventions":8496},"NCT01862835","Impact of Estradiol Addback",[90],"2016-09-30","2018-12-30",[7698],[5126,8202,82,8497],"Estrogen patch",{"trials":8499,"activeCount":676,"soonestReadout":5115},[8500],{"nctId":5112,"briefTitle":5113,"status":265,"phases":8501,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":5117,"conditions":8502,"interventions":8503},[91],[5119,5120,5121,3298],[5123,5124,5125,5126,5127,5128,5129,5130,3427,5131,5132],{"trials":8505,"activeCount":128},[],{"trials":8507,"activeCount":128},[],{"trials":8509,"activeCount":128},[],{"intervention":570,"totalTrials":224,"cells":8511},{"EARLY_PHASE1":8512,"PHASE1":8514,"PHASE2":8516,"PHASE3":8526,"PHASE4":8528,"NA":8530},{"trials":8513,"activeCount":128},[],{"trials":8515,"activeCount":128},[],{"trials":8517,"activeCount":676,"soonestReadout":556},[8518,8522],{"nctId":7984,"briefTitle":7985,"status":104,"phases":8519,"primaryCompletion":7987,"completion":7987,"start":7988,"enrollment":301,"conditions":8520,"interventions":8521},[91],[7990,7991,4383,7992,562,563,564,7993],[569,570],{"nctId":553,"briefTitle":554,"status":265,"phases":8523,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":8524,"interventions":8525},[91],[560,561,562,563,564,565],[537,567,568,539,72,569,570],{"trials":8527,"activeCount":128},[],{"trials":8529,"activeCount":128},[],{"trials":8531,"activeCount":128},[],{"intervention":1422,"totalTrials":224,"cells":8533},{"EARLY_PHASE1":8534,"PHASE1":8536,"PHASE2":8538,"PHASE3":8554,"PHASE4":8556,"NA":8558},{"trials":8535,"activeCount":128},[],{"trials":8537,"activeCount":128},[],{"trials":8539,"activeCount":676,"soonestReadout":8544},[8540,8550],{"nctId":8541,"briefTitle":8542,"status":169,"phases":8543,"primaryCompletion":8544,"completion":8545,"start":8546,"enrollment":8547,"conditions":8548,"interventions":8549},"NCT03879629","Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure",[91],"2026-02-28","2027-02-28","2019-08-21",184,[21],[1422],{"nctId":1411,"briefTitle":1412,"status":1413,"phases":8551,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":128,"conditions":8552,"interventions":8553},[91],[30,1418,1419,1420],[1422,1402,1423,1424],{"trials":8555,"activeCount":128},[],{"trials":8557,"activeCount":128},[],{"trials":8559,"activeCount":128},[],{"intervention":5127,"totalTrials":224,"cells":8561},{"EARLY_PHASE1":8562,"PHASE1":8564,"PHASE2":8566,"PHASE3":8581,"PHASE4":8583,"NA":8585},{"trials":8563,"activeCount":128},[],{"trials":8565,"activeCount":128},[],{"trials":8567,"activeCount":676,"soonestReadout":5115},[8568,8577],{"nctId":8569,"briefTitle":8570,"status":104,"phases":8571,"primaryCompletion":8572,"completion":8572,"start":8573,"enrollment":120,"conditions":8574,"interventions":8575},"NCT05730712","Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer",[91],"2025-04-10","2024-03-08",[5061,5063],[5127,8576],"Hyaluronidase-zzxf\u002FPertuzumab\u002FTrastuzumab",{"nctId":5112,"briefTitle":5113,"status":265,"phases":8578,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":5117,"conditions":8579,"interventions":8580},[91],[5119,5120,5121,3298],[5123,5124,5125,5126,5127,5128,5129,5130,3427,5131,5132],{"trials":8582,"activeCount":128},[],{"trials":8584,"activeCount":128},[],{"trials":8586,"activeCount":128},[],{"intervention":5065,"totalTrials":676,"cells":8588},{"EARLY_PHASE1":8589,"PHASE1":8591,"PHASE2":8593,"PHASE3":8599,"PHASE4":8601,"NA":8603},{"trials":8590,"activeCount":128},[],{"trials":8592,"activeCount":128},[],{"trials":8594,"activeCount":676,"soonestReadout":5058},[8595],{"nctId":5055,"briefTitle":5056,"status":169,"phases":8596,"primaryCompletion":5058,"completion":5058,"start":5059,"enrollment":2563,"conditions":8597,"interventions":8598},[91],[5061,5062,5063],[5065,3427],{"trials":8600,"activeCount":128},[],{"trials":8602,"activeCount":128},[],{"trials":8604,"activeCount":128},[],{"intervention":8606,"totalTrials":676,"cells":8607},"Gallium Ga 68 FAPi-46",{"EARLY_PHASE1":8608,"PHASE1":8610,"PHASE2":8612,"PHASE3":8627,"PHASE4":8629,"NA":8631},{"trials":8609,"activeCount":128},[],{"trials":8611,"activeCount":128},[],{"trials":8613,"activeCount":676,"soonestReadout":8618},[8614],{"nctId":8615,"briefTitle":8616,"status":265,"phases":8617,"primaryCompletion":8618,"completion":496,"start":8619,"enrollment":1320,"conditions":8620,"interventions":8626},"NCT05518903","Investigational Scan (68Ga-FAPI-46 PET\u002FCT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma",[91],"2027-06-30","2022-11-15",[8621,8622,8623,8624,8625],"Localized Pancreatic Adenocarcinoma","Resectable Pancreatic Ductal Adenocarcinoma","Stage 0 Pancreatic Cancer AJCC v8","Stage I Pancreatic Cancer AJCC v8","Stage IIA Pancreatic Cancer AJCC v8",[8606],{"trials":8628,"activeCount":128},[],{"trials":8630,"activeCount":128},[],{"trials":8632,"activeCount":128},[],{"intervention":8634,"totalTrials":676,"cells":8635},"Etentamig",{"EARLY_PHASE1":8636,"PHASE1":8638,"PHASE2":8640,"PHASE3":8651,"PHASE4":8653,"NA":8655},{"trials":8637,"activeCount":128},[],{"trials":8639,"activeCount":128},[],{"trials":8641,"activeCount":676,"soonestReadout":8646},[8642],{"nctId":8643,"briefTitle":8644,"status":1096,"phases":8645,"primaryCompletion":8646,"completion":8647,"start":8648,"enrollment":956,"conditions":8649,"interventions":8650},"NCT07420959","ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia",[90,91],"2036-03-25","2038-03-25","2026-03-25",[441,449],[8634],{"trials":8652,"activeCount":128},[],{"trials":8654,"activeCount":128},[],{"trials":8656,"activeCount":128},[],{"intervention":8658,"totalTrials":676,"cells":8659},"Standard Varenicline Dosing",{"EARLY_PHASE1":8660,"PHASE1":8662,"PHASE2":8664,"PHASE3":8678,"PHASE4":8680,"NA":8682},{"trials":8661,"activeCount":128},[],{"trials":8663,"activeCount":128},[],{"trials":8665,"activeCount":676,"soonestReadout":1160},[8666],{"nctId":8667,"briefTitle":8668,"status":265,"phases":8669,"primaryCompletion":1160,"completion":8670,"start":8671,"enrollment":461,"conditions":8672,"interventions":8675},"NCT07171112","Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis",[91],"2028-10-01","2025-11-06",[6941,6942,8673,8674],"Recurrent Acute Pancreatitis","Smoking (Tobacco) Addiction",[8658,8676,8677],"Bupropion 150 mg twice daily","Increased Varenicline Dosing",{"trials":8679,"activeCount":128},[],{"trials":8681,"activeCount":128},[],{"trials":8683,"activeCount":128},[],{"intervention":8676,"totalTrials":676,"cells":8685},{"EARLY_PHASE1":8686,"PHASE1":8688,"PHASE2":8690,"PHASE3":8696,"PHASE4":8698,"NA":8700},{"trials":8687,"activeCount":128},[],{"trials":8689,"activeCount":128},[],{"trials":8691,"activeCount":676,"soonestReadout":1160},[8692],{"nctId":8667,"briefTitle":8668,"status":265,"phases":8693,"primaryCompletion":1160,"completion":8670,"start":8671,"enrollment":461,"conditions":8694,"interventions":8695},[91],[6941,6942,8673,8674],[8658,8676,8677],{"trials":8697,"activeCount":128},[],{"trials":8699,"activeCount":128},[],{"trials":8701,"activeCount":128},[],{"intervention":8677,"totalTrials":676,"cells":8703},{"EARLY_PHASE1":8704,"PHASE1":8706,"PHASE2":8708,"PHASE3":8714,"PHASE4":8716,"NA":8718},{"trials":8705,"activeCount":128},[],{"trials":8707,"activeCount":128},[],{"trials":8709,"activeCount":676,"soonestReadout":1160},[8710],{"nctId":8667,"briefTitle":8668,"status":265,"phases":8711,"primaryCompletion":1160,"completion":8670,"start":8671,"enrollment":461,"conditions":8712,"interventions":8713},[91],[6941,6942,8673,8674],[8658,8676,8677],{"trials":8715,"activeCount":128},[],{"trials":8717,"activeCount":128},[],{"trials":8719,"activeCount":128},[],{"intervention":8721,"totalTrials":676,"cells":8722},"Autologous, Adipose Derived Mesenchymal Stem Cells",{"EARLY_PHASE1":8723,"PHASE1":8725,"PHASE2":8727,"PHASE3":8738,"PHASE4":8740,"NA":8742},{"trials":8724,"activeCount":128},[],{"trials":8726,"activeCount":128},[],{"trials":8728,"activeCount":676,"soonestReadout":2902},[8729],{"nctId":8730,"briefTitle":8731,"status":169,"phases":8732,"primaryCompletion":2902,"completion":2902,"start":8733,"enrollment":498,"conditions":8734,"interventions":8737},"NCT04520373","Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients",[91],"2020-06-25",[8735,8736],"Spinal Cord Injuries","Paralysis",[8721],{"trials":8739,"activeCount":128},[],{"trials":8741,"activeCount":128},[],{"trials":8743,"activeCount":128},[],{"intervention":8745,"totalTrials":676,"cells":8746},"Coriolus Versicolor Extract",{"EARLY_PHASE1":8747,"PHASE1":8749,"PHASE2":8751,"PHASE3":8763,"PHASE4":8765,"NA":8767},{"trials":8748,"activeCount":128},[],{"trials":8750,"activeCount":128},[],{"trials":8752,"activeCount":676,"soonestReadout":8757},[8753],{"nctId":8754,"briefTitle":8755,"status":265,"phases":8756,"primaryCompletion":8757,"completion":4909,"start":8758,"enrollment":498,"conditions":8759,"interventions":8762},"NCT06450873","Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery",[91],"2027-12-30","2024-10-25",[8760,8761],"Estrogen Receptor-Positive Breast Carcinoma","HER2-Negative Breast Carcinoma",[8745],{"trials":8764,"activeCount":128},[],{"trials":8766,"activeCount":128},[],{"trials":8768,"activeCount":128},[],{"intervention":87,"totalTrials":676,"cells":8770},{"EARLY_PHASE1":8771,"PHASE1":8773,"PHASE2":8775,"PHASE3":8781,"PHASE4":8783,"NA":8785},{"trials":8772,"activeCount":128},[],{"trials":8774,"activeCount":128},[],{"trials":8776,"activeCount":676,"soonestReadout":86},[8777],{"nctId":84,"briefTitle":85,"status":169,"phases":8778,"primaryCompletion":86,"completion":244,"start":245,"enrollment":173,"conditions":8779,"interventions":8780},[90,91],[247,248,249,250,251],[87,72],{"trials":8782,"activeCount":128},[],{"trials":8784,"activeCount":128},[],{"trials":8786,"activeCount":128},[],{"intervention":8788,"totalTrials":676,"cells":8789},"Magnesium",{"EARLY_PHASE1":8790,"PHASE1":8792,"PHASE2":8794,"PHASE3":8804,"PHASE4":8806,"NA":8808},{"trials":8791,"activeCount":128},[],{"trials":8793,"activeCount":128},[],{"trials":8795,"activeCount":676,"soonestReadout":2068},[8796],{"nctId":8797,"briefTitle":8798,"status":265,"phases":8799,"primaryCompletion":2068,"completion":171,"start":8800,"enrollment":785,"conditions":8801,"interventions":8803},"NCT05806996","A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures",[91],"2023-07-31",[8802],"Bladder Spasms",[8788],{"trials":8805,"activeCount":128},[],{"trials":8807,"activeCount":128},[],{"trials":8809,"activeCount":128},[],{"intervention":6469,"totalTrials":676,"cells":8811},{"EARLY_PHASE1":8812,"PHASE1":8814,"PHASE2":8816,"PHASE3":8822,"PHASE4":8824,"NA":8826},{"trials":8813,"activeCount":128},[],{"trials":8815,"activeCount":128},[],{"trials":8817,"activeCount":676,"soonestReadout":861},[8818],{"nctId":6450,"briefTitle":6451,"status":265,"phases":8819,"primaryCompletion":861,"completion":861,"start":6453,"enrollment":6454,"conditions":8820,"interventions":8821},[91],[6456,6457,6458,6459,6460,6461,6462,6463,6464,500,5601,5602,6465,6466,6467,501,5615,5616],[6469,517,6470],{"trials":8823,"activeCount":128},[],{"trials":8825,"activeCount":128},[],{"trials":8827,"activeCount":128},[],{"intervention":6470,"totalTrials":676,"cells":8829},{"EARLY_PHASE1":8830,"PHASE1":8832,"PHASE2":8834,"PHASE3":8840,"PHASE4":8842,"NA":8844},{"trials":8831,"activeCount":128},[],{"trials":8833,"activeCount":128},[],{"trials":8835,"activeCount":676,"soonestReadout":861},[8836],{"nctId":6450,"briefTitle":6451,"status":265,"phases":8837,"primaryCompletion":861,"completion":861,"start":6453,"enrollment":6454,"conditions":8838,"interventions":8839},[91],[6456,6457,6458,6459,6460,6461,6462,6463,6464,500,5601,5602,6465,6466,6467,501,5615,5616],[6469,517,6470],{"trials":8841,"activeCount":128},[],{"trials":8843,"activeCount":128},[],{"trials":8845,"activeCount":128},[],{"intervention":276,"totalTrials":676,"cells":8847},{"EARLY_PHASE1":8848,"PHASE1":8850,"PHASE2":8852,"PHASE3":8858,"PHASE4":8860,"NA":8862},{"trials":8849,"activeCount":128},[],{"trials":8851,"activeCount":128},[],{"trials":8853,"activeCount":676,"soonestReadout":267},[8854],{"nctId":263,"briefTitle":264,"status":265,"phases":8855,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":8856,"interventions":8857},[91],[272,273,274],[276,72],{"trials":8859,"activeCount":128},[],{"trials":8861,"activeCount":128},[],{"trials":8863,"activeCount":128},[],{"intervention":8865,"totalTrials":676,"cells":8866},"Osilodrostat 1 MG",{"EARLY_PHASE1":8867,"PHASE1":8869,"PHASE2":8871,"PHASE3":8883,"PHASE4":8885,"NA":8887},{"trials":8868,"activeCount":128},[],{"trials":8870,"activeCount":128},[],{"trials":8872,"activeCount":676,"soonestReadout":8877},[8873],{"nctId":8874,"briefTitle":8875,"status":265,"phases":8876,"primaryCompletion":8877,"completion":8877,"start":8878,"enrollment":4565,"conditions":8879,"interventions":8882},"NCT07104812","Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)",[91],"2027-01","2026-01-14",[8880,8881],"Mild Autonomous Cortisol Secretion","Autonomous Cortisol Secretion (ACS)",[8865],{"trials":8884,"activeCount":128},[],{"trials":8886,"activeCount":128},[],{"trials":8888,"activeCount":128},[],{"intervention":5632,"totalTrials":676,"cells":8890},{"EARLY_PHASE1":8891,"PHASE1":8893,"PHASE2":8895,"PHASE3":8901,"PHASE4":8903,"NA":8905},{"trials":8892,"activeCount":128},[],{"trials":8894,"activeCount":128},[],{"trials":8896,"activeCount":676,"soonestReadout":81},[8897],{"nctId":79,"briefTitle":80,"status":169,"phases":8898,"primaryCompletion":81,"completion":5625,"start":5626,"enrollment":139,"conditions":8899,"interventions":8900},[91],[5628,5629,579,583,5630],[82,5632,5633,5634,5635,540,165],{"trials":8902,"activeCount":128},[],{"trials":8904,"activeCount":128},[],{"trials":8906,"activeCount":128},[],{"intervention":77,"totalTrials":676,"cells":8908},{"EARLY_PHASE1":8909,"PHASE1":8911,"PHASE2":8913,"PHASE3":8921,"PHASE4":8923,"NA":8925},{"trials":8910,"activeCount":128},[],{"trials":8912,"activeCount":128},[],{"trials":8914,"activeCount":676,"soonestReadout":76},[8915],{"nctId":74,"briefTitle":75,"status":169,"phases":8916,"primaryCompletion":76,"completion":171,"start":8917,"enrollment":2563,"conditions":8918,"interventions":8920},[91],"2019-08-28",[8919,579,583,235,143],"Advanced Triple-Negative Breast Carcinoma",[77],{"trials":8922,"activeCount":128},[],{"trials":8924,"activeCount":128},[],{"trials":8926,"activeCount":128},[],{"intervention":293,"totalTrials":676,"cells":8928},{"EARLY_PHASE1":8929,"PHASE1":8931,"PHASE2":8933,"PHASE3":8939,"PHASE4":8941,"NA":8943},{"trials":8930,"activeCount":128},[],{"trials":8932,"activeCount":128},[],{"trials":8934,"activeCount":676,"soonestReadout":281},[8935],{"nctId":278,"briefTitle":279,"status":265,"phases":8936,"primaryCompletion":281,"completion":282,"start":283,"enrollment":187,"conditions":8937,"interventions":8938},[91],[285,286,287,288,289,273,274,290,291],[293,72],{"trials":8940,"activeCount":128},[],{"trials":8942,"activeCount":128},[],{"trials":8944,"activeCount":128},[],{"intervention":6728,"totalTrials":676,"cells":8946},{"EARLY_PHASE1":8947,"PHASE1":8949,"PHASE2":8951,"PHASE3":8957,"PHASE4":8959,"NA":8961},{"trials":8948,"activeCount":128},[],{"trials":8950,"activeCount":128},[],{"trials":8952,"activeCount":676,"soonestReadout":6720},[8953],{"nctId":6717,"briefTitle":6718,"status":1096,"phases":8954,"primaryCompletion":6720,"completion":6720,"start":6721,"enrollment":31,"conditions":8955,"interventions":8956},[90,91],[6723,6724,6725,6726,285,4760],[6699,6728],{"trials":8958,"activeCount":128},[],{"trials":8960,"activeCount":128},[],{"trials":8962,"activeCount":128},[],{"intervention":8964,"totalTrials":676,"cells":8965},"Ravulizumab",{"EARLY_PHASE1":8966,"PHASE1":8968,"PHASE2":8970,"PHASE3":8979,"PHASE4":8981,"NA":8983},{"trials":8967,"activeCount":128},[],{"trials":8969,"activeCount":128},[],{"trials":8971,"activeCount":676,"soonestReadout":1738},[8972],{"nctId":8973,"briefTitle":8974,"status":265,"phases":8975,"primaryCompletion":1738,"completion":1738,"start":4700,"enrollment":355,"conditions":8976,"interventions":8978},"NCT06333652","Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders",[91],[8977],"Preeclampsia",[8964],{"trials":8980,"activeCount":128},[],{"trials":8982,"activeCount":128},[],{"trials":8984,"activeCount":128},[],{"intervention":8986,"totalTrials":676,"cells":8987},"Abiraterone Acetate",{"EARLY_PHASE1":8988,"PHASE1":8990,"PHASE2":8992,"PHASE3":9004,"PHASE4":9006,"NA":9008},{"trials":8989,"activeCount":128},[],{"trials":8991,"activeCount":128},[],{"trials":8993,"activeCount":676,"soonestReadout":8998},[8994],{"nctId":8995,"briefTitle":8996,"status":265,"phases":8997,"primaryCompletion":8998,"completion":8998,"start":8999,"enrollment":9000,"conditions":9001,"interventions":9002},"NCT06369610","Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer",[91],"2027-04-22","2024-04-22",110,[3299,6368],[8986,9003],"Gonadotropin-releasing Hormone Analog",{"trials":9005,"activeCount":128},[],{"trials":9007,"activeCount":128},[],{"trials":9009,"activeCount":128},[],{"intervention":9003,"totalTrials":676,"cells":9011},{"EARLY_PHASE1":9012,"PHASE1":9014,"PHASE2":9016,"PHASE3":9022,"PHASE4":9024,"NA":9026},{"trials":9013,"activeCount":128},[],{"trials":9015,"activeCount":128},[],{"trials":9017,"activeCount":676,"soonestReadout":8998},[9018],{"nctId":8995,"briefTitle":8996,"status":265,"phases":9019,"primaryCompletion":8998,"completion":8998,"start":8999,"enrollment":9000,"conditions":9020,"interventions":9021},[91],[3299,6368],[8986,9003],{"trials":9023,"activeCount":128},[],{"trials":9025,"activeCount":128},[],{"trials":9027,"activeCount":128},[],{"intervention":9029,"totalTrials":676,"cells":9030},"68Ga-FAPI",{"EARLY_PHASE1":9031,"PHASE1":9033,"PHASE2":9035,"PHASE3":9043,"PHASE4":9045,"NA":9047},{"trials":9032,"activeCount":128},[],{"trials":9034,"activeCount":128},[],{"trials":9036,"activeCount":676,"soonestReadout":2023},[9037],{"nctId":9038,"briefTitle":9039,"status":265,"phases":9040,"primaryCompletion":2023,"completion":2023,"start":2491,"enrollment":3726,"conditions":9041,"interventions":9042},"NCT07083011","A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure",[91],[7184],[9029],{"trials":9044,"activeCount":128},[],{"trials":9046,"activeCount":128},[],{"trials":9048,"activeCount":128},[],{"intervention":323,"totalTrials":676,"cells":9050},{"EARLY_PHASE1":9051,"PHASE1":9053,"PHASE2":9055,"PHASE3":9061,"PHASE4":9063,"NA":9065},{"trials":9052,"activeCount":128},[],{"trials":9054,"activeCount":128},[],{"trials":9056,"activeCount":676,"soonestReadout":311},[9057],{"nctId":308,"briefTitle":309,"status":265,"phases":9058,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":9059,"interventions":9060},[91],[315,316,317,318,319,320],[322,72,323],{"trials":9062,"activeCount":128},[],{"trials":9064,"activeCount":128},[],{"trials":9066,"activeCount":128},[],{"intervention":4709,"totalTrials":676,"cells":9068},{"EARLY_PHASE1":9069,"PHASE1":9071,"PHASE2":9073,"PHASE3":9079,"PHASE4":9081,"NA":9083},{"trials":9070,"activeCount":128},[],{"trials":9072,"activeCount":128},[],{"trials":9074,"activeCount":676,"soonestReadout":4700},[9075],{"nctId":4697,"briefTitle":4698,"status":169,"phases":9076,"primaryCompletion":4700,"completion":4701,"start":4702,"enrollment":34,"conditions":9077,"interventions":9078},[91],[4704,4705,4706,4707],[4645,4709],{"trials":9080,"activeCount":128},[],{"trials":9082,"activeCount":128},[],{"trials":9084,"activeCount":128},[],{"intervention":9086,"totalTrials":676,"cells":9087},"Lutetium Lu 177 Dotatate",{"EARLY_PHASE1":9088,"PHASE1":9090,"PHASE2":9092,"PHASE3":9108,"PHASE4":9110,"NA":9112},{"trials":9089,"activeCount":128},[],{"trials":9091,"activeCount":128},[],{"trials":9093,"activeCount":676,"soonestReadout":9098},[9094],{"nctId":9095,"briefTitle":9096,"status":265,"phases":9097,"primaryCompletion":9098,"completion":9099,"start":9100,"enrollment":7658,"conditions":9101,"interventions":9107},"NCT04082520","Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy",[91],"2027-09-04","2032-03-04","2020-04-14",[9102,9103,9104,9105,9106],"Grade 1 Meningioma","Grade 2 Meningioma","Grade 3 Meningioma","Recurrent Meningioma","Unresectable Meningioma",[9086],{"trials":9109,"activeCount":128},[],{"trials":9111,"activeCount":128},[],{"trials":9113,"activeCount":128},[],{"intervention":9115,"totalTrials":676,"cells":9116},"Single Agent Therapy",{"EARLY_PHASE1":9117,"PHASE1":9119,"PHASE2":9121,"PHASE3":9130,"PHASE4":9132,"NA":9134},{"trials":9118,"activeCount":128},[],{"trials":9120,"activeCount":128},[],{"trials":9122,"activeCount":676,"soonestReadout":4744},[9123],{"nctId":9124,"briefTitle":9125,"status":1096,"phases":9126,"primaryCompletion":4744,"completion":4744,"start":2303,"enrollment":2800,"conditions":9127,"interventions":9129},"NCT07565974","THC Versus THC\u002FCBD Versus Placebo to Improve Sleep Quality for Patients With Solid Organ Cancer and Insomnia",[91],[9128,24],"Insomnia",[9115,9115],{"trials":9131,"activeCount":128},[],{"trials":9133,"activeCount":128},[],{"trials":9135,"activeCount":128},[],{"intervention":5553,"totalTrials":676,"cells":9137},{"EARLY_PHASE1":9138,"PHASE1":9140,"PHASE2":9142,"PHASE3":9148,"PHASE4":9150,"NA":9152},{"trials":9139,"activeCount":128},[],{"trials":9141,"activeCount":128},[],{"trials":9143,"activeCount":676,"soonestReadout":171},[9144],{"nctId":5543,"briefTitle":5544,"status":265,"phases":9145,"primaryCompletion":171,"completion":171,"start":5546,"enrollment":498,"conditions":9146,"interventions":9147},[90,91],[5548,5549,5550,5551],[5553,346,4600,4375],{"trials":9149,"activeCount":128},[],{"trials":9151,"activeCount":128},[],{"trials":9153,"activeCount":128},[],{"intervention":9155,"totalTrials":676,"cells":9156},"Modified GCN+TTF treatment",{"EARLY_PHASE1":9157,"PHASE1":9159,"PHASE2":9161,"PHASE3":9174,"PHASE4":9176,"NA":9178},{"trials":9158,"activeCount":128},[],{"trials":9160,"activeCount":128},[],{"trials":9162,"activeCount":676,"soonestReadout":1160},[9163],{"nctId":9164,"briefTitle":9165,"status":265,"phases":9166,"primaryCompletion":1160,"completion":8670,"start":9167,"enrollment":498,"conditions":9168,"interventions":9173},"NCT04605913","Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w\u002F Metastatic PAC",[90,91],"2022-04-01",[9169,9170,9171,9172],"Pancreas Cancer","Metastatic Pancreatic Cancer","Pancreatic Adenocarcinoma","Metastatic Adenocarcinoma",[9155],{"trials":9175,"activeCount":128},[],{"trials":9177,"activeCount":128},[],{"trials":9179,"activeCount":128},[],{"intervention":9181,"totalTrials":676,"cells":9182},"Lutetium Lu 177 Vipivotide Tetraxetan",{"EARLY_PHASE1":9183,"PHASE1":9185,"PHASE2":9187,"PHASE3":9197,"PHASE4":9199,"NA":9201},{"trials":9184,"activeCount":128},[],{"trials":9186,"activeCount":128},[],{"trials":9188,"activeCount":676,"soonestReadout":5219},[9189],{"nctId":9190,"briefTitle":9191,"status":265,"phases":9192,"primaryCompletion":5219,"completion":5219,"start":9193,"enrollment":9194,"conditions":9195,"interventions":9196},"NCT06200103","Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer",[91],"2024-05-03",236,[5061,5063],[9181],{"trials":9198,"activeCount":128},[],{"trials":9200,"activeCount":128},[],{"trials":9202,"activeCount":128},[],{"intervention":5099,"totalTrials":676,"cells":9204},{"EARLY_PHASE1":9205,"PHASE1":9207,"PHASE2":9209,"PHASE3":9215,"PHASE4":9217,"NA":9219},{"trials":9206,"activeCount":128},[],{"trials":9208,"activeCount":128},[],{"trials":9210,"activeCount":676,"soonestReadout":5092},[9211],{"nctId":5089,"briefTitle":5090,"status":265,"phases":9212,"primaryCompletion":5092,"completion":5093,"start":5094,"enrollment":2742,"conditions":9213,"interventions":9214},[91],[5096],[5098,3427,1342,5099],{"trials":9216,"activeCount":128},[],{"trials":9218,"activeCount":128},[],{"trials":9220,"activeCount":128},[],{"intervention":401,"totalTrials":676,"cells":9222},{"EARLY_PHASE1":9223,"PHASE1":9225,"PHASE2":9227,"PHASE3":9233,"PHASE4":9235,"NA":9237},{"trials":9224,"activeCount":128},[],{"trials":9226,"activeCount":128},[],{"trials":9228,"activeCount":676,"soonestReadout":368},[9229],{"nctId":365,"briefTitle":366,"status":169,"phases":9230,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":9231,"interventions":9232},[91],[372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399],[401,72,402],{"trials":9234,"activeCount":128},[],{"trials":9236,"activeCount":128},[],{"trials":9238,"activeCount":128},[],{"intervention":402,"totalTrials":676,"cells":9240},{"EARLY_PHASE1":9241,"PHASE1":9243,"PHASE2":9245,"PHASE3":9251,"PHASE4":9253,"NA":9255},{"trials":9242,"activeCount":128},[],{"trials":9244,"activeCount":128},[],{"trials":9246,"activeCount":676,"soonestReadout":368},[9247],{"nctId":365,"briefTitle":366,"status":169,"phases":9248,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":9249,"interventions":9250},[91],[372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399],[401,72,402],{"trials":9252,"activeCount":128},[],{"trials":9254,"activeCount":128},[],{"trials":9256,"activeCount":128},[],{"intervention":7231,"totalTrials":676,"cells":9258},{"EARLY_PHASE1":9259,"PHASE1":9261,"PHASE2":9263,"PHASE3":9269,"PHASE4":9271,"NA":9273},{"trials":9260,"activeCount":128},[],{"trials":9262,"activeCount":128},[],{"trials":9264,"activeCount":676,"soonestReadout":496},[9265],{"nctId":7210,"briefTitle":7211,"status":265,"phases":9266,"primaryCompletion":496,"completion":496,"start":1935,"enrollment":558,"conditions":9267,"interventions":9268},[91],[7214,7215,7216,4237,7217,4481,7218,7219,7220,7221,7222,7223,7224,7225,7226,7227,7228,7229],[2725,7231,7232],{"trials":9270,"activeCount":128},[],{"trials":9272,"activeCount":128},[],{"trials":9274,"activeCount":128},[],{"intervention":9276,"totalTrials":676,"cells":9277},"BM-MSC",{"EARLY_PHASE1":9278,"PHASE1":9280,"PHASE2":9282,"PHASE3":9293,"PHASE4":9295,"NA":9297},{"trials":9279,"activeCount":128},[],{"trials":9281,"activeCount":128},[],{"trials":9283,"activeCount":676,"soonestReadout":2902},[9284],{"nctId":9285,"briefTitle":9286,"status":169,"phases":9287,"primaryCompletion":2902,"completion":2902,"start":9288,"enrollment":498,"conditions":9289,"interventions":9291},"NCT06001853","Allogeneic BM-MSC's in Patients With Lumbar Facet Arthropathy",[91],"2023-11-03",[9290],"Facet-Mediated Low Back Pain",[9276,9292],"DSMO",{"trials":9294,"activeCount":128},[],{"trials":9296,"activeCount":128},[],{"trials":9298,"activeCount":128},[],{"intervention":9292,"totalTrials":676,"cells":9300},{"EARLY_PHASE1":9301,"PHASE1":9303,"PHASE2":9305,"PHASE3":9311,"PHASE4":9313,"NA":9315},{"trials":9302,"activeCount":128},[],{"trials":9304,"activeCount":128},[],{"trials":9306,"activeCount":676,"soonestReadout":2902},[9307],{"nctId":9285,"briefTitle":9286,"status":169,"phases":9308,"primaryCompletion":2902,"completion":2902,"start":9288,"enrollment":498,"conditions":9309,"interventions":9310},[91],[9290],[9276,9292],{"trials":9312,"activeCount":128},[],{"trials":9314,"activeCount":128},[],{"trials":9316,"activeCount":128},[],{"intervention":9318,"totalTrials":676,"cells":9319},"Ga 68 PSMA-11",{"EARLY_PHASE1":9320,"PHASE1":9322,"PHASE2":9324,"PHASE3":9336,"PHASE4":9338,"NA":9340},{"trials":9321,"activeCount":128},[],{"trials":9323,"activeCount":128},[],{"trials":9325,"activeCount":676,"soonestReadout":9330},[9326],{"nctId":9327,"briefTitle":9328,"status":265,"phases":9329,"primaryCompletion":9330,"completion":9330,"start":9331,"enrollment":558,"conditions":9332,"interventions":9335},"NCT06444412","An Investigational Scan (Ga-68 PSMA-11 PET\u002FCT) for Detection of Disease Recurrence or Progression in Patients With Glioma",[91],"2028-07-31","2026-01-12",[9333,9334],"WHO Grade 3 Glioma","WHO Grade 4 Glioma",[9318],{"trials":9337,"activeCount":128},[],{"trials":9339,"activeCount":128},[],{"trials":9341,"activeCount":128},[],{"intervention":9343,"totalTrials":676,"cells":9344},"WBF-038",{"EARLY_PHASE1":9345,"PHASE1":9347,"PHASE2":9349,"PHASE3":9361,"PHASE4":9363,"NA":9365},{"trials":9346,"activeCount":128},[],{"trials":9348,"activeCount":128},[],{"trials":9350,"activeCount":676,"soonestReadout":9355},[9351],{"nctId":9352,"briefTitle":9353,"status":265,"phases":9354,"primaryCompletion":9355,"completion":9355,"start":9356,"enrollment":956,"conditions":9357,"interventions":9360},"NCT07044310","5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss",[91],"2027-07-25","2025-07-25",[9358,5197,5198,579,9359],"Anatomic Stage 0 Breast Cancer AJCC v8","Hormone Receptor-Positive Breast Carcinoma",[9343],{"trials":9362,"activeCount":128},[],{"trials":9364,"activeCount":128},[],{"trials":9366,"activeCount":128},[],{"intervention":9368,"totalTrials":676,"cells":9369},"Ondansetron 8mg",{"EARLY_PHASE1":9370,"PHASE1":9372,"PHASE2":9374,"PHASE3":9384,"PHASE4":9386,"NA":9388},{"trials":9371,"activeCount":128},[],{"trials":9373,"activeCount":128},[],{"trials":9375,"activeCount":676,"soonestReadout":2553},[9376],{"nctId":9377,"briefTitle":9378,"status":265,"phases":9379,"primaryCompletion":2553,"completion":2553,"start":9380,"enrollment":3067,"conditions":9381,"interventions":9383},"NCT03865290","Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia",[91],"2019-04-02",[9382,6505],"Indigestion",[9368],{"trials":9385,"activeCount":128},[],{"trials":9387,"activeCount":128},[],{"trials":9389,"activeCount":128},[],{"intervention":3692,"totalTrials":676,"cells":9391},{"EARLY_PHASE1":9392,"PHASE1":9394,"PHASE2":9396,"PHASE3":9402,"PHASE4":9404,"NA":9406},{"trials":9393,"activeCount":128},[],{"trials":9395,"activeCount":128},[],{"trials":9397,"activeCount":676,"soonestReadout":3685},[9398],{"nctId":3682,"briefTitle":3683,"status":265,"phases":9399,"primaryCompletion":3685,"completion":3685,"start":3686,"enrollment":3687,"conditions":9400,"interventions":9401},[91],[3689,3690],[3692,57,3693,3405,3694],{"trials":9403,"activeCount":128},[],{"trials":9405,"activeCount":128},[],{"trials":9407,"activeCount":128},[],{"intervention":5399,"totalTrials":676,"cells":9409},{"EARLY_PHASE1":9410,"PHASE1":9412,"PHASE2":9414,"PHASE3":9420,"PHASE4":9422,"NA":9424},{"trials":9411,"activeCount":128},[],{"trials":9413,"activeCount":128},[],{"trials":9415,"activeCount":676,"soonestReadout":5381},[9416],{"nctId":5378,"briefTitle":5379,"status":265,"phases":9417,"primaryCompletion":5381,"completion":5381,"start":5382,"enrollment":28,"conditions":9418,"interventions":9419},[91],[5384,5385,5386,5387,374,5388,375,376,377,5389,381,382,383,5390,385,5391,5392,5393,5394,387,5395,388,389,390,5396,394,395,396,397,398,5397],[5399,5400,163],{"trials":9421,"activeCount":128},[],{"trials":9423,"activeCount":128},[],{"trials":9425,"activeCount":128},[],{"intervention":5400,"totalTrials":676,"cells":9427},{"EARLY_PHASE1":9428,"PHASE1":9430,"PHASE2":9432,"PHASE3":9438,"PHASE4":9440,"NA":9442},{"trials":9429,"activeCount":128},[],{"trials":9431,"activeCount":128},[],{"trials":9433,"activeCount":676,"soonestReadout":5381},[9434],{"nctId":5378,"briefTitle":5379,"status":265,"phases":9435,"primaryCompletion":5381,"completion":5381,"start":5382,"enrollment":28,"conditions":9436,"interventions":9437},[91],[5384,5385,5386,5387,374,5388,375,376,377,5389,381,382,383,5390,385,5391,5392,5393,5394,387,5395,388,389,390,5396,394,395,396,397,398,5397],[5399,5400,163],{"trials":9439,"activeCount":128},[],{"trials":9441,"activeCount":128},[],{"trials":9443,"activeCount":128},[],{"intervention":9445,"totalTrials":676,"cells":9446},"Liraglutide Pen Injector",{"EARLY_PHASE1":9447,"PHASE1":9449,"PHASE2":9451,"PHASE3":9462,"PHASE4":9464,"NA":9466},{"trials":9448,"activeCount":128},[],{"trials":9450,"activeCount":128},[],{"trials":9452,"activeCount":676,"soonestReadout":9457},[9453],{"nctId":9454,"briefTitle":9455,"status":265,"phases":9456,"primaryCompletion":9457,"completion":8290,"start":9458,"enrollment":25,"conditions":9459,"interventions":9461},"NCT06976619","The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes",[91],"2028-10-30","2025-10-03",[9460,1868],"Type 1 Diabetes",[9445],{"trials":9463,"activeCount":128},[],{"trials":9465,"activeCount":128},[],{"trials":9467,"activeCount":128},[],{"intervention":4601,"totalTrials":676,"cells":9469},{"EARLY_PHASE1":9470,"PHASE1":9472,"PHASE2":9474,"PHASE3":9480,"PHASE4":9482,"NA":9484},{"trials":9471,"activeCount":128},[],{"trials":9473,"activeCount":128},[],{"trials":9475,"activeCount":676,"soonestReadout":3824},[9476],{"nctId":4593,"briefTitle":4594,"status":265,"phases":9477,"primaryCompletion":3824,"completion":3824,"start":4596,"enrollment":2980,"conditions":9478,"interventions":9479},[91],[561,4598,564],[4600,4601,4385,112],{"trials":9481,"activeCount":128},[],{"trials":9483,"activeCount":128},[],{"trials":9485,"activeCount":128},[],{"intervention":9487,"totalTrials":676,"cells":9488},"C-11 ER176 Radiotracer",{"EARLY_PHASE1":9489,"PHASE1":9491,"PHASE2":9493,"PHASE3":9505,"PHASE4":9507,"NA":9509},{"trials":9490,"activeCount":128},[],{"trials":9492,"activeCount":128},[],{"trials":9494,"activeCount":676,"soonestReadout":8469},[9495],{"nctId":9496,"briefTitle":9497,"status":692,"phases":9498,"primaryCompletion":8469,"completion":8469,"start":9499,"enrollment":923,"conditions":9500,"interventions":9503},"NCT05805839","A Study of Imaging in Demyelinating Diseases",[91],"2023-07-10",[9501,9502],"Multiple Sclerosis","Inflammatory Demyelinating Disease",[9487,9504],"C11 Pittsburgh Compound B",{"trials":9506,"activeCount":128},[],{"trials":9508,"activeCount":128},[],{"trials":9510,"activeCount":128},[],{"intervention":9504,"totalTrials":676,"cells":9512},{"EARLY_PHASE1":9513,"PHASE1":9515,"PHASE2":9517,"PHASE3":9523,"PHASE4":9525,"NA":9527},{"trials":9514,"activeCount":128},[],{"trials":9516,"activeCount":128},[],{"trials":9518,"activeCount":676,"soonestReadout":8469},[9519],{"nctId":9496,"briefTitle":9497,"status":692,"phases":9520,"primaryCompletion":8469,"completion":8469,"start":9499,"enrollment":923,"conditions":9521,"interventions":9522},[91],[9501,9502],[9487,9504],{"trials":9524,"activeCount":128},[],{"trials":9526,"activeCount":128},[],{"trials":9528,"activeCount":128},[],{"intervention":9530,"totalTrials":676,"cells":9531},"Metyrapone",{"EARLY_PHASE1":9532,"PHASE1":9534,"PHASE2":9536,"PHASE3":9547,"PHASE4":9549,"NA":9551},{"trials":9533,"activeCount":128},[],{"trials":9535,"activeCount":128},[],{"trials":9537,"activeCount":676,"soonestReadout":727},[9538],{"nctId":9539,"briefTitle":9540,"status":169,"phases":9541,"primaryCompletion":727,"completion":709,"start":9542,"enrollment":729,"conditions":9543,"interventions":9546},"NCT06106295","Metyrapone for Mild Autonomous Cortisol Secretion (MACS)",[91],"2023-12-19",[9544,9545],"Autonomous Cortisol Secretion","Mild Autonomous Cortisol Secretion (MACS)",[9530],{"trials":9548,"activeCount":128},[],{"trials":9550,"activeCount":128},[],{"trials":9552,"activeCount":128},[],{"intervention":9554,"totalTrials":676,"cells":9555},"Pegylated SN-38 Conjugate PLX038",{"EARLY_PHASE1":9556,"PHASE1":9558,"PHASE2":9560,"PHASE3":9574,"PHASE4":9576,"NA":9578},{"trials":9557,"activeCount":128},[],{"trials":9559,"activeCount":128},[],{"trials":9561,"activeCount":676,"soonestReadout":9566},[9562],{"nctId":9563,"briefTitle":9564,"status":265,"phases":9565,"primaryCompletion":9566,"completion":9567,"start":9568,"enrollment":2980,"conditions":9569,"interventions":9573},"NCT05465941","PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",[91],"2027-02-15","2031-12-31","2022-09-14",[3491,3492,3493,9570,9571,9572],"Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8",[9554],{"trials":9575,"activeCount":128},[],{"trials":9577,"activeCount":128},[],{"trials":9579,"activeCount":128},[],{"intervention":9581,"totalTrials":676,"cells":9582},"Tau PET scan",{"EARLY_PHASE1":9583,"PHASE1":9585,"PHASE2":9587,"PHASE3":9597,"PHASE4":9599,"NA":9601},{"trials":9584,"activeCount":128},[],{"trials":9586,"activeCount":128},[],{"trials":9588,"activeCount":676,"soonestReadout":1650},[9589],{"nctId":9590,"briefTitle":9591,"status":692,"phases":9592,"primaryCompletion":1650,"completion":1650,"start":9593,"enrollment":2925,"conditions":9594,"interventions":9596},"NCT03618186","Neuroimaging Study",[91],"2018-11-26",[9595],"Cognitive Impairment",[9581],{"trials":9598,"activeCount":128},[],{"trials":9600,"activeCount":128},[],{"trials":9602,"activeCount":128},[],{"intervention":6944,"totalTrials":676,"cells":9604},{"EARLY_PHASE1":9605,"PHASE1":9607,"PHASE2":9609,"PHASE3":9615,"PHASE4":9617,"NA":9619},{"trials":9606,"activeCount":128},[],{"trials":9608,"activeCount":128},[],{"trials":9610,"activeCount":676,"soonestReadout":3065},[9611],{"nctId":6936,"briefTitle":6937,"status":265,"phases":9612,"primaryCompletion":3065,"completion":3065,"start":6939,"enrollment":498,"conditions":9613,"interventions":9614},[91],[6941,6942,6505],[6909,6944],{"trials":9616,"activeCount":128},[],{"trials":9618,"activeCount":128},[],{"trials":9620,"activeCount":128},[],{"intervention":9622,"totalTrials":676,"cells":9623},"Darizmetinib",{"EARLY_PHASE1":9624,"PHASE1":9626,"PHASE2":9628,"PHASE3":9639,"PHASE4":9641,"NA":9643},{"trials":9625,"activeCount":128},[],{"trials":9627,"activeCount":128},[],{"trials":9629,"activeCount":676,"soonestReadout":4411},[9630],{"nctId":9631,"briefTitle":9632,"status":1096,"phases":9633,"primaryCompletion":4411,"completion":4411,"start":4700,"enrollment":2678,"conditions":9634,"interventions":9637},"NCT07612007","HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization",[91],[4618,9635,9636,4623],"Metastatic Malignant Neoplasm in the Liver","Resectable Colorectal Carcinoma",[9622,9638],"Embolization Therapy",{"trials":9640,"activeCount":128},[],{"trials":9642,"activeCount":128},[],{"trials":9644,"activeCount":128},[],{"intervention":9638,"totalTrials":676,"cells":9646},{"EARLY_PHASE1":9647,"PHASE1":9649,"PHASE2":9651,"PHASE3":9657,"PHASE4":9659,"NA":9661},{"trials":9648,"activeCount":128},[],{"trials":9650,"activeCount":128},[],{"trials":9652,"activeCount":676,"soonestReadout":4411},[9653],{"nctId":9631,"briefTitle":9632,"status":1096,"phases":9654,"primaryCompletion":4411,"completion":4411,"start":4700,"enrollment":2678,"conditions":9655,"interventions":9656},[91],[4618,9635,9636,4623],[9622,9638],{"trials":9658,"activeCount":128},[],{"trials":9660,"activeCount":128},[],{"trials":9662,"activeCount":128},[],{"intervention":9664,"totalTrials":676,"cells":9665},"Neostigmine",{"EARLY_PHASE1":9666,"PHASE1":9668,"PHASE2":9670,"PHASE3":9681,"PHASE4":9683,"NA":9685},{"trials":9667,"activeCount":128},[],{"trials":9669,"activeCount":128},[],{"trials":9671,"activeCount":676,"soonestReadout":737},[9672],{"nctId":9673,"briefTitle":9674,"status":265,"phases":9675,"primaryCompletion":737,"completion":737,"start":9676,"enrollment":108,"conditions":9677,"interventions":9679},"NCT05116930","Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture",[91],"2021-11-19",[9678],"Post-Dural Puncture Headache",[9664,9680],"Glycopyrrolate",{"trials":9682,"activeCount":128},[],{"trials":9684,"activeCount":128},[],{"trials":9686,"activeCount":128},[],{"intervention":9680,"totalTrials":676,"cells":9688},{"EARLY_PHASE1":9689,"PHASE1":9691,"PHASE2":9693,"PHASE3":9699,"PHASE4":9701,"NA":9703},{"trials":9690,"activeCount":128},[],{"trials":9692,"activeCount":128},[],{"trials":9694,"activeCount":676,"soonestReadout":737},[9695],{"nctId":9673,"briefTitle":9674,"status":265,"phases":9696,"primaryCompletion":737,"completion":737,"start":9676,"enrollment":108,"conditions":9697,"interventions":9698},[91],[9678],[9664,9680],{"trials":9700,"activeCount":128},[],{"trials":9702,"activeCount":128},[],{"trials":9704,"activeCount":128},[],{"intervention":9706,"totalTrials":676,"cells":9707},"Bupivacaine HCl 0.5% Injectable Solution",{"EARLY_PHASE1":9708,"PHASE1":9710,"PHASE2":9712,"PHASE3":9722,"PHASE4":9724,"NA":9726},{"trials":9709,"activeCount":128},[],{"trials":9711,"activeCount":128},[],{"trials":9713,"activeCount":676,"soonestReadout":2111},[9714],{"nctId":9715,"briefTitle":9716,"status":265,"phases":9717,"primaryCompletion":2111,"completion":2023,"start":9499,"enrollment":25,"conditions":9718,"interventions":9720},"NCT05734625","Efficacy of Nerve Blocks for Episodic Migraine",[91],[9719],"Episodic Migraine",[9706,9721],"Methylprednisolone 40 MG",{"trials":9723,"activeCount":128},[],{"trials":9725,"activeCount":128},[],{"trials":9727,"activeCount":128},[],{"intervention":9721,"totalTrials":676,"cells":9729},{"EARLY_PHASE1":9730,"PHASE1":9732,"PHASE2":9734,"PHASE3":9740,"PHASE4":9742,"NA":9744},{"trials":9731,"activeCount":128},[],{"trials":9733,"activeCount":128},[],{"trials":9735,"activeCount":676,"soonestReadout":2111},[9736],{"nctId":9715,"briefTitle":9716,"status":265,"phases":9737,"primaryCompletion":2111,"completion":2023,"start":9499,"enrollment":25,"conditions":9738,"interventions":9739},[91],[9719],[9706,9721],{"trials":9741,"activeCount":128},[],{"trials":9743,"activeCount":128},[],{"trials":9745,"activeCount":128},[],{"intervention":9747,"totalTrials":676,"cells":9748},"Cilostazol",{"EARLY_PHASE1":9749,"PHASE1":9751,"PHASE2":9753,"PHASE3":9766,"PHASE4":9768,"NA":9770},{"trials":9750,"activeCount":128},[],{"trials":9752,"activeCount":128},[],{"trials":9754,"activeCount":676,"soonestReadout":921},[9755],{"nctId":9756,"briefTitle":9757,"status":265,"phases":9758,"primaryCompletion":921,"completion":921,"start":9759,"enrollment":712,"conditions":9760,"interventions":9765},"NCT04753970","Retina is a Marker for Cerebrovascular Heath",[90,91],"2021-02-09",[9761,9762,9763,9764],"Cerebral Small Vessel Diseases","Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy","Cerebral Microbleeding","Sporadic White Matter Disease",[9747],{"trials":9767,"activeCount":128},[],{"trials":9769,"activeCount":128},[],{"trials":9771,"activeCount":128},[],{"intervention":3744,"totalTrials":676,"cells":9773},{"EARLY_PHASE1":9774,"PHASE1":9776,"PHASE2":9778,"PHASE3":9784,"PHASE4":9786,"NA":9788},{"trials":9775,"activeCount":128},[],{"trials":9777,"activeCount":128},[],{"trials":9779,"activeCount":676,"soonestReadout":3227},[9780],{"nctId":3738,"briefTitle":3739,"status":1096,"phases":9781,"primaryCompletion":3227,"completion":3741,"start":2303,"enrollment":2894,"conditions":9782,"interventions":9783},[91],[36],[3744,57,1698,3745],{"trials":9785,"activeCount":128},[],{"trials":9787,"activeCount":128},[],{"trials":9789,"activeCount":128},[],{"intervention":9791,"totalTrials":676,"cells":9792},"Rilonacept",{"EARLY_PHASE1":9793,"PHASE1":9795,"PHASE2":9797,"PHASE3":9807,"PHASE4":9809,"NA":9811},{"trials":9794,"activeCount":128},[],{"trials":9796,"activeCount":128},[],{"trials":9798,"activeCount":676,"soonestReadout":3011},[9799],{"nctId":9800,"briefTitle":9801,"status":265,"phases":9802,"primaryCompletion":3011,"completion":2233,"start":9803,"enrollment":25,"conditions":9804,"interventions":9806},"NCT06660732","Rilonacept in Subjects With Cardiac Sarcoidosis",[91],"2025-03-05",[9805],"Cardiac Sarcoidosis",[9791],{"trials":9808,"activeCount":128},[],{"trials":9810,"activeCount":128},[],{"trials":9812,"activeCount":128},[],{"intervention":5760,"totalTrials":676,"cells":9814},{"EARLY_PHASE1":9815,"PHASE1":9817,"PHASE2":9819,"PHASE3":9825,"PHASE4":9827,"NA":9829},{"trials":9816,"activeCount":128},[],{"trials":9818,"activeCount":128},[],{"trials":9820,"activeCount":676,"soonestReadout":5755},[9821],{"nctId":5752,"briefTitle":5753,"status":169,"phases":9822,"primaryCompletion":5755,"completion":5756,"start":5757,"enrollment":2894,"conditions":9823,"interventions":9824},[91],[3573,419],[5760,3819],{"trials":9826,"activeCount":128},[],{"trials":9828,"activeCount":128},[],{"trials":9830,"activeCount":128},[],{"intervention":5818,"totalTrials":676,"cells":9832},{"EARLY_PHASE1":9833,"PHASE1":9835,"PHASE2":9837,"PHASE3":9843,"PHASE4":9845,"NA":9847},{"trials":9834,"activeCount":128},[],{"trials":9836,"activeCount":128},[],{"trials":9838,"activeCount":676,"soonestReadout":5813},[9839],{"nctId":5810,"briefTitle":5811,"status":265,"phases":9840,"primaryCompletion":5813,"completion":5813,"start":5814,"enrollment":25,"conditions":9841,"interventions":9842},[91],[4617,5816,4435,618,622],[3450,5818],{"trials":9844,"activeCount":128},[],{"trials":9846,"activeCount":128},[],{"trials":9848,"activeCount":128},[],{"intervention":9850,"totalTrials":676,"cells":9851},"Metyrapone 250 mg Oral",{"EARLY_PHASE1":9852,"PHASE1":9854,"PHASE2":9856,"PHASE3":9866,"PHASE4":9868,"NA":9870},{"trials":9853,"activeCount":128},[],{"trials":9855,"activeCount":128},[],{"trials":9857,"activeCount":676,"soonestReadout":9862},[9858],{"nctId":9859,"briefTitle":9860,"status":1096,"phases":9861,"primaryCompletion":9862,"completion":9863,"start":760,"enrollment":1151,"conditions":9864,"interventions":9865},"NCT07138274","Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS",[91],"2031-06","2031-12",[9545,8881],[9850],{"trials":9867,"activeCount":128},[],{"trials":9869,"activeCount":128},[],{"trials":9871,"activeCount":128},[],{"intervention":4916,"totalTrials":676,"cells":9873},{"EARLY_PHASE1":9874,"PHASE1":9876,"PHASE2":9878,"PHASE3":9884,"PHASE4":9886,"NA":9888},{"trials":9875,"activeCount":128},[],{"trials":9877,"activeCount":128},[],{"trials":9879,"activeCount":676,"soonestReadout":4909},[9880],{"nctId":4906,"briefTitle":4907,"status":265,"phases":9881,"primaryCompletion":4909,"completion":4910,"start":4911,"enrollment":25,"conditions":9882,"interventions":9883},[90,91],[4913],[4915,4916,537,4917],{"trials":9885,"activeCount":128},[],{"trials":9887,"activeCount":128},[],{"trials":9889,"activeCount":128},[],{"intervention":4917,"totalTrials":676,"cells":9891},{"EARLY_PHASE1":9892,"PHASE1":9894,"PHASE2":9896,"PHASE3":9902,"PHASE4":9904,"NA":9906},{"trials":9893,"activeCount":128},[],{"trials":9895,"activeCount":128},[],{"trials":9897,"activeCount":676,"soonestReadout":4909},[9898],{"nctId":4906,"briefTitle":4907,"status":265,"phases":9899,"primaryCompletion":4909,"completion":4910,"start":4911,"enrollment":25,"conditions":9900,"interventions":9901},[90,91],[4913],[4915,4916,537,4917],{"trials":9903,"activeCount":128},[],{"trials":9905,"activeCount":128},[],{"trials":9907,"activeCount":128},[],{"intervention":568,"totalTrials":676,"cells":9909},{"EARLY_PHASE1":9910,"PHASE1":9912,"PHASE2":9914,"PHASE3":9920,"PHASE4":9922,"NA":9924},{"trials":9911,"activeCount":128},[],{"trials":9913,"activeCount":128},[],{"trials":9915,"activeCount":676,"soonestReadout":556},[9916],{"nctId":553,"briefTitle":554,"status":265,"phases":9917,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":9918,"interventions":9919},[91],[560,561,562,563,564,565],[537,567,568,539,72,569,570],{"trials":9921,"activeCount":128},[],{"trials":9923,"activeCount":128},[],{"trials":9925,"activeCount":128},[],{"intervention":6516,"totalTrials":676,"cells":9927},{"EARLY_PHASE1":9928,"PHASE1":9930,"PHASE2":9932,"PHASE3":9938,"PHASE4":9940,"NA":9942},{"trials":9929,"activeCount":128},[],{"trials":9931,"activeCount":128},[],{"trials":9933,"activeCount":676,"soonestReadout":2112},[9934],{"nctId":6510,"briefTitle":6511,"status":692,"phases":9935,"primaryCompletion":2112,"completion":2112,"start":3842,"enrollment":729,"conditions":9936,"interventions":9937},[91],[6514],[6516,6482],{"trials":9939,"activeCount":128},[],{"trials":9941,"activeCount":128},[],{"trials":9943,"activeCount":128},[],{"intervention":9945,"totalTrials":676,"cells":9946},"Opioid",{"EARLY_PHASE1":9947,"PHASE1":9949,"PHASE2":9951,"PHASE3":9962,"PHASE4":9964,"NA":9966},{"trials":9948,"activeCount":128},[],{"trials":9950,"activeCount":128},[],{"trials":9952,"activeCount":676,"soonestReadout":1447},[9953],{"nctId":9954,"briefTitle":9955,"status":265,"phases":9956,"primaryCompletion":1447,"completion":5219,"start":9957,"enrollment":923,"conditions":9958,"interventions":9960},"NCT06837857","Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain",[91],"2025-04-16",[9959],"Pain, Chronic",[9945,9961],"Opioid Placebo",{"trials":9963,"activeCount":128},[],{"trials":9965,"activeCount":128},[],{"trials":9967,"activeCount":128},[],{"intervention":9961,"totalTrials":676,"cells":9969},{"EARLY_PHASE1":9970,"PHASE1":9972,"PHASE2":9974,"PHASE3":9980,"PHASE4":9982,"NA":9984},{"trials":9971,"activeCount":128},[],{"trials":9973,"activeCount":128},[],{"trials":9975,"activeCount":676,"soonestReadout":1447},[9976],{"nctId":9954,"briefTitle":9955,"status":265,"phases":9977,"primaryCompletion":1447,"completion":5219,"start":9957,"enrollment":923,"conditions":9978,"interventions":9979},[91],[9959],[9945,9961],{"trials":9981,"activeCount":128},[],{"trials":9983,"activeCount":128},[],{"trials":9985,"activeCount":128},[],{"intervention":656,"totalTrials":676,"cells":9987},{"EARLY_PHASE1":9988,"PHASE1":9990,"PHASE2":9992,"PHASE3":9998,"PHASE4":10000,"NA":10002},{"trials":9989,"activeCount":128},[],{"trials":9991,"activeCount":128},[],{"trials":9993,"activeCount":676,"soonestReadout":575},[9994],{"nctId":572,"briefTitle":573,"status":265,"phases":9995,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":9996,"interventions":9997},[90,91],[579,580,581,582,583,189,190,191,584,192,193,194,585,586,587,588,589,590,591,195,196,592,593,594,595,596,597,598,599,600,601,602,603,604,605,197,606,607,198,199,200,361,201,202,122,608,609,610,235,203,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,206,629,207,630,631,632,633,634,635,636,637,638,221,639,640,641,642,643,644,645,208,177,646,647,648,649,650,141,651,652,653,654],[57,656,72,657],{"trials":9999,"activeCount":128},[],{"trials":10001,"activeCount":128},[],{"trials":10003,"activeCount":128},[],{"intervention":5123,"totalTrials":676,"cells":10005},{"EARLY_PHASE1":10006,"PHASE1":10008,"PHASE2":10010,"PHASE3":10016,"PHASE4":10018,"NA":10020},{"trials":10007,"activeCount":128},[],{"trials":10009,"activeCount":128},[],{"trials":10011,"activeCount":676,"soonestReadout":5115},[10012],{"nctId":5112,"briefTitle":5113,"status":265,"phases":10013,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":5117,"conditions":10014,"interventions":10015},[91],[5119,5120,5121,3298],[5123,5124,5125,5126,5127,5128,5129,5130,3427,5131,5132],{"trials":10017,"activeCount":128},[],{"trials":10019,"activeCount":128},[],{"trials":10021,"activeCount":128},[],{"intervention":5124,"totalTrials":676,"cells":10023},{"EARLY_PHASE1":10024,"PHASE1":10026,"PHASE2":10028,"PHASE3":10034,"PHASE4":10036,"NA":10038},{"trials":10025,"activeCount":128},[],{"trials":10027,"activeCount":128},[],{"trials":10029,"activeCount":676,"soonestReadout":5115},[10030],{"nctId":5112,"briefTitle":5113,"status":265,"phases":10031,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":5117,"conditions":10032,"interventions":10033},[91],[5119,5120,5121,3298],[5123,5124,5125,5126,5127,5128,5129,5130,3427,5131,5132],{"trials":10035,"activeCount":128},[],{"trials":10037,"activeCount":128},[],{"trials":10039,"activeCount":128},[],{"intervention":5125,"totalTrials":676,"cells":10041},{"EARLY_PHASE1":10042,"PHASE1":10044,"PHASE2":10046,"PHASE3":10052,"PHASE4":10054,"NA":10056},{"trials":10043,"activeCount":128},[],{"trials":10045,"activeCount":128},[],{"trials":10047,"activeCount":676,"soonestReadout":5115},[10048],{"nctId":5112,"briefTitle":5113,"status":265,"phases":10049,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":5117,"conditions":10050,"interventions":10051},[91],[5119,5120,5121,3298],[5123,5124,5125,5126,5127,5128,5129,5130,3427,5131,5132],{"trials":10053,"activeCount":128},[],{"trials":10055,"activeCount":128},[],{"trials":10057,"activeCount":128},[],{"intervention":5128,"totalTrials":676,"cells":10059},{"EARLY_PHASE1":10060,"PHASE1":10062,"PHASE2":10064,"PHASE3":10070,"PHASE4":10072,"NA":10074},{"trials":10061,"activeCount":128},[],{"trials":10063,"activeCount":128},[],{"trials":10065,"activeCount":676,"soonestReadout":5115},[10066],{"nctId":5112,"briefTitle":5113,"status":265,"phases":10067,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":5117,"conditions":10068,"interventions":10069},[91],[5119,5120,5121,3298],[5123,5124,5125,5126,5127,5128,5129,5130,3427,5131,5132],{"trials":10071,"activeCount":128},[],{"trials":10073,"activeCount":128},[],{"trials":10075,"activeCount":128},[],{"intervention":5129,"totalTrials":676,"cells":10077},{"EARLY_PHASE1":10078,"PHASE1":10080,"PHASE2":10082,"PHASE3":10088,"PHASE4":10090,"NA":10092},{"trials":10079,"activeCount":128},[],{"trials":10081,"activeCount":128},[],{"trials":10083,"activeCount":676,"soonestReadout":5115},[10084],{"nctId":5112,"briefTitle":5113,"status":265,"phases":10085,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":5117,"conditions":10086,"interventions":10087},[91],[5119,5120,5121,3298],[5123,5124,5125,5126,5127,5128,5129,5130,3427,5131,5132],{"trials":10089,"activeCount":128},[],{"trials":10091,"activeCount":128},[],{"trials":10093,"activeCount":128},[],{"intervention":5132,"totalTrials":676,"cells":10095},{"EARLY_PHASE1":10096,"PHASE1":10098,"PHASE2":10100,"PHASE3":10106,"PHASE4":10108,"NA":10110},{"trials":10097,"activeCount":128},[],{"trials":10099,"activeCount":128},[],{"trials":10101,"activeCount":676,"soonestReadout":5115},[10102],{"nctId":5112,"briefTitle":5113,"status":265,"phases":10103,"primaryCompletion":5115,"completion":5115,"start":5116,"enrollment":5117,"conditions":10104,"interventions":10105},[91],[5119,5120,5121,3298],[5123,5124,5125,5126,5127,5128,5129,5130,3427,5131,5132],{"trials":10107,"activeCount":128},[],{"trials":10109,"activeCount":128},[],{"trials":10111,"activeCount":128},[],{"intervention":10113,"totalTrials":676,"cells":10114},"18F-AV-1451",{"EARLY_PHASE1":10115,"PHASE1":10117,"PHASE2":10119,"PHASE3":10131,"PHASE4":10133,"NA":10135},{"trials":10116,"activeCount":128},[],{"trials":10118,"activeCount":128},[],{"trials":10120,"activeCount":676,"soonestReadout":10125},[10121],{"nctId":10122,"briefTitle":10123,"status":692,"phases":10124,"primaryCompletion":10125,"completion":10125,"start":10126,"enrollment":740,"conditions":10127,"interventions":10130},"NCT06723015","Tau PET Outcomes With Anti-amyloid Immunotherapies",[91],"2028-08","2025-11-04",[10128,10129,1654],"Cognitive Impairment, Mild","Dementia, Mild",[10113],{"trials":10132,"activeCount":128},[],{"trials":10134,"activeCount":128},[],{"trials":10136,"activeCount":128},[],{"intervention":161,"totalTrials":218,"cells":10138},{"EARLY_PHASE1":10139,"PHASE1":10141,"PHASE2":10177,"PHASE3":10212,"PHASE4":10214,"NA":10216},{"trials":10140,"activeCount":128},[],{"trials":10142,"activeCount":128},[10143,10147,10151,10161,10165,10169,10173],{"nctId":132,"briefTitle":133,"status":134,"phases":10144,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":10145,"interventions":10146},[90],[141,142,143,144,145,146,147,148,149,150,151,152,153,154],[156,157,158,159,160,161,112,162,72,163,164,165],{"nctId":4275,"briefTitle":4276,"status":104,"phases":10148,"primaryCompletion":4278,"completion":4278,"start":4279,"enrollment":676,"conditions":10149,"interventions":10150},[90],[4281],[4089,161,4283],{"nctId":10152,"briefTitle":10153,"status":104,"phases":10154,"primaryCompletion":10155,"completion":10155,"start":10156,"enrollment":2980,"conditions":10157,"interventions":10159},"NCT03237390","Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors",[90],"2022-05-17","2018-01-04",[10158,202],"Advanced Malignant Solid Neoplasm",[161,10160],"Ribociclib",{"nctId":4297,"briefTitle":4298,"status":104,"phases":10162,"primaryCompletion":4300,"completion":4300,"start":2883,"enrollment":956,"conditions":10163,"interventions":10164},[90],[4302,4303,4304,4293],[4306,4307,4240],{"nctId":4309,"briefTitle":4310,"status":1413,"phases":10166,"primaryCompletion":4312,"completion":4312,"start":4313,"enrollment":128,"conditions":10167,"interventions":10168},[90],[4315,4316,4317,4318,4319,4320,4321,4322,4323,4324,4325,4326,4327],[4089,161,4329],{"nctId":5177,"briefTitle":5178,"status":134,"phases":10170,"primaryCompletion":5180,"completion":5181,"start":5182,"enrollment":2742,"conditions":10171,"interventions":10172},[90],[561,5184,564],[5158,5186,161],{"nctId":4881,"briefTitle":4882,"status":104,"phases":10174,"primaryCompletion":4884,"completion":4884,"start":4885,"enrollment":676,"conditions":10175,"interventions":10176},[90],[4887,4888,4889],[4307,4865],{"trials":10178,"activeCount":676,"soonestReadout":4080},[10179,10183,10204,10208],{"nctId":5595,"briefTitle":5596,"status":134,"phases":10180,"primaryCompletion":5598,"completion":5598,"start":5599,"enrollment":139,"conditions":10181,"interventions":10182},[91],[500,5601,5602,5603,5604,5605,5606,5607,5608,5609,5610,5611,5612,5613,5614,3491,3492,3493,501,5615,5616,5617,5618,5619,502,506,511],[4719,161,67,540,5621,5622],{"nctId":10184,"briefTitle":10185,"status":134,"phases":10186,"primaryCompletion":10187,"completion":10187,"start":10188,"enrollment":558,"conditions":10189,"interventions":10203},"NCT04398368","Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study",[91],"2023-02-02","2020-06-05",[10190,10191,10192,10193,10194,10195,10196,10197,10198,10199,4364,4365,10200,4367,4368,674,10201,10202],"Stage 0a Renal Pelvis and Ureter Cancer AJCC v8","Stage 0a Renal Pelvis Cancer AJCC v8","Stage 0a Ureter Cancer AJCC v8","Stage 0is Renal Pelvis and Ureter Cancer AJCC v8","Stage 0is Renal Pelvis Cancer AJCC v8","Stage 0is Ureter Cancer AJCC v8","Stage I Renal Pelvis and Ureter Cancer AJCC v8","Stage I Renal Pelvis Cancer AJCC v8","Stage I Ureter Cancer AJCC v8","Stage II Renal Pelvis and Ureter Cancer AJCC v8","Stage III Renal Pelvis and Ureter Cancer AJCC v8","Stage IV Renal Pelvis Cancer AJCC v8","Stage IV Ureter Cancer AJCC v8",[161],{"nctId":4077,"briefTitle":4078,"status":265,"phases":10205,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":2678,"conditions":10206,"interventions":10207},[91],[4084,3422,414,144,4085,3398,4086,4087],[536,4089,4090,305,4091,161,4092,539,163,4093],{"nctId":5653,"briefTitle":5654,"status":104,"phases":10209,"primaryCompletion":1310,"completion":1310,"start":5656,"enrollment":301,"conditions":10210,"interventions":10211},[91],[502,506,511],[4719,161,540,5621,5622],{"trials":10213,"activeCount":128},[],{"trials":10215,"activeCount":128},[],{"trials":10217,"activeCount":128},[10218],{"nctId":4488,"briefTitle":4489,"status":1413,"phases":10219,"primaryCompletion":3559,"completion":3559,"start":1471,"enrollment":128,"conditions":10220,"interventions":10221},[94],[4492,4493,4494,4495],[4089,161,4497],{"intervention":3779,"totalTrials":120,"cells":10223},{"EARLY_PHASE1":10224,"PHASE1":10239,"PHASE2":10249,"PHASE3":10269,"PHASE4":10271,"NA":10273},{"trials":10225,"activeCount":128},[10226,10230],{"nctId":3772,"briefTitle":3773,"status":104,"phases":10227,"primaryCompletion":3775,"completion":3775,"start":2665,"enrollment":2980,"conditions":10228,"interventions":10229},[89],[3777,1340],[305,3779],{"nctId":10231,"briefTitle":10232,"status":104,"phases":10233,"primaryCompletion":10234,"completion":10234,"start":10235,"enrollment":218,"conditions":10236,"interventions":10237},"NCT03867500","Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus",[89],"2021-12-22","2018-11-01",[6975,15],[10238,3779],"Niacin",{"trials":10240,"activeCount":128},[10241],{"nctId":10242,"briefTitle":10243,"status":104,"phases":10244,"primaryCompletion":7317,"completion":7317,"start":10245,"enrollment":498,"conditions":10246,"interventions":10247},"NCT01800370","The Effect of Mixed Exercise and Metabolic Stress in Relationship to Age in Healthy Men",[90],"2013-02",[18],[10248,3779],"Hyperglycemia",{"trials":10250,"activeCount":676,"soonestReadout":6555},[10251,10265],{"nctId":10252,"briefTitle":10253,"status":104,"phases":10254,"primaryCompletion":10255,"completion":10256,"start":10257,"enrollment":1236,"conditions":10258,"interventions":10262},"NCT01188733","Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis",[90,91],"2000-07","2000-12","1998-06",[10259,10260,10261],"Cirrhosis","Portal Hypertension","Esophageal Varices",[10263,10264,3779],"Long acting octreotide 10mg","Long acting Octreotide 30mg",{"nctId":6552,"briefTitle":6553,"status":265,"phases":10266,"primaryCompletion":6555,"completion":575,"start":2491,"enrollment":25,"conditions":10267,"interventions":10268},[91],[6557],[6524,3779],{"trials":10270,"activeCount":128},[],{"trials":10272,"activeCount":128},[],{"trials":10274,"activeCount":128},[10275,10284],{"nctId":10276,"briefTitle":10277,"status":104,"phases":10278,"primaryCompletion":10279,"completion":10280,"start":10281,"enrollment":233,"conditions":10282,"interventions":10283},"NCT03073668","Pericardial Resection to Treat Heart Failure",[94],"2018-01-23","2019-02-02","2017-03-20",[27],[3779],{"nctId":10285,"briefTitle":10286,"status":104,"phases":10287,"primaryCompletion":10288,"completion":3000,"start":4278,"enrollment":34,"conditions":10289,"interventions":10290},"NCT02779075","Exendin-9,39 and Satiety After Bariatric Surgery",[94],"2019-07",[15],[3779,6977],{"intervention":5635,"totalTrials":120,"cells":10292},{"EARLY_PHASE1":10293,"PHASE1":10295,"PHASE2":10297,"PHASE3":10361,"PHASE4":10363,"NA":10365},{"trials":10294,"activeCount":128},[],{"trials":10296,"activeCount":128},[],{"trials":10298,"activeCount":676,"soonestReadout":81},[10299,10308,10312,10322,10330,10349],{"nctId":10300,"briefTitle":10301,"status":134,"phases":10302,"primaryCompletion":4885,"completion":4885,"start":934,"enrollment":681,"conditions":10303,"interventions":10304},"NCT00573755","Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and\u002For Progesterone Receptor-Positive Metastatic Breast Cancer",[91],[21],[10305,10306,10307,3845],"anastrozole","exemestane","letrozole",{"nctId":79,"briefTitle":80,"status":169,"phases":10309,"primaryCompletion":81,"completion":5625,"start":5626,"enrollment":139,"conditions":10310,"interventions":10311},[91],[5628,5629,579,583,5630],[82,5632,5633,5634,5635,540,165],{"nctId":10313,"briefTitle":10314,"status":104,"phases":10315,"primaryCompletion":10316,"completion":10317,"start":10318,"enrollment":498,"conditions":10319,"interventions":10321},"NCT02657928","Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer",[91],"2018-05-21","2020-10-07","2016-07-08",[7526,7721,502,506,511,10320],"Recurrent Uterine Corpus Carcinoma",[5635,10160],{"nctId":10323,"briefTitle":10324,"status":134,"phases":10325,"primaryCompletion":41,"completion":41,"start":10326,"enrollment":676,"conditions":10327,"interventions":10329},"NCT04577001","Letrozole in Patients With Hepatopulmonary Syndrome",[91],"2021-02-18",[10328],"Hepatopulmonary Syndrome",[5635],{"nctId":10331,"briefTitle":10332,"status":104,"phases":10333,"primaryCompletion":10334,"completion":10334,"start":10335,"enrollment":1472,"conditions":10336,"interventions":10348},"NCT04294225","Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer",[91],"2022-12-12","2020-04-28",[5197,10337,10338,5198,10339,10340,579,580,581,582,10341,7530,10342,10343,10344,10345,10346,10347,6193,6194,6195,6196],"Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Early-Stage Breast Carcinoma","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8",[82,5635],{"nctId":10350,"briefTitle":10351,"status":104,"phases":10352,"primaryCompletion":10353,"completion":10354,"start":10355,"enrollment":173,"conditions":10356,"interventions":10359},"NCT02283658","Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",[91],"2016-06-15","2018-06-21","2014-11-14",[5609,5611,6441,10357,502,506,10358,511,6443],"Ovarian Serous Surface Papillary Adenocarcinoma","Recurrent Ovarian Germ Cell Tumor",[10360,5635],"Everolimus",{"trials":10362,"activeCount":128},[],{"trials":10364,"activeCount":128},[],{"trials":10366,"activeCount":128},[10367],{"nctId":10368,"briefTitle":10369,"status":104,"phases":10370,"primaryCompletion":10371,"completion":10372,"start":10373,"enrollment":10374,"conditions":10375,"interventions":10376},"NCT00719966","Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer",[],"2013-06-13","2020-01-24","2008-09-18",109,[21],[10305,10306,10307],{"intervention":82,"totalTrials":1197,"cells":10378},{"EARLY_PHASE1":10379,"PHASE1":10381,"PHASE2":10391,"PHASE3":10405,"PHASE4":10407,"NA":10409},{"trials":10380,"activeCount":128},[],{"trials":10382,"activeCount":128},[10383,10387],{"nctId":7693,"briefTitle":7694,"status":104,"phases":10384,"primaryCompletion":7696,"completion":7696,"start":3001,"enrollment":3034,"conditions":10385,"interventions":10386},[90],[7698],[5634,82,7700],{"nctId":8490,"briefTitle":8491,"status":104,"phases":10388,"primaryCompletion":8493,"completion":8494,"start":3569,"enrollment":2980,"conditions":10389,"interventions":10390},[90],[7698],[5126,8202,82,8497],{"trials":10392,"activeCount":676,"soonestReadout":81},[10393,10397,10401],{"nctId":10300,"briefTitle":10301,"status":134,"phases":10394,"primaryCompletion":4885,"completion":4885,"start":934,"enrollment":681,"conditions":10395,"interventions":10396},[91],[21],[10305,10306,10307,3845],{"nctId":79,"briefTitle":80,"status":169,"phases":10398,"primaryCompletion":81,"completion":5625,"start":5626,"enrollment":139,"conditions":10399,"interventions":10400},[91],[5628,5629,579,583,5630],[82,5632,5633,5634,5635,540,165],{"nctId":10331,"briefTitle":10332,"status":104,"phases":10402,"primaryCompletion":10334,"completion":10334,"start":10335,"enrollment":1472,"conditions":10403,"interventions":10404},[91],[5197,10337,10338,5198,10339,10340,579,580,581,582,10341,7530,10342,10343,10344,10345,10346,10347,6193,6194,6195,6196],[82,5635],{"trials":10406,"activeCount":128},[],{"trials":10408,"activeCount":128},[],{"trials":10410,"activeCount":128},[10411],{"nctId":10368,"briefTitle":10369,"status":104,"phases":10412,"primaryCompletion":10371,"completion":10372,"start":10373,"enrollment":10374,"conditions":10413,"interventions":10414},[],[21],[10305,10306,10307],{"intervention":10416,"totalTrials":895,"cells":10417},"Atorvastatin",{"EARLY_PHASE1":10418,"PHASE1":10420,"PHASE2":10422,"PHASE3":10441,"PHASE4":10443,"NA":10453},{"trials":10419,"activeCount":128},[],{"trials":10421,"activeCount":128},[],{"trials":10423,"activeCount":676,"soonestReadout":761},[10424,10432],{"nctId":10425,"briefTitle":10426,"status":169,"phases":10427,"primaryCompletion":761,"completion":761,"start":10428,"enrollment":313,"conditions":10429,"interventions":10431},"NCT04679376","Statins for the Treatment of NASH",[91],"2023-01-25",[10430],"NASH - Nonalcoholic Steatohepatitis",[10416],{"nctId":10433,"briefTitle":10434,"status":104,"phases":10435,"primaryCompletion":10436,"completion":10436,"start":10437,"enrollment":773,"conditions":10438,"interventions":10440},"NCT03308578","Statins and CPAP in Adipose Tissue of OSA",[90,91],"2023-12-12","2018-01-08",[10439],"Sleep Apnea, Obstructive",[10416],{"trials":10442,"activeCount":128},[],{"trials":10444,"activeCount":128},[10445],{"nctId":10446,"briefTitle":10447,"status":104,"phases":10448,"primaryCompletion":1021,"completion":1021,"start":934,"enrollment":1300,"conditions":10449,"interventions":10452},"NCT00579098","The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation",[93],[33,10450,7090,10451],"Arrhythmia","Endothelial Dysfunction",[10416],{"trials":10454,"activeCount":128},[10455,10461],{"nctId":10456,"briefTitle":10457,"status":1413,"phases":10458,"primaryCompletion":5033,"completion":5033,"start":2573,"enrollment":128,"conditions":10459,"interventions":10460},"NCT00587379","Effect of Chronic Statin and Viagra Therapy in Persons With Endothelial Cell Dysfunction",[94],[10451],[10416],{"nctId":10462,"briefTitle":10463,"status":104,"phases":10464,"primaryCompletion":2787,"completion":7107,"start":2883,"enrollment":10465,"conditions":10466,"interventions":10468},"NCT01222182","Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA)",[],260,[10467],"Hypercholesterolemia",[10469],"atorvastatin",{"intervention":3745,"totalTrials":895,"cells":10471},{"EARLY_PHASE1":10472,"PHASE1":10474,"PHASE2":10476,"PHASE3":10486,"PHASE4":10488,"NA":10504},{"trials":10473,"activeCount":128},[],{"trials":10475,"activeCount":128},[],{"trials":10477,"activeCount":676,"soonestReadout":3227},[10478,10482],{"nctId":7348,"briefTitle":7349,"status":1413,"phases":10479,"enrollment":128,"conditions":10480,"interventions":10481},[90,91],[3562,3690],[3513,3759,7353,7354,7355],{"nctId":3738,"briefTitle":3739,"status":1096,"phases":10483,"primaryCompletion":3227,"completion":3741,"start":2303,"enrollment":2894,"conditions":10484,"interventions":10485},[91],[36],[3744,57,1698,3745],{"trials":10487,"activeCount":128},[],{"trials":10489,"activeCount":128},[10490,10494],{"nctId":5138,"briefTitle":5139,"status":104,"phases":10491,"primaryCompletion":2643,"completion":5141,"start":5142,"enrollment":1162,"conditions":10492,"interventions":10493},[93],[5144],[5146,5147,3427,3745,4283],{"nctId":10495,"briefTitle":10496,"status":104,"phases":10497,"primaryCompletion":10498,"completion":10498,"start":10499,"enrollment":370,"conditions":10500,"interventions":10503},"NCT04041219","Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients",[93],"2019-10-08","2019-06-17",[10501,8228,10502],"Immunosuppression","Bone Marrow Transplant",[3745,3745],{"trials":10505,"activeCount":128},[10506],{"nctId":5151,"briefTitle":5152,"status":134,"phases":10507,"primaryCompletion":3613,"completion":3613,"start":3546,"enrollment":224,"conditions":10508,"interventions":10509},[94],[5155],[3745,4283,1698,3427],{"intervention":3326,"totalTrials":681,"cells":10511},{"EARLY_PHASE1":10512,"PHASE1":10518,"PHASE2":10520,"PHASE3":10530,"PHASE4":10532,"NA":10534},{"trials":10513,"activeCount":128},[10514],{"nctId":3315,"briefTitle":3316,"status":104,"phases":10515,"primaryCompletion":3318,"completion":3318,"start":3319,"enrollment":817,"conditions":10516,"interventions":10517},[89],[3321,1420],[3323,3324,3325,3326,3327],{"trials":10519,"activeCount":128},[],{"trials":10521,"activeCount":676,"soonestReadout":4080},[10522,10526],{"nctId":4396,"briefTitle":4397,"status":104,"phases":10523,"primaryCompletion":4399,"start":4400,"enrollment":1236,"conditions":10524,"interventions":10525},[91],[4402,1420],[4404,4405,4240,3324,3326,4406],{"nctId":4077,"briefTitle":4078,"status":265,"phases":10527,"primaryCompletion":4080,"completion":4081,"start":4082,"enrollment":2678,"conditions":10528,"interventions":10529},[91],[4084,3422,414,144,4085,3398,4086,4087],[536,4089,4090,305,4091,161,4092,539,163,4093],{"trials":10531,"activeCount":128},[],{"trials":10533,"activeCount":128},[],{"trials":10535,"activeCount":128},[10536],{"nctId":4499,"briefTitle":4500,"status":104,"phases":10537,"primaryCompletion":4502,"completion":4503,"start":4504,"enrollment":25,"conditions":10538,"interventions":10539},[94],[1420],[4240,3324,3326,3622],{"intervention":1698,"totalTrials":342,"cells":10541},{"EARLY_PHASE1":10542,"PHASE1":10544,"PHASE2":10546,"PHASE3":10552,"PHASE4":10554,"NA":10560},{"trials":10543,"activeCount":128},[],{"trials":10545,"activeCount":128},[],{"trials":10547,"activeCount":676,"soonestReadout":3227},[10548],{"nctId":3738,"briefTitle":3739,"status":1096,"phases":10549,"primaryCompletion":3227,"completion":3741,"start":2303,"enrollment":2894,"conditions":10550,"interventions":10551},[91],[36],[3744,57,1698,3745],{"trials":10553,"activeCount":128},[],{"trials":10555,"activeCount":128},[10556],{"nctId":5138,"briefTitle":5139,"status":104,"phases":10557,"primaryCompletion":2643,"completion":5141,"start":5142,"enrollment":1162,"conditions":10558,"interventions":10559},[93],[5144],[5146,5147,3427,3745,4283],{"trials":10561,"activeCount":128},[10562],{"nctId":5151,"briefTitle":5152,"status":134,"phases":10563,"primaryCompletion":3613,"completion":3613,"start":3546,"enrollment":224,"conditions":10564,"interventions":10565},[94],[5155],[3745,4283,1698,3427],{"intervention":10306,"totalTrials":342,"cells":10567},{"EARLY_PHASE1":10568,"PHASE1":10570,"PHASE2":10572,"PHASE3":10582,"PHASE4":10584,"NA":10586},{"trials":10569,"activeCount":128},[],{"trials":10571,"activeCount":128},[],{"trials":10573,"activeCount":676,"soonestReadout":81},[10574,10578],{"nctId":10300,"briefTitle":10301,"status":134,"phases":10575,"primaryCompletion":4885,"completion":4885,"start":934,"enrollment":681,"conditions":10576,"interventions":10577},[91],[21],[10305,10306,10307,3845],{"nctId":79,"briefTitle":80,"status":169,"phases":10579,"primaryCompletion":81,"completion":5625,"start":5626,"enrollment":139,"conditions":10580,"interventions":10581},[91],[5628,5629,579,583,5630],[82,5632,5633,5634,5635,540,165],{"trials":10583,"activeCount":128},[],{"trials":10585,"activeCount":128},[],{"trials":10587,"activeCount":128},[10588],{"nctId":10368,"briefTitle":10369,"status":104,"phases":10589,"primaryCompletion":10371,"completion":10372,"start":10373,"enrollment":10374,"conditions":10590,"interventions":10591},[],[21],[10305,10306,10307],{"intervention":3622,"totalTrials":342,"cells":10593},{"EARLY_PHASE1":10594,"PHASE1":10596,"PHASE2":10598,"PHASE3":10608,"PHASE4":10610,"NA":10612},{"trials":10595,"activeCount":128},[],{"trials":10597,"activeCount":128},[],{"trials":10599,"activeCount":676,"soonestReadout":496},[10600,10604],{"nctId":3610,"briefTitle":3611,"status":1413,"phases":10601,"primaryCompletion":905,"completion":2697,"start":3613,"enrollment":128,"conditions":10602,"interventions":10603},[91],[3615,3616,3617,3618,3619],[3621,3553,3323,3324,3327,3622,3623,3525,3624,3514,3625],{"nctId":7210,"briefTitle":7211,"status":265,"phases":10605,"primaryCompletion":496,"completion":496,"start":1935,"enrollment":558,"conditions":10606,"interventions":10607},[91],[7214,7215,7216,4237,7217,4481,7218,7219,7220,7221,7222,7223,7224,7225,7226,7227,7228,7229],[2725,7231,7232],{"trials":10609,"activeCount":128},[],{"trials":10611,"activeCount":128},[],{"trials":10613,"activeCount":128},[10614],{"nctId":4499,"briefTitle":4500,"status":104,"phases":10615,"primaryCompletion":4502,"completion":4503,"start":4504,"enrollment":25,"conditions":10616,"interventions":10617},[94],[1420],[4240,3324,3326,3622],{"intervention":3404,"totalTrials":342,"cells":10619},{"EARLY_PHASE1":10620,"PHASE1":10622,"PHASE2":10636,"PHASE3":10638,"PHASE4":10640,"NA":10642},{"trials":10621,"activeCount":128},[],{"trials":10623,"activeCount":342,"soonestReadout":3457},[10624,10628,10632],{"nctId":3390,"briefTitle":3391,"status":265,"phases":10625,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":97,"conditions":10626,"interventions":10627},[90],[3396,432,414,415,416,417,439,3397,443,3398,445,3399,3400,447,3401],[3403,3404,57,3405],{"nctId":3454,"briefTitle":3455,"status":265,"phases":10629,"primaryCompletion":3457,"completion":3458,"start":137,"enrollment":558,"conditions":10630,"interventions":10631},[90],[373,432,439,3397,442,443,447,3401],[3461,3404,57,3405],{"nctId":3485,"briefTitle":3486,"status":265,"phases":10633,"primaryCompletion":3488,"completion":3488,"start":3489,"enrollment":218,"conditions":10634,"interventions":10635},[90],[3491,3492,3493,502,3494,3495,506,507,3496,3497,511,515,3498,3499,3500,3501],[3470,3404,57],{"trials":10637,"activeCount":128},[],{"trials":10639,"activeCount":128},[],{"trials":10641,"activeCount":128},[],{"trials":10643,"activeCount":128},[],{"intervention":10645,"totalTrials":224,"cells":10646},"Autologous adipose derived mesenchymal stromal cells",{"EARLY_PHASE1":10647,"PHASE1":10649,"PHASE2":10669,"PHASE3":10671,"PHASE4":10673,"NA":10675},{"trials":10648,"activeCount":128},[],{"trials":10650,"activeCount":224,"soonestReadout":6807},[10651,10660],{"nctId":10652,"briefTitle":10653,"status":1096,"phases":10654,"primaryCompletion":10655,"completion":2279,"start":2111,"enrollment":173,"conditions":10656,"interventions":10659},"NCT06649864","Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications",[90],"2028-01",[10657,10658],"Liver Transplant; Complications","Liver Diseases",[10645],{"nctId":10661,"briefTitle":10662,"status":169,"phases":10663,"primaryCompletion":6807,"completion":761,"start":10664,"enrollment":2555,"conditions":10665,"interventions":10667},"NCT03608579","Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA",[90],"2018-11-05",[10666],"Osteoarthritis, Hip",[10668],"Autologous Adipose Derived Mesenchymal Stromal Cells",{"trials":10670,"activeCount":128},[],{"trials":10672,"activeCount":128},[],{"trials":10674,"activeCount":128},[],{"trials":10676,"activeCount":128},[],{"intervention":3470,"totalTrials":224,"cells":10678},{"EARLY_PHASE1":10679,"PHASE1":10681,"PHASE2":10691,"PHASE3":10693,"PHASE4":10695,"NA":10697},{"trials":10680,"activeCount":128},[],{"trials":10682,"activeCount":224,"soonestReadout":3466},[10683,10687],{"nctId":3463,"briefTitle":3464,"status":169,"phases":10684,"primaryCompletion":3466,"completion":3466,"start":3467,"enrollment":895,"conditions":10685,"interventions":10686},[90],[303,3447],[3470,57],{"nctId":3485,"briefTitle":3486,"status":265,"phases":10688,"primaryCompletion":3488,"completion":3488,"start":3489,"enrollment":218,"conditions":10689,"interventions":10690},[90],[3491,3492,3493,502,3494,3495,506,507,3496,3497,511,515,3498,3499,3500,3501],[3470,3404,57],{"trials":10692,"activeCount":128},[],{"trials":10694,"activeCount":128},[],{"trials":10696,"activeCount":128},[],{"trials":10698,"activeCount":128},[],{"intervention":179,"totalTrials":2563,"cells":10700},{"EARLY_PHASE1":10701,"PHASE1":10703,"PHASE2":10713,"PHASE3":10754,"PHASE4":10756,"NA":10758},{"trials":10702,"activeCount":128},[],{"trials":10704,"activeCount":676,"soonestReadout":171},[10705,10709],{"nctId":3802,"briefTitle":3803,"status":134,"phases":10706,"primaryCompletion":3805,"completion":3805,"start":3806,"enrollment":108,"conditions":10707,"interventions":10708},[90],[303,3447],[305,179,551],{"nctId":167,"briefTitle":168,"status":169,"phases":10710,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":10711,"interventions":10712},[90],[122,175,176,123,124,125,177],[179,72],{"trials":10714,"activeCount":128},[10715,10724,10733,10737,10741,10745],{"nctId":10716,"briefTitle":10717,"status":104,"phases":10718,"primaryCompletion":10719,"completion":10720,"start":10721,"enrollment":3726,"conditions":10722,"interventions":10723},"NCT02649387","Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy",[91],"2023-12-14","2026-01-15","2016-02-08",[3575,3577,3579,3581],[179],{"nctId":10725,"briefTitle":10726,"status":134,"phases":10727,"primaryCompletion":10728,"completion":10728,"start":10729,"enrollment":224,"conditions":10730,"interventions":10732},"NCT06271616","Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant",[91],"2026-05-14","2024-12-13",[10731,36],"Chronic Graft Versus Host Disease",[179],{"nctId":4157,"briefTitle":4158,"status":134,"phases":10734,"primaryCompletion":4160,"completion":4161,"start":4162,"enrollment":2563,"conditions":10735,"interventions":10736},[91],[432,4164,439,443,447],[159,179],{"nctId":3923,"briefTitle":3924,"status":1413,"phases":10738,"primaryCompletion":3926,"completion":3926,"start":2698,"enrollment":128,"conditions":10739,"interventions":10740},[91],[3654,3928],[3680,305,179],{"nctId":424,"briefTitle":425,"status":104,"phases":10742,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":10743,"interventions":10744},[91],[373,432,433,434,435,436,437,417,438,439,440,441,442,443,444,445,446,151,447,448,449,450,451],[179,453,72],{"nctId":10746,"briefTitle":10747,"status":134,"phases":10748,"primaryCompletion":10749,"completion":10750,"start":10751,"enrollment":3674,"conditions":10752,"interventions":10753},"NCT03506373","Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia",[91],"2023-02-06","2026-02-03","2018-08-14",[441,449,451],[179,306],{"trials":10755,"activeCount":128},[],{"trials":10757,"activeCount":128},[],{"trials":10759,"activeCount":128},[],{"intervention":3354,"totalTrials":681,"cells":10761},{"EARLY_PHASE1":10762,"PHASE1":10764,"PHASE2":10774,"PHASE3":10784,"PHASE4":10786,"NA":10788},{"trials":10763,"activeCount":128},[],{"trials":10765,"activeCount":676,"soonestReadout":56},[10766,10770],{"nctId":3331,"briefTitle":3332,"status":134,"phases":10767,"primaryCompletion":3334,"completion":3335,"start":3336,"enrollment":681,"conditions":10768,"interventions":10769},[90],[3338,561,143,3339,3340,3341,3342,3343,3344,3345,3346,3347,3348,3349,3350,3351,3352],[57,3354,3355],{"nctId":54,"briefTitle":55,"status":169,"phases":10771,"primaryCompletion":56,"completion":3408,"start":3409,"enrollment":773,"conditions":10772,"interventions":10773},[90],[3411,3412,3413,3414,3415,3416,3417,3418,3419,3420,3421,3422,3423,413],[57,347,3425,3354,3426,3427,163,3428],{"trials":10775,"activeCount":128},[10776,10780],{"nctId":3541,"briefTitle":3542,"status":104,"phases":10777,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":10778,"interventions":10779},[91],[3549,1419],[3551,3552,3553,3323,3554],{"nctId":3627,"briefTitle":3628,"status":104,"phases":10781,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":10782,"interventions":10783},[90,91],[1419],[3552,3553,3323,3324,3539,3525,3327,3636],{"trials":10785,"activeCount":128},[],{"trials":10787,"activeCount":128},[],{"trials":10789,"activeCount":128},[],{"intervention":3327,"totalTrials":681,"cells":10791},{"EARLY_PHASE1":10792,"PHASE1":10798,"PHASE2":10804,"PHASE3":10814,"PHASE4":10816,"NA":10818},{"trials":10793,"activeCount":128},[10794],{"nctId":3315,"briefTitle":3316,"status":104,"phases":10795,"primaryCompletion":3318,"completion":3318,"start":3319,"enrollment":817,"conditions":10796,"interventions":10797},[89],[3321,1420],[3323,3324,3325,3326,3327],{"trials":10799,"activeCount":676,"soonestReadout":56},[10800],{"nctId":54,"briefTitle":55,"status":169,"phases":10801,"primaryCompletion":56,"completion":3408,"start":3409,"enrollment":773,"conditions":10802,"interventions":10803},[90],[3411,3412,3413,3414,3415,3416,3417,3418,3419,3420,3421,3422,3423,413],[57,347,3425,3354,3426,3427,163,3428],{"trials":10805,"activeCount":128},[10806,10810],{"nctId":3610,"briefTitle":3611,"status":1413,"phases":10807,"primaryCompletion":905,"completion":2697,"start":3613,"enrollment":128,"conditions":10808,"interventions":10809},[91],[3615,3616,3617,3618,3619],[3621,3553,3323,3324,3327,3622,3623,3525,3624,3514,3625],{"nctId":3627,"briefTitle":3628,"status":104,"phases":10811,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":10812,"interventions":10813},[90,91],[1419],[3552,3553,3323,3324,3539,3525,3327,3636],{"trials":10815,"activeCount":128},[],{"trials":10817,"activeCount":128},[],{"trials":10819,"activeCount":128},[],{"intervention":210,"totalTrials":342,"cells":10821},{"EARLY_PHASE1":10822,"PHASE1":10824,"PHASE2":10834,"PHASE3":10840,"PHASE4":10842,"NA":10844},{"trials":10823,"activeCount":128},[],{"trials":10825,"activeCount":676,"soonestReadout":184},[10826,10830],{"nctId":181,"briefTitle":182,"status":169,"phases":10827,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":10828,"interventions":10829},[90],[189,190,191,192,193,194,195,196,197,198,199,200,201,202,122,203,204,205,206,207,208,177],[72,210],{"nctId":6305,"briefTitle":6306,"status":104,"phases":10831,"primaryCompletion":6308,"completion":6309,"start":5405,"enrollment":3719,"conditions":10832,"interventions":10833},[90],[4087,6311,6312,3438,6313,6314,3439,6315,3440,6316,6317],[6319,4093,210],{"trials":10835,"activeCount":128},[10836],{"nctId":6054,"briefTitle":6055,"status":104,"phases":10837,"primaryCompletion":327,"completion":6057,"start":6058,"enrollment":817,"conditions":10838,"interventions":10839},[91],[303,3447],[551,210],{"trials":10841,"activeCount":128},[],{"trials":10843,"activeCount":128},[],{"trials":10845,"activeCount":128},[],{"intervention":223,"totalTrials":342,"cells":10847},{"EARLY_PHASE1":10848,"PHASE1":10850,"PHASE2":10860,"PHASE3":10873,"PHASE4":10875,"NA":10877},{"trials":10849,"activeCount":128},[],{"trials":10851,"activeCount":676,"soonestReadout":51},[10852,10856],{"nctId":212,"briefTitle":213,"status":104,"phases":10853,"primaryCompletion":215,"completion":216,"start":217,"enrollment":218,"conditions":10854,"interventions":10855},[90],[220,154,221],[72,223],{"nctId":49,"briefTitle":50,"status":169,"phases":10857,"primaryCompletion":51,"completion":4999,"start":5000,"enrollment":885,"conditions":10858,"interventions":10859},[90],[607,5002,5003,5004,5005,5006,5007,5008,5009,5010],[52,223,5012],{"trials":10861,"activeCount":128},[10862],{"nctId":10863,"briefTitle":10864,"status":104,"phases":10865,"primaryCompletion":10866,"completion":10867,"start":4885,"enrollment":355,"conditions":10868,"interventions":10870},"NCT01732445","Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis",[91],"2016-07-14","2017-08-10",[10869,6315,3523],"Anemia",[10871,10872],"ruxolitinib phosphate","danazol",{"trials":10874,"activeCount":128},[],{"trials":10876,"activeCount":128},[],{"trials":10878,"activeCount":128},[],{"intervention":10880,"totalTrials":224,"cells":10881},"aldesleukin",{"EARLY_PHASE1":10882,"PHASE1":10884,"PHASE2":10890,"PHASE3":10900,"PHASE4":10902,"NA":10904},{"trials":10883,"activeCount":128},[],{"trials":10885,"activeCount":676,"soonestReadout":4562},[10886],{"nctId":4559,"briefTitle":4560,"status":265,"phases":10887,"primaryCompletion":4562,"completion":4563,"start":4564,"enrollment":4565,"conditions":10888,"interventions":10889},[90],[193,4344,528,4567,4353],[4569,537,538,112,539],{"trials":10891,"activeCount":128},[10892],{"nctId":10893,"briefTitle":10894,"status":104,"phases":10895,"primaryCompletion":2643,"completion":2643,"start":4400,"enrollment":4565,"conditions":10896,"interventions":10897},"NCT00616720","Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma",[91],[3665],[10880,10898,10899,5425,3599],"idiotype-pulsed autologous dendritic cell vaccine APC8020","recombinant interferon gamma",{"trials":10901,"activeCount":128},[],{"trials":10903,"activeCount":128},[],{"trials":10905,"activeCount":128},[],{"intervention":10907,"totalTrials":676,"cells":10908},"Single Application of Adipose Derived Mesenchymal Stem Cells",{"EARLY_PHASE1":10909,"PHASE1":10911,"PHASE2":10924,"PHASE3":10926,"PHASE4":10928,"NA":10930},{"trials":10910,"activeCount":128},[],{"trials":10912,"activeCount":676,"soonestReadout":761},[10913],{"nctId":10914,"briefTitle":10915,"status":169,"phases":10916,"primaryCompletion":761,"completion":761,"start":10917,"enrollment":10918,"conditions":10919,"interventions":10922},"NCT02808208","Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure",[90],"2017-06-07",74,[10920,10921],"End Stage Renal Disease (ESRD)","Vascular Access Complication",[10907,10923],"Two Applications of Adipose Derived Mesenchymal Stem Cells",{"trials":10925,"activeCount":128},[],{"trials":10927,"activeCount":128},[],{"trials":10929,"activeCount":128},[],{"trials":10931,"activeCount":128},[],{"intervention":10923,"totalTrials":676,"cells":10933},{"EARLY_PHASE1":10934,"PHASE1":10936,"PHASE2":10942,"PHASE3":10944,"PHASE4":10946,"NA":10948},{"trials":10935,"activeCount":128},[],{"trials":10937,"activeCount":676,"soonestReadout":761},[10938],{"nctId":10914,"briefTitle":10915,"status":169,"phases":10939,"primaryCompletion":761,"completion":761,"start":10917,"enrollment":10918,"conditions":10940,"interventions":10941},[90],[10920,10921],[10907,10923],{"trials":10943,"activeCount":128},[],{"trials":10945,"activeCount":128},[],{"trials":10947,"activeCount":128},[],{"trials":10949,"activeCount":128},[],{"intervention":10951,"totalTrials":676,"cells":10952},"Axl\u002FMer\u002FCSF1R Inhibitor Q702",{"EARLY_PHASE1":10953,"PHASE1":10955,"PHASE2":10989,"PHASE3":10991,"PHASE4":10993,"NA":10995},{"trials":10954,"activeCount":128},[],{"trials":10956,"activeCount":676,"soonestReadout":10961},[10957],{"nctId":10958,"briefTitle":10959,"status":265,"phases":10960,"primaryCompletion":10961,"completion":10961,"start":6642,"enrollment":3767,"conditions":10962,"interventions":10988},"NCT06712810","Q702 for the Treatment of Patients With Hematologic Malignancies",[90],"2030-09-15",[36,10963,10964,4988,10965,432,10966,415,10967,437,10968,10969,439,441,443,10970,10971,445,10972,446,10973,10974,447,449,10975,10976,10977,10978,10979,10980,10981,10982,10983,10984,10985,10986,10987],"Histiocytic Sarcoma","Malignant Histiocytosis","Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Recurrent Chronic Myelomonocytic Leukemia","Recurrent Langerhans Cell Histiocytosis","Recurrent Myelodysplastic Syndrome","Recurrent Myelofibrosis","Refractory Chronic Myelomonocytic Leukemia","Refractory Erdheim-Chester Disease","Refractory Langerhans Cell Histiocytosis","Refractory Myelodysplastic Syndrome","Refractory Myelofibrosis","Rosai-Dorfman-Destombes Disease","Primary Central Nervous System Lymphoma","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","Recurrent Erdheim-Chester Disease","Recurrent Fibroblastic Reticular Cell Sarcoma","Recurrent Histiocytic Sarcoma","Recurrent Interdigitating Dendritic Cell Sarcoma","Recurrent Rosai-Dorfman-Destombes Disease","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","Refractory Fibroblastic Reticular Cell Sarcoma","Refractory Histiocytic Sarcoma","Refractory Interdigitating Dendritic Cell Sarcoma","Refractory Rosai-Dorfman-Destombes Disease",[10951],{"trials":10990,"activeCount":128},[],{"trials":10992,"activeCount":128},[],{"trials":10994,"activeCount":128},[],{"trials":10996,"activeCount":128},[],{"intervention":4664,"totalTrials":676,"cells":10998},{"EARLY_PHASE1":10999,"PHASE1":11001,"PHASE2":11007,"PHASE3":11009,"PHASE4":11011,"NA":11013},{"trials":11000,"activeCount":128},[],{"trials":11002,"activeCount":676,"soonestReadout":4206},[11003],{"nctId":4652,"briefTitle":4653,"status":265,"phases":11004,"primaryCompletion":4206,"completion":4655,"start":4656,"enrollment":2742,"conditions":11005,"interventions":11006},[90],[4658,4659,4660,4661,4662],[4645,4664],{"trials":11008,"activeCount":128},[],{"trials":11010,"activeCount":128},[],{"trials":11012,"activeCount":128},[],{"trials":11014,"activeCount":128},[],{"intervention":47,"totalTrials":676,"cells":11016},{"EARLY_PHASE1":11017,"PHASE1":11019,"PHASE2":11030,"PHASE3":11032,"PHASE4":11034,"NA":11036},{"trials":11018,"activeCount":128},[],{"trials":11020,"activeCount":676,"soonestReadout":46},[11021],{"nctId":44,"briefTitle":45,"status":169,"phases":11022,"primaryCompletion":46,"completion":11023,"start":11024,"enrollment":11025,"conditions":11026,"interventions":11029},[90],"2031-02-06","2019-12-20",56,[11027,285,201,11028,207],"Anaplastic Astrocytoma, IDH-Wildtype","Metastatic Malignant Neoplasm in the Central Nervous System",[47],{"trials":11031,"activeCount":128},[],{"trials":11033,"activeCount":128},[],{"trials":11035,"activeCount":128},[],{"trials":11037,"activeCount":128},[],{"intervention":3403,"totalTrials":676,"cells":11039},{"EARLY_PHASE1":11040,"PHASE1":11042,"PHASE2":11048,"PHASE3":11050,"PHASE4":11052,"NA":11054},{"trials":11041,"activeCount":128},[],{"trials":11043,"activeCount":676,"soonestReadout":3393},[11044],{"nctId":3390,"briefTitle":3391,"status":265,"phases":11045,"primaryCompletion":3393,"completion":3393,"start":3394,"enrollment":97,"conditions":11046,"interventions":11047},[90],[3396,432,414,415,416,417,439,3397,443,3398,445,3399,3400,447,3401],[3403,3404,57,3405],{"trials":11049,"activeCount":128},[],{"trials":11051,"activeCount":128},[],{"trials":11053,"activeCount":128},[],{"trials":11055,"activeCount":128},[],{"intervention":11057,"totalTrials":676,"cells":11058},"Onvansertib",{"EARLY_PHASE1":11059,"PHASE1":11061,"PHASE2":11075,"PHASE3":11077,"PHASE4":11079,"NA":11081},{"trials":11060,"activeCount":128},[],{"trials":11062,"activeCount":676,"soonestReadout":11067},[11063],{"nctId":11064,"briefTitle":11065,"status":265,"phases":11066,"primaryCompletion":11067,"completion":1149,"start":11068,"enrollment":558,"conditions":11069,"interventions":11074},"NCT05549661","Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome\u002FMPN Overlap Neoplasms",[90],"2027-06-01","2023-04-04",[10966,10970,11070,11071,11072,11073],"Myelodysplastic\u002FMyeloproliferative Neoplasm, Not Otherwise Specified","Recurrent Atypical Chronic Myeloid Leukemia","Recurrent Myelodysplastic\u002FMyeloproliferative Neoplasm","Refractory Myelodysplastic\u002FMyeloproliferative Neoplasm",[11057],{"trials":11076,"activeCount":128},[],{"trials":11078,"activeCount":128},[],{"trials":11080,"activeCount":128},[],{"trials":11082,"activeCount":128},[],{"intervention":11084,"totalTrials":676,"cells":11085},"Adipose-derived stromal cells",{"EARLY_PHASE1":11086,"PHASE1":11088,"PHASE2":11097,"PHASE3":11099,"PHASE4":11101,"NA":11103},{"trials":11087,"activeCount":128},[],{"trials":11089,"activeCount":676,"soonestReadout":737},[11090],{"nctId":11091,"briefTitle":11092,"status":692,"phases":11093,"primaryCompletion":737,"completion":737,"start":1318,"enrollment":218,"conditions":11094,"interventions":11096},"NCT02375802","Adipose-Derived Stromal Cells (ASC's) for Pressure Ulcers",[90],[11095],"Pressure Ulcer",[11084,11084],{"trials":11098,"activeCount":128},[],{"trials":11100,"activeCount":128},[],{"trials":11102,"activeCount":128},[],{"trials":11104,"activeCount":128},[],{"intervention":11106,"totalTrials":676,"cells":11107},"Adipose derived, autologous mesenchymal stem cells",{"EARLY_PHASE1":11108,"PHASE1":11110,"PHASE2":11120,"PHASE3":11122,"PHASE4":11124,"NA":11126},{"trials":11109,"activeCount":128},[],{"trials":11111,"activeCount":676,"soonestReadout":6807},[11112],{"nctId":11113,"briefTitle":11114,"status":169,"phases":11115,"primaryCompletion":6807,"completion":761,"start":11116,"enrollment":173,"conditions":11117,"interventions":11119},"NCT04312113","Angiographic Delivery of AD-MSC for Ulcerative Colitis",[90],"2020-11-16",[11118],"Ulcerative Colitis",[11106],{"trials":11121,"activeCount":128},[],{"trials":11123,"activeCount":128},[],{"trials":11125,"activeCount":128},[],{"trials":11127,"activeCount":128},[],{"intervention":11129,"totalTrials":676,"cells":11130},"Autologous HPV6 E6-and E7-derived peptide-loaded dendritic cell",{"EARLY_PHASE1":11131,"PHASE1":11133,"PHASE2":11142,"PHASE3":11144,"PHASE4":11146,"NA":11148},{"trials":11132,"activeCount":128},[],{"trials":11134,"activeCount":676,"soonestReadout":3011},[11135],{"nctId":11136,"briefTitle":11137,"status":265,"phases":11138,"primaryCompletion":3011,"completion":2111,"start":760,"enrollment":476,"conditions":11139,"interventions":11141},"NCT07317154","Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients",[90],[11140],"Recurrent Respiratory Papillomatosis",[11129],{"trials":11143,"activeCount":128},[],{"trials":11145,"activeCount":128},[],{"trials":11147,"activeCount":128},[],{"trials":11149,"activeCount":128},[],{"intervention":11151,"totalTrials":676,"cells":11152},"Low dose adipose tissue derived mesenchymal stromal cells",{"EARLY_PHASE1":11153,"PHASE1":11155,"PHASE2":11166,"PHASE3":11168,"PHASE4":11170,"NA":11172},{"trials":11154,"activeCount":128},[],{"trials":11156,"activeCount":676,"soonestReadout":760},[11157],{"nctId":11158,"briefTitle":11159,"status":265,"phases":11160,"primaryCompletion":760,"completion":760,"start":11161,"enrollment":218,"conditions":11162,"interventions":11164},"NCT05456243","Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients",[90],"2023-01-30",[11163],"Kidney Transplant",[11151,11165],"High dose adipose tissue derived mesenchymal stromal cells",{"trials":11167,"activeCount":128},[],{"trials":11169,"activeCount":128},[],{"trials":11171,"activeCount":128},[],{"trials":11173,"activeCount":128},[],{"intervention":11165,"totalTrials":676,"cells":11175},{"EARLY_PHASE1":11176,"PHASE1":11178,"PHASE2":11184,"PHASE3":11186,"PHASE4":11188,"NA":11190},{"trials":11177,"activeCount":128},[],{"trials":11179,"activeCount":676,"soonestReadout":760},[11180],{"nctId":11158,"briefTitle":11159,"status":265,"phases":11181,"primaryCompletion":760,"completion":760,"start":11161,"enrollment":218,"conditions":11182,"interventions":11183},[90],[11163],[11151,11165],{"trials":11185,"activeCount":128},[],{"trials":11187,"activeCount":128},[],{"trials":11189,"activeCount":128},[],{"trials":11191,"activeCount":128},[],{"intervention":11193,"totalTrials":676,"cells":11194},"Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein",{"EARLY_PHASE1":11195,"PHASE1":11197,"PHASE2":11208,"PHASE3":11210,"PHASE4":11212,"NA":11214},{"trials":11196,"activeCount":128},[],{"trials":11198,"activeCount":676,"soonestReadout":11203},[11199],{"nctId":11200,"briefTitle":11201,"status":265,"phases":11202,"primaryCompletion":11203,"completion":11203,"start":11204,"enrollment":270,"conditions":11205,"interventions":11207},"NCT04521764","A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer",[90],"2027-08-15","2020-09-23",[583,7530,11206,143,154],"Metastatic Breast Adenocarcinoma",[11193],{"trials":11209,"activeCount":128},[],{"trials":11211,"activeCount":128},[],{"trials":11213,"activeCount":128},[],{"trials":11215,"activeCount":128},[],{"intervention":11217,"totalTrials":676,"cells":11218},"FET-PET\u002FMRI",{"EARLY_PHASE1":11219,"PHASE1":11221,"PHASE2":11231,"PHASE3":11233,"PHASE4":11235,"NA":11237},{"trials":11220,"activeCount":128},[],{"trials":11222,"activeCount":676,"soonestReadout":761},[11223],{"nctId":11224,"briefTitle":11225,"status":265,"phases":11226,"primaryCompletion":761,"completion":761,"start":11227,"enrollment":895,"conditions":11228,"interventions":11230},"NCT07456878","Use of [18F] Fluoroethyl-L-tyrosine PET\u002FMRI for Identifying Small Functional Pituitary Adenomas",[90],"2026-01-08",[11229],"Pituitary Adenoma",[11217],{"trials":11232,"activeCount":128},[],{"trials":11234,"activeCount":128},[],{"trials":11236,"activeCount":128},[],{"trials":11238,"activeCount":128},[],{"intervention":3425,"totalTrials":676,"cells":11240},{"EARLY_PHASE1":11241,"PHASE1":11243,"PHASE2":11249,"PHASE3":11251,"PHASE4":11253,"NA":11255},{"trials":11242,"activeCount":128},[],{"trials":11244,"activeCount":676,"soonestReadout":56},[11245],{"nctId":54,"briefTitle":55,"status":169,"phases":11246,"primaryCompletion":56,"completion":3408,"start":3409,"enrollment":773,"conditions":11247,"interventions":11248},[90],[3411,3412,3413,3414,3415,3416,3417,3418,3419,3420,3421,3422,3423,413],[57,347,3425,3354,3426,3427,163,3428],{"trials":11250,"activeCount":128},[],{"trials":11252,"activeCount":128},[],{"trials":11254,"activeCount":128},[],{"trials":11256,"activeCount":128},[],{"intervention":3426,"totalTrials":676,"cells":11258},{"EARLY_PHASE1":11259,"PHASE1":11261,"PHASE2":11267,"PHASE3":11269,"PHASE4":11271,"NA":11273},{"trials":11260,"activeCount":128},[],{"trials":11262,"activeCount":676,"soonestReadout":56},[11263],{"nctId":54,"briefTitle":55,"status":169,"phases":11264,"primaryCompletion":56,"completion":3408,"start":3409,"enrollment":773,"conditions":11265,"interventions":11266},[90],[3411,3412,3413,3414,3415,3416,3417,3418,3419,3420,3421,3422,3423,413],[57,347,3425,3354,3426,3427,163,3428],{"trials":11268,"activeCount":128},[],{"trials":11270,"activeCount":128},[],{"trials":11272,"activeCount":128},[],{"trials":11274,"activeCount":128},[],{"intervention":11276,"totalTrials":676,"cells":11277},"SCD1 Inhibitor MTI-301",{"EARLY_PHASE1":11278,"PHASE1":11280,"PHASE2":11290,"PHASE3":11292,"PHASE4":11294,"NA":11296},{"trials":11279,"activeCount":128},[],{"trials":11281,"activeCount":676,"soonestReadout":11286},[11282],{"nctId":11283,"briefTitle":11284,"status":265,"phases":11285,"primaryCompletion":11286,"completion":11286,"start":11287,"enrollment":7658,"conditions":11288,"interventions":11289},"NCT06911008","MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers",[90],"2027-04-09","2025-11-07",[202,5184,208],[11276],{"trials":11291,"activeCount":128},[],{"trials":11293,"activeCount":128},[],{"trials":11295,"activeCount":128},[],{"trials":11297,"activeCount":128},[],{"intervention":3451,"totalTrials":676,"cells":11299},{"EARLY_PHASE1":11300,"PHASE1":11302,"PHASE2":11308,"PHASE3":11310,"PHASE4":11312,"NA":11314},{"trials":11301,"activeCount":128},[],{"trials":11303,"activeCount":676,"soonestReadout":1738},[11304],{"nctId":3430,"briefTitle":3431,"status":265,"phases":11305,"primaryCompletion":1738,"completion":3433,"start":3434,"enrollment":3435,"conditions":11306,"interventions":11307},[90],[3396,3437,3438,3439,3440,3441,3442,145,303,147,418,3443,3444,3445,150,3446,3447,153,3448],[57,52,3450,3451,3452,112],{"trials":11309,"activeCount":128},[],{"trials":11311,"activeCount":128},[],{"trials":11313,"activeCount":128},[],{"trials":11315,"activeCount":128},[],{"intervention":11317,"totalTrials":676,"cells":11318},"Lactated Ringers Solution for",{"EARLY_PHASE1":11319,"PHASE1":11321,"PHASE2":11333,"PHASE3":11335,"PHASE4":11337,"NA":11339},{"trials":11320,"activeCount":128},[],{"trials":11322,"activeCount":676,"soonestReadout":171},[11323],{"nctId":11324,"briefTitle":11325,"status":265,"phases":11326,"primaryCompletion":171,"completion":861,"start":7706,"enrollment":498,"conditions":11327,"interventions":11332},"NCT03723564","Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia",[90],[11328,11329,11330,11331],"Renal Failure Congenital","Congenital Renal Anomaly Nos","Renal Agenesis and Dysgenesis","Lower Urinary Tract Obstructive Syndrome",[11317],{"trials":11334,"activeCount":128},[],{"trials":11336,"activeCount":128},[],{"trials":11338,"activeCount":128},[],{"trials":11340,"activeCount":128},[],{"intervention":3461,"totalTrials":676,"cells":11342},{"EARLY_PHASE1":11343,"PHASE1":11345,"PHASE2":11351,"PHASE3":11353,"PHASE4":11355,"NA":11357},{"trials":11344,"activeCount":128},[],{"trials":11346,"activeCount":676,"soonestReadout":3457},[11347],{"nctId":3454,"briefTitle":3455,"status":265,"phases":11348,"primaryCompletion":3457,"completion":3458,"start":137,"enrollment":558,"conditions":11349,"interventions":11350},[90],[373,432,439,3397,442,443,447,3401],[3461,3404,57,3405],{"trials":11352,"activeCount":128},[],{"trials":11354,"activeCount":128},[],{"trials":11356,"activeCount":128},[],{"trials":11358,"activeCount":128},[],{"intervention":5012,"totalTrials":676,"cells":11360},{"EARLY_PHASE1":11361,"PHASE1":11363,"PHASE2":11369,"PHASE3":11371,"PHASE4":11373,"NA":11375},{"trials":11362,"activeCount":128},[],{"trials":11364,"activeCount":676,"soonestReadout":51},[11365],{"nctId":49,"briefTitle":50,"status":169,"phases":11366,"primaryCompletion":51,"completion":4999,"start":5000,"enrollment":885,"conditions":11367,"interventions":11368},[90],[607,5002,5003,5004,5005,5006,5007,5008,5009,5010],[52,223,5012],{"trials":11370,"activeCount":128},[],{"trials":11372,"activeCount":128},[],{"trials":11374,"activeCount":128},[],{"trials":11376,"activeCount":128},[],{"intervention":11378,"totalTrials":676,"cells":11379},"WSD0628",{"EARLY_PHASE1":11380,"PHASE1":11382,"PHASE2":11393,"PHASE3":11395,"PHASE4":11397,"NA":11399},{"trials":11381,"activeCount":128},[],{"trials":11383,"activeCount":676,"soonestReadout":5867},[11384],{"nctId":11385,"briefTitle":11386,"status":265,"phases":11387,"primaryCompletion":5867,"completion":11388,"start":11389,"enrollment":11390,"conditions":11391,"interventions":11392},"NCT05917145","ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma",[90],"2029-05-31","2024-01-17",94,[330],[11378],{"trials":11394,"activeCount":128},[],{"trials":11396,"activeCount":128},[],{"trials":11398,"activeCount":128},[],{"trials":11400,"activeCount":128},[],{"intervention":11402,"totalTrials":676,"cells":11403},"Allogeneic Adipose-derived Mesenchymal Stem Cells",{"EARLY_PHASE1":11404,"PHASE1":11406,"PHASE2":11417,"PHASE3":11419,"PHASE4":11421,"NA":11423},{"trials":11405,"activeCount":128},[],{"trials":11407,"activeCount":676,"soonestReadout":11412},[11408],{"nctId":11409,"briefTitle":11410,"status":265,"phases":11411,"primaryCompletion":11412,"completion":11412,"start":11413,"enrollment":173,"conditions":11414,"interventions":11416},"NCT05789394","Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy",[90],"2027-07-24","2023-06-16",[273,289,11415],"Astrocytoma, Grade IV",[11402],{"trials":11418,"activeCount":128},[],{"trials":11420,"activeCount":128},[],{"trials":11422,"activeCount":128},[],{"trials":11424,"activeCount":128},[],{"intervention":11426,"totalTrials":676,"cells":11427},"Granulocyte-Macrophage Colony-Stimulating Factor",{"EARLY_PHASE1":11428,"PHASE1":11430,"PHASE2":11440,"PHASE3":11442,"PHASE4":11444,"NA":11446},{"trials":11429,"activeCount":128},[],{"trials":11431,"activeCount":676,"soonestReadout":861},[11432],{"nctId":11433,"briefTitle":11434,"status":265,"phases":11435,"primaryCompletion":861,"completion":861,"start":1651,"enrollment":2980,"conditions":11436,"interventions":11438},"NCT04144023","A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ",[90],[11437],"Breast Ductal Carcinoma In Situ",[11426,11439],"Multi-epitope HER2 Peptide Vaccine H2NVAC",{"trials":11441,"activeCount":128},[],{"trials":11443,"activeCount":128},[],{"trials":11445,"activeCount":128},[],{"trials":11447,"activeCount":128},[],{"intervention":11439,"totalTrials":676,"cells":11449},{"EARLY_PHASE1":11450,"PHASE1":11452,"PHASE2":11458,"PHASE3":11460,"PHASE4":11462,"NA":11464},{"trials":11451,"activeCount":128},[],{"trials":11453,"activeCount":676,"soonestReadout":861},[11454],{"nctId":11433,"briefTitle":11434,"status":265,"phases":11455,"primaryCompletion":861,"completion":861,"start":1651,"enrollment":2980,"conditions":11456,"interventions":11457},[90],[11437],[11426,11439],{"trials":11459,"activeCount":128},[],{"trials":11461,"activeCount":128},[],{"trials":11463,"activeCount":128},[],{"trials":11465,"activeCount":128},[],{"intervention":3324,"totalTrials":476,"cells":11467},{"EARLY_PHASE1":11468,"PHASE1":11474,"PHASE2":11490,"PHASE3":11512,"PHASE4":11514,"NA":11516},{"trials":11469,"activeCount":128},[11470],{"nctId":3315,"briefTitle":3316,"status":104,"phases":11471,"primaryCompletion":3318,"completion":3318,"start":3319,"enrollment":817,"conditions":11472,"interventions":11473},[89],[3321,1420],[3323,3324,3325,3326,3327],{"trials":11475,"activeCount":676,"soonestReadout":56},[11476,11486],{"nctId":11477,"briefTitle":11478,"status":104,"phases":11479,"primaryCompletion":11480,"completion":11480,"start":11481,"conditions":11482,"interventions":11484},"NCT00003038","Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors",[90],"2003-01","1997-10",[11483,21,4854,4292,4293],"Adrenocortical Carcinoma",[3324,11485],"suramin",{"nctId":54,"briefTitle":55,"status":169,"phases":11487,"primaryCompletion":56,"completion":3408,"start":3409,"enrollment":773,"conditions":11488,"interventions":11489},[90],[3411,3412,3413,3414,3415,3416,3417,3418,3419,3420,3421,3422,3423,413],[57,347,3425,3354,3426,3427,163,3428],{"trials":11491,"activeCount":128},[11492,11496,11500,11504,11508],{"nctId":3587,"briefTitle":3588,"status":104,"phases":11493,"primaryCompletion":1563,"completion":3590,"start":3591,"enrollment":936,"conditions":11494,"interventions":11495},[91],[21,3593],[3595,3323,3324,3596,3597,3598,3599],{"nctId":3610,"briefTitle":3611,"status":1413,"phases":11497,"primaryCompletion":905,"completion":2697,"start":3613,"enrollment":128,"conditions":11498,"interventions":11499},[91],[3615,3616,3617,3618,3619],[3621,3553,3323,3324,3327,3622,3623,3525,3624,3514,3625],{"nctId":3627,"briefTitle":3628,"status":104,"phases":11501,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":11502,"interventions":11503},[90,91],[1419],[3552,3553,3323,3324,3539,3525,3327,3636],{"nctId":336,"briefTitle":337,"status":104,"phases":11505,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":11506,"interventions":11507},[91],[344],[346,347,72],{"nctId":4396,"briefTitle":4397,"status":104,"phases":11509,"primaryCompletion":4399,"start":4400,"enrollment":1236,"conditions":11510,"interventions":11511},[91],[4402,1420],[4404,4405,4240,3324,3326,4406],{"trials":11513,"activeCount":128},[],{"trials":11515,"activeCount":128},[],{"trials":11517,"activeCount":128},[11518],{"nctId":4499,"briefTitle":4500,"status":104,"phases":11519,"primaryCompletion":4502,"completion":4503,"start":4504,"enrollment":25,"conditions":11520,"interventions":11521},[94],[1420],[4240,3324,3326,3622],{"intervention":7700,"totalTrials":681,"cells":11523},{"EARLY_PHASE1":11524,"PHASE1":11533,"PHASE2":11539,"PHASE3":11541,"PHASE4":11543,"NA":11563},{"trials":11525,"activeCount":676,"soonestReadout":4999},[11526],{"nctId":11527,"briefTitle":11528,"status":265,"phases":11529,"primaryCompletion":4999,"completion":4999,"start":11530,"enrollment":2555,"conditions":11531,"interventions":11532},"NCT06416969","Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation",[89],"2024-01-01",[15],[7700,2953],{"trials":11534,"activeCount":128},[11535],{"nctId":7693,"briefTitle":7694,"status":104,"phases":11536,"primaryCompletion":7696,"completion":7696,"start":3001,"enrollment":3034,"conditions":11537,"interventions":11538},[90],[7698],[5634,82,7700],{"trials":11540,"activeCount":128},[],{"trials":11542,"activeCount":128},[],{"trials":11544,"activeCount":128},[11545,11555],{"nctId":11546,"briefTitle":11547,"status":1413,"phases":11548,"primaryCompletion":11549,"completion":11550,"start":11551,"enrollment":128,"conditions":11552,"interventions":11553},"NCT03998709","Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion",[93],"2021-12-31","2022-07-31","2020-02-01",[18],[7700,11554],"Insulin",{"nctId":11556,"briefTitle":11557,"status":1413,"phases":11558,"primaryCompletion":11559,"completion":11559,"start":11560,"enrollment":128,"conditions":11561,"interventions":11562},"NCT03998293","Direct Measurement of Proinsulin Clearance in Humans",[93],"2023-12","2022-11",[18],[7700],{"trials":11564,"activeCount":128},[],{"intervention":2953,"totalTrials":224,"cells":11566},{"EARLY_PHASE1":11567,"PHASE1":11573,"PHASE2":11575,"PHASE3":11577,"PHASE4":11579,"NA":11585},{"trials":11568,"activeCount":676,"soonestReadout":4999},[11569],{"nctId":11527,"briefTitle":11528,"status":265,"phases":11570,"primaryCompletion":4999,"completion":4999,"start":11530,"enrollment":2555,"conditions":11571,"interventions":11572},[89],[15],[7700,2953],{"trials":11574,"activeCount":128},[],{"trials":11576,"activeCount":128},[],{"trials":11578,"activeCount":128},[],{"trials":11580,"activeCount":128},[11581],{"nctId":2943,"briefTitle":2944,"status":104,"phases":11582,"primaryCompletion":2946,"completion":2946,"start":874,"enrollment":1162,"conditions":11583,"interventions":11584},[93],[2948],[2950,2951,2952,2953,2910],{"trials":11586,"activeCount":128},[],{"intervention":10238,"totalTrials":224,"cells":11588},{"EARLY_PHASE1":11589,"PHASE1":11602,"PHASE2":11604,"PHASE3":11606,"PHASE4":11608,"NA":11610},{"trials":11590,"activeCount":676,"soonestReadout":3065},[11591,11595],{"nctId":10231,"briefTitle":10232,"status":104,"phases":11592,"primaryCompletion":10234,"completion":10234,"start":10235,"enrollment":218,"conditions":11593,"interventions":11594},[89],[6975,15],[10238,3779],{"nctId":11596,"briefTitle":11597,"status":265,"phases":11598,"primaryCompletion":3065,"completion":3065,"start":11530,"enrollment":1225,"conditions":11599,"interventions":11601},"NCT06175403","A Study of Niacin Regulation",[89],[11600],"Excessive Weight Gain",[10238],{"trials":11603,"activeCount":128},[],{"trials":11605,"activeCount":128},[],{"trials":11607,"activeCount":128},[],{"trials":11609,"activeCount":128},[],{"trials":11611,"activeCount":128},[],{"intervention":11613,"totalTrials":676,"cells":11614},"Aminolevulinic Acid Intravenous Formulation SONALA-001",{"EARLY_PHASE1":11615,"PHASE1":11626,"PHASE2":11628,"PHASE3":11630,"PHASE4":11632,"NA":11634},{"trials":11616,"activeCount":676,"soonestReadout":171},[11617],{"nctId":11618,"briefTitle":11619,"status":265,"phases":11620,"primaryCompletion":171,"completion":171,"start":11621,"enrollment":2563,"conditions":11622,"interventions":11624},"NCT07076472","Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma",[89],"2025-08-14",[287,11623],"Recurrent Glioblastoma",[11613,11625],"Oral Aminolevulinic Acid Hydrochloride",{"trials":11627,"activeCount":128},[],{"trials":11629,"activeCount":128},[],{"trials":11631,"activeCount":128},[],{"trials":11633,"activeCount":128},[],{"trials":11635,"activeCount":128},[],{"intervention":11625,"totalTrials":676,"cells":11637},{"EARLY_PHASE1":11638,"PHASE1":11644,"PHASE2":11646,"PHASE3":11648,"PHASE4":11650,"NA":11652},{"trials":11639,"activeCount":676,"soonestReadout":171},[11640],{"nctId":11618,"briefTitle":11619,"status":265,"phases":11641,"primaryCompletion":171,"completion":171,"start":11621,"enrollment":2563,"conditions":11642,"interventions":11643},[89],[287,11623],[11613,11625],{"trials":11645,"activeCount":128},[],{"trials":11647,"activeCount":128},[],{"trials":11649,"activeCount":128},[],{"trials":11651,"activeCount":128},[],{"trials":11653,"activeCount":128},[],{"intervention":11655,"totalTrials":676,"cells":11656},"Ga68-FAPI-46",{"EARLY_PHASE1":11657,"PHASE1":11671,"PHASE2":11673,"PHASE3":11675,"PHASE4":11677,"NA":11679},{"trials":11658,"activeCount":676,"soonestReadout":8545},[11659],{"nctId":11660,"briefTitle":11661,"status":265,"phases":11662,"primaryCompletion":8545,"completion":11663,"start":11664,"enrollment":461,"conditions":11665,"interventions":11670},"NCT07273188","68Ga-FAPI-46 PET\u002FCT for Assessing Small Bowel Fibrostenosis in Crohn's Disease",[89],"2027-04-30","2026-01-26",[11666,11667,11668,11669],"Crohn's Disease","Intestinal Fibrosis","Inflamatory Bowel Disease","Intestinal Strictures Related to Crohn´s Disease",[11655],{"trials":11672,"activeCount":128},[],{"trials":11674,"activeCount":128},[],{"trials":11676,"activeCount":128},[],{"trials":11678,"activeCount":128},[],{"trials":11680,"activeCount":128},[],{"intervention":11682,"totalTrials":676,"cells":11683},"Growth Hormone",{"EARLY_PHASE1":11684,"PHASE1":11694,"PHASE2":11696,"PHASE3":11698,"PHASE4":11700,"NA":11702},{"trials":11685,"activeCount":676,"soonestReadout":2024},[11686],{"nctId":11687,"briefTitle":11688,"status":265,"phases":11689,"primaryCompletion":2024,"completion":737,"start":11690,"enrollment":370,"conditions":11691,"interventions":11693},"NCT06803589","Growth Hormone for the Treatment of Gastroparesis",[89],"2024-10-22",[11692],"Gastroparesis",[11682],{"trials":11695,"activeCount":128},[],{"trials":11697,"activeCount":128},[],{"trials":11699,"activeCount":128},[],{"trials":11701,"activeCount":128},[],{"trials":11703,"activeCount":128},[],{"intervention":11705,"totalTrials":676,"cells":11706},"Mirtazapine",{"EARLY_PHASE1":11707,"PHASE1":11719,"PHASE2":11721,"PHASE3":11723,"PHASE4":11725,"NA":11727},{"trials":11708,"activeCount":676,"soonestReadout":11713},[11709],{"nctId":11710,"briefTitle":11711,"status":265,"phases":11712,"primaryCompletion":11713,"completion":11713,"start":11714,"enrollment":173,"conditions":11715,"interventions":11718},"NCT06684470","Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator",[89],"2026-12-19","2024-12-19",[11716,11717],"IBS - Irritable Bowel Syndrome","Diarrhea",[11705],{"trials":11720,"activeCount":128},[],{"trials":11722,"activeCount":128},[],{"trials":11724,"activeCount":128},[],{"trials":11726,"activeCount":128},[],{"trials":11728,"activeCount":128},[],{"intervention":11730,"totalTrials":676,"cells":11731},"Magnesium Chloride-based Lotion",{"EARLY_PHASE1":11732,"PHASE1":11742,"PHASE2":11744,"PHASE3":11746,"PHASE4":11748,"NA":11750},{"trials":11733,"activeCount":676,"soonestReadout":11738},[11734],{"nctId":11735,"briefTitle":11736,"status":265,"phases":11737,"primaryCompletion":11738,"completion":11738,"start":11739,"enrollment":25,"conditions":11740,"interventions":11741},"NCT05294367","Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma",[89],"2027-04-01","2022-04-15",[1419],[11730],{"trials":11743,"activeCount":128},[],{"trials":11745,"activeCount":128},[],{"trials":11747,"activeCount":128},[],{"trials":11749,"activeCount":128},[],{"trials":11751,"activeCount":128},[],{"intervention":6711,"totalTrials":676,"cells":11753},{"EARLY_PHASE1":11754,"PHASE1":11760,"PHASE2":11762,"PHASE3":11764,"PHASE4":11766,"NA":11768},{"trials":11755,"activeCount":676,"soonestReadout":3064},[11756],{"nctId":6704,"briefTitle":6705,"status":265,"phases":11757,"primaryCompletion":3064,"completion":4757,"start":6707,"enrollment":108,"conditions":11758,"interventions":11759},[89],[6709,4760],[6699,6711],{"trials":11761,"activeCount":128},[],{"trials":11763,"activeCount":128},[],{"trials":11765,"activeCount":128},[],{"trials":11767,"activeCount":128},[],{"trials":11769,"activeCount":128},[],{"intervention":11771,"totalTrials":676,"cells":11772},"Dupilumab 300 MG\u002F2 ML Subcutaneous Solution [DUPIXENT]",{"EARLY_PHASE1":11773,"PHASE1":11784,"PHASE2":11786,"PHASE3":11788,"PHASE4":11790,"NA":11792},{"trials":11774,"activeCount":676,"soonestReadout":737},[11775],{"nctId":11776,"briefTitle":11777,"status":692,"phases":11778,"primaryCompletion":737,"completion":737,"start":11779,"enrollment":25,"conditions":11780,"interventions":11782},"NCT07358234","Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.",[89],"2026-02-04",[11781],"Eosinophilic Esophagitis (EoE)",[11771,11783],"budesonide oral suspension",{"trials":11785,"activeCount":128},[],{"trials":11787,"activeCount":128},[],{"trials":11789,"activeCount":128},[],{"trials":11791,"activeCount":128},[],{"trials":11793,"activeCount":128},[],{"intervention":11783,"totalTrials":676,"cells":11795},{"EARLY_PHASE1":11796,"PHASE1":11802,"PHASE2":11804,"PHASE3":11806,"PHASE4":11808,"NA":11810},{"trials":11797,"activeCount":676,"soonestReadout":737},[11798],{"nctId":11776,"briefTitle":11777,"status":692,"phases":11799,"primaryCompletion":737,"completion":737,"start":11779,"enrollment":25,"conditions":11800,"interventions":11801},[89],[11781],[11771,11783],{"trials":11803,"activeCount":128},[],{"trials":11805,"activeCount":128},[],{"trials":11807,"activeCount":128},[],{"trials":11809,"activeCount":128},[],{"trials":11811,"activeCount":128},[],{"intervention":11813,"totalTrials":676,"cells":11814},"Gallium Ga 68-DOTATATE",{"EARLY_PHASE1":11815,"PHASE1":11827,"PHASE2":11829,"PHASE3":11831,"PHASE4":11833,"NA":11835},{"trials":11816,"activeCount":676,"soonestReadout":5058},[11817],{"nctId":11818,"briefTitle":11819,"status":169,"phases":11820,"primaryCompletion":5058,"completion":5058,"start":11821,"enrollment":173,"conditions":11822,"interventions":11826},"NCT04040088","An Investigational Scan (68Ga-DOTATATE PET\u002FCT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors",[89],"2019-09-23",[11823,11824,11825],"Ganglioneuroblastoma","Ganglioneuroma","Neuroblastoma",[11813],{"trials":11828,"activeCount":128},[],{"trials":11830,"activeCount":128},[],{"trials":11832,"activeCount":128},[],{"trials":11834,"activeCount":128},[],{"trials":11836,"activeCount":128},[],{"intervention":11838,"totalTrials":676,"cells":11839},"Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET",{"EARLY_PHASE1":11840,"PHASE1":11850,"PHASE2":11852,"PHASE3":11854,"PHASE4":11856,"NA":11858},{"trials":11841,"activeCount":676,"soonestReadout":2893},[11842],{"nctId":11843,"briefTitle":11844,"status":265,"phases":11845,"primaryCompletion":2893,"completion":11846,"start":760,"enrollment":773,"conditions":11847,"interventions":11849},"NCT07460232","FET PET\u002FCT Imaging To Localize Pituitary Adenomas In Cushing Disease",[89],"2028-07",[11848,11229],"Cushing Disease",[11838],{"trials":11851,"activeCount":128},[],{"trials":11853,"activeCount":128},[],{"trials":11855,"activeCount":128},[],{"trials":11857,"activeCount":128},[],{"trials":11859,"activeCount":128},[],{"intervention":11554,"totalTrials":681,"cells":11861},{"EARLY_PHASE1":11862,"PHASE1":11871,"PHASE2":11881,"PHASE3":11883,"PHASE4":11885,"NA":11891},{"trials":11863,"activeCount":676,"soonestReadout":2279},[11864],{"nctId":11865,"briefTitle":11866,"status":265,"phases":11867,"primaryCompletion":2279,"completion":2279,"start":11868,"enrollment":2608,"conditions":11869,"interventions":11870},"NCT06392854","Regional Lipolysis Insulin Regulation",[89],"2024-05-01",[15],[11554],{"trials":11872,"activeCount":128},[11873],{"nctId":11874,"briefTitle":11875,"status":104,"phases":11876,"primaryCompletion":11877,"completion":11877,"start":4885,"enrollment":31,"conditions":11878,"interventions":11879},"NCT01860911","Plasma Triglyceride Extraction by The Muscle",[90],"2016-08-31",[15,6930],[11554,11880],"NG-monomethyl-L-arginine",{"trials":11882,"activeCount":128},[],{"trials":11884,"activeCount":128},[],{"trials":11886,"activeCount":128},[11887],{"nctId":11546,"briefTitle":11547,"status":1413,"phases":11888,"primaryCompletion":11549,"completion":11550,"start":11551,"enrollment":128,"conditions":11889,"interventions":11890},[93],[18],[7700,11554],{"trials":11892,"activeCount":128},[11893],{"nctId":11894,"briefTitle":11895,"status":104,"phases":11896,"primaryCompletion":11897,"completion":11897,"start":1299,"enrollment":11898,"conditions":11899,"interventions":11900},"NCT00166491","Comparing Two Ways of Controlling Blood Sugar With Insulin in Patients Admitted to the Intensive Care Unit",[94],"2007-03",238,[1474,10248],[11554],{"intervention":1369,"totalTrials":895,"cells":11902},{"EARLY_PHASE1":11903,"PHASE1":11905,"PHASE2":11924,"PHASE3":11926,"PHASE4":11928,"NA":11930},{"trials":11904,"activeCount":128},[],{"trials":11906,"activeCount":128},[11907,11911,11920],{"nctId":1353,"briefTitle":1354,"status":104,"phases":11908,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":1358,"conditions":11909,"interventions":11910},[90],[1360,1361,1362,1363,1364,1365,1366,1367],[1369,1346],{"nctId":11912,"briefTitle":11913,"status":104,"phases":11914,"primaryCompletion":2863,"completion":2863,"start":4030,"enrollment":97,"conditions":11915,"interventions":11919},"NCT01723553","Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD",[90],[11916,11917,11918],"Atypical Alzheimers Disease","Logopenic Variant of Primary Progressive Aphasia (LPA)","Posterior Cortical Atrophy (PCA)",[1369],{"nctId":1371,"briefTitle":1372,"status":104,"phases":11921,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":28,"conditions":11922,"interventions":11923},[90],[1377],[1346,1369],{"trials":11925,"activeCount":128},[],{"trials":11927,"activeCount":128},[],{"trials":11929,"activeCount":128},[],{"trials":11931,"activeCount":224,"soonestReadout":2233},[11932,11950],{"nctId":11933,"briefTitle":11934,"status":692,"phases":11935,"primaryCompletion":11936,"completion":11936,"start":11937,"enrollment":1997,"conditions":11938,"interventions":11947},"NCT04680130","Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders",[],"2050-11","2020-11-01",[11939,11940,11941,11942,1364,11943,11944,11945,1360,1365,11946,7196],"PSP","CBD","PCA","LPA","Semantic Aphasia","Behavioral Variant of Frontotemporal Dementia","FTD","MSA - Multiple System Atrophy",[1369,11948,11949],"AV1451 Tau","C-11 ER176",{"nctId":11951,"briefTitle":11952,"status":169,"phases":11953,"primaryCompletion":2233,"completion":2233,"start":1234,"enrollment":25,"conditions":11954,"interventions":11961},"NCT02740634","Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study",[94],[11955,11956,11918,1654,11957,11958,11959,11960],"Atypical Alzheimer's Disease","Logopenic Progressive Aphasia (LPA)","Alzheimer Disease, Early Onset","Amnestic Disorder","Amnestic Symptoms","Amnestic Mild Cognitive Disorder",[11962,1369],"F-18 AV 1451",{"intervention":11962,"totalTrials":342,"cells":11964},{"EARLY_PHASE1":11965,"PHASE1":11967,"PHASE2":11977,"PHASE3":11979,"PHASE4":11981,"NA":11983},{"trials":11966,"activeCount":128},[],{"trials":11968,"activeCount":128},[11969],{"nctId":11970,"briefTitle":11971,"status":104,"phases":11972,"primaryCompletion":11973,"completion":11973,"start":872,"enrollment":696,"conditions":11974,"interventions":11976},"NCT02736695","Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia",[90],"2024-08-01",[1361,11944,11975],"Frontotemporal Dementia, Behavioral Variant",[11962],{"trials":11978,"activeCount":128},[],{"trials":11980,"activeCount":128},[],{"trials":11982,"activeCount":128},[],{"trials":11984,"activeCount":224,"soonestReadout":2233},[11985,11989],{"nctId":11951,"briefTitle":11952,"status":169,"phases":11986,"primaryCompletion":2233,"completion":2233,"start":1234,"enrollment":25,"conditions":11987,"interventions":11988},[94],[11955,11956,11918,1654,11957,11958,11959,11960],[11962,1369],{"nctId":11990,"briefTitle":11991,"status":265,"phases":11992,"primaryCompletion":11993,"completion":11993,"start":7696,"enrollment":11994,"conditions":11995,"interventions":11997},"NCT02605785","A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy",[94],"2030-01",332,[11996],"Progressive Supranuclear Palsy",[11962],{"intervention":11999,"totalTrials":681,"cells":12000},"Omeprazole",{"EARLY_PHASE1":12001,"PHASE1":12011,"PHASE2":12021,"PHASE3":12023,"PHASE4":12025,"NA":12035},{"trials":12002,"activeCount":128},[12003],{"nctId":12004,"briefTitle":12005,"status":1413,"phases":12006,"primaryCompletion":1471,"completion":1471,"start":12007,"enrollment":128,"conditions":12008,"interventions":12010},"NCT01824199","CYP2C19 Genotype Predictor of Gastric Acid Suppression",[89],"2013-03",[12009],"Esophagitis",[11999],{"trials":12012,"activeCount":128},[12013],{"nctId":12014,"briefTitle":12015,"status":104,"phases":12016,"primaryCompletion":4795,"completion":4795,"start":12007,"enrollment":4565,"conditions":12017,"interventions":12019},"NCT01822977","The Impact of Proton Pump Inhibitors on the Fecal Microbiome",[90],[18,12018],"Clostridium Difficile Infection",[12020],"omeprazole",{"trials":12022,"activeCount":128},[],{"trials":12024,"activeCount":128},[],{"trials":12026,"activeCount":128},[12027],{"nctId":12028,"briefTitle":12029,"status":104,"phases":12030,"primaryCompletion":5361,"completion":5361,"start":1357,"enrollment":729,"conditions":12031,"interventions":12033},"NCT01093755","Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?",[93],[7090,12032],"Barrett's Esophagus",[12034,11999],"dexlansoprazole",{"trials":12036,"activeCount":676,"soonestReadout":761},[12037],{"nctId":12038,"briefTitle":12039,"status":265,"phases":12040,"primaryCompletion":761,"completion":761,"start":12041,"enrollment":729,"conditions":12042,"interventions":12043},"NCT05517928","A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis",[94],"2023-03-03",[18],[11999],{"intervention":12045,"totalTrials":224,"cells":12046},"Acetylcholine",{"EARLY_PHASE1":12047,"PHASE1":12049,"PHASE2":12051,"PHASE3":12053,"PHASE4":12055,"NA":12057},{"trials":12048,"activeCount":128},[],{"trials":12050,"activeCount":128},[],{"trials":12052,"activeCount":128},[],{"trials":12054,"activeCount":128},[],{"trials":12056,"activeCount":128},[],{"trials":12058,"activeCount":676,"soonestReadout":761},[12059,12070],{"nctId":12060,"briefTitle":12061,"status":104,"phases":12062,"primaryCompletion":12063,"completion":12063,"start":4885,"enrollment":817,"conditions":12064,"interventions":12066},"NCT02123069","Vascular Function and Uterine Fibroids",[],"2018-03-01",[12065],"Leiomyoma",[12045,12067,12068,12069],"Nitroprusside","Norepinephrine","Nitroprusside and phenylephrine",{"nctId":12071,"briefTitle":12072,"status":265,"phases":12073,"primaryCompletion":761,"completion":761,"start":12074,"enrollment":785,"conditions":12075,"interventions":12077},"NCT05193968","Hot Flashes and Neurovascular Function in Women",[94],"2022-02-24",[2760,1604,12076],"Vasomotor System; Labile",[12078,12045,12079,12068],"Sodium Nitroprusside","Terbutaline",{"intervention":12068,"totalTrials":224,"cells":12081},{"EARLY_PHASE1":12082,"PHASE1":12084,"PHASE2":12086,"PHASE3":12088,"PHASE4":12090,"NA":12092},{"trials":12083,"activeCount":128},[],{"trials":12085,"activeCount":128},[],{"trials":12087,"activeCount":128},[],{"trials":12089,"activeCount":128},[],{"trials":12091,"activeCount":128},[],{"trials":12093,"activeCount":676,"soonestReadout":761},[12094,12098],{"nctId":12060,"briefTitle":12061,"status":104,"phases":12095,"primaryCompletion":12063,"completion":12063,"start":4885,"enrollment":817,"conditions":12096,"interventions":12097},[],[12065],[12045,12067,12068,12069],{"nctId":12071,"briefTitle":12072,"status":265,"phases":12099,"primaryCompletion":761,"completion":761,"start":12074,"enrollment":785,"conditions":12100,"interventions":12101},[94],[2760,1604,12076],[12078,12045,12079,12068],{"intervention":12103,"totalTrials":224,"cells":12104},"Fluorescein Sodium",{"EARLY_PHASE1":12105,"PHASE1":12107,"PHASE2":12109,"PHASE3":12120,"PHASE4":12122,"NA":12124},{"trials":12106,"activeCount":128},[],{"trials":12108,"activeCount":128},[],{"trials":12110,"activeCount":128},[12111],{"nctId":12112,"briefTitle":12113,"status":104,"phases":12114,"primaryCompletion":12115,"completion":12115,"start":12116,"enrollment":218,"conditions":12117,"interventions":12119},"NCT04351373","Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560",[91],"2022-05-25","2021-10-06",[12118],"Vestibular Schwannoma",[12103],{"trials":12121,"activeCount":128},[],{"trials":12123,"activeCount":128},[],{"trials":12125,"activeCount":676,"soonestReadout":12130},[12126],{"nctId":12127,"briefTitle":12128,"status":265,"phases":12129,"primaryCompletion":12130,"completion":12130,"start":12131,"enrollment":19,"conditions":12132,"interventions":12143},"NCT03823144","Intravital Microscopy in Human Solid Tumors",[94],"2027-09-30","2019-02-28",[12133,193,24,4618,4567,12134,12135,12136,9636,12137,12138,4267,4623,583,5870,142,12139,4383,12140,12141,12142,629,564],"Solid Tumor, Adult","Metastatic Primary Malignant Brain Neoplasm","Metastatic Sarcoma","Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8","Resectable Liver and Intrahepatic Bile Duct Carcinoma","Resectable Pancreatic Carcinoma","Metastatic Liver Carcinoma","Resectable Brain Neoplasm","Resectable Breast Carcinoma","Resectable Gastric Carcinoma",[12103],{"intervention":12145,"totalTrials":224,"cells":12146},"Collagenase Clostridium Histolyticum",{"EARLY_PHASE1":12147,"PHASE1":12149,"PHASE2":12151,"PHASE3":12153,"PHASE4":12155,"NA":12157},{"trials":12148,"activeCount":128},[],{"trials":12150,"activeCount":128},[],{"trials":12152,"activeCount":128},[],{"trials":12154,"activeCount":128},[],{"trials":12156,"activeCount":128},[],{"trials":12158,"activeCount":676,"soonestReadout":761},[12159,12169],{"nctId":12160,"briefTitle":12161,"status":1413,"phases":12162,"primaryCompletion":1470,"completion":1470,"start":12163,"enrollment":128,"conditions":12164,"interventions":12168},"NCT05646602","Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction",[94],"2023-03",[12165,12166,12167],"Peyronie Disease","Penile Curvature","Erectile Dysfunction",[12145],{"nctId":12170,"briefTitle":12171,"status":265,"phases":12172,"primaryCompletion":761,"completion":8877,"start":12173,"enrollment":25,"conditions":12174,"interventions":12175},"NCT06065436","Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease",[94],"2024-01-19",[12165,12167],[12145],{"intervention":12177,"totalTrials":224,"cells":12178},"Polygenic Risk Score",{"EARLY_PHASE1":12179,"PHASE1":12181,"PHASE2":12183,"PHASE3":12193,"PHASE4":12195,"NA":12197},{"trials":12180,"activeCount":128},[],{"trials":12182,"activeCount":128},[],{"trials":12184,"activeCount":128},[12185],{"nctId":12186,"briefTitle":12187,"status":104,"phases":12188,"primaryCompletion":12189,"completion":12189,"start":6973,"enrollment":12190,"conditions":12191,"interventions":12192},"NCT02517593","Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake",[90,91],"2019-12-01",151,[21],[12177],{"trials":12194,"activeCount":128},[],{"trials":12196,"activeCount":128},[],{"trials":12198,"activeCount":676,"soonestReadout":12203},[12199],{"nctId":12200,"briefTitle":12201,"status":169,"phases":12202,"primaryCompletion":12203,"completion":12203,"start":12204,"enrollment":12205,"conditions":12206,"interventions":12207},"NCT04474834","Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study",[],"2029-12-15","2019-10-17",737,[21],[12177],{"intervention":12078,"totalTrials":676,"cells":12209},{"EARLY_PHASE1":12210,"PHASE1":12212,"PHASE2":12214,"PHASE3":12216,"PHASE4":12218,"NA":12220},{"trials":12211,"activeCount":128},[],{"trials":12213,"activeCount":128},[],{"trials":12215,"activeCount":128},[],{"trials":12217,"activeCount":128},[],{"trials":12219,"activeCount":128},[],{"trials":12221,"activeCount":676,"soonestReadout":761},[12222],{"nctId":12071,"briefTitle":12072,"status":265,"phases":12223,"primaryCompletion":761,"completion":761,"start":12074,"enrollment":785,"conditions":12224,"interventions":12225},[94],[2760,1604,12076],[12078,12045,12079,12068],{"intervention":12079,"totalTrials":676,"cells":12227},{"EARLY_PHASE1":12228,"PHASE1":12230,"PHASE2":12232,"PHASE3":12234,"PHASE4":12236,"NA":12238},{"trials":12229,"activeCount":128},[],{"trials":12231,"activeCount":128},[],{"trials":12233,"activeCount":128},[],{"trials":12235,"activeCount":128},[],{"trials":12237,"activeCount":128},[],{"trials":12239,"activeCount":676,"soonestReadout":761},[12240],{"nctId":12071,"briefTitle":12072,"status":265,"phases":12241,"primaryCompletion":761,"completion":761,"start":12074,"enrollment":785,"conditions":12242,"interventions":12243},[94],[2760,1604,12076],[12078,12045,12079,12068],{"intervention":42,"totalTrials":676,"cells":12245},{"EARLY_PHASE1":12246,"PHASE1":12248,"PHASE2":12250,"PHASE3":12252,"PHASE4":12254,"NA":12256},{"trials":12247,"activeCount":128},[],{"trials":12249,"activeCount":128},[],{"trials":12251,"activeCount":128},[],{"trials":12253,"activeCount":128},[],{"trials":12255,"activeCount":128},[],{"trials":12257,"activeCount":676,"soonestReadout":41},[12258],{"nctId":39,"briefTitle":40,"status":169,"phases":12259,"primaryCompletion":41,"completion":12260,"start":12261,"enrollment":558,"conditions":12262,"interventions":12263},[],"2031-03","2014-04-08",[4760],[42],{"intervention":11948,"totalTrials":676,"cells":12265},{"EARLY_PHASE1":12266,"PHASE1":12268,"PHASE2":12270,"PHASE3":12272,"PHASE4":12274,"NA":12276},{"trials":12267,"activeCount":128},[],{"trials":12269,"activeCount":128},[],{"trials":12271,"activeCount":128},[],{"trials":12273,"activeCount":128},[],{"trials":12275,"activeCount":128},[],{"trials":12277,"activeCount":676,"soonestReadout":11936},[12278],{"nctId":11933,"briefTitle":11934,"status":692,"phases":12279,"primaryCompletion":11936,"completion":11936,"start":11937,"enrollment":1997,"conditions":12280,"interventions":12281},[],[11939,11940,11941,11942,1364,11943,11944,11945,1360,1365,11946,7196],[1369,11948,11949],{"intervention":11949,"totalTrials":676,"cells":12283},{"EARLY_PHASE1":12284,"PHASE1":12286,"PHASE2":12288,"PHASE3":12290,"PHASE4":12292,"NA":12294},{"trials":12285,"activeCount":128},[],{"trials":12287,"activeCount":128},[],{"trials":12289,"activeCount":128},[],{"trials":12291,"activeCount":128},[],{"trials":12293,"activeCount":128},[],{"trials":12295,"activeCount":676,"soonestReadout":11936},[12296],{"nctId":11933,"briefTitle":11934,"status":692,"phases":12297,"primaryCompletion":11936,"completion":11936,"start":11937,"enrollment":1997,"conditions":12298,"interventions":12299},[],[11939,11940,11941,11942,1364,11943,11944,11945,1360,1365,11946,7196],[1369,11948,11949],{"intervention":12301,"totalTrials":676,"cells":12302},"Menopausal Hormone Therapy",{"EARLY_PHASE1":12303,"PHASE1":12305,"PHASE2":12307,"PHASE3":12309,"PHASE4":12311,"NA":12313},{"trials":12304,"activeCount":128},[],{"trials":12306,"activeCount":128},[],{"trials":12308,"activeCount":128},[],{"trials":12310,"activeCount":128},[],{"trials":12312,"activeCount":128},[],{"trials":12314,"activeCount":676,"soonestReadout":737},[12315],{"nctId":12316,"briefTitle":12317,"status":1096,"phases":12318,"primaryCompletion":737,"completion":737,"start":2902,"enrollment":773,"conditions":12319,"interventions":12321},"NCT07242391","Menopausal Hormone Therapy And Left Ventricular Function",[],[1604,12320],"Left Ventricular Dysfunction",[12301],{"intervention":12323,"totalTrials":676,"cells":12324},"C11 ER176 Tracer",{"EARLY_PHASE1":12325,"PHASE1":12327,"PHASE2":12329,"PHASE3":12331,"PHASE4":12333,"NA":12335},{"trials":12326,"activeCount":128},[],{"trials":12328,"activeCount":128},[],{"trials":12330,"activeCount":128},[],{"trials":12332,"activeCount":128},[],{"trials":12334,"activeCount":128},[],{"trials":12336,"activeCount":676,"soonestReadout":737},[12337],{"nctId":12338,"briefTitle":12339,"status":1096,"phases":12340,"primaryCompletion":737,"completion":737,"start":2112,"enrollment":370,"conditions":12341,"interventions":12343},"NCT07527130","C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome",[],[12342],"COVID-19",[12323],{"intervention":12345,"totalTrials":676,"cells":12346},"Genetic Testing for Cancer Risk",{"EARLY_PHASE1":12347,"PHASE1":12349,"PHASE2":12351,"PHASE3":12353,"PHASE4":12355,"NA":12357},{"trials":12348,"activeCount":128},[],{"trials":12350,"activeCount":128},[],{"trials":12352,"activeCount":128},[],{"trials":12354,"activeCount":128},[],{"trials":12356,"activeCount":128},[],{"trials":12358,"activeCount":676,"soonestReadout":2068},[12359],{"nctId":12360,"briefTitle":12361,"status":692,"phases":12362,"primaryCompletion":2068,"completion":2068,"start":12363,"enrollment":498,"conditions":12364,"interventions":12365},"NCT06744595","Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic Cancer",[94],"2025-02-12",[6666],[12345],{"intervention":12367,"totalTrials":676,"cells":12368},"Pan-genomic Testing",{"EARLY_PHASE1":12369,"PHASE1":12371,"PHASE2":12373,"PHASE3":12375,"PHASE4":12377,"NA":12379},{"trials":12370,"activeCount":128},[],{"trials":12372,"activeCount":128},[],{"trials":12374,"activeCount":128},[],{"trials":12376,"activeCount":128},[],{"trials":12378,"activeCount":128},[],{"trials":12380,"activeCount":676,"soonestReadout":12385},[12381],{"nctId":12382,"briefTitle":12383,"status":265,"phases":12384,"primaryCompletion":12385,"completion":12385,"start":12386,"enrollment":1997,"conditions":12387,"interventions":12391},"NCT06008392","INTERogating Cancer for Etiology, Prevention and Therapy Navigation",[],"2033-09","2023-10-12",[897,12388,12389,12390,24],"Cancer Gene Mutation","PAN Gene Mutation","Hematopoietic and Lymphoid System Neoplasm",[12367],{"intervention":12393,"totalTrials":676,"cells":12394},"Perflutren Lipid Microspheres",{"EARLY_PHASE1":12395,"PHASE1":12397,"PHASE2":12399,"PHASE3":12401,"PHASE4":12403,"NA":12405},{"trials":12396,"activeCount":128},[],{"trials":12398,"activeCount":128},[],{"trials":12400,"activeCount":128},[],{"trials":12402,"activeCount":128},[],{"trials":12404,"activeCount":128},[],{"trials":12406,"activeCount":676,"soonestReadout":1601},[12407],{"nctId":12408,"briefTitle":12409,"status":265,"phases":12410,"primaryCompletion":1601,"completion":1601,"start":12411,"enrollment":25,"conditions":12412,"interventions":12413},"NCT06797193","Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension",[94],"2025-03-13",[10260],[12393],{"intervention":12415,"totalTrials":676,"cells":12416},"Allogeneic, vertebral bone marrow-derived mesenchymal stem cells",{"EARLY_PHASE1":12417,"PHASE1":12419,"PHASE2":12421,"PHASE3":12423,"PHASE4":12425,"NA":12427},{"trials":12418,"activeCount":128},[],{"trials":12420,"activeCount":128},[],{"trials":12422,"activeCount":128},[],{"trials":12424,"activeCount":128},[],{"trials":12426,"activeCount":128},[],{"trials":12428,"activeCount":676,"soonestReadout":1625},[12429],{"nctId":12430,"briefTitle":12431,"status":265,"phases":12432,"primaryCompletion":1625,"completion":9567,"start":12433,"enrollment":668,"conditions":12434,"interventions":12435},"NCT06752577","Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)",[],"2024-12-22",[1062,11163],[12415],{"intervention":7117,"totalTrials":1197,"cells":12437},{"EARLY_PHASE1":12438,"PHASE1":12440,"PHASE2":12442,"PHASE3":12468,"PHASE4":12479,"NA":12492},{"trials":12439,"activeCount":128},[],{"trials":12441,"activeCount":128},[],{"trials":12443,"activeCount":128},[12444,12455,12462],{"nctId":12445,"briefTitle":12446,"status":104,"phases":12447,"primaryCompletion":12448,"completion":12448,"start":12449,"enrollment":729,"conditions":12450,"interventions":12454},"NCT03270085","Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption",[91],"2019-05-31","2017-12-07",[12451,12452,12453],"Chronic Diarrhea","Irritable Bowel Syndrome With Diarrhea","Bile Acid Malabsorption",[7117],{"nctId":12456,"briefTitle":12457,"status":134,"phases":12458,"primaryCompletion":12459,"completion":12459,"start":2719,"enrollment":681,"conditions":12460,"interventions":12461},"NCT02619812","Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT",[91],"2016-12",[3562],[7117],{"nctId":12463,"briefTitle":12464,"status":104,"phases":12465,"primaryCompletion":4784,"completion":4784,"start":3717,"enrollment":2555,"conditions":12466,"interventions":12467},"NCT00911612","Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?",[91],[2885,11717],[7117],{"trials":12469,"activeCount":128},[12470],{"nctId":12471,"briefTitle":12472,"status":104,"phases":12473,"primaryCompletion":12474,"completion":12474,"start":7696,"enrollment":797,"conditions":12475,"interventions":12477},"NCT02628626","A Study of Colesevelam in Fecal Incontinence",[92],"2022-04-14",[12476,12453],"Fecal Incontinence",[7117,12478],"Clonidine",{"trials":12480,"activeCount":128},[12481,12488],{"nctId":12482,"briefTitle":12483,"status":104,"phases":12484,"primaryCompletion":2978,"completion":905,"start":7317,"enrollment":301,"conditions":12485,"interventions":12487},"NCT02111603","Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids",[93],[12486],"Diarrhea Predominant Irritable Bowel Syndrome",[7117],{"nctId":7111,"briefTitle":7112,"status":104,"phases":12489,"primaryCompletion":1375,"completion":3613,"start":7114,"enrollment":956,"conditions":12490,"interventions":12491},[93],[1868],[7117,7039],{"trials":12493,"activeCount":128},[],{"intervention":12495,"totalTrials":681,"cells":12496},"Apixaban",{"EARLY_PHASE1":12497,"PHASE1":12499,"PHASE2":12501,"PHASE3":12521,"PHASE4":12531,"NA":12542},{"trials":12498,"activeCount":128},[],{"trials":12500,"activeCount":128},[],{"trials":12502,"activeCount":128},[12503,12512],{"nctId":12504,"briefTitle":12505,"status":1413,"phases":12506,"primaryCompletion":12507,"completion":12507,"start":1235,"enrollment":128,"conditions":12508,"interventions":12511},"NCT02378623","Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli",[91],"2020-01",[12509,12510],"Patent Foramen Ovale","Cardiac Implantable Electronic Device",[12495],{"nctId":12513,"briefTitle":12514,"status":1413,"phases":12515,"primaryCompletion":12516,"completion":12517,"start":3642,"enrollment":128,"conditions":12518,"interventions":12519},"NCT02450682","Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study",[91],"2017-01","2017-03",[33],[12495,12520],"Warfarin",{"trials":12522,"activeCount":128},[12523],{"nctId":12524,"briefTitle":12525,"status":134,"phases":12526,"primaryCompletion":12527,"completion":12527,"start":12528,"enrollment":885,"conditions":12529,"interventions":12530},"NCT03839355","Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation",[92],"2020-12-15","2018-12-19",[33],[12495,12520],{"trials":12532,"activeCount":128},[12533],{"nctId":12534,"briefTitle":12535,"status":134,"phases":12536,"primaryCompletion":12537,"completion":12537,"start":12538,"enrollment":895,"conditions":12539,"interventions":12541},"NCT03590743","Calf Deep Vein Thrombosis Treatment Trial",[93],"2019-06-03","2019-02-19",[12540],"Deep Vein Thrombosis",[12495],{"trials":12543,"activeCount":128},[],{"intervention":12545,"totalTrials":681,"cells":12546},"Erenumab",{"EARLY_PHASE1":12547,"PHASE1":12549,"PHASE2":12560,"PHASE3":12580,"PHASE4":12582,"NA":12591},{"trials":12548,"activeCount":128},[],{"trials":12550,"activeCount":128},[12551],{"nctId":12552,"briefTitle":12553,"status":1413,"phases":12554,"primaryCompletion":12555,"completion":12555,"start":12556,"enrollment":128,"conditions":12557,"interventions":12559},"NCT04920331","Study of Intravenous Erenumab in Patients With Status Migrainosus",[90],"2022-02-04","2021-09-07",[12558],"Status Migrainosus",[12545],{"trials":12561,"activeCount":128},[12562,12571],{"nctId":12563,"briefTitle":12564,"status":104,"phases":12565,"primaryCompletion":12566,"completion":12566,"start":12567,"enrollment":1197,"conditions":12568,"interventions":12570},"NCT04098250","Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH",[91],"2024-01-10","2021-01-04",[12569],"Post-Traumatic Headache",[12545],{"nctId":12572,"briefTitle":12573,"status":134,"phases":12574,"primaryCompletion":12575,"completion":12575,"start":12576,"enrollment":224,"conditions":12577,"interventions":12579},"NCT04303845","Erenumab For Treatment of Hemicrania Continua",[91],"2022-04-06","2021-08-04",[12578],"Hemicrania Continua",[12545],{"trials":12581,"activeCount":128},[],{"trials":12583,"activeCount":128},[12584],{"nctId":12585,"briefTitle":12586,"status":104,"phases":12587,"primaryCompletion":4776,"completion":4776,"start":12588,"enrollment":773,"conditions":12589,"interventions":12590},"NCT03773562","Imaging the Migraine Brain Pre- and Post-Erenumab",[93],"2019-03-25",[1938],[12545],{"trials":12592,"activeCount":128},[],{"intervention":1229,"totalTrials":681,"cells":12594},{"EARLY_PHASE1":12595,"PHASE1":12604,"PHASE2":12606,"PHASE3":12608,"PHASE4":12610,"NA":12624},{"trials":12596,"activeCount":128},[12597],{"nctId":12598,"briefTitle":12599,"status":104,"phases":12600,"primaryCompletion":946,"completion":946,"start":1563,"enrollment":370,"conditions":12601,"interventions":12602},"NCT00879164","Stellate Ganglion Nerve Block in Treating Women With Hot Flashes",[89],[2760],[12603],"bupivacaine hydrochloride",{"trials":12605,"activeCount":128},[],{"trials":12607,"activeCount":128},[],{"trials":12609,"activeCount":128},[],{"trials":12611,"activeCount":128},[12612,12616,12620],{"nctId":1220,"briefTitle":1221,"status":104,"phases":12613,"primaryCompletion":1223,"completion":1223,"start":1224,"enrollment":1225,"conditions":12614,"interventions":12615},[93],[1227],[1229,1196],{"nctId":1243,"briefTitle":1244,"status":134,"phases":12617,"primaryCompletion":460,"completion":460,"start":1246,"enrollment":817,"conditions":12618,"interventions":12619},[93],[1248],[1218,1229],{"nctId":1262,"briefTitle":1263,"status":104,"phases":12621,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":12622,"interventions":12623},[93],[1269],[1196,1229],{"trials":12625,"activeCount":128},[],{"intervention":7353,"totalTrials":342,"cells":12627},{"EARLY_PHASE1":12628,"PHASE1":12630,"PHASE2":12632,"PHASE3":12644,"PHASE4":12646,"NA":12652},{"trials":12629,"activeCount":128},[],{"trials":12631,"activeCount":128},[],{"trials":12633,"activeCount":128},[12634,12638],{"nctId":7348,"briefTitle":7349,"status":1413,"phases":12635,"enrollment":128,"conditions":12636,"interventions":12637},[90,91],[3562,3690],[3513,3759,7353,7354,7355],{"nctId":12639,"briefTitle":12640,"status":134,"phases":12641,"primaryCompletion":5351,"completion":2936,"start":5033,"enrollment":676,"conditions":12642,"interventions":12643},"NCT00635024","Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma",[91],[3665],[7353,3759],{"trials":12645,"activeCount":128},[],{"trials":12647,"activeCount":128},[12648],{"nctId":5138,"briefTitle":5139,"status":104,"phases":12649,"primaryCompletion":2643,"completion":5141,"start":5142,"enrollment":1162,"conditions":12650,"interventions":12651},[93],[5144],[5146,5147,3427,3745,4283],{"trials":12653,"activeCount":128},[],{"intervention":12655,"totalTrials":342,"cells":12656},"tranexamic acid",{"EARLY_PHASE1":12657,"PHASE1":12659,"PHASE2":12661,"PHASE3":12675,"PHASE4":12684,"NA":12693},{"trials":12658,"activeCount":128},[],{"trials":12660,"activeCount":128},[],{"trials":12662,"activeCount":128},[12663],{"nctId":12664,"briefTitle":12665,"status":104,"phases":12666,"primaryCompletion":12667,"completion":12667,"start":12668,"enrollment":12669,"conditions":12670,"interventions":12673},"NCT03182751","Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement",[91],"2022-05-24","2018-04-02",128,[12671,12672],"Hip Fractures","Intertrochanteric Fractures",[12674],"Tranexamic Acid",{"trials":12676,"activeCount":128},[12677],{"nctId":12678,"briefTitle":12679,"status":104,"phases":12680,"primaryCompletion":934,"completion":3673,"start":12681,"enrollment":173,"conditions":12682,"interventions":12683},"NCT00588133","A Preliminary Study of a New Tranexamic Acid Dosing Schedule for Cardiac Surgery",[92],"2004-01",[925],[12655,12655],{"trials":12685,"activeCount":128},[12686],{"nctId":12687,"briefTitle":12688,"status":104,"phases":12689,"primaryCompletion":1338,"completion":1338,"start":3971,"enrollment":3633,"conditions":12690,"interventions":12692},"NCT01714336","Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?",[93],[12691],"Hip Fracture",[12655],{"trials":12694,"activeCount":128},[],{"intervention":2724,"totalTrials":342,"cells":12696},{"EARLY_PHASE1":12697,"PHASE1":12699,"PHASE2":12701,"PHASE3":12719,"PHASE4":12721,"NA":12727},{"trials":12698,"activeCount":128},[],{"trials":12700,"activeCount":128},[],{"trials":12702,"activeCount":128},[12703,12710],{"nctId":12704,"briefTitle":12705,"status":104,"phases":12706,"primaryCompletion":4300,"completion":4300,"start":6955,"enrollment":28,"conditions":12707,"interventions":12709},"NCT00982423","The Effects of Decreasing the Lasix Dose on the Cardiorenal System",[90,91],[27,12708],"Kidney Dysfunction",[2724],{"nctId":12711,"briefTitle":12712,"status":104,"phases":12713,"primaryCompletion":474,"completion":474,"start":12714,"enrollment":173,"conditions":12715,"interventions":12717},"NCT06036914","A Study of Ultra High Dose Diuretics to Treat Heart Failure",[91],"2023-11-27",[12716],"Heart Failure; With Decompensation",[12718,2724],"Bumetanide",{"trials":12720,"activeCount":128},[],{"trials":12722,"activeCount":128},[12723],{"nctId":2716,"briefTitle":2717,"status":104,"phases":12724,"primaryCompletion":2719,"completion":2719,"start":796,"enrollment":2720,"conditions":12725,"interventions":12726},[93],[2722],[2724,2725,1013],{"trials":12728,"activeCount":128},[],{"intervention":12730,"totalTrials":342,"cells":12731},"Pregabalin",{"EARLY_PHASE1":12732,"PHASE1":12734,"PHASE2":12736,"PHASE3":12744,"PHASE4":12746,"NA":12760},{"trials":12733,"activeCount":128},[],{"trials":12735,"activeCount":128},[],{"trials":12737,"activeCount":128},[12738],{"nctId":12739,"briefTitle":12740,"status":104,"phases":12741,"primaryCompletion":5418,"completion":5418,"start":1357,"enrollment":19,"conditions":12742,"interventions":12743},"NCT00977197","A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome",[91],[2885],[12730],{"trials":12745,"activeCount":128},[],{"trials":12747,"activeCount":128},[12748,12754],{"nctId":12749,"briefTitle":12750,"status":104,"phases":12751,"primaryCompletion":2787,"completion":2787,"start":1357,"enrollment":3034,"conditions":12752,"interventions":12753},"NCT01094808","Pregabalin and Colonic Function",[93],[18],[12730],{"nctId":12755,"briefTitle":12756,"status":104,"phases":12757,"primaryCompletion":10245,"completion":10245,"start":3661,"enrollment":108,"conditions":12758,"interventions":12759},"NCT01331213","Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome",[93],[2885],[12730],{"trials":12761,"activeCount":128},[],{"intervention":12763,"totalTrials":342,"cells":12764},"Oral Placebo",{"EARLY_PHASE1":12765,"PHASE1":12767,"PHASE2":12790,"PHASE3":12792,"PHASE4":12794,"NA":12805},{"trials":12766,"activeCount":128},[],{"trials":12768,"activeCount":128},[12769,12779],{"nctId":12770,"briefTitle":12771,"status":134,"phases":12772,"primaryCompletion":12773,"completion":12773,"start":12774,"enrollment":139,"conditions":12775,"interventions":12777},"NCT04286529","Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons",[90],"2021-05-28","2020-10-01",[12776],"Pre-Diabetic",[12778,12763],"Calcitriol",{"nctId":12780,"briefTitle":12781,"status":104,"phases":12782,"primaryCompletion":12459,"completion":2606,"start":2665,"enrollment":5517,"conditions":12783,"interventions":12784},"NCT02272647","Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women",[90],[18],[12785,12786,12785,12786,12787,12763,12788,12789,12763],"IM Saline Placebo","IM Estradiol valerate","Oral Micronized Progesterone","Ghrelin","Medroxyprogesterone - Acetate",{"trials":12791,"activeCount":128},[],{"trials":12793,"activeCount":128},[],{"trials":12795,"activeCount":128},[12796],{"nctId":12797,"briefTitle":12798,"status":104,"phases":12799,"primaryCompletion":12800,"completion":12800,"start":12801,"enrollment":3719,"conditions":12802,"interventions":12803},"NCT03469271","Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients",[93],"2020-05-21","2018-05-25",[897],[12804,12763],"1,25 (OH)2 D3",{"trials":12806,"activeCount":128},[],{"intervention":12808,"totalTrials":224,"cells":12809},"Exenatide",{"EARLY_PHASE1":12810,"PHASE1":12812,"PHASE2":12814,"PHASE3":12816,"PHASE4":12818,"NA":12833},{"trials":12811,"activeCount":128},[],{"trials":12813,"activeCount":128},[],{"trials":12815,"activeCount":128},[],{"trials":12817,"activeCount":128},[],{"trials":12819,"activeCount":128},[12820,12827],{"nctId":12821,"briefTitle":12822,"status":1413,"phases":12823,"primaryCompletion":2667,"completion":2667,"start":12007,"enrollment":128,"conditions":12824,"interventions":12826},"NCT01818648","Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome",[93],[12825],"Short Bowel Syndrome",[12808],{"nctId":12828,"briefTitle":12829,"status":104,"phases":12830,"primaryCompletion":2863,"completion":2863,"start":5417,"enrollment":173,"conditions":12831,"interventions":12832},"NCT02160990","Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying",[93],[15],[12808],{"trials":12834,"activeCount":128},[],{"intervention":12836,"totalTrials":224,"cells":12837},"Propranolol",{"EARLY_PHASE1":12838,"PHASE1":12852,"PHASE2":12854,"PHASE3":12856,"PHASE4":12858,"NA":12867},{"trials":12839,"activeCount":128},[12840],{"nctId":12841,"briefTitle":12842,"status":104,"phases":12843,"primaryCompletion":12844,"completion":12845,"start":12846,"enrollment":1162,"conditions":12847,"interventions":12849},"NCT02467400","Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism",[89],"2017-10-26","2018-04-01","2015-07-01",[12848],"Osteoporosis, Age-Related",[12850,12851,12836],"Atenolol","Nebivolol",{"trials":12853,"activeCount":128},[],{"trials":12855,"activeCount":128},[],{"trials":12857,"activeCount":128},[],{"trials":12859,"activeCount":128},[12860],{"nctId":12861,"briefTitle":12862,"status":104,"phases":12863,"primaryCompletion":1356,"completion":1356,"start":2667,"enrollment":956,"conditions":12864,"interventions":12866},"NCT02032758","Study of Arm and Putter Movement in Golfers With Golfer's Cramp",[93],[12865],"Occupational; Cramp(s)",[12836],{"trials":12868,"activeCount":128},[],{"intervention":12870,"totalTrials":224,"cells":12871},"metoprolol succinate",{"EARLY_PHASE1":12872,"PHASE1":12874,"PHASE2":12876,"PHASE3":12878,"PHASE4":12880,"NA":12898},{"trials":12873,"activeCount":128},[],{"trials":12875,"activeCount":128},[],{"trials":12877,"activeCount":128},[],{"trials":12879,"activeCount":128},[],{"trials":12881,"activeCount":128},[12882,12890],{"nctId":12883,"briefTitle":12884,"status":104,"phases":12885,"primaryCompletion":4928,"completion":4928,"start":12886,"enrollment":25,"conditions":12887,"interventions":12889},"NCT00166400","A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation.",[93],"2004-07",[12888],"Heart Valve Diseases",[12870],{"nctId":12891,"briefTitle":12892,"status":134,"phases":12893,"primaryCompletion":12007,"completion":12007,"start":3509,"enrollment":676,"conditions":12894,"interventions":12896},"NCT01605370","Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?",[93],[12895],"Hypertension",[12851,12897],"Metoprolol succinate",{"trials":12899,"activeCount":128},[],{"intervention":12901,"totalTrials":224,"cells":12902},"CellCept",{"EARLY_PHASE1":12903,"PHASE1":12905,"PHASE2":12915,"PHASE3":12917,"PHASE4":12919,"NA":12929},{"trials":12904,"activeCount":128},[],{"trials":12906,"activeCount":128},[12907],{"nctId":12908,"briefTitle":12909,"status":104,"phases":12910,"primaryCompletion":5351,"completion":5351,"start":12911,"enrollment":108,"conditions":12912,"interventions":12914},"NCT00405860","CellCept in p-ANCA Vasculitis",[90],"2002-12",[12913,5447],"MPO-ANCA Vasculitis",[12901],{"trials":12916,"activeCount":128},[],{"trials":12918,"activeCount":128},[],{"trials":12920,"activeCount":128},[12921],{"nctId":12922,"briefTitle":12923,"status":134,"phases":12924,"primaryCompletion":1564,"completion":1564,"start":12925,"enrollment":218,"conditions":12926,"interventions":12928},"NCT00217152","A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors",[93],"2005-03",[1697,12927],"Delayed Graft Function",[12901],{"trials":12930,"activeCount":128},[],{"intervention":12932,"totalTrials":224,"cells":12933},"Perampanel",{"EARLY_PHASE1":12934,"PHASE1":12944,"PHASE2":12946,"PHASE3":12948,"PHASE4":12950,"NA":12963},{"trials":12935,"activeCount":128},[12936],{"nctId":12937,"briefTitle":12938,"status":104,"phases":12939,"primaryCompletion":12940,"completion":1416,"start":12941,"enrollment":3002,"conditions":12942,"interventions":12943},"NCT03793868","Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis",[89],"2020-08-01","2018-12-04",[6260],[12932],{"trials":12945,"activeCount":128},[],{"trials":12947,"activeCount":128},[],{"trials":12949,"activeCount":128},[],{"trials":12951,"activeCount":128},[12952],{"nctId":12953,"briefTitle":12954,"status":134,"phases":12955,"primaryCompletion":12956,"completion":12956,"start":4702,"enrollment":681,"conditions":12957,"interventions":12961},"NCT04650204","Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy",[93],"2023-04-30",[12958,4760,12959,12960,9333],"Intractable Epilepsy","Seizure Disorder","WHO Grade 2 Glioma",[12962,12932],"Anticonvulsant Agent",{"trials":12964,"activeCount":128},[],{"intervention":12034,"totalTrials":224,"cells":12966},{"EARLY_PHASE1":12967,"PHASE1":12969,"PHASE2":12971,"PHASE3":12982,"PHASE4":12984,"NA":12990},{"trials":12968,"activeCount":128},[],{"trials":12970,"activeCount":128},[],{"trials":12972,"activeCount":128},[12973],{"nctId":12974,"briefTitle":12975,"status":1413,"phases":12976,"primaryCompletion":954,"completion":954,"start":954,"enrollment":128,"conditions":12977,"interventions":12981},"NCT01479231","Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis",[90,91],[12978,12979,12980],"Gastroesophageal Reflux Disease","Eosinophilic Esophagitis","Dysphagia",[12034],{"trials":12983,"activeCount":128},[],{"trials":12985,"activeCount":128},[12986],{"nctId":12028,"briefTitle":12029,"status":104,"phases":12987,"primaryCompletion":5361,"completion":5361,"start":1357,"enrollment":729,"conditions":12988,"interventions":12989},[93],[7090,12032],[12034,11999],{"trials":12991,"activeCount":128},[],{"intervention":8172,"totalTrials":224,"cells":12993},{"EARLY_PHASE1":12994,"PHASE1":12996,"PHASE2":13002,"PHASE3":13004,"PHASE4":13006,"NA":13016},{"trials":12995,"activeCount":128},[],{"trials":12997,"activeCount":128},[12998],{"nctId":8164,"briefTitle":8165,"status":104,"phases":12999,"primaryCompletion":8167,"completion":8167,"start":3988,"enrollment":370,"conditions":13000,"interventions":13001},[90],[8169],[8171,8172,8157],{"trials":13003,"activeCount":128},[],{"trials":13005,"activeCount":128},[],{"trials":13007,"activeCount":128},[13008],{"nctId":13009,"briefTitle":13010,"status":104,"phases":13011,"primaryCompletion":13012,"completion":3000,"start":7696,"enrollment":498,"conditions":13013,"interventions":13015},"NCT02625428","IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?",[93],"2018-12",[13014],"Transplantation, Kidney",[8172],{"trials":13017,"activeCount":128},[],{"intervention":13019,"totalTrials":224,"cells":13020},"Aprepitant",{"EARLY_PHASE1":13021,"PHASE1":13023,"PHASE2":13034,"PHASE3":13036,"PHASE4":13038,"NA":13048},{"trials":13022,"activeCount":128},[],{"trials":13024,"activeCount":128},[13025],{"nctId":13026,"briefTitle":13027,"status":104,"phases":13028,"primaryCompletion":13029,"completion":13030,"start":13031,"enrollment":97,"conditions":13032,"interventions":13033},"NCT02989467","Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying",[90],"2017-11-20","2018-01-01","2017-01-27",[18],[13019],{"trials":13035,"activeCount":128},[],{"trials":13037,"activeCount":128},[],{"trials":13039,"activeCount":128},[13040],{"nctId":13041,"briefTitle":13042,"status":134,"phases":13043,"primaryCompletion":1020,"completion":1020,"start":4928,"enrollment":13044,"conditions":13045,"interventions":13047},"NCT00888329","Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy",[93],256,[13046],"Postoperative Nausea and Vomiting",[13019],{"trials":13049,"activeCount":128},[],{"intervention":13051,"totalTrials":224,"cells":13052},"sibutramine",{"EARLY_PHASE1":13053,"PHASE1":13055,"PHASE2":13057,"PHASE3":13066,"PHASE4":13068,"NA":13077},{"trials":13054,"activeCount":128},[],{"trials":13056,"activeCount":128},[],{"trials":13058,"activeCount":128},[13059],{"nctId":13060,"briefTitle":13061,"status":104,"phases":13062,"primaryCompletion":5515,"completion":5515,"start":4391,"enrollment":2894,"conditions":13063,"interventions":13065},"NCT00330525","Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity",[91],[15,13064],"Overweight",[13051],{"trials":13067,"activeCount":128},[],{"trials":13069,"activeCount":128},[13070],{"nctId":13071,"briefTitle":13072,"status":104,"phases":13073,"primaryCompletion":2643,"completion":2643,"start":3662,"enrollment":13074,"conditions":13075,"interventions":13076},"NCT00433641","Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes",[93],181,[15],[13051,13051,13051],{"trials":13078,"activeCount":128},[],{"intervention":13080,"totalTrials":224,"cells":13081},"68Ga-DOTATATE PET\u002FCT",{"EARLY_PHASE1":13082,"PHASE1":13084,"PHASE2":13086,"PHASE3":13095,"PHASE4":13097,"NA":13109},{"trials":13083,"activeCount":128},[],{"trials":13085,"activeCount":128},[],{"trials":13087,"activeCount":128},[13088],{"nctId":13089,"briefTitle":13090,"status":104,"phases":13091,"primaryCompletion":523,"completion":523,"start":6266,"enrollment":108,"conditions":13092,"interventions":13094},"NCT03736564","Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia",[90,91],[13093],"Osteomalacia",[13080],{"trials":13096,"activeCount":128},[],{"trials":13098,"activeCount":128},[13099],{"nctId":13100,"briefTitle":13101,"status":104,"phases":13102,"primaryCompletion":13103,"completion":13103,"start":13104,"enrollment":4565,"conditions":13105,"interventions":13106},"NCT03549598","d68Ga-DOTATATE PET\u002FCT Assessment of Cardiac Sarcoidosis",[93],"2019-10-02","2018-07-20",[9805],[13080,13107,13108],"18FDG PET\u002FCT scan","13NH3 PET\u002FCT scan",{"trials":13110,"activeCount":128},[],{"intervention":7198,"totalTrials":224,"cells":13112},{"EARLY_PHASE1":13113,"PHASE1":13115,"PHASE2":13117,"PHASE3":13119,"PHASE4":13121,"NA":13134},{"trials":13114,"activeCount":128},[],{"trials":13116,"activeCount":128},[],{"trials":13118,"activeCount":128},[],{"trials":13120,"activeCount":128},[],{"trials":13122,"activeCount":128},[13123,13127],{"nctId":7191,"briefTitle":7192,"status":104,"phases":13124,"primaryCompletion":667,"completion":667,"start":5443,"enrollment":108,"conditions":13125,"interventions":13126},[93],[7195,7196],[7198,7159],{"nctId":13128,"briefTitle":13129,"status":104,"phases":13130,"primaryCompletion":5141,"completion":5141,"start":935,"enrollment":3002,"conditions":13131,"interventions":13133},"NCT00364377","Incretins in Impaired Fasting Glucose",[93],[13132],"Pre-diabetes",[7198],{"trials":13135,"activeCount":128},[],{"intervention":13137,"totalTrials":224,"cells":13138},"Clopidogrel",{"EARLY_PHASE1":13139,"PHASE1":13141,"PHASE2":13143,"PHASE3":13145,"PHASE4":13147,"NA":13171},{"trials":13140,"activeCount":128},[],{"trials":13142,"activeCount":128},[],{"trials":13144,"activeCount":128},[],{"trials":13146,"activeCount":128},[],{"trials":13148,"activeCount":128},[13149,13160],{"nctId":13150,"briefTitle":13151,"status":104,"phases":13152,"primaryCompletion":13153,"completion":13153,"start":3569,"enrollment":13154,"conditions":13155,"interventions":13158},"NCT01742117","Tailored Antiplatelet Therapy Following PCI",[93],"2020-10-31",5276,[1216,13156,13157],"Acute Coronary Syndrome","Stenosis",[13137,13159],"Ticagrelor",{"nctId":13161,"briefTitle":13162,"status":104,"phases":13163,"primaryCompletion":13164,"completion":13164,"start":13165,"enrollment":7851,"conditions":13166,"interventions":13168},"NCT05223335","Clopidogrel Monotherapy in Patients With High Bleeding Risk",[93],"2023-03-16","2022-03-29",[13167],"Bleeding Complications",[13137,13169,13170],"Prasugrel","Tricagrelor",{"trials":13172,"activeCount":128},[],{"intervention":13174,"totalTrials":224,"cells":13175},"Lubiprostone",{"EARLY_PHASE1":13176,"PHASE1":13178,"PHASE2":13188,"PHASE3":13190,"PHASE4":13192,"NA":13202},{"trials":13177,"activeCount":128},[],{"trials":13179,"activeCount":128},[13180],{"nctId":13181,"briefTitle":13182,"status":104,"phases":13183,"primaryCompletion":2979,"completion":2979,"start":13184,"enrollment":3674,"conditions":13185,"interventions":13187},"NCT00934479","Intestinal Microecology in Chronic Constipation",[90],"2010-04",[13186,2885],"Other Constipation",[13174],{"trials":13189,"activeCount":128},[],{"trials":13191,"activeCount":128},[],{"trials":13193,"activeCount":128},[13194],{"nctId":13195,"briefTitle":13196,"status":104,"phases":13197,"primaryCompletion":5351,"completion":6955,"start":13198,"enrollment":25,"conditions":13199,"interventions":13200},"NCT00953043","Lubiprostone, Colonic Motility and Sensation",[93],"2007-09",[18],[13201],"lubiprostone",{"trials":13203,"activeCount":128},[],{"intervention":13205,"totalTrials":224,"cells":13206},"GM-CSF",{"EARLY_PHASE1":13207,"PHASE1":13209,"PHASE2":13222,"PHASE3":13224,"PHASE4":13226,"NA":13235},{"trials":13208,"activeCount":128},[],{"trials":13210,"activeCount":128},[13211],{"nctId":13212,"briefTitle":13213,"status":104,"phases":13214,"primaryCompletion":1563,"completion":13215,"start":11897,"enrollment":173,"conditions":13216,"interventions":13217},"NCT00470015","Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma",[90],"2013-01-02",[4291],[13218,13219,13220,13205,13221],"MART-1 antigen","IL-2","gp100 antigen","MART-1a peptide",{"trials":13223,"activeCount":128},[],{"trials":13225,"activeCount":128},[],{"trials":13227,"activeCount":128},[13228],{"nctId":13229,"briefTitle":13230,"status":104,"phases":13231,"primaryCompletion":13232,"completion":13232,"start":1235,"enrollment":2563,"conditions":13233,"interventions":13234},"NCT02451488","Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma",[93],"2016-11-04",[110],[13205],{"trials":13236,"activeCount":128},[],{"intervention":889,"totalTrials":224,"cells":13238},{"EARLY_PHASE1":13239,"PHASE1":13241,"PHASE2":13243,"PHASE3":13249,"PHASE4":13251,"NA":13262},{"trials":13240,"activeCount":128},[],{"trials":13242,"activeCount":128},[],{"trials":13244,"activeCount":128},[13245],{"nctId":880,"briefTitle":881,"status":104,"phases":13246,"primaryCompletion":883,"completion":883,"start":884,"enrollment":885,"conditions":13247,"interventions":13248},[91],[887,839],[839,889],{"trials":13250,"activeCount":128},[],{"trials":13252,"activeCount":128},[13253],{"nctId":13254,"briefTitle":13255,"status":1413,"phases":13256,"primaryCompletion":13257,"completion":13257,"start":2731,"enrollment":128,"conditions":13258,"interventions":13260},"NCT03054948","SMOFLipid in Patients Who Are Intralipid Intolerant",[93],"2018-03-20",[13259,12825],"Home Parenteral Nutrition",[13261,889],"SMOFLipid",{"trials":13263,"activeCount":128},[],{"intervention":12851,"totalTrials":224,"cells":13265},{"EARLY_PHASE1":13266,"PHASE1":13272,"PHASE2":13274,"PHASE3":13276,"PHASE4":13278,"NA":13284},{"trials":13267,"activeCount":128},[13268],{"nctId":12841,"briefTitle":12842,"status":104,"phases":13269,"primaryCompletion":12844,"completion":12845,"start":12846,"enrollment":1162,"conditions":13270,"interventions":13271},[89],[12848],[12850,12851,12836],{"trials":13273,"activeCount":128},[],{"trials":13275,"activeCount":128},[],{"trials":13277,"activeCount":128},[],{"trials":13279,"activeCount":128},[13280],{"nctId":12891,"briefTitle":12892,"status":134,"phases":13281,"primaryCompletion":12007,"completion":12007,"start":3509,"enrollment":676,"conditions":13282,"interventions":13283},[93],[12895],[12851,12897],{"trials":13285,"activeCount":128},[],{"intervention":13287,"totalTrials":224,"cells":13288},"Lamotrigine",{"EARLY_PHASE1":13289,"PHASE1":13291,"PHASE2":13293,"PHASE3":13295,"PHASE4":13303,"NA":13314},{"trials":13290,"activeCount":128},[],{"trials":13292,"activeCount":128},[],{"trials":13294,"activeCount":128},[],{"trials":13296,"activeCount":128},[13297],{"nctId":13298,"briefTitle":13299,"status":104,"phases":13300,"primaryCompletion":874,"completion":3887,"start":7928,"enrollment":2894,"conditions":13301,"interventions":13302},"NCT01042496","Bipolar Depression Before and After Lamotrigine Treatment",[92],[851],[13287],{"trials":13304,"activeCount":128},[13305],{"nctId":13306,"briefTitle":13307,"status":134,"phases":13308,"primaryCompletion":13309,"completion":13309,"start":2863,"enrollment":224,"conditions":13310,"interventions":13312},"NCT02389712","16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression",[93],"2018-05-23",[13311],"Bipolar Disorder",[13287,13313],"Fluoxetine",{"trials":13315,"activeCount":128},[],{"intervention":13317,"totalTrials":224,"cells":13318},"Hydroxocobalamin",{"EARLY_PHASE1":13319,"PHASE1":13321,"PHASE2":13323,"PHASE3":13333,"PHASE4":13335,"NA":13346},{"trials":13320,"activeCount":128},[],{"trials":13322,"activeCount":128},[],{"trials":13324,"activeCount":128},[13325],{"nctId":13326,"briefTitle":13327,"status":134,"phases":13328,"primaryCompletion":9167,"completion":9167,"start":13329,"enrollment":2563,"conditions":13330,"interventions":13332},"NCT03735316","Vitamin B12a Vasoplegic Syndrome",[91],"2019-04-25",[13331],"Vasoplegic Syndrome",[13317,7013],{"trials":13334,"activeCount":128},[],{"trials":13336,"activeCount":128},[13337],{"nctId":13338,"briefTitle":13339,"status":104,"phases":13340,"primaryCompletion":13341,"completion":13342,"start":7892,"enrollment":6434,"conditions":13343,"interventions":13344},"NCT04054999","Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients",[93],"2023-02-27","2024-02-27",[13331,10657],[13317,13345],"Methylene Blue",{"trials":13347,"activeCount":128},[],{"intervention":2793,"totalTrials":676,"cells":13349},{"EARLY_PHASE1":13350,"PHASE1":13352,"PHASE2":13354,"PHASE3":13356,"PHASE4":13358,"NA":13364},{"trials":13351,"activeCount":128},[],{"trials":13353,"activeCount":128},[],{"trials":13355,"activeCount":128},[],{"trials":13357,"activeCount":128},[],{"trials":13359,"activeCount":128},[13360],{"nctId":2784,"briefTitle":2785,"status":134,"phases":13361,"primaryCompletion":945,"completion":945,"start":2787,"enrollment":301,"conditions":13362,"interventions":13363},[93],[2789,2790,2791],[2793,2793,2771],{"trials":13365,"activeCount":128},[],{"intervention":13367,"totalTrials":676,"cells":13368},"Sotatercept",{"EARLY_PHASE1":13369,"PHASE1":13371,"PHASE2":13373,"PHASE3":13375,"PHASE4":13377,"NA":13387},{"trials":13370,"activeCount":128},[],{"trials":13372,"activeCount":128},[],{"trials":13374,"activeCount":128},[],{"trials":13376,"activeCount":128},[],{"trials":13378,"activeCount":128},[13379],{"nctId":13380,"briefTitle":13381,"status":104,"phases":13382,"primaryCompletion":8878,"completion":8878,"start":13383,"enrollment":729,"conditions":13384,"interventions":13386},"NCT06409026","Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension",[93],"2024-07-05",[13385],"Pulmonary Arterial Hypertension",[13367],{"trials":13388,"activeCount":128},[],{"intervention":13390,"totalTrials":676,"cells":13391},"PCV13",{"EARLY_PHASE1":13392,"PHASE1":13394,"PHASE2":13396,"PHASE3":13398,"PHASE4":13400,"NA":13412},{"trials":13393,"activeCount":128},[],{"trials":13395,"activeCount":128},[],{"trials":13397,"activeCount":128},[],{"trials":13399,"activeCount":128},[],{"trials":13401,"activeCount":128},[13402],{"nctId":13403,"briefTitle":13404,"status":104,"phases":13405,"primaryCompletion":13406,"completion":13407,"start":5464,"enrollment":139,"conditions":13408,"interventions":13410},"NCT03260790","Pneumococcal Vaccines in Patients With Asthma",[93],"2020-12-21","2020-12-25",[13409],"Asthma",[13390,13411],"PPSV23",{"trials":13413,"activeCount":128},[],{"intervention":13411,"totalTrials":676,"cells":13415},{"EARLY_PHASE1":13416,"PHASE1":13418,"PHASE2":13420,"PHASE3":13422,"PHASE4":13424,"NA":13430},{"trials":13417,"activeCount":128},[],{"trials":13419,"activeCount":128},[],{"trials":13421,"activeCount":128},[],{"trials":13423,"activeCount":128},[],{"trials":13425,"activeCount":128},[13426],{"nctId":13403,"briefTitle":13404,"status":104,"phases":13427,"primaryCompletion":13406,"completion":13407,"start":5464,"enrollment":139,"conditions":13428,"interventions":13429},[93],[13409],[13390,13411],{"trials":13431,"activeCount":128},[],{"intervention":13433,"totalTrials":676,"cells":13434},"Nicotine Lozenge",{"EARLY_PHASE1":13435,"PHASE1":13437,"PHASE2":13439,"PHASE3":13441,"PHASE4":13443,"NA":13452},{"trials":13436,"activeCount":128},[],{"trials":13438,"activeCount":128},[],{"trials":13440,"activeCount":128},[],{"trials":13442,"activeCount":128},[],{"trials":13444,"activeCount":128},[13445],{"nctId":13446,"briefTitle":13447,"status":104,"phases":13448,"primaryCompletion":2620,"completion":2620,"start":935,"enrollment":3767,"conditions":13449,"interventions":13451},"NCT00586482","Pilot Study: Preoperative Nicotine Lozenges",[93],[13450],"Smoking",[13433],{"trials":13453,"activeCount":128},[],{"intervention":13455,"totalTrials":676,"cells":13456},"Methylnaltrexone only",{"EARLY_PHASE1":13457,"PHASE1":13459,"PHASE2":13461,"PHASE3":13463,"PHASE4":13465,"NA":13476},{"trials":13458,"activeCount":128},[],{"trials":13460,"activeCount":128},[],{"trials":13462,"activeCount":128},[],{"trials":13464,"activeCount":128},[],{"trials":13466,"activeCount":128},[13467],{"nctId":13468,"briefTitle":13469,"status":104,"phases":13470,"primaryCompletion":4032,"completion":4032,"start":7657,"enrollment":2608,"conditions":13471,"interventions":13473},"NCT01055704","Effect of Methylnaltrexone on GI Transit in Healthy Volunteers",[93],[13472],"Gastric Motility Disorder",[13455,13474,13475],"Codeine only","Methylnaltrexone + codeine",{"trials":13477,"activeCount":128},[],{"intervention":13474,"totalTrials":676,"cells":13479},{"EARLY_PHASE1":13480,"PHASE1":13482,"PHASE2":13484,"PHASE3":13486,"PHASE4":13488,"NA":13494},{"trials":13481,"activeCount":128},[],{"trials":13483,"activeCount":128},[],{"trials":13485,"activeCount":128},[],{"trials":13487,"activeCount":128},[],{"trials":13489,"activeCount":128},[13490],{"nctId":13468,"briefTitle":13469,"status":104,"phases":13491,"primaryCompletion":4032,"completion":4032,"start":7657,"enrollment":2608,"conditions":13492,"interventions":13493},[93],[13472],[13455,13474,13475],{"trials":13495,"activeCount":128},[],{"intervention":13475,"totalTrials":676,"cells":13497},{"EARLY_PHASE1":13498,"PHASE1":13500,"PHASE2":13502,"PHASE3":13504,"PHASE4":13506,"NA":13512},{"trials":13499,"activeCount":128},[],{"trials":13501,"activeCount":128},[],{"trials":13503,"activeCount":128},[],{"trials":13505,"activeCount":128},[],{"trials":13507,"activeCount":128},[13508],{"nctId":13468,"briefTitle":13469,"status":104,"phases":13509,"primaryCompletion":4032,"completion":4032,"start":7657,"enrollment":2608,"conditions":13510,"interventions":13511},[93],[13472],[13455,13474,13475],{"trials":13513,"activeCount":128},[],{"intervention":13515,"totalTrials":676,"cells":13516},"HTX-011",{"EARLY_PHASE1":13517,"PHASE1":13519,"PHASE2":13521,"PHASE3":13523,"PHASE4":13525,"NA":13536},{"trials":13518,"activeCount":128},[],{"trials":13520,"activeCount":128},[],{"trials":13522,"activeCount":128},[],{"trials":13524,"activeCount":128},[],{"trials":13526,"activeCount":128},[13527],{"nctId":13528,"briefTitle":13529,"status":104,"phases":13530,"primaryCompletion":13531,"completion":13531,"start":13532,"enrollment":2864,"conditions":13533,"interventions":13534},"NCT05188053","Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty",[93],"2024-04-18","2022-03-11",[972],[13515,13535],"ropivacaine , epinephrine , ketorolac diluted in sodium chloride",{"trials":13537,"activeCount":128},[],{"intervention":13535,"totalTrials":676,"cells":13539},{"EARLY_PHASE1":13540,"PHASE1":13542,"PHASE2":13544,"PHASE3":13546,"PHASE4":13548,"NA":13554},{"trials":13541,"activeCount":128},[],{"trials":13543,"activeCount":128},[],{"trials":13545,"activeCount":128},[],{"trials":13547,"activeCount":128},[],{"trials":13549,"activeCount":128},[13550],{"nctId":13528,"briefTitle":13529,"status":104,"phases":13551,"primaryCompletion":13531,"completion":13531,"start":13532,"enrollment":2864,"conditions":13552,"interventions":13553},[93],[972],[13515,13535],{"trials":13555,"activeCount":128},[],{"intervention":13557,"totalTrials":676,"cells":13558},"Armodafinil",{"EARLY_PHASE1":13559,"PHASE1":13561,"PHASE2":13563,"PHASE3":13565,"PHASE4":13567,"NA":13575},{"trials":13560,"activeCount":128},[],{"trials":13562,"activeCount":128},[],{"trials":13564,"activeCount":128},[],{"trials":13566,"activeCount":128},[],{"trials":13568,"activeCount":128},[13569],{"nctId":13570,"briefTitle":13571,"status":104,"phases":13572,"primaryCompletion":954,"completion":954,"start":7657,"enrollment":173,"conditions":13573,"interventions":13574},"NCT01023672","\"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies\"",[93],[1393],[13557],{"trials":13576,"activeCount":128},[],{"intervention":13578,"totalTrials":676,"cells":13579},"Entresto™ 49Mg-51 mg",{"EARLY_PHASE1":13580,"PHASE1":13582,"PHASE2":13584,"PHASE3":13586,"PHASE4":13588,"NA":13598},{"trials":13581,"activeCount":128},[],{"trials":13583,"activeCount":128},[],{"trials":13585,"activeCount":128},[],{"trials":13587,"activeCount":128},[],{"trials":13589,"activeCount":128},[13590],{"nctId":13591,"briefTitle":13592,"status":104,"phases":13593,"primaryCompletion":13594,"completion":13594,"start":13595,"enrollment":498,"conditions":13596,"interventions":13597},"NCT03506412","Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction",[93],"2021-03-23","2018-06-25",[7184],[13578],{"trials":13599,"activeCount":128},[],{"intervention":13601,"totalTrials":676,"cells":13602},"Basal insulin",{"EARLY_PHASE1":13603,"PHASE1":13605,"PHASE2":13607,"PHASE3":13609,"PHASE4":13611,"NA":13621},{"trials":13604,"activeCount":128},[],{"trials":13606,"activeCount":128},[],{"trials":13608,"activeCount":128},[],{"trials":13610,"activeCount":128},[],{"trials":13612,"activeCount":128},[13613],{"nctId":13614,"briefTitle":13615,"status":104,"phases":13616,"primaryCompletion":13617,"completion":13617,"start":13618,"enrollment":3002,"conditions":13619,"interventions":13620},"NCT00276393","Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes",[93],"2003-12","2002-07",[9460],[13601],{"trials":13622,"activeCount":128},[],{"intervention":13624,"totalTrials":676,"cells":13625},"Peripheral nerve blocks with Bupivacaine",{"EARLY_PHASE1":13626,"PHASE1":13628,"PHASE2":13630,"PHASE3":13632,"PHASE4":13634,"NA":13644},{"trials":13627,"activeCount":128},[],{"trials":13629,"activeCount":128},[],{"trials":13631,"activeCount":128},[],{"trials":13633,"activeCount":128},[],{"trials":13635,"activeCount":128},[13636],{"nctId":13637,"briefTitle":13638,"status":104,"phases":13639,"primaryCompletion":872,"completion":872,"start":4300,"enrollment":1162,"conditions":13640,"interventions":13641},"NCT02223364","Peripheral Nerve Blocks vs Periarticular Local Anesthetic Injection for Total Knee Arthroplasty (TKA)",[93],[972],[13624,13642,13643],"Intra articular injection with Ropivacaine","Intra articular injection with liposomal bupivacaine",{"trials":13645,"activeCount":128},[],{"intervention":13642,"totalTrials":676,"cells":13647},{"EARLY_PHASE1":13648,"PHASE1":13650,"PHASE2":13652,"PHASE3":13654,"PHASE4":13656,"NA":13662},{"trials":13649,"activeCount":128},[],{"trials":13651,"activeCount":128},[],{"trials":13653,"activeCount":128},[],{"trials":13655,"activeCount":128},[],{"trials":13657,"activeCount":128},[13658],{"nctId":13637,"briefTitle":13638,"status":104,"phases":13659,"primaryCompletion":872,"completion":872,"start":4300,"enrollment":1162,"conditions":13660,"interventions":13661},[93],[972],[13624,13642,13643],{"trials":13663,"activeCount":128},[],{"intervention":13643,"totalTrials":676,"cells":13665},{"EARLY_PHASE1":13666,"PHASE1":13668,"PHASE2":13670,"PHASE3":13672,"PHASE4":13674,"NA":13680},{"trials":13667,"activeCount":128},[],{"trials":13669,"activeCount":128},[],{"trials":13671,"activeCount":128},[],{"trials":13673,"activeCount":128},[],{"trials":13675,"activeCount":128},[13676],{"nctId":13637,"briefTitle":13638,"status":104,"phases":13677,"primaryCompletion":872,"completion":872,"start":4300,"enrollment":1162,"conditions":13678,"interventions":13679},[93],[972],[13624,13642,13643],{"trials":13681,"activeCount":128},[],{"intervention":13683,"totalTrials":676,"cells":13684},"Envarsus XR",{"EARLY_PHASE1":13685,"PHASE1":13687,"PHASE2":13689,"PHASE3":13691,"PHASE4":13693,"NA":13705},{"trials":13686,"activeCount":128},[],{"trials":13688,"activeCount":128},[],{"trials":13690,"activeCount":128},[],{"trials":13692,"activeCount":128},[],{"trials":13694,"activeCount":128},[13695],{"nctId":13696,"briefTitle":13697,"status":104,"phases":13698,"primaryCompletion":13165,"completion":13165,"start":13699,"enrollment":13700,"conditions":13701,"interventions":13703},"NCT03979365","Envarsus XR Compared to Immediate Release Tacrolimus",[93],"2019-07-18",261,[13702],"Kidney Transplant Recipients",[13683,13704],"Tacrolimus twice daily",{"trials":13706,"activeCount":128},[],{"intervention":13704,"totalTrials":676,"cells":13708},{"EARLY_PHASE1":13709,"PHASE1":13711,"PHASE2":13713,"PHASE3":13715,"PHASE4":13717,"NA":13723},{"trials":13710,"activeCount":128},[],{"trials":13712,"activeCount":128},[],{"trials":13714,"activeCount":128},[],{"trials":13716,"activeCount":128},[],{"trials":13718,"activeCount":128},[13719],{"nctId":13696,"briefTitle":13697,"status":104,"phases":13720,"primaryCompletion":13165,"completion":13165,"start":13699,"enrollment":13700,"conditions":13721,"interventions":13722},[93],[13702],[13683,13704],{"trials":13724,"activeCount":128},[],{"intervention":13726,"totalTrials":676,"cells":13727},"bupivacaine and epinephrine",{"EARLY_PHASE1":13728,"PHASE1":13730,"PHASE2":13732,"PHASE3":13734,"PHASE4":13736,"NA":13745},{"trials":13729,"activeCount":128},[],{"trials":13731,"activeCount":128},[],{"trials":13733,"activeCount":128},[],{"trials":13735,"activeCount":128},[],{"trials":13737,"activeCount":128},[13738],{"nctId":13739,"briefTitle":13740,"status":104,"phases":13741,"primaryCompletion":13742,"completion":13742,"start":7604,"enrollment":1151,"conditions":13743,"interventions":13744},"NCT00318292","Preemptive Local Anesthesia in Vaginal Surgery",[93],"2008-03",[799],[13726],{"trials":13746,"activeCount":128},[],{"intervention":13748,"totalTrials":676,"cells":13749},"Bupivacaine liposome",{"EARLY_PHASE1":13750,"PHASE1":13752,"PHASE2":13754,"PHASE3":13756,"PHASE4":13758,"NA":13770},{"trials":13751,"activeCount":128},[],{"trials":13753,"activeCount":128},[],{"trials":13755,"activeCount":128},[],{"trials":13757,"activeCount":128},[],{"trials":13759,"activeCount":128},[13760],{"nctId":13761,"briefTitle":13762,"status":134,"phases":13763,"primaryCompletion":13764,"completion":13765,"start":13766,"enrollment":342,"conditions":13767,"interventions":13769},"NCT05992896","A Study of Loco-Regional Liposomal Bupivacaine Injection",[93],"2025-05-15","2025-06-30","2023-09-26",[13768],"Peripheral Arterial Disease",[13748],{"trials":13771,"activeCount":128},[],{"intervention":13159,"totalTrials":676,"cells":13773},{"EARLY_PHASE1":13774,"PHASE1":13776,"PHASE2":13778,"PHASE3":13780,"PHASE4":13782,"NA":13788},{"trials":13775,"activeCount":128},[],{"trials":13777,"activeCount":128},[],{"trials":13779,"activeCount":128},[],{"trials":13781,"activeCount":128},[],{"trials":13783,"activeCount":128},[13784],{"nctId":13150,"briefTitle":13151,"status":104,"phases":13785,"primaryCompletion":13153,"completion":13153,"start":3569,"enrollment":13154,"conditions":13786,"interventions":13787},[93],[1216,13156,13157],[13137,13159],{"trials":13789,"activeCount":128},[],{"intervention":13791,"totalTrials":676,"cells":13792},"Nitrofurantoin",{"EARLY_PHASE1":13793,"PHASE1":13795,"PHASE2":13797,"PHASE3":13799,"PHASE4":13801,"NA":13813},{"trials":13794,"activeCount":128},[],{"trials":13796,"activeCount":128},[],{"trials":13798,"activeCount":128},[],{"trials":13800,"activeCount":128},[],{"trials":13802,"activeCount":128},[13803],{"nctId":13804,"briefTitle":13805,"status":1413,"phases":13806,"primaryCompletion":13807,"completion":13807,"start":13808,"enrollment":128,"conditions":13809,"interventions":13811},"NCT03299387","INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI",[93],"2018-07-05","2017-06-28",[13810],"Urinary Tract Infections",[13791,13812],"Gentamicin",{"trials":13814,"activeCount":128},[],{"intervention":13812,"totalTrials":676,"cells":13816},{"EARLY_PHASE1":13817,"PHASE1":13819,"PHASE2":13821,"PHASE3":13823,"PHASE4":13825,"NA":13831},{"trials":13818,"activeCount":128},[],{"trials":13820,"activeCount":128},[],{"trials":13822,"activeCount":128},[],{"trials":13824,"activeCount":128},[],{"trials":13826,"activeCount":128},[13827],{"nctId":13804,"briefTitle":13805,"status":1413,"phases":13828,"primaryCompletion":13807,"completion":13807,"start":13808,"enrollment":128,"conditions":13829,"interventions":13830},[93],[13810],[13791,13812],{"trials":13832,"activeCount":128},[],{"intervention":13834,"totalTrials":676,"cells":13835},"Hydromorphone 2.5 mcg\u002Fkg",{"EARLY_PHASE1":13836,"PHASE1":13838,"PHASE2":13840,"PHASE3":13842,"PHASE4":13844,"NA":13866},{"trials":13837,"activeCount":128},[],{"trials":13839,"activeCount":128},[],{"trials":13841,"activeCount":128},[],{"trials":13843,"activeCount":128},[],{"trials":13845,"activeCount":128},[13846],{"nctId":13847,"briefTitle":13848,"status":134,"phases":13849,"primaryCompletion":13850,"completion":13851,"start":4820,"enrollment":525,"conditions":13852,"interventions":13854},"NCT05552443","A Study of Intrathecal Hydromorphone for Pediatric Idiopathic Scoliosis Repair",[93],"2024-10-27","2024-12-31",[13853],"Pain Control",[13834,13855,13856,13857,13858,13859,13860,13861,13862,13863,13864,13865],"Hydromorphone 2.75 mcg\u002Fkg","Hydromorphone 3 mcg\u002Fkg","Hydromorphone 3.25 mcg\u002Fkg","Hydromorphone 3.5 mcg\u002Fkg","Hydromorphone 4 mcg\u002Fkg","Hydromorphone 4.5 mcg\u002Fkg","Hydromorphone 5 mcg\u002Fkg","Hydromorphone 5.5 mcg\u002Fkg","Hydromorphone 6 mcg\u002Fkg","Hydromorphone 6.5 mcg\u002Fkg","Hydromorphone 7 mcg\u002Fkg",{"trials":13867,"activeCount":128},[],{"intervention":13855,"totalTrials":676,"cells":13869},{"EARLY_PHASE1":13870,"PHASE1":13872,"PHASE2":13874,"PHASE3":13876,"PHASE4":13878,"NA":13884},{"trials":13871,"activeCount":128},[],{"trials":13873,"activeCount":128},[],{"trials":13875,"activeCount":128},[],{"trials":13877,"activeCount":128},[],{"trials":13879,"activeCount":128},[13880],{"nctId":13847,"briefTitle":13848,"status":134,"phases":13881,"primaryCompletion":13850,"completion":13851,"start":4820,"enrollment":525,"conditions":13882,"interventions":13883},[93],[13853],[13834,13855,13856,13857,13858,13859,13860,13861,13862,13863,13864,13865],{"trials":13885,"activeCount":128},[],{"intervention":13856,"totalTrials":676,"cells":13887},{"EARLY_PHASE1":13888,"PHASE1":13890,"PHASE2":13892,"PHASE3":13894,"PHASE4":13896,"NA":13902},{"trials":13889,"activeCount":128},[],{"trials":13891,"activeCount":128},[],{"trials":13893,"activeCount":128},[],{"trials":13895,"activeCount":128},[],{"trials":13897,"activeCount":128},[13898],{"nctId":13847,"briefTitle":13848,"status":134,"phases":13899,"primaryCompletion":13850,"completion":13851,"start":4820,"enrollment":525,"conditions":13900,"interventions":13901},[93],[13853],[13834,13855,13856,13857,13858,13859,13860,13861,13862,13863,13864,13865],{"trials":13903,"activeCount":128},[],{"intervention":13857,"totalTrials":676,"cells":13905},{"EARLY_PHASE1":13906,"PHASE1":13908,"PHASE2":13910,"PHASE3":13912,"PHASE4":13914,"NA":13920},{"trials":13907,"activeCount":128},[],{"trials":13909,"activeCount":128},[],{"trials":13911,"activeCount":128},[],{"trials":13913,"activeCount":128},[],{"trials":13915,"activeCount":128},[13916],{"nctId":13847,"briefTitle":13848,"status":134,"phases":13917,"primaryCompletion":13850,"completion":13851,"start":4820,"enrollment":525,"conditions":13918,"interventions":13919},[93],[13853],[13834,13855,13856,13857,13858,13859,13860,13861,13862,13863,13864,13865],{"trials":13921,"activeCount":128},[],{"intervention":13858,"totalTrials":676,"cells":13923},{"EARLY_PHASE1":13924,"PHASE1":13926,"PHASE2":13928,"PHASE3":13930,"PHASE4":13932,"NA":13938},{"trials":13925,"activeCount":128},[],{"trials":13927,"activeCount":128},[],{"trials":13929,"activeCount":128},[],{"trials":13931,"activeCount":128},[],{"trials":13933,"activeCount":128},[13934],{"nctId":13847,"briefTitle":13848,"status":134,"phases":13935,"primaryCompletion":13850,"completion":13851,"start":4820,"enrollment":525,"conditions":13936,"interventions":13937},[93],[13853],[13834,13855,13856,13857,13858,13859,13860,13861,13862,13863,13864,13865],{"trials":13939,"activeCount":128},[],{"intervention":13859,"totalTrials":676,"cells":13941},{"EARLY_PHASE1":13942,"PHASE1":13944,"PHASE2":13946,"PHASE3":13948,"PHASE4":13950,"NA":13956},{"trials":13943,"activeCount":128},[],{"trials":13945,"activeCount":128},[],{"trials":13947,"activeCount":128},[],{"trials":13949,"activeCount":128},[],{"trials":13951,"activeCount":128},[13952],{"nctId":13847,"briefTitle":13848,"status":134,"phases":13953,"primaryCompletion":13850,"completion":13851,"start":4820,"enrollment":525,"conditions":13954,"interventions":13955},[93],[13853],[13834,13855,13856,13857,13858,13859,13860,13861,13862,13863,13864,13865],{"trials":13957,"activeCount":128},[],{"intervention":13860,"totalTrials":676,"cells":13959},{"EARLY_PHASE1":13960,"PHASE1":13962,"PHASE2":13964,"PHASE3":13966,"PHASE4":13968,"NA":13974},{"trials":13961,"activeCount":128},[],{"trials":13963,"activeCount":128},[],{"trials":13965,"activeCount":128},[],{"trials":13967,"activeCount":128},[],{"trials":13969,"activeCount":128},[13970],{"nctId":13847,"briefTitle":13848,"status":134,"phases":13971,"primaryCompletion":13850,"completion":13851,"start":4820,"enrollment":525,"conditions":13972,"interventions":13973},[93],[13853],[13834,13855,13856,13857,13858,13859,13860,13861,13862,13863,13864,13865],{"trials":13975,"activeCount":128},[],{"intervention":13861,"totalTrials":676,"cells":13977},{"EARLY_PHASE1":13978,"PHASE1":13980,"PHASE2":13982,"PHASE3":13984,"PHASE4":13986,"NA":13992},{"trials":13979,"activeCount":128},[],{"trials":13981,"activeCount":128},[],{"trials":13983,"activeCount":128},[],{"trials":13985,"activeCount":128},[],{"trials":13987,"activeCount":128},[13988],{"nctId":13847,"briefTitle":13848,"status":134,"phases":13989,"primaryCompletion":13850,"completion":13851,"start":4820,"enrollment":525,"conditions":13990,"interventions":13991},[93],[13853],[13834,13855,13856,13857,13858,13859,13860,13861,13862,13863,13864,13865],{"trials":13993,"activeCount":128},[],{"intervention":13862,"totalTrials":676,"cells":13995},{"EARLY_PHASE1":13996,"PHASE1":13998,"PHASE2":14000,"PHASE3":14002,"PHASE4":14004,"NA":14010},{"trials":13997,"activeCount":128},[],{"trials":13999,"activeCount":128},[],{"trials":14001,"activeCount":128},[],{"trials":14003,"activeCount":128},[],{"trials":14005,"activeCount":128},[14006],{"nctId":13847,"briefTitle":13848,"status":134,"phases":14007,"primaryCompletion":13850,"completion":13851,"start":4820,"enrollment":525,"conditions":14008,"interventions":14009},[93],[13853],[13834,13855,13856,13857,13858,13859,13860,13861,13862,13863,13864,13865],{"trials":14011,"activeCount":128},[],{"intervention":13863,"totalTrials":676,"cells":14013},{"EARLY_PHASE1":14014,"PHASE1":14016,"PHASE2":14018,"PHASE3":14020,"PHASE4":14022,"NA":14028},{"trials":14015,"activeCount":128},[],{"trials":14017,"activeCount":128},[],{"trials":14019,"activeCount":128},[],{"trials":14021,"activeCount":128},[],{"trials":14023,"activeCount":128},[14024],{"nctId":13847,"briefTitle":13848,"status":134,"phases":14025,"primaryCompletion":13850,"completion":13851,"start":4820,"enrollment":525,"conditions":14026,"interventions":14027},[93],[13853],[13834,13855,13856,13857,13858,13859,13860,13861,13862,13863,13864,13865],{"trials":14029,"activeCount":128},[],{"intervention":13864,"totalTrials":676,"cells":14031},{"EARLY_PHASE1":14032,"PHASE1":14034,"PHASE2":14036,"PHASE3":14038,"PHASE4":14040,"NA":14046},{"trials":14033,"activeCount":128},[],{"trials":14035,"activeCount":128},[],{"trials":14037,"activeCount":128},[],{"trials":14039,"activeCount":128},[],{"trials":14041,"activeCount":128},[14042],{"nctId":13847,"briefTitle":13848,"status":134,"phases":14043,"primaryCompletion":13850,"completion":13851,"start":4820,"enrollment":525,"conditions":14044,"interventions":14045},[93],[13853],[13834,13855,13856,13857,13858,13859,13860,13861,13862,13863,13864,13865],{"trials":14047,"activeCount":128},[],{"intervention":13865,"totalTrials":676,"cells":14049},{"EARLY_PHASE1":14050,"PHASE1":14052,"PHASE2":14054,"PHASE3":14056,"PHASE4":14058,"NA":14064},{"trials":14051,"activeCount":128},[],{"trials":14053,"activeCount":128},[],{"trials":14055,"activeCount":128},[],{"trials":14057,"activeCount":128},[],{"trials":14059,"activeCount":128},[14060],{"nctId":13847,"briefTitle":13848,"status":134,"phases":14061,"primaryCompletion":13850,"completion":13851,"start":4820,"enrollment":525,"conditions":14062,"interventions":14063},[93],[13853],[13834,13855,13856,13857,13858,13859,13860,13861,13862,13863,13864,13865],{"trials":14065,"activeCount":128},[],{"intervention":14067,"totalTrials":676,"cells":14068},"Single shot interscalene nerve block",{"EARLY_PHASE1":14069,"PHASE1":14071,"PHASE2":14073,"PHASE3":14075,"PHASE4":14077,"NA":14087},{"trials":14070,"activeCount":128},[],{"trials":14072,"activeCount":128},[],{"trials":14074,"activeCount":128},[],{"trials":14076,"activeCount":128},[],{"trials":14078,"activeCount":128},[14079],{"nctId":14080,"briefTitle":14081,"status":104,"phases":14082,"primaryCompletion":2606,"completion":2606,"start":1471,"enrollment":1300,"conditions":14083,"interventions":14084},"NCT02876055","Analgesic Efficacy of Interscalene Nerve Block Versus Local Infiltration Analgesia Following Total Shoulder Arthroplasty",[93],[799],[14067,14085,14086],"Continuous interscalene nerve block","Local Infiltration Analgesia",{"trials":14088,"activeCount":128},[],{"intervention":14085,"totalTrials":676,"cells":14090},{"EARLY_PHASE1":14091,"PHASE1":14093,"PHASE2":14095,"PHASE3":14097,"PHASE4":14099,"NA":14105},{"trials":14092,"activeCount":128},[],{"trials":14094,"activeCount":128},[],{"trials":14096,"activeCount":128},[],{"trials":14098,"activeCount":128},[],{"trials":14100,"activeCount":128},[14101],{"nctId":14080,"briefTitle":14081,"status":104,"phases":14102,"primaryCompletion":2606,"completion":2606,"start":1471,"enrollment":1300,"conditions":14103,"interventions":14104},[93],[799],[14067,14085,14086],{"trials":14106,"activeCount":128},[],{"intervention":14086,"totalTrials":676,"cells":14108},{"EARLY_PHASE1":14109,"PHASE1":14111,"PHASE2":14113,"PHASE3":14115,"PHASE4":14117,"NA":14123},{"trials":14110,"activeCount":128},[],{"trials":14112,"activeCount":128},[],{"trials":14114,"activeCount":128},[],{"trials":14116,"activeCount":128},[],{"trials":14118,"activeCount":128},[14119],{"nctId":14080,"briefTitle":14081,"status":104,"phases":14120,"primaryCompletion":2606,"completion":2606,"start":1471,"enrollment":1300,"conditions":14121,"interventions":14122},[93],[799],[14067,14085,14086],{"trials":14124,"activeCount":128},[],{"intervention":14126,"totalTrials":676,"cells":14127},"Pegasys",{"EARLY_PHASE1":14128,"PHASE1":14130,"PHASE2":14132,"PHASE3":14134,"PHASE4":14136,"NA":14145},{"trials":14129,"activeCount":128},[],{"trials":14131,"activeCount":128},[],{"trials":14133,"activeCount":128},[],{"trials":14135,"activeCount":128},[],{"trials":14137,"activeCount":128},[14138],{"nctId":14139,"briefTitle":14140,"status":104,"phases":14141,"primaryCompletion":1297,"completion":1563,"start":12886,"enrollment":218,"conditions":14142,"interventions":14143},"NCT00275548","Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C",[93],[8331,2494],[14126,14144],"Copegus",{"trials":14146,"activeCount":128},[],{"intervention":14144,"totalTrials":676,"cells":14148},{"EARLY_PHASE1":14149,"PHASE1":14151,"PHASE2":14153,"PHASE3":14155,"PHASE4":14157,"NA":14163},{"trials":14150,"activeCount":128},[],{"trials":14152,"activeCount":128},[],{"trials":14154,"activeCount":128},[],{"trials":14156,"activeCount":128},[],{"trials":14158,"activeCount":128},[14159],{"nctId":14139,"briefTitle":14140,"status":104,"phases":14160,"primaryCompletion":1297,"completion":1563,"start":12886,"enrollment":218,"conditions":14161,"interventions":14162},[93],[8331,2494],[14126,14144],{"trials":14164,"activeCount":128},[],{"intervention":14166,"totalTrials":676,"cells":14167},"Lofexidine Oral",{"EARLY_PHASE1":14168,"PHASE1":14170,"PHASE2":14172,"PHASE3":14174,"PHASE4":14176,"NA":14187},{"trials":14169,"activeCount":128},[],{"trials":14171,"activeCount":128},[],{"trials":14173,"activeCount":128},[],{"trials":14175,"activeCount":128},[],{"trials":14177,"activeCount":128},[14178],{"nctId":14179,"briefTitle":14180,"status":104,"phases":14181,"primaryCompletion":14182,"completion":14182,"start":14183,"enrollment":1197,"conditions":14184,"interventions":14186},"NCT04126083","Lofexidine for Adults Undergoing Lumbar Spine Surgery",[93],"2021-04-15","2019-09-01",[14185],"Opioid Withdrawal",[14166],{"trials":14188,"activeCount":128},[],{"intervention":14190,"totalTrials":676,"cells":14191},"Low bicarbonate solution",{"EARLY_PHASE1":14192,"PHASE1":14194,"PHASE2":14196,"PHASE3":14198,"PHASE4":14200,"NA":14211},{"trials":14193,"activeCount":128},[],{"trials":14195,"activeCount":128},[],{"trials":14197,"activeCount":128},[],{"trials":14199,"activeCount":128},[],{"trials":14201,"activeCount":128},[14202],{"nctId":14203,"briefTitle":14204,"status":1413,"phases":14205,"primaryCompletion":3228,"completion":3228,"start":14206,"enrollment":128,"conditions":14207,"interventions":14209},"NCT03846258","High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy",[93],"2019-05-01",[2115,909,14208],"Acute Kidney Failure",[14190,14210],"High Bicarbonate solution",{"trials":14212,"activeCount":128},[],{"intervention":14210,"totalTrials":676,"cells":14214},{"EARLY_PHASE1":14215,"PHASE1":14217,"PHASE2":14219,"PHASE3":14221,"PHASE4":14223,"NA":14229},{"trials":14216,"activeCount":128},[],{"trials":14218,"activeCount":128},[],{"trials":14220,"activeCount":128},[],{"trials":14222,"activeCount":128},[],{"trials":14224,"activeCount":128},[14225],{"nctId":14203,"briefTitle":14204,"status":1413,"phases":14226,"primaryCompletion":3228,"completion":3228,"start":14206,"enrollment":128,"conditions":14227,"interventions":14228},[93],[2115,909,14208],[14190,14210],{"trials":14230,"activeCount":128},[],{"intervention":14232,"totalTrials":676,"cells":14233},"nicotine replacement patch",{"EARLY_PHASE1":14234,"PHASE1":14236,"PHASE2":14238,"PHASE3":14240,"PHASE4":14242,"NA":14252},{"trials":14235,"activeCount":128},[],{"trials":14237,"activeCount":128},[],{"trials":14239,"activeCount":128},[],{"trials":14241,"activeCount":128},[],{"trials":14243,"activeCount":128},[14244],{"nctId":14245,"briefTitle":14246,"status":104,"phases":14247,"primaryCompletion":11480,"completion":11480,"start":3754,"enrollment":14248,"conditions":14249,"interventions":14251},"NCT00004551","Behavioral Counseling for Alcohol Dependent Smokers (Nicotine Patch)",[93],144,[14250,13450],"Alcoholism",[14232],{"trials":14253,"activeCount":128},[],{"intervention":14255,"totalTrials":676,"cells":14256},"Sulfur Hexafluoride",{"EARLY_PHASE1":14257,"PHASE1":14259,"PHASE2":14261,"PHASE3":14263,"PHASE4":14265,"NA":14276},{"trials":14258,"activeCount":128},[],{"trials":14260,"activeCount":128},[],{"trials":14262,"activeCount":128},[],{"trials":14264,"activeCount":128},[],{"trials":14266,"activeCount":128},[14267],{"nctId":14268,"briefTitle":14269,"status":134,"phases":14270,"primaryCompletion":14271,"completion":14271,"start":14272,"enrollment":476,"conditions":14273,"interventions":14275},"NCT03235180","Ultrasound Evaluation of Crohn's Disease",[93],"2021-10-12","2017-06-16",[14274],"Crohn Disease",[14255],{"trials":14277,"activeCount":128},[],{"intervention":2735,"totalTrials":676,"cells":14279},{"EARLY_PHASE1":14280,"PHASE1":14282,"PHASE2":14284,"PHASE3":14286,"PHASE4":14288,"NA":14294},{"trials":14281,"activeCount":128},[],{"trials":14283,"activeCount":128},[],{"trials":14285,"activeCount":128},[],{"trials":14287,"activeCount":128},[],{"trials":14289,"activeCount":128},[14290],{"nctId":2727,"briefTitle":2728,"status":104,"phases":14291,"primaryCompletion":2730,"completion":2730,"start":2731,"enrollment":797,"conditions":14292,"interventions":14293},[93],[2733],[1013,2735,2736],{"trials":14295,"activeCount":128},[],{"intervention":2736,"totalTrials":676,"cells":14297},{"EARLY_PHASE1":14298,"PHASE1":14300,"PHASE2":14302,"PHASE3":14304,"PHASE4":14306,"NA":14312},{"trials":14299,"activeCount":128},[],{"trials":14301,"activeCount":128},[],{"trials":14303,"activeCount":128},[],{"trials":14305,"activeCount":128},[],{"trials":14307,"activeCount":128},[14308],{"nctId":2727,"briefTitle":2728,"status":104,"phases":14309,"primaryCompletion":2730,"completion":2730,"start":2731,"enrollment":797,"conditions":14310,"interventions":14311},[93],[2733],[1013,2735,2736],{"trials":14313,"activeCount":128},[],{"intervention":13169,"totalTrials":676,"cells":14315},{"EARLY_PHASE1":14316,"PHASE1":14318,"PHASE2":14320,"PHASE3":14322,"PHASE4":14324,"NA":14330},{"trials":14317,"activeCount":128},[],{"trials":14319,"activeCount":128},[],{"trials":14321,"activeCount":128},[],{"trials":14323,"activeCount":128},[],{"trials":14325,"activeCount":128},[14326],{"nctId":13161,"briefTitle":13162,"status":104,"phases":14327,"primaryCompletion":13164,"completion":13164,"start":13165,"enrollment":7851,"conditions":14328,"interventions":14329},[93],[13167],[13137,13169,13170],{"trials":14331,"activeCount":128},[],{"intervention":13170,"totalTrials":676,"cells":14333},{"EARLY_PHASE1":14334,"PHASE1":14336,"PHASE2":14338,"PHASE3":14340,"PHASE4":14342,"NA":14348},{"trials":14335,"activeCount":128},[],{"trials":14337,"activeCount":128},[],{"trials":14339,"activeCount":128},[],{"trials":14341,"activeCount":128},[],{"trials":14343,"activeCount":128},[14344],{"nctId":13161,"briefTitle":13162,"status":104,"phases":14345,"primaryCompletion":13164,"completion":13164,"start":13165,"enrollment":7851,"conditions":14346,"interventions":14347},[93],[13167],[13137,13169,13170],{"trials":14349,"activeCount":128},[],{"intervention":14351,"totalTrials":676,"cells":14352},"Sugammadex",{"EARLY_PHASE1":14353,"PHASE1":14355,"PHASE2":14357,"PHASE3":14359,"PHASE4":14361,"NA":14370},{"trials":14354,"activeCount":128},[],{"trials":14356,"activeCount":128},[],{"trials":14358,"activeCount":128},[],{"trials":14360,"activeCount":128},[],{"trials":14362,"activeCount":128},[14363],{"nctId":14364,"briefTitle":14365,"status":104,"phases":14366,"primaryCompletion":3000,"completion":3000,"start":4278,"enrollment":10465,"conditions":14367,"interventions":14369},"NCT02728726","Sugammadex vs Placebo to Prevent Residual Neuromuscular Block",[93],[14368],"General Surgery",[14351],{"trials":14371,"activeCount":128},[],{"intervention":14373,"totalTrials":676,"cells":14374},"Recombinant antithrombin",{"EARLY_PHASE1":14375,"PHASE1":14377,"PHASE2":14379,"PHASE3":14381,"PHASE4":14383,"NA":14393},{"trials":14376,"activeCount":128},[],{"trials":14378,"activeCount":128},[],{"trials":14380,"activeCount":128},[],{"trials":14382,"activeCount":128},[],{"trials":14384,"activeCount":128},[14385],{"nctId":14386,"briefTitle":14387,"status":134,"phases":14388,"primaryCompletion":14389,"completion":14389,"start":2979,"enrollment":7658,"conditions":14390,"interventions":14392},"NCT01547728","Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery",[93],"2014-02",[14391],"Thrombophilia Due to Acquired Antithrombin III Deficiency",[14373],{"trials":14394,"activeCount":128},[],{"intervention":14396,"totalTrials":676,"cells":14397},"Withdrawal of Oral Budesonide",{"EARLY_PHASE1":14398,"PHASE1":14400,"PHASE2":14402,"PHASE3":14404,"PHASE4":14406,"NA":14421},{"trials":14399,"activeCount":128},[],{"trials":14401,"activeCount":128},[],{"trials":14403,"activeCount":128},[],{"trials":14405,"activeCount":128},[],{"trials":14407,"activeCount":128},[14408],{"nctId":14409,"briefTitle":14410,"status":134,"phases":14411,"primaryCompletion":14412,"completion":14412,"start":14413,"enrollment":676,"conditions":14414,"interventions":14420},"NCT03866538","Budesonide in Patients With Immune Mediated Enteropathies",[93],"2021-10-19","2019-09-10",[14415,14416,14417,14418,14419],"Enteropathy","Celiac Disease","CVID Enteropathy","Collagenous Sprue","Autoimmune Enteropathy",[14396],{"trials":14422,"activeCount":128},[],{"intervention":14424,"totalTrials":676,"cells":14425},"Adderall",{"EARLY_PHASE1":14426,"PHASE1":14428,"PHASE2":14430,"PHASE3":14432,"PHASE4":14434,"NA":14444},{"trials":14427,"activeCount":128},[],{"trials":14429,"activeCount":128},[],{"trials":14431,"activeCount":128},[],{"trials":14433,"activeCount":128},[],{"trials":14435,"activeCount":128},[14436],{"nctId":14437,"briefTitle":14438,"status":104,"phases":14439,"primaryCompletion":460,"completion":460,"start":5071,"enrollment":729,"conditions":14440,"interventions":14443},"NCT02979327","Cardiovascular Effects of Adderall in Healthy Adults.",[93],[14441,14442],"Hemodynamics","Cardiovascular System",[14424],{"trials":14445,"activeCount":128},[],{"intervention":14447,"totalTrials":676,"cells":14448},"Prothrombin complex concentrate",{"EARLY_PHASE1":14449,"PHASE1":14451,"PHASE2":14453,"PHASE3":14455,"PHASE4":14457,"NA":14474},{"trials":14450,"activeCount":128},[],{"trials":14452,"activeCount":128},[],{"trials":14454,"activeCount":128},[],{"trials":14456,"activeCount":128},[],{"trials":14458,"activeCount":128},[14459],{"nctId":14460,"briefTitle":14461,"status":104,"phases":14462,"primaryCompletion":14463,"completion":14464,"start":873,"enrollment":14465,"conditions":14466,"interventions":14472},"NCT02557672","PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding",[93],"2021-06","2022-01",106,[14467,14468,14469,14470,14471],"Bleeding","Blood Loss, Surgical","Cardiovascular Surgical Procedures","Prothrombin Complex Concentrates","Fresh Frozen Plasma",[14447,14473],"Fresh frozen plasma",{"trials":14475,"activeCount":128},[],{"intervention":14473,"totalTrials":676,"cells":14477},{"EARLY_PHASE1":14478,"PHASE1":14480,"PHASE2":14482,"PHASE3":14484,"PHASE4":14486,"NA":14492},{"trials":14479,"activeCount":128},[],{"trials":14481,"activeCount":128},[],{"trials":14483,"activeCount":128},[],{"trials":14485,"activeCount":128},[],{"trials":14487,"activeCount":128},[14488],{"nctId":14460,"briefTitle":14461,"status":104,"phases":14489,"primaryCompletion":14463,"completion":14464,"start":873,"enrollment":14465,"conditions":14490,"interventions":14491},[93],[14467,14468,14469,14470,14471],[14447,14473],{"trials":14493,"activeCount":128},[],{"intervention":14495,"totalTrials":676,"cells":14496},"Intravenous line (IV) Methadone",{"EARLY_PHASE1":14497,"PHASE1":14499,"PHASE2":14501,"PHASE3":14503,"PHASE4":14505,"NA":14517},{"trials":14498,"activeCount":128},[],{"trials":14500,"activeCount":128},[],{"trials":14502,"activeCount":128},[],{"trials":14504,"activeCount":128},[],{"trials":14506,"activeCount":128},[14507],{"nctId":14508,"briefTitle":14509,"status":104,"phases":14510,"primaryCompletion":14511,"completion":14512,"start":12363,"enrollment":729,"conditions":14513,"interventions":14515},"NCT06826742","Intravenous Methadone Versus Intrathecal Morphine for Analgesia Following Cesarean Delivery",[93],"2025-09-14","2025-09-23",[14514],"Cesarean Delivery",[14495,14516],"Intrathecal Morphine",{"trials":14518,"activeCount":128},[],{"intervention":14516,"totalTrials":676,"cells":14520},{"EARLY_PHASE1":14521,"PHASE1":14523,"PHASE2":14525,"PHASE3":14527,"PHASE4":14529,"NA":14535},{"trials":14522,"activeCount":128},[],{"trials":14524,"activeCount":128},[],{"trials":14526,"activeCount":128},[],{"trials":14528,"activeCount":128},[],{"trials":14530,"activeCount":128},[14531],{"nctId":14508,"briefTitle":14509,"status":104,"phases":14532,"primaryCompletion":14511,"completion":14512,"start":12363,"enrollment":729,"conditions":14533,"interventions":14534},[93],[14514],[14495,14516],{"trials":14536,"activeCount":128},[],{"intervention":13261,"totalTrials":676,"cells":14538},{"EARLY_PHASE1":14539,"PHASE1":14541,"PHASE2":14543,"PHASE3":14545,"PHASE4":14547,"NA":14553},{"trials":14540,"activeCount":128},[],{"trials":14542,"activeCount":128},[],{"trials":14544,"activeCount":128},[],{"trials":14546,"activeCount":128},[],{"trials":14548,"activeCount":128},[14549],{"nctId":13254,"briefTitle":13255,"status":1413,"phases":14550,"primaryCompletion":13257,"completion":13257,"start":2731,"enrollment":128,"conditions":14551,"interventions":14552},[93],[13259,12825],[13261,889],{"trials":14554,"activeCount":128},[],{"intervention":14556,"totalTrials":676,"cells":14557},"Suvorexant",{"EARLY_PHASE1":14558,"PHASE1":14560,"PHASE2":14562,"PHASE3":14564,"PHASE4":14566,"NA":14576},{"trials":14559,"activeCount":128},[],{"trials":14561,"activeCount":128},[],{"trials":14563,"activeCount":128},[],{"trials":14565,"activeCount":128},[],{"trials":14567,"activeCount":128},[14568],{"nctId":14569,"briefTitle":14570,"status":1413,"phases":14571,"primaryCompletion":14572,"completion":14572,"start":14573,"enrollment":128,"conditions":14574,"interventions":14575},"NCT06834386","Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients",[93],"2025-04-24","2025-02-26",[10158,908,36,9128],[14556],{"trials":14577,"activeCount":128},[],{"intervention":12962,"totalTrials":676,"cells":14579},{"EARLY_PHASE1":14580,"PHASE1":14582,"PHASE2":14584,"PHASE3":14586,"PHASE4":14588,"NA":14594},{"trials":14581,"activeCount":128},[],{"trials":14583,"activeCount":128},[],{"trials":14585,"activeCount":128},[],{"trials":14587,"activeCount":128},[],{"trials":14589,"activeCount":128},[14590],{"nctId":12953,"briefTitle":12954,"status":134,"phases":14591,"primaryCompletion":12956,"completion":12956,"start":4702,"enrollment":681,"conditions":14592,"interventions":14593},[93],[12958,4760,12959,12960,9333],[12962,12932],{"trials":14595,"activeCount":128},[],{"intervention":14597,"totalTrials":676,"cells":14598},"Cozaar",{"EARLY_PHASE1":14599,"PHASE1":14601,"PHASE2":14603,"PHASE3":14605,"PHASE4":14607,"NA":14616},{"trials":14600,"activeCount":128},[],{"trials":14602,"activeCount":128},[],{"trials":14604,"activeCount":128},[],{"trials":14606,"activeCount":128},[],{"trials":14608,"activeCount":128},[14609],{"nctId":14610,"briefTitle":14611,"status":104,"phases":14612,"primaryCompletion":1564,"completion":1564,"start":5352,"enrollment":3034,"conditions":14613,"interventions":14615},"NCT00275639","The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant",[93],[14614],"Liver Transplant Recipients",[14597],{"trials":14617,"activeCount":128},[],{"intervention":14619,"totalTrials":676,"cells":14620},"Ferrous sulfate",{"EARLY_PHASE1":14621,"PHASE1":14623,"PHASE2":14625,"PHASE3":14627,"PHASE4":14629,"NA":14642},{"trials":14622,"activeCount":128},[],{"trials":14624,"activeCount":128},[],{"trials":14626,"activeCount":128},[],{"trials":14628,"activeCount":128},[],{"trials":14630,"activeCount":128},[14631],{"nctId":14632,"briefTitle":14633,"status":134,"phases":14634,"primaryCompletion":14635,"completion":14635,"start":11116,"enrollment":1197,"conditions":14636,"interventions":14641},"NCT04610827","Oral Iron Frequency for Childhood Restless Leg Syndrome\u002FPeriodic Limb Movement Disorder",[93],"2021-06-29",[14637,14638,14639,14640],"Sleep Disorder","Restless Legs Syndrome","Periodic Limb Movement Sleep Disorder","Iron-deficiency",[14619],{"trials":14643,"activeCount":128},[],{"intervention":14645,"totalTrials":676,"cells":14646},"Tiotropium",{"EARLY_PHASE1":14647,"PHASE1":14649,"PHASE2":14651,"PHASE3":14653,"PHASE4":14655,"NA":14665},{"trials":14648,"activeCount":128},[],{"trials":14650,"activeCount":128},[],{"trials":14652,"activeCount":128},[],{"trials":14654,"activeCount":128},[],{"trials":14656,"activeCount":128},[14657],{"nctId":14658,"briefTitle":14659,"status":104,"phases":14660,"primaryCompletion":3673,"completion":3673,"start":3519,"enrollment":187,"conditions":14661,"interventions":14664},"NCT00578968","Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation",[93],[14662,14663],"Chronic Obstructive Pulmonary Disease","COPD",[14645],{"trials":14666,"activeCount":128},[],{"intervention":14668,"totalTrials":676,"cells":14669},"bacteriostatic saline",{"EARLY_PHASE1":14670,"PHASE1":14672,"PHASE2":14674,"PHASE3":14676,"PHASE4":14678,"NA":14688},{"trials":14671,"activeCount":128},[],{"trials":14673,"activeCount":128},[],{"trials":14675,"activeCount":128},[],{"trials":14677,"activeCount":128},[],{"trials":14679,"activeCount":128},[14680],{"nctId":14681,"briefTitle":14682,"status":104,"phases":14683,"primaryCompletion":2606,"completion":2606,"start":2978,"enrollment":3547,"conditions":14684,"interventions":14686},"NCT02209272","Comparison of Bacteriostatic Saline to Buffered Lidocaine for Ultrasound Guided Hip Joint Injection Local Anesthesia",[93],[14685],"Hip Pain",[14668,14687],"buffered lidocaine",{"trials":14689,"activeCount":128},[],{"intervention":14687,"totalTrials":676,"cells":14691},{"EARLY_PHASE1":14692,"PHASE1":14694,"PHASE2":14696,"PHASE3":14698,"PHASE4":14700,"NA":14706},{"trials":14693,"activeCount":128},[],{"trials":14695,"activeCount":128},[],{"trials":14697,"activeCount":128},[],{"trials":14699,"activeCount":128},[],{"trials":14701,"activeCount":128},[14702],{"nctId":14681,"briefTitle":14682,"status":104,"phases":14703,"primaryCompletion":2606,"completion":2606,"start":2978,"enrollment":3547,"conditions":14704,"interventions":14705},[93],[14685],[14668,14687],{"trials":14707,"activeCount":128},[],{"intervention":14709,"totalTrials":676,"cells":14710},"Intravenous Rituximab",{"EARLY_PHASE1":14711,"PHASE1":14713,"PHASE2":14715,"PHASE3":14717,"PHASE4":14719,"NA":14729},{"trials":14712,"activeCount":128},[],{"trials":14714,"activeCount":128},[],{"trials":14716,"activeCount":128},[],{"trials":14718,"activeCount":128},[],{"trials":14720,"activeCount":128},[14721],{"nctId":14722,"briefTitle":14723,"status":104,"phases":14724,"primaryCompletion":905,"completion":905,"start":3546,"enrollment":885,"conditions":14725,"interventions":14727},"NCT00498368","Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy",[93],[14726],"IgA Nephropathy",[14709,14728],"ACE\u002FARB",{"trials":14730,"activeCount":128},[],{"intervention":14728,"totalTrials":676,"cells":14732},{"EARLY_PHASE1":14733,"PHASE1":14735,"PHASE2":14737,"PHASE3":14739,"PHASE4":14741,"NA":14747},{"trials":14734,"activeCount":128},[],{"trials":14736,"activeCount":128},[],{"trials":14738,"activeCount":128},[],{"trials":14740,"activeCount":128},[],{"trials":14742,"activeCount":128},[14743],{"nctId":14722,"briefTitle":14723,"status":104,"phases":14744,"primaryCompletion":905,"completion":905,"start":3546,"enrollment":885,"conditions":14745,"interventions":14746},[93],[14726],[14709,14728],{"trials":14748,"activeCount":128},[],{"intervention":14750,"totalTrials":676,"cells":14751},"Omega-3 polyunsaturated fatty acids",{"EARLY_PHASE1":14752,"PHASE1":14754,"PHASE2":14756,"PHASE3":14758,"PHASE4":14760,"NA":14769},{"trials":14753,"activeCount":128},[],{"trials":14755,"activeCount":128},[],{"trials":14757,"activeCount":128},[],{"trials":14759,"activeCount":128},[],{"trials":14761,"activeCount":128},[14762],{"nctId":14763,"briefTitle":14764,"status":104,"phases":14765,"primaryCompletion":14766,"completion":14766,"start":4030,"enrollment":25,"conditions":14767,"interventions":14768},"NCT01733147","Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids",[93],"2018-09-12",[12032,15],[14750],{"trials":14770,"activeCount":128},[],{"intervention":2625,"totalTrials":676,"cells":14772},{"EARLY_PHASE1":14773,"PHASE1":14775,"PHASE2":14777,"PHASE3":14779,"PHASE4":14781,"NA":14787},{"trials":14774,"activeCount":128},[],{"trials":14776,"activeCount":128},[],{"trials":14778,"activeCount":128},[],{"trials":14780,"activeCount":128},[],{"trials":14782,"activeCount":128},[14783],{"nctId":2617,"briefTitle":2618,"status":104,"phases":14784,"primaryCompletion":2620,"completion":2620,"start":2621,"enrollment":313,"conditions":14785,"interventions":14786},[93],[2623],[2625,2626,2627,2586],{"trials":14788,"activeCount":128},[],{"intervention":14790,"totalTrials":676,"cells":14791},"Phentermine-Topiramate Extended Release",{"EARLY_PHASE1":14792,"PHASE1":14794,"PHASE2":14796,"PHASE3":14798,"PHASE4":14800,"NA":14811},{"trials":14793,"activeCount":128},[],{"trials":14795,"activeCount":128},[],{"trials":14797,"activeCount":128},[],{"trials":14799,"activeCount":128},[],{"trials":14801,"activeCount":128},[14802],{"nctId":14803,"briefTitle":14804,"status":104,"phases":14805,"primaryCompletion":14806,"completion":14807,"start":14808,"enrollment":2678,"conditions":14809,"interventions":14810},"NCT04408586","Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker",[93],"2022-06-13","2022-10-11","2020-06-03",[15],[14790],{"trials":14812,"activeCount":128},[],{"intervention":2950,"totalTrials":676,"cells":14814},{"EARLY_PHASE1":14815,"PHASE1":14817,"PHASE2":14819,"PHASE3":14821,"PHASE4":14823,"NA":14829},{"trials":14816,"activeCount":128},[],{"trials":14818,"activeCount":128},[],{"trials":14820,"activeCount":128},[],{"trials":14822,"activeCount":128},[],{"trials":14824,"activeCount":128},[14825],{"nctId":2943,"briefTitle":2944,"status":104,"phases":14826,"primaryCompletion":2946,"completion":2946,"start":874,"enrollment":1162,"conditions":14827,"interventions":14828},[93],[2948],[2950,2951,2952,2953,2910],{"trials":14830,"activeCount":128},[],{"intervention":2951,"totalTrials":676,"cells":14832},{"EARLY_PHASE1":14833,"PHASE1":14835,"PHASE2":14837,"PHASE3":14839,"PHASE4":14841,"NA":14847},{"trials":14834,"activeCount":128},[],{"trials":14836,"activeCount":128},[],{"trials":14838,"activeCount":128},[],{"trials":14840,"activeCount":128},[],{"trials":14842,"activeCount":128},[14843],{"nctId":2943,"briefTitle":2944,"status":104,"phases":14844,"primaryCompletion":2946,"completion":2946,"start":874,"enrollment":1162,"conditions":14845,"interventions":14846},[93],[2948],[2950,2951,2952,2953,2910],{"trials":14848,"activeCount":128},[],{"intervention":2952,"totalTrials":676,"cells":14850},{"EARLY_PHASE1":14851,"PHASE1":14853,"PHASE2":14855,"PHASE3":14857,"PHASE4":14859,"NA":14865},{"trials":14852,"activeCount":128},[],{"trials":14854,"activeCount":128},[],{"trials":14856,"activeCount":128},[],{"trials":14858,"activeCount":128},[],{"trials":14860,"activeCount":128},[14861],{"nctId":2943,"briefTitle":2944,"status":104,"phases":14862,"primaryCompletion":2946,"completion":2946,"start":874,"enrollment":1162,"conditions":14863,"interventions":14864},[93],[2948],[2950,2951,2952,2953,2910],{"trials":14866,"activeCount":128},[],{"intervention":14868,"totalTrials":676,"cells":14869},"Indocyanine green",{"EARLY_PHASE1":14870,"PHASE1":14872,"PHASE2":14874,"PHASE3":14876,"PHASE4":14878,"NA":14887},{"trials":14871,"activeCount":128},[],{"trials":14873,"activeCount":128},[],{"trials":14875,"activeCount":128},[],{"trials":14877,"activeCount":128},[],{"trials":14879,"activeCount":128},[14880],{"nctId":14881,"briefTitle":14882,"status":1413,"phases":14883,"primaryCompletion":14464,"completion":14884,"start":14464,"enrollment":128,"conditions":14885,"interventions":14886},"NCT04591028","A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients",[93],"2022-08-10",[4858],[14868],{"trials":14888,"activeCount":128},[],{"intervention":14890,"totalTrials":676,"cells":14891},"Intercostal Bupivicaine",{"EARLY_PHASE1":14892,"PHASE1":14894,"PHASE2":14896,"PHASE3":14898,"PHASE4":14900,"NA":14914},{"trials":14893,"activeCount":128},[],{"trials":14895,"activeCount":128},[],{"trials":14897,"activeCount":128},[],{"trials":14899,"activeCount":128},[],{"trials":14901,"activeCount":128},[14902],{"nctId":14903,"briefTitle":14904,"status":104,"phases":14905,"primaryCompletion":14906,"completion":14907,"start":14908,"enrollment":14909,"conditions":14910,"interventions":14912},"NCT02178553","Study of Exparel Versus Epidural for Pain Control After Thoracotomy",[93],"2018-10-09","2019-01-25","2014-10-15",102,[14911],"Pain Following Thoracotomy Surgery",[14913,14890],"Epidural",{"trials":14915,"activeCount":128},[],{"intervention":14917,"totalTrials":676,"cells":14918},"Fesoterodine fumarate",{"EARLY_PHASE1":14919,"PHASE1":14921,"PHASE2":14923,"PHASE3":14925,"PHASE4":14927,"NA":14936},{"trials":14920,"activeCount":128},[],{"trials":14922,"activeCount":128},[],{"trials":14924,"activeCount":128},[],{"trials":14926,"activeCount":128},[],{"trials":14928,"activeCount":128},[14929],{"nctId":14930,"briefTitle":14931,"status":134,"phases":14932,"primaryCompletion":12007,"completion":12007,"start":3509,"enrollment":681,"conditions":14933,"interventions":14935},"NCT01605617","Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate",[93],[14934],"Overactive Bladder",[14917],{"trials":14937,"activeCount":128},[],{"intervention":1025,"totalTrials":676,"cells":14939},{"EARLY_PHASE1":14940,"PHASE1":14942,"PHASE2":14944,"PHASE3":14946,"PHASE4":14948,"NA":14954},{"trials":14941,"activeCount":128},[],{"trials":14943,"activeCount":128},[],{"trials":14945,"activeCount":128},[],{"trials":14947,"activeCount":128},[],{"trials":14949,"activeCount":128},[14950],{"nctId":1017,"briefTitle":1018,"status":104,"phases":14951,"primaryCompletion":1020,"completion":1021,"start":955,"enrollment":956,"conditions":14952,"interventions":14953},[93],[1023],[1025,961],{"trials":14955,"activeCount":128},[],{"intervention":14957,"totalTrials":676,"cells":14958},"Phentermine-Topiramate ER",{"EARLY_PHASE1":14959,"PHASE1":14961,"PHASE2":14963,"PHASE3":14965,"PHASE4":14967,"NA":14975},{"trials":14960,"activeCount":128},[],{"trials":14962,"activeCount":128},[],{"trials":14964,"activeCount":128},[],{"trials":14966,"activeCount":128},[],{"trials":14968,"activeCount":128},[14969],{"nctId":14970,"briefTitle":14971,"status":104,"phases":14972,"primaryCompletion":3001,"completion":3001,"start":4885,"enrollment":2555,"conditions":14973,"interventions":14974},"NCT01834404","Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients",[93],[15],[14957],{"trials":14976,"activeCount":128},[],{"intervention":14978,"totalTrials":676,"cells":14979},"Oral methadone, immediately prior to transport",{"EARLY_PHASE1":14980,"PHASE1":14982,"PHASE2":14984,"PHASE3":14986,"PHASE4":14988,"NA":14999},{"trials":14981,"activeCount":128},[],{"trials":14983,"activeCount":128},[],{"trials":14985,"activeCount":128},[],{"trials":14987,"activeCount":128},[],{"trials":14989,"activeCount":128},[14990],{"nctId":14991,"briefTitle":14992,"status":104,"phases":14993,"primaryCompletion":7260,"completion":14994,"start":14995,"enrollment":28,"conditions":14996,"interventions":14997},"NCT06720415","Oral and Intravenous Methadone for Analgesia in Cardiac Surgery",[93],"2025-07-14","2025-04-14",[2071,925],[14978,14998],"Intravenous methadone",{"trials":15000,"activeCount":128},[],{"intervention":14998,"totalTrials":676,"cells":15002},{"EARLY_PHASE1":15003,"PHASE1":15005,"PHASE2":15007,"PHASE3":15009,"PHASE4":15011,"NA":15017},{"trials":15004,"activeCount":128},[],{"trials":15006,"activeCount":128},[],{"trials":15008,"activeCount":128},[],{"trials":15010,"activeCount":128},[],{"trials":15012,"activeCount":128},[15013],{"nctId":14991,"briefTitle":14992,"status":104,"phases":15014,"primaryCompletion":7260,"completion":14994,"start":14995,"enrollment":28,"conditions":15015,"interventions":15016},[93],[2071,925],[14978,14998],{"trials":15018,"activeCount":128},[],{"intervention":15020,"totalTrials":676,"cells":15021},"Bupivacaine HCl",{"EARLY_PHASE1":15022,"PHASE1":15024,"PHASE2":15026,"PHASE3":15028,"PHASE4":15030,"NA":15042},{"trials":15023,"activeCount":128},[],{"trials":15025,"activeCount":128},[],{"trials":15027,"activeCount":128},[],{"trials":15029,"activeCount":128},[],{"trials":15031,"activeCount":128},[15032],{"nctId":15033,"briefTitle":15034,"status":104,"phases":15035,"primaryCompletion":15036,"completion":15036,"start":15037,"enrollment":797,"conditions":15038,"interventions":15040},"NCT05005260","Liposomal Bupivacaine Single-Injection Interscalene Block vs. Continuous Interscalene Block for Primary Total Shoulder Arthroplasty",[93],"2023-03-18","2021-10-14",[799,15039],"Brachial Plexus Block",[15020,15041],"Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj",{"trials":15043,"activeCount":128},[],{"intervention":15041,"totalTrials":676,"cells":15045},{"EARLY_PHASE1":15046,"PHASE1":15048,"PHASE2":15050,"PHASE3":15052,"PHASE4":15054,"NA":15060},{"trials":15047,"activeCount":128},[],{"trials":15049,"activeCount":128},[],{"trials":15051,"activeCount":128},[],{"trials":15053,"activeCount":128},[],{"trials":15055,"activeCount":128},[15056],{"nctId":15033,"briefTitle":15034,"status":104,"phases":15057,"primaryCompletion":15036,"completion":15036,"start":15037,"enrollment":797,"conditions":15058,"interventions":15059},[93],[799,15039],[15020,15041],{"trials":15061,"activeCount":128},[],{"intervention":15063,"totalTrials":676,"cells":15064},"Teduglutide",{"EARLY_PHASE1":15065,"PHASE1":15067,"PHASE2":15069,"PHASE3":15071,"PHASE4":15073,"NA":15081},{"trials":15066,"activeCount":128},[],{"trials":15068,"activeCount":128},[],{"trials":15070,"activeCount":128},[],{"trials":15072,"activeCount":128},[],{"trials":15074,"activeCount":128},[15075],{"nctId":15076,"briefTitle":15077,"status":104,"phases":15078,"primaryCompletion":2863,"completion":2863,"start":2667,"enrollment":2563,"conditions":15079,"interventions":15080},"NCT02099084","Short Bowel Syndrome and Teduglutide Versus Placebo",[93],[12825],[15063],{"trials":15082,"activeCount":128},[],{"intervention":12804,"totalTrials":676,"cells":15084},{"EARLY_PHASE1":15085,"PHASE1":15087,"PHASE2":15089,"PHASE3":15091,"PHASE4":15093,"NA":15099},{"trials":15086,"activeCount":128},[],{"trials":15088,"activeCount":128},[],{"trials":15090,"activeCount":128},[],{"trials":15092,"activeCount":128},[],{"trials":15094,"activeCount":128},[15095],{"nctId":12797,"briefTitle":12798,"status":104,"phases":15096,"primaryCompletion":12800,"completion":12800,"start":12801,"enrollment":3719,"conditions":15097,"interventions":15098},[93],[897],[12804,12763],{"trials":15100,"activeCount":128},[],{"intervention":13345,"totalTrials":676,"cells":15102},{"EARLY_PHASE1":15103,"PHASE1":15105,"PHASE2":15107,"PHASE3":15109,"PHASE4":15111,"NA":15117},{"trials":15104,"activeCount":128},[],{"trials":15106,"activeCount":128},[],{"trials":15108,"activeCount":128},[],{"trials":15110,"activeCount":128},[],{"trials":15112,"activeCount":128},[15113],{"nctId":13338,"briefTitle":13339,"status":104,"phases":15114,"primaryCompletion":13341,"completion":13342,"start":7892,"enrollment":6434,"conditions":15115,"interventions":15116},[93],[13331,10657],[13317,13345],{"trials":15118,"activeCount":128},[],{"intervention":15120,"totalTrials":676,"cells":15121},"18F-FDG",{"EARLY_PHASE1":15122,"PHASE1":15124,"PHASE2":15126,"PHASE3":15128,"PHASE4":15130,"NA":15141},{"trials":15123,"activeCount":128},[],{"trials":15125,"activeCount":128},[],{"trials":15127,"activeCount":128},[],{"trials":15129,"activeCount":128},[],{"trials":15131,"activeCount":128},[15132],{"nctId":15133,"briefTitle":15134,"status":104,"phases":15135,"primaryCompletion":3833,"completion":3833,"start":14808,"enrollment":2678,"conditions":15136,"interventions":15139},"NCT04417998","Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction",[93],[15137,15138],"Brain Imaging","Whole Body Imaging",[15120,15140],"18F-AV1451",{"trials":15142,"activeCount":128},[],{"intervention":15140,"totalTrials":676,"cells":15144},{"EARLY_PHASE1":15145,"PHASE1":15147,"PHASE2":15149,"PHASE3":15151,"PHASE4":15153,"NA":15159},{"trials":15146,"activeCount":128},[],{"trials":15148,"activeCount":128},[],{"trials":15150,"activeCount":128},[],{"trials":15152,"activeCount":128},[],{"trials":15154,"activeCount":128},[15155],{"nctId":15133,"briefTitle":15134,"status":104,"phases":15156,"primaryCompletion":3833,"completion":3833,"start":14808,"enrollment":2678,"conditions":15157,"interventions":15158},[93],[15137,15138],[15120,15140],{"trials":15160,"activeCount":128},[],{"intervention":15162,"totalTrials":676,"cells":15163},"Randomization of two local anesthetics.",{"EARLY_PHASE1":15164,"PHASE1":15166,"PHASE2":15168,"PHASE3":15170,"PHASE4":15172,"NA":15182},{"trials":15165,"activeCount":128},[],{"trials":15167,"activeCount":128},[],{"trials":15169,"activeCount":128},[],{"trials":15171,"activeCount":128},[],{"trials":15173,"activeCount":128},[15174],{"nctId":15175,"briefTitle":15176,"status":104,"phases":15177,"primaryCompletion":15178,"completion":4671,"start":15179,"enrollment":173,"conditions":15180,"interventions":15181},"NCT04801368","Randomized Trial of Ropivacaine & Bupivacaine for Inflatable Penile Prosthesis",[93],"2024-01-07","2021-10-01",[12167],[15162],{"trials":15183,"activeCount":128},[],{"intervention":15185,"totalTrials":676,"cells":15186},"Granisetron",{"EARLY_PHASE1":15187,"PHASE1":15189,"PHASE2":15191,"PHASE3":15193,"PHASE4":15195,"NA":15207},{"trials":15188,"activeCount":128},[],{"trials":15190,"activeCount":128},[],{"trials":15192,"activeCount":128},[],{"trials":15194,"activeCount":128},[],{"trials":15196,"activeCount":128},[15197],{"nctId":15198,"briefTitle":15199,"status":104,"phases":15200,"primaryCompletion":15201,"completion":15201,"start":3815,"enrollment":15202,"conditions":15203,"interventions":15205},"NCT03503292","Pharmacogenomics and Post-Operative Nausea and Vomiting",[93],"2019-12-30",92,[15204],"Postoperative Nausea",[15185,15206],"Ondansetron",{"trials":15208,"activeCount":128},[],{"intervention":15206,"totalTrials":676,"cells":15210},{"EARLY_PHASE1":15211,"PHASE1":15213,"PHASE2":15215,"PHASE3":15217,"PHASE4":15219,"NA":15225},{"trials":15212,"activeCount":128},[],{"trials":15214,"activeCount":128},[],{"trials":15216,"activeCount":128},[],{"trials":15218,"activeCount":128},[],{"trials":15220,"activeCount":128},[15221],{"nctId":15198,"briefTitle":15199,"status":104,"phases":15222,"primaryCompletion":15201,"completion":15201,"start":3815,"enrollment":15202,"conditions":15223,"interventions":15224},[93],[15204],[15185,15206],{"trials":15226,"activeCount":128},[],{"intervention":15228,"totalTrials":676,"cells":15229},"Suzetrigine",{"EARLY_PHASE1":15230,"PHASE1":15232,"PHASE2":15234,"PHASE3":15236,"PHASE4":15238,"NA":15248},{"trials":15231,"activeCount":128},[],{"trials":15233,"activeCount":128},[],{"trials":15235,"activeCount":128},[],{"trials":15237,"activeCount":128},[],{"trials":15239,"activeCount":128},[15240],{"nctId":15241,"briefTitle":15242,"status":104,"phases":15243,"primaryCompletion":15244,"completion":283,"start":15245,"enrollment":712,"conditions":15246,"interventions":15247},"NCT07257133","A Study Of Opioid Avoidance In Surgery Through Integrating Suzetrigine",[93],"2026-03-01","2025-10-20",[999],[15228],{"trials":15249,"activeCount":128},[],{"intervention":15251,"totalTrials":676,"cells":15252},"Human Papillomavirus Vaccine",{"EARLY_PHASE1":15253,"PHASE1":15255,"PHASE2":15257,"PHASE3":15259,"PHASE4":15261,"NA":15271},{"trials":15254,"activeCount":128},[],{"trials":15256,"activeCount":128},[],{"trials":15258,"activeCount":128},[],{"trials":15260,"activeCount":128},[],{"trials":15262,"activeCount":128},[15263],{"nctId":15264,"briefTitle":15265,"status":104,"phases":15266,"primaryCompletion":7107,"completion":7107,"start":4032,"enrollment":4565,"conditions":15267,"interventions":15270},"NCT01034358","Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease",[93],[15268,15269],"Inflammatory Bowel Disease","Uterine Cervical Dysplasia",[15251],{"trials":15272,"activeCount":128},[],{"intervention":15274,"totalTrials":676,"cells":15275},"Perflutren Lipid Microsphere",{"EARLY_PHASE1":15276,"PHASE1":15278,"PHASE2":15280,"PHASE3":15282,"PHASE4":15284,"NA":15295},{"trials":15277,"activeCount":128},[],{"trials":15279,"activeCount":128},[],{"trials":15281,"activeCount":128},[],{"trials":15283,"activeCount":128},[],{"trials":15285,"activeCount":128},[15286],{"nctId":15287,"briefTitle":15288,"status":104,"phases":15289,"primaryCompletion":15290,"completion":15291,"start":2946,"enrollment":187,"conditions":15292,"interventions":15294},"NCT02880137","Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy",[93],"2018-06","2018-06-30",[15293],"Cardiac Allograft Vasculopathy",[15274],{"trials":15296,"activeCount":128},[],{"intervention":15298,"totalTrials":676,"cells":15299},"divalproex or olanzapine",{"EARLY_PHASE1":15300,"PHASE1":15302,"PHASE2":15304,"PHASE3":15306,"PHASE4":15308,"NA":15316},{"trials":15301,"activeCount":128},[],{"trials":15303,"activeCount":128},[],{"trials":15305,"activeCount":128},[],{"trials":15307,"activeCount":128},[],{"trials":15309,"activeCount":128},[15310],{"nctId":15311,"briefTitle":15312,"status":1413,"phases":15313,"completion":5515,"enrollment":128,"conditions":15314,"interventions":15315},"NCT00221481","An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder",[93],[13311],[15298],{"trials":15317,"activeCount":128},[],{"intervention":15319,"totalTrials":676,"cells":15320},"Pneumovax 23- pneumococcal polysaccharide",{"EARLY_PHASE1":15321,"PHASE1":15323,"PHASE2":15325,"PHASE3":15327,"PHASE4":15329,"NA":15338},{"trials":15322,"activeCount":128},[],{"trials":15324,"activeCount":128},[],{"trials":15326,"activeCount":128},[],{"trials":15328,"activeCount":128},[],{"trials":15330,"activeCount":128},[15331],{"nctId":15332,"briefTitle":15333,"status":104,"phases":15334,"primaryCompletion":15335,"completion":15335,"start":3650,"enrollment":34,"conditions":15336,"interventions":15337},"NCT04481243","A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes",[93],"2023-01-20",[9460],[15319],{"trials":15339,"activeCount":128},[],{"intervention":13313,"totalTrials":676,"cells":15341},{"EARLY_PHASE1":15342,"PHASE1":15344,"PHASE2":15346,"PHASE3":15348,"PHASE4":15350,"NA":15356},{"trials":15343,"activeCount":128},[],{"trials":15345,"activeCount":128},[],{"trials":15347,"activeCount":128},[],{"trials":15349,"activeCount":128},[],{"trials":15351,"activeCount":128},[15352],{"nctId":13306,"briefTitle":13307,"status":134,"phases":15353,"primaryCompletion":13309,"completion":13309,"start":2863,"enrollment":224,"conditions":15354,"interventions":15355},[93],[13311],[13287,13313],{"trials":15357,"activeCount":128},[],{"intervention":15359,"totalTrials":676,"cells":15360},"Apo-Prednisone Cordorol, Detasone - Prednisone",{"EARLY_PHASE1":15361,"PHASE1":15363,"PHASE2":15365,"PHASE3":15367,"PHASE4":15369,"NA":15379},{"trials":15362,"activeCount":128},[],{"trials":15364,"activeCount":128},[],{"trials":15366,"activeCount":128},[],{"trials":15368,"activeCount":128},[],{"trials":15370,"activeCount":128},[15371],{"nctId":15372,"briefTitle":15373,"status":1413,"phases":15374,"primaryCompletion":15375,"completion":15375,"start":12007,"enrollment":128,"conditions":15376,"interventions":15378},"NCT01903486","Assessing the Efficacy of Steroid Treatment of Achalasia",[93],"2020-12-28",[15377],"Achalasia",[15359],{"trials":15380,"activeCount":128},[],{"intervention":15382,"totalTrials":676,"cells":15383},"atacand",{"EARLY_PHASE1":15384,"PHASE1":15386,"PHASE2":15388,"PHASE3":15390,"PHASE4":15392,"NA":15402},{"trials":15385,"activeCount":128},[],{"trials":15387,"activeCount":128},[],{"trials":15389,"activeCount":128},[],{"trials":15391,"activeCount":128},[],{"trials":15393,"activeCount":128},[15394],{"nctId":15395,"briefTitle":15396,"status":104,"phases":15397,"primaryCompletion":4400,"completion":4400,"start":3477,"enrollment":25,"conditions":15398,"interventions":15400},"NCT00587470","Angiotensin-II Blockade in Mitral Regurgitation",[93],[15399],"Mitral Regurgitation",[15401,15382],"Candesartan",{"trials":15403,"activeCount":128},[],{"intervention":15405,"totalTrials":676,"cells":15406},"Fluad Vaccine",{"EARLY_PHASE1":15407,"PHASE1":15409,"PHASE2":15411,"PHASE3":15413,"PHASE4":15415,"NA":15428},{"trials":15408,"activeCount":128},[],{"trials":15410,"activeCount":128},[],{"trials":15412,"activeCount":128},[],{"trials":15414,"activeCount":128},[],{"trials":15416,"activeCount":128},[15417],{"nctId":15418,"briefTitle":15419,"status":104,"phases":15420,"primaryCompletion":15421,"completion":15421,"start":15422,"enrollment":15423,"conditions":15424,"interventions":15426},"NCT03603509","Gene Signatures of Influenza Vaccine Responses in Older Adults",[93],"2019-01-02","2018-08-27",241,[15425],"Influenza",[15405,15427],"Fluzone High-Dose",{"trials":15429,"activeCount":128},[],{"intervention":15427,"totalTrials":676,"cells":15431},{"EARLY_PHASE1":15432,"PHASE1":15434,"PHASE2":15436,"PHASE3":15438,"PHASE4":15440,"NA":15446},{"trials":15433,"activeCount":128},[],{"trials":15435,"activeCount":128},[],{"trials":15437,"activeCount":128},[],{"trials":15439,"activeCount":128},[],{"trials":15441,"activeCount":128},[15442],{"nctId":15418,"briefTitle":15419,"status":104,"phases":15443,"primaryCompletion":15421,"completion":15421,"start":15422,"enrollment":15423,"conditions":15444,"interventions":15445},[93],[15425],[15405,15427],{"trials":15447,"activeCount":128},[],{"intervention":15449,"totalTrials":676,"cells":15450},"Apremilast 30mg",{"EARLY_PHASE1":15451,"PHASE1":15453,"PHASE2":15455,"PHASE3":15457,"PHASE4":15459,"NA":15470},{"trials":15452,"activeCount":128},[],{"trials":15454,"activeCount":128},[],{"trials":15456,"activeCount":128},[],{"trials":15458,"activeCount":128},[],{"trials":15460,"activeCount":128},[15461],{"nctId":15462,"briefTitle":15463,"status":104,"phases":15464,"primaryCompletion":15465,"completion":15465,"start":15466,"enrollment":4565,"conditions":15467,"interventions":15469},"NCT03690544","Apremilast for RAS",[93],"2021-07-14","2018-10-12",[15468],"Recurrent Aphthous Stomatitis",[15449],{"trials":15471,"activeCount":128},[],{"intervention":15473,"totalTrials":676,"cells":15474},"Lidocaine jelly",{"EARLY_PHASE1":15475,"PHASE1":15477,"PHASE2":15479,"PHASE3":15481,"PHASE4":15483,"NA":15496},{"trials":15476,"activeCount":128},[],{"trials":15478,"activeCount":128},[],{"trials":15480,"activeCount":128},[],{"trials":15482,"activeCount":128},[],{"trials":15484,"activeCount":128},[15485],{"nctId":15486,"briefTitle":15487,"status":104,"phases":15488,"primaryCompletion":15489,"completion":15489,"start":15490,"enrollment":15491,"conditions":15492,"interventions":15494},"NCT03595449","Lidocaine Jelly for Pain Control During Mohs Surgery",[93],"2020-08-31","2018-08-13",233,[938,15493],"Satisfaction, Consumer",[15473,15495],"Surgilube",{"trials":15497,"activeCount":128},[],{"intervention":15495,"totalTrials":676,"cells":15499},{"EARLY_PHASE1":15500,"PHASE1":15502,"PHASE2":15504,"PHASE3":15506,"PHASE4":15508,"NA":15514},{"trials":15501,"activeCount":128},[],{"trials":15503,"activeCount":128},[],{"trials":15505,"activeCount":128},[],{"trials":15507,"activeCount":128},[],{"trials":15509,"activeCount":128},[15510],{"nctId":15486,"briefTitle":15487,"status":104,"phases":15511,"primaryCompletion":15489,"completion":15489,"start":15490,"enrollment":15491,"conditions":15512,"interventions":15513},[93],[938,15493],[15473,15495],{"trials":15515,"activeCount":128},[],{"intervention":13107,"totalTrials":676,"cells":15517},{"EARLY_PHASE1":15518,"PHASE1":15520,"PHASE2":15522,"PHASE3":15524,"PHASE4":15526,"NA":15532},{"trials":15519,"activeCount":128},[],{"trials":15521,"activeCount":128},[],{"trials":15523,"activeCount":128},[],{"trials":15525,"activeCount":128},[],{"trials":15527,"activeCount":128},[15528],{"nctId":13100,"briefTitle":13101,"status":104,"phases":15529,"primaryCompletion":13103,"completion":13103,"start":13104,"enrollment":4565,"conditions":15530,"interventions":15531},[93],[9805],[13080,13107,13108],{"trials":15533,"activeCount":128},[],{"intervention":13108,"totalTrials":676,"cells":15535},{"EARLY_PHASE1":15536,"PHASE1":15538,"PHASE2":15540,"PHASE3":15542,"PHASE4":15544,"NA":15550},{"trials":15537,"activeCount":128},[],{"trials":15539,"activeCount":128},[],{"trials":15541,"activeCount":128},[],{"trials":15543,"activeCount":128},[],{"trials":15545,"activeCount":128},[15546],{"nctId":13100,"briefTitle":13101,"status":104,"phases":15547,"primaryCompletion":13103,"completion":13103,"start":13104,"enrollment":4565,"conditions":15548,"interventions":15549},[93],[9805],[13080,13107,13108],{"trials":15551,"activeCount":128},[],{"intervention":3759,"totalTrials":476,"cells":15553},{"EARLY_PHASE1":15554,"PHASE1":15556,"PHASE2":15566,"PHASE3":15592,"PHASE4":15598,"NA":15600},{"trials":15555,"activeCount":128},[],{"trials":15557,"activeCount":128},[15558,15562],{"nctId":7285,"briefTitle":7286,"status":104,"phases":15559,"primaryCompletion":7288,"completion":7289,"start":1374,"enrollment":410,"conditions":15560,"interventions":15561},[90],[6117,6118,6119,3447],[3680,6121],{"nctId":5257,"briefTitle":5258,"status":104,"phases":15563,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":729,"conditions":15564,"interventions":15565},[90],[3665],[3553,3759,5265,657,5266],{"trials":15567,"activeCount":128},[15568,15572,15576,15580,15584,15588],{"nctId":5047,"briefTitle":5048,"status":104,"phases":15569,"primaryCompletion":1390,"completion":5050,"start":5051,"enrollment":31,"conditions":15570,"interventions":15571},[90,91],[3665],[3539,3759,3525],{"nctId":7484,"briefTitle":7485,"status":104,"phases":15573,"primaryCompletion":4871,"completion":5246,"start":4872,"enrollment":22,"conditions":15574,"interventions":15575},[90,91],[3665],[4405,3759],{"nctId":6110,"briefTitle":6111,"status":104,"phases":15577,"primaryCompletion":6113,"completion":6114,"start":6115,"enrollment":773,"conditions":15578,"interventions":15579},[90,91],[6117,6118,6119,3447],[157,6121],{"nctId":7348,"briefTitle":7349,"status":1413,"phases":15581,"enrollment":128,"conditions":15582,"interventions":15583},[90,91],[3562,3690],[3513,3759,7353,7354,7355],{"nctId":12639,"briefTitle":12640,"status":134,"phases":15585,"primaryCompletion":5351,"completion":2936,"start":5033,"enrollment":676,"conditions":15586,"interventions":15587},[91],[3665],[7353,3759],{"nctId":3751,"briefTitle":3752,"status":104,"phases":15589,"primaryCompletion":3754,"completion":3755,"start":3756,"enrollment":773,"conditions":15590,"interventions":15591},[91],[3665],[3481,3323,3759],{"trials":15593,"activeCount":128},[15594],{"nctId":4109,"briefTitle":4110,"status":104,"phases":15595,"primaryCompletion":1375,"completion":2665,"start":4112,"enrollment":4113,"conditions":15596,"interventions":15597},[92],[3665],[3481,3514,3759],{"trials":15599,"activeCount":128},[],{"trials":15601,"activeCount":128},[],{"intervention":15603,"totalTrials":1197,"cells":15604},"Vancomycin",{"EARLY_PHASE1":15605,"PHASE1":15607,"PHASE2":15637,"PHASE3":15651,"PHASE4":15668,"NA":15670},{"trials":15606,"activeCount":128},[],{"trials":15608,"activeCount":128},[15609,15617,15624],{"nctId":15610,"briefTitle":15611,"status":104,"phases":15612,"primaryCompletion":5418,"completion":6973,"start":7317,"enrollment":15613,"conditions":15614,"interventions":15616},"NCT02945241","Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project",[90],399,[15615,8295,1474],"Methicillin-resistant Staphylococcus Aureus",[15603],{"nctId":15618,"briefTitle":15619,"status":104,"phases":15620,"primaryCompletion":3842,"completion":3842,"start":4032,"enrollment":3726,"conditions":15621,"interventions":15622},"NCT01085760","A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis",[90],[8319],[15603,15603,15623,15623,15603],"Metronidazole",{"nctId":15625,"briefTitle":15626,"status":104,"phases":15627,"primaryCompletion":8329,"completion":8329,"start":15628,"enrollment":173,"conditions":15629,"interventions":15635},"NCT04673877","Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration",[90],"2021-08-26",[15630,15631,15632,15633,15634],"Infection","Hand Injury Wrist","Hand Injuries","Hand Injuries and Disorders","Hand Arthritis",[15636,15603],"Systemic IV Vancomycin",{"trials":15638,"activeCount":128},[15639],{"nctId":15640,"briefTitle":15641,"status":104,"phases":15642,"primaryCompletion":15643,"completion":15643,"start":15644,"enrollment":6434,"conditions":15645,"interventions":15647},"NCT03673956","Topical Antibiotics in Chronic Rhinosinusitis",[90,91],"2021-02-01","2018-09-26",[15646],"Chronic Rhinosinusitis (Diagnosis)",[15648,15649,15650,15603],"Mupirocin","Tobramycin","Levofloxacin",{"trials":15652,"activeCount":128},[15653,15660],{"nctId":15654,"briefTitle":15655,"status":104,"phases":15656,"primaryCompletion":5418,"completion":5418,"start":4795,"enrollment":3002,"conditions":15657,"interventions":15659},"NCT02020031","Regional Prophylactic Vancomycin in Revision Total Knee Replacement",[91,92],[15658],"Arthropathy of Knee Joint",[15603],{"nctId":15661,"briefTitle":15662,"status":104,"phases":15663,"primaryCompletion":15664,"completion":15664,"start":15665,"enrollment":2555,"conditions":15666,"interventions":15667},"NCT03506347","Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement",[91,92],"2019-01-17","2018-09-24",[15658],[15603],{"trials":15669,"activeCount":128},[],{"trials":15671,"activeCount":128},[],{"intervention":7013,"totalTrials":895,"cells":15673},{"EARLY_PHASE1":15674,"PHASE1":15676,"PHASE2":15678,"PHASE3":15694,"PHASE4":15719,"NA":15721},{"trials":15675,"activeCount":128},[],{"trials":15677,"activeCount":128},[],{"trials":15679,"activeCount":128},[15680,15690],{"nctId":15681,"briefTitle":15682,"status":104,"phases":15683,"primaryCompletion":6642,"completion":6642,"start":15684,"enrollment":2894,"conditions":15685,"interventions":15688},"NCT03744975","PDD in Type 2 Diabetes w\u002Fwo Diastolic Dysfunction",[91],"2018-05-01",[15686,15687],"Diabetes Mellitus, Type 2","Diastolic Dysfunction",[15689,7013],"LCZ 696",{"nctId":13326,"briefTitle":13327,"status":134,"phases":15691,"primaryCompletion":9167,"completion":9167,"start":13329,"enrollment":2563,"conditions":15692,"interventions":15693},[91],[13331],[13317,7013],{"trials":15695,"activeCount":128},[15696,15706,15710],{"nctId":15697,"briefTitle":15698,"status":1413,"phases":15699,"primaryCompletion":15700,"completion":15700,"start":15701,"enrollment":128,"conditions":15702,"interventions":15704},"NCT03749096","Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome",[92],"2019-04-26","2018-12-07",[15703],"Stiff-Person Syndrome",[15705,7013],"Intravenous Immunoglobulins, Human",{"nctId":7005,"briefTitle":7006,"status":134,"phases":15707,"primaryCompletion":7008,"completion":7008,"start":3642,"enrollment":139,"conditions":15708,"interventions":15709},[92],[7010],[7012,7013,867],{"nctId":15711,"briefTitle":15712,"status":104,"phases":15713,"primaryCompletion":56,"completion":15714,"start":15715,"enrollment":3767,"conditions":15716,"interventions":15717},"NCT03115424","Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy",[92],"2024-05-30","2017-06-22",[15],[15718,7013],"Saxenda",{"trials":15720,"activeCount":128},[],{"trials":15722,"activeCount":128},[],{"intervention":3481,"totalTrials":895,"cells":15724},{"EARLY_PHASE1":15725,"PHASE1":15727,"PHASE2":15737,"PHASE3":15750,"PHASE4":15756,"NA":15758},{"trials":15726,"activeCount":128},[],{"trials":15728,"activeCount":128},[15729,15733],{"nctId":7601,"briefTitle":7602,"status":104,"phases":15730,"primaryCompletion":7604,"completion":7604,"start":7605,"conditions":15731,"interventions":15732},[90],[3549,7607],[3481,3482,3483],{"nctId":3472,"briefTitle":3473,"status":104,"phases":15734,"primaryCompletion":3475,"completion":3476,"start":3477,"enrollment":2608,"conditions":15735,"interventions":15736},[90],[3321,3479],[3481,3482,3323,3483],{"trials":15738,"activeCount":128},[15739,15746],{"nctId":15740,"briefTitle":15741,"status":104,"phases":15742,"primaryCompletion":3842,"completion":2666,"start":7928,"enrollment":498,"conditions":15743,"interventions":15744},"NCT00998049","Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant",[91],[3562,3690,3535,3536,3537],[15745,3481],"plerixafor",{"nctId":3751,"briefTitle":3752,"status":104,"phases":15747,"primaryCompletion":3754,"completion":3755,"start":3756,"enrollment":773,"conditions":15748,"interventions":15749},[91],[3665],[3481,3323,3759],{"trials":15751,"activeCount":128},[15752],{"nctId":4109,"briefTitle":4110,"status":104,"phases":15753,"primaryCompletion":1375,"completion":2665,"start":4112,"enrollment":4113,"conditions":15754,"interventions":15755},[92],[3665],[3481,3514,3759],{"trials":15757,"activeCount":128},[],{"trials":15759,"activeCount":128},[],{"intervention":15761,"totalTrials":681,"cells":15762},"Botulinum Toxin Type A",{"EARLY_PHASE1":15763,"PHASE1":15765,"PHASE2":15783,"PHASE3":15793,"PHASE4":15806,"NA":15808},{"trials":15764,"activeCount":128},[],{"trials":15766,"activeCount":128},[15767,15776],{"nctId":15768,"briefTitle":15769,"status":104,"phases":15770,"primaryCompletion":3673,"completion":3673,"start":5280,"enrollment":3034,"conditions":15771,"interventions":15773},"NCT00279903","Is Botox Effective in Relieving Pain From Knee Osteoarthritis?",[90],[15772],"Osteoarthritis, Knee",[15774,15775],"Botulinum toxin type A","Cortisone",{"nctId":15777,"briefTitle":15778,"status":104,"phases":15779,"primaryCompletion":2978,"completion":5418,"start":3842,"enrollment":3767,"conditions":15780,"interventions":15782},"NCT01495962","The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy",[90],[15781],"Wound; Abdomen, Abdominal Wall",[15761],{"trials":15784,"activeCount":128},[15785],{"nctId":15786,"briefTitle":15787,"status":134,"phases":15788,"primaryCompletion":7657,"completion":7657,"start":5141,"enrollment":476,"conditions":15789,"interventions":15792},"NCT00732680","Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome Syndrome",[90,91],[15790,15791],"Empty Nose Syndrome","Atrophic Rhinitis",[15761],{"trials":15794,"activeCount":128},[15795],{"nctId":15796,"briefTitle":15797,"status":104,"phases":15798,"primaryCompletion":15799,"completion":15799,"start":894,"enrollment":15800,"conditions":15801,"interventions":15805},"NCT01591746","Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction",[92],"2017-07-18",131,[21,799,15802,15803,15804,1566],"BRCA1 Mutation","BRCA2 Mutation","Breast Diseases",[15761],{"trials":15807,"activeCount":128},[],{"trials":15809,"activeCount":128},[],{"intervention":2984,"totalTrials":681,"cells":15811},{"EARLY_PHASE1":15812,"PHASE1":15814,"PHASE2":15816,"PHASE3":15838,"PHASE4":15847,"NA":15849},{"trials":15813,"activeCount":128},[],{"trials":15815,"activeCount":128},[],{"trials":15817,"activeCount":128},[15818,15827,15834],{"nctId":15819,"briefTitle":15820,"status":104,"phases":15821,"primaryCompletion":4030,"completion":4885,"start":15822,"enrollment":15823,"conditions":15824,"interventions":15826},"NCT00573144","Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction",[91],"2006-09",59,[15825],"Acute Myocardial Infarction",[2984],{"nctId":15828,"briefTitle":15829,"status":104,"phases":15830,"primaryCompletion":3661,"completion":3569,"start":4786,"enrollment":3945,"conditions":15831,"interventions":15833},"NCT00405639","Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function",[90,91],[27,15832],"Asymptomatic Systolic Dysfunction",[2984],{"nctId":2975,"briefTitle":2976,"status":104,"phases":15835,"primaryCompletion":1374,"completion":2978,"start":2979,"enrollment":2980,"conditions":15836,"interventions":15837},[90,91],[2982],[2984,2966,2985],{"trials":15839,"activeCount":128},[15840],{"nctId":15841,"briefTitle":15842,"status":104,"phases":15843,"primaryCompletion":4928,"completion":5351,"start":15844,"enrollment":1267,"conditions":15845,"interventions":15846},"NCT00170183","Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure",[92],"2003-03",[5144,2982,698],[2984],{"trials":15848,"activeCount":128},[],{"trials":15850,"activeCount":128},[],{"intervention":3526,"totalTrials":681,"cells":15852},{"EARLY_PHASE1":15853,"PHASE1":15855,"PHASE2":15857,"PHASE3":15874,"PHASE4":15884,"NA":15886},{"trials":15854,"activeCount":128},[],{"trials":15856,"activeCount":128},[],{"trials":15858,"activeCount":128},[15859,15863,15867],{"nctId":3516,"briefTitle":3517,"status":104,"phases":15860,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":3002,"conditions":15861,"interventions":15862},[91],[3522,3523],[3323,3525,3526],{"nctId":3556,"briefTitle":3557,"status":104,"phases":15864,"primaryCompletion":3001,"completion":3559,"start":1357,"enrollment":3560,"conditions":15865,"interventions":15866},[90,91],[3562,3535,3536,3537],[3564,3323,3526,3514],{"nctId":15868,"briefTitle":15869,"status":134,"phases":15870,"primaryCompletion":4784,"completion":4784,"start":7604,"enrollment":676,"conditions":15871,"interventions":15872},"NCT00953615","Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)",[91],[8319],[15873],"Thalidomide",{"trials":15875,"activeCount":128},[15876],{"nctId":15877,"briefTitle":15878,"status":104,"phases":15879,"primaryCompletion":7107,"completion":4785,"start":15880,"enrollment":3547,"conditions":15881,"interventions":15882},"NCT00432458","Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma",[92],"2003-07",[3665],[15873,15883],"zoledronic acid",{"trials":15885,"activeCount":128},[],{"trials":15887,"activeCount":128},[],{"intervention":15889,"totalTrials":681,"cells":15890},"Gallium Ga 68 Gozetotide",{"EARLY_PHASE1":15891,"PHASE1":15900,"PHASE2":15902,"PHASE3":15918,"PHASE4":15928,"NA":15930},{"trials":15892,"activeCount":128},[15893],{"nctId":15894,"briefTitle":15895,"status":104,"phases":15896,"primaryCompletion":15897,"completion":15897,"start":10188,"enrollment":7658,"conditions":15898,"interventions":15899},"NCT04310540","PSMA PET\u002FMRI or PSMA PET\u002FCT for Evaluation of Liver Cancer",[89],"2023-11-02",[4616],[15889],{"trials":15901,"activeCount":128},[],{"trials":15903,"activeCount":128},[15904,15911],{"nctId":15905,"briefTitle":15906,"status":104,"phases":15907,"primaryCompletion":1865,"completion":1865,"start":15908,"enrollment":34,"conditions":15909,"interventions":15910},"NCT05176223","68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer",[91],"2022-01-30",[357,613,629,644],[15889],{"nctId":15912,"briefTitle":15913,"status":104,"phases":15914,"primaryCompletion":15915,"completion":15915,"start":7182,"enrollment":328,"conditions":15916,"interventions":15917},"NCT04762888","68Ga-PSMA-Dual-Contrast PET\u002FMRI or PET\u002FCT for Early Detection of Liver Cancer",[91],"2025-06-26",[4616],[15889],{"trials":15919,"activeCount":128},[15920],{"nctId":15921,"briefTitle":15922,"status":104,"phases":15923,"primaryCompletion":5562,"completion":5562,"start":15924,"enrollment":15925,"conditions":15926,"interventions":15927},"NCT05547386","68Ga-PSMA-11 PET\u002FCT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer",[92],"2022-05-09",163,[5061,6645,5063],[15889],{"trials":15929,"activeCount":128},[],{"trials":15931,"activeCount":128},[],{"intervention":15933,"totalTrials":342,"cells":15934},"Cannabidiol",{"EARLY_PHASE1":15935,"PHASE1":15937,"PHASE2":15939,"PHASE3":15958,"PHASE4":15969,"NA":15971},{"trials":15936,"activeCount":128},[],{"trials":15938,"activeCount":128},[],{"trials":15940,"activeCount":128},[15941,15949],{"nctId":15942,"briefTitle":15943,"status":104,"phases":15944,"primaryCompletion":15945,"completion":15945,"start":15946,"enrollment":15202,"conditions":15947,"interventions":15948},"NCT03941288","Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia",[91],"2023-02-23","2019-09-04",[11692,6538],[15933],{"nctId":15950,"briefTitle":15951,"status":104,"phases":15952,"primaryCompletion":15953,"completion":2924,"start":15954,"enrollment":498,"conditions":15955,"interventions":15957},"NCT05388058","Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy",[91],"2023-07-14","2022-06-09",[15956,24],"Chemotherapy-Induced Peripheral Neuropathy",[15933],{"trials":15959,"activeCount":128},[15960],{"nctId":15961,"briefTitle":15962,"status":104,"phases":15963,"primaryCompletion":15964,"completion":15964,"start":15965,"enrollment":1151,"conditions":15966,"interventions":15968},"NCT04387617","A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones",[91,92],"2022-01-31","2021-02-15",[15967],"Urinary Stone",[15933],{"trials":15970,"activeCount":128},[],{"trials":15972,"activeCount":128},[],{"intervention":15974,"totalTrials":342,"cells":15975},"Lorcaserin",{"EARLY_PHASE1":15976,"PHASE1":15978,"PHASE2":15980,"PHASE3":15992,"PHASE4":16009,"NA":16011},{"trials":15977,"activeCount":128},[],{"trials":15979,"activeCount":128},[],{"trials":15981,"activeCount":128},[15982],{"nctId":15983,"briefTitle":15984,"status":104,"phases":15985,"primaryCompletion":15986,"completion":15986,"start":4279,"enrollment":173,"conditions":15987,"interventions":15990},"NCT02393547","Lorcaserin for Preventing Weight Gain Among Smokers",[90,91],"2015-12",[15988,15989],"Tobacco Use Disorder","Weight Gain",[15991,15974],"Varenicline",{"trials":15993,"activeCount":128},[15994,16002],{"nctId":15995,"briefTitle":15996,"status":134,"phases":15997,"primaryCompletion":15998,"completion":15998,"start":10353,"enrollment":2668,"conditions":15999,"interventions":16000},"NCT02412631","Addressing Post Cessation Weight Gain",[91,92],"2020-04-17",[15,3069],[16001,15991],"lorcaserin",{"nctId":16003,"briefTitle":16004,"status":104,"phases":16005,"primaryCompletion":15986,"completion":15986,"start":5417,"enrollment":3687,"conditions":16006,"interventions":16008},"NCT02129608","Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management",[92],[13064,16007],"Obese",[15974],{"trials":16010,"activeCount":128},[],{"trials":16012,"activeCount":128},[],{"intervention":16014,"totalTrials":342,"cells":16015},"Rifaximin",{"EARLY_PHASE1":16016,"PHASE1":16018,"PHASE2":16020,"PHASE3":16041,"PHASE4":16050,"NA":16052},{"trials":16017,"activeCount":128},[],{"trials":16019,"activeCount":128},[],{"trials":16021,"activeCount":128},[16022,16031],{"nctId":16023,"briefTitle":16024,"status":134,"phases":16025,"primaryCompletion":16026,"completion":16026,"start":16027,"enrollment":173,"conditions":16028,"interventions":16030},"NCT04249622","Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer",[91],"2022-12-27","2020-09-18",[5197,10337,10338,5198,10339,10340,579,580,581,582,16029,10342,10343,10344,10345,10346,10347,6193,6194,6195,6196],"HER2 Positive Breast Carcinoma",[16014],{"nctId":16032,"briefTitle":16033,"status":134,"phases":16034,"primaryCompletion":16035,"completion":16036,"start":16037,"enrollment":895,"conditions":16038,"interventions":16040},"NCT04254549","Rifaximin in Patients With Diabetic Gastroparesis",[91],"2025-04-08","2025-04-11","2019-06-14",[14274,16039],"Diabetic Gastroparesis",[16014],{"trials":16042,"activeCount":128},[16043],{"nctId":16044,"briefTitle":16045,"status":104,"phases":16046,"primaryCompletion":1356,"completion":2863,"start":3971,"enrollment":3914,"conditions":16047,"interventions":16049},"NCT01662791","Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth",[92],[16048],"Parkinson's Disease",[16014],{"trials":16051,"activeCount":128},[],{"trials":16053,"activeCount":128},[],{"intervention":16055,"totalTrials":224,"cells":16056},"Acetazolamide",{"EARLY_PHASE1":16057,"PHASE1":16059,"PHASE2":16061,"PHASE3":16063,"PHASE4":16084,"NA":16086},{"trials":16058,"activeCount":128},[],{"trials":16060,"activeCount":128},[],{"trials":16062,"activeCount":128},[],{"trials":16064,"activeCount":128},[16065,16074],{"nctId":16066,"briefTitle":16067,"status":134,"phases":16068,"primaryCompletion":1224,"completion":1224,"start":16069,"enrollment":558,"conditions":16070,"interventions":16073},"NCT04679389","Acetazolamide Efficacy in Ataxia in PMM2-CDG",[91,92],"2021-03-17",[16071,16072],"Pmm2-CDG","CDG1A",[16055],{"nctId":16075,"briefTitle":16076,"status":134,"phases":16077,"primaryCompletion":16078,"completion":16078,"start":2946,"enrollment":342,"conditions":16079,"interventions":16082},"NCT02904265","Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave\u002FLandau-Kleffner Syndrome",[91,92],"2019-07-26",[16080,16081],"Landau-Kleffner Syndrome","Status Epilepticus, Electrographic",[16083,16055],"Diazepam",{"trials":16085,"activeCount":128},[],{"trials":16087,"activeCount":128},[],{"intervention":16089,"totalTrials":224,"cells":16090},"Pentoxifylline",{"EARLY_PHASE1":16091,"PHASE1":16100,"PHASE2":16102,"PHASE3":16104,"PHASE4":16124,"NA":16126},{"trials":16092,"activeCount":128},[16093],{"nctId":16094,"briefTitle":16095,"status":104,"phases":16096,"primaryCompletion":1375,"completion":1375,"start":1563,"enrollment":817,"conditions":16097,"interventions":16099},"NCT01292005","Pentoxifylline Treatment of Acute Pancreatitis",[89],[16098],"Acute Pancreatitis",[16089],{"trials":16101,"activeCount":128},[],{"trials":16103,"activeCount":128},[],{"trials":16105,"activeCount":128},[16106],{"nctId":16107,"briefTitle":16108,"status":104,"phases":16109,"primaryCompletion":16110,"completion":16111,"start":1235,"enrollment":16112,"conditions":16113,"interventions":16123},"NCT02487225","Pentoxifylline Treatment in Acute Pancreatitis (AP)",[92],"2017-04-30","2017-10-31",83,[16114,16115,16116,16117,16118,16119,16120,16121,16122],"Acute Pancreatitis (AP)","Gallstone Pancreatitis","Alcoholic Pancreatitis","Trauma Acute Pancreatitis","Hypertriglyceridemia Acute Pancreatitis","Idiopathic (Unknown) Acute Pancreatitis","Medication Induced Acute Pancreatitis","Cancer Acute Pancreatitis","Miscellaneous (i.e. Acute on Chronic Pancreatitis)",[16089],{"trials":16125,"activeCount":128},[],{"trials":16127,"activeCount":128},[],{"intervention":12520,"totalTrials":224,"cells":16129},{"EARLY_PHASE1":16130,"PHASE1":16132,"PHASE2":16134,"PHASE3":16140,"PHASE4":16146,"NA":16148},{"trials":16131,"activeCount":128},[],{"trials":16133,"activeCount":128},[],{"trials":16135,"activeCount":128},[16136],{"nctId":12513,"briefTitle":12514,"status":1413,"phases":16137,"primaryCompletion":12516,"completion":12517,"start":3642,"enrollment":128,"conditions":16138,"interventions":16139},[91],[33],[12495,12520],{"trials":16141,"activeCount":128},[16142],{"nctId":12524,"briefTitle":12525,"status":134,"phases":16143,"primaryCompletion":12527,"completion":12527,"start":12528,"enrollment":885,"conditions":16144,"interventions":16145},[92],[33],[12495,12520],{"trials":16147,"activeCount":128},[],{"trials":16149,"activeCount":128},[],{"intervention":1539,"totalTrials":224,"cells":16151},{"EARLY_PHASE1":16152,"PHASE1":16154,"PHASE2":16156,"PHASE3":16166,"PHASE4":16172,"NA":16174},{"trials":16153,"activeCount":128},[],{"trials":16155,"activeCount":128},[],{"trials":16157,"activeCount":128},[16158],{"nctId":16159,"briefTitle":16160,"status":104,"phases":16161,"primaryCompletion":16162,"completion":16162,"start":16163,"enrollment":498,"conditions":16164,"interventions":16165},"NCT02647944","Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity",[91],"2016-12-30","2015-12-18",[15],[1539],{"trials":16167,"activeCount":128},[16168],{"nctId":1531,"briefTitle":1532,"status":104,"phases":16169,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":1536,"conditions":16170,"interventions":16171},[92],[15],[721,1539,1540,1541],{"trials":16173,"activeCount":128},[],{"trials":16175,"activeCount":128},[],{"intervention":16177,"totalTrials":224,"cells":16178},"nicotine replacement therapy",{"EARLY_PHASE1":16179,"PHASE1":16181,"PHASE2":16183,"PHASE3":16192,"PHASE4":16200,"NA":16202},{"trials":16180,"activeCount":128},[],{"trials":16182,"activeCount":128},[],{"trials":16184,"activeCount":128},[16185],{"nctId":16186,"briefTitle":16187,"status":104,"phases":16188,"primaryCompletion":1563,"completion":4784,"start":1390,"enrollment":25,"conditions":16189,"interventions":16191},"NCT00888459","A Pilot Study Evaluating Nicotine Lozenges and Self Help",[91],[16190],"Smokeless Tobacco Use",[16177],{"trials":16193,"activeCount":128},[16194],{"nctId":16195,"briefTitle":16196,"status":104,"phases":16197,"primaryCompletion":6365,"completion":6365,"start":5246,"enrollment":328,"conditions":16198,"interventions":16199},"NCT00939029","Highdose Nicotine Patch Therapy for Smokeless Tobacco Use",[91,92],[16190],[16177],{"trials":16201,"activeCount":128},[],{"trials":16203,"activeCount":128},[],{"intervention":16205,"totalTrials":224,"cells":16206},"darbepoetin alfa",{"EARLY_PHASE1":16207,"PHASE1":16209,"PHASE2":16211,"PHASE3":16223,"PHASE4":16234,"NA":16236},{"trials":16208,"activeCount":128},[],{"trials":16210,"activeCount":128},[],{"trials":16212,"activeCount":128},[16213],{"nctId":16214,"briefTitle":16215,"status":104,"phases":16216,"primaryCompletion":2621,"completion":2621,"start":16217,"enrollment":16218,"conditions":16219,"interventions":16221},"NCT00416624","Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy",[91],"2007-05",239,[10869,3549,1419,16220,3665,5371,4293],"Lymphoproliferative Disorder",[16205,16222],"epoetin alfa",{"trials":16224,"activeCount":128},[16225],{"nctId":16226,"briefTitle":16227,"status":104,"phases":16228,"primaryCompletion":5279,"completion":5279,"start":16229,"enrollment":16230,"conditions":16231,"interventions":16232},"NCT00661999","Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer",[92],"2006-01",502,[10869,3549,1419,16220,3665,5371,4293],[16205,16233],"sodium ferric gluconate complex in sucrose",{"trials":16235,"activeCount":128},[],{"trials":16237,"activeCount":128},[],{"intervention":16239,"totalTrials":224,"cells":16240},"Albuterol",{"EARLY_PHASE1":16241,"PHASE1":16243,"PHASE2":16253,"PHASE3":16255,"PHASE4":16265,"NA":16267},{"trials":16242,"activeCount":128},[],{"trials":16244,"activeCount":128},[16245],{"nctId":16246,"briefTitle":16247,"status":104,"phases":16248,"primaryCompletion":1374,"completion":1374,"start":16249,"enrollment":3674,"conditions":16250,"interventions":16252},"NCT01203592","Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes",[90],"2010-09",[16251],"Congenital Myasthenic Syndrome",[16239],{"trials":16254,"activeCount":128},[],{"trials":16256,"activeCount":128},[16257],{"nctId":16258,"briefTitle":16259,"status":104,"phases":16260,"primaryCompletion":2697,"completion":2697,"start":2946,"enrollment":729,"conditions":16261,"interventions":16264},"NCT02885636","Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial",[92],[2982,16262,16263],"Heart Failure, Left-Sided","Left-Sided Heart Failure",[16239],{"trials":16266,"activeCount":128},[],{"trials":16268,"activeCount":128},[],{"intervention":16270,"totalTrials":224,"cells":16271},"Nicotine Lozenges",{"EARLY_PHASE1":16272,"PHASE1":16274,"PHASE2":16276,"PHASE3":16278,"PHASE4":16296,"NA":16298},{"trials":16273,"activeCount":128},[],{"trials":16275,"activeCount":128},[],{"trials":16277,"activeCount":128},[],{"trials":16279,"activeCount":128},[16280,16287],{"nctId":16281,"briefTitle":16282,"status":104,"phases":16283,"primaryCompletion":5279,"completion":5279,"start":5034,"enrollment":16284,"conditions":16285,"interventions":16286},"NCT00392379","Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction",[92],270,[16190],[16270],{"nctId":16288,"briefTitle":16289,"status":104,"phases":16290,"primaryCompletion":1375,"completion":1375,"start":3717,"enrollment":696,"conditions":16291,"interventions":16293},"NCT01018394","Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction",[91,92],[16292],"Tobacco Dependence",[16294,16295],"nicotine lozenges","tobacco-free snuff",{"trials":16297,"activeCount":128},[],{"trials":16299,"activeCount":128},[],{"intervention":16301,"totalTrials":224,"cells":16302},"Bupropion SR",{"EARLY_PHASE1":16303,"PHASE1":16305,"PHASE2":16307,"PHASE3":16309,"PHASE4":16328,"NA":16330},{"trials":16304,"activeCount":128},[],{"trials":16306,"activeCount":128},[],{"trials":16308,"activeCount":128},[],{"trials":16310,"activeCount":128},[16311,16320],{"nctId":16312,"briefTitle":16313,"status":104,"phases":16314,"primaryCompletion":16315,"completion":16315,"start":7296,"enrollment":16316,"conditions":16317,"interventions":16319},"NCT00414180","Bupropion SR for Treating Smokeless Tobacco Use",[92],"2005-05",225,[16318],"Smokeless Tobacco",[16301],{"nctId":16321,"briefTitle":16322,"status":104,"phases":16323,"primaryCompletion":4885,"completion":4885,"start":2883,"enrollment":16324,"conditions":16325,"interventions":16326},"NCT00935818","Varenicline and Bupropion for Smoking Cessation",[91,92],506,[13450],[15991,16327],"bupropion SR",{"trials":16329,"activeCount":128},[],{"trials":16331,"activeCount":128},[],{"intervention":16083,"totalTrials":224,"cells":16333},{"EARLY_PHASE1":16334,"PHASE1":16336,"PHASE2":16338,"PHASE3":16348,"PHASE4":16354,"NA":16356},{"trials":16335,"activeCount":128},[],{"trials":16337,"activeCount":128},[],{"trials":16339,"activeCount":128},[16340],{"nctId":16341,"briefTitle":16342,"status":1413,"phases":16343,"primaryCompletion":10729,"completion":10729,"start":16344,"enrollment":128,"conditions":16345,"interventions":16347},"NCT05361447","Diazepam Trial in GAD65 Associated Epilepsy",[90,91],"2023-01-11",[16346],"GAD 65 Antibody-associated Epilepsy",[16083],{"trials":16349,"activeCount":128},[16350],{"nctId":16075,"briefTitle":16076,"status":134,"phases":16351,"primaryCompletion":16078,"completion":16078,"start":2946,"enrollment":342,"conditions":16352,"interventions":16353},[91,92],[16080,16081],[16083,16055],{"trials":16355,"activeCount":128},[],{"trials":16357,"activeCount":128},[],{"intervention":16359,"totalTrials":676,"cells":16360},"darapladib",{"EARLY_PHASE1":16361,"PHASE1":16363,"PHASE2":16365,"PHASE3":16367,"PHASE4":16376,"NA":16378},{"trials":16362,"activeCount":128},[],{"trials":16364,"activeCount":128},[],{"trials":16366,"activeCount":128},[],{"trials":16368,"activeCount":128},[16369],{"nctId":16370,"briefTitle":16371,"status":104,"phases":16372,"primaryCompletion":7696,"completion":7696,"start":16373,"enrollment":313,"conditions":16374,"interventions":16375},"NCT01067339","Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans",[92],"2010-02-04",[10451],[16359],{"trials":16377,"activeCount":128},[],{"trials":16379,"activeCount":128},[],{"intervention":16381,"totalTrials":676,"cells":16382},"Atrasentan",{"EARLY_PHASE1":16383,"PHASE1":16385,"PHASE2":16387,"PHASE3":16389,"PHASE4":16399,"NA":16401},{"trials":16384,"activeCount":128},[],{"trials":16386,"activeCount":128},[],{"trials":16388,"activeCount":128},[],{"trials":16390,"activeCount":128},[16391],{"nctId":16392,"briefTitle":16393,"status":104,"phases":16394,"primaryCompletion":4786,"completion":4503,"start":16395,"enrollment":923,"conditions":16396,"interventions":16397},"NCT00271492","Correlation of Endothelial Function and Early Coronary Artery Disease in Humans",[92],"2001-07",[10451],[16381,16381,16398],"atrasentan",{"trials":16400,"activeCount":128},[],{"trials":16402,"activeCount":128},[],{"intervention":16404,"totalTrials":676,"cells":16405},"Itopride",{"EARLY_PHASE1":16406,"PHASE1":16408,"PHASE2":16410,"PHASE3":16412,"PHASE4":16421,"NA":16423},{"trials":16407,"activeCount":128},[],{"trials":16409,"activeCount":128},[],{"trials":16411,"activeCount":128},[],{"trials":16413,"activeCount":128},[16414],{"nctId":16415,"briefTitle":16416,"status":104,"phases":16417,"primaryCompletion":1297,"completion":1297,"start":5280,"enrollment":461,"conditions":16418,"interventions":16420},"NCT00308399","A Study to Evaluate the Effect of a Medicine on Gastric Functions in Healthy Volunteers.",[91,92],[16419],"Healthy Volunteers",[16404],{"trials":16422,"activeCount":128},[],{"trials":16424,"activeCount":128},[],{"intervention":15705,"totalTrials":676,"cells":16426},{"EARLY_PHASE1":16427,"PHASE1":16429,"PHASE2":16431,"PHASE3":16433,"PHASE4":16439,"NA":16441},{"trials":16428,"activeCount":128},[],{"trials":16430,"activeCount":128},[],{"trials":16432,"activeCount":128},[],{"trials":16434,"activeCount":128},[16435],{"nctId":15697,"briefTitle":15698,"status":1413,"phases":16436,"primaryCompletion":15700,"completion":15700,"start":15701,"enrollment":128,"conditions":16437,"interventions":16438},[92],[15703],[15705,7013],{"trials":16440,"activeCount":128},[],{"trials":16442,"activeCount":128},[],{"intervention":7012,"totalTrials":676,"cells":16444},{"EARLY_PHASE1":16445,"PHASE1":16447,"PHASE2":16449,"PHASE3":16451,"PHASE4":16457,"NA":16459},{"trials":16446,"activeCount":128},[],{"trials":16448,"activeCount":128},[],{"trials":16450,"activeCount":128},[],{"trials":16452,"activeCount":128},[16453],{"nctId":7005,"briefTitle":7006,"status":134,"phases":16454,"primaryCompletion":7008,"completion":7008,"start":3642,"enrollment":139,"conditions":16455,"interventions":16456},[92],[7010],[7012,7013,867],{"trials":16458,"activeCount":128},[],{"trials":16460,"activeCount":128},[],{"intervention":16462,"totalTrials":676,"cells":16463},"Octreotide",{"EARLY_PHASE1":16464,"PHASE1":16466,"PHASE2":16468,"PHASE3":16470,"PHASE4":16481,"NA":16483},{"trials":16465,"activeCount":128},[],{"trials":16467,"activeCount":128},[],{"trials":16469,"activeCount":128},[],{"trials":16471,"activeCount":128},[16472],{"nctId":16473,"briefTitle":16474,"status":104,"phases":16475,"primaryCompletion":2937,"completion":2937,"start":5034,"enrollment":7658,"conditions":16476,"interventions":16480},"NCT00426153","Octreotide in Severe Polycystic Liver Disease",[91,92],[16477,5155,16478,10658,16479,3036],"Polycystic Kidney, Autosomal Dominant","Hepatomegaly","Kidney, Polycystic",[16462],{"trials":16482,"activeCount":128},[],{"trials":16484,"activeCount":128},[],{"intervention":16486,"totalTrials":676,"cells":16487},"n3-PUFA",{"EARLY_PHASE1":16488,"PHASE1":16490,"PHASE2":16492,"PHASE3":16494,"PHASE4":16502,"NA":16504},{"trials":16489,"activeCount":128},[],{"trials":16491,"activeCount":128},[],{"trials":16493,"activeCount":128},[],{"trials":16495,"activeCount":128},[16496],{"nctId":16497,"briefTitle":16498,"status":104,"phases":16499,"primaryCompletion":11549,"completion":11549,"start":13030,"enrollment":3719,"conditions":16500,"interventions":16501},"NCT03350906","Enhancing Adaptations to Exercise",[92],[7090],[16486],{"trials":16503,"activeCount":128},[],{"trials":16505,"activeCount":128},[],{"intervention":16507,"totalTrials":676,"cells":16508},"Valganciclovir",{"EARLY_PHASE1":16509,"PHASE1":16511,"PHASE2":16513,"PHASE3":16515,"PHASE4":16525,"NA":16527},{"trials":16510,"activeCount":128},[],{"trials":16512,"activeCount":128},[],{"trials":16514,"activeCount":128},[],{"trials":16516,"activeCount":128},[16517],{"nctId":16518,"briefTitle":16519,"status":104,"phases":16520,"primaryCompletion":4928,"completion":4928,"start":16521,"enrollment":173,"conditions":16522,"interventions":16524},"NCT00275665","The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.",[92],"2001-11",[16523],"Bone Marrow Stem Cell Transplant",[16507],{"trials":16526,"activeCount":128},[],{"trials":16528,"activeCount":128},[],{"intervention":16530,"totalTrials":676,"cells":16531},"vapreotide",{"EARLY_PHASE1":16532,"PHASE1":16534,"PHASE2":16536,"PHASE3":16538,"PHASE4":16549,"NA":16551},{"trials":16533,"activeCount":128},[],{"trials":16535,"activeCount":128},[],{"trials":16537,"activeCount":128},[],{"trials":16539,"activeCount":128},[16540],{"nctId":16541,"briefTitle":16542,"status":134,"phases":16543,"primaryCompletion":16544,"completion":16545,"start":16544,"conditions":16546,"interventions":16548},"NCT00014651","Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection",[92],"2001-03","2002-04",[4862,16547],"Perioperative\u002FPostoperative Complications",[16530],{"trials":16550,"activeCount":128},[],{"trials":16552,"activeCount":128},[],{"intervention":16554,"totalTrials":676,"cells":16555},"Physician directed opioid prescribing",{"EARLY_PHASE1":16556,"PHASE1":16558,"PHASE2":16560,"PHASE3":16562,"PHASE4":16576,"NA":16578},{"trials":16557,"activeCount":128},[],{"trials":16559,"activeCount":128},[],{"trials":16561,"activeCount":128},[],{"trials":16563,"activeCount":128},[16564],{"nctId":16565,"briefTitle":16566,"status":104,"phases":16567,"primaryCompletion":16568,"completion":16568,"start":16569,"enrollment":430,"conditions":16570,"interventions":16574},"NCT03805386","Patient-Directed Postoperative Opioid Prescribing for Gynecologic Surgery",[91,92],"2020-04-15","2019-01-15",[16571,16572,16573],"Gynecology","Surgery","Opioid Use",[16554,16575],"Patient directed opioid prescribing",{"trials":16577,"activeCount":128},[],{"trials":16579,"activeCount":128},[],{"intervention":16575,"totalTrials":676,"cells":16581},{"EARLY_PHASE1":16582,"PHASE1":16584,"PHASE2":16586,"PHASE3":16588,"PHASE4":16594,"NA":16596},{"trials":16583,"activeCount":128},[],{"trials":16585,"activeCount":128},[],{"trials":16587,"activeCount":128},[],{"trials":16589,"activeCount":128},[16590],{"nctId":16565,"briefTitle":16566,"status":104,"phases":16591,"primaryCompletion":16568,"completion":16568,"start":16569,"enrollment":430,"conditions":16592,"interventions":16593},[91,92],[16571,16572,16573],[16554,16575],{"trials":16595,"activeCount":128},[],{"trials":16597,"activeCount":128},[],{"intervention":16599,"totalTrials":676,"cells":16600},"Levothyroxine",{"EARLY_PHASE1":16601,"PHASE1":16603,"PHASE2":16605,"PHASE3":16607,"PHASE4":16617,"NA":16619},{"trials":16602,"activeCount":128},[],{"trials":16604,"activeCount":128},[],{"trials":16606,"activeCount":128},[],{"trials":16608,"activeCount":128},[16609],{"nctId":16610,"briefTitle":16611,"status":104,"phases":16612,"primaryCompletion":5435,"completion":5435,"start":4279,"enrollment":16613,"conditions":16614,"interventions":16616},"NCT01950260","Early Levothyroxine Post Radioactive Iodine",[91,92],61,[16615],"Graves' Disease",[16599],{"trials":16618,"activeCount":128},[],{"trials":16620,"activeCount":128},[],{"intervention":16622,"totalTrials":676,"cells":16623},"Mesalamine",{"EARLY_PHASE1":16624,"PHASE1":16626,"PHASE2":16628,"PHASE3":16630,"PHASE4":16640,"NA":16642},{"trials":16625,"activeCount":128},[],{"trials":16627,"activeCount":128},[],{"trials":16629,"activeCount":128},[],{"trials":16631,"activeCount":128},[16632],{"nctId":16633,"briefTitle":16634,"status":104,"phases":16635,"primaryCompletion":2643,"completion":2643,"start":16636,"enrollment":313,"conditions":16637,"interventions":16639},"NCT00952952","Trial of Mesalamine for the Treatment of Active Microscopic Colitis",[91,92],"2007-02",[16638,11717],"Microscopic Colitis",[16622],{"trials":16641,"activeCount":128},[],{"trials":16643,"activeCount":128},[],{"intervention":16645,"totalTrials":676,"cells":16646},"C-11 choline PET tracer",{"EARLY_PHASE1":16647,"PHASE1":16649,"PHASE2":16651,"PHASE3":16653,"PHASE4":16663,"NA":16665},{"trials":16648,"activeCount":128},[],{"trials":16650,"activeCount":128},[],{"trials":16652,"activeCount":128},[],{"trials":16654,"activeCount":128},[16655],{"nctId":16656,"briefTitle":16657,"status":104,"phases":16658,"primaryCompletion":6190,"completion":6190,"start":16659,"enrollment":6434,"conditions":16660,"interventions":16661},"NCT03404648","Staging Prostate Cancer With Hybrid C11-Choline PET\u002FMR and mpMRI",[92],"2017-11-01",[6368],[16645,16662],"Gadobutrol",{"trials":16664,"activeCount":128},[],{"trials":16666,"activeCount":128},[],{"intervention":16662,"totalTrials":676,"cells":16668},{"EARLY_PHASE1":16669,"PHASE1":16671,"PHASE2":16673,"PHASE3":16675,"PHASE4":16681,"NA":16683},{"trials":16670,"activeCount":128},[],{"trials":16672,"activeCount":128},[],{"trials":16674,"activeCount":128},[],{"trials":16676,"activeCount":128},[16677],{"nctId":16656,"briefTitle":16657,"status":104,"phases":16678,"primaryCompletion":6190,"completion":6190,"start":16659,"enrollment":6434,"conditions":16679,"interventions":16680},[92],[6368],[16645,16662],{"trials":16682,"activeCount":128},[],{"trials":16684,"activeCount":128},[],{"intervention":16686,"totalTrials":676,"cells":16687},"LAF237 = vildagliptin",{"EARLY_PHASE1":16688,"PHASE1":16690,"PHASE2":16692,"PHASE3":16694,"PHASE4":16704,"NA":16706},{"trials":16689,"activeCount":128},[],{"trials":16691,"activeCount":128},[],{"trials":16693,"activeCount":128},[],{"trials":16695,"activeCount":128},[16696],{"nctId":16697,"briefTitle":16698,"status":104,"phases":16699,"primaryCompletion":16700,"completion":16700,"start":16315,"enrollment":108,"conditions":16701,"interventions":16703},"NCT00952991","The Effects of LAF237 on Gastric Function in Type 2 Diabetes",[92],"2006-02",[16702],"Diabetes Mellitus, Non-Insulin-Dependent",[16686],{"trials":16705,"activeCount":128},[],{"trials":16707,"activeCount":128},[],{"intervention":16709,"totalTrials":676,"cells":16710},"Lomotil",{"EARLY_PHASE1":16711,"PHASE1":16713,"PHASE2":16715,"PHASE3":16717,"PHASE4":16726,"NA":16728},{"trials":16712,"activeCount":128},[],{"trials":16714,"activeCount":128},[],{"trials":16716,"activeCount":128},[],{"trials":16718,"activeCount":128},[16719],{"nctId":16720,"briefTitle":16721,"status":104,"phases":16722,"primaryCompletion":7332,"completion":7332,"start":16723,"enrollment":25,"conditions":16724,"interventions":16725},"NCT00583323","Diphenoxylate \u002F Atropine to Decrease FDG Activity During F-18 FDG PET",[92],"2003-02",[1419],[16709],{"trials":16727,"activeCount":128},[],{"trials":16729,"activeCount":128},[],{"intervention":1540,"totalTrials":676,"cells":16731},{"EARLY_PHASE1":16732,"PHASE1":16734,"PHASE2":16736,"PHASE3":16738,"PHASE4":16744,"NA":16746},{"trials":16733,"activeCount":128},[],{"trials":16735,"activeCount":128},[],{"trials":16737,"activeCount":128},[],{"trials":16739,"activeCount":128},[16740],{"nctId":1531,"briefTitle":1532,"status":104,"phases":16741,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":1536,"conditions":16742,"interventions":16743},[92],[15],[721,1539,1540,1541],{"trials":16745,"activeCount":128},[],{"trials":16747,"activeCount":128},[],{"intervention":1541,"totalTrials":676,"cells":16749},{"EARLY_PHASE1":16750,"PHASE1":16752,"PHASE2":16754,"PHASE3":16756,"PHASE4":16762,"NA":16764},{"trials":16751,"activeCount":128},[],{"trials":16753,"activeCount":128},[],{"trials":16755,"activeCount":128},[],{"trials":16757,"activeCount":128},[16758],{"nctId":1531,"briefTitle":1532,"status":104,"phases":16759,"primaryCompletion":1534,"completion":1534,"start":1535,"enrollment":1536,"conditions":16760,"interventions":16761},[92],[15],[721,1539,1540,1541],{"trials":16763,"activeCount":128},[],{"trials":16765,"activeCount":128},[],{"intervention":16767,"totalTrials":676,"cells":16768},"Fresh Frozen Plasma Transfusion",{"EARLY_PHASE1":16769,"PHASE1":16771,"PHASE2":16773,"PHASE3":16775,"PHASE4":16785,"NA":16787},{"trials":16770,"activeCount":128},[],{"trials":16772,"activeCount":128},[],{"trials":16774,"activeCount":128},[],{"trials":16776,"activeCount":128},[16777],{"nctId":16778,"briefTitle":16779,"status":104,"phases":16780,"primaryCompletion":934,"completion":5141,"start":3662,"enrollment":224,"conditions":16781,"interventions":16784},"NCT00953901","Is Plasma Transfusion Beneficial Prior to Low-Risk Procedures in Hospitalized Patients With Blood Clotting Abnormalities?",[92],[16782,16783],"Blood Coagulation, Disorders","Surgical Procedures, Minimally Invasive",[16767],{"trials":16786,"activeCount":128},[],{"trials":16788,"activeCount":128},[],{"intervention":1511,"totalTrials":676,"cells":16790},{"EARLY_PHASE1":16791,"PHASE1":16793,"PHASE2":16795,"PHASE3":16797,"PHASE4":16803,"NA":16805},{"trials":16792,"activeCount":128},[],{"trials":16794,"activeCount":128},[],{"trials":16796,"activeCount":128},[],{"trials":16798,"activeCount":128},[16799],{"nctId":1501,"briefTitle":1502,"status":104,"phases":16800,"primaryCompletion":1504,"completion":1504,"start":1505,"enrollment":1506,"conditions":16801,"interventions":16802},[91,92],[1508,1509],[1511,778],{"trials":16804,"activeCount":128},[],{"trials":16806,"activeCount":128},[],{"intervention":16808,"totalTrials":676,"cells":16809},"Calcium Gluconate",{"EARLY_PHASE1":16810,"PHASE1":16812,"PHASE2":16814,"PHASE3":16816,"PHASE4":16827,"NA":16829},{"trials":16811,"activeCount":128},[],{"trials":16813,"activeCount":128},[],{"trials":16815,"activeCount":128},[],{"trials":16817,"activeCount":128},[16818],{"nctId":16819,"briefTitle":16820,"status":134,"phases":16821,"primaryCompletion":5246,"completion":2620,"start":7657,"enrollment":676,"conditions":16822,"interventions":16824},"NCT00998738","Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer",[92],[16823,938,143,3345],"Neuropathy",[16808,16825,16826],"Magnesium Sulfate","Ixabepilone",{"trials":16828,"activeCount":128},[],{"trials":16830,"activeCount":128},[],{"intervention":16825,"totalTrials":676,"cells":16832},{"EARLY_PHASE1":16833,"PHASE1":16835,"PHASE2":16837,"PHASE3":16839,"PHASE4":16845,"NA":16847},{"trials":16834,"activeCount":128},[],{"trials":16836,"activeCount":128},[],{"trials":16838,"activeCount":128},[],{"trials":16840,"activeCount":128},[16841],{"nctId":16819,"briefTitle":16820,"status":134,"phases":16842,"primaryCompletion":5246,"completion":2620,"start":7657,"enrollment":676,"conditions":16843,"interventions":16844},[92],[16823,938,143,3345],[16808,16825,16826],{"trials":16846,"activeCount":128},[],{"trials":16848,"activeCount":128},[],{"intervention":16826,"totalTrials":676,"cells":16850},{"EARLY_PHASE1":16851,"PHASE1":16853,"PHASE2":16855,"PHASE3":16857,"PHASE4":16863,"NA":16865},{"trials":16852,"activeCount":128},[],{"trials":16854,"activeCount":128},[],{"trials":16856,"activeCount":128},[],{"trials":16858,"activeCount":128},[16859],{"nctId":16819,"briefTitle":16820,"status":134,"phases":16860,"primaryCompletion":5246,"completion":2620,"start":7657,"enrollment":676,"conditions":16861,"interventions":16862},[92],[16823,938,143,3345],[16808,16825,16826],{"trials":16864,"activeCount":128},[],{"trials":16866,"activeCount":128},[],{"intervention":16868,"totalTrials":676,"cells":16869},"Tamsulosin hydrochloride",{"EARLY_PHASE1":16870,"PHASE1":16872,"PHASE2":16874,"PHASE3":16876,"PHASE4":16886,"NA":16888},{"trials":16871,"activeCount":128},[],{"trials":16873,"activeCount":128},[],{"trials":16875,"activeCount":128},[],{"trials":16877,"activeCount":128},[16878],{"nctId":16879,"briefTitle":16880,"status":134,"phases":16881,"primaryCompletion":16882,"completion":16882,"start":1319,"enrollment":1151,"conditions":16883,"interventions":16885},"NCT01568918","Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery",[92],"2019-11-21",[16884],"Postoperative Urinary Retention",[16868],{"trials":16887,"activeCount":128},[],{"trials":16889,"activeCount":128},[],{"intervention":16891,"totalTrials":676,"cells":16892},"Lenalidamide",{"EARLY_PHASE1":16893,"PHASE1":16895,"PHASE2":16897,"PHASE3":16899,"PHASE4":16908,"NA":16910},{"trials":16894,"activeCount":128},[],{"trials":16896,"activeCount":128},[],{"trials":16898,"activeCount":128},[],{"trials":16900,"activeCount":128},[16901],{"nctId":16902,"briefTitle":16903,"status":104,"phases":16904,"primaryCompletion":5472,"completion":3546,"start":1299,"enrollment":120,"conditions":16905,"interventions":16907},"NCT00166452","A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1",[92],[16906],"Complex Regional Pain Syndrome, Type 1",[16891],{"trials":16909,"activeCount":128},[],{"trials":16911,"activeCount":128},[],{"intervention":15718,"totalTrials":676,"cells":16913},{"EARLY_PHASE1":16914,"PHASE1":16916,"PHASE2":16918,"PHASE3":16920,"PHASE4":16926,"NA":16928},{"trials":16915,"activeCount":128},[],{"trials":16917,"activeCount":128},[],{"trials":16919,"activeCount":128},[],{"trials":16921,"activeCount":128},[16922],{"nctId":15711,"briefTitle":15712,"status":104,"phases":16923,"primaryCompletion":56,"completion":15714,"start":15715,"enrollment":3767,"conditions":16924,"interventions":16925},[92],[15],[15718,7013],{"trials":16927,"activeCount":128},[],{"trials":16929,"activeCount":128},[],{"intervention":16931,"totalTrials":676,"cells":16932},"Omega-3",{"EARLY_PHASE1":16933,"PHASE1":16935,"PHASE2":16937,"PHASE3":16939,"PHASE4":16950,"NA":16952},{"trials":16934,"activeCount":128},[],{"trials":16936,"activeCount":128},[],{"trials":16938,"activeCount":128},[],{"trials":16940,"activeCount":128},[16941],{"nctId":16942,"briefTitle":16943,"status":104,"phases":16944,"primaryCompletion":16945,"completion":16946,"start":16947,"enrollment":525,"conditions":16948,"interventions":16949},"NCT01686568","Omega-3 Fatty Acids and Insulin Sensitivity",[92],"2014-10-30","2015-06-08","2012-12-21",[6930],[16931],{"trials":16951,"activeCount":128},[],{"trials":16953,"activeCount":128},[],{"intervention":16955,"totalTrials":676,"cells":16956},"Amitriptyline",{"EARLY_PHASE1":16957,"PHASE1":16959,"PHASE2":16961,"PHASE3":16963,"PHASE4":16974,"NA":16976},{"trials":16958,"activeCount":128},[],{"trials":16960,"activeCount":128},[],{"trials":16962,"activeCount":128},[],{"trials":16964,"activeCount":128},[16965],{"nctId":16966,"briefTitle":16967,"status":104,"phases":16968,"primaryCompletion":3544,"completion":3544,"start":3519,"enrollment":16969,"conditions":16970,"interventions":16972},"NCT00248651","Functional Dyspepsia Treatment Trial",[91,92],292,[16971],"Dyspepsia and Other Specified Disorders of Function of Stomach",[16955,16973],"Escitalopram",{"trials":16975,"activeCount":128},[],{"trials":16977,"activeCount":128},[],{"intervention":16973,"totalTrials":676,"cells":16979},{"EARLY_PHASE1":16980,"PHASE1":16982,"PHASE2":16984,"PHASE3":16986,"PHASE4":16992,"NA":16994},{"trials":16981,"activeCount":128},[],{"trials":16983,"activeCount":128},[],{"trials":16985,"activeCount":128},[],{"trials":16987,"activeCount":128},[16988],{"nctId":16966,"briefTitle":16967,"status":104,"phases":16989,"primaryCompletion":3544,"completion":3544,"start":3519,"enrollment":16969,"conditions":16990,"interventions":16991},[91,92],[16971],[16955,16973],{"trials":16993,"activeCount":128},[],{"trials":16995,"activeCount":128},[],{"intervention":16997,"totalTrials":676,"cells":16998},"LdT (Telbivudine) and lamivudine",{"EARLY_PHASE1":16999,"PHASE1":17001,"PHASE2":17003,"PHASE3":17005,"PHASE4":17014,"NA":17016},{"trials":17000,"activeCount":128},[],{"trials":17002,"activeCount":128},[],{"trials":17004,"activeCount":128},[],{"trials":17006,"activeCount":128},[17007],{"nctId":17008,"briefTitle":17009,"status":104,"phases":17010,"primaryCompletion":1564,"completion":1564,"start":2573,"enrollment":1197,"conditions":17011,"interventions":17013},"NCT00275652","A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.",[92],[17012,10259],"Hepatitis B",[16997],{"trials":17015,"activeCount":128},[],{"trials":17017,"activeCount":128},[],{"intervention":16295,"totalTrials":676,"cells":17019},{"EARLY_PHASE1":17020,"PHASE1":17022,"PHASE2":17024,"PHASE3":17026,"PHASE4":17032,"NA":17034},{"trials":17021,"activeCount":128},[],{"trials":17023,"activeCount":128},[],{"trials":17025,"activeCount":128},[],{"trials":17027,"activeCount":128},[17028],{"nctId":16288,"briefTitle":16289,"status":104,"phases":17029,"primaryCompletion":1375,"completion":1375,"start":3717,"enrollment":696,"conditions":17030,"interventions":17031},[91,92],[16292],[16294,16295],{"trials":17033,"activeCount":128},[],{"trials":17035,"activeCount":128},[],{"intervention":17037,"totalTrials":676,"cells":17038},"ACEI \u002F Angiotensin converting enzyme inhibitor",{"EARLY_PHASE1":17039,"PHASE1":17041,"PHASE2":17043,"PHASE3":17045,"PHASE4":17055,"NA":17057},{"trials":17040,"activeCount":128},[],{"trials":17042,"activeCount":128},[],{"trials":17044,"activeCount":128},[],{"trials":17046,"activeCount":128},[17047],{"nctId":17048,"briefTitle":17049,"status":1413,"phases":17050,"primaryCompletion":1021,"completion":1021,"start":934,"enrollment":128,"conditions":17051,"interventions":17053},"NCT00280215","Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria",[92],[17052],"Hyperoxaluria",[17037,17054],"ARB \u002FAngiotensin Receptor Blocker",{"trials":17056,"activeCount":128},[],{"trials":17058,"activeCount":128},[],{"intervention":17054,"totalTrials":676,"cells":17060},{"EARLY_PHASE1":17061,"PHASE1":17063,"PHASE2":17065,"PHASE3":17067,"PHASE4":17073,"NA":17075},{"trials":17062,"activeCount":128},[],{"trials":17064,"activeCount":128},[],{"trials":17066,"activeCount":128},[],{"trials":17068,"activeCount":128},[17069],{"nctId":17048,"briefTitle":17049,"status":1413,"phases":17070,"primaryCompletion":1021,"completion":1021,"start":934,"enrollment":128,"conditions":17071,"interventions":17072},[92],[17052],[17037,17054],{"trials":17074,"activeCount":128},[],{"trials":17076,"activeCount":128},[],{"intervention":17078,"totalTrials":676,"cells":17079},"2.5 g of lidocaine 23% \u002F tetracaine 7% ointment without occlusion",{"EARLY_PHASE1":17080,"PHASE1":17082,"PHASE2":17084,"PHASE3":17086,"PHASE4":17100,"NA":17102},{"trials":17081,"activeCount":128},[],{"trials":17083,"activeCount":128},[],{"trials":17085,"activeCount":128},[],{"trials":17087,"activeCount":128},[17088],{"nctId":17089,"briefTitle":17090,"status":104,"phases":17091,"primaryCompletion":17092,"completion":17092,"start":17093,"enrollment":3002,"conditions":17094,"interventions":17098},"NCT04523961","Comparative Study of Two Topical Anesthetics Prior to Fractional Nonablative Laser Treatment of the Face",[91,92],"2025-02-19","2021-01-08",[17095,17096,17097],"Anesthesia, Local","Photodamaged Skin","Topical and Infiltration Anesthetic Toxicity",[17078,17099],"7.5 g lidocaine 2.5%\u002F prilocaine 2.5% cream with occlusion",{"trials":17101,"activeCount":128},[],{"trials":17103,"activeCount":128},[],{"intervention":17099,"totalTrials":676,"cells":17105},{"EARLY_PHASE1":17106,"PHASE1":17108,"PHASE2":17110,"PHASE3":17112,"PHASE4":17118,"NA":17120},{"trials":17107,"activeCount":128},[],{"trials":17109,"activeCount":128},[],{"trials":17111,"activeCount":128},[],{"trials":17113,"activeCount":128},[17114],{"nctId":17089,"briefTitle":17090,"status":104,"phases":17115,"primaryCompletion":17092,"completion":17092,"start":17093,"enrollment":3002,"conditions":17116,"interventions":17117},[91,92],[17095,17096,17097],[17078,17099],{"trials":17119,"activeCount":128},[],{"trials":17121,"activeCount":128},[],{"intervention":17123,"totalTrials":676,"cells":17124},"FDA approved rate and rhythm control drugs",{"EARLY_PHASE1":17125,"PHASE1":17127,"PHASE2":17129,"PHASE3":17131,"PHASE4":17140,"NA":17142},{"trials":17126,"activeCount":128},[],{"trials":17128,"activeCount":128},[],{"trials":17130,"activeCount":128},[],{"trials":17132,"activeCount":128},[17133],{"nctId":17134,"briefTitle":17135,"status":134,"phases":17136,"primaryCompletion":17137,"completion":17137,"start":934,"enrollment":97,"conditions":17138,"interventions":17139},"NCT00589303","AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study",[92],"2011-07",[33,27],[17123],{"trials":17141,"activeCount":128},[],{"trials":17143,"activeCount":128},[],{"intervention":17145,"totalTrials":676,"cells":17146},"Colchicine",{"EARLY_PHASE1":17147,"PHASE1":17149,"PHASE2":17151,"PHASE3":17153,"PHASE4":17163,"NA":17165},{"trials":17148,"activeCount":128},[],{"trials":17150,"activeCount":128},[],{"trials":17152,"activeCount":128},[],{"trials":17154,"activeCount":128},[17155],{"nctId":17156,"briefTitle":17157,"status":134,"phases":17158,"primaryCompletion":1471,"completion":1471,"start":1235,"enrollment":224,"conditions":17159,"interventions":17162},"NCT02177266","Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation",[92],[33,17160,17161],"Post-pericardiotomy Syndrome","Constriction",[17145],{"trials":17164,"activeCount":128},[],{"trials":17166,"activeCount":128},[],{"intervention":17168,"totalTrials":676,"cells":17169},"etanercept",{"EARLY_PHASE1":17170,"PHASE1":17172,"PHASE2":17174,"PHASE3":17176,"PHASE4":17187,"NA":17189},{"trials":17171,"activeCount":128},[],{"trials":17173,"activeCount":128},[],{"trials":17175,"activeCount":128},[],{"trials":17177,"activeCount":128},[17178],{"nctId":17179,"briefTitle":17180,"status":104,"phases":17181,"primaryCompletion":13198,"start":17182,"conditions":17183,"interventions":17186},"NCT00046904","Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer",[92],"2003-05",[17184,17185,4293],"Anorexia","Cachexia",[17168],{"trials":17188,"activeCount":128},[],{"trials":17190,"activeCount":128},[],{"intervention":17192,"totalTrials":676,"cells":17193},"Rose Geranium in Sesame Oil Nasal Spray",{"EARLY_PHASE1":17194,"PHASE1":17196,"PHASE2":17198,"PHASE3":17200,"PHASE4":17210,"NA":17212},{"trials":17195,"activeCount":128},[],{"trials":17197,"activeCount":128},[],{"trials":17199,"activeCount":128},[],{"trials":17201,"activeCount":128},[17202],{"nctId":17203,"briefTitle":17204,"status":104,"phases":17205,"primaryCompletion":3988,"completion":3988,"start":17206,"enrollment":14465,"conditions":17207,"interventions":17209},"NCT04620369","Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy",[92],"2020-11-13",[1418,24,17208],"Nasal Vestibulitis",[17192],{"trials":17211,"activeCount":128},[],{"trials":17213,"activeCount":128},[],{"intervention":17215,"totalTrials":676,"cells":17216},"Bupropion SR & Varenicline",{"EARLY_PHASE1":17217,"PHASE1":17219,"PHASE2":17221,"PHASE3":17223,"PHASE4":17231,"NA":17233},{"trials":17218,"activeCount":128},[],{"trials":17220,"activeCount":128},[],{"trials":17222,"activeCount":128},[],{"trials":17224,"activeCount":128},[17225],{"nctId":17226,"briefTitle":17227,"status":104,"phases":17228,"primaryCompletion":5351,"completion":5351,"start":4928,"enrollment":956,"conditions":17229,"interventions":17230},"NCT00587769","Chantix & Bupropion for Smoking Cessation",[92],[13450,15988],[17215],{"trials":17232,"activeCount":128},[],{"trials":17234,"activeCount":128},[],{"intervention":17236,"totalTrials":676,"cells":17237},"Ketamine \u002F Propofol Admixture",{"EARLY_PHASE1":17238,"PHASE1":17240,"PHASE2":17242,"PHASE3":17244,"PHASE4":17256,"NA":17258},{"trials":17239,"activeCount":128},[],{"trials":17241,"activeCount":128},[],{"trials":17243,"activeCount":128},[],{"trials":17245,"activeCount":128},[17246],{"nctId":17247,"briefTitle":17248,"status":104,"phases":17249,"primaryCompletion":17250,"completion":17251,"start":7317,"enrollment":17252,"conditions":17253,"interventions":17254},"NCT02105415","Ketamine \u002F Propofol Admixture \"Ketofol\" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial",[91,92],"2017-11-28","2018-08-01",160,[1474],[17236,17255],"Etomidate",{"trials":17257,"activeCount":128},[],{"trials":17259,"activeCount":128},[],{"intervention":17255,"totalTrials":676,"cells":17261},{"EARLY_PHASE1":17262,"PHASE1":17264,"PHASE2":17266,"PHASE3":17268,"PHASE4":17274,"NA":17276},{"trials":17263,"activeCount":128},[],{"trials":17265,"activeCount":128},[],{"trials":17267,"activeCount":128},[],{"trials":17269,"activeCount":128},[17270],{"nctId":17247,"briefTitle":17248,"status":104,"phases":17271,"primaryCompletion":17250,"completion":17251,"start":7317,"enrollment":17252,"conditions":17272,"interventions":17273},[91,92],[1474],[17236,17255],{"trials":17275,"activeCount":128},[],{"trials":17277,"activeCount":128},[],{"intervention":17279,"totalTrials":676,"cells":17280},"Insulin like growth factor, type 1",{"EARLY_PHASE1":17281,"PHASE1":17283,"PHASE2":17285,"PHASE3":17287,"PHASE4":17296,"NA":17298},{"trials":17282,"activeCount":128},[],{"trials":17284,"activeCount":128},[],{"trials":17286,"activeCount":128},[],{"trials":17288,"activeCount":128},[17289],{"nctId":17290,"briefTitle":17291,"status":104,"phases":17292,"primaryCompletion":1564,"completion":934,"start":4871,"enrollment":17293,"conditions":17294,"interventions":17295},"NCT00035815","Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial",[92],330,[6260],[17279],{"trials":17297,"activeCount":128},[],{"trials":17299,"activeCount":128},[],{"intervention":17301,"totalTrials":676,"cells":17302},"ACTH (Acthar) Gel",{"EARLY_PHASE1":17303,"PHASE1":17305,"PHASE2":17307,"PHASE3":17309,"PHASE4":17319,"NA":17321},{"trials":17304,"activeCount":128},[],{"trials":17306,"activeCount":128},[],{"trials":17308,"activeCount":128},[],{"trials":17310,"activeCount":128},[17311],{"nctId":17312,"briefTitle":17313,"status":104,"phases":17314,"primaryCompletion":15291,"completion":15291,"start":2863,"enrollment":173,"conditions":17315,"interventions":17318},"NCT02282930","Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression",[92],[17316,17317],"Progressive IgA Nephropathy","Proteinuria",[17301],{"trials":17320,"activeCount":128},[],{"trials":17322,"activeCount":128},[],{"intervention":17324,"totalTrials":676,"cells":17325},"Heparin",{"EARLY_PHASE1":17326,"PHASE1":17328,"PHASE2":17330,"PHASE3":17332,"PHASE4":17344,"NA":17346},{"trials":17327,"activeCount":128},[],{"trials":17329,"activeCount":128},[],{"trials":17331,"activeCount":128},[],{"trials":17333,"activeCount":128},[17334],{"nctId":17335,"briefTitle":17336,"status":104,"phases":17337,"primaryCompletion":933,"completion":933,"start":17338,"enrollment":16284,"conditions":17339,"interventions":17341},"NCT00587444","Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass",[92],"2001-06",[17340],"Postoperative Hemorrhage",[17324,17342,17343],"HH or high heparin","heparin concentration HC",{"trials":17345,"activeCount":128},[],{"trials":17347,"activeCount":128},[],{"intervention":17342,"totalTrials":676,"cells":17349},{"EARLY_PHASE1":17350,"PHASE1":17352,"PHASE2":17354,"PHASE3":17356,"PHASE4":17362,"NA":17364},{"trials":17351,"activeCount":128},[],{"trials":17353,"activeCount":128},[],{"trials":17355,"activeCount":128},[],{"trials":17357,"activeCount":128},[17358],{"nctId":17335,"briefTitle":17336,"status":104,"phases":17359,"primaryCompletion":933,"completion":933,"start":17338,"enrollment":16284,"conditions":17360,"interventions":17361},[92],[17340],[17324,17342,17343],{"trials":17363,"activeCount":128},[],{"trials":17365,"activeCount":128},[],{"intervention":17343,"totalTrials":676,"cells":17367},{"EARLY_PHASE1":17368,"PHASE1":17370,"PHASE2":17372,"PHASE3":17374,"PHASE4":17380,"NA":17382},{"trials":17369,"activeCount":128},[],{"trials":17371,"activeCount":128},[],{"trials":17373,"activeCount":128},[],{"trials":17375,"activeCount":128},[17376],{"nctId":17335,"briefTitle":17336,"status":104,"phases":17377,"primaryCompletion":933,"completion":933,"start":17338,"enrollment":16284,"conditions":17378,"interventions":17379},[92],[17340],[17324,17342,17343],{"trials":17381,"activeCount":128},[],{"trials":17383,"activeCount":128},[],{"intervention":16233,"totalTrials":676,"cells":17385},{"EARLY_PHASE1":17386,"PHASE1":17388,"PHASE2":17390,"PHASE3":17392,"PHASE4":17398,"NA":17400},{"trials":17387,"activeCount":128},[],{"trials":17389,"activeCount":128},[],{"trials":17391,"activeCount":128},[],{"trials":17393,"activeCount":128},[17394],{"nctId":16226,"briefTitle":16227,"status":104,"phases":17395,"primaryCompletion":5279,"completion":5279,"start":16229,"enrollment":16230,"conditions":17396,"interventions":17397},[92],[10869,3549,1419,16220,3665,5371,4293],[16205,16233],{"trials":17399,"activeCount":128},[],{"trials":17401,"activeCount":128},[],{"intervention":17403,"totalTrials":676,"cells":17404},"Ropivacaine Continuous",{"EARLY_PHASE1":17405,"PHASE1":17407,"PHASE2":17409,"PHASE3":17411,"PHASE4":17421,"NA":17423},{"trials":17406,"activeCount":128},[],{"trials":17408,"activeCount":128},[],{"trials":17410,"activeCount":128},[],{"trials":17412,"activeCount":128},[17413],{"nctId":17414,"briefTitle":17415,"status":104,"phases":17416,"primaryCompletion":13341,"completion":13341,"start":17417,"enrollment":25,"conditions":17418,"interventions":17419},"NCT05053087","A Study to Compare the Effectiveness of Adductor Canal Pain Catheters Following Total Knee Arthroplasty",[92],"2022-04-13",[15772],[17403,17420],"Ropivacaine Intermittent Bolus",{"trials":17422,"activeCount":128},[],{"trials":17424,"activeCount":128},[],{"intervention":17420,"totalTrials":676,"cells":17426},{"EARLY_PHASE1":17427,"PHASE1":17429,"PHASE2":17431,"PHASE3":17433,"PHASE4":17439,"NA":17441},{"trials":17428,"activeCount":128},[],{"trials":17430,"activeCount":128},[],{"trials":17432,"activeCount":128},[],{"trials":17434,"activeCount":128},[17435],{"nctId":17414,"briefTitle":17415,"status":104,"phases":17436,"primaryCompletion":13341,"completion":13341,"start":17417,"enrollment":25,"conditions":17437,"interventions":17438},[92],[15772],[17403,17420],{"trials":17440,"activeCount":128},[],{"trials":17442,"activeCount":128},[],{"intervention":17444,"totalTrials":676,"cells":17445},"Vitamin E, Evening Oil of Primrose, and Placebo",{"EARLY_PHASE1":17446,"PHASE1":17448,"PHASE2":17450,"PHASE3":17452,"PHASE4":17461,"NA":17463},{"trials":17447,"activeCount":128},[],{"trials":17449,"activeCount":128},[],{"trials":17451,"activeCount":128},[],{"trials":17453,"activeCount":128},[17454],{"nctId":17455,"briefTitle":17456,"status":104,"phases":17457,"primaryCompletion":13198,"completion":13198,"start":11480,"enrollment":3571,"conditions":17458,"interventions":17460},"NCT00275600","Randomized Clinical Trial of Vitamin E and Evening Oil of Primrose for the Managment of Breast Pain",[91,92],[17459],"Cyclical Breast Pain",[17444],{"trials":17462,"activeCount":128},[],{"trials":17464,"activeCount":128},[],{"intervention":17466,"totalTrials":676,"cells":17467},"PET\u002FCT Scan with 11C-ER176",{"EARLY_PHASE1":17468,"PHASE1":17470,"PHASE2":17472,"PHASE3":17474,"PHASE4":17484,"NA":17486},{"trials":17469,"activeCount":128},[],{"trials":17471,"activeCount":128},[],{"trials":17473,"activeCount":128},[],{"trials":17475,"activeCount":128},[17476],{"nctId":17477,"briefTitle":17478,"status":104,"phases":17479,"primaryCompletion":576,"completion":576,"start":17480,"enrollment":218,"conditions":17481,"interventions":17483},"NCT04762719","PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis",[91,92],"2021-05-10",[1063,17482],"Gastroparesis With Diabetes Mellitus",[17466],{"trials":17485,"activeCount":128},[],{"trials":17487,"activeCount":128},[],{"intervention":17489,"totalTrials":676,"cells":17490},"Triamcinolone acetonide nasal spray",{"EARLY_PHASE1":17491,"PHASE1":17493,"PHASE2":17495,"PHASE3":17497,"PHASE4":17511,"NA":17513},{"trials":17492,"activeCount":128},[],{"trials":17494,"activeCount":128},[],{"trials":17496,"activeCount":128},[],{"trials":17498,"activeCount":128},[17499],{"nctId":17500,"briefTitle":17501,"status":104,"phases":17502,"primaryCompletion":3546,"completion":5279,"start":17503,"enrollment":4796,"conditions":17504,"interventions":17510},"NCT00279916","Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays",[92],"2005-09-01",[17505,17506,17507,17508,17509],"Otitis Media, Serous","Negative Middle Ear Pressure","Rhinitis","Otitis Media With Effusion","Otitis Media, Secretory",[17489],{"trials":17512,"activeCount":128},[],{"trials":17514,"activeCount":128},[],{"intervention":17516,"totalTrials":676,"cells":17517},"Insulin infusion with a goal",{"EARLY_PHASE1":17518,"PHASE1":17520,"PHASE2":17522,"PHASE3":17524,"PHASE4":17533,"NA":17535},{"trials":17519,"activeCount":128},[],{"trials":17521,"activeCount":128},[],{"trials":17523,"activeCount":128},[],{"trials":17525,"activeCount":128},[17526],{"nctId":17527,"briefTitle":17528,"status":104,"phases":17529,"primaryCompletion":16315,"completion":16315,"start":12886,"enrollment":3138,"conditions":17530,"interventions":17532},"NCT00282698","Outcomes With Tight Control of Hyperglycemia in Cardiac Surgery Patients",[92],[17531,10248],"Cardiac Surgical Procedures",[17516],{"trials":17534,"activeCount":128},[],{"trials":17536,"activeCount":128},[],{"intervention":17538,"totalTrials":676,"cells":17539},"Diclofenac",{"EARLY_PHASE1":17540,"PHASE1":17542,"PHASE2":17544,"PHASE3":17546,"PHASE4":17557,"NA":17559},{"trials":17541,"activeCount":128},[],{"trials":17543,"activeCount":128},[],{"trials":17545,"activeCount":128},[],{"trials":17547,"activeCount":128},[17548],{"nctId":17549,"briefTitle":17550,"status":134,"phases":17551,"primaryCompletion":4784,"completion":4784,"start":5051,"enrollment":558,"conditions":17552,"interventions":17556},"NCT00276419","Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin",[91,92],[17553,17554,17555],"Breast Pain","Non-cyclical Mastalgia","Surgical Scar-Related Breast Pain",[17538],{"trials":17558,"activeCount":128},[],{"trials":17560,"activeCount":128},[],{"intervention":17562,"totalTrials":676,"cells":17563},"Esomeprazole",{"EARLY_PHASE1":17564,"PHASE1":17566,"PHASE2":17568,"PHASE3":17570,"PHASE4":17582,"NA":17584},{"trials":17565,"activeCount":128},[],{"trials":17567,"activeCount":128},[],{"trials":17569,"activeCount":128},[],{"trials":17571,"activeCount":128},[17572],{"nctId":17573,"briefTitle":17574,"status":104,"phases":17575,"primaryCompletion":946,"completion":946,"start":5033,"enrollment":17576,"conditions":17577,"interventions":17580},"NCT00728481","The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis",[91,92],51,[12979,12978,17578,17579],"EE","GERD",[17562,17581],"Budesonide",{"trials":17583,"activeCount":128},[],{"trials":17585,"activeCount":128},[],{"intervention":17587,"totalTrials":676,"cells":17588},"High Dose Aspirin",{"EARLY_PHASE1":17589,"PHASE1":17591,"PHASE2":17593,"PHASE3":17595,"PHASE4":17605,"NA":17607},{"trials":17590,"activeCount":128},[],{"trials":17592,"activeCount":128},[],{"trials":17594,"activeCount":128},[],{"trials":17596,"activeCount":128},[17597],{"nctId":17598,"briefTitle":17599,"status":134,"phases":17600,"primaryCompletion":4279,"completion":4279,"start":4928,"enrollment":3034,"conditions":17601,"interventions":17603},"NCT00467584","Aspirin for Treatment of Multiple Sclerosis-Related Fatigue",[92],[9501,17602],"Fatigue",[17587,17604],"Low Dose Aspirin",{"trials":17606,"activeCount":128},[],{"trials":17608,"activeCount":128},[],{"intervention":17604,"totalTrials":676,"cells":17610},{"EARLY_PHASE1":17611,"PHASE1":17613,"PHASE2":17615,"PHASE3":17617,"PHASE4":17623,"NA":17625},{"trials":17612,"activeCount":128},[],{"trials":17614,"activeCount":128},[],{"trials":17616,"activeCount":128},[],{"trials":17618,"activeCount":128},[17619],{"nctId":17598,"briefTitle":17599,"status":134,"phases":17620,"primaryCompletion":4279,"completion":4279,"start":4928,"enrollment":3034,"conditions":17621,"interventions":17622},[92],[9501,17602],[17587,17604],{"trials":17624,"activeCount":128},[],{"trials":17626,"activeCount":128},[],{"intervention":17628,"totalTrials":676,"cells":17629},"Erythromycin",{"EARLY_PHASE1":17630,"PHASE1":17632,"PHASE2":17634,"PHASE3":17636,"PHASE4":17644,"NA":17646},{"trials":17631,"activeCount":128},[],{"trials":17633,"activeCount":128},[],{"trials":17635,"activeCount":128},[],{"trials":17637,"activeCount":128},[17638],{"nctId":17639,"briefTitle":17640,"status":104,"phases":17641,"primaryCompletion":954,"completion":954,"start":7107,"enrollment":498,"conditions":17642,"interventions":17643},"NCT01379183","Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility",[91,92],[18],[17628],{"trials":17645,"activeCount":128},[],{"trials":17647,"activeCount":128},[],{"intervention":17649,"totalTrials":676,"cells":17650},"Sildenafil",{"EARLY_PHASE1":17651,"PHASE1":17653,"PHASE2":17655,"PHASE3":17657,"PHASE4":17667,"NA":17669},{"trials":17652,"activeCount":128},[],{"trials":17654,"activeCount":128},[],{"trials":17656,"activeCount":128},[],{"trials":17658,"activeCount":128},[17659],{"nctId":17660,"briefTitle":17661,"status":104,"phases":17662,"primaryCompletion":17663,"completion":17663,"start":17664,"enrollment":173,"conditions":17665,"interventions":17666},"NCT03154476","Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study",[92],"2019-06-30","2017-07-05",[10259,3273],[17649],{"trials":17668,"activeCount":128},[],{"trials":17670,"activeCount":128},[],{"intervention":17672,"totalTrials":676,"cells":17673},"S-Adenosyl-L-Methionine",{"EARLY_PHASE1":17674,"PHASE1":17676,"PHASE2":17678,"PHASE3":17680,"PHASE4":17688,"NA":17690},{"trials":17675,"activeCount":128},[],{"trials":17677,"activeCount":128},[],{"trials":17679,"activeCount":128},[],{"trials":17681,"activeCount":128},[17682],{"nctId":17683,"briefTitle":17684,"status":104,"phases":17685,"primaryCompletion":7928,"completion":6258,"start":3660,"enrollment":3067,"conditions":17686,"interventions":17687},"NCT00722124","S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence",[91,92],[16292],[17672,17672],{"trials":17689,"activeCount":128},[],{"trials":17691,"activeCount":128},[],{"intervention":17693,"totalTrials":676,"cells":17694},"Ranolazine",{"EARLY_PHASE1":17695,"PHASE1":17697,"PHASE2":17699,"PHASE3":17701,"PHASE4":17709,"NA":17711},{"trials":17696,"activeCount":128},[],{"trials":17698,"activeCount":128},[],{"trials":17700,"activeCount":128},[],{"trials":17702,"activeCount":128},[17703],{"nctId":17704,"briefTitle":17705,"status":134,"phases":17706,"primaryCompletion":905,"completion":905,"start":874,"enrollment":895,"conditions":17707,"interventions":17708},"NCT02239926","Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D",[91,92],[12486],[17693],{"trials":17710,"activeCount":128},[],{"trials":17712,"activeCount":128},[],{"intervention":17714,"totalTrials":676,"cells":17715},"Somatostatin analog",{"EARLY_PHASE1":17716,"PHASE1":17718,"PHASE2":17720,"PHASE3":17722,"PHASE4":17734,"NA":17736},{"trials":17717,"activeCount":128},[],{"trials":17719,"activeCount":128},[],{"trials":17721,"activeCount":128},[],{"trials":17723,"activeCount":128},[17724],{"nctId":17725,"briefTitle":17726,"status":17727,"phases":17728,"primaryCompletion":17729,"completion":17729,"start":7140,"enrollment":17730,"conditions":17731,"interventions":17733},"NCT04329039","Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics","SUSPENDED",[91,92],"2027-05-06",103,[17732],"Pancreatic Diseases",[17714],{"trials":17735,"activeCount":128},[],{"trials":17737,"activeCount":128},[],{"intervention":17739,"totalTrials":676,"cells":17740},"Botox Instillation",{"EARLY_PHASE1":17741,"PHASE1":17743,"PHASE2":17745,"PHASE3":17747,"PHASE4":17760,"NA":17762},{"trials":17742,"activeCount":128},[],{"trials":17744,"activeCount":128},[],{"trials":17746,"activeCount":128},[],{"trials":17748,"activeCount":128},[17749],{"nctId":17750,"briefTitle":17751,"status":134,"phases":17752,"primaryCompletion":3033,"completion":3033,"start":1390,"enrollment":558,"conditions":17753,"interventions":17758},"NCT00667095","Over Active Bladder Instillation Study - Botox",[92],[14934,17754,17755,17756,17757],"Urinary Urge Incontinence","Urinary Incontinence","Detrusor Hyperreflexia","Urge Incontinence",[17739,17759],"DMSO Instillation",{"trials":17761,"activeCount":128},[],{"trials":17763,"activeCount":128},[],{"intervention":17759,"totalTrials":676,"cells":17765},{"EARLY_PHASE1":17766,"PHASE1":17768,"PHASE2":17770,"PHASE3":17772,"PHASE4":17778,"NA":17780},{"trials":17767,"activeCount":128},[],{"trials":17769,"activeCount":128},[],{"trials":17771,"activeCount":128},[],{"trials":17773,"activeCount":128},[17774],{"nctId":17750,"briefTitle":17751,"status":134,"phases":17775,"primaryCompletion":3033,"completion":3033,"start":1390,"enrollment":558,"conditions":17776,"interventions":17777},[92],[14934,17754,17755,17756,17757],[17739,17759],{"trials":17779,"activeCount":128},[],{"trials":17781,"activeCount":128},[],{"intervention":306,"totalTrials":370,"cells":17783},{"EARLY_PHASE1":17784,"PHASE1":17790,"PHASE2":17796,"PHASE3":17830,"PHASE4":17832,"NA":17834},{"trials":17785,"activeCount":128},[17786],{"nctId":3781,"briefTitle":3782,"status":104,"phases":17787,"primaryCompletion":3784,"completion":3785,"start":3786,"enrollment":3674,"conditions":17788,"interventions":17789},[89],[3788,3789],[305,306,551],{"trials":17791,"activeCount":128},[17792],{"nctId":3810,"briefTitle":3811,"status":104,"phases":17793,"primaryCompletion":3813,"completion":3814,"start":3815,"enrollment":2563,"conditions":17794,"interventions":17795},[90],[303,3817],[305,306,3819],{"trials":17797,"activeCount":128},[17798,17802,17806,17810,17814,17818,17822,17826],{"nctId":295,"briefTitle":296,"status":104,"phases":17799,"primaryCompletion":298,"completion":299,"start":300,"enrollment":301,"conditions":17800,"interventions":17801},[91],[303],[305,306,72],{"nctId":3931,"briefTitle":3932,"status":104,"phases":17803,"primaryCompletion":3934,"completion":3934,"start":3935,"enrollment":139,"conditions":17804,"interventions":17805},[91],[3937,549,3788],[305,306,3861],{"nctId":3647,"briefTitle":3648,"status":104,"phases":17807,"primaryCompletion":3650,"completion":3651,"start":3652,"enrollment":16,"conditions":17808,"interventions":17809},[90,91],[3654,549],[57,305,306],{"nctId":3985,"briefTitle":3986,"status":104,"phases":17811,"primaryCompletion":3988,"completion":3988,"start":3989,"enrollment":2678,"conditions":17812,"interventions":17813},[91],[549],[159,305,306,551],{"nctId":4002,"briefTitle":4003,"status":104,"phases":17815,"primaryCompletion":4005,"completion":4006,"start":4007,"enrollment":31,"conditions":17816,"interventions":17817},[90,91],[4009,303],[305,4011,306],{"nctId":3696,"briefTitle":3697,"status":104,"phases":17819,"primaryCompletion":3699,"completion":3700,"start":3701,"enrollment":1162,"conditions":17820,"interventions":17821},[91],[303,3447],[57,159,305,306],{"nctId":4095,"briefTitle":4096,"status":104,"phases":17823,"primaryCompletion":4098,"completion":4098,"start":4099,"enrollment":2563,"conditions":17824,"interventions":17825},[91],[303,3447],[305,306,3861],{"nctId":10746,"briefTitle":10747,"status":134,"phases":17827,"primaryCompletion":10749,"completion":10750,"start":10751,"enrollment":3674,"conditions":17828,"interventions":17829},[91],[441,449,451],[179,306],{"trials":17831,"activeCount":128},[],{"trials":17833,"activeCount":128},[],{"trials":17835,"activeCount":128},[],{"intervention":4306,"totalTrials":476,"cells":17837},{"EARLY_PHASE1":17838,"PHASE1":17840,"PHASE2":17879,"PHASE3":17925,"PHASE4":17927,"NA":17929},{"trials":17839,"activeCount":128},[],{"trials":17841,"activeCount":128},[17842,17851,17875],{"nctId":17843,"briefTitle":17844,"status":134,"phases":17845,"primaryCompletion":17846,"completion":17846,"start":17847,"enrollment":370,"conditions":17848,"interventions":17849},"NCT02254239","Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma",[90],"2018-12-12","2016-02-04",[144,149],[17850,10360],"Brentuximab Vedotin",{"nctId":17852,"briefTitle":17853,"status":104,"phases":17854,"primaryCompletion":17855,"completion":17856,"start":5352,"enrollment":4208,"conditions":17857,"interventions":17874},"NCT00655655","Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors",[90],"2009-09-15","2018-01-11",[17858,17859,17860,17861,17862,17863,17864,17865,4542,17866,17867,17868,17869,17870,17871,4812,17872,3347,17873,4293],"Gastrinoma","Glucagonoma","Insulinoma","Metastatic Gastrointestinal Carcinoid Tumor","Metastatic Pheochromocytoma","Pancreatic Polypeptide Tumor","Recurrent Gastrointestinal Carcinoid Tumor","Recurrent Islet Cell Carcinoma","Recurrent Neuroendocrine Carcinoma of the Skin","Recurrent Non-small Cell Lung Cancer","Recurrent Pheochromocytoma","Recurrent Renal Cell Cancer","Somatostatinoma","Stage III Neuroendocrine Carcinoma of the Skin","Stage IV Non-small Cell Lung Cancer","Thyroid Gland Medullary Carcinoma",[4306,8046],{"nctId":4297,"briefTitle":4298,"status":104,"phases":17876,"primaryCompletion":4300,"completion":4300,"start":2883,"enrollment":956,"conditions":17877,"interventions":17878},[90],[4302,4303,4304,4293],[4306,4307,4240],{"trials":17880,"activeCount":128},[17881,17888,17892,17905,17913,17921],{"nctId":17882,"briefTitle":17883,"status":104,"phases":17884,"primaryCompletion":15986,"completion":15986,"start":6955,"enrollment":817,"conditions":17885,"interventions":17887},"NCT00935792","Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[90,91],[17886],"Lymphocytic Leukemia",[5408,4306],{"nctId":5980,"briefTitle":5981,"status":104,"phases":17889,"primaryCompletion":5983,"completion":186,"start":5984,"enrollment":5985,"conditions":17890,"interventions":17891},[90,91],[5987,4989,5988,5316,5989,5317,5990,5991,5319,3858,5992,5993,434,435,436,416,5994,3678,451],[4306,3539,3636,5996,5424],{"nctId":17893,"briefTitle":17894,"status":104,"phases":17895,"primaryCompletion":17896,"completion":17897,"start":2621,"enrollment":17898,"conditions":17899,"interventions":17903},"NCT00918333","Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma",[90,91],"2015-12-01","2019-07-16",124,[5987,4989,5988,3615,5316,5989,5317,5991,17900,5318,5319,3858,5992,5324,5993,17901,434,435,436,416,417,5994,439,443,3690,3678,17902,5328],"Primary Central Nervous System Non-Hodgkin Lymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","T-cell Adult Acute Lymphoblastic Leukemia",[17904,4306],"panobinostat",{"nctId":17906,"briefTitle":17907,"status":104,"phases":17908,"primaryCompletion":3519,"completion":3673,"start":12925,"enrollment":3726,"conditions":17909,"interventions":17910},"NCT00618345","Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma",[91],[3665],[4306,5423,17911,17912],"protein analysis","western blotting",{"nctId":17914,"briefTitle":17915,"status":104,"phases":17916,"primaryCompletion":946,"completion":17917,"start":4464,"enrollment":17918,"conditions":17919,"interventions":17920},"NCT00436618","Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment",[91],"2019-10-09",277,[3549,1419,16220],[10360],{"nctId":10350,"briefTitle":10351,"status":104,"phases":17922,"primaryCompletion":10353,"completion":10354,"start":10355,"enrollment":173,"conditions":17923,"interventions":17924},[91],[5609,5611,6441,10357,502,506,10358,511,6443],[10360,5635],{"trials":17926,"activeCount":128},[],{"trials":17928,"activeCount":128},[],{"trials":17930,"activeCount":128},[],{"intervention":5408,"totalTrials":895,"cells":17932},{"EARLY_PHASE1":17933,"PHASE1":17935,"PHASE2":17937,"PHASE3":17959,"PHASE4":17961,"NA":17963},{"trials":17934,"activeCount":128},[],{"trials":17936,"activeCount":128},[],{"trials":17938,"activeCount":128},[17939,17943,17947,17951,17955],{"nctId":17882,"briefTitle":17883,"status":104,"phases":17940,"primaryCompletion":15986,"completion":15986,"start":6955,"enrollment":817,"conditions":17941,"interventions":17942},[90,91],[17886],[5408,4306],{"nctId":5348,"briefTitle":5349,"status":104,"phases":17944,"primaryCompletion":5351,"completion":3842,"start":5352,"enrollment":729,"conditions":17945,"interventions":17946},[91],[3549],[5355,163],{"nctId":5402,"briefTitle":5403,"status":104,"phases":17948,"primaryCompletion":3569,"completion":5405,"start":5351,"enrollment":28,"conditions":17949,"interventions":17950},[91],[3549,1419],[5408,3553,3554,4405],{"nctId":5414,"briefTitle":5415,"status":104,"phases":17952,"primaryCompletion":5417,"completion":5418,"start":4810,"enrollment":3002,"conditions":17953,"interventions":17954},[90,91],[5420,443,3574,3575,3577],[5408,3553,5422,5423,5424,5425,3636,5426],{"nctId":5451,"briefTitle":5452,"status":104,"phases":17956,"primaryCompletion":5454,"completion":5455,"start":4503,"enrollment":31,"conditions":17957,"interventions":17958},[91],[3549],[5355,163,657],{"trials":17960,"activeCount":128},[],{"trials":17962,"activeCount":128},[],{"trials":17964,"activeCount":128},[],{"intervention":17966,"totalTrials":895,"cells":17967},"auranofin",{"EARLY_PHASE1":17968,"PHASE1":17982,"PHASE2":17990,"PHASE3":18024,"PHASE4":18026,"NA":18028},{"trials":17969,"activeCount":128},[17970],{"nctId":17971,"briefTitle":17972,"status":104,"phases":17973,"primaryCompletion":17974,"completion":17975,"start":17976,"enrollment":370,"conditions":17977,"interventions":17981},"NCT01747798","Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[89],"2014-01-10","2015-04-06","2012-11-02",[17978,17979,17980],"Recurrent Fallopian Tube Cancer","Recurrent Ovarian Epithelial Cancer","Recurrent Primary Peritoneal Cavity Cancer",[17966],{"trials":17983,"activeCount":128},[17984],{"nctId":17985,"briefTitle":17986,"status":1413,"phases":17987,"primaryCompletion":874,"start":1374,"enrollment":128,"conditions":17988,"interventions":17989},"NCT02126527","Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer",[90],[17867,4293],[17966,7354],{"trials":17991,"activeCount":128},[17992,18006,18015],{"nctId":17993,"briefTitle":17994,"status":104,"phases":17995,"primaryCompletion":1310,"completion":1310,"start":17996,"enrollment":34,"conditions":17997,"interventions":18004},"NCT01737502","Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer",[90,91],"2014-05-14",[17998,17999,3341,18000,18001,18002,18003,3346],"Extensive Stage Small Cell Lung Carcinoma","Lung Adenocarcinoma","Recurrent Small Cell Lung Carcinoma","Squamous Cell Lung Carcinoma","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Non-Small Cell Lung Cancer",[18005,4283],"Auranofin",{"nctId":18007,"briefTitle":18008,"status":104,"phases":18009,"primaryCompletion":18010,"completion":18011,"start":18012,"enrollment":729,"conditions":18013,"interventions":18014},"NCT02063698","Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome",[91],"2015-11-11","2016-11-11","2014-02-19",[938],[17966],{"nctId":18016,"briefTitle":18017,"status":134,"phases":18018,"primaryCompletion":18019,"completion":18019,"start":18020,"enrollment":3002,"conditions":18021,"interventions":18023},"NCT03456700","Auranofin and Sirolimus in Treating Participants With Ovarian Cancer",[91],"2019-07-31","2018-03-30",[18022,506],"Ovarian Serous Tumor",[18005,4283],{"trials":18025,"activeCount":128},[],{"trials":18027,"activeCount":128},[],{"trials":18029,"activeCount":128},[],{"intervention":4799,"totalTrials":681,"cells":18031},{"EARLY_PHASE1":18032,"PHASE1":18067,"PHASE2":18069,"PHASE3":18084,"PHASE4":18086,"NA":18088},{"trials":18033,"activeCount":128},[18034,18042],{"nctId":18035,"briefTitle":18036,"status":104,"phases":18037,"primaryCompletion":6309,"completion":12566,"start":18038,"enrollment":2894,"conditions":18039,"interventions":18041},"NCT02020720","18F-DOPA-PET in Planning Surgery in Patients With Gliomas",[89],"2014-01-22",[4760,18040],"Recurrent Brain Neoplasm",[4799],{"nctId":18043,"briefTitle":18044,"status":104,"phases":18045,"primaryCompletion":18046,"completion":16078,"start":18047,"enrollment":2555,"conditions":18048,"interventions":18065},"NCT01165632","Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma",[89],"2013-11-05","2010-07-26",[18049,18050,18051,18052,18053,18054,18055,18056,18057,18058,18059,18060,18061,18062,18063,18064],"Adult Anaplastic Astrocytoma","Adult Anaplastic Ependymoma","Adult Anaplastic Oligodendroglioma","Adult Brain Stem Glioma","Adult Diffuse Astrocytoma","Adult Ependymoma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Mixed Glioma","Adult Myxopapillary Ependymoma","Adult Oligodendroglioma","Adult Pilocytic Astrocytoma","Adult Pineal Gland Astrocytoma","Adult Subependymal Giant Cell Astrocytoma","Adult Subependymoma",[18066],"fluorine F 18 fluorodopa",{"trials":18068,"activeCount":128},[],{"trials":18070,"activeCount":128},[18071,18080],{"nctId":18072,"briefTitle":18073,"status":104,"phases":18074,"primaryCompletion":18075,"completion":18076,"start":18077,"enrollment":3674,"conditions":18078,"interventions":18079},"NCT03242824","The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma",[91],"2020-06-16","2021-06-16","2017-09-29",[4747],[4799],{"nctId":4790,"briefTitle":4791,"status":104,"phases":18081,"primaryCompletion":4793,"completion":4794,"start":4795,"enrollment":4796,"conditions":18082,"interventions":18083},[91],[4760],[4799,334],{"trials":18085,"activeCount":128},[],{"trials":18087,"activeCount":128},[],{"trials":18089,"activeCount":128},[],{"intervention":3599,"totalTrials":681,"cells":18091},{"EARLY_PHASE1":18092,"PHASE1":18094,"PHASE2":18110,"PHASE3":18120,"PHASE4":18122,"NA":18124},{"trials":18093,"activeCount":128},[],{"trials":18095,"activeCount":128},[18096,18100],{"nctId":7536,"briefTitle":7537,"status":104,"phases":18097,"primaryCompletion":894,"completion":7539,"start":7540,"enrollment":3945,"conditions":18098,"interventions":18099},[90],[3321,7542],[7544,7545,3599],{"nctId":18101,"briefTitle":18102,"status":134,"phases":18103,"primaryCompletion":18104,"completion":18104,"start":18105,"enrollment":2563,"conditions":18106,"interventions":18107},"NCT00788307","Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy",[90],"2018-02-07","2008-11-03",[4292],[18108,18109,3599],"Ad5-CMV-NIS","liothyronine sodium",{"trials":18111,"activeCount":128},[18112,18116],{"nctId":10893,"briefTitle":10894,"status":104,"phases":18113,"primaryCompletion":2643,"completion":2643,"start":4400,"enrollment":4565,"conditions":18114,"interventions":18115},[91],[3665],[10880,10898,10899,5425,3599],{"nctId":3587,"briefTitle":3588,"status":104,"phases":18117,"primaryCompletion":1563,"completion":3590,"start":3591,"enrollment":936,"conditions":18118,"interventions":18119},[91],[21,3593],[3595,3323,3324,3596,3597,3598,3599],{"trials":18121,"activeCount":128},[],{"trials":18123,"activeCount":128},[],{"trials":18125,"activeCount":128},[],{"intervention":18127,"totalTrials":681,"cells":18128},"bicalutamide",{"EARLY_PHASE1":18129,"PHASE1":18141,"PHASE2":18143,"PHASE3":18167,"PHASE4":18169,"NA":18171},{"trials":18130,"activeCount":128},[18131],{"nctId":18132,"briefTitle":18133,"status":104,"phases":18134,"primaryCompletion":1319,"completion":18135,"start":4032,"enrollment":108,"conditions":18136,"interventions":18139},"NCT01050842","Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer",[89],"2012-10-04",[4292,18137,18138,6372],"Adenocarcinoma of the Prostate","Hormone-resistant Prostate Cancer",[18127,18140],"raloxifene",{"trials":18142,"activeCount":128},[],{"trials":18144,"activeCount":128},[18145,18152,18163],{"nctId":18146,"briefTitle":18147,"status":104,"phases":18148,"primaryCompletion":4112,"completion":4112,"start":18149,"enrollment":773,"conditions":18150,"interventions":18151},"NCT00684905","Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy",[91],"2000-04",[4292],[18127,7836],{"nctId":18153,"briefTitle":18154,"status":1413,"phases":18155,"primaryCompletion":18156,"completion":18156,"start":18157,"enrollment":128,"conditions":18158,"interventions":18161},"NCT03147196","Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery",[91],"2022-06","2017-06-27",[18159,18160],"Stage I Prostate Adenocarcinoma","Stage II Prostate Adenocarcinoma",[6374,18162],"Raloxifene Hydrochloride",{"nctId":6362,"briefTitle":6363,"status":104,"phases":18164,"primaryCompletion":3661,"completion":6365,"start":2573,"enrollment":6366,"conditions":18165,"interventions":18166},[91],[6368,6369,6370,6371,6372],[6374,6375,6376,4557,6377],{"trials":18168,"activeCount":128},[],{"trials":18170,"activeCount":128},[],{"trials":18172,"activeCount":128},[],{"intervention":7836,"totalTrials":681,"cells":18174},{"EARLY_PHASE1":18175,"PHASE1":18177,"PHASE2":18179,"PHASE3":18197,"PHASE4":18199,"NA":18201},{"trials":18176,"activeCount":128},[],{"trials":18178,"activeCount":128},[],{"trials":18180,"activeCount":128},[18181,18185,18189,18193],{"nctId":18146,"briefTitle":18147,"status":104,"phases":18182,"primaryCompletion":4112,"completion":4112,"start":18149,"enrollment":773,"conditions":18183,"interventions":18184},[91],[4292],[18127,7836],{"nctId":7829,"briefTitle":7830,"status":104,"phases":18186,"primaryCompletion":3718,"completion":934,"start":7832,"enrollment":712,"conditions":18187,"interventions":18188},[90,91],[4292],[7835,7836],{"nctId":7838,"briefTitle":7839,"status":134,"phases":18190,"primaryCompletion":3509,"completion":1375,"start":6955,"enrollment":2742,"conditions":18191,"interventions":18192},[91],[6368,7842,7843,6371,6372],[6376,6377],{"nctId":6362,"briefTitle":6363,"status":104,"phases":18194,"primaryCompletion":3661,"completion":6365,"start":2573,"enrollment":6366,"conditions":18195,"interventions":18196},[91],[6368,6369,6370,6371,6372],[6374,6375,6376,4557,6377],{"trials":18198,"activeCount":128},[],{"trials":18200,"activeCount":128},[],{"trials":18202,"activeCount":128},[],{"intervention":3554,"totalTrials":681,"cells":18204},{"EARLY_PHASE1":18205,"PHASE1":18207,"PHASE2":18209,"PHASE3":18227,"PHASE4":18229,"NA":18231},{"trials":18206,"activeCount":128},[],{"trials":18208,"activeCount":128},[],{"trials":18210,"activeCount":128},[18211,18215,18219,18223],{"nctId":3541,"briefTitle":3542,"status":104,"phases":18212,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":18213,"interventions":18214},[91],[3549,1419],[3551,3552,3553,3323,3554],{"nctId":3566,"briefTitle":3567,"status":104,"phases":18216,"primaryCompletion":3569,"completion":3570,"start":1357,"enrollment":3571,"conditions":18217,"interventions":18218},[91],[3573,3574,3575,3576,3577,3578,3579,3580,3581,3582],[57,3584,3585],{"nctId":5402,"briefTitle":5403,"status":104,"phases":18220,"primaryCompletion":3569,"completion":5405,"start":5351,"enrollment":28,"conditions":18221,"interventions":18222},[91],[3549,1419],[5408,3553,3554,4405],{"nctId":3730,"briefTitle":3731,"status":104,"phases":18224,"primaryCompletion":946,"completion":3733,"start":3734,"enrollment":461,"conditions":18225,"interventions":18226},[91],[3549,1419],[163,57,551,3585],{"trials":18228,"activeCount":128},[],{"trials":18230,"activeCount":128},[],{"trials":18232,"activeCount":128},[],{"intervention":5622,"totalTrials":681,"cells":18234},{"EARLY_PHASE1":18235,"PHASE1":18237,"PHASE2":18247,"PHASE3":18257,"PHASE4":18259,"NA":18261},{"trials":18236,"activeCount":128},[],{"trials":18238,"activeCount":128},[18239,18243],{"nctId":7601,"briefTitle":7602,"status":104,"phases":18240,"primaryCompletion":7604,"completion":7604,"start":7605,"conditions":18241,"interventions":18242},[90],[3549,7607],[3481,3482,3483],{"nctId":3472,"briefTitle":3473,"status":104,"phases":18244,"primaryCompletion":3475,"completion":3476,"start":3477,"enrollment":2608,"conditions":18245,"interventions":18246},[90],[3321,3479],[3481,3482,3323,3483],{"trials":18248,"activeCount":128},[18249,18253],{"nctId":5595,"briefTitle":5596,"status":134,"phases":18250,"primaryCompletion":5598,"completion":5598,"start":5599,"enrollment":139,"conditions":18251,"interventions":18252},[91],[500,5601,5602,5603,5604,5605,5606,5607,5608,5609,5610,5611,5612,5613,5614,3491,3492,3493,501,5615,5616,5617,5618,5619,502,506,511],[4719,161,67,540,5621,5622],{"nctId":5653,"briefTitle":5654,"status":104,"phases":18254,"primaryCompletion":1310,"completion":1310,"start":5656,"enrollment":301,"conditions":18255,"interventions":18256},[91],[502,506,511],[4719,161,540,5621,5622],{"trials":18258,"activeCount":128},[],{"trials":18260,"activeCount":128},[],{"trials":18262,"activeCount":128},[],{"intervention":18264,"totalTrials":342,"cells":18265},"Indomethacin",{"EARLY_PHASE1":18266,"PHASE1":18277,"PHASE2":18288,"PHASE3":18297,"PHASE4":18299,"NA":18301},{"trials":18267,"activeCount":128},[18268],{"nctId":18269,"briefTitle":18270,"status":104,"phases":18271,"primaryCompletion":18272,"completion":18273,"start":18274,"enrollment":11025,"conditions":18275,"interventions":18276},"NCT05538247","Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function",[89],"2025-12-30","2026-03-31","2023-04-13",[18],[18264],{"trials":18278,"activeCount":128},[18279],{"nctId":18280,"briefTitle":18281,"status":104,"phases":18282,"primaryCompletion":18283,"completion":18283,"start":18284,"enrollment":558,"conditions":18285,"interventions":18287},"NCT02603822","Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability",[90],"2018-07-17","2015-08",[18286],"Impaired Small Intestinal Permeability",[18264],{"trials":18289,"activeCount":128},[18290],{"nctId":18291,"briefTitle":18292,"status":104,"phases":18293,"primaryCompletion":1310,"completion":1310,"start":18294,"enrollment":97,"conditions":18295,"interventions":18296},"NCT04207060","Trial of Indomethacin in Chronic Pancreatitis",[90,91],"2020-07-15",[2558],[18264],{"trials":18298,"activeCount":128},[],{"trials":18300,"activeCount":128},[],{"trials":18302,"activeCount":128},[],{"intervention":4866,"totalTrials":342,"cells":18304},{"EARLY_PHASE1":18305,"PHASE1":18307,"PHASE2":18317,"PHASE3":18323,"PHASE4":18325,"NA":18327},{"trials":18306,"activeCount":128},[],{"trials":18308,"activeCount":128},[18309,18313],{"nctId":4847,"briefTitle":4848,"status":104,"phases":18310,"primaryCompletion":2936,"completion":4850,"start":1298,"enrollment":120,"conditions":18311,"interventions":18312},[90],[4852,4853,4854,4855,4856,4857,4858,4859,4860,4861,4862,4863],[4865,4866,3625],{"nctId":4868,"briefTitle":4869,"status":104,"phases":18314,"primaryCompletion":4871,"completion":4871,"start":4872,"conditions":18315,"interventions":18316},[90],[4293],[4865,4866,3625,4875],{"trials":18318,"activeCount":128},[18319],{"nctId":8348,"briefTitle":8349,"status":104,"phases":18320,"primaryCompletion":6057,"completion":6057,"start":8351,"enrollment":817,"conditions":18321,"interventions":18322},[91],[8353,8354,8355,8356,8357,8358,8359,8360,8361,8362,8363,8364,8365,8366,8367,8368,8369,8370],[567,8372,8373],{"trials":18324,"activeCount":128},[],{"trials":18326,"activeCount":128},[],{"trials":18328,"activeCount":128},[],{"intervention":5423,"totalTrials":342,"cells":18330},{"EARLY_PHASE1":18331,"PHASE1":18333,"PHASE2":18335,"PHASE3":18353,"PHASE4":18355,"NA":18357},{"trials":18332,"activeCount":128},[],{"trials":18334,"activeCount":128},[],{"trials":18336,"activeCount":128},[18337,18341,18349],{"nctId":17906,"briefTitle":17907,"status":104,"phases":18338,"primaryCompletion":3519,"completion":3673,"start":12925,"enrollment":3726,"conditions":18339,"interventions":18340},[91],[3665],[4306,5423,17911,17912],{"nctId":18342,"briefTitle":18343,"status":104,"phases":18344,"primaryCompletion":18345,"completion":7141,"start":18346,"enrollment":28,"conditions":18347,"interventions":18348},"NCT01261247","Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",[91],"2016-05-09","2011-01-17",[5987,4989,5988,5316,5989,5317,5990,5991,5319,3858,5324,5993,434,435,436,416,5994,439,5326,3678,451],[17904,17912,5423],{"nctId":5414,"briefTitle":5415,"status":104,"phases":18350,"primaryCompletion":5417,"completion":5418,"start":4810,"enrollment":3002,"conditions":18351,"interventions":18352},[90,91],[5420,443,3574,3575,3577],[5408,3553,5422,5423,5424,5425,3636,5426],{"trials":18354,"activeCount":128},[],{"trials":18356,"activeCount":128},[],{"trials":18358,"activeCount":128},[],{"intervention":18360,"totalTrials":342,"cells":18361},"Eculizumab",{"EARLY_PHASE1":18362,"PHASE1":18364,"PHASE2":18366,"PHASE3":18389,"PHASE4":18391,"NA":18393},{"trials":18363,"activeCount":128},[],{"trials":18365,"activeCount":128},[],{"trials":18367,"activeCount":128},[18368,18375,18381],{"nctId":18369,"briefTitle":18370,"status":134,"phases":18371,"primaryCompletion":18372,"completion":18372,"start":1357,"enrollment":224,"conditions":18373,"interventions":18374},"NCT01106027","Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant",[90,91],"2016-08-19",[11163],[18360],{"nctId":18376,"briefTitle":18377,"status":134,"phases":18378,"primaryCompletion":7317,"completion":7317,"start":6577,"enrollment":1197,"conditions":18379,"interventions":18380},"NCT01095887","Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation",[90,91],[11163],[18360],{"nctId":18382,"briefTitle":18383,"status":104,"phases":18384,"primaryCompletion":1021,"completion":1021,"start":1563,"enrollment":355,"conditions":18385,"interventions":18388},"NCT00904826","An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica",[90,91],[18386,18387],"Neuromyelitis Optica","Devic's Disease",[18360],{"trials":18390,"activeCount":128},[],{"trials":18392,"activeCount":128},[],{"trials":18394,"activeCount":128},[],{"intervention":3596,"totalTrials":224,"cells":18396},{"EARLY_PHASE1":18397,"PHASE1":18399,"PHASE2":18405,"PHASE3":18411,"PHASE4":18413,"NA":18415},{"trials":18398,"activeCount":128},[],{"trials":18400,"activeCount":128},[18401],{"nctId":5676,"briefTitle":5677,"status":104,"phases":18402,"primaryCompletion":5455,"completion":5455,"start":3673,"enrollment":97,"conditions":18403,"interventions":18404},[90],[4293],[5681,3596],{"trials":18406,"activeCount":128},[18407],{"nctId":3587,"briefTitle":3588,"status":104,"phases":18408,"primaryCompletion":1563,"completion":3590,"start":3591,"enrollment":936,"conditions":18409,"interventions":18410},[91],[21,3593],[3595,3323,3324,3596,3597,3598,3599],{"trials":18412,"activeCount":128},[],{"trials":18414,"activeCount":128},[],{"trials":18416,"activeCount":128},[],{"intervention":18418,"totalTrials":224,"cells":18419},"azacitidine",{"EARLY_PHASE1":18420,"PHASE1":18422,"PHASE2":18428,"PHASE3":18436,"PHASE4":18438,"NA":18440},{"trials":18421,"activeCount":128},[],{"trials":18423,"activeCount":128},[18424],{"nctId":6305,"briefTitle":6306,"status":104,"phases":18425,"primaryCompletion":6308,"completion":6309,"start":5405,"enrollment":3719,"conditions":18426,"interventions":18427},[90],[4087,6311,6312,3438,6313,6314,3439,6315,3440,6316,6317],[6319,4093,210],{"trials":18429,"activeCount":128},[18430],{"nctId":18431,"briefTitle":18432,"status":134,"phases":18433,"primaryCompletion":13742,"completion":1563,"start":935,"enrollment":370,"conditions":18434,"interventions":18435},"NCT00381693","Azacitidine in Treating Patients With Myelofibrosis",[91],[3522,3523],[18418],{"trials":18437,"activeCount":128},[],{"trials":18439,"activeCount":128},[],{"trials":18441,"activeCount":128},[],{"intervention":18443,"totalTrials":224,"cells":18444},"Contrast-Enhanced Ultrasound",{"EARLY_PHASE1":18445,"PHASE1":18447,"PHASE2":18460,"PHASE3":18470,"PHASE4":18472,"NA":18474},{"trials":18446,"activeCount":128},[],{"trials":18448,"activeCount":128},[18449],{"nctId":18450,"briefTitle":18451,"status":1413,"phases":18452,"primaryCompletion":18453,"completion":18453,"start":12845,"enrollment":128,"conditions":18454,"interventions":18459},"NCT03335020","Using Ultrasonography, Shear Wave Elastography, Strain Imaging, and 3-D Volume Ultrasonography on Cardiovascular Disease",[90],"2020-12-31",[18455,18456,18457,18458],"Fibromuscular Dysplasia of Arteries","Segmental Arterial Mediolysis","Spontaneous Coronary Artery Dissection","Atherosclerosis of Artery",[18443],{"trials":18461,"activeCount":128},[18462],{"nctId":18463,"briefTitle":18464,"status":104,"phases":18465,"primaryCompletion":15908,"completion":15908,"start":258,"enrollment":270,"conditions":18466,"interventions":18468},"NCT03335033","New Technologies to Determine Carotid Plaque Vulnerability in Patients With Significant Carotid Plaques",[91],[18467],"Carotid Artery Plaque",[18469],"Contrast-enhanced ultrasound",{"trials":18471,"activeCount":128},[],{"trials":18473,"activeCount":128},[],{"trials":18475,"activeCount":128},[],{"intervention":5424,"totalTrials":224,"cells":18477},{"EARLY_PHASE1":18478,"PHASE1":18480,"PHASE2":18482,"PHASE3":18492,"PHASE4":18494,"NA":18496},{"trials":18479,"activeCount":128},[],{"trials":18481,"activeCount":128},[],{"trials":18483,"activeCount":128},[18484,18488],{"nctId":5980,"briefTitle":5981,"status":104,"phases":18485,"primaryCompletion":5983,"completion":186,"start":5984,"enrollment":5985,"conditions":18486,"interventions":18487},[90,91],[5987,4989,5988,5316,5989,5317,5990,5991,5319,3858,5992,5993,434,435,436,416,5994,3678,451],[4306,3539,3636,5996,5424],{"nctId":5414,"briefTitle":5415,"status":104,"phases":18489,"primaryCompletion":5417,"completion":5418,"start":4810,"enrollment":3002,"conditions":18490,"interventions":18491},[90,91],[5420,443,3574,3575,3577],[5408,3553,5422,5423,5424,5425,3636,5426],{"trials":18493,"activeCount":128},[],{"trials":18495,"activeCount":128},[],{"trials":18497,"activeCount":128},[],{"intervention":3845,"totalTrials":224,"cells":18499},{"EARLY_PHASE1":18500,"PHASE1":18502,"PHASE2":18508,"PHASE3":18514,"PHASE4":18516,"NA":18518},{"trials":18501,"activeCount":128},[],{"trials":18503,"activeCount":128},[18504],{"nctId":3839,"briefTitle":3840,"status":134,"phases":18505,"primaryCompletion":3842,"completion":3842,"start":3673,"enrollment":301,"conditions":18506,"interventions":18507},[90],[3665],[3514,3845,551],{"trials":18509,"activeCount":128},[18510],{"nctId":10300,"briefTitle":10301,"status":134,"phases":18511,"primaryCompletion":4885,"completion":4885,"start":934,"enrollment":681,"conditions":18512,"interventions":18513},[91],[21],[10305,10306,10307,3845],{"trials":18515,"activeCount":128},[],{"trials":18517,"activeCount":128},[],{"trials":18519,"activeCount":128},[],{"intervention":7710,"totalTrials":224,"cells":18521},{"EARLY_PHASE1":18522,"PHASE1":18524,"PHASE2":18530,"PHASE3":18536,"PHASE4":18538,"NA":18540},{"trials":18523,"activeCount":128},[],{"trials":18525,"activeCount":128},[18526],{"nctId":7702,"briefTitle":7703,"status":104,"phases":18527,"primaryCompletion":7705,"completion":7706,"start":7707,"enrollment":370,"conditions":18528,"interventions":18529},[90],[7526,7532,143,3376,3380,3345],[7710,5634],{"trials":18531,"activeCount":128},[18532],{"nctId":7714,"briefTitle":7715,"status":104,"phases":18533,"primaryCompletion":7717,"completion":7718,"start":545,"enrollment":4208,"conditions":18534,"interventions":18535},[91],[7720,7528,7530,7721,7722,3372,3376,3380,3345],[7710,5634],{"trials":18537,"activeCount":128},[],{"trials":18539,"activeCount":128},[],{"trials":18541,"activeCount":128},[],{"intervention":5330,"totalTrials":224,"cells":18543},{"EARLY_PHASE1":18544,"PHASE1":18546,"PHASE2":18552,"PHASE3":18558,"PHASE4":18560,"NA":18562},{"trials":18545,"activeCount":128},[],{"trials":18547,"activeCount":128},[18548],{"nctId":132,"briefTitle":133,"status":134,"phases":18549,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":18550,"interventions":18551},[90],[141,142,143,144,145,146,147,148,149,150,151,152,153,154],[156,157,158,159,160,161,112,162,72,163,164,165],{"trials":18553,"activeCount":128},[18554],{"nctId":5311,"briefTitle":5312,"status":1413,"phases":18555,"primaryCompletion":5314,"start":1337,"enrollment":128,"conditions":18556,"interventions":18557},[90,91],[3615,5316,3856,5317,5318,5319,3858,5320,5321,5322,5323,5324,434,435,436,416,417,439,5325,5326,3678,5327,5328],[3553,3539,5330],{"trials":18559,"activeCount":128},[],{"trials":18561,"activeCount":128},[],{"trials":18563,"activeCount":128},[],{"intervention":18565,"totalTrials":224,"cells":18566},"Trifluridine\u002FTipiracil Hydrochloride Combination Agent TAS-102",{"EARLY_PHASE1":18567,"PHASE1":18569,"PHASE2":18582,"PHASE3":18599,"PHASE4":18601,"NA":18603},{"trials":18568,"activeCount":128},[],{"trials":18570,"activeCount":128},[18571],{"nctId":18572,"briefTitle":18573,"status":104,"phases":18574,"primaryCompletion":18575,"completion":3650,"start":1535,"enrollment":120,"conditions":18576,"interventions":18581},"NCT03297710","TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery",[90],"2020-03-16",[18577,4254,18578,18579,18580],"Rectal Adenocarcinoma","Stage IV Rectal Cancer AJCC v7","Stage IVA Rectal Cancer AJCC v7","Stage IVB Rectal Cancer AJCC v7",[18565],{"trials":18583,"activeCount":128},[18584],{"nctId":18585,"briefTitle":18586,"status":104,"phases":18587,"primaryCompletion":18588,"completion":4554,"start":18589,"enrollment":817,"conditions":18590,"interventions":18598},"NCT03278106","TAS-102 in Treating Advanced Biliary Tract Cancers",[91],"2018-11-30","2017-10-20",[18591,18592,18593,18594,18595,18596,18597],"Cholangiocarcinoma","Stage III Gallbladder Cancer AJCC v7","Stage IIIA Gallbladder Cancer AJCC v7","Stage IIIB Gallbladder Cancer AJCC v7","Stage IV Gallbladder Cancer AJCC v7","Stage IVA Gallbladder Cancer AJCC v7","Stage IVB Gallbladder Cancer AJCC v7",[18565],{"trials":18600,"activeCount":128},[],{"trials":18602,"activeCount":128},[],{"trials":18604,"activeCount":128},[],{"intervention":3872,"totalTrials":224,"cells":18606},{"EARLY_PHASE1":18607,"PHASE1":18609,"PHASE2":18615,"PHASE3":18625,"PHASE4":18627,"NA":18629},{"trials":18608,"activeCount":128},[],{"trials":18610,"activeCount":128},[18611],{"nctId":3863,"briefTitle":3864,"status":104,"phases":18612,"primaryCompletion":3866,"completion":3867,"start":2719,"enrollment":355,"conditions":18613,"interventions":18614},[90],[3869,549,3870],[3872,305,551],{"trials":18616,"activeCount":128},[18617],{"nctId":18618,"briefTitle":18619,"status":104,"phases":18620,"primaryCompletion":7928,"completion":2936,"start":12911,"enrollment":18621,"conditions":18622,"interventions":18623},"NCT00635154","Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma",[91],55,[3665],[3872,18624],"Dexamethasone acetate",{"trials":18626,"activeCount":128},[],{"trials":18628,"activeCount":128},[],{"trials":18630,"activeCount":128},[],{"intervention":5621,"totalTrials":224,"cells":18632},{"EARLY_PHASE1":18633,"PHASE1":18635,"PHASE2":18637,"PHASE3":18647,"PHASE4":18649,"NA":18651},{"trials":18634,"activeCount":128},[],{"trials":18636,"activeCount":128},[],{"trials":18638,"activeCount":128},[18639,18643],{"nctId":5595,"briefTitle":5596,"status":134,"phases":18640,"primaryCompletion":5598,"completion":5598,"start":5599,"enrollment":139,"conditions":18641,"interventions":18642},[91],[500,5601,5602,5603,5604,5605,5606,5607,5608,5609,5610,5611,5612,5613,5614,3491,3492,3493,501,5615,5616,5617,5618,5619,502,506,511],[4719,161,67,540,5621,5622],{"nctId":5653,"briefTitle":5654,"status":104,"phases":18644,"primaryCompletion":1310,"completion":1310,"start":5656,"enrollment":301,"conditions":18645,"interventions":18646},[91],[502,506,511],[4719,161,540,5621,5622],{"trials":18648,"activeCount":128},[],{"trials":18650,"activeCount":128},[],{"trials":18652,"activeCount":128},[],{"intervention":10160,"totalTrials":224,"cells":18654},{"EARLY_PHASE1":18655,"PHASE1":18657,"PHASE2":18663,"PHASE3":18669,"PHASE4":18671,"NA":18673},{"trials":18656,"activeCount":128},[],{"trials":18658,"activeCount":128},[18659],{"nctId":10152,"briefTitle":10153,"status":104,"phases":18660,"primaryCompletion":10155,"completion":10155,"start":10156,"enrollment":2980,"conditions":18661,"interventions":18662},[90],[10158,202],[161,10160],{"trials":18664,"activeCount":128},[18665],{"nctId":10313,"briefTitle":10314,"status":104,"phases":18666,"primaryCompletion":10316,"completion":10317,"start":10318,"enrollment":498,"conditions":18667,"interventions":18668},[91],[7526,7721,502,506,511,10320],[5635,10160],{"trials":18670,"activeCount":128},[],{"trials":18672,"activeCount":128},[],{"trials":18674,"activeCount":128},[],{"intervention":4544,"totalTrials":224,"cells":18676},{"EARLY_PHASE1":18677,"PHASE1":18679,"PHASE2":18685,"PHASE3":18691,"PHASE4":18693,"NA":18695},{"trials":18678,"activeCount":128},[],{"trials":18680,"activeCount":128},[18681],{"nctId":4535,"briefTitle":4536,"status":1413,"phases":18682,"primaryCompletion":4538,"completion":4538,"start":4539,"enrollment":128,"conditions":18683,"interventions":18684},[90],[192,4541,122,4542,177],[4544,112],{"trials":18686,"activeCount":128},[18687],{"nctId":4396,"briefTitle":4397,"status":104,"phases":18688,"primaryCompletion":4399,"start":4400,"enrollment":1236,"conditions":18689,"interventions":18690},[91],[4402,1420],[4404,4405,4240,3324,3326,4406],{"trials":18692,"activeCount":128},[],{"trials":18694,"activeCount":128},[],{"trials":18696,"activeCount":128},[],{"intervention":3621,"totalTrials":224,"cells":18698},{"EARLY_PHASE1":18699,"PHASE1":18701,"PHASE2":18703,"PHASE3":18713,"PHASE4":18715,"NA":18717},{"trials":18700,"activeCount":128},[],{"trials":18702,"activeCount":128},[],{"trials":18704,"activeCount":128},[18705,18709],{"nctId":3610,"briefTitle":3611,"status":1413,"phases":18706,"primaryCompletion":905,"completion":2697,"start":3613,"enrollment":128,"conditions":18707,"interventions":18708},[91],[3615,3616,3617,3618,3619],[3621,3553,3323,3324,3327,3622,3623,3525,3624,3514,3625],{"nctId":7889,"briefTitle":7890,"status":104,"phases":18710,"primaryCompletion":4432,"completion":7892,"start":7893,"enrollment":885,"conditions":18711,"interventions":18712},[91],[6317],[4090,7896,7897],{"trials":18714,"activeCount":128},[],{"trials":18716,"activeCount":128},[],{"trials":18718,"activeCount":128},[],{"intervention":3837,"totalTrials":224,"cells":18720},{"EARLY_PHASE1":18721,"PHASE1":18723,"PHASE2":18729,"PHASE3":18735,"PHASE4":18737,"NA":18739},{"trials":18722,"activeCount":128},[],{"trials":18724,"activeCount":128},[18725],{"nctId":3829,"briefTitle":3830,"status":104,"phases":18726,"primaryCompletion":3832,"completion":3833,"start":3834,"enrollment":370,"conditions":18727,"interventions":18728},[90],[303],[305,551,3837],{"trials":18730,"activeCount":128},[18731],{"nctId":6014,"briefTitle":6015,"status":134,"phases":18732,"primaryCompletion":6017,"completion":6017,"start":6018,"enrollment":895,"conditions":18733,"interventions":18734},[90,91],[432],[551,3837],{"trials":18736,"activeCount":128},[],{"trials":18738,"activeCount":128},[],{"trials":18740,"activeCount":128},[],{"intervention":18742,"totalTrials":224,"cells":18743},"BNP",{"EARLY_PHASE1":18744,"PHASE1":18746,"PHASE2":18748,"PHASE3":18766,"PHASE4":18768,"NA":18770},{"trials":18745,"activeCount":128},[],{"trials":18747,"activeCount":128},[],{"trials":18749,"activeCount":128},[18750,18757],{"nctId":18751,"briefTitle":18752,"status":104,"phases":18753,"primaryCompletion":3661,"completion":894,"start":13742,"enrollment":28,"conditions":18754,"interventions":18756},"NCT00405548","Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.",[90,91],[18755],"Left Ventricular Diastolic Dysfunction",[18742],{"nctId":18758,"briefTitle":18759,"status":104,"phases":18760,"primaryCompletion":2999,"completion":3000,"start":18761,"enrollment":25,"conditions":18762,"interventions":18764},"NCT00972569","Low Dose Intravenous (IV) Infusion of BNP in the Presence and Absence of Acute Type V Phosphodiesterase (PDE V) in Improving Renal Function in Hospitalized Chronic Heart Failure (CHF) Patients With Renal Dysfunction",[90,91],"2009-10",[27,18763],"Renal Dysfunction",[18765,18742],"BNP and PDE-V",{"trials":18767,"activeCount":128},[],{"trials":18769,"activeCount":128},[],{"trials":18771,"activeCount":128},[],{"intervention":2577,"totalTrials":224,"cells":18773},{"EARLY_PHASE1":18774,"PHASE1":18776,"PHASE2":18782,"PHASE3":18788,"PHASE4":18790,"NA":18792},{"trials":18775,"activeCount":128},[],{"trials":18777,"activeCount":128},[18778],{"nctId":2570,"briefTitle":2571,"status":104,"phases":18779,"primaryCompletion":905,"completion":905,"start":2573,"enrollment":31,"conditions":18780,"interventions":18781},[90],[2575],[2577,790],{"trials":18783,"activeCount":128},[18784],{"nctId":6979,"briefTitle":6980,"status":134,"phases":18785,"primaryCompletion":1337,"completion":1337,"start":4300,"enrollment":1236,"conditions":18786,"interventions":18787},[90,91],[6983,6984,6985],[2577,6987,867],{"trials":18789,"activeCount":128},[],{"trials":18791,"activeCount":128},[],{"trials":18793,"activeCount":128},[],{"intervention":8373,"totalTrials":224,"cells":18795},{"EARLY_PHASE1":18796,"PHASE1":18798,"PHASE2":18817,"PHASE3":18823,"PHASE4":18825,"NA":18827},{"trials":18797,"activeCount":128},[],{"trials":18799,"activeCount":128},[18800],{"nctId":18801,"briefTitle":18802,"status":104,"phases":18803,"primaryCompletion":18804,"completion":18804,"start":7717,"enrollment":4565,"conditions":18805,"interventions":18815},"NCT05130060","A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer",[90],"2023-06-11",[18806,18807,4618,18808,18809,18810,18811,4623,18812,18813,18814],"Metastatic Colon Adenocarcinoma","Metastatic Colorectal Adenocarcinoma","Metastatic Microsatellite Stable Colon Carcinoma","Metastatic Microsatellite Stable Colorectal Carcinoma","Metastatic Rectal Adenocarcinoma","Microsatellite Stable Rectal Carcinoma","Stage IVA Colorectal Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVC Colorectal Cancer AJCC v8",[18816,8373],"Colorectal Cancer Peptide Vaccine PolyPEPI1018",{"trials":18818,"activeCount":128},[18819],{"nctId":8348,"briefTitle":8349,"status":104,"phases":18820,"primaryCompletion":6057,"completion":6057,"start":8351,"enrollment":817,"conditions":18821,"interventions":18822},[91],[8353,8354,8355,8356,8357,8358,8359,8360,8361,8362,8363,8364,8365,8366,8367,8368,8369,8370],[567,8372,8373],{"trials":18824,"activeCount":128},[],{"trials":18826,"activeCount":128},[],{"trials":18828,"activeCount":128},[],{"intervention":17904,"totalTrials":224,"cells":18830},{"EARLY_PHASE1":18831,"PHASE1":18833,"PHASE2":18835,"PHASE3":18845,"PHASE4":18847,"NA":18849},{"trials":18832,"activeCount":128},[],{"trials":18834,"activeCount":128},[],{"trials":18836,"activeCount":128},[18837,18841],{"nctId":17893,"briefTitle":17894,"status":104,"phases":18838,"primaryCompletion":17896,"completion":17897,"start":2621,"enrollment":17898,"conditions":18839,"interventions":18840},[90,91],[5987,4989,5988,3615,5316,5989,5317,5991,17900,5318,5319,3858,5992,5324,5993,17901,434,435,436,416,417,5994,439,443,3690,3678,17902,5328],[17904,4306],{"nctId":18342,"briefTitle":18343,"status":104,"phases":18842,"primaryCompletion":18345,"completion":7141,"start":18346,"enrollment":28,"conditions":18843,"interventions":18844},[91],[5987,4989,5988,5316,5989,5317,5990,5991,5319,3858,5324,5993,434,435,436,416,5994,439,5326,3678,451],[17904,17912,5423],{"trials":18846,"activeCount":128},[],{"trials":18848,"activeCount":128},[],{"trials":18850,"activeCount":128},[],{"intervention":18852,"totalTrials":224,"cells":18853},"Paclitaxel Albumin-Stabilized Nanoparticle Formulation",{"EARLY_PHASE1":18854,"PHASE1":18856,"PHASE2":18858,"PHASE3":18876,"PHASE4":18878,"NA":18880},{"trials":18855,"activeCount":128},[],{"trials":18857,"activeCount":128},[],{"trials":18859,"activeCount":128},[18860,18869],{"nctId":18861,"briefTitle":18862,"status":134,"phases":18863,"primaryCompletion":18864,"completion":18865,"start":18866,"enrollment":301,"conditions":18867,"interventions":18868},"NCT01646762","Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma",[91],"2015-01-15","2015-10-27","2012-11-05",[3447],[18852],{"nctId":18870,"briefTitle":18871,"status":1413,"phases":18872,"primaryCompletion":14463,"start":4278,"enrollment":128,"conditions":18873,"interventions":18875},"NCT02718742","Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer",[91],[18874,4495],"Recurrent Bladder Urothelial Carcinoma",[18852],{"trials":18877,"activeCount":128},[],{"trials":18879,"activeCount":128},[],{"trials":18881,"activeCount":128},[],{"intervention":17912,"totalTrials":224,"cells":18883},{"EARLY_PHASE1":18884,"PHASE1":18886,"PHASE2":18888,"PHASE3":18898,"PHASE4":18900,"NA":18902},{"trials":18885,"activeCount":128},[],{"trials":18887,"activeCount":128},[],{"trials":18889,"activeCount":128},[18890,18894],{"nctId":17906,"briefTitle":17907,"status":104,"phases":18891,"primaryCompletion":3519,"completion":3673,"start":12925,"enrollment":3726,"conditions":18892,"interventions":18893},[91],[3665],[4306,5423,17911,17912],{"nctId":18342,"briefTitle":18343,"status":104,"phases":18895,"primaryCompletion":18345,"completion":7141,"start":18346,"enrollment":28,"conditions":18896,"interventions":18897},[91],[5987,4989,5988,5316,5989,5317,5990,5991,5319,3858,5324,5993,434,435,436,416,5994,439,5326,3678,451],[17904,17912,5423],{"trials":18899,"activeCount":128},[],{"trials":18901,"activeCount":128},[],{"trials":18903,"activeCount":128},[],{"intervention":18905,"totalTrials":224,"cells":18906},"Topotecan",{"EARLY_PHASE1":18907,"PHASE1":18909,"PHASE2":18919,"PHASE3":18928,"PHASE4":18930,"NA":18932},{"trials":18908,"activeCount":128},[],{"trials":18910,"activeCount":128},[18911],{"nctId":18912,"briefTitle":18913,"status":104,"phases":18914,"completion":4399,"start":18915,"enrollment":558,"conditions":18916,"interventions":18918},"NCT00295243","Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies",[90],"2004-09",[18917],"Advanced Solid Malignancies",[18905],{"trials":18920,"activeCount":128},[18921],{"nctId":18922,"briefTitle":18923,"status":104,"phases":18924,"primaryCompletion":5279,"completion":4030,"start":11897,"enrollment":108,"conditions":18925,"interventions":18926},"NCT00436644","Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin",[91],[3321,3479],[18927,18905],"Lapatinib",{"trials":18929,"activeCount":128},[],{"trials":18931,"activeCount":128},[],{"trials":18933,"activeCount":128},[],{"intervention":7309,"totalTrials":224,"cells":18935},{"EARLY_PHASE1":18936,"PHASE1":18938,"PHASE2":18944,"PHASE3":18955,"PHASE4":18957,"NA":18959},{"trials":18937,"activeCount":128},[],{"trials":18939,"activeCount":128},[18940],{"nctId":7301,"briefTitle":7302,"status":104,"phases":18941,"primaryCompletion":7304,"completion":7305,"start":7306,"enrollment":476,"conditions":18942,"interventions":18943},[90],[303,3447],[3680,7309,7310],{"trials":18945,"activeCount":128},[18946],{"nctId":18947,"briefTitle":18948,"status":104,"phases":18949,"primaryCompletion":18950,"completion":18950,"start":18951,"enrollment":498,"conditions":18952,"interventions":18954},"NCT03733132","Metformin Effect on Brain Function in Insulin Resistant Elderly People",[91],"2023-04-05","2019-03-15",[6930,15,18953],"Obesity, Abdominal",[7309],{"trials":18956,"activeCount":128},[],{"trials":18958,"activeCount":128},[],{"trials":18960,"activeCount":128},[],{"intervention":18962,"totalTrials":224,"cells":18963},"vismodegib",{"EARLY_PHASE1":18964,"PHASE1":18966,"PHASE2":18977,"PHASE3":18988,"PHASE4":18990,"NA":18992},{"trials":18965,"activeCount":128},[],{"trials":18967,"activeCount":128},[18968],{"nctId":18969,"briefTitle":18970,"status":104,"phases":18971,"primaryCompletion":4045,"completion":4045,"start":18972,"enrollment":525,"conditions":18973,"interventions":18976},"NCT01537107","Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery",[90],"2012-03-05",[18974,4887,18975,4889,4293],"Acinar Cell Adenocarcinoma of the Pancreas","Recurrent Pancreatic Cancer",[18962,7354],{"trials":18978,"activeCount":128},[18979],{"nctId":18980,"briefTitle":18981,"status":104,"phases":18982,"primaryCompletion":18983,"completion":18984,"start":18985,"enrollment":817,"conditions":18986,"interventions":18987},"NCT01700049","Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes",[91],"2017-07-03","2018-07-03","2013-01-14",[6654],[18962],{"trials":18989,"activeCount":128},[],{"trials":18991,"activeCount":128},[],{"trials":18993,"activeCount":128},[],{"intervention":18995,"totalTrials":224,"cells":18996},"Hemin",{"EARLY_PHASE1":18997,"PHASE1":18999,"PHASE2":19007,"PHASE3":19016,"PHASE4":19018,"NA":19020},{"trials":18998,"activeCount":128},[],{"trials":19000,"activeCount":128},[19001],{"nctId":19002,"briefTitle":19003,"status":104,"phases":19004,"primaryCompletion":1563,"completion":1563,"start":3546,"enrollment":370,"conditions":19005,"interventions":19006},"NCT00882804","Hemin in Healthy Subjects",[90],[16419],[18995],{"trials":19008,"activeCount":128},[19009],{"nctId":19010,"briefTitle":19011,"status":104,"phases":19012,"primaryCompletion":2665,"completion":2665,"start":6577,"enrollment":173,"conditions":19013,"interventions":19014},"NCT01206582","A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)",[91],[11692,6505],[18995,19015],"Albumin",{"trials":19017,"activeCount":128},[],{"trials":19019,"activeCount":128},[],{"trials":19021,"activeCount":128},[],{"intervention":19023,"totalTrials":676,"cells":19024},"BF4",{"EARLY_PHASE1":19025,"PHASE1":19027,"PHASE2":19029,"PHASE3":19040,"PHASE4":19042,"NA":19044},{"trials":19026,"activeCount":128},[],{"trials":19028,"activeCount":128},[],{"trials":19030,"activeCount":128},[19031],{"nctId":19032,"briefTitle":19033,"status":134,"phases":19034,"primaryCompletion":19035,"completion":19035,"start":2946,"enrollment":2563,"conditions":19036,"interventions":19039},"NCT02907073","Positron Emission Tomography (PET) Imaging Studies With NIS Reporter",[90,91],"2017-12",[19037,19038],"Myeloma","Endometrial Cancer",[19023],{"trials":19041,"activeCount":128},[],{"trials":19043,"activeCount":128},[],{"trials":19045,"activeCount":128},[],{"intervention":19047,"totalTrials":676,"cells":19048},"Phosphorus Supplement",{"EARLY_PHASE1":19049,"PHASE1":19051,"PHASE2":19053,"PHASE3":19063,"PHASE4":19065,"NA":19067},{"trials":19050,"activeCount":128},[],{"trials":19052,"activeCount":128},[],{"trials":19054,"activeCount":128},[19055],{"nctId":19056,"briefTitle":19057,"status":104,"phases":19058,"primaryCompletion":19059,"completion":19059,"start":874,"enrollment":729,"conditions":19060,"interventions":19062},"NCT02016235","Role Of Phosphorus And FGF 23 In Patients With Dent Disease",[90,91],"2019-01",[19061],"Dent Disease",[19047],{"trials":19064,"activeCount":128},[],{"trials":19066,"activeCount":128},[],{"trials":19068,"activeCount":128},[],{"intervention":19070,"totalTrials":676,"cells":19071},"Minoxidil Foam",{"EARLY_PHASE1":19072,"PHASE1":19074,"PHASE2":19076,"PHASE3":19087,"PHASE4":19089,"NA":19091},{"trials":19073,"activeCount":128},[],{"trials":19075,"activeCount":128},[],{"trials":19077,"activeCount":128},[19078],{"nctId":19079,"briefTitle":19080,"status":104,"phases":19081,"primaryCompletion":19082,"completion":10499,"start":19083,"enrollment":173,"conditions":19084,"interventions":19086},"NCT03488108","Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women",[90,91],"2018-05-31","2017-01-23",[19085],"Alopecia",[19070],{"trials":19088,"activeCount":128},[],{"trials":19090,"activeCount":128},[],{"trials":19092,"activeCount":128},[],{"intervention":241,"totalTrials":676,"cells":19094},{"EARLY_PHASE1":19095,"PHASE1":19097,"PHASE2":19099,"PHASE3":19105,"PHASE4":19107,"NA":19109},{"trials":19096,"activeCount":128},[],{"trials":19098,"activeCount":128},[],{"trials":19100,"activeCount":128},[19101],{"nctId":228,"briefTitle":229,"status":104,"phases":19102,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":19103,"interventions":19104},[90,91],[141,235,236,237,238,239,154],[241,72],{"trials":19106,"activeCount":128},[],{"trials":19108,"activeCount":128},[],{"trials":19110,"activeCount":128},[],{"intervention":19112,"totalTrials":676,"cells":19113},"Mydayis Extended-Release",{"EARLY_PHASE1":19114,"PHASE1":19116,"PHASE2":19118,"PHASE3":19127,"PHASE4":19129,"NA":19131},{"trials":19115,"activeCount":128},[],{"trials":19117,"activeCount":128},[],{"trials":19119,"activeCount":128},[19120],{"nctId":19121,"briefTitle":19122,"status":104,"phases":19123,"primaryCompletion":9356,"completion":9356,"start":19124,"enrollment":10918,"conditions":19125,"interventions":19126},"NCT04235686","8 Week Multi-site Study of MYDAYIS® for Bipolar Depression",[91],"2020-07-17",[851],[19112],{"trials":19128,"activeCount":128},[],{"trials":19130,"activeCount":128},[],{"trials":19132,"activeCount":128},[],{"intervention":19134,"totalTrials":676,"cells":19135},"ROSE-010",{"EARLY_PHASE1":19136,"PHASE1":19138,"PHASE2":19140,"PHASE3":19149,"PHASE4":19151,"NA":19153},{"trials":19137,"activeCount":128},[],{"trials":19139,"activeCount":128},[],{"trials":19141,"activeCount":128},[19142],{"nctId":19143,"briefTitle":19144,"status":104,"phases":19145,"primaryCompletion":1021,"completion":1021,"start":2642,"enrollment":328,"conditions":19146,"interventions":19148},"NCT01056107","Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients",[90,91],[19147],"Irritable Bowel Syndrome Constipation Predominant",[19134],{"trials":19150,"activeCount":128},[],{"trials":19152,"activeCount":128},[],{"trials":19154,"activeCount":128},[],{"intervention":5996,"totalTrials":676,"cells":19156},{"EARLY_PHASE1":19157,"PHASE1":19159,"PHASE2":19161,"PHASE3":19167,"PHASE4":19169,"NA":19171},{"trials":19158,"activeCount":128},[],{"trials":19160,"activeCount":128},[],{"trials":19162,"activeCount":128},[19163],{"nctId":5980,"briefTitle":5981,"status":104,"phases":19164,"primaryCompletion":5983,"completion":186,"start":5984,"enrollment":5985,"conditions":19165,"interventions":19166},[90,91],[5987,4989,5988,5316,5989,5317,5990,5991,5319,3858,5992,5993,434,435,436,416,5994,3678,451],[4306,3539,3636,5996,5424],{"trials":19168,"activeCount":128},[],{"trials":19170,"activeCount":128},[],{"trials":19172,"activeCount":128},[],{"intervention":15648,"totalTrials":676,"cells":19174},{"EARLY_PHASE1":19175,"PHASE1":19177,"PHASE2":19179,"PHASE3":19185,"PHASE4":19187,"NA":19189},{"trials":19176,"activeCount":128},[],{"trials":19178,"activeCount":128},[],{"trials":19180,"activeCount":128},[19181],{"nctId":15640,"briefTitle":15641,"status":104,"phases":19182,"primaryCompletion":15643,"completion":15643,"start":15644,"enrollment":6434,"conditions":19183,"interventions":19184},[90,91],[15646],[15648,15649,15650,15603],{"trials":19186,"activeCount":128},[],{"trials":19188,"activeCount":128},[],{"trials":19190,"activeCount":128},[],{"intervention":15649,"totalTrials":676,"cells":19192},{"EARLY_PHASE1":19193,"PHASE1":19195,"PHASE2":19197,"PHASE3":19203,"PHASE4":19205,"NA":19207},{"trials":19194,"activeCount":128},[],{"trials":19196,"activeCount":128},[],{"trials":19198,"activeCount":128},[19199],{"nctId":15640,"briefTitle":15641,"status":104,"phases":19200,"primaryCompletion":15643,"completion":15643,"start":15644,"enrollment":6434,"conditions":19201,"interventions":19202},[90,91],[15646],[15648,15649,15650,15603],{"trials":19204,"activeCount":128},[],{"trials":19206,"activeCount":128},[],{"trials":19208,"activeCount":128},[],{"intervention":15650,"totalTrials":676,"cells":19210},{"EARLY_PHASE1":19211,"PHASE1":19213,"PHASE2":19215,"PHASE3":19221,"PHASE4":19223,"NA":19225},{"trials":19212,"activeCount":128},[],{"trials":19214,"activeCount":128},[],{"trials":19216,"activeCount":128},[19217],{"nctId":15640,"briefTitle":15641,"status":104,"phases":19218,"primaryCompletion":15643,"completion":15643,"start":15644,"enrollment":6434,"conditions":19219,"interventions":19220},[90,91],[15646],[15648,15649,15650,15603],{"trials":19222,"activeCount":128},[],{"trials":19224,"activeCount":128},[],{"trials":19226,"activeCount":128},[],{"intervention":5075,"totalTrials":676,"cells":19228},{"EARLY_PHASE1":19229,"PHASE1":19231,"PHASE2":19233,"PHASE3":19239,"PHASE4":19241,"NA":19243},{"trials":19230,"activeCount":128},[],{"trials":19232,"activeCount":128},[],{"trials":19234,"activeCount":128},[19235],{"nctId":5067,"briefTitle":5068,"status":1413,"phases":19236,"primaryCompletion":5070,"completion":5070,"start":5071,"enrollment":128,"conditions":19237,"interventions":19238},[91],[5073],[5075,3427],{"trials":19240,"activeCount":128},[],{"trials":19242,"activeCount":128},[],{"trials":19244,"activeCount":128},[],{"intervention":19246,"totalTrials":676,"cells":19247},"C11 PiB",{"EARLY_PHASE1":19248,"PHASE1":19250,"PHASE2":19252,"PHASE3":19261,"PHASE4":19263,"NA":19265},{"trials":19249,"activeCount":128},[],{"trials":19251,"activeCount":128},[],{"trials":19253,"activeCount":128},[19254],{"nctId":19255,"briefTitle":19256,"status":104,"phases":19257,"primaryCompletion":2665,"completion":6973,"start":1375,"enrollment":4113,"conditions":19258,"interventions":19259},"NCT01607476","Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)",[91],[1377],[19246,19260],"F18 Flutametamol",{"trials":19262,"activeCount":128},[],{"trials":19264,"activeCount":128},[],{"trials":19266,"activeCount":128},[],{"intervention":19260,"totalTrials":676,"cells":19268},{"EARLY_PHASE1":19269,"PHASE1":19271,"PHASE2":19273,"PHASE3":19279,"PHASE4":19281,"NA":19283},{"trials":19270,"activeCount":128},[],{"trials":19272,"activeCount":128},[],{"trials":19274,"activeCount":128},[19275],{"nctId":19255,"briefTitle":19256,"status":104,"phases":19276,"primaryCompletion":2665,"completion":6973,"start":1375,"enrollment":4113,"conditions":19277,"interventions":19278},[91],[1377],[19246,19260],{"trials":19280,"activeCount":128},[],{"trials":19282,"activeCount":128},[],{"trials":19284,"activeCount":128},[],{"intervention":19286,"totalTrials":676,"cells":19287},"Ataciguat",{"EARLY_PHASE1":19288,"PHASE1":19290,"PHASE2":19292,"PHASE3":19301,"PHASE4":19303,"NA":19305},{"trials":19289,"activeCount":128},[],{"trials":19291,"activeCount":128},[],{"trials":19293,"activeCount":128},[19294],{"nctId":19295,"briefTitle":19296,"status":104,"phases":19297,"primaryCompletion":2280,"completion":12189,"start":5418,"enrollment":3726,"conditions":19298,"interventions":19300},"NCT02481258","A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification",[91],[19299],"Aortic Valve Stenosis",[19286],{"trials":19302,"activeCount":128},[],{"trials":19304,"activeCount":128},[],{"trials":19306,"activeCount":128},[],{"intervention":19308,"totalTrials":676,"cells":19309},"bupropion",{"EARLY_PHASE1":19310,"PHASE1":19312,"PHASE2":19314,"PHASE3":19323,"PHASE4":19325,"NA":19327},{"trials":19311,"activeCount":128},[],{"trials":19313,"activeCount":128},[],{"trials":19315,"activeCount":128},[19316],{"nctId":19317,"briefTitle":19318,"status":104,"phases":19319,"primaryCompletion":16545,"completion":1564,"start":10257,"enrollment":19320,"conditions":19321,"interventions":19322},"NCT00000457","Pharmacologic Relapse Prevention for Alcoholic Smokers",[91],195,[14250,13450],[19308],{"trials":19324,"activeCount":128},[],{"trials":19326,"activeCount":128},[],{"trials":19328,"activeCount":128},[],{"intervention":19330,"totalTrials":676,"cells":19331},"Nicotinamide Riboside + Pterostilbene",{"EARLY_PHASE1":19332,"PHASE1":19334,"PHASE2":19336,"PHASE3":19346,"PHASE4":19348,"NA":19350},{"trials":19333,"activeCount":128},[],{"trials":19335,"activeCount":128},[],{"trials":19337,"activeCount":128},[19338],{"nctId":19339,"briefTitle":19340,"status":104,"phases":19341,"primaryCompletion":19342,"completion":19342,"start":8279,"enrollment":270,"conditions":19343,"interventions":19345},"NCT04342975","Protection From Acute Kidney Injury (AKI) With Basis™ Treatment",[91],"2024-03-14",[19344],"AKI",[19330],{"trials":19347,"activeCount":128},[],{"trials":19349,"activeCount":128},[],{"trials":19351,"activeCount":128},[],{"intervention":19353,"totalTrials":676,"cells":19354},"S-adenosyl-L-methionine disulfate p-toluene-sulfonate",{"EARLY_PHASE1":19355,"PHASE1":19357,"PHASE2":19359,"PHASE3":19368,"PHASE4":19370,"NA":19372},{"trials":19356,"activeCount":128},[],{"trials":19358,"activeCount":128},[],{"trials":19360,"activeCount":128},[19361],{"nctId":19362,"briefTitle":19363,"status":104,"phases":19364,"primaryCompletion":4030,"completion":4030,"start":5360,"enrollment":461,"conditions":19365,"interventions":19367},"NCT01140646","Evaluation of SAMe for Hot Flashes",[91],[19366,2760],"Healthy, no Evidence of Disease",[19353],{"trials":19369,"activeCount":128},[],{"trials":19371,"activeCount":128},[],{"trials":19373,"activeCount":128},[],{"intervention":19375,"totalTrials":676,"cells":19376},"ABT-510",{"EARLY_PHASE1":19377,"PHASE1":19379,"PHASE2":19381,"PHASE3":19390,"PHASE4":19392,"NA":19394},{"trials":19378,"activeCount":128},[],{"trials":19380,"activeCount":128},[],{"trials":19382,"activeCount":128},[19383],{"nctId":19384,"briefTitle":19385,"status":104,"phases":19386,"primaryCompletion":5051,"completion":5051,"start":19387,"enrollment":7658,"conditions":19388,"interventions":19389},"NCT00602199","ABT-510 in Treating Patients With Metastatic Melanoma",[91],"2004-11",[4291],[19375],{"trials":19391,"activeCount":128},[],{"trials":19393,"activeCount":128},[],{"trials":19395,"activeCount":128},[],{"intervention":19397,"totalTrials":676,"cells":19398},"Conjugated bile acids sodium",{"EARLY_PHASE1":19399,"PHASE1":19401,"PHASE2":19403,"PHASE3":19414,"PHASE4":19416,"NA":19418},{"trials":19400,"activeCount":128},[],{"trials":19402,"activeCount":128},[],{"trials":19404,"activeCount":128},[19405],{"nctId":19406,"briefTitle":19407,"status":104,"phases":19408,"primaryCompletion":19409,"completion":19410,"start":19411,"enrollment":2555,"conditions":19412,"interventions":19413},"NCT02871882","Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus",[91],"2017-10-18","2017-10-30","2016-09-15",[6975,16007,13064],[19397],{"trials":19415,"activeCount":128},[],{"trials":19417,"activeCount":128},[],{"trials":19419,"activeCount":128},[],{"intervention":19421,"totalTrials":676,"cells":19422},"1.8% lidocaine plus 0.76% sodium bicarbonate",{"EARLY_PHASE1":19423,"PHASE1":19425,"PHASE2":19427,"PHASE3":19438,"PHASE4":19440,"NA":19442},{"trials":19424,"activeCount":128},[],{"trials":19426,"activeCount":128},[],{"trials":19428,"activeCount":128},[19429],{"nctId":19430,"briefTitle":19431,"status":104,"phases":19432,"primaryCompletion":7706,"completion":19433,"start":19434,"enrollment":1225,"conditions":19435,"interventions":19437},"NCT03343080","Lidocaine as an Endotracheal Tube (ETT) Cuff Media",[91],"2019-08-01","2018-07-27",[19436],"Cardiac Disease",[19421],{"trials":19439,"activeCount":128},[],{"trials":19441,"activeCount":128},[],{"trials":19443,"activeCount":128},[],{"intervention":19445,"totalTrials":676,"cells":19446},"Dostarlimab",{"EARLY_PHASE1":19447,"PHASE1":19449,"PHASE2":19451,"PHASE3":19462,"PHASE4":19464,"NA":19466},{"trials":19448,"activeCount":128},[],{"trials":19450,"activeCount":128},[],{"trials":19452,"activeCount":128},[19453],{"nctId":19454,"briefTitle":19455,"status":104,"phases":19456,"primaryCompletion":19457,"completion":783,"start":15375,"enrollment":3002,"conditions":19458,"interventions":19460},"NCT04493060","Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1\u002F2 and PALB2 Mutated Metastatic Pancreatic Cancer",[91],"2023-12-07",[19459,564],"Metastatic Pancreatic Ductal Adenocarcinoma",[19445,19461],"Niraparib",{"trials":19463,"activeCount":128},[],{"trials":19465,"activeCount":128},[],{"trials":19467,"activeCount":128},[],{"intervention":19461,"totalTrials":676,"cells":19469},{"EARLY_PHASE1":19470,"PHASE1":19472,"PHASE2":19474,"PHASE3":19480,"PHASE4":19482,"NA":19484},{"trials":19471,"activeCount":128},[],{"trials":19473,"activeCount":128},[],{"trials":19475,"activeCount":128},[19476],{"nctId":19454,"briefTitle":19455,"status":104,"phases":19477,"primaryCompletion":19457,"completion":783,"start":15375,"enrollment":3002,"conditions":19478,"interventions":19479},[91],[19459,564],[19445,19461],{"trials":19481,"activeCount":128},[],{"trials":19483,"activeCount":128},[],{"trials":19485,"activeCount":128},[],{"intervention":19487,"totalTrials":676,"cells":19488},"Hydroxyurea",{"EARLY_PHASE1":19489,"PHASE1":19491,"PHASE2":19493,"PHASE3":19506,"PHASE4":19508,"NA":19510},{"trials":19490,"activeCount":128},[],{"trials":19492,"activeCount":128},[],{"trials":19494,"activeCount":128},[19495],{"nctId":19496,"briefTitle":19497,"status":134,"phases":19498,"primaryCompletion":19499,"completion":19500,"start":19501,"enrollment":342,"conditions":19502,"interventions":19504},"NCT05005182","Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic\u002FMyeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts",[91],"2023-04-17","2023-06-17","2023-02-20",[19503,11070],"Myelodysplastic\u002FMyeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified",[19487,19505],"Luspatercept",{"trials":19507,"activeCount":128},[],{"trials":19509,"activeCount":128},[],{"trials":19511,"activeCount":128},[],{"intervention":19505,"totalTrials":676,"cells":19513},{"EARLY_PHASE1":19514,"PHASE1":19516,"PHASE2":19518,"PHASE3":19524,"PHASE4":19526,"NA":19528},{"trials":19515,"activeCount":128},[],{"trials":19517,"activeCount":128},[],{"trials":19519,"activeCount":128},[19520],{"nctId":19496,"briefTitle":19497,"status":134,"phases":19521,"primaryCompletion":19499,"completion":19500,"start":19501,"enrollment":342,"conditions":19522,"interventions":19523},[91],[19503,11070],[19487,19505],{"trials":19525,"activeCount":128},[],{"trials":19527,"activeCount":128},[],{"trials":19529,"activeCount":128},[],{"intervention":10898,"totalTrials":676,"cells":19531},{"EARLY_PHASE1":19532,"PHASE1":19534,"PHASE2":19536,"PHASE3":19542,"PHASE4":19544,"NA":19546},{"trials":19533,"activeCount":128},[],{"trials":19535,"activeCount":128},[],{"trials":19537,"activeCount":128},[19538],{"nctId":10893,"briefTitle":10894,"status":104,"phases":19539,"primaryCompletion":2643,"completion":2643,"start":4400,"enrollment":4565,"conditions":19540,"interventions":19541},[91],[3665],[10880,10898,10899,5425,3599],{"trials":19543,"activeCount":128},[],{"trials":19545,"activeCount":128},[],{"trials":19547,"activeCount":128},[],{"intervention":10899,"totalTrials":676,"cells":19549},{"EARLY_PHASE1":19550,"PHASE1":19552,"PHASE2":19554,"PHASE3":19560,"PHASE4":19562,"NA":19564},{"trials":19551,"activeCount":128},[],{"trials":19553,"activeCount":128},[],{"trials":19555,"activeCount":128},[19556],{"nctId":10893,"briefTitle":10894,"status":104,"phases":19557,"primaryCompletion":2643,"completion":2643,"start":4400,"enrollment":4565,"conditions":19558,"interventions":19559},[91],[3665],[10880,10898,10899,5425,3599],{"trials":19561,"activeCount":128},[],{"trials":19563,"activeCount":128},[],{"trials":19565,"activeCount":128},[],{"intervention":18624,"totalTrials":676,"cells":19567},{"EARLY_PHASE1":19568,"PHASE1":19570,"PHASE2":19572,"PHASE3":19578,"PHASE4":19580,"NA":19582},{"trials":19569,"activeCount":128},[],{"trials":19571,"activeCount":128},[],{"trials":19573,"activeCount":128},[19574],{"nctId":18618,"briefTitle":18619,"status":104,"phases":19575,"primaryCompletion":7928,"completion":2936,"start":12911,"enrollment":18621,"conditions":19576,"interventions":19577},[91],[3665],[3872,18624],{"trials":19579,"activeCount":128},[],{"trials":19581,"activeCount":128},[],{"trials":19583,"activeCount":128},[],{"intervention":19585,"totalTrials":676,"cells":19586},"Hydroxyproline and Leucine",{"EARLY_PHASE1":19587,"PHASE1":19589,"PHASE2":19591,"PHASE3":19599,"PHASE4":19601,"NA":19603},{"trials":19588,"activeCount":128},[],{"trials":19590,"activeCount":128},[],{"trials":19592,"activeCount":128},[19593],{"nctId":19594,"briefTitle":19595,"status":104,"phases":19596,"primaryCompletion":2946,"completion":12516,"start":4279,"enrollment":3002,"conditions":19597,"interventions":19598},"NCT02038543","Hydroxyproline Influence on Oxalate Metabolism",[90,91],[17052],[19585],{"trials":19600,"activeCount":128},[],{"trials":19602,"activeCount":128},[],{"trials":19604,"activeCount":128},[],{"intervention":19606,"totalTrials":676,"cells":19607},"Pasireotide LAR",{"EARLY_PHASE1":19608,"PHASE1":19610,"PHASE2":19612,"PHASE3":19624,"PHASE4":19626,"NA":19628},{"trials":19609,"activeCount":128},[],{"trials":19611,"activeCount":128},[],{"trials":19613,"activeCount":128},[19614],{"nctId":19615,"briefTitle":19616,"status":104,"phases":19617,"primaryCompletion":19618,"completion":19618,"start":894,"enrollment":2608,"conditions":19619,"interventions":19623},"NCT01670110","Pasireotide LAR in Severe Polycystic Liver Disease",[91],"2018-09",[19620,5155,19621,19622],"Somatostatin Analogs","Autosomal Dominant Polycystic Kidney Disease","Autosomal Dominant Polycystic Liver Disease",[19606],{"trials":19625,"activeCount":128},[],{"trials":19627,"activeCount":128},[],{"trials":19629,"activeCount":128},[],{"intervention":15745,"totalTrials":676,"cells":19631},{"EARLY_PHASE1":19632,"PHASE1":19634,"PHASE2":19636,"PHASE3":19642,"PHASE4":19644,"NA":19646},{"trials":19633,"activeCount":128},[],{"trials":19635,"activeCount":128},[],{"trials":19637,"activeCount":128},[19638],{"nctId":15740,"briefTitle":15741,"status":104,"phases":19639,"primaryCompletion":3842,"completion":2666,"start":7928,"enrollment":498,"conditions":19640,"interventions":19641},[91],[3562,3690,3535,3536,3537],[15745,3481],{"trials":19643,"activeCount":128},[],{"trials":19645,"activeCount":128},[],{"trials":19647,"activeCount":128},[],{"intervention":19649,"totalTrials":676,"cells":19650},"St. John's Wort-900 mg\u002Fday",{"EARLY_PHASE1":19651,"PHASE1":19653,"PHASE2":19655,"PHASE3":19665,"PHASE4":19667,"NA":19669},{"trials":19652,"activeCount":128},[],{"trials":19654,"activeCount":128},[],{"trials":19656,"activeCount":128},[19657],{"nctId":19658,"briefTitle":19659,"status":104,"phases":19660,"primaryCompletion":13742,"completion":13742,"start":7332,"enrollment":3296,"conditions":19661,"interventions":19663},"NCT00405912","St. John's Wort for Tobacco Cessation",[91],[13450,19662],"Nicotine Dependence",[19649,19664],"St. John's Wort-1800mg\u002Fday",{"trials":19666,"activeCount":128},[],{"trials":19668,"activeCount":128},[],{"trials":19670,"activeCount":128},[],{"intervention":19664,"totalTrials":676,"cells":19672},{"EARLY_PHASE1":19673,"PHASE1":19675,"PHASE2":19677,"PHASE3":19683,"PHASE4":19685,"NA":19687},{"trials":19674,"activeCount":128},[],{"trials":19676,"activeCount":128},[],{"trials":19678,"activeCount":128},[19679],{"nctId":19658,"briefTitle":19659,"status":104,"phases":19680,"primaryCompletion":13742,"completion":13742,"start":7332,"enrollment":3296,"conditions":19681,"interventions":19682},[91],[13450,19662],[19649,19664],{"trials":19684,"activeCount":128},[],{"trials":19686,"activeCount":128},[],{"trials":19688,"activeCount":128},[],{"intervention":6541,"totalTrials":676,"cells":19690},{"EARLY_PHASE1":19691,"PHASE1":19693,"PHASE2":19695,"PHASE3":19701,"PHASE4":19703,"NA":19705},{"trials":19692,"activeCount":128},[],{"trials":19694,"activeCount":128},[],{"trials":19696,"activeCount":128},[19697],{"nctId":6533,"briefTitle":6534,"status":104,"phases":19698,"primaryCompletion":6536,"completion":6536,"start":5417,"enrollment":1267,"conditions":19699,"interventions":19700},[91],[6538,6539],[6524,6541],{"trials":19702,"activeCount":128},[],{"trials":19704,"activeCount":128},[],{"trials":19706,"activeCount":128},[],{"intervention":19708,"totalTrials":676,"cells":19709},"Colchicine, 0.6 mg PO BID",{"EARLY_PHASE1":19710,"PHASE1":19712,"PHASE2":19714,"PHASE3":19723,"PHASE4":19725,"NA":19727},{"trials":19711,"activeCount":128},[],{"trials":19713,"activeCount":128},[],{"trials":19715,"activeCount":128},[19716],{"nctId":19717,"briefTitle":19718,"status":104,"phases":19719,"primaryCompletion":19720,"completion":19720,"start":12007,"enrollment":7368,"conditions":19721,"interventions":19722},"NCT01755949","Colchicine and CRP in Atrial Fibrillation and AF Ablation",[91],"2016-12-06",[33],[19708],{"trials":19724,"activeCount":128},[],{"trials":19726,"activeCount":128},[],{"trials":19728,"activeCount":128},[],{"intervention":19730,"totalTrials":676,"cells":19731},"Pamidronate",{"EARLY_PHASE1":19732,"PHASE1":19734,"PHASE2":19736,"PHASE3":19748,"PHASE4":19750,"NA":19752},{"trials":19733,"activeCount":128},[],{"trials":19735,"activeCount":128},[],{"trials":19737,"activeCount":128},[19738],{"nctId":19739,"briefTitle":19740,"status":104,"phases":19741,"primaryCompletion":19742,"completion":19743,"start":19744,"enrollment":1236,"conditions":19745,"interventions":19746},"NCT00482378","Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain",[90,91],"2007-05-22","2008-12-02","2005-03-21",[3665,938],[19730,19747],"Zoledronic acid",{"trials":19749,"activeCount":128},[],{"trials":19751,"activeCount":128},[],{"trials":19753,"activeCount":128},[],{"intervention":19755,"totalTrials":676,"cells":19756},"Ixazomib 1 MG",{"EARLY_PHASE1":19757,"PHASE1":19759,"PHASE2":19761,"PHASE3":19774,"PHASE4":19776,"NA":19778},{"trials":19758,"activeCount":128},[],{"trials":19760,"activeCount":128},[],{"trials":19762,"activeCount":128},[19763],{"nctId":19764,"briefTitle":19765,"status":104,"phases":19766,"primaryCompletion":19767,"completion":19767,"start":10281,"enrollment":139,"conditions":19768,"interventions":19770},"NCT02946047","The Effect of Ixazomib on the Latent HIV Reservoir",[90,91],"2019-08-19",[19769],"Human Immunodeficiency Virus (HIV)",[19755,19771,19772,19773],"Ixazomib 2 MG","Ixazomib 3 MG","Ixazomib 4 MG",{"trials":19775,"activeCount":128},[],{"trials":19777,"activeCount":128},[],{"trials":19779,"activeCount":128},[],{"intervention":19771,"totalTrials":676,"cells":19781},{"EARLY_PHASE1":19782,"PHASE1":19784,"PHASE2":19786,"PHASE3":19792,"PHASE4":19794,"NA":19796},{"trials":19783,"activeCount":128},[],{"trials":19785,"activeCount":128},[],{"trials":19787,"activeCount":128},[19788],{"nctId":19764,"briefTitle":19765,"status":104,"phases":19789,"primaryCompletion":19767,"completion":19767,"start":10281,"enrollment":139,"conditions":19790,"interventions":19791},[90,91],[19769],[19755,19771,19772,19773],{"trials":19793,"activeCount":128},[],{"trials":19795,"activeCount":128},[],{"trials":19797,"activeCount":128},[],{"intervention":19772,"totalTrials":676,"cells":19799},{"EARLY_PHASE1":19800,"PHASE1":19802,"PHASE2":19804,"PHASE3":19810,"PHASE4":19812,"NA":19814},{"trials":19801,"activeCount":128},[],{"trials":19803,"activeCount":128},[],{"trials":19805,"activeCount":128},[19806],{"nctId":19764,"briefTitle":19765,"status":104,"phases":19807,"primaryCompletion":19767,"completion":19767,"start":10281,"enrollment":139,"conditions":19808,"interventions":19809},[90,91],[19769],[19755,19771,19772,19773],{"trials":19811,"activeCount":128},[],{"trials":19813,"activeCount":128},[],{"trials":19815,"activeCount":128},[],{"intervention":19773,"totalTrials":676,"cells":19817},{"EARLY_PHASE1":19818,"PHASE1":19820,"PHASE2":19822,"PHASE3":19828,"PHASE4":19830,"NA":19832},{"trials":19819,"activeCount":128},[],{"trials":19821,"activeCount":128},[],{"trials":19823,"activeCount":128},[19824],{"nctId":19764,"briefTitle":19765,"status":104,"phases":19825,"primaryCompletion":19767,"completion":19767,"start":10281,"enrollment":139,"conditions":19826,"interventions":19827},[90,91],[19769],[19755,19771,19772,19773],{"trials":19829,"activeCount":128},[],{"trials":19831,"activeCount":128},[],{"trials":19833,"activeCount":128},[],{"intervention":19835,"totalTrials":676,"cells":19836},"Famotidine",{"EARLY_PHASE1":19837,"PHASE1":19839,"PHASE2":19841,"PHASE3":19851,"PHASE4":19853,"NA":19855},{"trials":19838,"activeCount":128},[],{"trials":19840,"activeCount":128},[],{"trials":19842,"activeCount":128},[19843],{"nctId":19844,"briefTitle":19845,"status":134,"phases":19846,"primaryCompletion":11549,"completion":11549,"start":19847,"enrollment":676,"conditions":19848,"interventions":19849},"NCT04248712","Antihistamines in Eosinophilic Esophagitis",[91],"2020-07-10",[12979],[19835,19850],"Loratadine",{"trials":19852,"activeCount":128},[],{"trials":19854,"activeCount":128},[],{"trials":19856,"activeCount":128},[],{"intervention":19850,"totalTrials":676,"cells":19858},{"EARLY_PHASE1":19859,"PHASE1":19861,"PHASE2":19863,"PHASE3":19869,"PHASE4":19871,"NA":19873},{"trials":19860,"activeCount":128},[],{"trials":19862,"activeCount":128},[],{"trials":19864,"activeCount":128},[19865],{"nctId":19844,"briefTitle":19845,"status":134,"phases":19866,"primaryCompletion":11549,"completion":11549,"start":19847,"enrollment":676,"conditions":19867,"interventions":19868},[91],[12979],[19835,19850],{"trials":19870,"activeCount":128},[],{"trials":19872,"activeCount":128},[],{"trials":19874,"activeCount":128},[],{"intervention":19876,"totalTrials":676,"cells":19877},"Unfractionated heparin",{"EARLY_PHASE1":19878,"PHASE1":19880,"PHASE2":19882,"PHASE3":19896,"PHASE4":19898,"NA":19900},{"trials":19879,"activeCount":128},[],{"trials":19881,"activeCount":128},[],{"trials":19883,"activeCount":128},[19884],{"nctId":19885,"briefTitle":19886,"status":104,"phases":19887,"primaryCompletion":19888,"completion":19888,"start":19889,"enrollment":19890,"conditions":19891,"interventions":19895},"NCT03772613","The Randomized OPTIMAL-ACT Trial",[91],"2021-10-25","2019-02-08",180,[1216,19892,19893,19894],"Ischemic Heart Disease","Anticoagulant-induced Bleeding","Coronary Syndrome",[19876],{"trials":19897,"activeCount":128},[],{"trials":19899,"activeCount":128},[],{"trials":19901,"activeCount":128},[],{"intervention":19903,"totalTrials":676,"cells":19904},"Ursodiol",{"EARLY_PHASE1":19905,"PHASE1":19907,"PHASE2":19909,"PHASE3":19917,"PHASE4":19919,"NA":19921},{"trials":19906,"activeCount":128},[],{"trials":19908,"activeCount":128},[],{"trials":19910,"activeCount":128},[19911],{"nctId":19912,"briefTitle":19913,"status":104,"phases":19914,"primaryCompletion":12516,"completion":12517,"start":3641,"enrollment":2555,"conditions":19915,"interventions":19916},"NCT02033876","Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin",[91],[6975],[19903],{"trials":19918,"activeCount":128},[],{"trials":19920,"activeCount":128},[],{"trials":19922,"activeCount":128},[],{"intervention":19924,"totalTrials":676,"cells":19925},"Dextrose prolotherapy",{"EARLY_PHASE1":19926,"PHASE1":19928,"PHASE2":19930,"PHASE3":19940,"PHASE4":19942,"NA":19944},{"trials":19927,"activeCount":128},[],{"trials":19929,"activeCount":128},[],{"trials":19931,"activeCount":128},[19932],{"nctId":19933,"briefTitle":19934,"status":104,"phases":19935,"primaryCompletion":19936,"completion":19936,"start":19937,"enrollment":2608,"conditions":19938,"interventions":19939},"NCT05160532","Intraarticular Dextrose Prolotherapy for Symptomatic Knee Osteoarthritis",[91],"2025-05-31","2022-04-10",[1508],[19924],{"trials":19941,"activeCount":128},[],{"trials":19943,"activeCount":128},[],{"trials":19945,"activeCount":128},[],{"intervention":19947,"totalTrials":676,"cells":19948},"PB",{"EARLY_PHASE1":19949,"PHASE1":19951,"PHASE2":19953,"PHASE3":19965,"PHASE4":19967,"NA":19969},{"trials":19950,"activeCount":128},[],{"trials":19952,"activeCount":128},[],{"trials":19954,"activeCount":128},[19955],{"nctId":19956,"briefTitle":19957,"status":104,"phases":19958,"primaryCompletion":2798,"completion":2798,"start":19959,"enrollment":187,"conditions":19960,"interventions":19964},"NCT05190744","Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration",[91],"2022-09-01",[19621,19961,19962,19963],"Nephrogenic Diabetes Insipidus","Acquired Nephrogenic Diabetes Insipidus","Congenital Nephrogenic Diabetes Insipidus",[19947],{"trials":19966,"activeCount":128},[],{"trials":19968,"activeCount":128},[],{"trials":19970,"activeCount":128},[],{"intervention":3584,"totalTrials":676,"cells":19972},{"EARLY_PHASE1":19973,"PHASE1":19975,"PHASE2":19977,"PHASE3":19983,"PHASE4":19985,"NA":19987},{"trials":19974,"activeCount":128},[],{"trials":19976,"activeCount":128},[],{"trials":19978,"activeCount":128},[19979],{"nctId":3566,"briefTitle":3567,"status":104,"phases":19980,"primaryCompletion":3569,"completion":3570,"start":1357,"enrollment":3571,"conditions":19981,"interventions":19982},[91],[3573,3574,3575,3576,3577,3578,3579,3580,3581,3582],[57,3584,3585],{"trials":19984,"activeCount":128},[],{"trials":19986,"activeCount":128},[],{"trials":19988,"activeCount":128},[],{"intervention":19990,"totalTrials":676,"cells":19991},"Gabapentin - 1800 mg\u002Fday",{"EARLY_PHASE1":19992,"PHASE1":19994,"PHASE2":19996,"PHASE3":20006,"PHASE4":20008,"NA":20010},{"trials":19993,"activeCount":128},[],{"trials":19995,"activeCount":128},[],{"trials":19997,"activeCount":128},[19998],{"nctId":19999,"briefTitle":20000,"status":104,"phases":20001,"primaryCompletion":3546,"completion":4784,"start":933,"enrollment":2678,"conditions":20002,"interventions":20004},"NCT00578552","Gabapentin for Smoking Cessation",[91],[20003,1066],"Cigarette Smoking",[19990,20005],"Gabapentin - 2700 mg\u002Fday",{"trials":20007,"activeCount":128},[],{"trials":20009,"activeCount":128},[],{"trials":20011,"activeCount":128},[],{"intervention":20005,"totalTrials":676,"cells":20013},{"EARLY_PHASE1":20014,"PHASE1":20016,"PHASE2":20018,"PHASE3":20024,"PHASE4":20026,"NA":20028},{"trials":20015,"activeCount":128},[],{"trials":20017,"activeCount":128},[],{"trials":20019,"activeCount":128},[20020],{"nctId":19999,"briefTitle":20000,"status":104,"phases":20021,"primaryCompletion":3546,"completion":4784,"start":933,"enrollment":2678,"conditions":20022,"interventions":20023},[91],[20003,1066],[19990,20005],{"trials":20025,"activeCount":128},[],{"trials":20027,"activeCount":128},[],{"trials":20029,"activeCount":128},[],{"intervention":20031,"totalTrials":676,"cells":20032},"radioactive drug",{"EARLY_PHASE1":20033,"PHASE1":20035,"PHASE2":20037,"PHASE3":20046,"PHASE4":20048,"NA":20050},{"trials":20034,"activeCount":128},[],{"trials":20036,"activeCount":128},[],{"trials":20038,"activeCount":128},[20039],{"nctId":20040,"briefTitle":20041,"status":104,"phases":20042,"primaryCompletion":231,"completion":231,"start":20043,"enrollment":1197,"conditions":20044,"interventions":20045},"NCT04538950","PET\u002FCT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy",[90,91],"2020-08-14",[897],[20031],{"trials":20047,"activeCount":128},[],{"trials":20049,"activeCount":128},[],{"trials":20051,"activeCount":128},[],{"intervention":6581,"totalTrials":676,"cells":20053},{"EARLY_PHASE1":20054,"PHASE1":20056,"PHASE2":20058,"PHASE3":20064,"PHASE4":20066,"NA":20068},{"trials":20055,"activeCount":128},[],{"trials":20057,"activeCount":128},[],{"trials":20059,"activeCount":128},[20060],{"nctId":6574,"briefTitle":6575,"status":104,"phases":20061,"primaryCompletion":6577,"completion":6578,"start":4464,"enrollment":773,"conditions":20062,"interventions":20063},[91],[21],[4600,6581],{"trials":20065,"activeCount":128},[],{"trials":20067,"activeCount":128},[],{"trials":20069,"activeCount":128},[],{"intervention":20071,"totalTrials":676,"cells":20072},"Iron Dextran",{"EARLY_PHASE1":20073,"PHASE1":20075,"PHASE2":20077,"PHASE3":20088,"PHASE4":20090,"NA":20092},{"trials":20074,"activeCount":128},[],{"trials":20076,"activeCount":128},[],{"trials":20078,"activeCount":128},[20079],{"nctId":20080,"briefTitle":20081,"status":104,"phases":20082,"primaryCompletion":3825,"completion":20083,"start":20084,"enrollment":712,"conditions":20085,"interventions":20086},"NCT05167734","Practical Anemia Bundle for SusTained Blood Recovery",[91],"2024-11-26","2021-11-30",[10869,1474],[20071,20087],"Erythropoietin",{"trials":20089,"activeCount":128},[],{"trials":20091,"activeCount":128},[],{"trials":20093,"activeCount":128},[],{"intervention":20087,"totalTrials":676,"cells":20095},{"EARLY_PHASE1":20096,"PHASE1":20098,"PHASE2":20100,"PHASE3":20106,"PHASE4":20108,"NA":20110},{"trials":20097,"activeCount":128},[],{"trials":20099,"activeCount":128},[],{"trials":20101,"activeCount":128},[20102],{"nctId":20080,"briefTitle":20081,"status":104,"phases":20103,"primaryCompletion":3825,"completion":20083,"start":20084,"enrollment":712,"conditions":20104,"interventions":20105},[91],[10869,1474],[20071,20087],{"trials":20107,"activeCount":128},[],{"trials":20109,"activeCount":128},[],{"trials":20111,"activeCount":128},[],{"intervention":20113,"totalTrials":676,"cells":20114},"Formoterol",{"EARLY_PHASE1":20115,"PHASE1":20117,"PHASE2":20119,"PHASE3":20128,"PHASE4":20130,"NA":20132},{"trials":20116,"activeCount":128},[],{"trials":20118,"activeCount":128},[],{"trials":20120,"activeCount":128},[20121],{"nctId":20122,"briefTitle":20123,"status":104,"phases":20124,"primaryCompletion":1318,"completion":15986,"start":3544,"enrollment":16613,"conditions":20125,"interventions":20127},"NCT01783821","LIPS-B: Lung Injury Prevention Study With Budesonide and Beta",[91],[20126],"Acute Respiratory Distress Syndrome (ARDS)",[17581,20113],{"trials":20129,"activeCount":128},[],{"trials":20131,"activeCount":128},[],{"trials":20133,"activeCount":128},[],{"intervention":20135,"totalTrials":676,"cells":20136},"F-652",{"EARLY_PHASE1":20137,"PHASE1":20139,"PHASE2":20141,"PHASE3":20150,"PHASE4":20152,"NA":20154},{"trials":20138,"activeCount":128},[],{"trials":20140,"activeCount":128},[],{"trials":20142,"activeCount":128},[20143],{"nctId":20144,"briefTitle":20145,"status":104,"phases":20146,"primaryCompletion":15291,"completion":15291,"start":3642,"enrollment":108,"conditions":20147,"interventions":20149},"NCT02655510","Use of F-652 in Patients With Alcoholic Hepatitis",[90,91],[20148],"Alcoholic Hepatitis",[20135],{"trials":20151,"activeCount":128},[],{"trials":20153,"activeCount":128},[],{"trials":20155,"activeCount":128},[],{"intervention":20157,"totalTrials":676,"cells":20158},"FEIBA",{"EARLY_PHASE1":20159,"PHASE1":20161,"PHASE2":20163,"PHASE3":20171,"PHASE4":20173,"NA":20175},{"trials":20160,"activeCount":128},[],{"trials":20162,"activeCount":128},[],{"trials":20164,"activeCount":128},[20165],{"nctId":20166,"briefTitle":20167,"status":1413,"phases":20168,"primaryCompletion":11559,"completion":11559,"start":4312,"enrollment":128,"conditions":20169,"interventions":20170},"NCT05020483","FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients",[91],[19436],[20157],{"trials":20172,"activeCount":128},[],{"trials":20174,"activeCount":128},[],{"trials":20176,"activeCount":128},[],{"intervention":20178,"totalTrials":676,"cells":20179},"Abemaciclib",{"EARLY_PHASE1":20180,"PHASE1":20182,"PHASE2":20184,"PHASE3":20196,"PHASE4":20198,"NA":20200},{"trials":20181,"activeCount":128},[],{"trials":20183,"activeCount":128},[],{"trials":20185,"activeCount":128},[20186],{"nctId":20187,"briefTitle":20188,"status":134,"phases":20189,"primaryCompletion":20190,"completion":20190,"start":20191,"enrollment":7368,"conditions":20192,"interventions":20195},"NCT03979508","Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer",[91],"2024-12-26","2020-01-10",[5197,5198,579,11437,20193,20194,7530,10342,10343,10344,10345,10346,10347,6193,6194,6195,6196,221],"Breast Fibrocystic Change","Breast Lobular Carcinoma In Situ",[20178],{"trials":20197,"activeCount":128},[],{"trials":20199,"activeCount":128},[],{"trials":20201,"activeCount":128},[],{"intervention":3624,"totalTrials":676,"cells":20203},{"EARLY_PHASE1":20204,"PHASE1":20206,"PHASE2":20208,"PHASE3":20214,"PHASE4":20216,"NA":20218},{"trials":20205,"activeCount":128},[],{"trials":20207,"activeCount":128},[],{"trials":20209,"activeCount":128},[20210],{"nctId":3610,"briefTitle":3611,"status":1413,"phases":20211,"primaryCompletion":905,"completion":2697,"start":3613,"enrollment":128,"conditions":20212,"interventions":20213},[91],[3615,3616,3617,3618,3619],[3621,3553,3323,3324,3327,3622,3623,3525,3624,3514,3625],{"trials":20215,"activeCount":128},[],{"trials":20217,"activeCount":128},[],{"trials":20219,"activeCount":128},[],{"intervention":20221,"totalTrials":676,"cells":20222},"Sodium Nitrite Inhalation Solution",{"EARLY_PHASE1":20223,"PHASE1":20225,"PHASE2":20227,"PHASE3":20235,"PHASE4":20237,"NA":20239},{"trials":20224,"activeCount":128},[],{"trials":20226,"activeCount":128},[],{"trials":20228,"activeCount":128},[20229],{"nctId":20230,"briefTitle":20231,"status":104,"phases":20232,"primaryCompletion":15986,"completion":15986,"start":3887,"enrollment":7368,"conditions":20233,"interventions":20234},"NCT02262078","Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction",[91],[27],[20221],{"trials":20236,"activeCount":128},[],{"trials":20238,"activeCount":128},[],{"trials":20240,"activeCount":128},[],{"intervention":15689,"totalTrials":676,"cells":20242},{"EARLY_PHASE1":20243,"PHASE1":20245,"PHASE2":20247,"PHASE3":20253,"PHASE4":20255,"NA":20257},{"trials":20244,"activeCount":128},[],{"trials":20246,"activeCount":128},[],{"trials":20248,"activeCount":128},[20249],{"nctId":15681,"briefTitle":15682,"status":104,"phases":20250,"primaryCompletion":6642,"completion":6642,"start":15684,"enrollment":2894,"conditions":20251,"interventions":20252},[91],[15686,15687],[15689,7013],{"trials":20254,"activeCount":128},[],{"trials":20256,"activeCount":128},[],{"trials":20258,"activeCount":128},[],{"intervention":20260,"totalTrials":676,"cells":20261},"Tolterodine",{"EARLY_PHASE1":20262,"PHASE1":20264,"PHASE2":20266,"PHASE3":20275,"PHASE4":20277,"NA":20279},{"trials":20263,"activeCount":128},[],{"trials":20265,"activeCount":128},[],{"trials":20267,"activeCount":128},[20268],{"nctId":20269,"briefTitle":20270,"status":104,"phases":20271,"primaryCompletion":1564,"completion":1564,"start":7332,"enrollment":187,"conditions":20272,"interventions":20274},"NCT00332137","Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects",[91],[20273],"Health",[20260],{"trials":20276,"activeCount":128},[],{"trials":20278,"activeCount":128},[],{"trials":20280,"activeCount":128},[],{"intervention":5522,"totalTrials":676,"cells":20282},{"EARLY_PHASE1":20283,"PHASE1":20285,"PHASE2":20287,"PHASE3":20293,"PHASE4":20295,"NA":20297},{"trials":20284,"activeCount":128},[],{"trials":20286,"activeCount":128},[],{"trials":20288,"activeCount":128},[20289],{"nctId":5512,"briefTitle":5513,"status":104,"phases":20290,"primaryCompletion":5515,"completion":5515,"start":5516,"enrollment":5517,"conditions":20291,"interventions":20292},[91],[21],[5520,5521,5522],{"trials":20294,"activeCount":128},[],{"trials":20296,"activeCount":128},[],{"trials":20298,"activeCount":128},[],{"intervention":18162,"totalTrials":676,"cells":20300},{"EARLY_PHASE1":20301,"PHASE1":20303,"PHASE2":20305,"PHASE3":20311,"PHASE4":20313,"NA":20315},{"trials":20302,"activeCount":128},[],{"trials":20304,"activeCount":128},[],{"trials":20306,"activeCount":128},[20307],{"nctId":18153,"briefTitle":18154,"status":1413,"phases":20308,"primaryCompletion":18156,"completion":18156,"start":18157,"enrollment":128,"conditions":20309,"interventions":20310},[91],[18159,18160],[6374,18162],{"trials":20312,"activeCount":128},[],{"trials":20314,"activeCount":128},[],{"trials":20316,"activeCount":128},[],{"intervention":20318,"totalTrials":676,"cells":20319},"Sodium chenodeoxycholate",{"EARLY_PHASE1":20320,"PHASE1":20322,"PHASE2":20324,"PHASE3":20333,"PHASE4":20335,"NA":20337},{"trials":20321,"activeCount":128},[],{"trials":20323,"activeCount":128},[],{"trials":20325,"activeCount":128},[20326],{"nctId":20327,"briefTitle":20328,"status":104,"phases":20329,"primaryCompletion":7657,"completion":7928,"start":1563,"enrollment":187,"conditions":20330,"interventions":20332},"NCT00912301","Cheno Effect on Transit in Health and IBS-C",[91],[20331],"Constipation-predominant Irritable Bowel Syndrome",[20318],{"trials":20334,"activeCount":128},[],{"trials":20336,"activeCount":128},[],{"trials":20338,"activeCount":128},[],{"intervention":16222,"totalTrials":676,"cells":20340},{"EARLY_PHASE1":20341,"PHASE1":20343,"PHASE2":20345,"PHASE3":20351,"PHASE4":20353,"NA":20355},{"trials":20342,"activeCount":128},[],{"trials":20344,"activeCount":128},[],{"trials":20346,"activeCount":128},[20347],{"nctId":16214,"briefTitle":16215,"status":104,"phases":20348,"primaryCompletion":2621,"completion":2621,"start":16217,"enrollment":16218,"conditions":20349,"interventions":20350},[91],[10869,3549,1419,16220,3665,5371,4293],[16205,16222],{"trials":20352,"activeCount":128},[],{"trials":20354,"activeCount":128},[],{"trials":20356,"activeCount":128},[],{"intervention":20358,"totalTrials":676,"cells":20359},"St. John's wort",{"EARLY_PHASE1":20360,"PHASE1":20362,"PHASE2":20364,"PHASE3":20372,"PHASE4":20374,"NA":20376},{"trials":20361,"activeCount":128},[],{"trials":20363,"activeCount":128},[],{"trials":20365,"activeCount":128},[20366],{"nctId":20367,"briefTitle":20368,"status":104,"phases":20369,"primaryCompletion":4503,"completion":13742,"start":16700,"enrollment":313,"conditions":20370,"interventions":20371},"NCT00587860","A Placebo-Controlled Trial of St. John's Wort for Irritable Bowel Syndrome",[91],[2885],[20358],{"trials":20373,"activeCount":128},[],{"trials":20375,"activeCount":128},[],{"trials":20377,"activeCount":128},[],{"intervention":20379,"totalTrials":676,"cells":20380},"Dupilumab 300Mg Solution for",{"EARLY_PHASE1":20381,"PHASE1":20383,"PHASE2":20385,"PHASE3":20395,"PHASE4":20397,"NA":20399},{"trials":20382,"activeCount":128},[],{"trials":20384,"activeCount":128},[],{"trials":20386,"activeCount":128},[20387],{"nctId":20388,"briefTitle":20389,"status":104,"phases":20390,"primaryCompletion":20391,"completion":20391,"start":1416,"enrollment":476,"conditions":20392,"interventions":20394},"NCT04256759","Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus",[91],"2024-09-06",[20393],"Pruritus",[20379],{"trials":20396,"activeCount":128},[],{"trials":20398,"activeCount":128},[],{"trials":20400,"activeCount":128},[],{"intervention":20402,"totalTrials":676,"cells":20403},"Androgen Suppression",{"EARLY_PHASE1":20404,"PHASE1":20406,"PHASE2":20408,"PHASE3":20420,"PHASE4":20422,"NA":20424},{"trials":20405,"activeCount":128},[],{"trials":20407,"activeCount":128},[],{"trials":20409,"activeCount":128},[20410],{"nctId":20411,"briefTitle":20412,"status":104,"phases":20413,"primaryCompletion":13764,"completion":13764,"start":20414,"enrollment":3663,"conditions":20415,"interventions":20419},"NCT03570827","Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy",[91],"2018-05-14",[6368,3301,3303,20416,20417,20418],"Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8",[20402],{"trials":20421,"activeCount":128},[],{"trials":20423,"activeCount":128},[],{"trials":20425,"activeCount":128},[],{"intervention":20427,"totalTrials":676,"cells":20428},"Exisulind",{"EARLY_PHASE1":20429,"PHASE1":20431,"PHASE2":20433,"PHASE3":20442,"PHASE4":20444,"NA":20446},{"trials":20430,"activeCount":128},[],{"trials":20432,"activeCount":128},[],{"trials":20434,"activeCount":128},[20435],{"nctId":20436,"briefTitle":20437,"status":104,"phases":20438,"primaryCompletion":16217,"completion":5033,"start":16723,"enrollment":2925,"conditions":20439,"interventions":20441},"NCT00166426","Exisulind Versus Placebo After Surgical Removal of the Prostate",[91],[20440],"Prostatic Neoplasms",[20427],{"trials":20443,"activeCount":128},[],{"trials":20445,"activeCount":128},[],{"trials":20447,"activeCount":128},[],{"intervention":20449,"totalTrials":676,"cells":20450},"megestrol acetate",{"EARLY_PHASE1":20451,"PHASE1":20453,"PHASE2":20455,"PHASE3":20464,"PHASE4":20466,"NA":20468},{"trials":20452,"activeCount":128},[],{"trials":20454,"activeCount":128},[],{"trials":20456,"activeCount":128},[20457],{"nctId":20458,"briefTitle":20459,"status":134,"phases":20460,"primaryCompletion":3842,"completion":3033,"start":945,"enrollment":676,"conditions":20461,"interventions":20463},"NCT01200602","Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and\u002For Chemotherapy",[91],[17184,20462],"Weight Changes",[20449],{"trials":20465,"activeCount":128},[],{"trials":20467,"activeCount":128},[],{"trials":20469,"activeCount":128},[],{"intervention":18765,"totalTrials":676,"cells":20471},{"EARLY_PHASE1":20472,"PHASE1":20474,"PHASE2":20476,"PHASE3":20482,"PHASE4":20484,"NA":20486},{"trials":20473,"activeCount":128},[],{"trials":20475,"activeCount":128},[],{"trials":20477,"activeCount":128},[20478],{"nctId":18758,"briefTitle":18759,"status":104,"phases":20479,"primaryCompletion":2999,"completion":3000,"start":18761,"enrollment":25,"conditions":20480,"interventions":20481},[90,91],[27,18763],[18765,18742],{"trials":20483,"activeCount":128},[],{"trials":20485,"activeCount":128},[],{"trials":20487,"activeCount":128},[],{"intervention":20489,"totalTrials":676,"cells":20490},"Moexipril",{"EARLY_PHASE1":20491,"PHASE1":20493,"PHASE2":20495,"PHASE3":20504,"PHASE4":20506,"NA":20508},{"trials":20492,"activeCount":128},[],{"trials":20494,"activeCount":128},[],{"trials":20496,"activeCount":128},[20497],{"nctId":20498,"briefTitle":20499,"status":104,"phases":20500,"primaryCompletion":1297,"completion":1297,"start":4871,"enrollment":173,"conditions":20501,"interventions":20503},"NCT00588302","Moexipril for Primary Biliary Cirrhosis",[91],[20502],"Primary Biliary Cirrhosis",[20489],{"trials":20505,"activeCount":128},[],{"trials":20507,"activeCount":128},[],{"trials":20509,"activeCount":128},[],{"intervention":20511,"totalTrials":676,"cells":20512},"Betaine",{"EARLY_PHASE1":20513,"PHASE1":20515,"PHASE2":20517,"PHASE3":20525,"PHASE4":20527,"NA":20529},{"trials":20514,"activeCount":128},[],{"trials":20516,"activeCount":128},[],{"trials":20518,"activeCount":128},[20519],{"nctId":20520,"briefTitle":20521,"status":104,"phases":20522,"primaryCompletion":3899,"completion":3899,"start":16636,"enrollment":4565,"conditions":20523,"interventions":20524},"NCT00283387","Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria",[91],[17052],[20511],{"trials":20526,"activeCount":128},[],{"trials":20528,"activeCount":128},[],{"trials":20530,"activeCount":128},[],{"intervention":10263,"totalTrials":676,"cells":20532},{"EARLY_PHASE1":20533,"PHASE1":20535,"PHASE2":20537,"PHASE3":20543,"PHASE4":20545,"NA":20547},{"trials":20534,"activeCount":128},[],{"trials":20536,"activeCount":128},[],{"trials":20538,"activeCount":128},[20539],{"nctId":10252,"briefTitle":10253,"status":104,"phases":20540,"primaryCompletion":10255,"completion":10256,"start":10257,"enrollment":1236,"conditions":20541,"interventions":20542},[90,91],[10259,10260,10261],[10263,10264,3779],{"trials":20544,"activeCount":128},[],{"trials":20546,"activeCount":128},[],{"trials":20548,"activeCount":128},[],{"intervention":10264,"totalTrials":676,"cells":20550},{"EARLY_PHASE1":20551,"PHASE1":20553,"PHASE2":20555,"PHASE3":20561,"PHASE4":20563,"NA":20565},{"trials":20552,"activeCount":128},[],{"trials":20554,"activeCount":128},[],{"trials":20556,"activeCount":128},[20557],{"nctId":10252,"briefTitle":10253,"status":104,"phases":20558,"primaryCompletion":10255,"completion":10256,"start":10257,"enrollment":1236,"conditions":20559,"interventions":20560},[90,91],[10259,10260,10261],[10263,10264,3779],{"trials":20562,"activeCount":128},[],{"trials":20564,"activeCount":128},[],{"trials":20566,"activeCount":128},[],{"intervention":20568,"totalTrials":676,"cells":20569},"CC-4047",{"EARLY_PHASE1":20570,"PHASE1":20572,"PHASE2":20574,"PHASE3":20585,"PHASE4":20587,"NA":20589},{"trials":20571,"activeCount":128},[],{"trials":20573,"activeCount":128},[],{"trials":20575,"activeCount":128},[20576],{"nctId":20577,"briefTitle":20578,"status":104,"phases":20579,"primaryCompletion":20580,"completion":20581,"start":5033,"enrollment":20582,"conditions":20583,"interventions":20584},"NCT00669578","CC-4047 in Treating Patients With Myelofibrosis",[90,91],"2010-07-07","2019-12-12",77,[3522,3523],[20568],{"trials":20586,"activeCount":128},[],{"trials":20588,"activeCount":128},[],{"trials":20590,"activeCount":128},[],{"intervention":5365,"totalTrials":676,"cells":20592},{"EARLY_PHASE1":20593,"PHASE1":20595,"PHASE2":20597,"PHASE3":20603,"PHASE4":20605,"NA":20607},{"trials":20594,"activeCount":128},[],{"trials":20596,"activeCount":128},[],{"trials":20598,"activeCount":128},[20599],{"nctId":5357,"briefTitle":5358,"status":104,"phases":20600,"primaryCompletion":5360,"completion":5361,"start":3520,"enrollment":956,"conditions":20601,"interventions":20602},[90,91],[5363,3676,3677,3858,434,435,436,416,417,439,3678,451],[5365,163],{"trials":20604,"activeCount":128},[],{"trials":20606,"activeCount":128},[],{"trials":20608,"activeCount":128},[],{"intervention":4374,"totalTrials":676,"cells":20610},{"EARLY_PHASE1":20611,"PHASE1":20613,"PHASE2":20615,"PHASE3":20621,"PHASE4":20623,"NA":20625},{"trials":20612,"activeCount":128},[],{"trials":20614,"activeCount":128},[],{"trials":20616,"activeCount":128},[20617],{"nctId":4356,"briefTitle":4357,"status":104,"phases":20618,"primaryCompletion":298,"completion":4359,"start":4360,"enrollment":224,"conditions":20619,"interventions":20620},[91],[4362,4363,4364,4365,4366,672,4367,4368,4369,4370,4371,4372],[4374,4089,537,4375],{"trials":20622,"activeCount":128},[],{"trials":20624,"activeCount":128},[],{"trials":20626,"activeCount":128},[],{"intervention":17911,"totalTrials":676,"cells":20628},{"EARLY_PHASE1":20629,"PHASE1":20631,"PHASE2":20633,"PHASE3":20639,"PHASE4":20641,"NA":20643},{"trials":20630,"activeCount":128},[],{"trials":20632,"activeCount":128},[],{"trials":20634,"activeCount":128},[20635],{"nctId":17906,"briefTitle":17907,"status":104,"phases":20636,"primaryCompletion":3519,"completion":3673,"start":12925,"enrollment":3726,"conditions":20637,"interventions":20638},[91],[3665],[4306,5423,17911,17912],{"trials":20640,"activeCount":128},[],{"trials":20642,"activeCount":128},[],{"trials":20644,"activeCount":128},[],{"intervention":363,"totalTrials":676,"cells":20646},{"EARLY_PHASE1":20647,"PHASE1":20649,"PHASE2":20651,"PHASE3":20657,"PHASE4":20659,"NA":20661},{"trials":20648,"activeCount":128},[],{"trials":20650,"activeCount":128},[],{"trials":20652,"activeCount":128},[20653],{"nctId":349,"briefTitle":350,"status":104,"phases":20654,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":20655,"interventions":20656},[91],[357,358,359,360,361],[363,72],{"trials":20658,"activeCount":128},[],{"trials":20660,"activeCount":128},[],{"trials":20662,"activeCount":128},[],{"intervention":18927,"totalTrials":676,"cells":20664},{"EARLY_PHASE1":20665,"PHASE1":20667,"PHASE2":20669,"PHASE3":20675,"PHASE4":20677,"NA":20679},{"trials":20666,"activeCount":128},[],{"trials":20668,"activeCount":128},[],{"trials":20670,"activeCount":128},[20671],{"nctId":18922,"briefTitle":18923,"status":104,"phases":20672,"primaryCompletion":5279,"completion":4030,"start":11897,"enrollment":108,"conditions":20673,"interventions":20674},[91],[3321,3479],[18927,18905],{"trials":20676,"activeCount":128},[],{"trials":20678,"activeCount":128},[],{"trials":20680,"activeCount":128},[],{"intervention":20682,"totalTrials":676,"cells":20683},"Doxepin Hydrochloride",{"EARLY_PHASE1":20684,"PHASE1":20686,"PHASE2":20688,"PHASE3":20706,"PHASE4":20708,"NA":20710},{"trials":20685,"activeCount":128},[],{"trials":20687,"activeCount":128},[],{"trials":20689,"activeCount":128},[20690],{"nctId":20691,"briefTitle":20692,"status":134,"phases":20693,"primaryCompletion":20694,"completion":20695,"start":6433,"enrollment":895,"conditions":20696,"interventions":20705},"NCT02062632","Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy",[91],"2015-05-29","2017-11-06",[4615,4449,4450,1419,20697,4541,20698,20699,20700,1420,20701,20702,20703,20704],"Mesothelioma","Metastatic Malignant Neoplasm in the Pleura","Metastatic Malignant Neoplasm in the Spinal Cord","Non-Small Cell Lung Carcinoma","Small Cell Lung Carcinoma","Thymic Carcinoma","Thymoma","Thyroid Gland Carcinoma",[20682],{"trials":20707,"activeCount":128},[],{"trials":20709,"activeCount":128},[],{"trials":20711,"activeCount":128},[],{"intervention":20713,"totalTrials":676,"cells":20714},"Campath-1H and Tacrolimus",{"EARLY_PHASE1":20715,"PHASE1":20717,"PHASE2":20719,"PHASE3":20728,"PHASE4":20730,"NA":20732},{"trials":20716,"activeCount":128},[],{"trials":20718,"activeCount":128},[],{"trials":20720,"activeCount":128},[20721],{"nctId":20722,"briefTitle":20723,"status":104,"phases":20724,"primaryCompletion":3718,"completion":3718,"start":4391,"enrollment":370,"conditions":20725,"interventions":20727},"NCT00166556","A Trial to Assess Campath-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver Transplantation",[91],[20726],"Transplantation, Liver",[20713],{"trials":20729,"activeCount":128},[],{"trials":20731,"activeCount":128},[],{"trials":20733,"activeCount":128},[],{"intervention":20735,"totalTrials":676,"cells":20736},"Concentrated Bone Marrow Aspirate",{"EARLY_PHASE1":20737,"PHASE1":20739,"PHASE2":20741,"PHASE3":20752,"PHASE4":20754,"NA":20756},{"trials":20738,"activeCount":128},[],{"trials":20740,"activeCount":128},[],{"trials":20742,"activeCount":128},[20743],{"nctId":20744,"briefTitle":20745,"status":1413,"phases":20746,"primaryCompletion":20747,"completion":20747,"start":2990,"enrollment":128,"conditions":20748,"interventions":20750},"NCT03271229","Conventional Platelet-Rich Plasma Versus Concentrated Bone Marrow Stem Cell Injections for Osteoarthritis of the Knee",[91],"2021-01",[20749],"Osteo Arthritis Knee",[20735,20751],"Platelet-Rich Plasma",{"trials":20753,"activeCount":128},[],{"trials":20755,"activeCount":128},[],{"trials":20757,"activeCount":128},[],{"intervention":421,"totalTrials":676,"cells":20759},{"EARLY_PHASE1":20760,"PHASE1":20762,"PHASE2":20764,"PHASE3":20770,"PHASE4":20772,"NA":20774},{"trials":20761,"activeCount":128},[],{"trials":20763,"activeCount":128},[],{"trials":20765,"activeCount":128},[20766],{"nctId":404,"briefTitle":405,"status":104,"phases":20767,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":20768,"interventions":20769},[90,91],[412,413,414,415,416,417,146,384,418,419],[421,72,422],{"trials":20771,"activeCount":128},[],{"trials":20773,"activeCount":128},[],{"trials":20775,"activeCount":128},[],{"intervention":453,"totalTrials":676,"cells":20777},{"EARLY_PHASE1":20778,"PHASE1":20780,"PHASE2":20782,"PHASE3":20788,"PHASE4":20790,"NA":20792},{"trials":20779,"activeCount":128},[],{"trials":20781,"activeCount":128},[],{"trials":20783,"activeCount":128},[20784],{"nctId":424,"briefTitle":425,"status":104,"phases":20785,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":20786,"interventions":20787},[91],[373,432,433,434,435,436,437,417,438,439,440,441,442,443,444,445,446,151,447,448,449,450,451],[179,453,72],{"trials":20789,"activeCount":128},[],{"trials":20791,"activeCount":128},[],{"trials":20793,"activeCount":128},[],{"intervention":20795,"totalTrials":676,"cells":20796},"BQ-123",{"EARLY_PHASE1":20797,"PHASE1":20799,"PHASE2":20801,"PHASE3":20810,"PHASE4":20812,"NA":20814},{"trials":20798,"activeCount":128},[],{"trials":20800,"activeCount":128},[],{"trials":20802,"activeCount":128},[20803],{"nctId":20804,"briefTitle":20805,"status":104,"phases":20806,"primaryCompletion":3033,"completion":3033,"start":16315,"enrollment":233,"conditions":20807,"interventions":20809},"NCT00586820","Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI",[91],[20808],"Myocardial Reperfusion Injury",[20795],{"trials":20811,"activeCount":128},[],{"trials":20813,"activeCount":128},[],{"trials":20815,"activeCount":128},[],{"intervention":20817,"totalTrials":676,"cells":20818},"Neseritide",{"EARLY_PHASE1":20819,"PHASE1":20821,"PHASE2":20823,"PHASE3":20831,"PHASE4":20833,"NA":20835},{"trials":20820,"activeCount":128},[],{"trials":20822,"activeCount":128},[],{"trials":20824,"activeCount":128},[20825],{"nctId":20826,"briefTitle":20827,"status":104,"phases":20828,"primaryCompletion":933,"completion":933,"start":15844,"enrollment":498,"conditions":20829,"interventions":20830},"NCT00252200","BNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery.",[90,91],[14208],[20817],{"trials":20832,"activeCount":128},[],{"trials":20834,"activeCount":128},[],{"trials":20836,"activeCount":128},[],{"intervention":20838,"totalTrials":676,"cells":20839},"Point-of-care washed red blood cell transfusion.",{"EARLY_PHASE1":20840,"PHASE1":20842,"PHASE2":20844,"PHASE3":20856,"PHASE4":20858,"NA":20860},{"trials":20841,"activeCount":128},[],{"trials":20843,"activeCount":128},[],{"trials":20845,"activeCount":128},[20846],{"nctId":20847,"briefTitle":20848,"status":104,"phases":20849,"primaryCompletion":20850,"completion":20850,"start":2607,"enrollment":20851,"conditions":20852,"interventions":20854},"NCT02094118","Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications",[90,91],"2019-05-30",171,[20853],"Blood Transfusion Complications",[20838,20855],"Standard of care red blood cell transfusion.",{"trials":20857,"activeCount":128},[],{"trials":20859,"activeCount":128},[],{"trials":20861,"activeCount":128},[],{"intervention":20855,"totalTrials":676,"cells":20863},{"EARLY_PHASE1":20864,"PHASE1":20866,"PHASE2":20868,"PHASE3":20874,"PHASE4":20876,"NA":20878},{"trials":20865,"activeCount":128},[],{"trials":20867,"activeCount":128},[],{"trials":20869,"activeCount":128},[20870],{"nctId":20847,"briefTitle":20848,"status":104,"phases":20871,"primaryCompletion":20850,"completion":20850,"start":2607,"enrollment":20851,"conditions":20872,"interventions":20873},[90,91],[20853],[20838,20855],{"trials":20875,"activeCount":128},[],{"trials":20877,"activeCount":128},[],{"trials":20879,"activeCount":128},[],{"intervention":2985,"totalTrials":676,"cells":20881},{"EARLY_PHASE1":20882,"PHASE1":20884,"PHASE2":20886,"PHASE3":20892,"PHASE4":20894,"NA":20896},{"trials":20883,"activeCount":128},[],{"trials":20885,"activeCount":128},[],{"trials":20887,"activeCount":128},[20888],{"nctId":2975,"briefTitle":2976,"status":104,"phases":20889,"primaryCompletion":1374,"completion":2978,"start":2979,"enrollment":2980,"conditions":20890,"interventions":20891},[90,91],[2982],[2984,2966,2985],{"trials":20893,"activeCount":128},[],{"trials":20895,"activeCount":128},[],{"trials":20897,"activeCount":128},[],{"intervention":20899,"totalTrials":676,"cells":20900},"Cystone",{"EARLY_PHASE1":20901,"PHASE1":20903,"PHASE2":20905,"PHASE3":20916,"PHASE4":20918,"NA":20920},{"trials":20902,"activeCount":128},[],{"trials":20904,"activeCount":128},[],{"trials":20906,"activeCount":128},[20907],{"nctId":20908,"briefTitle":20909,"status":104,"phases":20910,"primaryCompletion":2883,"completion":6258,"start":7604,"enrollment":173,"conditions":20911,"interventions":20914},"NCT00381849","Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones",[90,91],[20912,20913],"Cystinuria","Nephrolithiasis, Calcium Oxalate",[20899,20915],"Sugar Pill",{"trials":20917,"activeCount":128},[],{"trials":20919,"activeCount":128},[],{"trials":20921,"activeCount":128},[],{"intervention":20923,"totalTrials":676,"cells":20924},"Estradiol 100 Micrograms Patch",{"EARLY_PHASE1":20925,"PHASE1":20927,"PHASE2":20929,"PHASE3":20940,"PHASE4":20942,"NA":20944},{"trials":20926,"activeCount":128},[],{"trials":20928,"activeCount":128},[],{"trials":20930,"activeCount":128},[20931],{"nctId":20932,"briefTitle":20933,"status":104,"phases":20934,"primaryCompletion":20935,"completion":20935,"start":18951,"enrollment":3726,"conditions":20936,"interventions":20938},"NCT03815929","Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women",[91],"2023-08-28",[20937],"Cardiovascular Risk Reduction",[20923,20939],"Estradiol Patch",{"trials":20941,"activeCount":128},[],{"trials":20943,"activeCount":128},[],{"trials":20945,"activeCount":128},[],{"intervention":20939,"totalTrials":676,"cells":20947},{"EARLY_PHASE1":20948,"PHASE1":20950,"PHASE2":20952,"PHASE3":20958,"PHASE4":20960,"NA":20962},{"trials":20949,"activeCount":128},[],{"trials":20951,"activeCount":128},[],{"trials":20953,"activeCount":128},[20954],{"nctId":20932,"briefTitle":20933,"status":104,"phases":20955,"primaryCompletion":20935,"completion":20935,"start":18951,"enrollment":3726,"conditions":20956,"interventions":20957},[91],[20937],[20923,20939],{"trials":20959,"activeCount":128},[],{"trials":20961,"activeCount":128},[],{"trials":20963,"activeCount":128},[],{"intervention":20965,"totalTrials":676,"cells":20966},"tipifarnib",{"EARLY_PHASE1":20967,"PHASE1":20969,"PHASE2":20971,"PHASE3":20980,"PHASE4":20982,"NA":20984},{"trials":20968,"activeCount":128},[],{"trials":20970,"activeCount":128},[],{"trials":20972,"activeCount":128},[20973],{"nctId":20974,"briefTitle":20975,"status":104,"phases":20976,"primaryCompletion":4928,"completion":4928,"start":20977,"conditions":20978,"interventions":20979},"NCT00005989","R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer",[91],"2002-11",[8059],[20965],{"trials":20981,"activeCount":128},[],{"trials":20983,"activeCount":128},[],{"trials":20985,"activeCount":128},[],{"intervention":20987,"totalTrials":676,"cells":20988},"CC-5013",{"EARLY_PHASE1":20989,"PHASE1":20991,"PHASE2":20993,"PHASE3":21002,"PHASE4":21004,"NA":21006},{"trials":20990,"activeCount":128},[],{"trials":20992,"activeCount":128},[],{"trials":20994,"activeCount":128},[20995],{"nctId":20996,"briefTitle":20997,"status":104,"phases":20998,"primaryCompletion":3718,"start":20999,"enrollment":956,"conditions":21000,"interventions":21001},"NCT00166413","Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis",[91],"2005-04",[3654],[20987],{"trials":21003,"activeCount":128},[],{"trials":21005,"activeCount":128},[],{"trials":21007,"activeCount":128},[],{"intervention":6987,"totalTrials":676,"cells":21009},{"EARLY_PHASE1":21010,"PHASE1":21012,"PHASE2":21014,"PHASE3":21020,"PHASE4":21022,"NA":21024},{"trials":21011,"activeCount":128},[],{"trials":21013,"activeCount":128},[],{"trials":21015,"activeCount":128},[21016],{"nctId":6979,"briefTitle":6980,"status":134,"phases":21017,"primaryCompletion":1337,"completion":1337,"start":4300,"enrollment":1236,"conditions":21018,"interventions":21019},[90,91],[6983,6984,6985],[2577,6987,867],{"trials":21021,"activeCount":128},[],{"trials":21023,"activeCount":128},[],{"trials":21025,"activeCount":128},[],{"intervention":4406,"totalTrials":676,"cells":21027},{"EARLY_PHASE1":21028,"PHASE1":21030,"PHASE2":21032,"PHASE3":21038,"PHASE4":21040,"NA":21042},{"trials":21029,"activeCount":128},[],{"trials":21031,"activeCount":128},[],{"trials":21033,"activeCount":128},[21034],{"nctId":4396,"briefTitle":4397,"status":104,"phases":21035,"primaryCompletion":4399,"start":4400,"enrollment":1236,"conditions":21036,"interventions":21037},[91],[4402,1420],[4404,4405,4240,3324,3326,4406],{"trials":21039,"activeCount":128},[],{"trials":21041,"activeCount":128},[],{"trials":21043,"activeCount":128},[],{"intervention":21045,"totalTrials":676,"cells":21046},"Intravenous Thrombolysis",{"EARLY_PHASE1":21047,"PHASE1":21049,"PHASE2":21051,"PHASE3":21061,"PHASE4":21063,"NA":21065},{"trials":21048,"activeCount":128},[],{"trials":21050,"activeCount":128},[],{"trials":21052,"activeCount":128},[21053],{"nctId":21054,"briefTitle":21055,"status":134,"phases":21056,"primaryCompletion":905,"completion":905,"start":2620,"enrollment":676,"conditions":21057,"interventions":21060},"NCT01869478","Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke",[91],[21058,21059],"Stroke","Ischemic Stroke",[21045],{"trials":21062,"activeCount":128},[],{"trials":21064,"activeCount":128},[],{"trials":21066,"activeCount":128},[],{"intervention":21068,"totalTrials":676,"cells":21069},"Illuminate Cream",{"EARLY_PHASE1":21070,"PHASE1":21072,"PHASE2":21074,"PHASE3":21084,"PHASE4":21086,"NA":21088},{"trials":21071,"activeCount":128},[],{"trials":21073,"activeCount":128},[],{"trials":21075,"activeCount":128},[21076],{"nctId":21077,"briefTitle":21078,"status":104,"phases":21079,"primaryCompletion":16162,"completion":16162,"start":21080,"enrollment":6434,"conditions":21081,"interventions":21083},"NCT02730819","Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma",[91],"2016-05-15",[21082],"Melasma",[21068],{"trials":21085,"activeCount":128},[],{"trials":21087,"activeCount":128},[],{"trials":21089,"activeCount":128},[],{"intervention":21091,"totalTrials":676,"cells":21092},"Rimegepant 75 MG [Nurtec]",{"EARLY_PHASE1":21093,"PHASE1":21095,"PHASE2":21097,"PHASE3":21107,"PHASE4":21109,"NA":21111},{"trials":21094,"activeCount":128},[],{"trials":21096,"activeCount":128},[],{"trials":21098,"activeCount":128},[21099],{"nctId":21100,"briefTitle":21101,"status":104,"phases":21102,"primaryCompletion":21103,"completion":21104,"start":4656,"enrollment":1236,"conditions":21105,"interventions":21106},"NCT06221111","Comparison of Rimegepant and Placebo for Pain in IBS",[91],"2025-05-30","2025-06-03",[2885],[21091],{"trials":21108,"activeCount":128},[],{"trials":21110,"activeCount":128},[],{"trials":21112,"activeCount":128},[],{"intervention":21114,"totalTrials":676,"cells":21115},"Methylphenidate",{"EARLY_PHASE1":21116,"PHASE1":21118,"PHASE2":21120,"PHASE3":21128,"PHASE4":21130,"NA":21132},{"trials":21117,"activeCount":128},[],{"trials":21119,"activeCount":128},[],{"trials":21121,"activeCount":128},[21122],{"nctId":21123,"briefTitle":21124,"status":104,"phases":21125,"primaryCompletion":3717,"completion":4784,"start":4503,"enrollment":2678,"conditions":21126,"interventions":21127},"NCT00549640","Testing Methylphenidate for Smoking Abstinence",[91],[13450],[21114],{"trials":21129,"activeCount":128},[],{"trials":21131,"activeCount":128},[],{"trials":21133,"activeCount":128},[],{"intervention":7887,"totalTrials":676,"cells":21135},{"EARLY_PHASE1":21136,"PHASE1":21138,"PHASE2":21140,"PHASE3":21146,"PHASE4":21148,"NA":21150},{"trials":21137,"activeCount":128},[],{"trials":21139,"activeCount":128},[],{"trials":21141,"activeCount":128},[21142],{"nctId":7878,"briefTitle":7879,"status":104,"phases":21143,"primaryCompletion":7881,"completion":7882,"start":7883,"enrollment":342,"conditions":21144,"interventions":21145},[91],[4087,7885,6313,3439,3440,6317],[4090,7887],{"trials":21147,"activeCount":128},[],{"trials":21149,"activeCount":128},[],{"trials":21151,"activeCount":128},[],{"intervention":21153,"totalTrials":676,"cells":21154},"Oxazyme",{"EARLY_PHASE1":21155,"PHASE1":21157,"PHASE2":21159,"PHASE3":21167,"PHASE4":21169,"NA":21171},{"trials":21156,"activeCount":128},[],{"trials":21158,"activeCount":128},[],{"trials":21160,"activeCount":128},[21161],{"nctId":21162,"briefTitle":21163,"status":104,"phases":21164,"primaryCompletion":3899,"completion":1020,"start":6577,"enrollment":3002,"conditions":21165,"interventions":21166},"NCT01127087","Oxazyme in Patients With Hyperoxaluria",[90,91],[17052],[21153],{"trials":21168,"activeCount":128},[],{"trials":21170,"activeCount":128},[],{"trials":21172,"activeCount":128},[],{"intervention":6334,"totalTrials":676,"cells":21174},{"EARLY_PHASE1":21175,"PHASE1":21177,"PHASE2":21179,"PHASE3":21185,"PHASE4":21187,"NA":21189},{"trials":21176,"activeCount":128},[],{"trials":21178,"activeCount":128},[],{"trials":21180,"activeCount":128},[21181],{"nctId":6323,"briefTitle":6324,"status":134,"phases":21182,"primaryCompletion":6326,"completion":6327,"start":4007,"enrollment":676,"conditions":21183,"interventions":21184},[91],[6329,6330,6331,6332,6317],[4093,6334],{"trials":21186,"activeCount":128},[],{"trials":21188,"activeCount":128},[],{"trials":21190,"activeCount":128},[],{"intervention":4011,"totalTrials":676,"cells":21192},{"EARLY_PHASE1":21193,"PHASE1":21195,"PHASE2":21197,"PHASE3":21203,"PHASE4":21205,"NA":21207},{"trials":21194,"activeCount":128},[],{"trials":21196,"activeCount":128},[],{"trials":21198,"activeCount":128},[21199],{"nctId":4002,"briefTitle":4003,"status":104,"phases":21200,"primaryCompletion":4005,"completion":4006,"start":4007,"enrollment":31,"conditions":21201,"interventions":21202},[90,91],[4009,303],[305,4011,306],{"trials":21204,"activeCount":128},[],{"trials":21206,"activeCount":128},[],{"trials":21208,"activeCount":128},[],{"intervention":21210,"totalTrials":676,"cells":21211},"Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg\u002Feach breast\u002Fday",{"EARLY_PHASE1":21212,"PHASE1":21214,"PHASE2":21216,"PHASE3":21230,"PHASE4":21232,"NA":21234},{"trials":21213,"activeCount":128},[],{"trials":21215,"activeCount":128},[],{"trials":21217,"activeCount":128},[21218],{"nctId":21219,"briefTitle":21220,"status":134,"phases":21221,"primaryCompletion":21222,"completion":21222,"start":21223,"enrollment":430,"conditions":21224,"interventions":21228},"NCT04570956","Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk",[91],"2024-10-15","2021-07-26",[21225,21226,21227,30],"Breast Atypical Hyperplasia","Breast Lobular Carcinoma in Situ","Breast Atypical Lobular Hyperplasia",[21229,21210],"Tamoxifen",{"trials":21231,"activeCount":128},[],{"trials":21233,"activeCount":128},[],{"trials":21235,"activeCount":128},[],{"intervention":21237,"totalTrials":676,"cells":21238},"Pirfenidone",{"EARLY_PHASE1":21239,"PHASE1":21241,"PHASE2":21243,"PHASE3":21253,"PHASE4":21255,"NA":21257},{"trials":21240,"activeCount":128},[],{"trials":21242,"activeCount":128},[],{"trials":21244,"activeCount":128},[21245],{"nctId":21246,"briefTitle":21247,"status":104,"phases":21248,"primaryCompletion":5473,"start":21249,"enrollment":2555,"conditions":21250,"interventions":21252},"NCT00754780","Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1",[91],"2000-09",[21251],"Neurofibromatosis",[21237],{"trials":21254,"activeCount":128},[],{"trials":21256,"activeCount":128},[],{"trials":21258,"activeCount":128},[],{"intervention":21260,"totalTrials":676,"cells":21261},"ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin",{"EARLY_PHASE1":21262,"PHASE1":21264,"PHASE2":21266,"PHASE3":21275,"PHASE4":21277,"NA":21279},{"trials":21263,"activeCount":128},[],{"trials":21265,"activeCount":128},[],{"trials":21267,"activeCount":128},[21268],{"nctId":21269,"briefTitle":21270,"status":104,"phases":21271,"primaryCompletion":4786,"completion":4786,"start":7296,"enrollment":923,"conditions":21272,"interventions":21274},"NCT00166465","Stage IV Colorectal CA ALIMTA",[90,91],[21273],"Locally Advanced Unresectable or Stage IV Colorectal Cancer",[21260],{"trials":21276,"activeCount":128},[],{"trials":21278,"activeCount":128},[],{"trials":21280,"activeCount":128},[],{"intervention":12718,"totalTrials":676,"cells":21282},{"EARLY_PHASE1":21283,"PHASE1":21285,"PHASE2":21287,"PHASE3":21293,"PHASE4":21295,"NA":21297},{"trials":21284,"activeCount":128},[],{"trials":21286,"activeCount":128},[],{"trials":21288,"activeCount":128},[21289],{"nctId":12711,"briefTitle":12712,"status":104,"phases":21290,"primaryCompletion":474,"completion":474,"start":12714,"enrollment":173,"conditions":21291,"interventions":21292},[91],[12716],[12718,2724],{"trials":21294,"activeCount":128},[],{"trials":21296,"activeCount":128},[],{"trials":21298,"activeCount":128},[],{"intervention":3712,"totalTrials":676,"cells":21300},{"EARLY_PHASE1":21301,"PHASE1":21303,"PHASE2":21305,"PHASE3":21311,"PHASE4":21313,"NA":21315},{"trials":21302,"activeCount":128},[],{"trials":21304,"activeCount":128},[],{"trials":21306,"activeCount":128},[21307],{"nctId":3705,"briefTitle":3706,"status":104,"phases":21308,"primaryCompletion":3708,"completion":3709,"start":3671,"enrollment":558,"conditions":21309,"interventions":21310},[91],[303,3447],[57,3712],{"trials":21312,"activeCount":128},[],{"trials":21314,"activeCount":128},[],{"trials":21316,"activeCount":128},[],{"intervention":10872,"totalTrials":676,"cells":21318},{"EARLY_PHASE1":21319,"PHASE1":21321,"PHASE2":21323,"PHASE3":21329,"PHASE4":21331,"NA":21333},{"trials":21320,"activeCount":128},[],{"trials":21322,"activeCount":128},[],{"trials":21324,"activeCount":128},[21325],{"nctId":10863,"briefTitle":10864,"status":104,"phases":21326,"primaryCompletion":10866,"completion":10867,"start":4885,"enrollment":355,"conditions":21327,"interventions":21328},[91],[10869,6315,3523],[10871,10872],{"trials":21330,"activeCount":128},[],{"trials":21332,"activeCount":128},[],{"trials":21334,"activeCount":128},[],{"intervention":21336,"totalTrials":676,"cells":21337},"Mechlorethamine 0.016% Top Gel",{"EARLY_PHASE1":21338,"PHASE1":21340,"PHASE2":21342,"PHASE3":21351,"PHASE4":21353,"NA":21355},{"trials":21339,"activeCount":128},[],{"trials":21341,"activeCount":128},[],{"trials":21343,"activeCount":128},[21344],{"nctId":21345,"briefTitle":21346,"status":104,"phases":21347,"primaryCompletion":21348,"completion":21348,"start":12845,"enrollment":218,"conditions":21349,"interventions":21350},"NCT03417141","Valchlor in the Treatment of Lichen Planopilaris",[91],"2019-08-30",[8148],[21336],{"trials":21352,"activeCount":128},[],{"trials":21354,"activeCount":128},[],{"trials":21356,"activeCount":128},[],{"intervention":21358,"totalTrials":676,"cells":21359},"Ponatinib Hydrochloride",{"EARLY_PHASE1":21360,"PHASE1":21362,"PHASE2":21364,"PHASE3":21373,"PHASE4":21375,"NA":21377},{"trials":21361,"activeCount":128},[],{"trials":21363,"activeCount":128},[],{"trials":21365,"activeCount":128},[21366],{"nctId":21367,"briefTitle":21368,"status":104,"phases":21369,"primaryCompletion":15684,"completion":16037,"start":2665,"enrollment":218,"conditions":21370,"interventions":21372},"NCT02265341","Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions",[91],[21371],"Malignant Hepatobiliary Neoplasm",[21358],{"trials":21374,"activeCount":128},[],{"trials":21376,"activeCount":128},[],{"trials":21378,"activeCount":128},[],{"intervention":21380,"totalTrials":676,"cells":21381},"Acomprosate",{"EARLY_PHASE1":21382,"PHASE1":21384,"PHASE2":21386,"PHASE3":21397,"PHASE4":21399,"NA":21401},{"trials":21383,"activeCount":128},[],{"trials":21385,"activeCount":128},[],{"trials":21387,"activeCount":128},[21388],{"nctId":21389,"briefTitle":21390,"status":104,"phases":21391,"primaryCompletion":21392,"completion":21392,"start":21393,"enrollment":218,"conditions":21394,"interventions":21396},"NCT04287920","Acamprosate Safe to Use in Individuals With Liver Disease.",[91],"2022-01-05","2020-09-21",[21395],"Alcohol-related Liver Disease",[21380],{"trials":21398,"activeCount":128},[],{"trials":21400,"activeCount":128},[],{"trials":21402,"activeCount":128},[],{"intervention":21404,"totalTrials":676,"cells":21405},"acetylcysteine",{"EARLY_PHASE1":21406,"PHASE1":21408,"PHASE2":21410,"PHASE3":21503,"PHASE4":21505,"NA":21507},{"trials":21407,"activeCount":128},[],{"trials":21409,"activeCount":128},[],{"trials":21411,"activeCount":128},[21412],{"nctId":21413,"briefTitle":21414,"status":104,"phases":21415,"primaryCompletion":21416,"completion":21417,"start":7317,"enrollment":885,"conditions":21418,"interventions":21502},"NCT02123511","Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy",[91],"2016-03-22","2018-07-02",[21419,21420,21421,21422,21423,21424,21425,21426,21427,21428,21429,21430,21431,21432,21433,21434,21435,21436,21437,21438,21439,21440,21441,21442,21443,21444,21445,21446,21447,21448,21449,21450,21451,21452,21453,21454,21455,21456,21457,21458,21459,21460,21461,21462,21463,21464,21465,21466,21467,21468,21469,21470,21471,21472,21473,21474,21475,21476,21477,21478,21479,21480,21481,21482,21483,21484,21485,21486,21487,21488,21489,21490,21491,21492,21493,21494,21495,21496,21497,21498,21499,21500,21501],"Mucositis","Oral Complications","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage I Adenoid Cystic Carcinoma of the Oral Cavity","Stage I Basal Cell Carcinoma of the Lip","Stage I Lymphoepithelioma of the Nasopharynx","Stage I Lymphoepithelioma of the Oropharynx","Stage I Mucoepidermoid Carcinoma of the Oral Cavity","Stage I Salivary Gland Cancer","Stage I Squamous Cell Carcinoma of the Larynx","Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage I Squamous Cell Carcinoma of the Nasopharynx","Stage I Squamous Cell Carcinoma of the Oropharynx","Stage I Verrucous Carcinoma of the Larynx","Stage I Verrucous Carcinoma of the Oral Cavity","Stage II Adenoid Cystic Carcinoma of the Oral Cavity","Stage II Basal Cell Carcinoma of the Lip","Stage II Lymphoepithelioma of the Nasopharynx","Stage II Lymphoepithelioma of the Oropharynx","Stage II Mucoepidermoid Carcinoma of the Oral Cavity","Stage II Salivary Gland Cancer","Stage II Squamous Cell Carcinoma of the Larynx","Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage II Squamous Cell Carcinoma of the Nasopharynx","Stage II Squamous Cell Carcinoma of the Oropharynx","Stage II Verrucous Carcinoma of the Larynx","Stage II Verrucous Carcinoma of the Oral Cavity","Stage III Adenoid Cystic Carcinoma of the Oral Cavity","Stage III Basal Cell Carcinoma of the Lip","Stage III Lymphoepithelioma of the Nasopharynx","Stage III Lymphoepithelioma of the Oropharynx","Stage III Mucoepidermoid Carcinoma of the Oral Cavity","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity","Stage IVA Basal Cell Carcinoma of the Lip","Stage IVA Lymphoepithelioma of the Oropharynx","Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity","Stage IVB Basal Cell Carcinoma of the Lip","Stage IVB Lymphoepithelioma of the Oropharynx","Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity","Stage IVC Basal Cell Carcinoma of the Lip","Stage IVC Lymphoepithelioma of the Oropharynx","Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer",[21404],{"trials":21504,"activeCount":128},[],{"trials":21506,"activeCount":128},[],{"trials":21508,"activeCount":128},[],{"intervention":5567,"totalTrials":676,"cells":21510},{"EARLY_PHASE1":21511,"PHASE1":21513,"PHASE2":21515,"PHASE3":21521,"PHASE4":21523,"NA":21525},{"trials":21512,"activeCount":128},[],{"trials":21514,"activeCount":128},[],{"trials":21516,"activeCount":128},[21517],{"nctId":5559,"briefTitle":5560,"status":134,"phases":21518,"primaryCompletion":5562,"completion":5562,"start":5563,"enrollment":370,"conditions":21519,"interventions":21520},[91],[5565,614,618,622,624,207,633,637],[5567,346],{"trials":21522,"activeCount":128},[],{"trials":21524,"activeCount":128},[],{"trials":21526,"activeCount":128},[],{"intervention":21528,"totalTrials":676,"cells":21529},"Pazopanib Hydrochloride",{"EARLY_PHASE1":21530,"PHASE1":21532,"PHASE2":21534,"PHASE3":21551,"PHASE4":21553,"NA":21555},{"trials":21531,"activeCount":128},[],{"trials":21533,"activeCount":128},[],{"trials":21535,"activeCount":128},[21536],{"nctId":21537,"briefTitle":21538,"status":104,"phases":21539,"primaryCompletion":10280,"completion":21540,"start":21541,"enrollment":956,"conditions":21542,"interventions":21550},"NCT01767636","Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer",[91],"2021-01-20","2013-05-16",[21543,21544,21545,21546,21547,21548,3343,21549,3347],"Carcinoma of the Collecting Ducts of Bellini","Chromophobe Renal Cell Carcinoma","Kidney Medullary Carcinoma","Kidney Oncocytoma","Metastatic Renal Cell Cancer","Papillary Renal Cell Carcinoma","Sarcomatoid Renal Cell Carcinoma",[21528],{"trials":21552,"activeCount":128},[],{"trials":21554,"activeCount":128},[],{"trials":21556,"activeCount":128},[],{"intervention":21558,"totalTrials":676,"cells":21559},"Pegylated Interferon Alpha2b",{"EARLY_PHASE1":21560,"PHASE1":21562,"PHASE2":21564,"PHASE3":21574,"PHASE4":21576,"NA":21578},{"trials":21561,"activeCount":128},[],{"trials":21563,"activeCount":128},[],{"trials":21565,"activeCount":128},[21566],{"nctId":21567,"briefTitle":21568,"status":134,"phases":21569,"primaryCompletion":3899,"completion":3899,"start":5034,"enrollment":370,"conditions":21570,"interventions":21573},"NCT00588146","Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia",[91],[10869,21571,21572],"Liver Disease","Hypoxemia",[21558],{"trials":21575,"activeCount":128},[],{"trials":21577,"activeCount":128},[],{"trials":21579,"activeCount":128},[],{"intervention":21581,"totalTrials":676,"cells":21582},"AZD4831 Oral Myeloperoxidase Inhibitor",{"EARLY_PHASE1":21583,"PHASE1":21585,"PHASE2":21587,"PHASE3":21596,"PHASE4":21598,"NA":21600},{"trials":21584,"activeCount":128},[],{"trials":21586,"activeCount":128},[],{"trials":21588,"activeCount":128},[21589],{"nctId":21590,"briefTitle":21591,"status":104,"phases":21592,"primaryCompletion":21593,"completion":12074,"start":2280,"enrollment":729,"conditions":21594,"interventions":21595},"NCT03611153","Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)",[90,91],"2022-02-11",[27],[21581],{"trials":21597,"activeCount":128},[],{"trials":21599,"activeCount":128},[],{"trials":21601,"activeCount":128},[],{"intervention":4035,"totalTrials":676,"cells":21603},{"EARLY_PHASE1":21604,"PHASE1":21606,"PHASE2":21608,"PHASE3":21614,"PHASE4":21616,"NA":21618},{"trials":21605,"activeCount":128},[],{"trials":21607,"activeCount":128},[],{"trials":21609,"activeCount":128},[21610],{"nctId":4027,"briefTitle":4028,"status":104,"phases":21611,"primaryCompletion":4030,"completion":4031,"start":4032,"enrollment":313,"conditions":21612,"interventions":21613},[90,91],[3690],[4035,3539,3514],{"trials":21615,"activeCount":128},[],{"trials":21617,"activeCount":128},[],{"trials":21619,"activeCount":128},[],{"intervention":21621,"totalTrials":676,"cells":21622},"Eptinezumab",{"EARLY_PHASE1":21623,"PHASE1":21625,"PHASE2":21627,"PHASE3":21638,"PHASE4":21640,"NA":21642},{"trials":21624,"activeCount":128},[],{"trials":21626,"activeCount":128},[],{"trials":21628,"activeCount":128},[21629],{"nctId":21630,"briefTitle":21631,"status":1413,"phases":21632,"primaryCompletion":21633,"completion":21633,"start":21634,"enrollment":128,"conditions":21635,"interventions":21637},"NCT05937152","A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy",[91],"2025-11","2025-01",[21636],"Diabetic Polyneuropathy",[21621],{"trials":21639,"activeCount":128},[],{"trials":21641,"activeCount":128},[],{"trials":21643,"activeCount":128},[],{"intervention":3038,"totalTrials":676,"cells":21645},{"EARLY_PHASE1":21646,"PHASE1":21648,"PHASE2":21650,"PHASE3":21656,"PHASE4":21658,"NA":21660},{"trials":21647,"activeCount":128},[],{"trials":21649,"activeCount":128},[],{"trials":21651,"activeCount":128},[21652],{"nctId":3029,"briefTitle":3030,"status":104,"phases":21653,"primaryCompletion":3032,"completion":3032,"start":3033,"enrollment":3034,"conditions":21654,"interventions":21655},[91],[3036],[3038,2929],{"trials":21657,"activeCount":128},[],{"trials":21659,"activeCount":128},[],{"trials":21661,"activeCount":128},[],{"intervention":21663,"totalTrials":676,"cells":21664},"Islet Transplant",{"EARLY_PHASE1":21665,"PHASE1":21667,"PHASE2":21669,"PHASE3":21678,"PHASE4":21680,"NA":21682},{"trials":21666,"activeCount":128},[],{"trials":21668,"activeCount":128},[],{"trials":21670,"activeCount":128},[21671],{"nctId":21672,"briefTitle":21673,"status":134,"phases":21674,"primaryCompletion":3033,"completion":3033,"start":3662,"enrollment":224,"conditions":21675,"interventions":21677},"NCT00437398","Islet Transplantation for Type 1 Diabetes Mellitus",[90,91],[21676],"Type 1 Diabetes Mellitus",[21663],{"trials":21679,"activeCount":128},[],{"trials":21681,"activeCount":128},[],{"trials":21683,"activeCount":128},[],{"intervention":21685,"totalTrials":676,"cells":21686},"Rimegepant",{"EARLY_PHASE1":21687,"PHASE1":21689,"PHASE2":21691,"PHASE3":21701,"PHASE4":21703,"NA":21705},{"trials":21688,"activeCount":128},[],{"trials":21690,"activeCount":128},[],{"trials":21692,"activeCount":128},[21693],{"nctId":21694,"briefTitle":21695,"status":104,"phases":21696,"primaryCompletion":1865,"completion":1865,"start":21697,"enrollment":173,"conditions":21698,"interventions":21700},"NCT05264714","Cluster Headache Treatment With Rimegepant",[91],"2022-09-07",[21699],"Cluster Headache",[21685],{"trials":21702,"activeCount":128},[],{"trials":21704,"activeCount":128},[],{"trials":21706,"activeCount":128},[],{"intervention":21708,"totalTrials":676,"cells":21709},"EC-17",{"EARLY_PHASE1":21710,"PHASE1":21712,"PHASE2":21714,"PHASE3":21722,"PHASE4":21724,"NA":21726},{"trials":21711,"activeCount":128},[],{"trials":21713,"activeCount":128},[],{"trials":21715,"activeCount":128},[21716],{"nctId":21717,"briefTitle":21718,"status":134,"phases":21719,"primaryCompletion":5417,"completion":5417,"start":3033,"enrollment":97,"conditions":21720,"interventions":21721},"NCT01511055","Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand",[91],[3321],[21708],{"trials":21723,"activeCount":128},[],{"trials":21725,"activeCount":128},[],{"trials":21727,"activeCount":128},[],{"intervention":21729,"totalTrials":676,"cells":21730},"Lactose powder",{"EARLY_PHASE1":21731,"PHASE1":21733,"PHASE2":21735,"PHASE3":21745,"PHASE4":21747,"NA":21749},{"trials":21732,"activeCount":128},[],{"trials":21734,"activeCount":128},[],{"trials":21736,"activeCount":128},[21737],{"nctId":21738,"briefTitle":21739,"status":104,"phases":21740,"primaryCompletion":905,"completion":905,"start":3033,"enrollment":3138,"conditions":21741,"interventions":21743},"NCT01504867","LIPS-A: Lung Injury Prevention Study With Aspirin",[91],[21742],"Acute Respiratory Distress Syndrome",[21744,21729],"Aspirin",{"trials":21746,"activeCount":128},[],{"trials":21748,"activeCount":128},[],{"trials":21750,"activeCount":128},[],{"intervention":7896,"totalTrials":676,"cells":21752},{"EARLY_PHASE1":21753,"PHASE1":21755,"PHASE2":21757,"PHASE3":21763,"PHASE4":21765,"NA":21767},{"trials":21754,"activeCount":128},[],{"trials":21756,"activeCount":128},[],{"trials":21758,"activeCount":128},[21759],{"nctId":7889,"briefTitle":7890,"status":104,"phases":21760,"primaryCompletion":4432,"completion":7892,"start":7893,"enrollment":885,"conditions":21761,"interventions":21762},[91],[6317],[4090,7896,7897],{"trials":21764,"activeCount":128},[],{"trials":21766,"activeCount":128},[],{"trials":21768,"activeCount":128},[],{"intervention":21770,"totalTrials":676,"cells":21771},"dolastatin 10",{"EARLY_PHASE1":21772,"PHASE1":21774,"PHASE2":21776,"PHASE3":21787,"PHASE4":21789,"NA":21791},{"trials":21773,"activeCount":128},[],{"trials":21775,"activeCount":128},[],{"trials":21777,"activeCount":128},[21778],{"nctId":21779,"briefTitle":21780,"status":104,"phases":21781,"primaryCompletion":21782,"completion":4784,"start":21783,"enrollment":729,"conditions":21784,"interventions":21786},"NCT00003914","Dolastatin 10 in Treating Patients With Advanced Kidney Cancer",[91],"2002-08","1999-08",[21785],"Kidney Cancer",[21770],{"trials":21788,"activeCount":128},[],{"trials":21790,"activeCount":128},[],{"trials":21792,"activeCount":128},[],{"intervention":5422,"totalTrials":676,"cells":21794},{"EARLY_PHASE1":21795,"PHASE1":21797,"PHASE2":21799,"PHASE3":21805,"PHASE4":21807,"NA":21809},{"trials":21796,"activeCount":128},[],{"trials":21798,"activeCount":128},[],{"trials":21800,"activeCount":128},[21801],{"nctId":5414,"briefTitle":5415,"status":104,"phases":21802,"primaryCompletion":5417,"completion":5418,"start":4810,"enrollment":3002,"conditions":21803,"interventions":21804},[90,91],[5420,443,3574,3575,3577],[5408,3553,5422,5423,5424,5425,3636,5426],{"trials":21806,"activeCount":128},[],{"trials":21808,"activeCount":128},[],{"trials":21810,"activeCount":128},[],{"intervention":5426,"totalTrials":676,"cells":21812},{"EARLY_PHASE1":21813,"PHASE1":21815,"PHASE2":21817,"PHASE3":21823,"PHASE4":21825,"NA":21827},{"trials":21814,"activeCount":128},[],{"trials":21816,"activeCount":128},[],{"trials":21818,"activeCount":128},[21819],{"nctId":5414,"briefTitle":5415,"status":104,"phases":21820,"primaryCompletion":5417,"completion":5418,"start":4810,"enrollment":3002,"conditions":21821,"interventions":21822},[90,91],[5420,443,3574,3575,3577],[5408,3553,5422,5423,5424,5425,3636,5426],{"trials":21824,"activeCount":128},[],{"trials":21826,"activeCount":128},[],{"trials":21828,"activeCount":128},[],{"intervention":19015,"totalTrials":676,"cells":21830},{"EARLY_PHASE1":21831,"PHASE1":21833,"PHASE2":21835,"PHASE3":21841,"PHASE4":21843,"NA":21845},{"trials":21832,"activeCount":128},[],{"trials":21834,"activeCount":128},[],{"trials":21836,"activeCount":128},[21837],{"nctId":19010,"briefTitle":19011,"status":104,"phases":21838,"primaryCompletion":2665,"completion":2665,"start":6577,"enrollment":173,"conditions":21839,"interventions":21840},[91],[11692,6505],[18995,19015],{"trials":21842,"activeCount":128},[],{"trials":21844,"activeCount":128},[],{"trials":21846,"activeCount":128},[],{"intervention":21848,"totalTrials":676,"cells":21849},"Polyphenon E",{"EARLY_PHASE1":21850,"PHASE1":21852,"PHASE2":21854,"PHASE3":21863,"PHASE4":21865,"NA":21867},{"trials":21851,"activeCount":128},[],{"trials":21853,"activeCount":128},[],{"trials":21855,"activeCount":128},[21856],{"nctId":21857,"briefTitle":21858,"status":104,"phases":21859,"primaryCompletion":6577,"completion":894,"start":4464,"enrollment":21860,"conditions":21861,"interventions":21862},"NCT00262743","Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia",[90,91],73,[3549],[21848],{"trials":21864,"activeCount":128},[],{"trials":21866,"activeCount":128},[],{"trials":21868,"activeCount":128},[],{"intervention":21870,"totalTrials":676,"cells":21871},"Donepezil",{"EARLY_PHASE1":21872,"PHASE1":21874,"PHASE2":21876,"PHASE3":21884,"PHASE4":21886,"NA":21888},{"trials":21873,"activeCount":128},[],{"trials":21875,"activeCount":128},[],{"trials":21877,"activeCount":128},[21878],{"nctId":21879,"briefTitle":21880,"status":104,"phases":21881,"primaryCompletion":16249,"completion":16249,"start":3643,"enrollment":31,"conditions":21882,"interventions":21883},"NCT00805792","Mayo Acute Stroke Trial for Enhancing Recovery",[91],[21059],[21870],{"trials":21885,"activeCount":128},[],{"trials":21887,"activeCount":128},[],{"trials":21889,"activeCount":128},[],{"intervention":21891,"totalTrials":676,"cells":21892},"Ga-68 PSMA-11",{"EARLY_PHASE1":21893,"PHASE1":21895,"PHASE2":21897,"PHASE3":21907,"PHASE4":21909,"NA":21911},{"trials":21894,"activeCount":128},[],{"trials":21896,"activeCount":128},[],{"trials":21898,"activeCount":128},[21899],{"nctId":21900,"briefTitle":21901,"status":104,"phases":21902,"primaryCompletion":4745,"completion":4745,"start":21903,"enrollment":1197,"conditions":21904,"interventions":21906},"NCT06521775","An Investigational Scan (Ga-68 PSMA-11 PET\u002FCT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma",[91],"2024-08-12",[21905],"Metastatic Adenoid Cystic Carcinoma",[21891],{"trials":21908,"activeCount":128},[],{"trials":21910,"activeCount":128},[],{"trials":21912,"activeCount":128},[],{"intervention":21914,"totalTrials":676,"cells":21915},"asimadoline",{"EARLY_PHASE1":21916,"PHASE1":21918,"PHASE2":21920,"PHASE3":21928,"PHASE4":21930,"NA":21932},{"trials":21917,"activeCount":128},[],{"trials":21919,"activeCount":128},[],{"trials":21921,"activeCount":128},[21922],{"nctId":21923,"briefTitle":21924,"status":104,"phases":21925,"primaryCompletion":11897,"completion":11897,"start":4391,"enrollment":712,"conditions":21926,"interventions":21927},"NCT00955994","Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome",[91],[2885],[21914],{"trials":21929,"activeCount":128},[],{"trials":21931,"activeCount":128},[],{"trials":21933,"activeCount":128},[],{"intervention":8061,"totalTrials":676,"cells":21935},{"EARLY_PHASE1":21936,"PHASE1":21938,"PHASE2":21940,"PHASE3":21946,"PHASE4":21948,"NA":21950},{"trials":21937,"activeCount":128},[],{"trials":21939,"activeCount":128},[],{"trials":21941,"activeCount":128},[21942],{"nctId":8054,"briefTitle":8055,"status":104,"phases":21943,"primaryCompletion":4503,"completion":8057,"start":4399,"enrollment":6434,"conditions":21944,"interventions":21945},[91],[8059],[8061,8032,8061],{"trials":21947,"activeCount":128},[],{"trials":21949,"activeCount":128},[],{"trials":21951,"activeCount":128},[],{"intervention":21953,"totalTrials":676,"cells":21954},"Fluticasone",{"EARLY_PHASE1":21955,"PHASE1":21957,"PHASE2":21959,"PHASE3":21967,"PHASE4":21969,"NA":21971},{"trials":21956,"activeCount":128},[],{"trials":21958,"activeCount":128},[],{"trials":21960,"activeCount":128},[21961],{"nctId":21962,"briefTitle":21963,"status":104,"phases":21964,"primaryCompletion":13184,"completion":13184,"start":5280,"enrollment":7658,"conditions":21965,"interventions":21966},"NCT00275561","Topical Steroid Treatment for Eosinophilic Esophagitis",[91],[12979],[21953],{"trials":21968,"activeCount":128},[],{"trials":21970,"activeCount":128},[],{"trials":21972,"activeCount":128},[],{"intervention":4437,"totalTrials":676,"cells":21974},{"EARLY_PHASE1":21975,"PHASE1":21977,"PHASE2":21979,"PHASE3":21985,"PHASE4":21987,"NA":21989},{"trials":21976,"activeCount":128},[],{"trials":21978,"activeCount":128},[],{"trials":21980,"activeCount":128},[21981],{"nctId":4428,"briefTitle":4429,"status":104,"phases":21982,"primaryCompletion":4431,"completion":4431,"start":4432,"enrollment":173,"conditions":21983,"interventions":21984},[91],[4434,4435,614,645],[536,4089,4091,540,4437],{"trials":21986,"activeCount":128},[],{"trials":21988,"activeCount":128},[],{"trials":21990,"activeCount":128},[],{"intervention":21992,"totalTrials":676,"cells":21993},"RAD001",{"EARLY_PHASE1":21994,"PHASE1":21996,"PHASE2":21998,"PHASE3":22010,"PHASE4":22012,"NA":22014},{"trials":21995,"activeCount":128},[],{"trials":21997,"activeCount":128},[],{"trials":21999,"activeCount":128},[22000],{"nctId":22001,"briefTitle":22002,"status":104,"phases":22003,"primaryCompletion":22004,"completion":22005,"start":22006,"enrollment":17730,"conditions":22007,"interventions":22008},"NCT00474929","Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma",[90,91],"2011-11-05","2019-08-08","2007-08-29",[1419,3665],[21992,22009],"Sorafenib",{"trials":22011,"activeCount":128},[],{"trials":22013,"activeCount":128},[],{"trials":22015,"activeCount":128},[],{"intervention":22009,"totalTrials":676,"cells":22017},{"EARLY_PHASE1":22018,"PHASE1":22020,"PHASE2":22022,"PHASE3":22028,"PHASE4":22030,"NA":22032},{"trials":22019,"activeCount":128},[],{"trials":22021,"activeCount":128},[],{"trials":22023,"activeCount":128},[22024],{"nctId":22001,"briefTitle":22002,"status":104,"phases":22025,"primaryCompletion":22004,"completion":22005,"start":22006,"enrollment":17730,"conditions":22026,"interventions":22027},[90,91],[1419,3665],[21992,22009],{"trials":22029,"activeCount":128},[],{"trials":22031,"activeCount":128},[],{"trials":22033,"activeCount":128},[],{"intervention":7001,"totalTrials":676,"cells":22035},{"EARLY_PHASE1":22036,"PHASE1":22038,"PHASE2":22040,"PHASE3":22046,"PHASE4":22048,"NA":22050},{"trials":22037,"activeCount":128},[],{"trials":22039,"activeCount":128},[],{"trials":22041,"activeCount":128},[22042],{"nctId":6993,"briefTitle":6994,"status":134,"phases":22043,"primaryCompletion":6996,"completion":6996,"start":6997,"enrollment":342,"conditions":22044,"interventions":22045},[90,91],[6999],[7001,791],{"trials":22047,"activeCount":128},[],{"trials":22049,"activeCount":128},[],{"trials":22051,"activeCount":128},[],{"intervention":22053,"totalTrials":676,"cells":22054},"Exenatide SR",{"EARLY_PHASE1":22055,"PHASE1":22057,"PHASE2":22059,"PHASE3":22070,"PHASE4":22072,"NA":22074},{"trials":22056,"activeCount":128},[],{"trials":22058,"activeCount":128},[],{"trials":22060,"activeCount":128},[22061],{"nctId":22062,"briefTitle":22063,"status":104,"phases":22064,"primaryCompletion":22065,"completion":22065,"start":22066,"enrollment":476,"conditions":22067,"interventions":22069},"NCT03961256","Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation",[91],"2021-10-18","2019-05-09",[22068],"Pre Diabetes",[22053],{"trials":22071,"activeCount":128},[],{"trials":22073,"activeCount":128},[],{"trials":22075,"activeCount":128},[],{"intervention":6375,"totalTrials":676,"cells":22077},{"EARLY_PHASE1":22078,"PHASE1":22080,"PHASE2":22082,"PHASE3":22088,"PHASE4":22090,"NA":22092},{"trials":22079,"activeCount":128},[],{"trials":22081,"activeCount":128},[],{"trials":22083,"activeCount":128},[22084],{"nctId":6362,"briefTitle":6363,"status":104,"phases":22085,"primaryCompletion":3661,"completion":6365,"start":2573,"enrollment":6366,"conditions":22086,"interventions":22087},[91],[6368,6369,6370,6371,6372],[6374,6375,6376,4557,6377],{"trials":22089,"activeCount":128},[],{"trials":22091,"activeCount":128},[],{"trials":22093,"activeCount":128},[],{"intervention":22095,"totalTrials":676,"cells":22096},"Treprostinil",{"EARLY_PHASE1":22097,"PHASE1":22099,"PHASE2":22101,"PHASE3":22112,"PHASE4":22114,"NA":22116},{"trials":22098,"activeCount":128},[],{"trials":22100,"activeCount":128},[],{"trials":22102,"activeCount":128},[22103],{"nctId":22104,"briefTitle":22105,"status":104,"phases":22106,"primaryCompletion":22107,"completion":22107,"start":22108,"enrollment":34,"conditions":22109,"interventions":22111},"NCT05564637","A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension",[91],"2024-10-30","2023-03-13",[13385,6809,22110],"Healthy Adults",[22095],{"trials":22113,"activeCount":128},[],{"trials":22115,"activeCount":128},[],{"trials":22117,"activeCount":128},[],{"intervention":8576,"totalTrials":676,"cells":22119},{"EARLY_PHASE1":22120,"PHASE1":22122,"PHASE2":22124,"PHASE3":22130,"PHASE4":22132,"NA":22134},{"trials":22121,"activeCount":128},[],{"trials":22123,"activeCount":128},[],{"trials":22125,"activeCount":128},[22126],{"nctId":8569,"briefTitle":8570,"status":104,"phases":22127,"primaryCompletion":8572,"completion":8572,"start":8573,"enrollment":120,"conditions":22128,"interventions":22129},[91],[5061,5063],[5127,8576],{"trials":22131,"activeCount":128},[],{"trials":22133,"activeCount":128},[],{"trials":22135,"activeCount":128},[],{"intervention":22137,"totalTrials":676,"cells":22138},"Botulinum-A toxin",{"EARLY_PHASE1":22139,"PHASE1":22141,"PHASE2":22143,"PHASE3":22153,"PHASE4":22155,"NA":22157},{"trials":22140,"activeCount":128},[],{"trials":22142,"activeCount":128},[],{"trials":22144,"activeCount":128},[22145],{"nctId":22146,"briefTitle":22147,"status":104,"phases":22148,"primaryCompletion":5033,"completion":5033,"start":5515,"enrollment":558,"conditions":22149,"interventions":22151},"NCT00583219","Botulin-A Toxin Instillations and Overactive Bladder",[90,91],[14934,22150,17756],"Detrusor Instability",[22137,22152],"Dimethyl sulfoxide",{"trials":22154,"activeCount":128},[],{"trials":22156,"activeCount":128},[],{"trials":22158,"activeCount":128},[],{"intervention":22152,"totalTrials":676,"cells":22160},{"EARLY_PHASE1":22161,"PHASE1":22163,"PHASE2":22165,"PHASE3":22171,"PHASE4":22173,"NA":22175},{"trials":22162,"activeCount":128},[],{"trials":22164,"activeCount":128},[],{"trials":22166,"activeCount":128},[22167],{"nctId":22146,"briefTitle":22147,"status":104,"phases":22168,"primaryCompletion":5033,"completion":5033,"start":5515,"enrollment":558,"conditions":22169,"interventions":22170},[90,91],[14934,22150,17756],[22137,22152],{"trials":22172,"activeCount":128},[],{"trials":22174,"activeCount":128},[],{"trials":22176,"activeCount":128},[],{"intervention":7807,"totalTrials":676,"cells":22178},{"EARLY_PHASE1":22179,"PHASE1":22181,"PHASE2":22183,"PHASE3":22189,"PHASE4":22191,"NA":22193},{"trials":22180,"activeCount":128},[],{"trials":22182,"activeCount":128},[],{"trials":22184,"activeCount":128},[22185],{"nctId":7796,"briefTitle":7797,"status":104,"phases":22186,"primaryCompletion":3700,"completion":3700,"start":7799,"enrollment":3560,"conditions":22187,"interventions":22188},[91],[189,7801,7802,7803,7804,7805],[4718,7807,7808,7809],{"trials":22190,"activeCount":128},[],{"trials":22192,"activeCount":128},[],{"trials":22194,"activeCount":128},[],{"intervention":7808,"totalTrials":676,"cells":22196},{"EARLY_PHASE1":22197,"PHASE1":22199,"PHASE2":22201,"PHASE3":22207,"PHASE4":22209,"NA":22211},{"trials":22198,"activeCount":128},[],{"trials":22200,"activeCount":128},[],{"trials":22202,"activeCount":128},[22203],{"nctId":7796,"briefTitle":7797,"status":104,"phases":22204,"primaryCompletion":3700,"completion":3700,"start":7799,"enrollment":3560,"conditions":22205,"interventions":22206},[91],[189,7801,7802,7803,7804,7805],[4718,7807,7808,7809],{"trials":22208,"activeCount":128},[],{"trials":22210,"activeCount":128},[],{"trials":22212,"activeCount":128},[],{"intervention":7809,"totalTrials":676,"cells":22214},{"EARLY_PHASE1":22215,"PHASE1":22217,"PHASE2":22219,"PHASE3":22225,"PHASE4":22227,"NA":22229},{"trials":22216,"activeCount":128},[],{"trials":22218,"activeCount":128},[],{"trials":22220,"activeCount":128},[22221],{"nctId":7796,"briefTitle":7797,"status":104,"phases":22222,"primaryCompletion":3700,"completion":3700,"start":7799,"enrollment":3560,"conditions":22223,"interventions":22224},[91],[189,7801,7802,7803,7804,7805],[4718,7807,7808,7809],{"trials":22226,"activeCount":128},[],{"trials":22228,"activeCount":128},[],{"trials":22230,"activeCount":128},[],{"intervention":22232,"totalTrials":676,"cells":22233},"Alfuzosin",{"EARLY_PHASE1":22234,"PHASE1":22236,"PHASE2":22238,"PHASE3":22247,"PHASE4":22249,"NA":22251},{"trials":22235,"activeCount":128},[],{"trials":22237,"activeCount":128},[],{"trials":22239,"activeCount":128},[22240],{"nctId":22241,"briefTitle":22242,"status":104,"phases":22243,"primaryCompletion":22244,"completion":22244,"start":12007,"enrollment":10918,"conditions":22245,"interventions":22246},"NCT01834729","Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions",[91],"2017-09-06",[6504],[22232],{"trials":22248,"activeCount":128},[],{"trials":22250,"activeCount":128},[],{"trials":22252,"activeCount":128},[],{"intervention":22254,"totalTrials":676,"cells":22255},"Ropeginterferon Alfa-2B",{"EARLY_PHASE1":22256,"PHASE1":22258,"PHASE2":22260,"PHASE3":22270,"PHASE4":22272,"NA":22274},{"trials":22257,"activeCount":128},[],{"trials":22259,"activeCount":128},[],{"trials":22261,"activeCount":128},[22262],{"nctId":22263,"briefTitle":22264,"status":134,"phases":22265,"primaryCompletion":22266,"completion":22266,"start":22267,"enrollment":410,"conditions":22268,"interventions":22269},"NCT02370329","P1101 in Treating Patients With Myelofibrosis",[91],"2023-11-30","2015-08-12",[6315,3523],[22254],{"trials":22271,"activeCount":128},[],{"trials":22273,"activeCount":128},[],{"trials":22275,"activeCount":128},[],{"intervention":7371,"totalTrials":676,"cells":22277},{"EARLY_PHASE1":22278,"PHASE1":22280,"PHASE2":22282,"PHASE3":22288,"PHASE4":22290,"NA":22292},{"trials":22279,"activeCount":128},[],{"trials":22281,"activeCount":128},[],{"trials":22283,"activeCount":128},[22284],{"nctId":7365,"briefTitle":7366,"status":104,"phases":22285,"primaryCompletion":874,"completion":5361,"start":4032,"enrollment":7368,"conditions":22286,"interventions":22287},[90,91],[3690],[7371,3513],{"trials":22289,"activeCount":128},[],{"trials":22291,"activeCount":128},[],{"trials":22293,"activeCount":128},[],{"intervention":22295,"totalTrials":676,"cells":22296},"defined green tea catechin extract",{"EARLY_PHASE1":22297,"PHASE1":22299,"PHASE2":22301,"PHASE3":22315,"PHASE4":22317,"NA":22319},{"trials":22298,"activeCount":128},[],{"trials":22300,"activeCount":128},[],{"trials":22302,"activeCount":128},[22303],{"nctId":22304,"briefTitle":22305,"status":134,"phases":22306,"primaryCompletion":22307,"completion":22307,"start":3509,"enrollment":1236,"conditions":22308,"interventions":22314},"NCT01606124","Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer",[91],"2015-05-21",[22309,22310,22311,22312,22313],"Advanced Colorectal Adenomas","Adenocarcinoma of the Colon","Stage I Colon Cancer","Stage II Colon Cancer","Stage III Colon Cancer",[22295],{"trials":22316,"activeCount":128},[],{"trials":22318,"activeCount":128},[],{"trials":22320,"activeCount":128},[],{"intervention":22322,"totalTrials":676,"cells":22323},"Sucrose",{"EARLY_PHASE1":22324,"PHASE1":22326,"PHASE2":22328,"PHASE3":22338,"PHASE4":22340,"NA":22342},{"trials":22325,"activeCount":128},[],{"trials":22327,"activeCount":128},[],{"trials":22329,"activeCount":128},[22330],{"nctId":22331,"briefTitle":22332,"status":1413,"phases":22333,"primaryCompletion":22334,"completion":22334,"start":22335,"enrollment":128,"conditions":22336,"interventions":22337},"NCT04855266","Iron Sucrose in Patients With Iron Deficiency and POTS",[91],"2023-05","2021-04",[14640,6999],[22322],{"trials":22339,"activeCount":128},[],{"trials":22341,"activeCount":128},[],{"trials":22343,"activeCount":128},[],{"intervention":22345,"totalTrials":676,"cells":22346},"Flaxseed",{"EARLY_PHASE1":22347,"PHASE1":22349,"PHASE2":22351,"PHASE3":22359,"PHASE4":22361,"NA":22363},{"trials":22348,"activeCount":128},[],{"trials":22350,"activeCount":128},[],{"trials":22352,"activeCount":128},[22353],{"nctId":22354,"briefTitle":22355,"status":104,"phases":22356,"primaryCompletion":4786,"start":16315,"enrollment":729,"conditions":22357,"interventions":22358},"NCT00275704","Flaxseed for the Treatment of Hot Flashes",[91],[2760],[22345],{"trials":22360,"activeCount":128},[],{"trials":22362,"activeCount":128},[],{"trials":22364,"activeCount":128},[],{"intervention":1423,"totalTrials":676,"cells":22366},{"EARLY_PHASE1":22367,"PHASE1":22369,"PHASE2":22371,"PHASE3":22377,"PHASE4":22379,"NA":22381},{"trials":22368,"activeCount":128},[],{"trials":22370,"activeCount":128},[],{"trials":22372,"activeCount":128},[22373],{"nctId":1411,"briefTitle":1412,"status":1413,"phases":22374,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":128,"conditions":22375,"interventions":22376},[91],[30,1418,1419,1420],[1422,1402,1423,1424],{"trials":22378,"activeCount":128},[],{"trials":22380,"activeCount":128},[],{"trials":22382,"activeCount":128},[],{"intervention":7931,"totalTrials":676,"cells":22384},{"EARLY_PHASE1":22385,"PHASE1":22387,"PHASE2":22389,"PHASE3":22395,"PHASE4":22397,"NA":22399},{"trials":22386,"activeCount":128},[],{"trials":22388,"activeCount":128},[],{"trials":22390,"activeCount":128},[22391],{"nctId":7925,"briefTitle":7926,"status":134,"phases":22392,"primaryCompletion":7928,"completion":1357,"start":3717,"enrollment":224,"conditions":22393,"interventions":22394},[91],[4292],[7931,7932],{"trials":22396,"activeCount":128},[],{"trials":22398,"activeCount":128},[],{"trials":22400,"activeCount":128},[],{"intervention":22402,"totalTrials":676,"cells":22403},"Teriparatide",{"EARLY_PHASE1":22404,"PHASE1":22406,"PHASE2":22408,"PHASE3":22417,"PHASE4":22419,"NA":22421},{"trials":22405,"activeCount":128},[],{"trials":22407,"activeCount":128},[],{"trials":22409,"activeCount":128},[22410],{"nctId":22411,"briefTitle":22412,"status":134,"phases":22413,"primaryCompletion":4795,"completion":4795,"start":2936,"enrollment":895,"conditions":22414,"interventions":22416},"NCT01171690","Teriparatide for Postsurgical Hypoparathyroidism",[91],[22415],"Hypoparathyroidism Post-surgical",[22402],{"trials":22418,"activeCount":128},[],{"trials":22420,"activeCount":128},[],{"trials":22422,"activeCount":128},[],{"intervention":22424,"totalTrials":676,"cells":22425},"Exisulind Therapy",{"EARLY_PHASE1":22426,"PHASE1":22428,"PHASE2":22430,"PHASE3":22438,"PHASE4":22440,"NA":22442},{"trials":22427,"activeCount":128},[],{"trials":22429,"activeCount":128},[],{"trials":22431,"activeCount":128},[22432],{"nctId":22433,"briefTitle":22434,"status":104,"phases":22435,"primaryCompletion":933,"completion":933,"start":16545,"enrollment":1320,"conditions":22436,"interventions":22437},"NCT00166478","Exisulind Prior to Radical Prostatectomy",[91],[20440],[22424],{"trials":22439,"activeCount":128},[],{"trials":22441,"activeCount":128},[],{"trials":22443,"activeCount":128},[],{"intervention":22445,"totalTrials":676,"cells":22446},"Cystadane",{"EARLY_PHASE1":22447,"PHASE1":22449,"PHASE2":22451,"PHASE3":22461,"PHASE4":22463,"NA":22465},{"trials":22448,"activeCount":128},[],{"trials":22450,"activeCount":128},[],{"trials":22452,"activeCount":128},[22453],{"nctId":22454,"briefTitle":22455,"status":104,"phases":22456,"primaryCompletion":4786,"completion":4786,"start":11480,"enrollment":7368,"conditions":22457,"interventions":22459},"NCT00586911","Betaine in Patients With Nonalcoholic Steatohepatitis",[91],[22458],"Nonalcoholic Steatohepatitis",[22445,22460],"Identical Placebo",{"trials":22462,"activeCount":128},[],{"trials":22464,"activeCount":128},[],{"trials":22466,"activeCount":128},[],{"intervention":22460,"totalTrials":676,"cells":22468},{"EARLY_PHASE1":22469,"PHASE1":22471,"PHASE2":22473,"PHASE3":22479,"PHASE4":22481,"NA":22483},{"trials":22470,"activeCount":128},[],{"trials":22472,"activeCount":128},[],{"trials":22474,"activeCount":128},[22475],{"nctId":22454,"briefTitle":22455,"status":104,"phases":22476,"primaryCompletion":4786,"completion":4786,"start":11480,"enrollment":7368,"conditions":22477,"interventions":22478},[91],[22458],[22445,22460],{"trials":22480,"activeCount":128},[],{"trials":22482,"activeCount":128},[],{"trials":22484,"activeCount":128},[],{"intervention":22486,"totalTrials":676,"cells":22487},"ATI-7505",{"EARLY_PHASE1":22488,"PHASE1":22490,"PHASE2":22492,"PHASE3":22501,"PHASE4":22503,"NA":22505},{"trials":22489,"activeCount":128},[],{"trials":22491,"activeCount":128},[],{"trials":22493,"activeCount":128},[22494],{"nctId":22495,"briefTitle":22496,"status":104,"phases":22497,"primaryCompletion":22498,"completion":22498,"start":4391,"enrollment":2608,"conditions":22499,"interventions":22500},"NCT01094821","Effect of ATI-7505 on Gastrointestinal Transit in Healthy Volunteers",[90,91],"2005-12",[18],[22486,22486,22486],{"trials":22502,"activeCount":128},[],{"trials":22504,"activeCount":128},[],{"trials":22506,"activeCount":128},[],{"intervention":22508,"totalTrials":676,"cells":22509},"Lenvatinib",{"EARLY_PHASE1":22510,"PHASE1":22512,"PHASE2":22514,"PHASE3":22526,"PHASE4":22528,"NA":22530},{"trials":22511,"activeCount":128},[],{"trials":22513,"activeCount":128},[],{"trials":22515,"activeCount":128},[22516],{"nctId":22517,"briefTitle":22518,"status":104,"phases":22519,"primaryCompletion":8279,"completion":22520,"start":7988,"enrollment":342,"conditions":22521,"interventions":22525},"NCT03008369","Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery",[91],"2022-09-28",[22522,22523,22524],"Malignant Adrenal Gland Pheochromocytoma","Malignant Paraganglioma","Metastatic Adrenal Gland Pheochromocytoma",[22508],{"trials":22527,"activeCount":128},[],{"trials":22529,"activeCount":128},[],{"trials":22531,"activeCount":128},[],{"intervention":22533,"totalTrials":676,"cells":22534},"Fremanezumab",{"EARLY_PHASE1":22535,"PHASE1":22537,"PHASE2":22539,"PHASE3":22549,"PHASE4":22551,"NA":22553},{"trials":22536,"activeCount":128},[],{"trials":22538,"activeCount":128},[],{"trials":22540,"activeCount":128},[22541],{"nctId":22542,"briefTitle":22543,"status":1413,"phases":22544,"primaryCompletion":1470,"completion":1470,"start":22545,"enrollment":128,"conditions":22546,"interventions":22548},"NCT04334408","Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL",[91],"2021-12",[22547,1938],"Cadasil",[22533],{"trials":22550,"activeCount":128},[],{"trials":22552,"activeCount":128},[],{"trials":22554,"activeCount":128},[],{"intervention":22556,"totalTrials":676,"cells":22557},"Human Secretin",{"EARLY_PHASE1":22558,"PHASE1":22560,"PHASE2":22562,"PHASE3":22571,"PHASE4":22573,"NA":22575},{"trials":22559,"activeCount":128},[],{"trials":22561,"activeCount":128},[],{"trials":22563,"activeCount":128},[22564],{"nctId":22565,"briefTitle":22566,"status":104,"phases":22567,"primaryCompletion":4793,"completion":19433,"start":22568,"enrollment":173,"conditions":22569,"interventions":22570},"NCT03617861","Effect of Secretin in Functional Dyspepsia and Healthy Subjects",[90,91],"2018-11-07",[6538,18],[22556],{"trials":22572,"activeCount":128},[],{"trials":22574,"activeCount":128},[],{"trials":22576,"activeCount":128},[],{"intervention":22578,"totalTrials":676,"cells":22579},"Yohimbine,",{"EARLY_PHASE1":22580,"PHASE1":22582,"PHASE2":22584,"PHASE3":22592,"PHASE4":22594,"NA":22596},{"trials":22581,"activeCount":128},[],{"trials":22583,"activeCount":128},[],{"trials":22585,"activeCount":128},[22586],{"nctId":22587,"briefTitle":22588,"status":104,"phases":22589,"primaryCompletion":4112,"completion":4112,"start":5051,"enrollment":729,"conditions":22590,"interventions":22591},"NCT00217048","Effect of Yohimbine on Colon Transit",[90,91],[16419],[22578],{"trials":22593,"activeCount":128},[],{"trials":22595,"activeCount":128},[],{"trials":22597,"activeCount":128},[],{"intervention":22599,"totalTrials":676,"cells":22600},"Ixekizumab",{"EARLY_PHASE1":22601,"PHASE1":22603,"PHASE2":22605,"PHASE3":22616,"PHASE4":22618,"NA":22620},{"trials":22602,"activeCount":128},[],{"trials":22604,"activeCount":128},[],{"trials":22606,"activeCount":128},[22607],{"nctId":22608,"briefTitle":22609,"status":104,"phases":22610,"primaryCompletion":22611,"completion":22611,"start":409,"enrollment":681,"conditions":22612,"interventions":22615},"NCT03099538","Ixekizumab in the Treatment of Bullous Pemphigoid",[91],"2019-06-06",[22613,22614],"Bullous Pemphigoid","Pemphigoid",[22599],{"trials":22617,"activeCount":128},[],{"trials":22619,"activeCount":128},[],{"trials":22621,"activeCount":128},[],{"intervention":22623,"totalTrials":676,"cells":22624},"Pentamidine Isethionate",{"EARLY_PHASE1":22625,"PHASE1":22627,"PHASE2":22629,"PHASE3":22640,"PHASE4":22642,"NA":22644},{"trials":22626,"activeCount":128},[],{"trials":22628,"activeCount":128},[],{"trials":22630,"activeCount":128},[22631],{"nctId":22632,"briefTitle":22633,"status":134,"phases":22634,"primaryCompletion":22635,"completion":22635,"start":22636,"enrollment":1197,"conditions":22637,"interventions":22639},"NCT03403621","Hypertrophic Scar Prevention by Novel Topical Gel Application",[90,91],"2020-02-26","2018-03-05",[22638],"Hypertrophic Scar",[22623],{"trials":22641,"activeCount":128},[],{"trials":22643,"activeCount":128},[],{"trials":22645,"activeCount":128},[],{"intervention":22647,"totalTrials":676,"cells":22648},"Autologous Alpha-2 Macroglobulin Rich Plasma",{"EARLY_PHASE1":22649,"PHASE1":22651,"PHASE2":22653,"PHASE3":22664,"PHASE4":22666,"NA":22668},{"trials":22650,"activeCount":128},[],{"trials":22652,"activeCount":128},[],{"trials":22654,"activeCount":128},[22655],{"nctId":22656,"briefTitle":22657,"status":104,"phases":22658,"primaryCompletion":4538,"completion":22659,"start":22660,"enrollment":173,"conditions":22661,"interventions":22663},"NCT06329492","Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis",[90,91],"2026-02-06","2024-01-09",[1340,22662,1508],"OA",[22647],{"trials":22665,"activeCount":128},[],{"trials":22667,"activeCount":128},[],{"trials":22669,"activeCount":128},[],{"intervention":22671,"totalTrials":676,"cells":22672},"serum-derived bovine immunoglobulin protein isolate",{"EARLY_PHASE1":22673,"PHASE1":22675,"PHASE2":22677,"PHASE3":22688,"PHASE4":22690,"NA":22692},{"trials":22674,"activeCount":128},[],{"trials":22676,"activeCount":128},[],{"trials":22678,"activeCount":128},[22679],{"nctId":22680,"briefTitle":22681,"status":104,"phases":22682,"primaryCompletion":22683,"completion":22683,"start":22684,"enrollment":5985,"conditions":22685,"interventions":22687},"NCT01867606","Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery",[91],"2015-11-21","2013-10-04",[22686],"Female Reproductive Cancer",[22671],{"trials":22689,"activeCount":128},[],{"trials":22691,"activeCount":128},[],{"trials":22693,"activeCount":128},[],{"intervention":22695,"totalTrials":676,"cells":22696},"FolateScan",{"EARLY_PHASE1":22697,"PHASE1":22699,"PHASE2":22701,"PHASE3":22711,"PHASE4":22713,"NA":22715},{"trials":22698,"activeCount":128},[],{"trials":22700,"activeCount":128},[],{"trials":22702,"activeCount":128},[22703],{"nctId":22704,"briefTitle":22705,"status":104,"phases":22706,"primaryCompletion":934,"completion":934,"start":15822,"enrollment":668,"conditions":22707,"interventions":22710},"NCT00588393","FolateScan in Autoimmune Disease",[91],[22708,1340,9501,11666,22709],"Rheumatoid Arthritis","Systemic Lupus Erythematosus",[22695],{"trials":22712,"activeCount":128},[],{"trials":22714,"activeCount":128},[],{"trials":22716,"activeCount":128},[],{"intervention":22718,"totalTrials":676,"cells":22719},"Dacogen",{"EARLY_PHASE1":22720,"PHASE1":22722,"PHASE2":22724,"PHASE3":22732,"PHASE4":22734,"NA":22736},{"trials":22721,"activeCount":128},[],{"trials":22723,"activeCount":128},[],{"trials":22725,"activeCount":128},[22726],{"nctId":22727,"briefTitle":22728,"status":134,"phases":22729,"primaryCompletion":7114,"completion":4785,"start":13742,"enrollment":681,"conditions":22730,"interventions":22731},"NCT00630994","Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis",[91],[3522,3523],[22718],{"trials":22733,"activeCount":128},[],{"trials":22735,"activeCount":128},[],{"trials":22737,"activeCount":128},[],{"intervention":22739,"totalTrials":676,"cells":22740},"BKR-017",{"EARLY_PHASE1":22741,"PHASE1":22743,"PHASE2":22745,"PHASE3":22757,"PHASE4":22759,"NA":22761},{"trials":22742,"activeCount":128},[],{"trials":22744,"activeCount":128},[],{"trials":22746,"activeCount":128},[22747],{"nctId":22748,"briefTitle":22749,"status":104,"phases":22750,"primaryCompletion":22751,"completion":22752,"start":22753,"enrollment":1197,"conditions":22754,"interventions":22756},"NCT03999853","Butyrate Adjuvant Therapy for Type 1 Diabetes",[90,91],"2025-04-01","2025-12-01","2022-07-28",[22755],"Type1diabetes",[22739],{"trials":22758,"activeCount":128},[],{"trials":22760,"activeCount":128},[],{"trials":22762,"activeCount":128},[],{"intervention":22764,"totalTrials":676,"cells":22765},"clarithromycin",{"EARLY_PHASE1":22766,"PHASE1":22768,"PHASE2":22770,"PHASE3":22780,"PHASE4":22782,"NA":22784},{"trials":22767,"activeCount":128},[],{"trials":22769,"activeCount":128},[],{"trials":22771,"activeCount":128},[22772],{"nctId":22773,"briefTitle":22774,"status":104,"phases":22775,"primaryCompletion":3718,"completion":3718,"start":22776,"conditions":22777,"interventions":22778},"NCT00006219","Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma",[91],"2000-08",[3665],[22764,22779],"prasterone",{"trials":22781,"activeCount":128},[],{"trials":22783,"activeCount":128},[],{"trials":22785,"activeCount":128},[],{"intervention":22779,"totalTrials":676,"cells":22787},{"EARLY_PHASE1":22788,"PHASE1":22790,"PHASE2":22792,"PHASE3":22798,"PHASE4":22800,"NA":22802},{"trials":22789,"activeCount":128},[],{"trials":22791,"activeCount":128},[],{"trials":22793,"activeCount":128},[22794],{"nctId":22773,"briefTitle":22774,"status":104,"phases":22795,"primaryCompletion":3718,"completion":3718,"start":22776,"conditions":22796,"interventions":22797},[91],[3665],[22764,22779],{"trials":22799,"activeCount":128},[],{"trials":22801,"activeCount":128},[],{"trials":22803,"activeCount":128},[],{"intervention":22805,"totalTrials":681,"cells":22806},"CD-NP",{"EARLY_PHASE1":22807,"PHASE1":22809,"PHASE2":22844,"PHASE3":22846,"PHASE4":22848,"NA":22850},{"trials":22808,"activeCount":128},[],{"trials":22810,"activeCount":128},[22811,22820,22830,22837],{"nctId":22812,"briefTitle":22813,"status":104,"phases":22814,"primaryCompletion":22815,"completion":22816,"start":3641,"enrollment":729,"conditions":22817,"interventions":22819},"NCT02071602","CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function",[90],"2018-05","2018-11",[22818],"ST Elevation (STEMI) Myocardial Infarction of Anterior Wall",[22805],{"nctId":22821,"briefTitle":22822,"status":1413,"phases":22823,"primaryCompletion":14206,"completion":22824,"start":22825,"enrollment":128,"conditions":22826,"interventions":22829},"NCT03091998","Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support",[90],"2020-05-01","2017-09-30",[27,22827,22828],"Left Ventricular Assist Device","Natriuretic Peptide",[22805],{"nctId":22831,"briefTitle":22832,"status":104,"phases":22833,"primaryCompletion":2979,"completion":2979,"start":1298,"enrollment":6434,"conditions":22834,"interventions":22836},"NCT00620308","CD-NP in Subjects With Stable Chronic Heart Failure",[90],[22835],"Stable Chronic Heart Failure",[22805],{"nctId":22838,"briefTitle":22839,"status":104,"phases":22840,"primaryCompletion":1234,"completion":873,"start":4885,"enrollment":355,"conditions":22841,"interventions":22843},"NCT01750905","Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients",[90],[22842],"Left Ventricular Insufficiency",[22805],{"trials":22845,"activeCount":128},[],{"trials":22847,"activeCount":128},[],{"trials":22849,"activeCount":128},[],{"trials":22851,"activeCount":128},[],{"intervention":13218,"totalTrials":342,"cells":22853},{"EARLY_PHASE1":22854,"PHASE1":22889,"PHASE2":22895,"PHASE3":22897,"PHASE4":22899,"NA":22901},{"trials":22855,"activeCount":128},[22856,22873],{"nctId":22857,"briefTitle":22858,"status":104,"phases":22859,"primaryCompletion":22860,"completion":22861,"start":6275,"enrollment":729,"conditions":22862,"interventions":22869},"NCT01748747","Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery",[89],"2014-12-14","2017-03-30",[4542,22863,22864,22865,22866,22867,22868,4812],"Stage IIA Melanoma","Stage IIB Melanoma","Stage IIC Melanoma","Stage IIIA Melanoma","Stage IIIB Melanoma","Stage IIIC Melanoma",[22870,13218,22871,22872],"Montanide ISA 51 VG","Gag:267-274 peptide vaccine","resiquimod",{"nctId":22874,"briefTitle":22875,"status":104,"phases":22876,"primaryCompletion":22877,"completion":7560,"start":22878,"enrollment":233,"conditions":22879,"interventions":22886},"NCT02320305","MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery",[89],"2015-12-07","2015-01-27",[22880,22881,22882,22883,22884,22885,3348],"Stage IIA Skin Melanoma","Stage IIB Skin Melanoma","Stage IIC Skin Melanoma","Stage IIIA Skin Melanoma","Stage IIIB Skin Melanoma","Stage IIIC Skin Melanoma",[22887,22888],"MART-1 Antigen","TLR4 Agonist GLA-SE",{"trials":22890,"activeCount":128},[22891],{"nctId":13212,"briefTitle":13213,"status":104,"phases":22892,"primaryCompletion":1563,"completion":13215,"start":11897,"enrollment":173,"conditions":22893,"interventions":22894},[90],[4291],[13218,13219,13220,13205,13221],{"trials":22896,"activeCount":128},[],{"trials":22898,"activeCount":128},[],{"trials":22900,"activeCount":128},[],{"trials":22902,"activeCount":128},[],{"intervention":8202,"totalTrials":342,"cells":22904},{"EARLY_PHASE1":22905,"PHASE1":22907,"PHASE2":22925,"PHASE3":22927,"PHASE4":22929,"NA":22931},{"trials":22906,"activeCount":128},[],{"trials":22908,"activeCount":128},[22909,22913,22921],{"nctId":8197,"briefTitle":8198,"status":104,"phases":22910,"primaryCompletion":2620,"completion":2620,"start":6258,"enrollment":1236,"conditions":22911,"interventions":22912},[90],[15],[5130,8202],{"nctId":22914,"briefTitle":22915,"status":104,"phases":22916,"primaryCompletion":3673,"completion":3673,"start":22498,"enrollment":2678,"conditions":22917,"interventions":22918},"NCT00309855","Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men",[90],[7089],[8202,22919,22920],"Anastrazole","Dutasteride",{"nctId":8490,"briefTitle":8491,"status":104,"phases":22922,"primaryCompletion":8493,"completion":8494,"start":3569,"enrollment":2980,"conditions":22923,"interventions":22924},[90],[7698],[5126,8202,82,8497],{"trials":22926,"activeCount":128},[],{"trials":22928,"activeCount":128},[],{"trials":22930,"activeCount":128},[],{"trials":22932,"activeCount":128},[],{"intervention":22934,"totalTrials":342,"cells":22935},"MSC-AFP",{"EARLY_PHASE1":22936,"PHASE1":22938,"PHASE2":22965,"PHASE3":22967,"PHASE4":22969,"NA":22971},{"trials":22937,"activeCount":128},[],{"trials":22939,"activeCount":128},[22940,22948,22957],{"nctId":22941,"briefTitle":22942,"status":104,"phases":22943,"primaryCompletion":5562,"completion":5562,"start":22944,"enrollment":676,"conditions":22945,"interventions":22947},"NCT03449069","Pediatric MSC-AFP Sub-study for Crohn's Fistula",[90],"2018-07-23",[22946,14274],"Fistula in Ano",[22934],{"nctId":22949,"briefTitle":22950,"status":104,"phases":22951,"primaryCompletion":22952,"completion":22952,"start":22953,"enrollment":895,"conditions":22954,"interventions":22956},"NCT03220243","Stem Cell Coated Fistula Plug in Patients With Crohn's RVF",[90],"2020-09-20","2017-10-19",[22955,14274],"Fistula Vagina",[22934],{"nctId":22958,"briefTitle":22959,"status":104,"phases":22960,"primaryCompletion":2990,"completion":2990,"start":2607,"enrollment":4565,"conditions":22961,"interventions":22964},"NCT02589119","Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP)",[90],[22962,22963],"Perianal Fistula","Cryptoglandular Perianal Fistula",[22934],{"trials":22966,"activeCount":128},[],{"trials":22968,"activeCount":128},[],{"trials":22970,"activeCount":128},[],{"trials":22972,"activeCount":128},[],{"intervention":22974,"totalTrials":224,"cells":22975},"Fingolimod",{"EARLY_PHASE1":22976,"PHASE1":22988,"PHASE2":22997,"PHASE3":22999,"PHASE4":23001,"NA":23003},{"trials":22977,"activeCount":128},[22978],{"nctId":22979,"briefTitle":22980,"status":104,"phases":22981,"primaryCompletion":299,"completion":299,"start":22982,"enrollment":224,"conditions":22983,"interventions":22986},"NCT03943498","Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy",[89],"2019-05-24",[15956,22984,938,22985],"Numbness","Tingling",[22974,22987],"Fingolimod Hydrochloride",{"trials":22989,"activeCount":128},[22990],{"nctId":22991,"briefTitle":22992,"status":104,"phases":22993,"primaryCompletion":10188,"completion":22994,"start":20581,"enrollment":224,"conditions":22995,"interventions":22996},"NCT03941743","Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer",[90],"2021-11-23",[30],[22974,22987],{"trials":22998,"activeCount":128},[],{"trials":23000,"activeCount":128},[],{"trials":23002,"activeCount":128},[],{"trials":23004,"activeCount":128},[],{"intervention":22987,"totalTrials":224,"cells":23006},{"EARLY_PHASE1":23007,"PHASE1":23013,"PHASE2":23019,"PHASE3":23021,"PHASE4":23023,"NA":23025},{"trials":23008,"activeCount":128},[23009],{"nctId":22979,"briefTitle":22980,"status":104,"phases":23010,"primaryCompletion":299,"completion":299,"start":22982,"enrollment":224,"conditions":23011,"interventions":23012},[89],[15956,22984,938,22985],[22974,22987],{"trials":23014,"activeCount":128},[23015],{"nctId":22991,"briefTitle":22992,"status":104,"phases":23016,"primaryCompletion":10188,"completion":22994,"start":20581,"enrollment":224,"conditions":23017,"interventions":23018},[90],[30],[22974,22987],{"trials":23020,"activeCount":128},[],{"trials":23022,"activeCount":128},[],{"trials":23024,"activeCount":128},[],{"trials":23026,"activeCount":128},[],{"intervention":8171,"totalTrials":224,"cells":23028},{"EARLY_PHASE1":23029,"PHASE1":23040,"PHASE2":23046,"PHASE3":23048,"PHASE4":23050,"NA":23052},{"trials":23030,"activeCount":128},[23031],{"nctId":23032,"briefTitle":23033,"status":104,"phases":23034,"primaryCompletion":23035,"completion":23036,"start":118,"enrollment":342,"conditions":23037,"interventions":23039},"NCT03954015","Comparison of Three Methods for Early Detection of Breast Cancer",[89],"2020-06-30","2021-10-05",[23038],"Proliferative Breast Disease",[8171],{"trials":23041,"activeCount":128},[23042],{"nctId":8164,"briefTitle":8165,"status":104,"phases":23043,"primaryCompletion":8167,"completion":8167,"start":3988,"enrollment":370,"conditions":23044,"interventions":23045},[90],[8169],[8171,8172,8157],{"trials":23047,"activeCount":128},[],{"trials":23049,"activeCount":128},[],{"trials":23051,"activeCount":128},[],{"trials":23053,"activeCount":128},[],{"intervention":8046,"totalTrials":224,"cells":23055},{"EARLY_PHASE1":23056,"PHASE1":23058,"PHASE2":23068,"PHASE3":23070,"PHASE4":23072,"NA":23074},{"trials":23057,"activeCount":128},[],{"trials":23059,"activeCount":128},[23060,23064],{"nctId":17852,"briefTitle":17853,"status":104,"phases":23061,"primaryCompletion":17855,"completion":17856,"start":5352,"enrollment":4208,"conditions":23062,"interventions":23063},[90],[17858,17859,17860,17861,17862,17863,17864,17865,4542,17866,17867,17868,17869,17870,17871,4812,17872,3347,17873,4293],[4306,8046],{"nctId":8039,"briefTitle":8040,"status":104,"phases":23065,"primaryCompletion":8042,"completion":8042,"start":8043,"enrollment":34,"conditions":23066,"interventions":23067},[90],[4293],[8046,8032],{"trials":23069,"activeCount":128},[],{"trials":23071,"activeCount":128},[],{"trials":23073,"activeCount":128},[],{"trials":23075,"activeCount":128},[],{"intervention":7445,"totalTrials":224,"cells":23077},{"EARLY_PHASE1":23078,"PHASE1":23084,"PHASE2":23097,"PHASE3":23099,"PHASE4":23101,"NA":23103},{"trials":23079,"activeCount":128},[23080],{"nctId":7437,"briefTitle":7438,"status":104,"phases":23081,"primaryCompletion":7440,"completion":7440,"start":7441,"enrollment":461,"conditions":23082,"interventions":23083},[89],[21],[7444,7445,7446,7447,4405],{"trials":23085,"activeCount":128},[23086],{"nctId":23087,"briefTitle":23088,"status":104,"phases":23089,"primaryCompletion":23090,"completion":23091,"start":23092,"enrollment":3002,"conditions":23093,"interventions":23096},"NCT01632332","Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer",[90],"2014-03-24","2018-07-09","2012-07-09",[5630,23094,23095,3372,3376,3380],"Male Breast Cancer","Stage II Breast Cancer",[7445],{"trials":23098,"activeCount":128},[],{"trials":23100,"activeCount":128},[],{"trials":23102,"activeCount":128},[],{"trials":23104,"activeCount":128},[],{"intervention":7544,"totalTrials":224,"cells":23106},{"EARLY_PHASE1":23107,"PHASE1":23109,"PHASE2":23126,"PHASE3":23128,"PHASE4":23130,"NA":23132},{"trials":23108,"activeCount":128},[],{"trials":23110,"activeCount":128},[23111,23115],{"nctId":7536,"briefTitle":7537,"status":104,"phases":23112,"primaryCompletion":894,"completion":7539,"start":7540,"enrollment":3945,"conditions":23113,"interventions":23114},[90],[3321,7542],[7544,7545,3599],{"nctId":23116,"briefTitle":23117,"status":104,"phases":23118,"primaryCompletion":23119,"completion":7892,"start":23120,"enrollment":233,"conditions":23121,"interventions":23124},"NCT00390299","Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme",[90],"2018-11-29","2006-10-23",[23122,6723,23123,11623],"Anaplastic Astrocytoma","Mixed Glioma",[23125],"Carcinoembryonic Antigen-Expressing Measles Virus",{"trials":23127,"activeCount":128},[],{"trials":23129,"activeCount":128},[],{"trials":23131,"activeCount":128},[],{"trials":23133,"activeCount":128},[],{"intervention":23135,"totalTrials":224,"cells":23136},"ANX-042",{"EARLY_PHASE1":23137,"PHASE1":23139,"PHASE2":23156,"PHASE3":23158,"PHASE4":23160,"NA":23162},{"trials":23138,"activeCount":128},[],{"trials":23140,"activeCount":128},[23141,23150],{"nctId":23142,"briefTitle":23143,"status":104,"phases":23144,"primaryCompletion":23145,"completion":23145,"start":12516,"enrollment":498,"conditions":23146,"interventions":23149},"NCT03019653","Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome",[90],"2024-09-13",[27,23147,23148],"Cardiorenal Disease","Renal Disfunction",[23135],{"nctId":23151,"briefTitle":23152,"status":104,"phases":23153,"primaryCompletion":3613,"completion":3613,"start":894,"enrollment":729,"conditions":23154,"interventions":23155},"NCT01638104","ANX-042 Healthy Volunteer Dose Escalation Study",[90],[16419],[23135],{"trials":23157,"activeCount":128},[],{"trials":23159,"activeCount":128},[],{"trials":23161,"activeCount":128},[],{"trials":23163,"activeCount":128},[],{"intervention":23165,"totalTrials":224,"cells":23166},"gold sodium thiomalate",{"EARLY_PHASE1":23167,"PHASE1":23169,"PHASE2":23190,"PHASE3":23192,"PHASE4":23194,"NA":23196},{"trials":23168,"activeCount":128},[],{"trials":23170,"activeCount":128},[23171,23179],{"nctId":23172,"briefTitle":23173,"status":104,"phases":23174,"primaryCompletion":23175,"completion":23176,"start":8043,"enrollment":139,"conditions":23177,"interventions":23178},"NCT00575393","Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer",[90],"2011-06-30","2012-02-14",[8059],[23165,3598],{"nctId":23180,"briefTitle":23181,"status":1413,"phases":23182,"primaryCompletion":23183,"completion":23183,"start":7107,"enrollment":128,"conditions":23184,"interventions":23188},"NCT01383668","Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer",[90],"2013-02-08",[17867,23185,23186,23187,17872,4293],"Squamous Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer",[7354,23165,23189,5425],"RNA analysis",{"trials":23191,"activeCount":128},[],{"trials":23193,"activeCount":128},[],{"trials":23195,"activeCount":128},[],{"trials":23197,"activeCount":128},[],{"intervention":23199,"totalTrials":224,"cells":23200},"Nelfinavir",{"EARLY_PHASE1":23201,"PHASE1":23203,"PHASE2":23218,"PHASE3":23220,"PHASE4":23222,"NA":23224},{"trials":23202,"activeCount":128},[],{"trials":23204,"activeCount":128},[23205,23212],{"nctId":23206,"briefTitle":23207,"status":104,"phases":23208,"primaryCompletion":933,"completion":933,"start":4112,"enrollment":558,"conditions":23209,"interventions":23211},"NCT00346619","Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults",[90],[23210],"Immune Response",[23199],{"nctId":23213,"briefTitle":23214,"status":104,"phases":23215,"primaryCompletion":7332,"completion":7332,"start":4871,"enrollment":25,"conditions":23216,"interventions":23217},"NCT00346580","The Effects of HIV Protease Inhibitors in Severe Sepsis",[90],[8295],[23199],{"trials":23219,"activeCount":128},[],{"trials":23221,"activeCount":128},[],{"trials":23223,"activeCount":128},[],{"trials":23225,"activeCount":128},[],{"intervention":23227,"totalTrials":676,"cells":23228},"Human BNP",{"EARLY_PHASE1":23229,"PHASE1":23231,"PHASE2":23240,"PHASE3":23242,"PHASE4":23244,"NA":23246},{"trials":23230,"activeCount":128},[],{"trials":23232,"activeCount":128},[23233],{"nctId":23234,"briefTitle":23235,"status":134,"phases":23236,"completion":16229,"start":21782,"enrollment":2555,"conditions":23237,"interventions":23239},"NCT00252213","BELIEVE Study: Nesiritide and Post Myocardial Infarction Left Ventricular Modeling",[90],[23238],"Myocardial Infarction",[23227],{"trials":23241,"activeCount":128},[],{"trials":23243,"activeCount":128},[],{"trials":23245,"activeCount":128},[],{"trials":23247,"activeCount":128},[],{"intervention":23249,"totalTrials":676,"cells":23250},"Montelukast\u002F Singulair",{"EARLY_PHASE1":23251,"PHASE1":23253,"PHASE2":23261,"PHASE3":23263,"PHASE4":23265,"NA":23267},{"trials":23252,"activeCount":128},[],{"trials":23254,"activeCount":128},[23255],{"nctId":23256,"briefTitle":23257,"status":104,"phases":23258,"primaryCompletion":905,"completion":905,"start":1564,"enrollment":28,"conditions":23259,"interventions":23260},"NCT00511316","Trial of Montelukast in Eosinophilic Esophagitis",[90],[12979],[23249],{"trials":23262,"activeCount":128},[],{"trials":23264,"activeCount":128},[],{"trials":23266,"activeCount":128},[],{"trials":23268,"activeCount":128},[],{"intervention":23270,"totalTrials":676,"cells":23271},"Dabrafenib",{"EARLY_PHASE1":23272,"PHASE1":23274,"PHASE2":23287,"PHASE3":23289,"PHASE4":23291,"NA":23293},{"trials":23273,"activeCount":128},[],{"trials":23275,"activeCount":128},[23276],{"nctId":23277,"briefTitle":23278,"status":134,"phases":23279,"primaryCompletion":23280,"completion":23281,"start":23282,"enrollment":301,"conditions":23283,"interventions":23285},"NCT05388877","E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma",[90],"2024-11-19","2025-06-02","2022-10-20",[192,23284,11028,122],"Metastatic Malignant Neoplasm in the Brain",[23270,23286],"MEK-1\u002FMEKK-1 Inhibitor E6201",{"trials":23288,"activeCount":128},[],{"trials":23290,"activeCount":128},[],{"trials":23292,"activeCount":128},[],{"trials":23294,"activeCount":128},[],{"intervention":23286,"totalTrials":676,"cells":23296},{"EARLY_PHASE1":23297,"PHASE1":23299,"PHASE2":23305,"PHASE3":23307,"PHASE4":23309,"NA":23311},{"trials":23298,"activeCount":128},[],{"trials":23300,"activeCount":128},[23301],{"nctId":23277,"briefTitle":23278,"status":134,"phases":23302,"primaryCompletion":23280,"completion":23281,"start":23282,"enrollment":301,"conditions":23303,"interventions":23304},[90],[192,23284,11028,122],[23270,23286],{"trials":23306,"activeCount":128},[],{"trials":23308,"activeCount":128},[],{"trials":23310,"activeCount":128},[],{"trials":23312,"activeCount":128},[],{"intervention":23314,"totalTrials":676,"cells":23315},"Atuna Racemosa",{"EARLY_PHASE1":23316,"PHASE1":23318,"PHASE2":23327,"PHASE3":23329,"PHASE4":23331,"NA":23333},{"trials":23317,"activeCount":128},[],{"trials":23319,"activeCount":128},[23320],{"nctId":23321,"briefTitle":23322,"status":104,"phases":23323,"primaryCompletion":2643,"completion":2643,"start":7604,"enrollment":173,"conditions":23324,"interventions":23326},"NCT00318344","Evaluation of Atuna Racemosa Toxicity",[90],[23325],"Bacterial Infections",[23314],{"trials":23328,"activeCount":128},[],{"trials":23330,"activeCount":128},[],{"trials":23332,"activeCount":128},[],{"trials":23334,"activeCount":128},[],{"intervention":23336,"totalTrials":676,"cells":23337},"Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1",{"EARLY_PHASE1":23338,"PHASE1":23340,"PHASE2":23354,"PHASE3":23356,"PHASE4":23358,"NA":23360},{"trials":23339,"activeCount":128},[],{"trials":23341,"activeCount":128},[23342],{"nctId":23343,"briefTitle":23344,"status":134,"phases":23345,"primaryCompletion":23346,"completion":23346,"start":23347,"enrollment":218,"conditions":23348,"interventions":23353},"NCT03865212","Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma",[90],"2025-10-12","2019-06-12",[189,192,23349,122,23350,23351,7801,7802,7803,7804,7805,23352,177],"Metastatic Choroid Melanoma","Metastatic Mucosal Melanoma","Metastatic Uveal Melanoma","Pathologic Stage IV Cutaneous Melanoma AJCC v8",[23336],{"trials":23355,"activeCount":128},[],{"trials":23357,"activeCount":128},[],{"trials":23359,"activeCount":128},[],{"trials":23361,"activeCount":128},[],{"intervention":23363,"totalTrials":676,"cells":23364},"citalopram and escitalopram",{"EARLY_PHASE1":23365,"PHASE1":23367,"PHASE2":23376,"PHASE3":23378,"PHASE4":23380,"NA":23382},{"trials":23366,"activeCount":128},[],{"trials":23368,"activeCount":128},[23369],{"nctId":23370,"briefTitle":23371,"status":104,"phases":23372,"primaryCompletion":3569,"completion":3569,"start":12925,"enrollment":23373,"conditions":23374,"interventions":23375},"NCT00613470","Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram",[90],927,[876],[23363],{"trials":23377,"activeCount":128},[],{"trials":23379,"activeCount":128},[],{"trials":23381,"activeCount":128},[],{"trials":23383,"activeCount":128},[],{"intervention":23385,"totalTrials":676,"cells":23386},"Anti-PD-L1 Monoclonal Antibody IMC-001",{"EARLY_PHASE1":23387,"PHASE1":23389,"PHASE2":23400,"PHASE3":23402,"PHASE4":23404,"NA":23406},{"trials":23388,"activeCount":128},[],{"trials":23390,"activeCount":128},[23391],{"nctId":23392,"briefTitle":23393,"status":134,"phases":23394,"primaryCompletion":23395,"completion":23395,"start":23396,"enrollment":342,"conditions":23397,"interventions":23399},"NCT05393713","Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study",[90],"2025-02-16","2022-10-17",[189,110,122,23398],"Recurrent Metastatic Melanoma",[23385],{"trials":23401,"activeCount":128},[],{"trials":23403,"activeCount":128},[],{"trials":23405,"activeCount":128},[],{"trials":23407,"activeCount":128},[],{"intervention":23409,"totalTrials":676,"cells":23410},"BTA",{"EARLY_PHASE1":23411,"PHASE1":23413,"PHASE2":23421,"PHASE3":23423,"PHASE4":23425,"NA":23427},{"trials":23412,"activeCount":128},[],{"trials":23414,"activeCount":128},[23415],{"nctId":23416,"briefTitle":23417,"status":104,"phases":23418,"primaryCompletion":3899,"completion":3899,"start":2883,"enrollment":25,"conditions":23419,"interventions":23420},"NCT00976443","Effects of Gastric Antral Botulinum Toxin Injections in Obese Subjects",[90],[15],[23409],{"trials":23422,"activeCount":128},[],{"trials":23424,"activeCount":128},[],{"trials":23426,"activeCount":128},[],{"trials":23428,"activeCount":128},[],{"intervention":3355,"totalTrials":676,"cells":23430},{"EARLY_PHASE1":23431,"PHASE1":23433,"PHASE2":23439,"PHASE3":23441,"PHASE4":23443,"NA":23445},{"trials":23432,"activeCount":128},[],{"trials":23434,"activeCount":128},[23435],{"nctId":3331,"briefTitle":3332,"status":134,"phases":23436,"primaryCompletion":3334,"completion":3335,"start":3336,"enrollment":681,"conditions":23437,"interventions":23438},[90],[3338,561,143,3339,3340,3341,3342,3343,3344,3345,3346,3347,3348,3349,3350,3351,3352],[57,3354,3355],{"trials":23440,"activeCount":128},[],{"trials":23442,"activeCount":128},[],{"trials":23444,"activeCount":128},[],{"trials":23446,"activeCount":128},[],{"intervention":23448,"totalTrials":676,"cells":23449},"Cosyntropin",{"EARLY_PHASE1":23450,"PHASE1":23452,"PHASE2":23462,"PHASE3":23464,"PHASE4":23466,"NA":23468},{"trials":23451,"activeCount":128},[],{"trials":23453,"activeCount":128},[23454],{"nctId":23455,"briefTitle":23456,"status":104,"phases":23457,"primaryCompletion":6365,"completion":6365,"start":5279,"enrollment":3726,"conditions":23458,"interventions":23461},"NCT01839812","Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery",[90],[23459,23460],"Adrenal Cortex Diseases","Infant Morbidity",[23448],{"trials":23463,"activeCount":128},[],{"trials":23465,"activeCount":128},[],{"trials":23467,"activeCount":128},[],{"trials":23469,"activeCount":128},[],{"intervention":23471,"totalTrials":676,"cells":23472},"Midodrine Hydrochloride 10 milligrams",{"EARLY_PHASE1":23473,"PHASE1":23475,"PHASE2":23485,"PHASE3":23487,"PHASE4":23489,"NA":23491},{"trials":23474,"activeCount":128},[],{"trials":23476,"activeCount":128},[23477],{"nctId":23478,"briefTitle":23479,"status":104,"phases":23480,"primaryCompletion":10335,"completion":23481,"start":23482,"enrollment":31,"conditions":23483,"interventions":23484},"NCT03129542","Midodrine Hydrochloride in Early Sepsis",[90],"2020-05-15","2017-08-30",[8295,948],[23471],{"trials":23486,"activeCount":128},[],{"trials":23488,"activeCount":128},[],{"trials":23490,"activeCount":128},[],{"trials":23492,"activeCount":128},[],{"intervention":23494,"totalTrials":676,"cells":23495},"Regional anesthetic SPG block-bilateral",{"EARLY_PHASE1":23496,"PHASE1":23498,"PHASE2":23508,"PHASE3":23510,"PHASE4":23512,"NA":23514},{"trials":23497,"activeCount":128},[],{"trials":23499,"activeCount":128},[23500],{"nctId":23501,"briefTitle":23502,"status":104,"phases":23503,"primaryCompletion":23504,"completion":23504,"start":11937,"enrollment":224,"conditions":23505,"interventions":23507},"NCT04331938","Efficacy of Percutaneous SPG Block in Aneurysmal SAH",[90],"2024-04-08",[23506,787],"Subarachnoid Hemorrhage",[23494],{"trials":23509,"activeCount":128},[],{"trials":23511,"activeCount":128},[],{"trials":23513,"activeCount":128},[],{"trials":23515,"activeCount":128},[],{"intervention":23517,"totalTrials":676,"cells":23518},"Nab-paclitaxel\u002FDanburstotug Complex AP160",{"EARLY_PHASE1":23519,"PHASE1":23521,"PHASE2":23529,"PHASE3":23531,"PHASE4":23533,"NA":23535},{"trials":23520,"activeCount":128},[],{"trials":23522,"activeCount":128},[23523],{"nctId":23524,"briefTitle":23525,"status":1413,"phases":23526,"primaryCompletion":81,"completion":81,"start":81,"enrollment":128,"conditions":23527,"interventions":23528},"NCT05653661","Nab-Paclitaxel\u002FSTI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors",[90],[10158,202,177],[23517],{"trials":23530,"activeCount":128},[],{"trials":23532,"activeCount":128},[],{"trials":23534,"activeCount":128},[],{"trials":23536,"activeCount":128},[],{"intervention":23538,"totalTrials":676,"cells":23539},"Mepolizumab",{"EARLY_PHASE1":23540,"PHASE1":23542,"PHASE2":23553,"PHASE3":23555,"PHASE4":23557,"NA":23559},{"trials":23541,"activeCount":128},[],{"trials":23543,"activeCount":128},[23544],{"nctId":23545,"briefTitle":23546,"status":1413,"phases":23547,"primaryCompletion":23548,"completion":23548,"start":23549,"enrollment":128,"conditions":23550,"interventions":23552},"NCT04305678","Mepolizumab for Eosinophilic Fasciitis",[90],"2023-02-15","2023-02",[23551],"Eosinophilic Fasciitis",[23538],{"trials":23554,"activeCount":128},[],{"trials":23556,"activeCount":128},[],{"trials":23558,"activeCount":128},[],{"trials":23560,"activeCount":128},[],{"intervention":23562,"totalTrials":676,"cells":23563},"MANP - 1st Cycle",{"EARLY_PHASE1":23564,"PHASE1":23566,"PHASE2":23577,"PHASE3":23579,"PHASE4":23581,"NA":23583},{"trials":23565,"activeCount":128},[],{"trials":23567,"activeCount":128},[23568],{"nctId":23569,"briefTitle":23570,"status":1413,"phases":23571,"primaryCompletion":23572,"completion":5444,"start":15684,"enrollment":128,"conditions":23573,"interventions":23575},"NCT04542681","MANP in African Americans With Hypertension",[90],"2022-12-30",[23574],"Hypertension, Resistant to Conventional Therapy",[23562,23576],"MANP - 2nd Cycle",{"trials":23578,"activeCount":128},[],{"trials":23580,"activeCount":128},[],{"trials":23582,"activeCount":128},[],{"trials":23584,"activeCount":128},[],{"intervention":23576,"totalTrials":676,"cells":23586},{"EARLY_PHASE1":23587,"PHASE1":23589,"PHASE2":23595,"PHASE3":23597,"PHASE4":23599,"NA":23601},{"trials":23588,"activeCount":128},[],{"trials":23590,"activeCount":128},[23591],{"nctId":23569,"briefTitle":23570,"status":1413,"phases":23592,"primaryCompletion":23572,"completion":5444,"start":15684,"enrollment":128,"conditions":23593,"interventions":23594},[90],[23574],[23562,23576],{"trials":23596,"activeCount":128},[],{"trials":23598,"activeCount":128},[],{"trials":23600,"activeCount":128},[],{"trials":23602,"activeCount":128},[],{"intervention":23604,"totalTrials":676,"cells":23605},"Heat Shock Factor 1 Pathway Inhibitor NXP800",{"EARLY_PHASE1":23606,"PHASE1":23608,"PHASE2":23622,"PHASE3":23624,"PHASE4":23626,"NA":23628},{"trials":23607,"activeCount":128},[],{"trials":23609,"activeCount":128},[23610],{"nctId":23611,"briefTitle":23612,"status":134,"phases":23613,"primaryCompletion":4745,"completion":23614,"start":7066,"enrollment":120,"conditions":23615,"interventions":23621},"NCT06420349","NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma",[90],"2025-09-09",[23616,23617,23618,23619,4660,23620,4661],"Advanced Cholangiocarcinoma","Metastatic Cholangiocarcinoma","Refractory Cholangiocarcinoma","Stage III Hilar Cholangiocarcinoma AJCC v8","Stage IV Hilar Cholangiocarcinoma AJCC v8",[23604],{"trials":23623,"activeCount":128},[],{"trials":23625,"activeCount":128},[],{"trials":23627,"activeCount":128},[],{"trials":23629,"activeCount":128},[],{"intervention":23631,"totalTrials":676,"cells":23632},"Arm 1",{"EARLY_PHASE1":23633,"PHASE1":23635,"PHASE2":23646,"PHASE3":23648,"PHASE4":23650,"NA":23652},{"trials":23634,"activeCount":128},[],{"trials":23636,"activeCount":128},[23637],{"nctId":23638,"briefTitle":23639,"status":104,"phases":23640,"primaryCompletion":1021,"completion":1021,"start":16249,"enrollment":11025,"conditions":23641,"interventions":23644},"NCT01211912","Acetaminophen Transfer Across the Placenta and the Assessment of Fetal Well-being",[90],[23642,23643],"Fetal Testing","Transplacental Transfer of Acetaminophen",[23631,23645],"Arm 2",{"trials":23647,"activeCount":128},[],{"trials":23649,"activeCount":128},[],{"trials":23651,"activeCount":128},[],{"trials":23653,"activeCount":128},[],{"intervention":23645,"totalTrials":676,"cells":23655},{"EARLY_PHASE1":23656,"PHASE1":23658,"PHASE2":23664,"PHASE3":23666,"PHASE4":23668,"NA":23670},{"trials":23657,"activeCount":128},[],{"trials":23659,"activeCount":128},[23660],{"nctId":23638,"briefTitle":23639,"status":104,"phases":23661,"primaryCompletion":1021,"completion":1021,"start":16249,"enrollment":11025,"conditions":23662,"interventions":23663},[90],[23642,23643],[23631,23645],{"trials":23665,"activeCount":128},[],{"trials":23667,"activeCount":128},[],{"trials":23669,"activeCount":128},[],{"trials":23671,"activeCount":128},[],{"intervention":23673,"totalTrials":676,"cells":23674},"ACTH",{"EARLY_PHASE1":23675,"PHASE1":23677,"PHASE2":23685,"PHASE3":23687,"PHASE4":23689,"NA":23691},{"trials":23676,"activeCount":128},[],{"trials":23678,"activeCount":128},[23679],{"nctId":23680,"briefTitle":23681,"status":104,"phases":23682,"primaryCompletion":4279,"completion":874,"start":3717,"enrollment":173,"conditions":23683,"interventions":23684},"NCT00805753","Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy",[90],[5466],[23673],{"trials":23686,"activeCount":128},[],{"trials":23688,"activeCount":128},[],{"trials":23690,"activeCount":128},[],{"trials":23692,"activeCount":128},[],{"intervention":15775,"totalTrials":676,"cells":23694},{"EARLY_PHASE1":23695,"PHASE1":23697,"PHASE2":23703,"PHASE3":23705,"PHASE4":23707,"NA":23709},{"trials":23696,"activeCount":128},[],{"trials":23698,"activeCount":128},[23699],{"nctId":15768,"briefTitle":15769,"status":104,"phases":23700,"primaryCompletion":3673,"completion":3673,"start":5280,"enrollment":3034,"conditions":23701,"interventions":23702},[90],[15772],[15774,15775],{"trials":23704,"activeCount":128},[],{"trials":23706,"activeCount":128},[],{"trials":23708,"activeCount":128},[],{"trials":23710,"activeCount":128},[],{"intervention":23712,"totalTrials":676,"cells":23713},"Dabigatran Etexilate Mesylate",{"EARLY_PHASE1":23714,"PHASE1":23716,"PHASE2":23726,"PHASE3":23728,"PHASE4":23730,"NA":23732},{"trials":23715,"activeCount":128},[],{"trials":23717,"activeCount":128},[23718],{"nctId":23719,"briefTitle":23720,"status":134,"phases":23721,"primaryCompletion":23722,"completion":23722,"start":23723,"enrollment":224,"conditions":23724,"interventions":23725},"NCT03807856","Treating Acute Pancreatitis With Dabigatran, a Pilot Study",[90],"2020-07-23","2019-06-24",[16098],[23712],{"trials":23727,"activeCount":128},[],{"trials":23729,"activeCount":128},[],{"trials":23731,"activeCount":128},[],{"trials":23733,"activeCount":128},[],{"intervention":3388,"totalTrials":676,"cells":23735},{"EARLY_PHASE1":23736,"PHASE1":23738,"PHASE2":23744,"PHASE3":23746,"PHASE4":23748,"NA":23750},{"trials":23737,"activeCount":128},[],{"trials":23739,"activeCount":128},[23740],{"nctId":3357,"briefTitle":3358,"status":104,"phases":23741,"primaryCompletion":3360,"completion":3361,"start":3362,"enrollment":2555,"conditions":23742,"interventions":23743},[90],[143,502,506,511,3364,3365,3366,3367,3368,3369,3370,3371,3372,3373,3374,3375,3376,3377,3378,3379,3380,3381,3382,3383,3384,3385,3386],[57,3388],{"trials":23745,"activeCount":128},[],{"trials":23747,"activeCount":128},[],{"trials":23749,"activeCount":128},[],{"trials":23751,"activeCount":128},[],{"intervention":23753,"totalTrials":676,"cells":23754},"mangosteen juice",{"EARLY_PHASE1":23755,"PHASE1":23757,"PHASE2":23766,"PHASE3":23768,"PHASE4":23770,"NA":23772},{"trials":23756,"activeCount":128},[],{"trials":23758,"activeCount":128},[23759],{"nctId":23760,"briefTitle":23761,"status":134,"phases":23762,"primaryCompletion":6365,"completion":6365,"start":6955,"enrollment":23763,"conditions":23764,"interventions":23765},"NCT00951301","Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation",[90],143,[33],[23753],{"trials":23767,"activeCount":128},[],{"trials":23769,"activeCount":128},[],{"trials":23771,"activeCount":128},[],{"trials":23773,"activeCount":128},[],{"intervention":17850,"totalTrials":676,"cells":23775},{"EARLY_PHASE1":23776,"PHASE1":23778,"PHASE2":23784,"PHASE3":23786,"PHASE4":23788,"NA":23790},{"trials":23777,"activeCount":128},[],{"trials":23779,"activeCount":128},[23780],{"nctId":17843,"briefTitle":17844,"status":134,"phases":23781,"primaryCompletion":17846,"completion":17846,"start":17847,"enrollment":370,"conditions":23782,"interventions":23783},[90],[144,149],[17850,10360],{"trials":23785,"activeCount":128},[],{"trials":23787,"activeCount":128},[],{"trials":23789,"activeCount":128},[],{"trials":23791,"activeCount":128},[],{"intervention":23793,"totalTrials":676,"cells":23794},"SVF",{"EARLY_PHASE1":23795,"PHASE1":23797,"PHASE2":23810,"PHASE3":23812,"PHASE4":23814,"NA":23816},{"trials":23796,"activeCount":128},[],{"trials":23798,"activeCount":128},[23799],{"nctId":23800,"briefTitle":23801,"status":1413,"phases":23802,"primaryCompletion":2111,"completion":23803,"start":23804,"enrollment":128,"conditions":23805,"interventions":23809},"NCT03792360","Adipose Derived SVF for Aero-digestive & Enterocutaneous Fistulae",[90],"2028-02","2021-02",[23806,23807,23808],"Tracheoesopharyngeal Fistula","Bronchoesophageal Fistula","Tracheoesophageal Fistula",[23793],{"trials":23811,"activeCount":128},[],{"trials":23813,"activeCount":128},[],{"trials":23815,"activeCount":128},[],{"trials":23817,"activeCount":128},[],{"intervention":23819,"totalTrials":676,"cells":23820},"venlafaxine ER (extended-release) 75 mg",{"EARLY_PHASE1":23821,"PHASE1":23823,"PHASE2":23834,"PHASE3":23836,"PHASE4":23838,"NA":23840},{"trials":23822,"activeCount":128},[],{"trials":23824,"activeCount":128},[23825],{"nctId":23826,"briefTitle":23827,"status":104,"phases":23828,"primaryCompletion":2863,"completion":2863,"start":3641,"enrollment":370,"conditions":23829,"interventions":23833},"NCT01867255","Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels",[90],[23830,23831,23832],"Bariatric Surgery","Gastric Bypass","Roux-en-Y Gastric Bypass",[23819],{"trials":23835,"activeCount":128},[],{"trials":23837,"activeCount":128},[],{"trials":23839,"activeCount":128},[],{"trials":23841,"activeCount":128},[],{"intervention":23843,"totalTrials":676,"cells":23844},"Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta",{"EARLY_PHASE1":23845,"PHASE1":23847,"PHASE2":23857,"PHASE3":23859,"PHASE4":23861,"NA":23863},{"trials":23846,"activeCount":128},[],{"trials":23848,"activeCount":128},[23849],{"nctId":23850,"briefTitle":23851,"status":104,"phases":23852,"primaryCompletion":23853,"completion":23853,"start":23854,"enrollment":139,"conditions":23855,"interventions":23856},"NCT01628640","Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors",[90],"2019-04-19","2012-08-03",[10158,4616],[23843],{"trials":23858,"activeCount":128},[],{"trials":23860,"activeCount":128},[],{"trials":23862,"activeCount":128},[],{"trials":23864,"activeCount":128},[],{"intervention":23866,"totalTrials":676,"cells":23867},"B7-DC cross-linking antibody rHIgM12B7",{"EARLY_PHASE1":23868,"PHASE1":23870,"PHASE2":23881,"PHASE3":23883,"PHASE4":23885,"NA":23887},{"trials":23869,"activeCount":128},[],{"trials":23871,"activeCount":128},[23872],{"nctId":23873,"briefTitle":23874,"status":104,"phases":23875,"primaryCompletion":23876,"completion":23877,"start":23878,"enrollment":120,"conditions":23879,"interventions":23880},"NCT00658892","Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma",[90],"2010-02-15","2012-05-22","2008-04-08",[4291],[23866],{"trials":23882,"activeCount":128},[],{"trials":23884,"activeCount":128},[],{"trials":23886,"activeCount":128},[],{"trials":23888,"activeCount":128},[],{"intervention":23890,"totalTrials":676,"cells":23891},"Mexiletine",{"EARLY_PHASE1":23892,"PHASE1":23894,"PHASE2":23903,"PHASE3":23905,"PHASE4":23907,"NA":23909},{"trials":23893,"activeCount":128},[],{"trials":23895,"activeCount":128},[23896],{"nctId":23897,"briefTitle":23898,"status":104,"phases":23899,"primaryCompletion":4030,"completion":4030,"start":6275,"enrollment":676,"conditions":23900,"interventions":23902},"NCT01717404","Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)",[90],[23901],"IBS",[23890],{"trials":23904,"activeCount":128},[],{"trials":23906,"activeCount":128},[],{"trials":23908,"activeCount":128},[],{"trials":23910,"activeCount":128},[],{"intervention":156,"totalTrials":676,"cells":23912},{"EARLY_PHASE1":23913,"PHASE1":23915,"PHASE2":23921,"PHASE3":23923,"PHASE4":23925,"NA":23927},{"trials":23914,"activeCount":128},[],{"trials":23916,"activeCount":128},[23917],{"nctId":132,"briefTitle":133,"status":134,"phases":23918,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":23919,"interventions":23920},[90],[141,142,143,144,145,146,147,148,149,150,151,152,153,154],[156,157,158,159,160,161,112,162,72,163,164,165],{"trials":23922,"activeCount":128},[],{"trials":23924,"activeCount":128},[],{"trials":23926,"activeCount":128},[],{"trials":23928,"activeCount":128},[],{"intervention":158,"totalTrials":676,"cells":23930},{"EARLY_PHASE1":23931,"PHASE1":23933,"PHASE2":23939,"PHASE3":23941,"PHASE4":23943,"NA":23945},{"trials":23932,"activeCount":128},[],{"trials":23934,"activeCount":128},[23935],{"nctId":132,"briefTitle":133,"status":134,"phases":23936,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":23937,"interventions":23938},[90],[141,142,143,144,145,146,147,148,149,150,151,152,153,154],[156,157,158,159,160,161,112,162,72,163,164,165],{"trials":23940,"activeCount":128},[],{"trials":23942,"activeCount":128},[],{"trials":23944,"activeCount":128},[],{"trials":23946,"activeCount":128},[],{"intervention":160,"totalTrials":676,"cells":23948},{"EARLY_PHASE1":23949,"PHASE1":23951,"PHASE2":23957,"PHASE3":23959,"PHASE4":23961,"NA":23963},{"trials":23950,"activeCount":128},[],{"trials":23952,"activeCount":128},[23953],{"nctId":132,"briefTitle":133,"status":134,"phases":23954,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":23955,"interventions":23956},[90],[141,142,143,144,145,146,147,148,149,150,151,152,153,154],[156,157,158,159,160,161,112,162,72,163,164,165],{"trials":23958,"activeCount":128},[],{"trials":23960,"activeCount":128},[],{"trials":23962,"activeCount":128},[],{"trials":23964,"activeCount":128},[],{"intervention":23966,"totalTrials":676,"cells":23967},"Topical SR-01",{"EARLY_PHASE1":23968,"PHASE1":23970,"PHASE2":23980,"PHASE3":23982,"PHASE4":23984,"NA":23986},{"trials":23969,"activeCount":128},[],{"trials":23971,"activeCount":128},[23972],{"nctId":23973,"briefTitle":23974,"status":104,"phases":23975,"primaryCompletion":5034,"completion":5034,"start":1299,"enrollment":173,"conditions":23976,"interventions":23979},"NCT00279890","Topical Agent for Treatment of Red Skin",[90],[23977,23978],"Rosacea","Bilaterally Symmetric Red Skin on Cheeks",[23966],{"trials":23981,"activeCount":128},[],{"trials":23983,"activeCount":128},[],{"trials":23985,"activeCount":128},[],{"trials":23987,"activeCount":128},[],{"intervention":23989,"totalTrials":676,"cells":23990},"Hypertonic Saline Aerosol",{"EARLY_PHASE1":23991,"PHASE1":23993,"PHASE2":24002,"PHASE3":24004,"PHASE4":24006,"NA":24008},{"trials":23992,"activeCount":128},[],{"trials":23994,"activeCount":128},[23995],{"nctId":23996,"briefTitle":23997,"status":1413,"phases":23998,"primaryCompletion":1235,"completion":1235,"start":3641,"enrollment":128,"conditions":23999,"interventions":24001},"NCT01713595","Safety Study of Inhaled Saline in Acute Lung Injury",[90],[24000],"Pulmonary Edema",[23989],{"trials":24003,"activeCount":128},[],{"trials":24005,"activeCount":128},[],{"trials":24007,"activeCount":128},[],{"trials":24009,"activeCount":128},[],{"intervention":24011,"totalTrials":676,"cells":24012},"Vaginal Bromocriptine",{"EARLY_PHASE1":24013,"PHASE1":24015,"PHASE2":24025,"PHASE3":24027,"PHASE4":24029,"NA":24031},{"trials":24014,"activeCount":128},[],{"trials":24016,"activeCount":128},[24017],{"nctId":24018,"briefTitle":24019,"status":104,"phases":24020,"primaryCompletion":2697,"completion":24021,"start":12007,"enrollment":676,"conditions":24022,"interventions":24024},"NCT01821001","Vaginal Bromocriptine for Treatment of Adenomyosis",[90],"2018-01",[24023],"Adenomyosis",[24011],{"trials":24026,"activeCount":128},[],{"trials":24028,"activeCount":128},[],{"trials":24030,"activeCount":128},[],{"trials":24032,"activeCount":128},[],{"intervention":24034,"totalTrials":676,"cells":24035},"Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy",{"EARLY_PHASE1":24036,"PHASE1":24038,"PHASE2":24046,"PHASE3":24048,"PHASE4":24050,"NA":24052},{"trials":24037,"activeCount":128},[],{"trials":24039,"activeCount":128},[24040],{"nctId":24041,"briefTitle":24042,"status":104,"phases":24043,"primaryCompletion":66,"completion":66,"start":10335,"enrollment":370,"conditions":24044,"interventions":24045},"NCT04410731","Allogeneic BM-MSCs in Patients with Lumbar Facet Arthropathy",[90],[9290],[24034],{"trials":24047,"activeCount":128},[],{"trials":24049,"activeCount":128},[],{"trials":24051,"activeCount":128},[],{"trials":24053,"activeCount":128},[],{"intervention":24055,"totalTrials":676,"cells":24056},"Rapamune",{"EARLY_PHASE1":24057,"PHASE1":24059,"PHASE2":24068,"PHASE3":24070,"PHASE4":24072,"NA":24074},{"trials":24058,"activeCount":128},[],{"trials":24060,"activeCount":128},[24061],{"nctId":24062,"briefTitle":24063,"status":104,"phases":24064,"primaryCompletion":24065,"completion":24065,"start":12667,"enrollment":2555,"conditions":24066,"interventions":24067},"NCT04996719","Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults",[90],"2023-08-25",[27],[24055],{"trials":24069,"activeCount":128},[],{"trials":24071,"activeCount":128},[],{"trials":24073,"activeCount":128},[],{"trials":24075,"activeCount":128},[],{"intervention":11485,"totalTrials":676,"cells":24077},{"EARLY_PHASE1":24078,"PHASE1":24080,"PHASE2":24086,"PHASE3":24088,"PHASE4":24090,"NA":24092},{"trials":24079,"activeCount":128},[],{"trials":24081,"activeCount":128},[24082],{"nctId":11477,"briefTitle":11478,"status":104,"phases":24083,"primaryCompletion":11480,"completion":11480,"start":11481,"conditions":24084,"interventions":24085},[90],[11483,21,4854,4292,4293],[3324,11485],{"trials":24087,"activeCount":128},[],{"trials":24089,"activeCount":128},[],{"trials":24091,"activeCount":128},[],{"trials":24093,"activeCount":128},[],{"intervention":24095,"totalTrials":676,"cells":24096},"sc-rAAV2.5IL-1Ra",{"EARLY_PHASE1":24097,"PHASE1":24099,"PHASE2":24108,"PHASE3":24110,"PHASE4":24112,"NA":24114},{"trials":24098,"activeCount":128},[],{"trials":24100,"activeCount":128},[24101],{"nctId":24102,"briefTitle":24103,"status":104,"phases":24104,"primaryCompletion":24105,"completion":24105,"start":3866,"enrollment":476,"conditions":24106,"interventions":24107},"NCT02790723","Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OA",[90],"2022-03-17",[15772],[24095],{"trials":24109,"activeCount":128},[],{"trials":24111,"activeCount":128},[],{"trials":24113,"activeCount":128},[],{"trials":24115,"activeCount":128},[],{"intervention":24117,"totalTrials":676,"cells":24118},"Autologous adipose-derived mesenchymal stem\u002Fstromal cells (MSC) Lower Dose",{"EARLY_PHASE1":24119,"PHASE1":24121,"PHASE2":24138,"PHASE3":24140,"PHASE4":24142,"NA":24144},{"trials":24120,"activeCount":128},[],{"trials":24122,"activeCount":128},[24123],{"nctId":24124,"briefTitle":24125,"status":134,"phases":24126,"primaryCompletion":24127,"completion":24127,"start":24128,"enrollment":224,"conditions":24129,"interventions":24136},"NCT03840343","Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease",[90],"2020-08-04","2019-10-23",[24130,24131,15686,24132,6957,24133,24134,24135],"Diabetic Kidney Disease","Diabetic Nephropathies","Diabetes Mellitus, Type 1","Diabetic Nephropathy Type 2","Kidney Failure","Kidney Insufficiency",[24117,24137],"Autologous adipose-derived mesenchymal stem\u002Fstromal cells (MSC) Higher Dose",{"trials":24139,"activeCount":128},[],{"trials":24141,"activeCount":128},[],{"trials":24143,"activeCount":128},[],{"trials":24145,"activeCount":128},[],{"intervention":24137,"totalTrials":676,"cells":24147},{"EARLY_PHASE1":24148,"PHASE1":24150,"PHASE2":24156,"PHASE3":24158,"PHASE4":24160,"NA":24162},{"trials":24149,"activeCount":128},[],{"trials":24151,"activeCount":128},[24152],{"nctId":24124,"briefTitle":24125,"status":134,"phases":24153,"primaryCompletion":24127,"completion":24127,"start":24128,"enrollment":224,"conditions":24154,"interventions":24155},[90],[24130,24131,15686,24132,6957,24133,24134,24135],[24117,24137],{"trials":24157,"activeCount":128},[],{"trials":24159,"activeCount":128},[],{"trials":24161,"activeCount":128},[],{"trials":24163,"activeCount":128},[],{"intervention":24165,"totalTrials":676,"cells":24166},"REcycled CartiLage Auto\u002FAllo IMplantation",{"EARLY_PHASE1":24167,"PHASE1":24169,"PHASE2":24180,"PHASE3":24182,"PHASE4":24184,"NA":24186},{"trials":24168,"activeCount":128},[],{"trials":24170,"activeCount":128},[24171],{"nctId":24172,"briefTitle":24165,"status":104,"phases":24173,"primaryCompletion":24174,"completion":24175,"start":24176,"enrollment":558,"conditions":24177,"interventions":24179},"NCT03672825",[90],"2024-05-09","2024-06-21","2018-09-13",[24178],"Cartilage Defect",[24165],{"trials":24181,"activeCount":128},[],{"trials":24183,"activeCount":128},[],{"trials":24185,"activeCount":128},[],{"trials":24187,"activeCount":128},[],{"intervention":24189,"totalTrials":676,"cells":24190},"Ketoconazole, Dexamethesone, Androgel,GnRH",{"EARLY_PHASE1":24191,"PHASE1":24193,"PHASE2":24203,"PHASE3":24205,"PHASE4":24207,"NA":24209},{"trials":24192,"activeCount":128},[],{"trials":24194,"activeCount":128},[24195],{"nctId":24196,"briefTitle":24197,"status":104,"phases":24198,"primaryCompletion":934,"completion":934,"start":24199,"enrollment":498,"conditions":24200,"interventions":24202},"NCT00431197","Steady-State Feedback Actions of Testosterone on Luteinizing Hormone Secretion in Young and Older Men",[90],"2004-02",[24201],"Hypogonadism",[24189],{"trials":24204,"activeCount":128},[],{"trials":24206,"activeCount":128},[],{"trials":24208,"activeCount":128},[],{"trials":24210,"activeCount":128},[],{"intervention":22919,"totalTrials":676,"cells":24212},{"EARLY_PHASE1":24213,"PHASE1":24215,"PHASE2":24221,"PHASE3":24223,"PHASE4":24225,"NA":24227},{"trials":24214,"activeCount":128},[],{"trials":24216,"activeCount":128},[24217],{"nctId":22914,"briefTitle":22915,"status":104,"phases":24218,"primaryCompletion":3673,"completion":3673,"start":22498,"enrollment":2678,"conditions":24219,"interventions":24220},[90],[7089],[8202,22919,22920],{"trials":24222,"activeCount":128},[],{"trials":24224,"activeCount":128},[],{"trials":24226,"activeCount":128},[],{"trials":24228,"activeCount":128},[],{"intervention":22920,"totalTrials":676,"cells":24230},{"EARLY_PHASE1":24231,"PHASE1":24233,"PHASE2":24239,"PHASE3":24241,"PHASE4":24243,"NA":24245},{"trials":24232,"activeCount":128},[],{"trials":24234,"activeCount":128},[24235],{"nctId":22914,"briefTitle":22915,"status":104,"phases":24236,"primaryCompletion":3673,"completion":3673,"start":22498,"enrollment":2678,"conditions":24237,"interventions":24238},[90],[7089],[8202,22919,22920],{"trials":24240,"activeCount":128},[],{"trials":24242,"activeCount":128},[],{"trials":24244,"activeCount":128},[],{"trials":24246,"activeCount":128},[],{"intervention":24248,"totalTrials":676,"cells":24249},"Autologous CD34+ Cells",{"EARLY_PHASE1":24250,"PHASE1":24252,"PHASE2":24264,"PHASE3":24266,"PHASE4":24268,"NA":24270},{"trials":24251,"activeCount":128},[],{"trials":24253,"activeCount":128},[24254],{"nctId":24255,"briefTitle":24256,"status":104,"phases":24257,"primaryCompletion":24258,"completion":24258,"start":24259,"enrollment":3674,"conditions":24260,"interventions":24262},"NCT03471611","Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis",[90],"2020-10-02","2018-06-15",[24261],"Atherosclerosis, Coronary",[24248,24263],"Granulocyte Colony-Stimulating Factor",{"trials":24265,"activeCount":128},[],{"trials":24267,"activeCount":128},[],{"trials":24269,"activeCount":128},[],{"trials":24271,"activeCount":128},[],{"intervention":24263,"totalTrials":676,"cells":24273},{"EARLY_PHASE1":24274,"PHASE1":24276,"PHASE2":24282,"PHASE3":24284,"PHASE4":24286,"NA":24288},{"trials":24275,"activeCount":128},[],{"trials":24277,"activeCount":128},[24278],{"nctId":24255,"briefTitle":24256,"status":104,"phases":24279,"primaryCompletion":24258,"completion":24258,"start":24259,"enrollment":3674,"conditions":24280,"interventions":24281},[90],[24261],[24248,24263],{"trials":24283,"activeCount":128},[],{"trials":24285,"activeCount":128},[],{"trials":24287,"activeCount":128},[],{"trials":24289,"activeCount":128},[],{"intervention":24291,"totalTrials":676,"cells":24292},"tanespimycin",{"EARLY_PHASE1":24293,"PHASE1":24295,"PHASE2":24303,"PHASE3":24305,"PHASE4":24307,"NA":24309},{"trials":24294,"activeCount":128},[],{"trials":24296,"activeCount":128},[24297],{"nctId":24298,"briefTitle":24299,"status":104,"phases":24300,"primaryCompletion":5034,"completion":5034,"start":21783,"conditions":24301,"interventions":24302},"NCT00004075","17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery",[90],[1419,4293],[24291],{"trials":24304,"activeCount":128},[],{"trials":24306,"activeCount":128},[],{"trials":24308,"activeCount":128},[],{"trials":24310,"activeCount":128},[],{"intervention":24312,"totalTrials":676,"cells":24313},"Combination Prep",{"EARLY_PHASE1":24314,"PHASE1":24316,"PHASE2":24325,"PHASE3":24327,"PHASE4":24329,"NA":24331},{"trials":24315,"activeCount":128},[],{"trials":24317,"activeCount":128},[24318],{"nctId":24319,"briefTitle":24320,"status":104,"phases":24321,"primaryCompletion":3671,"completion":3671,"start":13184,"enrollment":773,"conditions":24322,"interventions":24324},"NCT01243736","Assessment of Combined Bowel Preparation for Capsule Endoscopy Study",[90],[24323],"Gastrointestinal Hemorrhage",[24312],{"trials":24326,"activeCount":128},[],{"trials":24328,"activeCount":128},[],{"trials":24330,"activeCount":128},[],{"trials":24332,"activeCount":128},[],{"intervention":5265,"totalTrials":676,"cells":24334},{"EARLY_PHASE1":24335,"PHASE1":24337,"PHASE2":24343,"PHASE3":24345,"PHASE4":24347,"NA":24349},{"trials":24336,"activeCount":128},[],{"trials":24338,"activeCount":128},[24339],{"nctId":5257,"briefTitle":5258,"status":104,"phases":24340,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":729,"conditions":24341,"interventions":24342},[90],[3665],[3553,3759,5265,657,5266],{"trials":24344,"activeCount":128},[],{"trials":24346,"activeCount":128},[],{"trials":24348,"activeCount":128},[],{"trials":24350,"activeCount":128},[],{"intervention":5266,"totalTrials":676,"cells":24352},{"EARLY_PHASE1":24353,"PHASE1":24355,"PHASE2":24361,"PHASE3":24363,"PHASE4":24365,"NA":24367},{"trials":24354,"activeCount":128},[],{"trials":24356,"activeCount":128},[24357],{"nctId":5257,"briefTitle":5258,"status":104,"phases":24358,"primaryCompletion":5260,"completion":5261,"start":5262,"enrollment":729,"conditions":24359,"interventions":24360},[90],[3665],[3553,3759,5265,657,5266],{"trials":24362,"activeCount":128},[],{"trials":24364,"activeCount":128},[],{"trials":24366,"activeCount":128},[],{"trials":24368,"activeCount":128},[],{"intervention":24370,"totalTrials":676,"cells":24371},"brain natriuretic peptide",{"EARLY_PHASE1":24372,"PHASE1":24374,"PHASE2":24383,"PHASE3":24385,"PHASE4":24387,"NA":24389},{"trials":24373,"activeCount":128},[],{"trials":24375,"activeCount":128},[24376],{"nctId":24377,"briefTitle":24378,"status":134,"phases":24379,"primaryCompletion":3661,"completion":3661,"start":3546,"enrollment":2563,"conditions":24380,"interventions":24382},"NCT00953472","B-type Natriuretic Peptide (BNP) in Human Hypertension",[90],[24381],"Hypertension Stage 1",[24370],{"trials":24384,"activeCount":128},[],{"trials":24386,"activeCount":128},[],{"trials":24388,"activeCount":128},[],{"trials":24390,"activeCount":128},[],{"intervention":24392,"totalTrials":676,"cells":24393},"Minocycline",{"EARLY_PHASE1":24394,"PHASE1":24396,"PHASE2":24404,"PHASE3":24406,"PHASE4":24408,"NA":24410},{"trials":24395,"activeCount":128},[],{"trials":24397,"activeCount":128},[24398],{"nctId":24399,"briefTitle":24400,"status":104,"phases":24401,"primaryCompletion":16217,"completion":16217,"start":16723,"enrollment":2742,"conditions":24402,"interventions":24403},"NCT00630942","Minocycline in Primary Sclerosing Cholangitis (PSC)",[90],[8319],[24392],{"trials":24405,"activeCount":128},[],{"trials":24407,"activeCount":128},[],{"trials":24409,"activeCount":128},[],{"trials":24411,"activeCount":128},[],{"intervention":24413,"totalTrials":676,"cells":24414},"pneumococcal vaccination",{"EARLY_PHASE1":24415,"PHASE1":24417,"PHASE2":24425,"PHASE3":24427,"PHASE4":24429,"NA":24431},{"trials":24416,"activeCount":128},[],{"trials":24418,"activeCount":128},[24419],{"nctId":24420,"briefTitle":24421,"status":104,"phases":24422,"primaryCompletion":5141,"completion":2642,"start":4928,"enrollment":712,"conditions":24423,"interventions":24424},"NCT00589394","Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine",[90],[18],[24413],{"trials":24426,"activeCount":128},[],{"trials":24428,"activeCount":128},[],{"trials":24430,"activeCount":128},[],{"trials":24432,"activeCount":128},[],{"intervention":24434,"totalTrials":676,"cells":24435},"Triamcinolone Acetonide",{"EARLY_PHASE1":24436,"PHASE1":24438,"PHASE2":24449,"PHASE3":24451,"PHASE4":24453,"NA":24455},{"trials":24437,"activeCount":128},[],{"trials":24439,"activeCount":128},[24440],{"nctId":24441,"briefTitle":24442,"status":104,"phases":24443,"primaryCompletion":24444,"completion":24444,"start":24445,"enrollment":370,"conditions":24446,"interventions":24448},"NCT03627741","A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors",[90],"2022-07-05","2018-06-07",[24447],"Fibromatosis",[24434],{"trials":24450,"activeCount":128},[],{"trials":24452,"activeCount":128},[],{"trials":24454,"activeCount":128},[],{"trials":24456,"activeCount":128},[],{"intervention":15623,"totalTrials":676,"cells":24458},{"EARLY_PHASE1":24459,"PHASE1":24461,"PHASE2":24467,"PHASE3":24469,"PHASE4":24471,"NA":24473},{"trials":24460,"activeCount":128},[],{"trials":24462,"activeCount":128},[24463],{"nctId":15618,"briefTitle":15619,"status":104,"phases":24464,"primaryCompletion":3842,"completion":3842,"start":4032,"enrollment":3726,"conditions":24465,"interventions":24466},[90],[8319],[15603,15603,15623,15623,15603],{"trials":24468,"activeCount":128},[],{"trials":24470,"activeCount":128},[],{"trials":24472,"activeCount":128},[],{"trials":24474,"activeCount":128},[],{"intervention":24476,"totalTrials":676,"cells":24477},"Human insulin",{"EARLY_PHASE1":24478,"PHASE1":24480,"PHASE2":24488,"PHASE3":24490,"PHASE4":24492,"NA":24494},{"trials":24479,"activeCount":128},[],{"trials":24481,"activeCount":128},[24482],{"nctId":24483,"briefTitle":24484,"status":104,"phases":24485,"primaryCompletion":1375,"completion":1375,"start":954,"enrollment":355,"conditions":24486,"interventions":24487},"NCT01240252","Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance",[90],[6975],[24476],{"trials":24489,"activeCount":128},[],{"trials":24491,"activeCount":128},[],{"trials":24493,"activeCount":128},[],{"trials":24495,"activeCount":128},[],{"intervention":18816,"totalTrials":676,"cells":24497},{"EARLY_PHASE1":24498,"PHASE1":24500,"PHASE2":24506,"PHASE3":24508,"PHASE4":24510,"NA":24512},{"trials":24499,"activeCount":128},[],{"trials":24501,"activeCount":128},[24502],{"nctId":18801,"briefTitle":18802,"status":104,"phases":24503,"primaryCompletion":18804,"completion":18804,"start":7717,"enrollment":4565,"conditions":24504,"interventions":24505},[90],[18806,18807,4618,18808,18809,18810,18811,4623,18812,18813,18814],[18816,8373],{"trials":24507,"activeCount":128},[],{"trials":24509,"activeCount":128},[],{"trials":24511,"activeCount":128},[],{"trials":24513,"activeCount":128},[],{"intervention":24515,"totalTrials":676,"cells":24516},"Autologous Adipose-Derived SVF",{"EARLY_PHASE1":24517,"PHASE1":24519,"PHASE2":24531,"PHASE3":24533,"PHASE4":24535,"NA":24537},{"trials":24518,"activeCount":128},[],{"trials":24520,"activeCount":128},[24521],{"nctId":24522,"briefTitle":24523,"status":104,"phases":24524,"primaryCompletion":24525,"completion":24526,"start":24527,"enrollment":476,"conditions":24528,"interventions":24530},"NCT03940950","Intra-articular Transplantation of Autologous Adipose Derived Stromal Vascular Faction (SVF) for Treatment of Osteoarthritis of the Knee",[90],"2025-05-05","2025-05-23","2019-07-02",[20749,24529],"Degenerative Joint Disease of Knee",[24515],{"trials":24532,"activeCount":128},[],{"trials":24534,"activeCount":128},[],{"trials":24536,"activeCount":128},[],{"trials":24538,"activeCount":128},[],{"intervention":24540,"totalTrials":676,"cells":24541},"Anhydrous Enol-oxaloacetate",{"EARLY_PHASE1":24542,"PHASE1":24544,"PHASE2":24553,"PHASE3":24555,"PHASE4":24557,"NA":24559},{"trials":24543,"activeCount":128},[],{"trials":24545,"activeCount":128},[24546],{"nctId":24547,"briefTitle":24548,"status":1413,"phases":24549,"primaryCompletion":15245,"completion":15245,"start":15245,"enrollment":128,"conditions":24550,"interventions":24552},"NCT05720624","Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation",[90],[24551],"Malignant Central Nervous System Neoplasm",[24540],{"trials":24554,"activeCount":128},[],{"trials":24556,"activeCount":128},[],{"trials":24558,"activeCount":128},[],{"trials":24560,"activeCount":128},[],{"intervention":24562,"totalTrials":676,"cells":24563},"Tolvaptan",{"EARLY_PHASE1":24564,"PHASE1":24566,"PHASE2":24575,"PHASE3":24577,"PHASE4":24579,"NA":24581},{"trials":24565,"activeCount":128},[],{"trials":24567,"activeCount":128},[24568],{"nctId":24569,"briefTitle":24570,"status":104,"phases":24571,"primaryCompletion":7696,"completion":7696,"start":3001,"enrollment":173,"conditions":24572,"interventions":24574},"NCT02096965","Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study",[90],[20913,24573],"Nephrolithiasis, Calcium Phosphate",[24562],{"trials":24576,"activeCount":128},[],{"trials":24578,"activeCount":128},[],{"trials":24580,"activeCount":128},[],{"trials":24582,"activeCount":128},[],{"intervention":24584,"totalTrials":676,"cells":24585},"18F-TFB-PET",{"EARLY_PHASE1":24586,"PHASE1":24588,"PHASE2":24600,"PHASE3":24602,"PHASE4":24604,"NA":24606},{"trials":24587,"activeCount":128},[],{"trials":24589,"activeCount":128},[24590],{"nctId":24591,"briefTitle":24592,"status":104,"phases":24593,"primaryCompletion":24594,"completion":24594,"start":24595,"enrollment":224,"conditions":24596,"interventions":24599},"NCT03456908","F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies",[90],"2019-12-31","2018-03-16",[24597,24598],"Myeloma Before MV-NIS Treatment","Endometrial Cancer Before VSV-hINF-NIS Treatment",[24584],{"trials":24601,"activeCount":128},[],{"trials":24603,"activeCount":128},[],{"trials":24605,"activeCount":128},[],{"trials":24607,"activeCount":128},[],{"intervention":24609,"totalTrials":676,"cells":24610},"Microbiota-based Formulation RBX7455",{"EARLY_PHASE1":24611,"PHASE1":24613,"PHASE2":24621,"PHASE3":24623,"PHASE4":24625,"NA":24627},{"trials":24612,"activeCount":128},[],{"trials":24614,"activeCount":128},[24615],{"nctId":24616,"briefTitle":24617,"status":134,"phases":24618,"primaryCompletion":16344,"completion":16344,"start":15489,"enrollment":342,"conditions":24619,"interventions":24620},"NCT04139993","RBX7455 Before Surgery for the Treatment of Operable Breast Cancer",[90],[5197,10337,10338,5198,10339,10340,579,580,581,582,141,7530,10342,10343,10344,10345,10346,10347,6193,6194,6195,6196,221],[24609],{"trials":24622,"activeCount":128},[],{"trials":24624,"activeCount":128},[],{"trials":24626,"activeCount":128},[],{"trials":24628,"activeCount":128},[],{"intervention":24630,"totalTrials":676,"cells":24631},"Cosentyx",{"EARLY_PHASE1":24632,"PHASE1":24634,"PHASE2":24645,"PHASE3":24647,"PHASE4":24649,"NA":24651},{"trials":24633,"activeCount":128},[],{"trials":24635,"activeCount":128},[24636],{"nctId":24637,"briefTitle":24638,"status":104,"phases":24639,"primaryCompletion":24640,"completion":24641,"start":12845,"enrollment":218,"conditions":24642,"interventions":24644},"NCT03342573","Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris",[90],"2022-01-01","2022-02-01",[24643],"PITYRIASIS RUBRA PILARIS",[24630],{"trials":24646,"activeCount":128},[],{"trials":24648,"activeCount":128},[],{"trials":24650,"activeCount":128},[],{"trials":24652,"activeCount":128},[],{"intervention":24654,"totalTrials":676,"cells":24655},"Alefacept",{"EARLY_PHASE1":24656,"PHASE1":24658,"PHASE2":24668,"PHASE3":24670,"PHASE4":24672,"NA":24674},{"trials":24657,"activeCount":128},[],{"trials":24659,"activeCount":128},[24660],{"nctId":24661,"briefTitle":24662,"status":104,"phases":24663,"primaryCompletion":24664,"completion":24665,"start":5515,"enrollment":233,"conditions":24666,"interventions":24667},"NCT00438802","Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma",[90],"2010-08-24","2019-07-25",[1419],[24654],{"trials":24669,"activeCount":128},[],{"trials":24671,"activeCount":128},[],{"trials":24673,"activeCount":128},[],{"trials":24675,"activeCount":128},[],{"intervention":24677,"totalTrials":676,"cells":24678},"Human platelet extract",{"EARLY_PHASE1":24679,"PHASE1":24681,"PHASE2":24691,"PHASE3":24693,"PHASE4":24695,"NA":24697},{"trials":24680,"activeCount":128},[],{"trials":24682,"activeCount":128},[24683],{"nctId":24684,"briefTitle":24685,"status":134,"phases":24686,"primaryCompletion":24687,"completion":24687,"start":15179,"enrollment":11025,"conditions":24688,"interventions":24690},"NCT05457491","Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)",[90],"2022-07-07",[24689],"Skin Aging",[24677],{"trials":24692,"activeCount":128},[],{"trials":24694,"activeCount":128},[],{"trials":24696,"activeCount":128},[],{"trials":24698,"activeCount":128},[],{"intervention":24700,"totalTrials":676,"cells":24701},"Nelfinavir\u002Fplacebo",{"EARLY_PHASE1":24702,"PHASE1":24704,"PHASE2":24713,"PHASE3":24715,"PHASE4":24717,"NA":24719},{"trials":24703,"activeCount":128},[],{"trials":24705,"activeCount":128},[24706],{"nctId":24707,"briefTitle":24708,"status":134,"phases":24709,"primaryCompletion":2937,"completion":2937,"start":3519,"enrollment":28,"conditions":24710,"interventions":24712},"NCT00385450","Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor",[90],[24711],"Cardiopulmonary Bypass",[24700],{"trials":24714,"activeCount":128},[],{"trials":24716,"activeCount":128},[],{"trials":24718,"activeCount":128},[],{"trials":24720,"activeCount":128},[],{"intervention":24722,"totalTrials":676,"cells":24723},"Arterial infusion of autologous mesenchymal stem cells",{"EARLY_PHASE1":24724,"PHASE1":24726,"PHASE2":24737,"PHASE3":24739,"PHASE4":24741,"NA":24743},{"trials":24725,"activeCount":128},[],{"trials":24727,"activeCount":128},[24728],{"nctId":24729,"briefTitle":24730,"status":104,"phases":24731,"primaryCompletion":3001,"completion":5435,"start":4885,"enrollment":1197,"conditions":24732,"interventions":24736},"NCT01840540","MSC for Occlusive Disease of the Kidney",[90],[24733,24734,24735],"Atherosclerotic Renal Artery Stenosis","Ischemic Nephropathy","Renovascular Hypertension",[24722],{"trials":24738,"activeCount":128},[],{"trials":24740,"activeCount":128},[],{"trials":24742,"activeCount":128},[],{"trials":24744,"activeCount":128},[],{"intervention":24746,"totalTrials":676,"cells":24747},"Allogeneic Bone Marrow Derived Mesenchymal Stem Cells",{"EARLY_PHASE1":24748,"PHASE1":24750,"PHASE2":24761,"PHASE3":24763,"PHASE4":24765,"NA":24767},{"trials":24749,"activeCount":128},[],{"trials":24751,"activeCount":128},[24752],{"nctId":24753,"briefTitle":24754,"status":104,"phases":24755,"primaryCompletion":6432,"completion":24756,"start":24757,"enrollment":370,"conditions":24758,"interventions":24760},"NCT03929120","Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)",[90],"2022-02-02","2019-11-05",[6809,24759],"Connective Tissue Diseases",[24746],{"trials":24762,"activeCount":128},[],{"trials":24764,"activeCount":128},[],{"trials":24766,"activeCount":128},[],{"trials":24768,"activeCount":128},[],{"intervention":8444,"totalTrials":676,"cells":24770},{"EARLY_PHASE1":24771,"PHASE1":24773,"PHASE2":24779,"PHASE3":24781,"PHASE4":24783,"NA":24785},{"trials":24772,"activeCount":128},[],{"trials":24774,"activeCount":128},[24775],{"nctId":8435,"briefTitle":8436,"status":104,"phases":24776,"primaryCompletion":8438,"completion":8438,"start":8439,"enrollment":3002,"conditions":24777,"interventions":24778},[90],[8441,144,146,303,8442,149,152,3447],[8444,3966],{"trials":24780,"activeCount":128},[],{"trials":24782,"activeCount":128},[],{"trials":24784,"activeCount":128},[],{"trials":24786,"activeCount":128},[],{"intervention":24788,"totalTrials":676,"cells":24789},"Autologous Bone Marrow Aspirate Concentrate",{"EARLY_PHASE1":24790,"PHASE1":24792,"PHASE2":24802,"PHASE3":24804,"PHASE4":24806,"NA":24808},{"trials":24791,"activeCount":128},[],{"trials":24793,"activeCount":128},[24794],{"nctId":24795,"briefTitle":24796,"status":104,"phases":24797,"primaryCompletion":2607,"completion":2607,"start":1374,"enrollment":558,"conditions":24798,"interventions":24800},"NCT01931007","Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis",[90],[24799],"Bilateral Primary Osteoarthritis of Knee",[24788,24801],"Sterile saline",{"trials":24803,"activeCount":128},[],{"trials":24805,"activeCount":128},[],{"trials":24807,"activeCount":128},[],{"trials":24809,"activeCount":128},[],{"intervention":24801,"totalTrials":676,"cells":24811},{"EARLY_PHASE1":24812,"PHASE1":24814,"PHASE2":24820,"PHASE3":24822,"PHASE4":24824,"NA":24826},{"trials":24813,"activeCount":128},[],{"trials":24815,"activeCount":128},[24816],{"nctId":24795,"briefTitle":24796,"status":104,"phases":24817,"primaryCompletion":2607,"completion":2607,"start":1374,"enrollment":558,"conditions":24818,"interventions":24819},[90],[24799],[24788,24801],{"trials":24821,"activeCount":128},[],{"trials":24823,"activeCount":128},[],{"trials":24825,"activeCount":128},[],{"trials":24827,"activeCount":128},[],{"intervention":24829,"totalTrials":676,"cells":24830},"Synbiotic AKSB",{"EARLY_PHASE1":24831,"PHASE1":24833,"PHASE2":24841,"PHASE3":24843,"PHASE4":24845,"NA":24847},{"trials":24832,"activeCount":128},[],{"trials":24834,"activeCount":128},[24835],{"nctId":24836,"briefTitle":24837,"status":104,"phases":24838,"primaryCompletion":3661,"completion":3661,"start":946,"enrollment":3002,"conditions":24839,"interventions":24840},"NCT01304771","Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly",[90],[15425],[24829],{"trials":24842,"activeCount":128},[],{"trials":24844,"activeCount":128},[],{"trials":24846,"activeCount":128},[],{"trials":24848,"activeCount":128},[],{"intervention":24850,"totalTrials":676,"cells":24851},"bioidentical hormone",{"EARLY_PHASE1":24852,"PHASE1":24854,"PHASE2":24862,"PHASE3":24864,"PHASE4":24866,"NA":24868},{"trials":24853,"activeCount":128},[],{"trials":24855,"activeCount":128},[24856],{"nctId":24857,"briefTitle":24858,"status":104,"phases":24859,"primaryCompletion":7928,"completion":13184,"start":1298,"enrollment":498,"conditions":24860,"interventions":24861},"NCT00864214","A Pharmacokinetic Evaluation of Bioidentical Compounded Estrogen Cream and Natural Progesterone",[90],[1604],[24850,24850,24850,24850],{"trials":24863,"activeCount":128},[],{"trials":24865,"activeCount":128},[],{"trials":24867,"activeCount":128},[],{"trials":24869,"activeCount":128},[],{"intervention":10248,"totalTrials":676,"cells":24871},{"EARLY_PHASE1":24872,"PHASE1":24874,"PHASE2":24880,"PHASE3":24882,"PHASE4":24884,"NA":24886},{"trials":24873,"activeCount":128},[],{"trials":24875,"activeCount":128},[24876],{"nctId":10242,"briefTitle":10243,"status":104,"phases":24877,"primaryCompletion":7317,"completion":7317,"start":10245,"enrollment":498,"conditions":24878,"interventions":24879},[90],[18],[10248,3779],{"trials":24881,"activeCount":128},[],{"trials":24883,"activeCount":128},[],{"trials":24885,"activeCount":128},[],{"trials":24887,"activeCount":128},[],{"intervention":7310,"totalTrials":676,"cells":24889},{"EARLY_PHASE1":24890,"PHASE1":24892,"PHASE2":24898,"PHASE3":24900,"PHASE4":24902,"NA":24904},{"trials":24891,"activeCount":128},[],{"trials":24893,"activeCount":128},[24894],{"nctId":7301,"briefTitle":7302,"status":104,"phases":24895,"primaryCompletion":7304,"completion":7305,"start":7306,"enrollment":476,"conditions":24896,"interventions":24897},[90],[303,3447],[3680,7309,7310],{"trials":24899,"activeCount":128},[],{"trials":24901,"activeCount":128},[],{"trials":24903,"activeCount":128},[],{"trials":24905,"activeCount":128},[],{"intervention":4295,"totalTrials":676,"cells":24907},{"EARLY_PHASE1":24908,"PHASE1":24910,"PHASE2":24916,"PHASE3":24918,"PHASE4":24920,"NA":24922},{"trials":24909,"activeCount":128},[],{"trials":24911,"activeCount":128},[24912],{"nctId":4285,"briefTitle":4286,"status":104,"phases":24913,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":2608,"conditions":24914,"interventions":24915},[90],[21,4291,4292,4293],[4295,3482,4240],{"trials":24917,"activeCount":128},[],{"trials":24919,"activeCount":128},[],{"trials":24921,"activeCount":128},[],{"trials":24923,"activeCount":128},[],{"intervention":24925,"totalTrials":676,"cells":24926},"Taste Test",{"EARLY_PHASE1":24927,"PHASE1":24929,"PHASE2":24937,"PHASE3":24939,"PHASE4":24941,"NA":24943},{"trials":24928,"activeCount":128},[],{"trials":24930,"activeCount":128},[24931],{"nctId":24932,"briefTitle":24933,"status":104,"phases":24934,"primaryCompletion":2620,"completion":2620,"start":4030,"enrollment":773,"conditions":24935,"interventions":24936},"NCT01734759","Influence of Medication Taste on Pediatric Prescribers' Prescribing Habits",[90],[18],[24925],{"trials":24938,"activeCount":128},[],{"trials":24940,"activeCount":128},[],{"trials":24942,"activeCount":128},[],{"trials":24944,"activeCount":128},[],{"intervention":24946,"totalTrials":676,"cells":24947},"Botulinum toxin",{"EARLY_PHASE1":24948,"PHASE1":24950,"PHASE2":24958,"PHASE3":24960,"PHASE4":24962,"NA":24964},{"trials":24949,"activeCount":128},[],{"trials":24951,"activeCount":128},[24952],{"nctId":24953,"briefTitle":24954,"status":104,"phases":24955,"primaryCompletion":2665,"completion":2665,"start":894,"enrollment":370,"conditions":24956,"interventions":24957},"NCT01682733","Endoscopic Gastric Reduction for Weight Management",[90],[15],[24946],{"trials":24959,"activeCount":128},[],{"trials":24961,"activeCount":128},[],{"trials":24963,"activeCount":128},[],{"trials":24965,"activeCount":128},[],{"intervention":24967,"totalTrials":676,"cells":24968},"Curcumin",{"EARLY_PHASE1":24969,"PHASE1":24971,"PHASE2":24982,"PHASE3":24984,"PHASE4":24986,"NA":24988},{"trials":24970,"activeCount":128},[],{"trials":24972,"activeCount":128},[24973],{"nctId":24974,"briefTitle":24975,"status":104,"phases":24976,"primaryCompletion":4360,"completion":4360,"start":8226,"enrollment":476,"conditions":24977,"interventions":24981},"NCT02598726","Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer",[90],[24978,24979,938,24980],"Bladder Spasm","Malignant Neoplasm","Urinary Urgency",[24967],{"trials":24983,"activeCount":128},[],{"trials":24985,"activeCount":128},[],{"trials":24987,"activeCount":128},[],{"trials":24989,"activeCount":128},[],{"intervention":24991,"totalTrials":676,"cells":24992},"Nitazoxanide",{"EARLY_PHASE1":24993,"PHASE1":24995,"PHASE2":25004,"PHASE3":25006,"PHASE4":25008,"NA":25010},{"trials":24994,"activeCount":128},[],{"trials":24996,"activeCount":128},[24997],{"nctId":24998,"briefTitle":24999,"status":104,"phases":25000,"primaryCompletion":4810,"completion":4810,"start":3546,"enrollment":2563,"conditions":25001,"interventions":25003},"NCT01074203","A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation",[90],[25002],"Hepatitis C Recurrence",[24991],{"trials":25005,"activeCount":128},[],{"trials":25007,"activeCount":128},[],{"trials":25009,"activeCount":128},[],{"trials":25011,"activeCount":128},[],{"intervention":7480,"totalTrials":676,"cells":25013},{"EARLY_PHASE1":25014,"PHASE1":25016,"PHASE2":25022,"PHASE3":25024,"PHASE4":25026,"NA":25028},{"trials":25015,"activeCount":128},[],{"trials":25017,"activeCount":128},[25018],{"nctId":7463,"briefTitle":7464,"status":104,"phases":25019,"primaryCompletion":7466,"completion":7467,"start":7468,"enrollment":1197,"conditions":25020,"interventions":25021},[90],[7470,7471,7472,4747,7473,7474,7475,7476,7477,7478],[657,7480],{"trials":25023,"activeCount":128},[],{"trials":25025,"activeCount":128},[],{"trials":25027,"activeCount":128},[],{"trials":25029,"activeCount":128},[],{"intervention":5274,"totalTrials":676,"cells":25031},{"EARLY_PHASE1":25032,"PHASE1":25034,"PHASE2":25040,"PHASE3":25042,"PHASE4":25044,"NA":25046},{"trials":25033,"activeCount":128},[],{"trials":25035,"activeCount":128},[25036],{"nctId":5268,"briefTitle":5269,"status":104,"phases":25037,"primaryCompletion":4871,"completion":4871,"start":5271,"conditions":25038,"interventions":25039},[90],[1419],[5274,3553],{"trials":25041,"activeCount":128},[],{"trials":25043,"activeCount":128},[],{"trials":25045,"activeCount":128},[],{"trials":25047,"activeCount":128},[],{"intervention":25049,"totalTrials":676,"cells":25050},"Autologous Platelet Rich Plasma",{"EARLY_PHASE1":25051,"PHASE1":25053,"PHASE2":25063,"PHASE3":25065,"PHASE4":25067,"NA":25069},{"trials":25052,"activeCount":128},[],{"trials":25054,"activeCount":128},[25055],{"nctId":25056,"briefTitle":25057,"status":104,"phases":25058,"primaryCompletion":25059,"completion":25059,"start":25060,"enrollment":681,"conditions":25061,"interventions":25062},"NCT04350125","PRP for the Treatment of Erectile Dysfunction (ED)",[90],"2023-10-23","2022-03-04",[12167],[25049],{"trials":25064,"activeCount":128},[],{"trials":25066,"activeCount":128},[],{"trials":25068,"activeCount":128},[],{"trials":25070,"activeCount":128},[],{"intervention":25072,"totalTrials":676,"cells":25073},"RBX7455",{"EARLY_PHASE1":25074,"PHASE1":25076,"PHASE2":25085,"PHASE3":25087,"PHASE4":25089,"NA":25091},{"trials":25075,"activeCount":128},[],{"trials":25077,"activeCount":128},[25078],{"nctId":25079,"briefTitle":25080,"status":104,"phases":25081,"primaryCompletion":25082,"completion":25082,"start":1471,"enrollment":729,"conditions":25083,"interventions":25084},"NCT02981316","Treatment of Recurrent Clostridium Difficile Infection With RBX7455",[90],"2020-07-22",[12018],[25072],{"trials":25086,"activeCount":128},[],{"trials":25088,"activeCount":128},[],{"trials":25090,"activeCount":128},[],{"trials":25092,"activeCount":128},[],{"intervention":25094,"totalTrials":676,"cells":25095},"Adipose Derived Regenerative Cells",{"EARLY_PHASE1":25096,"PHASE1":25098,"PHASE2":25108,"PHASE3":25110,"PHASE4":25112,"NA":25114},{"trials":25097,"activeCount":128},[],{"trials":25099,"activeCount":128},[25100],{"nctId":25101,"briefTitle":25102,"status":134,"phases":25103,"primaryCompletion":25104,"completion":25104,"start":258,"enrollment":2563,"conditions":25105,"interventions":25107},"NCT03269409","Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis",[90],"2021-06-28",[25106],"Osteonecrosis",[25094],{"trials":25109,"activeCount":128},[],{"trials":25111,"activeCount":128},[],{"trials":25113,"activeCount":128},[],{"trials":25115,"activeCount":128},[],{"intervention":25117,"totalTrials":676,"cells":25118},"Modafinil",{"EARLY_PHASE1":25119,"PHASE1":25121,"PHASE2":25129,"PHASE3":25131,"PHASE4":25133,"NA":25135},{"trials":25120,"activeCount":128},[],{"trials":25122,"activeCount":128},[25123],{"nctId":25124,"briefTitle":25125,"status":104,"phases":25126,"primaryCompletion":3661,"completion":3661,"start":2621,"enrollment":498,"conditions":25127,"interventions":25128},"NCT00943176","Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC)",[90],[17602,20502],[25117],{"trials":25130,"activeCount":128},[],{"trials":25132,"activeCount":128},[],{"trials":25134,"activeCount":128},[],{"trials":25136,"activeCount":128},[],{"intervention":25138,"totalTrials":676,"cells":25139},"Nab-paclitaxel\u002FRituximab-coated Nanoparticle AR160",{"EARLY_PHASE1":25140,"PHASE1":25142,"PHASE2":25153,"PHASE3":25155,"PHASE4":25157,"NA":25159},{"trials":25141,"activeCount":128},[],{"trials":25143,"activeCount":128},[25144],{"nctId":25145,"briefTitle":25146,"status":104,"phases":25147,"primaryCompletion":25148,"completion":25148,"start":13329,"enrollment":476,"conditions":25149,"interventions":25152},"NCT03003546","Nab-paclitaxel\u002FRituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial",[90],"2023-05-16",[25150,373,439,25151,442,447],"Recurrent Aggressive Non-Hodgkin Lymphoma","Refractory Aggressive Non-Hodgkin Lymphoma",[25138],{"trials":25154,"activeCount":128},[],{"trials":25156,"activeCount":128},[],{"trials":25158,"activeCount":128},[],{"trials":25160,"activeCount":128},[],{"intervention":7792,"totalTrials":676,"cells":25162},{"EARLY_PHASE1":25163,"PHASE1":25165,"PHASE2":25171,"PHASE3":25173,"PHASE4":25175,"NA":25177},{"trials":25164,"activeCount":128},[],{"trials":25166,"activeCount":128},[25167],{"nctId":7779,"briefTitle":7780,"status":134,"phases":25168,"primaryCompletion":7782,"completion":7783,"start":7784,"enrollment":676,"conditions":25169,"interventions":25170},[90],[7786,7787,7788,7789,7790],[7792,4718],{"trials":25172,"activeCount":128},[],{"trials":25174,"activeCount":128},[],{"trials":25176,"activeCount":128},[],{"trials":25178,"activeCount":128},[],{"intervention":12778,"totalTrials":676,"cells":25180},{"EARLY_PHASE1":25181,"PHASE1":25183,"PHASE2":25189,"PHASE3":25191,"PHASE4":25193,"NA":25195},{"trials":25182,"activeCount":128},[],{"trials":25184,"activeCount":128},[25185],{"nctId":12770,"briefTitle":12771,"status":134,"phases":25186,"primaryCompletion":12773,"completion":12773,"start":12774,"enrollment":139,"conditions":25187,"interventions":25188},[90],[12776],[12778,12763],{"trials":25190,"activeCount":128},[],{"trials":25192,"activeCount":128},[],{"trials":25194,"activeCount":128},[],{"trials":25196,"activeCount":128},[],{"intervention":25198,"totalTrials":676,"cells":25199},"Caffeine",{"EARLY_PHASE1":25200,"PHASE1":25202,"PHASE2":25211,"PHASE3":25213,"PHASE4":25215,"NA":25217},{"trials":25201,"activeCount":128},[],{"trials":25203,"activeCount":128},[25204],{"nctId":25205,"briefTitle":25206,"status":104,"phases":25207,"primaryCompletion":2666,"completion":2666,"start":4279,"enrollment":1506,"conditions":25208,"interventions":25210},"NCT01944215","Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue",[90],[25209],"Molecular Imaging",[25198],{"trials":25212,"activeCount":128},[],{"trials":25214,"activeCount":128},[],{"trials":25216,"activeCount":128},[],{"trials":25218,"activeCount":128},[],{"intervention":25220,"totalTrials":676,"cells":25221},"Toremifene",{"EARLY_PHASE1":25222,"PHASE1":25224,"PHASE2":25233,"PHASE3":25235,"PHASE4":25237,"NA":25239},{"trials":25223,"activeCount":128},[],{"trials":25225,"activeCount":128},[25226],{"nctId":25227,"briefTitle":25228,"status":104,"phases":25229,"primaryCompletion":1234,"completion":1234,"start":2665,"enrollment":498,"conditions":25230,"interventions":25231},"NCT02271282","Estradiol-Receptor Blockade in Older Men and Women",[90],[7698],[25220,25232],"GHRH\u002FGhrelin combined",{"trials":25234,"activeCount":128},[],{"trials":25236,"activeCount":128},[],{"trials":25238,"activeCount":128},[],{"trials":25240,"activeCount":128},[],{"intervention":25232,"totalTrials":676,"cells":25242},{"EARLY_PHASE1":25243,"PHASE1":25245,"PHASE2":25251,"PHASE3":25253,"PHASE4":25255,"NA":25257},{"trials":25244,"activeCount":128},[],{"trials":25246,"activeCount":128},[25247],{"nctId":25227,"briefTitle":25228,"status":104,"phases":25248,"primaryCompletion":1234,"completion":1234,"start":2665,"enrollment":498,"conditions":25249,"interventions":25250},[90],[7698],[25220,25232],{"trials":25252,"activeCount":128},[],{"trials":25254,"activeCount":128},[],{"trials":25256,"activeCount":128},[],{"trials":25258,"activeCount":128},[],{"intervention":8497,"totalTrials":676,"cells":25260},{"EARLY_PHASE1":25261,"PHASE1":25263,"PHASE2":25269,"PHASE3":25271,"PHASE4":25273,"NA":25275},{"trials":25262,"activeCount":128},[],{"trials":25264,"activeCount":128},[25265],{"nctId":8490,"briefTitle":8491,"status":104,"phases":25266,"primaryCompletion":8493,"completion":8494,"start":3569,"enrollment":2980,"conditions":25267,"interventions":25268},[90],[7698],[5126,8202,82,8497],{"trials":25270,"activeCount":128},[],{"trials":25272,"activeCount":128},[],{"trials":25274,"activeCount":128},[],{"trials":25276,"activeCount":128},[],{"intervention":25278,"totalTrials":676,"cells":25279},"MSC Fistula Plug",{"EARLY_PHASE1":25280,"PHASE1":25282,"PHASE2":25292,"PHASE3":25294,"PHASE4":25296,"NA":25298},{"trials":25281,"activeCount":128},[],{"trials":25283,"activeCount":128},[25284],{"nctId":25285,"briefTitle":25286,"status":104,"phases":25287,"primaryCompletion":9380,"completion":9380,"start":25288,"enrollment":224,"conditions":25289,"interventions":25291},"NCT02807389","Stem Cell Fistula Plug in Post Surgical Leak Fistulas",[90],"2017-03-14",[25290],"Surgical Leak Fistula",[25278],{"trials":25293,"activeCount":128},[],{"trials":25295,"activeCount":128},[],{"trials":25297,"activeCount":128},[],{"trials":25299,"activeCount":128},[],{"intervention":25301,"totalTrials":676,"cells":25302},"123 iodine metaiodobenzylguanidine",{"EARLY_PHASE1":25303,"PHASE1":25305,"PHASE2":25313,"PHASE3":25315,"PHASE4":25317,"NA":25319},{"trials":25304,"activeCount":128},[],{"trials":25306,"activeCount":128},[25307],{"nctId":25308,"briefTitle":25309,"status":134,"phases":25310,"primaryCompletion":3642,"completion":3642,"start":2979,"enrollment":355,"conditions":25311,"interventions":25312},"NCT01522378","Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging",[90],[2982],[25301],{"trials":25314,"activeCount":128},[],{"trials":25316,"activeCount":128},[],{"trials":25318,"activeCount":128},[],{"trials":25320,"activeCount":128},[],{"intervention":2585,"totalTrials":676,"cells":25322},{"EARLY_PHASE1":25323,"PHASE1":25325,"PHASE2":25331,"PHASE3":25333,"PHASE4":25335,"NA":25337},{"trials":25324,"activeCount":128},[],{"trials":25326,"activeCount":128},[25327],{"nctId":2579,"briefTitle":2580,"status":1413,"phases":25328,"primaryCompletion":872,"completion":872,"start":872,"enrollment":128,"conditions":25329,"interventions":25330},[90],[2583],[2585,2586],{"trials":25332,"activeCount":128},[],{"trials":25334,"activeCount":128},[],{"trials":25336,"activeCount":128},[],{"trials":25338,"activeCount":128},[],{"intervention":25340,"totalTrials":676,"cells":25341},"linaclotide acetate",{"EARLY_PHASE1":25342,"PHASE1":25344,"PHASE2":25354,"PHASE3":25356,"PHASE4":25358,"NA":25360},{"trials":25343,"activeCount":128},[],{"trials":25345,"activeCount":128},[25346],{"nctId":25347,"briefTitle":25348,"status":104,"phases":25349,"primaryCompletion":25350,"completion":25351,"start":4279,"enrollment":2555,"conditions":25352,"interventions":25353},"NCT01950403","Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers",[90],"2016-04-28","2018-02-22",[4854,19366],[25340],{"trials":25355,"activeCount":128},[],{"trials":25357,"activeCount":128},[],{"trials":25359,"activeCount":128},[],{"trials":25361,"activeCount":128},[],{"intervention":25363,"totalTrials":676,"cells":25364},"Omega-3 fatty acids",{"EARLY_PHASE1":25365,"PHASE1":25367,"PHASE2":25376,"PHASE3":25378,"PHASE4":25380,"NA":25382},{"trials":25366,"activeCount":128},[],{"trials":25368,"activeCount":128},[25369],{"nctId":25370,"briefTitle":25371,"status":104,"phases":25372,"primaryCompletion":1318,"completion":1318,"start":3001,"enrollment":2555,"conditions":25373,"interventions":25375},"NCT02103842","Omega-3 Fatty Acids to Combat Sarcopenia",[90],[25374],"Sarcopenia",[25363],{"trials":25377,"activeCount":128},[],{"trials":25379,"activeCount":128},[],{"trials":25381,"activeCount":128},[],{"trials":25383,"activeCount":128},[],{"intervention":25385,"totalTrials":676,"cells":25386},"Estrogens",{"EARLY_PHASE1":25387,"PHASE1":25389,"PHASE2":25398,"PHASE3":25400,"PHASE4":25402,"NA":25404},{"trials":25388,"activeCount":128},[],{"trials":25390,"activeCount":128},[25391],{"nctId":25392,"briefTitle":25393,"status":104,"phases":25394,"primaryCompletion":3971,"completion":3971,"start":2979,"enrollment":173,"conditions":25395,"interventions":25397},"NCT02349113","Effects of Acute Estrogen Therapy on Bone Formation",[90],[25396],"Bone Loss, Age-related",[25385],{"trials":25399,"activeCount":128},[],{"trials":25401,"activeCount":128},[],{"trials":25403,"activeCount":128},[],{"trials":25405,"activeCount":128},[],{"intervention":25407,"totalTrials":676,"cells":25408},"Mesenchymal Stem Cells",{"EARLY_PHASE1":25409,"PHASE1":25411,"PHASE2":25422,"PHASE3":25424,"PHASE4":25426,"NA":25428},{"trials":25410,"activeCount":128},[],{"trials":25412,"activeCount":128},[25413],{"nctId":25414,"briefTitle":25415,"status":104,"phases":25416,"primaryCompletion":25417,"completion":25418,"start":25419,"enrollment":4565,"conditions":25420,"interventions":25421},"NCT04047810","Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)",[90],"2023-11-21","2025-08-15","2020-01-06",[14662],[25407],{"trials":25423,"activeCount":128},[],{"trials":25425,"activeCount":128},[],{"trials":25427,"activeCount":128},[],{"trials":25429,"activeCount":128},[],{"intervention":25431,"totalTrials":676,"cells":25432},"Plasmapheresis",{"EARLY_PHASE1":25433,"PHASE1":25435,"PHASE2":25445,"PHASE3":25447,"PHASE4":25449,"NA":25451},{"trials":25434,"activeCount":128},[],{"trials":25436,"activeCount":128},[25437],{"nctId":25438,"briefTitle":25439,"status":104,"phases":25440,"primaryCompletion":25441,"completion":25441,"start":4522,"enrollment":342,"conditions":25442,"interventions":25443},"NCT03887741","Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression",[90],"2024-02-16",[2001],[25431,25444],"Plasma",{"trials":25446,"activeCount":128},[],{"trials":25448,"activeCount":128},[],{"trials":25450,"activeCount":128},[],{"trials":25452,"activeCount":128},[],{"intervention":25444,"totalTrials":676,"cells":25454},{"EARLY_PHASE1":25455,"PHASE1":25457,"PHASE2":25463,"PHASE3":25465,"PHASE4":25467,"NA":25469},{"trials":25456,"activeCount":128},[],{"trials":25458,"activeCount":128},[25459],{"nctId":25438,"briefTitle":25439,"status":104,"phases":25460,"primaryCompletion":25441,"completion":25441,"start":4522,"enrollment":342,"conditions":25461,"interventions":25462},[90],[2001],[25431,25444],{"trials":25464,"activeCount":128},[],{"trials":25466,"activeCount":128},[],{"trials":25468,"activeCount":128},[],{"trials":25470,"activeCount":128},[],{"intervention":25472,"totalTrials":676,"cells":25473},"Quetiapine 25 mg gel applied topically",{"EARLY_PHASE1":25474,"PHASE1":25476,"PHASE2":25486,"PHASE3":25488,"PHASE4":25490,"NA":25492},{"trials":25475,"activeCount":128},[],{"trials":25477,"activeCount":128},[25478],{"nctId":25479,"briefTitle":25480,"status":104,"phases":25481,"primaryCompletion":872,"completion":872,"start":5417,"enrollment":370,"conditions":25482,"interventions":25483},"NCT02131545","Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine",[90],[1999,908],[25472,25484,25485,25472],"Quetiapine 25 mg tablet by mouth","Quetiapine 25 mg rectal suppository",{"trials":25487,"activeCount":128},[],{"trials":25489,"activeCount":128},[],{"trials":25491,"activeCount":128},[],{"trials":25493,"activeCount":128},[],{"intervention":25484,"totalTrials":676,"cells":25495},{"EARLY_PHASE1":25496,"PHASE1":25498,"PHASE2":25504,"PHASE3":25506,"PHASE4":25508,"NA":25510},{"trials":25497,"activeCount":128},[],{"trials":25499,"activeCount":128},[25500],{"nctId":25479,"briefTitle":25480,"status":104,"phases":25501,"primaryCompletion":872,"completion":872,"start":5417,"enrollment":370,"conditions":25502,"interventions":25503},[90],[1999,908],[25472,25484,25485,25472],{"trials":25505,"activeCount":128},[],{"trials":25507,"activeCount":128},[],{"trials":25509,"activeCount":128},[],{"trials":25511,"activeCount":128},[],{"intervention":25485,"totalTrials":676,"cells":25513},{"EARLY_PHASE1":25514,"PHASE1":25516,"PHASE2":25522,"PHASE3":25524,"PHASE4":25526,"NA":25528},{"trials":25515,"activeCount":128},[],{"trials":25517,"activeCount":128},[25518],{"nctId":25479,"briefTitle":25480,"status":104,"phases":25519,"primaryCompletion":872,"completion":872,"start":5417,"enrollment":370,"conditions":25520,"interventions":25521},[90],[1999,908],[25472,25484,25485,25472],{"trials":25523,"activeCount":128},[],{"trials":25525,"activeCount":128},[],{"trials":25527,"activeCount":128},[],{"trials":25529,"activeCount":128},[],{"intervention":25531,"totalTrials":676,"cells":25532},"C-13 labeled oxalate",{"EARLY_PHASE1":25533,"PHASE1":25535,"PHASE2":25545,"PHASE3":25547,"PHASE4":25549,"NA":25551},{"trials":25534,"activeCount":128},[],{"trials":25536,"activeCount":128},[25537],{"nctId":25538,"briefTitle":25539,"status":104,"phases":25540,"primaryCompletion":12507,"completion":12507,"start":4289,"enrollment":25541,"conditions":25542,"interventions":25544},"NCT00588120","Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria",[90],114,[25543,17052],"Enteric Hyperoxaluria",[25531],{"trials":25546,"activeCount":128},[],{"trials":25548,"activeCount":128},[],{"trials":25550,"activeCount":128},[],{"trials":25552,"activeCount":128},[],{"intervention":25554,"totalTrials":676,"cells":25555},"Yamani-15\u002F5 chemical solution",{"EARLY_PHASE1":25556,"PHASE1":25558,"PHASE2":25568,"PHASE3":25570,"PHASE4":25572,"NA":25574},{"trials":25557,"activeCount":128},[],{"trials":25559,"activeCount":128},[25560],{"nctId":25561,"briefTitle":25562,"status":1413,"phases":25563,"primaryCompletion":25564,"completion":25565,"start":18284,"enrollment":128,"conditions":25566,"interventions":25567},"NCT02539303","Delivery of Yamani-15\u002F5 Chemical Solution for PAD",[90],"2022-08","2023-08",[13768],[25554],{"trials":25569,"activeCount":128},[],{"trials":25571,"activeCount":128},[],{"trials":25573,"activeCount":128},[],{"trials":25575,"activeCount":128},[],{"intervention":25577,"totalTrials":676,"cells":25578},"Erlotinib",{"EARLY_PHASE1":25579,"PHASE1":25581,"PHASE2":25591,"PHASE3":25593,"PHASE4":25595,"NA":25597},{"trials":25580,"activeCount":128},[],{"trials":25582,"activeCount":128},[25583],{"nctId":25584,"briefTitle":25585,"status":104,"phases":25586,"primaryCompletion":4885,"completion":4885,"start":7114,"enrollment":1197,"conditions":25587,"interventions":25590},"NCT00955149","Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)",[90],[8319,25588,18591,25589],"Trisomy 7","Chemoprevention",[25577],{"trials":25592,"activeCount":128},[],{"trials":25594,"activeCount":128},[],{"trials":25596,"activeCount":128},[],{"trials":25598,"activeCount":128},[],{"intervention":11880,"totalTrials":676,"cells":25600},{"EARLY_PHASE1":25601,"PHASE1":25603,"PHASE2":25609,"PHASE3":25611,"PHASE4":25613,"NA":25615},{"trials":25602,"activeCount":128},[],{"trials":25604,"activeCount":128},[25605],{"nctId":11874,"briefTitle":11875,"status":104,"phases":25606,"primaryCompletion":11877,"completion":11877,"start":4885,"enrollment":31,"conditions":25607,"interventions":25608},[90],[15,6930],[11554,11880],{"trials":25610,"activeCount":128},[],{"trials":25612,"activeCount":128},[],{"trials":25614,"activeCount":128},[],{"trials":25616,"activeCount":128},[],{"intervention":12785,"totalTrials":676,"cells":25618},{"EARLY_PHASE1":25619,"PHASE1":25621,"PHASE2":25627,"PHASE3":25629,"PHASE4":25631,"NA":25633},{"trials":25620,"activeCount":128},[],{"trials":25622,"activeCount":128},[25623],{"nctId":12780,"briefTitle":12781,"status":104,"phases":25624,"primaryCompletion":12459,"completion":2606,"start":2665,"enrollment":5517,"conditions":25625,"interventions":25626},[90],[18],[12785,12786,12785,12786,12787,12763,12788,12789,12763],{"trials":25628,"activeCount":128},[],{"trials":25630,"activeCount":128},[],{"trials":25632,"activeCount":128},[],{"trials":25634,"activeCount":128},[],{"intervention":12786,"totalTrials":676,"cells":25636},{"EARLY_PHASE1":25637,"PHASE1":25639,"PHASE2":25645,"PHASE3":25647,"PHASE4":25649,"NA":25651},{"trials":25638,"activeCount":128},[],{"trials":25640,"activeCount":128},[25641],{"nctId":12780,"briefTitle":12781,"status":104,"phases":25642,"primaryCompletion":12459,"completion":2606,"start":2665,"enrollment":5517,"conditions":25643,"interventions":25644},[90],[18],[12785,12786,12785,12786,12787,12763,12788,12789,12763],{"trials":25646,"activeCount":128},[],{"trials":25648,"activeCount":128},[],{"trials":25650,"activeCount":128},[],{"trials":25652,"activeCount":128},[],{"intervention":12787,"totalTrials":676,"cells":25654},{"EARLY_PHASE1":25655,"PHASE1":25657,"PHASE2":25663,"PHASE3":25665,"PHASE4":25667,"NA":25669},{"trials":25656,"activeCount":128},[],{"trials":25658,"activeCount":128},[25659],{"nctId":12780,"briefTitle":12781,"status":104,"phases":25660,"primaryCompletion":12459,"completion":2606,"start":2665,"enrollment":5517,"conditions":25661,"interventions":25662},[90],[18],[12785,12786,12785,12786,12787,12763,12788,12789,12763],{"trials":25664,"activeCount":128},[],{"trials":25666,"activeCount":128},[],{"trials":25668,"activeCount":128},[],{"trials":25670,"activeCount":128},[],{"intervention":12788,"totalTrials":676,"cells":25672},{"EARLY_PHASE1":25673,"PHASE1":25675,"PHASE2":25681,"PHASE3":25683,"PHASE4":25685,"NA":25687},{"trials":25674,"activeCount":128},[],{"trials":25676,"activeCount":128},[25677],{"nctId":12780,"briefTitle":12781,"status":104,"phases":25678,"primaryCompletion":12459,"completion":2606,"start":2665,"enrollment":5517,"conditions":25679,"interventions":25680},[90],[18],[12785,12786,12785,12786,12787,12763,12788,12789,12763],{"trials":25682,"activeCount":128},[],{"trials":25684,"activeCount":128},[],{"trials":25686,"activeCount":128},[],{"trials":25688,"activeCount":128},[],{"intervention":12789,"totalTrials":676,"cells":25690},{"EARLY_PHASE1":25691,"PHASE1":25693,"PHASE2":25699,"PHASE3":25701,"PHASE4":25703,"NA":25705},{"trials":25692,"activeCount":128},[],{"trials":25694,"activeCount":128},[25695],{"nctId":12780,"briefTitle":12781,"status":104,"phases":25696,"primaryCompletion":12459,"completion":2606,"start":2665,"enrollment":5517,"conditions":25697,"interventions":25698},[90],[18],[12785,12786,12785,12786,12787,12763,12788,12789,12763],{"trials":25700,"activeCount":128},[],{"trials":25702,"activeCount":128},[],{"trials":25704,"activeCount":128},[],{"trials":25706,"activeCount":128},[],{"intervention":25708,"totalTrials":676,"cells":25709},"Transplant uses frozen anonymous stool",{"EARLY_PHASE1":25710,"PHASE1":25712,"PHASE2":25723,"PHASE3":25725,"PHASE4":25727,"NA":25729},{"trials":25711,"activeCount":128},[],{"trials":25713,"activeCount":128},[25714],{"nctId":25715,"briefTitle":25716,"status":104,"phases":25717,"primaryCompletion":25718,"completion":25718,"start":2666,"enrollment":817,"conditions":25719,"interventions":25721},"NCT02423967","Fresh Versus Frozen Stool for Fecal Transplant in Children",[90],"2019-03-04",[25720],"Clostridium Difficile",[25708,25722],"Transplant uses fresh familial stool",{"trials":25724,"activeCount":128},[],{"trials":25726,"activeCount":128},[],{"trials":25728,"activeCount":128},[],{"trials":25730,"activeCount":128},[],{"intervention":25722,"totalTrials":676,"cells":25732},{"EARLY_PHASE1":25733,"PHASE1":25735,"PHASE2":25741,"PHASE3":25743,"PHASE4":25745,"NA":25747},{"trials":25734,"activeCount":128},[],{"trials":25736,"activeCount":128},[25737],{"nctId":25715,"briefTitle":25716,"status":104,"phases":25738,"primaryCompletion":25718,"completion":25718,"start":2666,"enrollment":817,"conditions":25739,"interventions":25740},[90],[25720],[25708,25722],{"trials":25742,"activeCount":128},[],{"trials":25744,"activeCount":128},[],{"trials":25746,"activeCount":128},[],{"trials":25748,"activeCount":128},[],{"intervention":25750,"totalTrials":676,"cells":25751},"Itraconazole",{"EARLY_PHASE1":25752,"PHASE1":25754,"PHASE2":25763,"PHASE3":25765,"PHASE4":25767,"NA":25769},{"trials":25753,"activeCount":128},[],{"trials":25755,"activeCount":128},[25756],{"nctId":25757,"briefTitle":25758,"status":104,"phases":25759,"primaryCompletion":4795,"completion":4795,"start":5472,"enrollment":1197,"conditions":25760,"interventions":25762},"NCT00588016","Concentration of Itraconazole Solution in Nasal Secretions",[90],[25761],"Sinusitis",[25750],{"trials":25764,"activeCount":128},[],{"trials":25766,"activeCount":128},[],{"trials":25768,"activeCount":128},[],{"trials":25770,"activeCount":128},[],{"intervention":25772,"totalTrials":676,"cells":25773},"Mesenchymal stem cell 0.5",{"EARLY_PHASE1":25774,"PHASE1":25776,"PHASE2":25788,"PHASE3":25790,"PHASE4":25792,"NA":25794},{"trials":25775,"activeCount":128},[],{"trials":25777,"activeCount":128},[25778],{"nctId":25779,"briefTitle":25780,"status":104,"phases":25781,"primaryCompletion":25782,"completion":25782,"start":4300,"enrollment":6434,"conditions":25783,"interventions":25786},"NCT02181712","Mesenchymal Stem Cell Therapy for Lung Rejection",[90],"2021-08-12",[25784,25785],"Lung Transplant Reject","Bronchiolitis Obliterans",[25772,25787],"Mesenchymal stem cell 1.0",{"trials":25789,"activeCount":128},[],{"trials":25791,"activeCount":128},[],{"trials":25793,"activeCount":128},[],{"trials":25795,"activeCount":128},[],{"intervention":25787,"totalTrials":676,"cells":25797},{"EARLY_PHASE1":25798,"PHASE1":25800,"PHASE2":25806,"PHASE3":25808,"PHASE4":25810,"NA":25812},{"trials":25799,"activeCount":128},[],{"trials":25801,"activeCount":128},[25802],{"nctId":25779,"briefTitle":25780,"status":104,"phases":25803,"primaryCompletion":25782,"completion":25782,"start":4300,"enrollment":6434,"conditions":25804,"interventions":25805},[90],[25784,25785],[25772,25787],{"trials":25807,"activeCount":128},[],{"trials":25809,"activeCount":128},[],{"trials":25811,"activeCount":128},[],{"trials":25813,"activeCount":128},[],{"intervention":25815,"totalTrials":676,"cells":25816},"Rapamycin",{"EARLY_PHASE1":25817,"PHASE1":25819,"PHASE2":25828,"PHASE3":25830,"PHASE4":25832,"NA":25834},{"trials":25818,"activeCount":128},[],{"trials":25820,"activeCount":128},[25821],{"nctId":25822,"briefTitle":25823,"status":104,"phases":25824,"primaryCompletion":15986,"completion":15986,"start":894,"enrollment":301,"conditions":25825,"interventions":25827},"NCT01649960","Exercise and Low-Dose Rapamycin in Older Adults With CAD:Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial",[90],[7089,25826],"CAD",[25815],{"trials":25829,"activeCount":128},[],{"trials":25831,"activeCount":128},[],{"trials":25833,"activeCount":128},[],{"trials":25835,"activeCount":128},[],{"intervention":4329,"totalTrials":676,"cells":25837},{"EARLY_PHASE1":25838,"PHASE1":25840,"PHASE2":25846,"PHASE3":25848,"PHASE4":25850,"NA":25852},{"trials":25839,"activeCount":128},[],{"trials":25841,"activeCount":128},[25842],{"nctId":4309,"briefTitle":4310,"status":1413,"phases":25843,"primaryCompletion":4312,"completion":4312,"start":4313,"enrollment":128,"conditions":25844,"interventions":25845},[90],[4315,4316,4317,4318,4319,4320,4321,4322,4323,4324,4325,4326,4327],[4089,161,4329],{"trials":25847,"activeCount":128},[],{"trials":25849,"activeCount":128},[],{"trials":25851,"activeCount":128},[],{"trials":25853,"activeCount":128},[],{"intervention":25855,"totalTrials":676,"cells":25856},"Capsaicin 0.1%",{"EARLY_PHASE1":25857,"PHASE1":25859,"PHASE2":25867,"PHASE3":25869,"PHASE4":25871,"NA":25873},{"trials":25858,"activeCount":128},[],{"trials":25860,"activeCount":128},[25861],{"nctId":25862,"briefTitle":25863,"status":104,"phases":25864,"primaryCompletion":6365,"completion":6365,"start":6365,"enrollment":676,"conditions":25865,"interventions":25866},"NCT01883102","The Effect of Ablation of Epidermal Nerve Fibers Using Capsaicin Cream",[90],[938],[25855],{"trials":25868,"activeCount":128},[],{"trials":25870,"activeCount":128},[],{"trials":25872,"activeCount":128},[],{"trials":25874,"activeCount":128},[],{"intervention":25876,"totalTrials":676,"cells":25877},"Chromoendoscopy",{"EARLY_PHASE1":25878,"PHASE1":25880,"PHASE2":25889,"PHASE3":25891,"PHASE4":25893,"NA":25895},{"trials":25879,"activeCount":128},[],{"trials":25881,"activeCount":128},[25882],{"nctId":25883,"briefTitle":25884,"status":104,"phases":25885,"primaryCompletion":4300,"completion":4300,"start":3569,"enrollment":3674,"conditions":25886,"interventions":25888},"NCT01901510","Panchromoendoscopy Using Oral Indigo Carmine Mixed With Polyethylene Glycol Prep",[90],[25887],"Colonic Polyps",[25876],{"trials":25890,"activeCount":128},[],{"trials":25892,"activeCount":128},[],{"trials":25894,"activeCount":128},[],{"trials":25896,"activeCount":128},[],{"intervention":25898,"totalTrials":676,"cells":25899},"Mesenchymal stem cell",{"EARLY_PHASE1":25900,"PHASE1":25902,"PHASE2":25914,"PHASE3":25916,"PHASE4":25918,"NA":25920},{"trials":25901,"activeCount":128},[],{"trials":25903,"activeCount":128},[25904],{"nctId":25905,"briefTitle":25906,"status":104,"phases":25907,"primaryCompletion":25908,"completion":25908,"start":25909,"enrollment":7658,"conditions":25910,"interventions":25913},"NCT02266394","Hypoxia and Inflammatory Injury in Human Renovascular Hypertension",[90],"2020-09-25","2014-10-21",[25911,24734,25912,6957],"Renal Artery Stenosis","Renovascular Disease",[25898],{"trials":25915,"activeCount":128},[],{"trials":25917,"activeCount":128},[],{"trials":25919,"activeCount":128},[],{"trials":25921,"activeCount":128},[],{"intervention":15636,"totalTrials":676,"cells":25923},{"EARLY_PHASE1":25924,"PHASE1":25926,"PHASE2":25932,"PHASE3":25934,"PHASE4":25936,"NA":25938},{"trials":25925,"activeCount":128},[],{"trials":25927,"activeCount":128},[25928],{"nctId":15625,"briefTitle":15626,"status":104,"phases":25929,"primaryCompletion":8329,"completion":8329,"start":15628,"enrollment":173,"conditions":25930,"interventions":25931},[90],[15630,15631,15632,15633,15634],[15636,15603],{"trials":25933,"activeCount":128},[],{"trials":25935,"activeCount":128},[],{"trials":25937,"activeCount":128},[],{"trials":25939,"activeCount":128},[],{"intervention":4769,"totalTrials":676,"cells":25941},{"EARLY_PHASE1":25942,"PHASE1":25944,"PHASE2":25950,"PHASE3":25952,"PHASE4":25954,"NA":25956},{"trials":25943,"activeCount":128},[],{"trials":25945,"activeCount":128},[25946],{"nctId":4763,"briefTitle":4764,"status":1413,"phases":25947,"primaryCompletion":2642,"start":4503,"enrollment":128,"conditions":25948,"interventions":25949},[90],[4293],[4768,4769],{"trials":25951,"activeCount":128},[],{"trials":25953,"activeCount":128},[],{"trials":25955,"activeCount":128},[],{"trials":25957,"activeCount":128},[],{"intervention":25959,"totalTrials":676,"cells":25960},"Short-Chain Fructooligosaccharide",{"EARLY_PHASE1":25961,"PHASE1":25963,"PHASE2":25973,"PHASE3":25975,"PHASE4":25977,"NA":25979},{"trials":25962,"activeCount":128},[],{"trials":25964,"activeCount":128},[25965],{"nctId":25966,"briefTitle":25967,"status":104,"phases":25968,"primaryCompletion":19035,"completion":13012,"start":2978,"enrollment":301,"conditions":25969,"interventions":25971},"NCT02203955","Study of Sc-FOS for Pouchitis Prevention",[90],[25970],"Pouchitis",[25959,25972],"Maltodextrin",{"trials":25974,"activeCount":128},[],{"trials":25976,"activeCount":128},[],{"trials":25978,"activeCount":128},[],{"trials":25980,"activeCount":128},[],{"intervention":25972,"totalTrials":676,"cells":25982},{"EARLY_PHASE1":25983,"PHASE1":25985,"PHASE2":25991,"PHASE3":25993,"PHASE4":25995,"NA":25997},{"trials":25984,"activeCount":128},[],{"trials":25986,"activeCount":128},[25987],{"nctId":25966,"briefTitle":25967,"status":104,"phases":25988,"primaryCompletion":19035,"completion":13012,"start":2978,"enrollment":301,"conditions":25989,"interventions":25990},[90],[25970],[25959,25972],{"trials":25992,"activeCount":128},[],{"trials":25994,"activeCount":128},[],{"trials":25996,"activeCount":128},[],{"trials":25998,"activeCount":128},[],{"intervention":26000,"totalTrials":676,"cells":26001},"Cyclophosphamide,Campath IH and TBI",{"EARLY_PHASE1":26002,"PHASE1":26004,"PHASE2":26014,"PHASE3":26016,"PHASE4":26018,"NA":26020},{"trials":26003,"activeCount":128},[],{"trials":26005,"activeCount":128},[26006],{"nctId":26007,"briefTitle":26008,"status":104,"phases":26009,"primaryCompletion":26010,"completion":26010,"start":16636,"enrollment":2563,"conditions":26011,"interventions":26013},"NCT00578266","Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia",[90],"2016-08-16",[26012],"Anemia, Aplastic",[26000],{"trials":26015,"activeCount":128},[],{"trials":26017,"activeCount":128},[],{"trials":26019,"activeCount":128},[],{"trials":26021,"activeCount":128},[],{"intervention":5186,"totalTrials":676,"cells":26023},{"EARLY_PHASE1":26024,"PHASE1":26026,"PHASE2":26032,"PHASE3":26034,"PHASE4":26036,"NA":26038},{"trials":26025,"activeCount":128},[],{"trials":26027,"activeCount":128},[26028],{"nctId":5177,"briefTitle":5178,"status":134,"phases":26029,"primaryCompletion":5180,"completion":5181,"start":5182,"enrollment":2742,"conditions":26030,"interventions":26031},[90],[561,5184,564],[5158,5186,161],{"trials":26033,"activeCount":128},[],{"trials":26035,"activeCount":128},[],{"trials":26037,"activeCount":128},[],{"trials":26039,"activeCount":128},[],{"intervention":26041,"totalTrials":676,"cells":26042},"Therapeutic Autologous Platelet-rich Plasma",{"EARLY_PHASE1":26043,"PHASE1":26045,"PHASE2":26055,"PHASE3":26057,"PHASE4":26059,"NA":26061},{"trials":26044,"activeCount":128},[],{"trials":26046,"activeCount":128},[26047],{"nctId":26048,"briefTitle":26049,"status":104,"phases":26050,"primaryCompletion":12566,"completion":12566,"start":11204,"enrollment":173,"conditions":26051,"interventions":26054},"NCT04535323","Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer",[90],[9358,5197,10337,10338,5198,10339,10340,579,580,581,582,141,26052,26053,10342,10343,10344,10345,10346,10347,6193,6194,6195,6196],"Genitourinary Syndrome of Menopause","Prognostic Stage 0 Breast Cancer AJCC v8",[26041],{"trials":26056,"activeCount":128},[],{"trials":26058,"activeCount":128},[],{"trials":26060,"activeCount":128},[],{"trials":26062,"activeCount":128},[],{"intervention":26064,"totalTrials":676,"cells":26065},"Verapamil",{"EARLY_PHASE1":26066,"PHASE1":26068,"PHASE2":26079,"PHASE3":26081,"PHASE4":26083,"NA":26085},{"trials":26067,"activeCount":128},[],{"trials":26069,"activeCount":128},[26070],{"nctId":26071,"briefTitle":26072,"status":104,"phases":26073,"primaryCompletion":3887,"completion":3887,"start":894,"enrollment":1225,"conditions":26074,"interventions":26077},"NCT01669304","Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness",[90],[26075,26076],"Vestibular Migraine","Chronic Subjective Dizziness",[26064,26078],"Sertraline",{"trials":26080,"activeCount":128},[],{"trials":26082,"activeCount":128},[],{"trials":26084,"activeCount":128},[],{"trials":26086,"activeCount":128},[],{"intervention":26078,"totalTrials":676,"cells":26088},{"EARLY_PHASE1":26089,"PHASE1":26091,"PHASE2":26097,"PHASE3":26099,"PHASE4":26101,"NA":26103},{"trials":26090,"activeCount":128},[],{"trials":26092,"activeCount":128},[26093],{"nctId":26071,"briefTitle":26072,"status":104,"phases":26094,"primaryCompletion":3887,"completion":3887,"start":894,"enrollment":1225,"conditions":26095,"interventions":26096},[90],[26075,26076],[26064,26078],{"trials":26098,"activeCount":128},[],{"trials":26100,"activeCount":128},[],{"trials":26102,"activeCount":128},[],{"trials":26104,"activeCount":128},[],{"intervention":23189,"totalTrials":676,"cells":26106},{"EARLY_PHASE1":26107,"PHASE1":26109,"PHASE2":26115,"PHASE3":26117,"PHASE4":26119,"NA":26121},{"trials":26108,"activeCount":128},[],{"trials":26110,"activeCount":128},[26111],{"nctId":23180,"briefTitle":23181,"status":1413,"phases":26112,"primaryCompletion":23183,"completion":23183,"start":7107,"enrollment":128,"conditions":26113,"interventions":26114},[90],[17867,23185,23186,23187,17872,4293],[7354,23165,23189,5425],{"trials":26116,"activeCount":128},[],{"trials":26118,"activeCount":128},[],{"trials":26120,"activeCount":128},[],{"trials":26122,"activeCount":128},[],{"intervention":13219,"totalTrials":676,"cells":26124},{"EARLY_PHASE1":26125,"PHASE1":26127,"PHASE2":26133,"PHASE3":26135,"PHASE4":26137,"NA":26139},{"trials":26126,"activeCount":128},[],{"trials":26128,"activeCount":128},[26129],{"nctId":13212,"briefTitle":13213,"status":104,"phases":26130,"primaryCompletion":1563,"completion":13215,"start":11897,"enrollment":173,"conditions":26131,"interventions":26132},[90],[4291],[13218,13219,13220,13205,13221],{"trials":26134,"activeCount":128},[],{"trials":26136,"activeCount":128},[],{"trials":26138,"activeCount":128},[],{"trials":26140,"activeCount":128},[],{"intervention":13220,"totalTrials":676,"cells":26142},{"EARLY_PHASE1":26143,"PHASE1":26145,"PHASE2":26151,"PHASE3":26153,"PHASE4":26155,"NA":26157},{"trials":26144,"activeCount":128},[],{"trials":26146,"activeCount":128},[26147],{"nctId":13212,"briefTitle":13213,"status":104,"phases":26148,"primaryCompletion":1563,"completion":13215,"start":11897,"enrollment":173,"conditions":26149,"interventions":26150},[90],[4291],[13218,13219,13220,13205,13221],{"trials":26152,"activeCount":128},[],{"trials":26154,"activeCount":128},[],{"trials":26156,"activeCount":128},[],{"trials":26158,"activeCount":128},[],{"intervention":13221,"totalTrials":676,"cells":26160},{"EARLY_PHASE1":26161,"PHASE1":26163,"PHASE2":26169,"PHASE3":26171,"PHASE4":26173,"NA":26175},{"trials":26162,"activeCount":128},[],{"trials":26164,"activeCount":128},[26165],{"nctId":13212,"briefTitle":13213,"status":104,"phases":26166,"primaryCompletion":1563,"completion":13215,"start":11897,"enrollment":173,"conditions":26167,"interventions":26168},[90],[4291],[13218,13219,13220,13205,13221],{"trials":26170,"activeCount":128},[],{"trials":26172,"activeCount":128},[],{"trials":26174,"activeCount":128},[],{"trials":26176,"activeCount":128},[],{"intervention":26178,"totalTrials":676,"cells":26179},"thiamine hydrochloride 100 mg",{"EARLY_PHASE1":26180,"PHASE1":26182,"PHASE2":26191,"PHASE3":26193,"PHASE4":26195,"NA":26197},{"trials":26181,"activeCount":128},[],{"trials":26183,"activeCount":128},[26184],{"nctId":26185,"briefTitle":26186,"status":104,"phases":26187,"primaryCompletion":1375,"completion":3971,"start":3033,"enrollment":2555,"conditions":26188,"interventions":26190},"NCT01864057","Pharmacokinetics of Thiamine in Breastfeeding Mothers and Infants",[90],[26189],"Beriberi",[26178],{"trials":26192,"activeCount":128},[],{"trials":26194,"activeCount":128},[],{"trials":26196,"activeCount":128},[],{"trials":26198,"activeCount":128},[],{"intervention":26200,"totalTrials":676,"cells":26201},"Adalimumab",{"EARLY_PHASE1":26202,"PHASE1":26204,"PHASE2":26212,"PHASE3":26214,"PHASE4":26216,"NA":26218},{"trials":26203,"activeCount":128},[],{"trials":26205,"activeCount":128},[26206],{"nctId":26207,"briefTitle":26208,"status":104,"phases":26209,"primaryCompletion":1390,"completion":1390,"start":3519,"enrollment":173,"conditions":26210,"interventions":26211},"NCT00421642","Open-Label Adalimumab for Ulcerative Colitis Patients",[90],[11118],[26200],{"trials":26213,"activeCount":128},[],{"trials":26215,"activeCount":128},[],{"trials":26217,"activeCount":128},[],{"trials":26219,"activeCount":128},[],{"intervention":26221,"totalTrials":676,"cells":26222},"U100 Humulin",{"EARLY_PHASE1":26223,"PHASE1":26225,"PHASE2":26233,"PHASE3":26235,"PHASE4":26237,"NA":26239},{"trials":26224,"activeCount":128},[],{"trials":26226,"activeCount":128},[26227],{"nctId":26228,"briefTitle":26229,"status":134,"phases":26230,"primaryCompletion":2719,"completion":2719,"start":4785,"enrollment":2608,"conditions":26231,"interventions":26232},"NCT01581736","Molecular Regulation of Muscle Glucose Metabolism",[90],[15,6975],[26221],{"trials":26234,"activeCount":128},[],{"trials":26236,"activeCount":128},[],{"trials":26238,"activeCount":128},[],{"trials":26240,"activeCount":128},[],{"intervention":18108,"totalTrials":676,"cells":26242},{"EARLY_PHASE1":26243,"PHASE1":26245,"PHASE2":26251,"PHASE3":26253,"PHASE4":26255,"NA":26257},{"trials":26244,"activeCount":128},[],{"trials":26246,"activeCount":128},[26247],{"nctId":18101,"briefTitle":18102,"status":134,"phases":26248,"primaryCompletion":18104,"completion":18104,"start":18105,"enrollment":2563,"conditions":26249,"interventions":26250},[90],[4292],[18108,18109,3599],{"trials":26252,"activeCount":128},[],{"trials":26254,"activeCount":128},[],{"trials":26256,"activeCount":128},[],{"trials":26258,"activeCount":128},[],{"intervention":18109,"totalTrials":676,"cells":26260},{"EARLY_PHASE1":26261,"PHASE1":26263,"PHASE2":26269,"PHASE3":26271,"PHASE4":26273,"NA":26275},{"trials":26262,"activeCount":128},[],{"trials":26264,"activeCount":128},[26265],{"nctId":18101,"briefTitle":18102,"status":134,"phases":26266,"primaryCompletion":18104,"completion":18104,"start":18105,"enrollment":2563,"conditions":26267,"interventions":26268},[90],[4292],[18108,18109,3599],{"trials":26270,"activeCount":128},[],{"trials":26272,"activeCount":128},[],{"trials":26274,"activeCount":128},[],{"trials":26276,"activeCount":128},[],{"intervention":26278,"totalTrials":676,"cells":26279},"MANP",{"EARLY_PHASE1":26280,"PHASE1":26282,"PHASE2":26292,"PHASE3":26294,"PHASE4":26296,"NA":26298},{"trials":26281,"activeCount":128},[],{"trials":26283,"activeCount":128},[26284],{"nctId":26285,"briefTitle":26286,"status":104,"phases":26287,"primaryCompletion":298,"completion":26288,"start":26289,"enrollment":3002,"conditions":26290,"interventions":26291},"NCT03781739","MANP in Hypertension and Metabolic Syndrome",[90],"2019-12-10","2017-08-18",[12895,6931],[26278],{"trials":26293,"activeCount":128},[],{"trials":26295,"activeCount":128},[],{"trials":26297,"activeCount":128},[],{"trials":26299,"activeCount":128},[],{"intervention":26301,"totalTrials":676,"cells":26302},"MSC",{"EARLY_PHASE1":26303,"PHASE1":26305,"PHASE2":26317,"PHASE3":26319,"PHASE4":26321,"NA":26323},{"trials":26304,"activeCount":128},[],{"trials":26306,"activeCount":128},[26307],{"nctId":26308,"briefTitle":26309,"status":104,"phases":26310,"primaryCompletion":26311,"completion":26311,"start":26312,"enrollment":476,"conditions":26313,"interventions":26316},"NCT03371329","Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage",[90],"2020-10-09","2017-12-12",[26314,26315],"Hemorrhagic Stroke","Intracerebral Hemorrhage",[26301],{"trials":26318,"activeCount":128},[],{"trials":26320,"activeCount":128},[],{"trials":26322,"activeCount":128},[],{"trials":26324,"activeCount":128},[],{"intervention":26326,"totalTrials":676,"cells":26327},"low dose Nesiritide",{"EARLY_PHASE1":26328,"PHASE1":26330,"PHASE2":26339,"PHASE3":26341,"PHASE4":26343,"NA":26345},{"trials":26329,"activeCount":128},[],{"trials":26331,"activeCount":128},[26332],{"nctId":26333,"briefTitle":26334,"status":134,"phases":26335,"primaryCompletion":6578,"completion":6578,"start":3546,"enrollment":676,"conditions":26336,"interventions":26337},"NCT00818701","Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction",[90],[2982,18763],[26326,26338],"nesiritide, Sildenafil",{"trials":26340,"activeCount":128},[],{"trials":26342,"activeCount":128},[],{"trials":26344,"activeCount":128},[],{"trials":26346,"activeCount":128},[],{"intervention":26338,"totalTrials":676,"cells":26348},{"EARLY_PHASE1":26349,"PHASE1":26351,"PHASE2":26357,"PHASE3":26359,"PHASE4":26361,"NA":26363},{"trials":26350,"activeCount":128},[],{"trials":26352,"activeCount":128},[26353],{"nctId":26333,"briefTitle":26334,"status":134,"phases":26354,"primaryCompletion":6578,"completion":6578,"start":3546,"enrollment":676,"conditions":26355,"interventions":26356},[90],[2982,18763],[26326,26338],{"trials":26358,"activeCount":128},[],{"trials":26360,"activeCount":128},[],{"trials":26362,"activeCount":128},[],{"trials":26364,"activeCount":128},[],{"intervention":4739,"totalTrials":224,"cells":26366},{"EARLY_PHASE1":26367,"PHASE1":26381,"PHASE2":26383,"PHASE3":26385,"PHASE4":26387,"NA":26389},{"trials":26368,"activeCount":128},[26369,26377],{"nctId":26370,"briefTitle":26371,"status":104,"phases":26372,"primaryCompletion":26373,"completion":26373,"start":26374,"enrollment":173,"conditions":26375,"interventions":26376},"NCT03360708","Vaccine Therapy in Treating Patients With Recurrent Glioblastoma",[89],"2021-06-02","2013-11-27",[4737,11623,274],[4739],{"nctId":4731,"briefTitle":4732,"status":104,"phases":26378,"primaryCompletion":4734,"completion":4734,"start":4735,"enrollment":3674,"conditions":26379,"interventions":26380},[89],[4737,330,331],[4739,334],{"trials":26382,"activeCount":128},[],{"trials":26384,"activeCount":128},[],{"trials":26386,"activeCount":128},[],{"trials":26388,"activeCount":128},[],{"trials":26390,"activeCount":128},[],{"intervention":22872,"totalTrials":224,"cells":26392},{"EARLY_PHASE1":26393,"PHASE1":26405,"PHASE2":26407,"PHASE3":26409,"PHASE4":26411,"NA":26413},{"trials":26394,"activeCount":128},[26395,26399],{"nctId":22857,"briefTitle":22858,"status":104,"phases":26396,"primaryCompletion":22860,"completion":22861,"start":6275,"enrollment":729,"conditions":26397,"interventions":26398},[89],[4542,22863,22864,22865,22866,22867,22868,4812],[22870,13218,22871,22872],{"nctId":26400,"briefTitle":26401,"status":104,"phases":26402,"primaryCompletion":1020,"completion":1020,"start":7604,"enrollment":729,"conditions":26403,"interventions":26404},"NCT00470379","Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery",[89],[4291],[22872],{"trials":26406,"activeCount":128},[],{"trials":26408,"activeCount":128},[],{"trials":26410,"activeCount":128},[],{"trials":26412,"activeCount":128},[],{"trials":26414,"activeCount":128},[],{"intervention":26416,"totalTrials":224,"cells":26417},"99mTc-PYP",{"EARLY_PHASE1":26418,"PHASE1":26439,"PHASE2":26441,"PHASE3":26443,"PHASE4":26445,"NA":26447},{"trials":26419,"activeCount":128},[26420,26429],{"nctId":26421,"briefTitle":26422,"status":104,"phases":26423,"primaryCompletion":26424,"completion":26424,"start":26425,"enrollment":26426,"conditions":26427,"interventions":26428},"NCT03414632","Transthyretin Cardiac Amyloidosis in HFpEF",[89],"2020-03-31","2017-12-01",287,[7184],[26416],{"nctId":26430,"briefTitle":26431,"status":104,"phases":26432,"primaryCompletion":4984,"completion":4984,"start":15953,"enrollment":681,"conditions":26433,"interventions":26438},"NCT04899180","Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis",[89],[26434,26435,26436,26437],"Aortic Stenosis","Transthyretin Amyloidosis","Transthyretin Amyloid Cardiomyopathy","Transthyretin Cardiac Amyloidosis",[26416],{"trials":26440,"activeCount":128},[],{"trials":26442,"activeCount":128},[],{"trials":26444,"activeCount":128},[],{"trials":26446,"activeCount":128},[],{"trials":26448,"activeCount":128},[],{"intervention":26450,"totalTrials":676,"cells":26451},"Hydroxychloroquine",{"EARLY_PHASE1":26452,"PHASE1":26462,"PHASE2":26464,"PHASE3":26466,"PHASE4":26468,"NA":26470},{"trials":26453,"activeCount":128},[26454],{"nctId":26455,"briefTitle":26456,"status":104,"phases":26457,"primaryCompletion":2666,"completion":2666,"start":1021,"enrollment":342,"conditions":26458,"interventions":26461},"NCT01495403","Treatment of Muscle Cramps in Patients With Liver Cirrhosis",[89],[26459,26460],"Liver Cirrhosis","Muscle Cramps",[26450],{"trials":26463,"activeCount":128},[],{"trials":26465,"activeCount":128},[],{"trials":26467,"activeCount":128},[],{"trials":26469,"activeCount":128},[],{"trials":26471,"activeCount":128},[],{"intervention":26473,"totalTrials":676,"cells":26474},"Nucala",{"EARLY_PHASE1":26475,"PHASE1":26487,"PHASE2":26489,"PHASE3":26491,"PHASE4":26493,"NA":26495},{"trials":26476,"activeCount":128},[26477],{"nctId":26478,"briefTitle":26479,"status":104,"phases":26480,"primaryCompletion":26481,"completion":26482,"start":26483,"enrollment":370,"conditions":26484,"interventions":26486},"NCT03494881","Mepolizumab for the Treatment of Chronic Spontaneous Urticaria",[89],"2023-11-15","2025-02-25","2019-07-30",[26485],"Chronic Spontaneous Urticaria",[26473],{"trials":26488,"activeCount":128},[],{"trials":26490,"activeCount":128},[],{"trials":26492,"activeCount":128},[],{"trials":26494,"activeCount":128},[],{"trials":26496,"activeCount":128},[],{"intervention":26498,"totalTrials":676,"cells":26499},"mRNA COVD19 vaccine",{"EARLY_PHASE1":26500,"PHASE1":26515,"PHASE2":26517,"PHASE3":26519,"PHASE4":26521,"NA":26523},{"trials":26501,"activeCount":128},[26502],{"nctId":26503,"briefTitle":26504,"status":134,"phases":26505,"primaryCompletion":26506,"completion":26506,"start":15965,"enrollment":5985,"conditions":26507,"interventions":26514},"NCT04839315","COVID-19 Vaccination in Rheumatic Disease Patients",[89],"2022-02-09",[22709,26508,26509,26510,26511,26512,26513,1340],"Sjogren's Syndrome","Inflammatory Myositis","Psoriatic Arthritis","Gout","Ankylosing Spondylitis","Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis)",[26498],{"trials":26516,"activeCount":128},[],{"trials":26518,"activeCount":128},[],{"trials":26520,"activeCount":128},[],{"trials":26522,"activeCount":128},[],{"trials":26524,"activeCount":128},[],{"intervention":26526,"totalTrials":676,"cells":26527},"Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2",{"EARLY_PHASE1":26528,"PHASE1":26536,"PHASE2":26538,"PHASE3":26540,"PHASE4":26542,"NA":26544},{"trials":26529,"activeCount":128},[26530],{"nctId":26531,"briefTitle":26532,"status":104,"phases":26533,"primaryCompletion":4045,"completion":4045,"start":3001,"enrollment":895,"conditions":26534,"interventions":26535},"NCT01789827","Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy",[89],[3348],[26526],{"trials":26537,"activeCount":128},[],{"trials":26539,"activeCount":128},[],{"trials":26541,"activeCount":128},[],{"trials":26543,"activeCount":128},[],{"trials":26545,"activeCount":128},[],{"intervention":113,"totalTrials":676,"cells":26547},{"EARLY_PHASE1":26548,"PHASE1":26554,"PHASE2":26556,"PHASE3":26558,"PHASE4":26560,"NA":26562},{"trials":26549,"activeCount":128},[26550],{"nctId":102,"briefTitle":103,"status":104,"phases":26551,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":26552,"interventions":26553},[89],[110],[112,72,113],{"trials":26555,"activeCount":128},[],{"trials":26557,"activeCount":128},[],{"trials":26559,"activeCount":128},[],{"trials":26561,"activeCount":128},[],{"trials":26563,"activeCount":128},[],{"intervention":26565,"totalTrials":676,"cells":26566},"Ga-68 PSMA11",{"EARLY_PHASE1":26567,"PHASE1":26577,"PHASE2":26579,"PHASE3":26581,"PHASE4":26583,"NA":26585},{"trials":26568,"activeCount":128},[26569],{"nctId":26570,"briefTitle":26571,"status":104,"phases":26572,"primaryCompletion":26573,"completion":26573,"start":847,"enrollment":2113,"conditions":26574,"interventions":26575},"NCT03768349","PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer",[89],"2021-07-21",[4292],[26565,26576],"F-18 PSMA 1007",{"trials":26578,"activeCount":128},[],{"trials":26580,"activeCount":128},[],{"trials":26582,"activeCount":128},[],{"trials":26584,"activeCount":128},[],{"trials":26586,"activeCount":128},[],{"intervention":26576,"totalTrials":676,"cells":26588},{"EARLY_PHASE1":26589,"PHASE1":26595,"PHASE2":26597,"PHASE3":26599,"PHASE4":26601,"NA":26603},{"trials":26590,"activeCount":128},[26591],{"nctId":26570,"briefTitle":26571,"status":104,"phases":26592,"primaryCompletion":26573,"completion":26573,"start":847,"enrollment":2113,"conditions":26593,"interventions":26594},[89],[4292],[26565,26576],{"trials":26596,"activeCount":128},[],{"trials":26598,"activeCount":128},[],{"trials":26600,"activeCount":128},[],{"trials":26602,"activeCount":128},[],{"trials":26604,"activeCount":128},[],{"intervention":22870,"totalTrials":676,"cells":26606},{"EARLY_PHASE1":26607,"PHASE1":26613,"PHASE2":26615,"PHASE3":26617,"PHASE4":26619,"NA":26621},{"trials":26608,"activeCount":128},[26609],{"nctId":22857,"briefTitle":22858,"status":104,"phases":26610,"primaryCompletion":22860,"completion":22861,"start":6275,"enrollment":729,"conditions":26611,"interventions":26612},[89],[4542,22863,22864,22865,22866,22867,22868,4812],[22870,13218,22871,22872],{"trials":26614,"activeCount":128},[],{"trials":26616,"activeCount":128},[],{"trials":26618,"activeCount":128},[],{"trials":26620,"activeCount":128},[],{"trials":26622,"activeCount":128},[],{"intervention":22871,"totalTrials":676,"cells":26624},{"EARLY_PHASE1":26625,"PHASE1":26631,"PHASE2":26633,"PHASE3":26635,"PHASE4":26637,"NA":26639},{"trials":26626,"activeCount":128},[26627],{"nctId":22857,"briefTitle":22858,"status":104,"phases":26628,"primaryCompletion":22860,"completion":22861,"start":6275,"enrollment":729,"conditions":26629,"interventions":26630},[89],[4542,22863,22864,22865,22866,22867,22868,4812],[22870,13218,22871,22872],{"trials":26632,"activeCount":128},[],{"trials":26634,"activeCount":128},[],{"trials":26636,"activeCount":128},[],{"trials":26638,"activeCount":128},[],{"trials":26640,"activeCount":128},[],{"intervention":26642,"totalTrials":676,"cells":26643},"fluorine F 18 fluorothymidine",{"EARLY_PHASE1":26644,"PHASE1":26659,"PHASE2":26661,"PHASE3":26663,"PHASE4":26665,"NA":26667},{"trials":26645,"activeCount":128},[26646],{"nctId":26647,"briefTitle":26648,"status":104,"phases":26649,"primaryCompletion":2667,"completion":26650,"start":12007,"enrollment":676,"conditions":26651,"interventions":26658},"NCT01825902","18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma",[89],"2015-11-23",[26652,26653,26654,26655,26656,26657],"Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)","Ewing Sarcoma of Bone","Extraosseous Ewing Sarcoma","Localized Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor","Metastatic Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor","Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor",[26642],{"trials":26660,"activeCount":128},[],{"trials":26662,"activeCount":128},[],{"trials":26664,"activeCount":128},[],{"trials":26666,"activeCount":128},[],{"trials":26668,"activeCount":128},[],{"intervention":7444,"totalTrials":676,"cells":26670},{"EARLY_PHASE1":26671,"PHASE1":26677,"PHASE2":26679,"PHASE3":26681,"PHASE4":26683,"NA":26685},{"trials":26672,"activeCount":128},[26673],{"nctId":7437,"briefTitle":7438,"status":104,"phases":26674,"primaryCompletion":7440,"completion":7440,"start":7441,"enrollment":461,"conditions":26675,"interventions":26676},[89],[21],[7444,7445,7446,7447,4405],{"trials":26678,"activeCount":128},[],{"trials":26680,"activeCount":128},[],{"trials":26682,"activeCount":128},[],{"trials":26684,"activeCount":128},[],{"trials":26686,"activeCount":128},[],{"intervention":7446,"totalTrials":676,"cells":26688},{"EARLY_PHASE1":26689,"PHASE1":26695,"PHASE2":26697,"PHASE3":26699,"PHASE4":26701,"NA":26703},{"trials":26690,"activeCount":128},[26691],{"nctId":7437,"briefTitle":7438,"status":104,"phases":26692,"primaryCompletion":7440,"completion":7440,"start":7441,"enrollment":461,"conditions":26693,"interventions":26694},[89],[21],[7444,7445,7446,7447,4405],{"trials":26696,"activeCount":128},[],{"trials":26698,"activeCount":128},[],{"trials":26700,"activeCount":128},[],{"trials":26702,"activeCount":128},[],{"trials":26704,"activeCount":128},[],{"intervention":7447,"totalTrials":676,"cells":26706},{"EARLY_PHASE1":26707,"PHASE1":26713,"PHASE2":26715,"PHASE3":26717,"PHASE4":26719,"NA":26721},{"trials":26708,"activeCount":128},[26709],{"nctId":7437,"briefTitle":7438,"status":104,"phases":26710,"primaryCompletion":7440,"completion":7440,"start":7441,"enrollment":461,"conditions":26711,"interventions":26712},[89],[21],[7444,7445,7446,7447,4405],{"trials":26714,"activeCount":128},[],{"trials":26716,"activeCount":128},[],{"trials":26718,"activeCount":128},[],{"trials":26720,"activeCount":128},[],{"trials":26722,"activeCount":128},[],{"intervention":26724,"totalTrials":676,"cells":26725},"Probiotic",{"EARLY_PHASE1":26726,"PHASE1":26735,"PHASE2":26737,"PHASE3":26739,"PHASE4":26741,"NA":26743},{"trials":26727,"activeCount":128},[26728],{"nctId":26729,"briefTitle":26730,"status":104,"phases":26731,"primaryCompletion":216,"completion":216,"start":522,"enrollment":1197,"conditions":26732,"interventions":26734},"NCT04857697","Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer",[89],[5197,5198,579,141,26733,4435,614],"Stage I Lung Cancer AJCC v8",[26724],{"trials":26736,"activeCount":128},[],{"trials":26738,"activeCount":128},[],{"trials":26740,"activeCount":128},[],{"trials":26742,"activeCount":128},[],{"trials":26744,"activeCount":128},[],{"intervention":26746,"totalTrials":676,"cells":26747},"Sucralfate",{"EARLY_PHASE1":26748,"PHASE1":26756,"PHASE2":26758,"PHASE3":26760,"PHASE4":26762,"NA":26764},{"trials":26749,"activeCount":128},[26750],{"nctId":26751,"briefTitle":26752,"status":104,"phases":26753,"primaryCompletion":12459,"completion":12459,"start":1356,"enrollment":342,"conditions":26754,"interventions":26755},"NCT02353078","The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis",[89],[12979],[26746],{"trials":26757,"activeCount":128},[],{"trials":26759,"activeCount":128},[],{"trials":26761,"activeCount":128},[],{"trials":26763,"activeCount":128},[],{"trials":26765,"activeCount":128},[],{"intervention":26767,"totalTrials":676,"cells":26768},"Dupilumab",{"EARLY_PHASE1":26769,"PHASE1":26779,"PHASE2":26781,"PHASE3":26783,"PHASE4":26785,"NA":26787},{"trials":26770,"activeCount":128},[26771],{"nctId":26772,"briefTitle":26773,"status":104,"phases":26774,"primaryCompletion":3814,"completion":3814,"start":26775,"enrollment":120,"conditions":26776,"interventions":26778},"NCT05372003","IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis",[89],"2022-08-09",[26777],"Atopic Dermatitis",[26767],{"trials":26780,"activeCount":128},[],{"trials":26782,"activeCount":128},[],{"trials":26784,"activeCount":128},[],{"trials":26786,"activeCount":128},[],{"trials":26788,"activeCount":128},[],{"intervention":7978,"totalTrials":676,"cells":26790},{"EARLY_PHASE1":26791,"PHASE1":26797,"PHASE2":26799,"PHASE3":26801,"PHASE4":26803,"NA":26805},{"trials":26792,"activeCount":128},[26793],{"nctId":7970,"briefTitle":7971,"status":104,"phases":26794,"primaryCompletion":7973,"completion":7974,"start":7975,"enrollment":410,"conditions":26795,"interventions":26796},[89],[150],[7978,569],{"trials":26798,"activeCount":128},[],{"trials":26800,"activeCount":128},[],{"trials":26802,"activeCount":128},[],{"trials":26804,"activeCount":128},[],{"trials":26806,"activeCount":128},[],{"intervention":12850,"totalTrials":676,"cells":26808},{"EARLY_PHASE1":26809,"PHASE1":26815,"PHASE2":26817,"PHASE3":26819,"PHASE4":26821,"NA":26823},{"trials":26810,"activeCount":128},[26811],{"nctId":12841,"briefTitle":12842,"status":104,"phases":26812,"primaryCompletion":12844,"completion":12845,"start":12846,"enrollment":1162,"conditions":26813,"interventions":26814},[89],[12848],[12850,12851,12836],{"trials":26816,"activeCount":128},[],{"trials":26818,"activeCount":128},[],{"trials":26820,"activeCount":128},[],{"trials":26822,"activeCount":128},[],{"trials":26824,"activeCount":128},[],{"intervention":22888,"totalTrials":676,"cells":26826},{"EARLY_PHASE1":26827,"PHASE1":26833,"PHASE2":26835,"PHASE3":26837,"PHASE4":26839,"NA":26841},{"trials":26828,"activeCount":128},[26829],{"nctId":22874,"briefTitle":22875,"status":104,"phases":26830,"primaryCompletion":22877,"completion":7560,"start":22878,"enrollment":233,"conditions":26831,"interventions":26832},[89],[22880,22881,22882,22883,22884,22885,3348],[22887,22888],{"trials":26834,"activeCount":128},[],{"trials":26836,"activeCount":128},[],{"trials":26838,"activeCount":128},[],{"trials":26840,"activeCount":128},[],{"trials":26842,"activeCount":128},[],{"intervention":18140,"totalTrials":676,"cells":26844},{"EARLY_PHASE1":26845,"PHASE1":26851,"PHASE2":26853,"PHASE3":26855,"PHASE4":26857,"NA":26859},{"trials":26846,"activeCount":128},[26847],{"nctId":18132,"briefTitle":18133,"status":104,"phases":26848,"primaryCompletion":1319,"completion":18135,"start":4032,"enrollment":108,"conditions":26849,"interventions":26850},[89],[4292,18137,18138,6372],[18127,18140],{"trials":26852,"activeCount":128},[],{"trials":26854,"activeCount":128},[],{"trials":26856,"activeCount":128},[],{"trials":26858,"activeCount":128},[],{"trials":26860,"activeCount":128},[],{"intervention":26862,"totalTrials":676,"cells":26863},"Memantine",{"EARLY_PHASE1":26864,"PHASE1":26876,"PHASE2":26878,"PHASE3":26880,"PHASE4":26882,"NA":26884},{"trials":26865,"activeCount":128},[26866],{"nctId":26867,"briefTitle":26868,"status":104,"phases":26869,"primaryCompletion":26870,"completion":21903,"start":26871,"enrollment":108,"conditions":26872,"interventions":26874},"NCT04217694","Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors",[89],"2022-09-15","2020-02-17",[24551,26873],"Primary Central Nervous System Neoplasm",[26862,26875],"Memantine Hydrochloride",{"trials":26877,"activeCount":128},[],{"trials":26879,"activeCount":128},[],{"trials":26881,"activeCount":128},[],{"trials":26883,"activeCount":128},[],{"trials":26885,"activeCount":128},[],{"intervention":26875,"totalTrials":676,"cells":26887},{"EARLY_PHASE1":26888,"PHASE1":26894,"PHASE2":26896,"PHASE3":26898,"PHASE4":26900,"NA":26902},{"trials":26889,"activeCount":128},[26890],{"nctId":26867,"briefTitle":26868,"status":104,"phases":26891,"primaryCompletion":26870,"completion":21903,"start":26871,"enrollment":108,"conditions":26892,"interventions":26893},[89],[24551,26873],[26862,26875],{"trials":26895,"activeCount":128},[],{"trials":26897,"activeCount":128},[],{"trials":26899,"activeCount":128},[],{"trials":26901,"activeCount":128},[],{"trials":26903,"activeCount":128},[],{"intervention":4239,"totalTrials":676,"cells":26905},{"EARLY_PHASE1":26906,"PHASE1":26912,"PHASE2":26914,"PHASE3":26916,"PHASE4":26918,"NA":26920},{"trials":26907,"activeCount":128},[26908],{"nctId":4232,"briefTitle":4233,"status":104,"phases":26909,"primaryCompletion":4235,"completion":3972,"start":3660,"enrollment":729,"conditions":26910,"interventions":26911},[89],[4237],[4239,4240,4241],{"trials":26913,"activeCount":128},[],{"trials":26915,"activeCount":128},[],{"trials":26917,"activeCount":128},[],{"trials":26919,"activeCount":128},[],{"trials":26921,"activeCount":128},[],{"intervention":4241,"totalTrials":676,"cells":26923},{"EARLY_PHASE1":26924,"PHASE1":26930,"PHASE2":26932,"PHASE3":26934,"PHASE4":26936,"NA":26938},{"trials":26925,"activeCount":128},[26926],{"nctId":4232,"briefTitle":4233,"status":104,"phases":26927,"primaryCompletion":4235,"completion":3972,"start":3660,"enrollment":729,"conditions":26928,"interventions":26929},[89],[4237],[4239,4240,4241],{"trials":26931,"activeCount":128},[],{"trials":26933,"activeCount":128},[],{"trials":26935,"activeCount":128},[],{"trials":26937,"activeCount":128},[],{"trials":26939,"activeCount":128},[],{"intervention":26941,"totalTrials":676,"cells":26942},"Platelet Rich Plasma",{"EARLY_PHASE1":26943,"PHASE1":26954,"PHASE2":26956,"PHASE3":26958,"PHASE4":26960,"NA":26962},{"trials":26944,"activeCount":128},[26945],{"nctId":26946,"briefTitle":26947,"status":104,"phases":26948,"primaryCompletion":26949,"completion":26949,"start":26950,"enrollment":218,"conditions":26951,"interventions":26953},"NCT03647917","A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation",[89],"2021-06-07","2019-06-18",[26952],"Skin Aging of Face and Hands",[26941,26941],{"trials":26955,"activeCount":128},[],{"trials":26957,"activeCount":128},[],{"trials":26959,"activeCount":128},[],{"trials":26961,"activeCount":128},[],{"trials":26963,"activeCount":128},[],{"intervention":26965,"totalTrials":676,"cells":26966},"Vedolizumab",{"EARLY_PHASE1":26967,"PHASE1":26979,"PHASE2":26981,"PHASE3":26983,"PHASE4":26985,"NA":26987},{"trials":26968,"activeCount":128},[26969],{"nctId":26970,"briefTitle":26971,"status":1413,"phases":26972,"primaryCompletion":26973,"completion":26974,"start":26975,"enrollment":128,"conditions":26976,"interventions":26978},"NCT03309865","Evaluating the Combined Effect of Vedolizumab and Semi-Vegetarian Diet on Ulcerative Colitis.",[89],"2018-08-31","2018-12-31","2017-12-25",[11118,26977],"Dietary Modification",[26965],{"trials":26980,"activeCount":128},[],{"trials":26982,"activeCount":128},[],{"trials":26984,"activeCount":128},[],{"trials":26986,"activeCount":128},[],{"trials":26988,"activeCount":128},[],{"intervention":26990,"totalTrials":676,"cells":26991},"American Ginseng",{"EARLY_PHASE1":26992,"PHASE1":27019,"PHASE2":27021,"PHASE3":27023,"PHASE4":27025,"NA":27027},{"trials":26993,"activeCount":128},[26994],{"nctId":26995,"briefTitle":26996,"status":104,"phases":26997,"primaryCompletion":26998,"completion":26999,"start":27000,"enrollment":224,"conditions":27001,"interventions":27018},"NCT03407716","Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors",[89],"2020-05-13","2021-02-22","2019-03-01",[27002,27003,27004,27005,27006,27007,27008,27009,27010,27011,27012,27013,236,27014,237,27015,238,27016,239,27017],"Cancer Survivor","Stage I Breast Cancer AJCC v7","Stage I Colon Cancer AJCC v6 and v7","Stage IA Breast Cancer AJCC v7","Stage IB Breast Cancer AJCC v7","Stage II Breast Cancer AJCC v6 and v7","Stage II Colon Cancer AJCC v7","Stage IIA Breast Cancer AJCC v6 and v7","Stage IIA Colon Cancer AJCC v7","Stage IIB Breast Cancer AJCC v6 and v7","Stage IIB Colon Cancer AJCC v7","Stage IIC Colon Cancer AJCC v7","Stage III Colon Cancer AJCC v7","Stage IIIA Colon Cancer AJCC v7","Stage IIIB Colon Cancer AJCC v7","Stage IIIC Colon Cancer AJCC v7",[26990],{"trials":27020,"activeCount":128},[],{"trials":27022,"activeCount":128},[],{"trials":27024,"activeCount":128},[],{"trials":27026,"activeCount":128},[],{"trials":27028,"activeCount":128},[],{"intervention":27030,"totalTrials":676,"cells":27031},"ATryn continuous",{"EARLY_PHASE1":27032,"PHASE1":27041,"PHASE2":27043,"PHASE3":27045,"PHASE4":27047,"NA":27049},{"trials":27033,"activeCount":128},[27034],{"nctId":27035,"briefTitle":27036,"status":1413,"phases":27037,"primaryCompletion":2999,"completion":2999,"start":5071,"enrollment":128,"conditions":27038,"interventions":27040},"NCT03090893","Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients",[89],[27039],"Antithrombin Deficiency Type 2",[27030],{"trials":27042,"activeCount":128},[],{"trials":27044,"activeCount":128},[],{"trials":27046,"activeCount":128},[],{"trials":27048,"activeCount":128},[],{"trials":27050,"activeCount":128},[],{"intervention":27052,"totalTrials":676,"cells":27053},"Ketoconazole",{"EARLY_PHASE1":27054,"PHASE1":27063,"PHASE2":27065,"PHASE3":27067,"PHASE4":27069,"NA":27071},{"trials":27055,"activeCount":128},[27056],{"nctId":27057,"briefTitle":27058,"status":104,"phases":27059,"primaryCompletion":27060,"completion":27060,"start":7881,"enrollment":5985,"conditions":27061,"interventions":27062},"NCT03471364","Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash",[89],"2024-09-15",[24979],[27052],{"trials":27064,"activeCount":128},[],{"trials":27066,"activeCount":128},[],{"trials":27068,"activeCount":128},[],{"trials":27070,"activeCount":128},[],{"trials":27072,"activeCount":128},[],{"intervention":127,"totalTrials":676,"cells":27074},{"EARLY_PHASE1":27075,"PHASE1":27081,"PHASE2":27083,"PHASE3":27085,"PHASE4":27087,"NA":27089},{"trials":27076,"activeCount":128},[27077],{"nctId":115,"briefTitle":116,"status":104,"phases":27078,"primaryCompletion":118,"completion":118,"start":119,"enrollment":120,"conditions":27079,"interventions":27080},[89],[122,123,124,125],[127,72],{"trials":27082,"activeCount":128},[],{"trials":27084,"activeCount":128},[],{"trials":27086,"activeCount":128},[],{"trials":27088,"activeCount":128},[],{"trials":27090,"activeCount":128},[],{"intervention":27092,"totalTrials":676,"cells":27093},"PS-341",{"EARLY_PHASE1":27094,"PHASE1":27102,"PHASE2":27104,"PHASE3":27106,"PHASE4":27108,"NA":27110},{"trials":27095,"activeCount":128},[27096],{"nctId":27097,"briefTitle":27098,"status":104,"phases":27099,"primaryCompletion":3643,"completion":3643,"start":7332,"enrollment":729,"conditions":27100,"interventions":27101},"NCT00437086","Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders",[89],[3522,3549],[27092],{"trials":27103,"activeCount":128},[],{"trials":27105,"activeCount":128},[],{"trials":27107,"activeCount":128},[],{"trials":27109,"activeCount":128},[],{"trials":27111,"activeCount":128},[],{"intervention":27113,"totalTrials":676,"cells":27114},"Buparlisib",{"EARLY_PHASE1":27115,"PHASE1":27124,"PHASE2":27126,"PHASE3":27128,"PHASE4":27130,"NA":27132},{"trials":27116,"activeCount":128},[27117],{"nctId":27118,"briefTitle":27119,"status":104,"phases":27120,"primaryCompletion":547,"completion":7550,"start":3613,"enrollment":120,"conditions":27121,"interventions":27123},"NCT01719250","Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",[89],[3858,436,416,3399,27122],"Transformed Recurrent Non-Hodgkin Lymphoma",[27113],{"trials":27125,"activeCount":128},[],{"trials":27127,"activeCount":128},[],{"trials":27129,"activeCount":128},[],{"trials":27131,"activeCount":128},[],{"trials":27133,"activeCount":128},[],{"intervention":27135,"totalTrials":676,"cells":27136},"Nanoparticle Albumin-Bound Rapamycin",{"EARLY_PHASE1":27137,"PHASE1":27159,"PHASE2":27161,"PHASE3":27163,"PHASE4":27165,"NA":27167},{"trials":27138,"activeCount":128},[27139],{"nctId":27140,"briefTitle":27141,"status":104,"phases":27142,"primaryCompletion":3559,"completion":27143,"start":2607,"enrollment":224,"conditions":27144,"interventions":27158},"NCT02646319","Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations",[89],"2018-04-24",[27145,6212,1101,27146,27147,143,27148,7533,27149,506,6370,3343,3344,27150,6371,27151,3372,27152,3374,3376,27153,3378,3380,3382,3345,3385,6372,3347,27154,27155,27156,27157],"Advanced Malignant Neoplasm","Malignant Uterine Neoplasm","Recurrent Bladder Carcinoma","Recurrent Cervical Carcinoma","Recurrent Malignant Neoplasm","Stage III Bladder Cancer","Stage III Renal Cell Cancer","Stage IIIA Cervical Cancer","Stage IIIB Cervical Cancer","Stage IVA Bladder Cancer","Stage IVA Cervical Cancer","Stage IVB Bladder Cancer","Stage IVB Cervical Cancer",[27135],{"trials":27160,"activeCount":128},[],{"trials":27162,"activeCount":128},[],{"trials":27164,"activeCount":128},[],{"trials":27166,"activeCount":128},[],{"trials":27168,"activeCount":128},[],{"intervention":27170,"totalTrials":676,"cells":27171},"dendritic cell vaccine therapy",{"EARLY_PHASE1":27172,"PHASE1":27195,"PHASE2":27197,"PHASE3":27199,"PHASE4":27201,"NA":27203},{"trials":27173,"activeCount":128},[27174],{"nctId":27175,"briefTitle":27176,"status":104,"phases":27177,"primaryCompletion":27178,"completion":27179,"start":2936,"enrollment":2742,"conditions":27180,"interventions":27192},"NCT01239875","Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma",[89],"2015-11-24","2019-07-17",[27181,5316,5317,27182,27183,27184,27185,27186,27187,27188,27189,6663,27190,419,3678,27191],"Cutaneous B-cell Non-Hodgkin Lymphoma","Adult Diffuse Mixed Cell Lymphoma","Adult Diffuse Small Cleaved Cell Lymphoma","Adult Grade III Lymphomatoid Granulomatosis","Adult Immunoblastic Large Cell Lymphoma","Adult Lymphoblastic Lymphoma","Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3 Follicular Lymphoma","Marginal Zone Lymphoma","Waldenstrom Macroglobulinemia With Nodal Disease",[27170,27193,27194],"pneumococcal polyvalent vaccine","autologous dendritic cell-tumor fusion vaccine",{"trials":27196,"activeCount":128},[],{"trials":27198,"activeCount":128},[],{"trials":27200,"activeCount":128},[],{"trials":27202,"activeCount":128},[],{"trials":27204,"activeCount":128},[],{"intervention":27193,"totalTrials":676,"cells":27206},{"EARLY_PHASE1":27207,"PHASE1":27213,"PHASE2":27215,"PHASE3":27217,"PHASE4":27219,"NA":27221},{"trials":27208,"activeCount":128},[27209],{"nctId":27175,"briefTitle":27176,"status":104,"phases":27210,"primaryCompletion":27178,"completion":27179,"start":2936,"enrollment":2742,"conditions":27211,"interventions":27212},[89],[27181,5316,5317,27182,27183,27184,27185,27186,27187,27188,27189,6663,27190,419,3678,27191],[27170,27193,27194],{"trials":27214,"activeCount":128},[],{"trials":27216,"activeCount":128},[],{"trials":27218,"activeCount":128},[],{"trials":27220,"activeCount":128},[],{"trials":27222,"activeCount":128},[],{"intervention":27194,"totalTrials":676,"cells":27224},{"EARLY_PHASE1":27225,"PHASE1":27231,"PHASE2":27233,"PHASE3":27235,"PHASE4":27237,"NA":27239},{"trials":27226,"activeCount":128},[27227],{"nctId":27175,"briefTitle":27176,"status":104,"phases":27228,"primaryCompletion":27178,"completion":27179,"start":2936,"enrollment":2742,"conditions":27229,"interventions":27230},[89],[27181,5316,5317,27182,27183,27184,27185,27186,27187,27188,27189,6663,27190,419,3678,27191],[27170,27193,27194],{"trials":27232,"activeCount":128},[],{"trials":27234,"activeCount":128},[],{"trials":27236,"activeCount":128},[],{"trials":27238,"activeCount":128},[],{"trials":27240,"activeCount":128},[],{"intervention":27242,"totalTrials":676,"cells":27243},"denosumab",{"EARLY_PHASE1":27244,"PHASE1":27255,"PHASE2":27257,"PHASE3":27259,"PHASE4":27261,"NA":27263},{"trials":27245,"activeCount":128},[27246],{"nctId":27247,"briefTitle":27248,"status":104,"phases":27249,"primaryCompletion":27250,"completion":27250,"start":27251,"enrollment":696,"conditions":27252,"interventions":27254},"NCT02554695","Osteoclast Inhibition and Bone Formation",[89],"2016-10-25","2015-10-20",[27253,7089],"Bone Loss",[27242],{"trials":27256,"activeCount":128},[],{"trials":27258,"activeCount":128},[],{"trials":27260,"activeCount":128},[],{"trials":27262,"activeCount":128},[],{"trials":27264,"activeCount":128},[],{"intervention":27266,"totalTrials":676,"cells":27267},"Ascorbic Acid",{"EARLY_PHASE1":27268,"PHASE1":27279,"PHASE2":27281,"PHASE3":27283,"PHASE4":27285,"NA":27287},{"trials":27269,"activeCount":128},[27270],{"nctId":27271,"briefTitle":27272,"status":104,"phases":27273,"primaryCompletion":27274,"completion":27274,"start":27275,"enrollment":4565,"conditions":27276,"interventions":27278},"NCT03744702","Impact of Ascorbic Acid Treatment on the Development and Treatment of Vasodilation in Cardiac Surgery",[89],"2021-02-05","2019-06-28",[27277],"Vasoplegia",[27266],{"trials":27280,"activeCount":128},[],{"trials":27282,"activeCount":128},[],{"trials":27284,"activeCount":128},[],{"trials":27286,"activeCount":128},[],{"trials":27288,"activeCount":128},[],{"intervention":4269,"totalTrials":676,"cells":27290},{"EARLY_PHASE1":27291,"PHASE1":27297,"PHASE2":27299,"PHASE3":27301,"PHASE4":27303,"NA":27305},{"trials":27292,"activeCount":128},[27293],{"nctId":4243,"briefTitle":4244,"status":134,"phases":27294,"primaryCompletion":3825,"completion":4246,"start":4247,"enrollment":224,"conditions":27295,"interventions":27296},[89],[3113,3115,4249,4250,502,4251,4252,4253,506,511,4254,4255,4256,4257,4258,3498,4259,4260,4261,3500,3501,4262,4263,4264,4265,4266,4267],[4089,4269,4270,4271],{"trials":27298,"activeCount":128},[],{"trials":27300,"activeCount":128},[],{"trials":27302,"activeCount":128},[],{"trials":27304,"activeCount":128},[],{"trials":27306,"activeCount":128},[],{"intervention":4271,"totalTrials":676,"cells":27308},{"EARLY_PHASE1":27309,"PHASE1":27315,"PHASE2":27317,"PHASE3":27319,"PHASE4":27321,"NA":27323},{"trials":27310,"activeCount":128},[27311],{"nctId":4243,"briefTitle":4244,"status":134,"phases":27312,"primaryCompletion":3825,"completion":4246,"start":4247,"enrollment":224,"conditions":27313,"interventions":27314},[89],[3113,3115,4249,4250,502,4251,4252,4253,506,511,4254,4255,4256,4257,4258,3498,4259,4260,4261,3500,3501,4262,4263,4264,4265,4266,4267],[4089,4269,4270,4271],{"trials":27316,"activeCount":128},[],{"trials":27318,"activeCount":128},[],{"trials":27320,"activeCount":128},[],{"trials":27322,"activeCount":128},[],{"trials":27324,"activeCount":128},[],{"intervention":27326,"totalTrials":676,"cells":27327},"1.25mg bevacizumab",{"EARLY_PHASE1":27328,"PHASE1":27341,"PHASE2":27343,"PHASE3":27345,"PHASE4":27347,"NA":27349},{"trials":27329,"activeCount":128},[27330],{"nctId":27331,"briefTitle":27332,"status":1413,"phases":27333,"primaryCompletion":27334,"completion":27335,"start":19433,"enrollment":128,"conditions":27336,"interventions":27339},"NCT02695641","Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients",[89],"2020-08","2021-11",[27337,27338],"End Stage Renal Disease","Hemodialysis Vascular Access Failure",[27326,27340],"2.50mg bevacizumab",{"trials":27342,"activeCount":128},[],{"trials":27344,"activeCount":128},[],{"trials":27346,"activeCount":128},[],{"trials":27348,"activeCount":128},[],{"trials":27350,"activeCount":128},[],{"intervention":27340,"totalTrials":676,"cells":27352},{"EARLY_PHASE1":27353,"PHASE1":27359,"PHASE2":27361,"PHASE3":27363,"PHASE4":27365,"NA":27367},{"trials":27354,"activeCount":128},[27355],{"nctId":27331,"briefTitle":27332,"status":1413,"phases":27356,"primaryCompletion":27334,"completion":27335,"start":19433,"enrollment":128,"conditions":27357,"interventions":27358},[89],[27337,27338],[27326,27340],{"trials":27360,"activeCount":128},[],{"trials":27362,"activeCount":128},[],{"trials":27364,"activeCount":128},[],{"trials":27366,"activeCount":128},[],{"trials":27368,"activeCount":128},[],{"intervention":15991,"totalTrials":218,"cells":27370},{"EARLY_PHASE1":27371,"PHASE1":27381,"PHASE2":27398,"PHASE3":27404,"PHASE4":27434,"NA":27443},{"trials":27372,"activeCount":128},[27373],{"nctId":27374,"briefTitle":27375,"status":1413,"phases":27376,"primaryCompletion":27377,"completion":27377,"start":27377,"enrollment":128,"conditions":27378,"interventions":27380},"NCT04317300","Feasibility of Treatment for Vaping Cessation",[89],"2023-02-01",[27379],"Vaping",[15991],{"trials":27382,"activeCount":128},[27383,27390],{"nctId":27384,"briefTitle":27385,"status":104,"phases":27386,"primaryCompletion":27387,"completion":1865,"start":783,"enrollment":2563,"conditions":27388,"interventions":27389},"NCT06854406","A Study of Varenicline in the Treatment of Visceral Sensation",[90],"2025-11-30",[2885],[15991],{"nctId":27391,"briefTitle":27392,"status":104,"phases":27393,"primaryCompletion":3971,"completion":3613,"start":7107,"enrollment":3674,"conditions":27394,"interventions":27397},"NCT01436474","Pilot Study of Varenicline to Treat Opioid Dependence",[90],[27395,27396],"Chronic Pain","Opioid Dependence",[15991],{"trials":27399,"activeCount":128},[27400],{"nctId":15983,"briefTitle":15984,"status":104,"phases":27401,"primaryCompletion":15986,"completion":15986,"start":4279,"enrollment":173,"conditions":27402,"interventions":27403},[90,91],[15988,15989],[15991,15974],{"trials":27405,"activeCount":128},[27406,27413,27417,27423,27427],{"nctId":27407,"briefTitle":27408,"status":104,"phases":27409,"primaryCompletion":2667,"completion":3001,"start":7107,"enrollment":31,"conditions":27410,"interventions":27412},"NCT01347112","Varenicline Treatment for Active Alcoholic Smokers",[91,92],[13450,16292,27411],"Alcohol Dependence",[15991],{"nctId":15995,"briefTitle":15996,"status":134,"phases":27414,"primaryCompletion":15998,"completion":15998,"start":10353,"enrollment":2668,"conditions":27415,"interventions":27416},[91,92],[15,3069],[16001,15991],{"nctId":27418,"briefTitle":27419,"status":134,"phases":27420,"primaryCompletion":6365,"completion":6365,"start":4810,"enrollment":676,"conditions":27421,"interventions":27422},"NCT01169610","Varenicline and Alcohol in Inpatient Addictions Program (IAP)",[92],[14250,19662],[15991],{"nctId":16321,"briefTitle":16322,"status":104,"phases":27424,"primaryCompletion":4885,"completion":4885,"start":2883,"enrollment":16324,"conditions":27425,"interventions":27426},[91,92],[13450],[15991,16327],{"nctId":27428,"briefTitle":27429,"status":104,"phases":27430,"primaryCompletion":3660,"completion":2883,"start":1390,"enrollment":1225,"conditions":27431,"interventions":27433},"NCT01092702","Varenicline For Smokers In Recovery From Alcohol Dependence",[91,92],[27432],"Tobacco Abstinence",[15991],{"trials":27435,"activeCount":128},[27436],{"nctId":27437,"briefTitle":27438,"status":104,"phases":27439,"primaryCompletion":15986,"completion":4278,"start":2620,"enrollment":27440,"conditions":27441,"interventions":27442},"NCT01639560","Varenicline for Light Smokers",[93],93,[13450],[15991],{"trials":27444,"activeCount":128},[27445,27451],{"nctId":27446,"briefTitle":27447,"status":134,"phases":27448,"primaryCompletion":3546,"completion":4032,"start":11897,"enrollment":6434,"conditions":27449,"interventions":27450},"NCT00673595","Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo",[94],[13450],[15991],{"nctId":27452,"briefTitle":27453,"status":104,"phases":27454,"primaryCompletion":5360,"completion":4810,"start":3546,"enrollment":22,"conditions":27455,"interventions":27456},"NCT00813917","Varenicline for the Treatment of Smokeless Tobacco",[94],[19662],[27457],"varenicline",{"intervention":4283,"totalTrials":410,"cells":27459},{"EARLY_PHASE1":27460,"PHASE1":27462,"PHASE2":27487,"PHASE3":27501,"PHASE4":27503,"NA":27515},{"trials":27461,"activeCount":128},[],{"trials":27463,"activeCount":128},[27464,27471,27475,27479,27483],{"nctId":27465,"briefTitle":27466,"status":104,"phases":27467,"primaryCompletion":3660,"completion":3660,"start":5051,"enrollment":27468,"conditions":27469,"interventions":27470},"NCT00170053","Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids",[90],177,[5144],[4283],{"nctId":4275,"briefTitle":4276,"status":104,"phases":27472,"primaryCompletion":4278,"completion":4278,"start":4279,"enrollment":676,"conditions":27473,"interventions":27474},[90],[4281],[4089,161,4283],{"nctId":17985,"briefTitle":17986,"status":1413,"phases":27476,"primaryCompletion":874,"start":1374,"enrollment":128,"conditions":27477,"interventions":27478},[90],[17867,4293],[17966,7354],{"nctId":18969,"briefTitle":18970,"status":104,"phases":27480,"primaryCompletion":4045,"completion":4045,"start":18972,"enrollment":525,"conditions":27481,"interventions":27482},[90],[18974,4887,18975,4889,4293],[18962,7354],{"nctId":23180,"briefTitle":23181,"status":1413,"phases":27484,"primaryCompletion":23183,"completion":23183,"start":7107,"enrollment":128,"conditions":27485,"interventions":27486},[90],[17867,23185,23186,23187,17872,4293],[7354,23165,23189,5425],{"trials":27488,"activeCount":128},[27489,27493,27497],{"nctId":17993,"briefTitle":17994,"status":104,"phases":27490,"primaryCompletion":1310,"completion":1310,"start":17996,"enrollment":34,"conditions":27491,"interventions":27492},[90,91],[17998,17999,3341,18000,18001,18002,18003,3346],[18005,4283],{"nctId":7348,"briefTitle":7349,"status":1413,"phases":27494,"enrollment":128,"conditions":27495,"interventions":27496},[90,91],[3562,3690],[3513,3759,7353,7354,7355],{"nctId":18016,"briefTitle":18017,"status":134,"phases":27498,"primaryCompletion":18019,"completion":18019,"start":18020,"enrollment":3002,"conditions":27499,"interventions":27500},[91],[18022,506],[18005,4283],{"trials":27502,"activeCount":128},[],{"trials":27504,"activeCount":128},[27505,27509],{"nctId":5138,"briefTitle":5139,"status":104,"phases":27506,"primaryCompletion":2643,"completion":5141,"start":5142,"enrollment":1162,"conditions":27507,"interventions":27508},[93],[5144],[5146,5147,3427,3745,4283],{"nctId":27510,"briefTitle":27511,"status":104,"phases":27512,"primaryCompletion":934,"completion":934,"start":22498,"enrollment":2742,"conditions":27513,"interventions":27514},"NCT00275522","The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.",[93],[11163],[4283],{"trials":27516,"activeCount":128},[27517],{"nctId":5151,"briefTitle":5152,"status":134,"phases":27518,"primaryCompletion":3613,"completion":3613,"start":3546,"enrollment":224,"conditions":27519,"interventions":27520},[94],[5155],[3745,4283,1698,3427],{"intervention":17581,"totalTrials":1197,"cells":27522},{"EARLY_PHASE1":27523,"PHASE1":27525,"PHASE2":27527,"PHASE3":27541,"PHASE4":27554,"NA":27556},{"trials":27524,"activeCount":128},[],{"trials":27526,"activeCount":128},[],{"trials":27528,"activeCount":128},[27529,27537],{"nctId":27530,"briefTitle":27531,"status":104,"phases":27532,"primaryCompletion":27533,"completion":27533,"start":14389,"enrollment":1151,"conditions":27534,"interventions":27536},"NCT02069847","Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy",[91],"2019-01-11",[27535],"Esophageal Stricture",[17581],{"nctId":20122,"briefTitle":20123,"status":104,"phases":27538,"primaryCompletion":1318,"completion":15986,"start":3544,"enrollment":16613,"conditions":27539,"interventions":27540},[91],[20126],[17581,20113],{"trials":27542,"activeCount":128},[27543,27550],{"nctId":27544,"briefTitle":27545,"status":134,"phases":27546,"primaryCompletion":3734,"completion":3734,"start":4871,"enrollment":2742,"conditions":27547,"interventions":27549},"NCT00217022","Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis",[91,92],[27548,11717],"Lymphocytic Colitis",[17581],{"nctId":17573,"briefTitle":17574,"status":104,"phases":27551,"primaryCompletion":946,"completion":946,"start":5033,"enrollment":17576,"conditions":27552,"interventions":27553},[91,92],[12979,12978,17578,17579],[17562,17581],{"trials":27555,"activeCount":128},[],{"trials":27557,"activeCount":128},[27558,27565],{"nctId":27559,"briefTitle":27560,"status":1413,"phases":27561,"primaryCompletion":6955,"completion":6955,"start":934,"enrollment":128,"conditions":27562,"interventions":27564},"NCT00587119","Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis",[94],[20502,27563],"Autoimmune Hepatitis",[17581],{"nctId":27566,"briefTitle":27567,"status":104,"phases":27568,"primaryCompletion":3699,"completion":27569,"start":27570,"enrollment":729,"conditions":27571,"interventions":27573},"NCT04952389","Acupuncture Therapy for COVID-Related Olfactory Loss",[94],"2023-06-09","2021-12-07",[27572,12342],"Olfactory Dysfunction",[17581],{"intervention":5425,"totalTrials":895,"cells":27575},{"EARLY_PHASE1":27576,"PHASE1":27578,"PHASE2":27584,"PHASE3":27594,"PHASE4":27596,"NA":27598},{"trials":27577,"activeCount":128},[],{"trials":27579,"activeCount":128},[27580],{"nctId":23180,"briefTitle":23181,"status":1413,"phases":27581,"primaryCompletion":23183,"completion":23183,"start":7107,"enrollment":128,"conditions":27582,"interventions":27583},[90],[17867,23185,23186,23187,17872,4293],[7354,23165,23189,5425],{"trials":27585,"activeCount":128},[27586,27590],{"nctId":10893,"briefTitle":10894,"status":104,"phases":27587,"primaryCompletion":2643,"completion":2643,"start":4400,"enrollment":4565,"conditions":27588,"interventions":27589},[91],[3665],[10880,10898,10899,5425,3599],{"nctId":5414,"briefTitle":5415,"status":104,"phases":27591,"primaryCompletion":5417,"completion":5418,"start":4810,"enrollment":3002,"conditions":27592,"interventions":27593},[90,91],[5420,443,3574,3575,3577],[5408,3553,5422,5423,5424,5425,3636,5426],{"trials":27595,"activeCount":128},[],{"trials":27597,"activeCount":128},[],{"trials":27599,"activeCount":128},[27600,27613],{"nctId":27601,"briefTitle":27602,"status":1413,"phases":27603,"primaryCompletion":955,"completion":27604,"start":2936,"enrollment":128,"conditions":27605,"interventions":27610},"NCT01165645","Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma",[94],"2011-12-14",[6661,27606,27607,27608,27609],"Stage I Adult Hodgkin Lymphoma","Stage II Adult Hodgkin Lymphoma","Stage III Adult Hodgkin Lymphoma","Stage IV Adult Hodgkin Lymphoma",[27611,27612,5425],"lopinavir","ritonavir",{"nctId":27614,"briefTitle":27615,"status":104,"phases":27616,"primaryCompletion":6502,"completion":6502,"start":16723,"enrollment":1320,"conditions":27617,"interventions":27619},"NCT00644384","Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer",[94],[27618],"Non-melanomatous Skin Cancer",[27620,3598,27621,5425,7661],"acitretin","northern blotting",{"intervention":3598,"totalTrials":895,"cells":27623},{"EARLY_PHASE1":27624,"PHASE1":27626,"PHASE2":27632,"PHASE3":27642,"PHASE4":27644,"NA":27646},{"trials":27625,"activeCount":128},[],{"trials":27627,"activeCount":128},[27628],{"nctId":23172,"briefTitle":23173,"status":104,"phases":27629,"primaryCompletion":23175,"completion":23176,"start":8043,"enrollment":139,"conditions":27630,"interventions":27631},[90],[8059],[23165,3598],{"trials":27633,"activeCount":128},[27634,27638],{"nctId":7654,"briefTitle":7655,"status":104,"phases":27635,"primaryCompletion":3718,"completion":7657,"start":7604,"enrollment":7658,"conditions":27636,"interventions":27637},[91],[3665],[3551,3598,7661],{"nctId":3587,"briefTitle":3588,"status":104,"phases":27639,"primaryCompletion":1563,"completion":3590,"start":3591,"enrollment":936,"conditions":27640,"interventions":27641},[91],[21,3593],[3595,3323,3324,3596,3597,3598,3599],{"trials":27643,"activeCount":128},[],{"trials":27645,"activeCount":128},[],{"trials":27647,"activeCount":128},[27648,27652],{"nctId":27614,"briefTitle":27615,"status":104,"phases":27649,"primaryCompletion":6502,"completion":6502,"start":16723,"enrollment":1320,"conditions":27650,"interventions":27651},[94],[27618],[27620,3598,27621,5425,7661],{"nctId":27653,"briefTitle":27654,"status":104,"phases":27655,"primaryCompletion":934,"completion":934,"start":4399,"enrollment":2678,"conditions":27656,"interventions":27657},"NCT00898820","Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524",[],[8059],[3598,3636,7661],{"intervention":1568,"totalTrials":681,"cells":27659},{"EARLY_PHASE1":27660,"PHASE1":27662,"PHASE2":27664,"PHASE3":27670,"PHASE4":27672,"NA":27682},{"trials":27661,"activeCount":128},[],{"trials":27663,"activeCount":128},[],{"trials":27665,"activeCount":128},[27666],{"nctId":1560,"briefTitle":1561,"status":134,"phases":27667,"primaryCompletion":1563,"completion":1563,"start":1564,"enrollment":676,"conditions":27668,"interventions":27669},[91],[1566,938],[1551,1568],{"trials":27671,"activeCount":128},[],{"trials":27673,"activeCount":128},[27674,27678],{"nctId":2662,"briefTitle":2663,"status":104,"phases":27675,"primaryCompletion":2665,"completion":2666,"start":2667,"enrollment":2668,"conditions":27676,"interventions":27677},[93],[2670,2671],[1568,1260],{"nctId":2674,"briefTitle":2675,"status":104,"phases":27679,"primaryCompletion":784,"completion":784,"start":2677,"enrollment":2678,"conditions":27680,"interventions":27681},[93],[2680,799,2681],[1568,1260],{"trials":27683,"activeCount":128},[27684],{"nctId":2694,"briefTitle":2695,"status":104,"phases":27685,"primaryCompletion":2697,"completion":2698,"start":1234,"enrollment":2699,"conditions":27686,"interventions":27687},[94],[2670,2701],[1568,1260],{"intervention":3636,"totalTrials":681,"cells":27689},{"EARLY_PHASE1":27690,"PHASE1":27692,"PHASE2":27694,"PHASE3":27708,"PHASE4":27710,"NA":27712},{"trials":27691,"activeCount":128},[],{"trials":27693,"activeCount":128},[],{"trials":27695,"activeCount":128},[27696,27700,27704],{"nctId":5980,"briefTitle":5981,"status":104,"phases":27697,"primaryCompletion":5983,"completion":186,"start":5984,"enrollment":5985,"conditions":27698,"interventions":27699},[90,91],[5987,4989,5988,5316,5989,5317,5990,5991,5319,3858,5992,5993,434,435,436,416,5994,3678,451],[4306,3539,3636,5996,5424],{"nctId":3627,"briefTitle":3628,"status":104,"phases":27701,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":27702,"interventions":27703},[90,91],[1419],[3552,3553,3323,3324,3539,3525,3327,3636],{"nctId":5414,"briefTitle":5415,"status":104,"phases":27705,"primaryCompletion":5417,"completion":5418,"start":4810,"enrollment":3002,"conditions":27706,"interventions":27707},[90,91],[5420,443,3574,3575,3577],[5408,3553,5422,5423,5424,5425,3636,5426],{"trials":27709,"activeCount":128},[],{"trials":27711,"activeCount":128},[],{"trials":27713,"activeCount":128},[27714],{"nctId":27653,"briefTitle":27654,"status":104,"phases":27715,"primaryCompletion":934,"completion":934,"start":4399,"enrollment":2678,"conditions":27716,"interventions":27717},[],[8059],[3598,3636,7661],{"intervention":27719,"totalTrials":681,"cells":27720},"Simvastatin",{"EARLY_PHASE1":27721,"PHASE1":27723,"PHASE2":27725,"PHASE3":27727,"PHASE4":27729,"NA":27738},{"trials":27722,"activeCount":128},[],{"trials":27724,"activeCount":128},[],{"trials":27726,"activeCount":128},[],{"trials":27728,"activeCount":128},[],{"trials":27730,"activeCount":128},[27731],{"nctId":27732,"briefTitle":27733,"status":104,"phases":27734,"primaryCompletion":6973,"completion":6973,"start":1390,"enrollment":16613,"conditions":27735,"interventions":27737},"NCT00656292","Assessing the Role of \"Statin\" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery",[93],[27736],"Perioperative Inflammatory Response",[27719],{"trials":27739,"activeCount":128},[27740,27748,27755],{"nctId":27741,"briefTitle":27742,"status":104,"phases":27743,"primaryCompletion":5034,"conditions":27744,"interventions":27747},"NCT02511418","Renal Hemodynamic Effects of the HMG-CoA Reductase Inhibitors in Normal Volunteers and in Patients With Chronic Renal Failure",[94],[27745,12895,27746],"Hyperlipidemia","Chronic Renal Failure",[27719],{"nctId":27749,"briefTitle":27750,"status":134,"phases":27751,"primaryCompletion":3661,"completion":3661,"start":20977,"enrollment":27752,"conditions":27753,"interventions":27754},"NCT00588471","Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention",[94],57,[1216],[27719],{"nctId":27756,"briefTitle":27757,"status":104,"phases":27758,"primaryCompletion":5515,"completion":5515,"start":27759,"enrollment":3726,"conditions":27760,"interventions":27762},"NCT00587717","The Acute Effect of Statins on Inflammatory Markers of Athersclerotic Tissue",[94],"2002-09",[27761],"Carotid Artery Disease",[27763],"simvastatin",{"intervention":5109,"totalTrials":342,"cells":27765},{"EARLY_PHASE1":27766,"PHASE1":27768,"PHASE2":27770,"PHASE3":27776,"PHASE4":27782,"NA":27784},{"trials":27767,"activeCount":128},[],{"trials":27769,"activeCount":128},[],{"trials":27771,"activeCount":128},[27772],{"nctId":5101,"briefTitle":5102,"status":104,"phases":27773,"primaryCompletion":1299,"completion":3662,"start":5104,"enrollment":498,"conditions":27774,"interventions":27775},[91],[5106,5107],[5109,2627,5110,3525],{"trials":27777,"activeCount":128},[27778],{"nctId":5461,"briefTitle":5462,"status":104,"phases":27779,"primaryCompletion":5464,"completion":5464,"start":3842,"enrollment":1320,"conditions":27780,"interventions":27781},[91,92],[5466],[163,5109],{"trials":27783,"activeCount":128},[],{"trials":27785,"activeCount":128},[27786],{"nctId":27787,"briefTitle":27788,"status":104,"phases":27789,"completion":4928,"start":4400,"enrollment":498,"conditions":27790,"interventions":27791},"NCT00027443","Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis",[94],[5106],[5110,5109],{"intervention":15401,"totalTrials":342,"cells":27793},{"EARLY_PHASE1":27794,"PHASE1":27796,"PHASE2":27798,"PHASE3":27808,"PHASE4":27810,"NA":27816},{"trials":27795,"activeCount":128},[],{"trials":27797,"activeCount":128},[],{"trials":27799,"activeCount":128},[27800],{"nctId":27801,"briefTitle":27802,"status":104,"phases":27803,"primaryCompletion":27804,"completion":27804,"start":2979,"enrollment":31,"conditions":27805,"interventions":27807},"NCT01678794","CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function",[90,91],"2016-06-29",[27806],"Cardiorenal Syndrome (CRS)",[15401],{"trials":27809,"activeCount":128},[],{"trials":27811,"activeCount":128},[27812],{"nctId":15395,"briefTitle":15396,"status":104,"phases":27813,"primaryCompletion":4400,"completion":4400,"start":3477,"enrollment":25,"conditions":27814,"interventions":27815},[93],[15399],[15401,15382],{"trials":27817,"activeCount":128},[27818],{"nctId":27819,"briefTitle":27820,"status":104,"phases":27821,"primaryCompletion":4503,"completion":4503,"start":27822,"enrollment":27823,"conditions":27824,"interventions":27827},"NCT00005520","Genetic Epidemiology of Responses to Antihypertensives",[],"1997-02",1200,[27825,27826,12895],"Cardiovascular Diseases","Heart Diseases",[27828,15401],"Hydrochlorothiazide",{"intervention":7661,"totalTrials":342,"cells":27830},{"EARLY_PHASE1":27831,"PHASE1":27833,"PHASE2":27835,"PHASE3":27841,"PHASE4":27843,"NA":27845},{"trials":27832,"activeCount":128},[],{"trials":27834,"activeCount":128},[],{"trials":27836,"activeCount":128},[27837],{"nctId":7654,"briefTitle":7655,"status":104,"phases":27838,"primaryCompletion":3718,"completion":7657,"start":7604,"enrollment":7658,"conditions":27839,"interventions":27840},[91],[3665],[3551,3598,7661],{"trials":27842,"activeCount":128},[],{"trials":27844,"activeCount":128},[],{"trials":27846,"activeCount":128},[27847,27851],{"nctId":27614,"briefTitle":27615,"status":104,"phases":27848,"primaryCompletion":6502,"completion":6502,"start":16723,"enrollment":1320,"conditions":27849,"interventions":27850},[94],[27618],[27620,3598,27621,5425,7661],{"nctId":27653,"briefTitle":27654,"status":104,"phases":27852,"primaryCompletion":934,"completion":934,"start":4399,"enrollment":2678,"conditions":27853,"interventions":27854},[],[8059],[3598,3636,7661],{"intervention":15883,"totalTrials":342,"cells":27856},{"EARLY_PHASE1":27857,"PHASE1":27859,"PHASE2":27861,"PHASE3":27867,"PHASE4":27873,"NA":27875},{"trials":27858,"activeCount":128},[],{"trials":27860,"activeCount":128},[],{"trials":27862,"activeCount":128},[27863],{"nctId":19739,"briefTitle":19740,"status":104,"phases":27864,"primaryCompletion":19742,"completion":19743,"start":19744,"enrollment":1236,"conditions":27865,"interventions":27866},[90,91],[3665,938],[19730,19747],{"trials":27868,"activeCount":128},[27869],{"nctId":15877,"briefTitle":15878,"status":104,"phases":27870,"primaryCompletion":7107,"completion":4785,"start":15880,"enrollment":3547,"conditions":27871,"interventions":27872},[92],[3665],[15873,15883],{"trials":27874,"activeCount":128},[],{"trials":27876,"activeCount":128},[27877],{"nctId":27878,"briefTitle":27879,"status":104,"phases":27880,"primaryCompletion":1298,"completion":18345,"start":7604,"enrollment":25,"conditions":27881,"interventions":27883},"NCT00436917","Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer",[94],[21,27882],"Osteoporosis",[15883],{"intervention":2768,"totalTrials":342,"cells":27885},{"EARLY_PHASE1":27886,"PHASE1":27888,"PHASE2":27890,"PHASE3":27892,"PHASE4":27894,"NA":27896},{"trials":27887,"activeCount":128},[],{"trials":27889,"activeCount":128},[],{"trials":27891,"activeCount":128},[],{"trials":27893,"activeCount":128},[],{"trials":27895,"activeCount":128},[],{"trials":27897,"activeCount":128},[27898,27908,27912],{"nctId":27899,"briefTitle":27900,"status":104,"phases":27901,"primaryCompletion":27902,"completion":27903,"start":27904,"enrollment":773,"conditions":27905,"interventions":27907},"NCT01611155","Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy",[94],"2014-03-07","2015-09-23","2012-02-17",[27906],"Peripheral Neuropathy",[2768],{"nctId":2753,"briefTitle":2754,"status":104,"phases":27909,"primaryCompletion":2756,"completion":2757,"start":2758,"enrollment":797,"conditions":27910,"interventions":27911},[],[21,876,2760,2761],[2763,2764,2765,2766,2767,2768,2769],{"nctId":27913,"briefTitle":27914,"status":104,"phases":27915,"primaryCompletion":27916,"completion":27917,"start":27918,"enrollment":6284,"conditions":27919,"interventions":27920},"NCT01000623","Venlafaxine and Hypnosis or Focused Attention in Treating Patients with Hot Flashes",[94],"2012-02-28","2015-09-08","2010-01-31",[2760],[2768],{"intervention":27922,"totalTrials":342,"cells":27923},"Genetic Analysis",{"EARLY_PHASE1":27924,"PHASE1":27926,"PHASE2":27928,"PHASE3":27930,"PHASE4":27932,"NA":27934},{"trials":27925,"activeCount":128},[],{"trials":27927,"activeCount":128},[],{"trials":27929,"activeCount":128},[],{"trials":27931,"activeCount":128},[],{"trials":27933,"activeCount":128},[],{"trials":27935,"activeCount":128},[27936,27944,27952],{"nctId":27937,"briefTitle":27938,"status":104,"phases":27939,"primaryCompletion":874,"completion":874,"start":13617,"enrollment":27940,"conditions":27941,"interventions":27943},"NCT00589225","Primary Hyperoxaluria Mutation Genotyping",[],902,[27942],"Primary Hyperoxaluria",[27922],{"nctId":27945,"briefTitle":27946,"status":104,"phases":27947,"primaryCompletion":27948,"completion":27948,"start":7832,"enrollment":27949,"conditions":27950,"interventions":27951},"NCT01161953","Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)",[],"2025-07-31",1500,[20502],[27922],{"nctId":27953,"briefTitle":27954,"status":104,"phases":27955,"primaryCompletion":27956,"completion":27948,"start":7832,"enrollment":27949,"conditions":27957,"interventions":27959},"NCT01161992","Genomics of Primary Sclerosing Cholangitis (PSC)",[],"2025-07",[27958],"Primary Sclerosing Cholangitis (PSC)",[27922],{"intervention":6977,"totalTrials":342,"cells":27961},{"EARLY_PHASE1":27962,"PHASE1":27964,"PHASE2":27972,"PHASE3":27978,"PHASE4":27980,"NA":27982},{"trials":27963,"activeCount":128},[],{"trials":27965,"activeCount":128},[27966],{"nctId":27967,"briefTitle":27968,"status":104,"phases":27969,"primaryCompletion":6973,"completion":10288,"start":5405,"enrollment":342,"conditions":27970,"interventions":27971},"NCT02128581","A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake",[90],[15,1063,23832],[6977],{"trials":27973,"activeCount":128},[27974],{"nctId":6969,"briefTitle":6970,"status":104,"phases":27975,"primaryCompletion":6972,"completion":6972,"start":6973,"enrollment":218,"conditions":27976,"interventions":27977},[91],[6975,15],[6977,867],{"trials":27979,"activeCount":128},[],{"trials":27981,"activeCount":128},[],{"trials":27983,"activeCount":128},[27984],{"nctId":10285,"briefTitle":10286,"status":104,"phases":27985,"primaryCompletion":10288,"completion":3000,"start":4278,"enrollment":34,"conditions":27986,"interventions":27987},[94],[15],[3779,6977],{"intervention":12478,"totalTrials":342,"cells":27989},{"EARLY_PHASE1":27990,"PHASE1":27992,"PHASE2":27994,"PHASE3":28002,"PHASE4":28008,"NA":28010},{"trials":27991,"activeCount":128},[],{"trials":27993,"activeCount":128},[],{"trials":27995,"activeCount":128},[27996],{"nctId":27997,"briefTitle":27998,"status":104,"phases":27999,"primaryCompletion":894,"completion":894,"start":2937,"enrollment":3687,"conditions":28000,"interventions":28001},"NCT00884832","A Placebo-Controlled Study of Clonidine for Fecal Incontinence.",[91],[12476],[12478],{"trials":28003,"activeCount":128},[28004],{"nctId":12471,"briefTitle":12472,"status":104,"phases":28005,"primaryCompletion":12474,"completion":12474,"start":7696,"enrollment":797,"conditions":28006,"interventions":28007},[92],[12476,12453],[7117,12478],{"trials":28009,"activeCount":128},[],{"trials":28011,"activeCount":128},[28012],{"nctId":28013,"briefTitle":28014,"status":134,"phases":28015,"primaryCompletion":3546,"completion":3546,"start":3519,"enrollment":7368,"conditions":28016,"interventions":28018},"NCT00588354","Epidural Clonidine for Lumbosacral Radiculopathy",[94],[28017],"Lumbar and Other Intervertebral Disc Disorders With Radiculopathy",[12478,28019,28020],"Triamcinolone hexacetonide","Lidocaine HCl",{"intervention":28022,"totalTrials":224,"cells":28023},"Aliskiren",{"EARLY_PHASE1":28024,"PHASE1":28026,"PHASE2":28028,"PHASE3":28030,"PHASE4":28038,"NA":28040},{"trials":28025,"activeCount":128},[],{"trials":28027,"activeCount":128},[],{"trials":28029,"activeCount":128},[],{"trials":28031,"activeCount":128},[28032],{"nctId":28033,"briefTitle":28034,"status":134,"phases":28035,"primaryCompletion":1021,"completion":1021,"start":4032,"enrollment":3002,"conditions":28036,"interventions":28037},"NCT01067326","The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis",[92],[10451],[28022],{"trials":28039,"activeCount":128},[],{"trials":28041,"activeCount":128},[28042],{"nctId":28043,"briefTitle":28044,"status":1413,"phases":28045,"primaryCompletion":1021,"completion":1021,"start":2936,"enrollment":128,"conditions":28046,"interventions":28047},"NCT01093781","Aliskiren in Patients With Idiopathic Membranous Nephropathy",[94],[5466],[28022],{"intervention":28049,"totalTrials":224,"cells":28050},"lorazepam",{"EARLY_PHASE1":28051,"PHASE1":28053,"PHASE2":28062,"PHASE3":28064,"PHASE4":28066,"NA":28068},{"trials":28052,"activeCount":128},[],{"trials":28054,"activeCount":128},[28055],{"nctId":28056,"briefTitle":28057,"status":104,"phases":28058,"primaryCompletion":2946,"completion":2946,"start":2620,"enrollment":27752,"conditions":28059,"interventions":28061},"NCT01780519","The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms",[90],[28060],"Alzheimer's Disease (AD)",[28049],{"trials":28063,"activeCount":128},[],{"trials":28065,"activeCount":128},[],{"trials":28067,"activeCount":128},[],{"trials":28069,"activeCount":128},[28070],{"nctId":28071,"briefTitle":28072,"status":104,"phases":28073,"primaryCompletion":4928,"completion":4928,"start":22498,"enrollment":187,"conditions":28074,"interventions":28075},"NCT00586430","The Impact of Lorazepam on Cognition in APOE e4 Carriers",[94],[1377],[28049],{"intervention":28077,"totalTrials":224,"cells":28078},"Acamprosate",{"EARLY_PHASE1":28079,"PHASE1":28081,"PHASE2":28083,"PHASE3":28085,"PHASE4":28087,"NA":28098},{"trials":28080,"activeCount":128},[],{"trials":28082,"activeCount":128},[],{"trials":28084,"activeCount":128},[],{"trials":28086,"activeCount":128},[],{"trials":28088,"activeCount":128},[28089],{"nctId":28090,"briefTitle":28091,"status":104,"phases":28092,"primaryCompletion":28093,"completion":28093,"start":3851,"enrollment":28094,"conditions":28095,"interventions":28097},"NCT03818191","Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome",[93],"2023-11-04",288,[28096],"Alcohol Use Disorder",[28077],{"trials":28099,"activeCount":128},[28100],{"nctId":28101,"briefTitle":28102,"status":104,"phases":28103,"primaryCompletion":10245,"completion":10245,"start":5033,"enrollment":28104,"conditions":28105,"interventions":28106},"NCT00662571","Acamprosate: Genes Associated With Response",[],485,[14250],[28107],"acamprosate",{"intervention":28109,"totalTrials":224,"cells":28110},"olanzapine",{"EARLY_PHASE1":28111,"PHASE1":28113,"PHASE2":28115,"PHASE3":28117,"PHASE4":28128,"NA":28130},{"trials":28112,"activeCount":128},[],{"trials":28114,"activeCount":128},[],{"trials":28116,"activeCount":128},[],{"trials":28118,"activeCount":128},[28119],{"nctId":28120,"briefTitle":28121,"status":1413,"phases":28122,"primaryCompletion":28123,"completion":1470,"start":28124,"enrollment":128,"conditions":28125,"interventions":28126},"NCT05403580","Olanzapine for the Treatment of Chronic Nausea and\u002For Vomiting in Patients With Advanced Cancer",[92],"2023-12-29","2022-06-03",[10158,1418],[28127],"Olanzapine",{"trials":28129,"activeCount":128},[],{"trials":28131,"activeCount":128},[28132],{"nctId":28133,"briefTitle":28134,"status":1413,"phases":28135,"primaryCompletion":7657,"completion":7657,"start":3673,"enrollment":128,"conditions":28136,"interventions":28138},"NCT00737191","Opioids With or Without Olanzapine in Treating Patients With Moderate to Severe Cancer Pain",[94],[28137,938,4293],"Hematopoietic\u002FLymphoid Cancer",[28109],{"intervention":28140,"totalTrials":224,"cells":28141},"Xifaxan",{"EARLY_PHASE1":28142,"PHASE1":28144,"PHASE2":28152,"PHASE3":28154,"PHASE4":28156,"NA":28158},{"trials":28143,"activeCount":128},[],{"trials":28145,"activeCount":128},[28146],{"nctId":28147,"briefTitle":28148,"status":104,"phases":28149,"primaryCompletion":4795,"completion":3001,"start":894,"enrollment":2742,"conditions":28150,"interventions":28151},"NCT01695174","A Pilot Study of Xifaxan to Treat Patients With PSC",[90],[27958],[28140],{"trials":28153,"activeCount":128},[],{"trials":28155,"activeCount":128},[],{"trials":28157,"activeCount":128},[],{"trials":28159,"activeCount":128},[28160],{"nctId":28161,"briefTitle":28162,"status":134,"phases":28163,"primaryCompletion":5246,"completion":5246,"start":2643,"enrollment":139,"conditions":28164,"interventions":28169},"NCT00577772","Transit Time and Bacterial Overgrowth Using SmartPill Capsule",[94],[28165,28166,28167,28168],"Small Bowel Bacterial Overgrowth","Gastrointestinal Diseases","Stomach Diseases","Digestive System Diseases",[28140],{"intervention":14913,"totalTrials":224,"cells":28171},{"EARLY_PHASE1":28172,"PHASE1":28174,"PHASE2":28176,"PHASE3":28178,"PHASE4":28180,"NA":28186},{"trials":28173,"activeCount":128},[],{"trials":28175,"activeCount":128},[],{"trials":28177,"activeCount":128},[],{"trials":28179,"activeCount":128},[],{"trials":28181,"activeCount":128},[28182],{"nctId":14903,"briefTitle":14904,"status":104,"phases":28183,"primaryCompletion":14906,"completion":14907,"start":14908,"enrollment":14909,"conditions":28184,"interventions":28185},[93],[14911],[14913,14890],{"trials":28187,"activeCount":128},[28188],{"nctId":28189,"briefTitle":28190,"status":104,"phases":28191,"primaryCompletion":1235,"completion":1235,"start":4885,"enrollment":19,"conditions":28192,"interventions":28194},"NCT01816477","Post Operative Pain Control Using Ropivacaine and the ON-Q System in the Adult Pectus Excavatum Patient",[94],[28193],"Pectus Excavatum",[14913],{"intervention":28196,"totalTrials":224,"cells":28197},"Synthetic Human Secretin",{"EARLY_PHASE1":28198,"PHASE1":28200,"PHASE2":28202,"PHASE3":28210,"PHASE4":28212,"NA":28214},{"trials":28199,"activeCount":128},[],{"trials":28201,"activeCount":128},[],{"trials":28203,"activeCount":128},[28204],{"nctId":28205,"briefTitle":28206,"status":134,"phases":28207,"primaryCompletion":2979,"completion":2979,"start":4399,"enrollment":681,"conditions":28208,"interventions":28209},"NCT00587132","Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma",[90,91],[4862],[28196],{"trials":28211,"activeCount":128},[],{"trials":28213,"activeCount":128},[],{"trials":28215,"activeCount":128},[28216],{"nctId":28217,"briefTitle":28218,"status":104,"phases":28219,"primaryCompletion":28220,"completion":28220,"start":17856,"enrollment":28221,"conditions":28222,"interventions":28223},"NCT03404661","Optical and Biochemical Biomarkers in Early Pancreatic Cancer",[],"2022-03-10",346,[4862],[28196],{"intervention":28225,"totalTrials":224,"cells":28226},"Convalescent Plasma",{"EARLY_PHASE1":28227,"PHASE1":28229,"PHASE2":28231,"PHASE3":28242,"PHASE4":28244,"NA":28246},{"trials":28228,"activeCount":128},[],{"trials":28230,"activeCount":128},[],{"trials":28232,"activeCount":128},[28233],{"nctId":28234,"briefTitle":28235,"status":1413,"phases":28236,"primaryCompletion":28237,"completion":28237,"start":28238,"enrollment":128,"conditions":28239,"interventions":28241},"NCT04325672","Convalescent Plasma to Limit Coronavirus Associated Complications",[91],"2022-12-31","2020-04-01",[28240],"Coronavirus",[28225],{"trials":28243,"activeCount":128},[],{"trials":28245,"activeCount":128},[],{"trials":28247,"activeCount":128},[28248],{"nctId":28249,"briefTitle":28250,"status":104,"phases":28251,"primaryCompletion":28252,"completion":28252,"start":28253,"enrollment":2644,"conditions":28254,"interventions":28257},"NCT04884477","COVID-19 Infection in Patients Receiving Anti-CD20 Therapy",[],"2023-01-15","2021-06-01",[12342,28255,28225,28256],"Immunosuppressed Host","Anti-CD20 Therapy",[28225],{"intervention":21744,"totalTrials":224,"cells":28259},{"EARLY_PHASE1":28260,"PHASE1":28262,"PHASE2":28264,"PHASE3":28270,"PHASE4":28272,"NA":28274},{"trials":28261,"activeCount":128},[],{"trials":28263,"activeCount":128},[],{"trials":28265,"activeCount":128},[28266],{"nctId":21738,"briefTitle":21739,"status":104,"phases":28267,"primaryCompletion":905,"completion":905,"start":3033,"enrollment":3138,"conditions":28268,"interventions":28269},[91],[21742],[21744,21729],{"trials":28271,"activeCount":128},[],{"trials":28273,"activeCount":128},[],{"trials":28275,"activeCount":128},[28276],{"nctId":28277,"briefTitle":28278,"status":1413,"phases":28279,"primaryCompletion":11559,"completion":11559,"start":28280,"enrollment":128,"conditions":28281,"interventions":28283},"NCT03232450","Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation",[94],"2019-08",[28282],"Foramen Ovale, Patent",[21744],{"intervention":28285,"totalTrials":224,"cells":28286},"Platelet-rich plasma",{"EARLY_PHASE1":28287,"PHASE1":28289,"PHASE2":28291,"PHASE3":28297,"PHASE4":28299,"NA":28301},{"trials":28288,"activeCount":128},[],{"trials":28290,"activeCount":128},[],{"trials":28292,"activeCount":128},[28293],{"nctId":20744,"briefTitle":20745,"status":1413,"phases":28294,"primaryCompletion":20747,"completion":20747,"start":2990,"enrollment":128,"conditions":28295,"interventions":28296},[91],[20749],[20735,20751],{"trials":28298,"activeCount":128},[],{"trials":28300,"activeCount":128},[],{"trials":28302,"activeCount":128},[28303],{"nctId":28304,"briefTitle":28305,"status":104,"phases":28306,"primaryCompletion":28307,"completion":28308,"start":12774,"enrollment":4821,"conditions":28309,"interventions":28311},"NCT04886349","Platelet-rich Plasma for Thumb Carpometacarpal Joint Osteoarthritis",[],"2021-04-01","2021-04-02",[28310],"Thumb Carpometacarpal Joint Osteoarthritis",[28285],{"intervention":2767,"totalTrials":224,"cells":28313},{"EARLY_PHASE1":28314,"PHASE1":28316,"PHASE2":28318,"PHASE3":28320,"PHASE4":28322,"NA":28324},{"trials":28315,"activeCount":128},[],{"trials":28317,"activeCount":128},[],{"trials":28319,"activeCount":128},[],{"trials":28321,"activeCount":128},[],{"trials":28323,"activeCount":128},[],{"trials":28325,"activeCount":128},[28326,28333],{"nctId":28327,"briefTitle":28328,"status":134,"phases":28329,"primaryCompletion":27903,"completion":27903,"start":4784,"enrollment":15202,"conditions":28330,"interventions":28331},"NCT00873366","Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer",[],[21],[28332,2767],"dextromethorphan hydrobromide",{"nctId":2753,"briefTitle":2754,"status":104,"phases":28334,"primaryCompletion":2756,"completion":2757,"start":2758,"enrollment":797,"conditions":28335,"interventions":28336},[],[21,876,2760,2761],[2763,2764,2765,2766,2767,2768,2769],{"intervention":20915,"totalTrials":224,"cells":28338},{"EARLY_PHASE1":28339,"PHASE1":28341,"PHASE2":28343,"PHASE3":28349,"PHASE4":28351,"NA":28353},{"trials":28340,"activeCount":128},[],{"trials":28342,"activeCount":128},[],{"trials":28344,"activeCount":128},[28345],{"nctId":20908,"briefTitle":20909,"status":104,"phases":28346,"primaryCompletion":2883,"completion":6258,"start":7604,"enrollment":173,"conditions":28347,"interventions":28348},[90,91],[20912,20913],[20899,20915],{"trials":28350,"activeCount":128},[],{"trials":28352,"activeCount":128},[],{"trials":28354,"activeCount":128},[28355],{"nctId":28356,"briefTitle":28357,"status":104,"phases":28358,"primaryCompletion":935,"completion":935,"start":20999,"enrollment":1997,"conditions":28359,"interventions":28361},"NCT00170001","Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy",[94],[28360],"Gastroesophageal Reflux",[28362,20915],"Nexium",{"intervention":5110,"totalTrials":224,"cells":28364},{"EARLY_PHASE1":28365,"PHASE1":28367,"PHASE2":28369,"PHASE3":28375,"PHASE4":28377,"NA":28379},{"trials":28366,"activeCount":128},[],{"trials":28368,"activeCount":128},[],{"trials":28370,"activeCount":128},[28371],{"nctId":5101,"briefTitle":5102,"status":104,"phases":28372,"primaryCompletion":1299,"completion":3662,"start":5104,"enrollment":498,"conditions":28373,"interventions":28374},[91],[5106,5107],[5109,2627,5110,3525],{"trials":28376,"activeCount":128},[],{"trials":28378,"activeCount":128},[],{"trials":28380,"activeCount":128},[28381],{"nctId":27787,"briefTitle":27788,"status":104,"phases":28382,"completion":4928,"start":4400,"enrollment":498,"conditions":28383,"interventions":28384},[94],[5106],[5110,5109],{"intervention":21229,"totalTrials":224,"cells":28386},{"EARLY_PHASE1":28387,"PHASE1":28389,"PHASE2":28391,"PHASE3":28397,"PHASE4":28399,"NA":28401},{"trials":28388,"activeCount":128},[],{"trials":28390,"activeCount":128},[],{"trials":28392,"activeCount":128},[28393],{"nctId":21219,"briefTitle":21220,"status":134,"phases":28394,"primaryCompletion":21222,"completion":21222,"start":21223,"enrollment":430,"conditions":28395,"interventions":28396},[91],[21225,21226,21227,30],[21229,21210],{"trials":28398,"activeCount":128},[],{"trials":28400,"activeCount":128},[],{"trials":28402,"activeCount":128},[28403],{"nctId":28404,"briefTitle":28405,"status":104,"phases":28406,"primaryCompletion":28407,"completion":10235,"start":28408,"enrollment":3002,"conditions":28409,"interventions":28411},"NCT02979301","Impact of Low-dose Tamoxifen on BPU",[94],"2018-02-25","2017-03-01",[28410],"High Background Uptake on MBI",[21229],{"intervention":28413,"totalTrials":224,"cells":28414},"Technetium (99mTc) sestamibi",{"EARLY_PHASE1":28415,"PHASE1":28417,"PHASE2":28419,"PHASE3":28421,"PHASE4":28423,"NA":28425},{"trials":28416,"activeCount":128},[],{"trials":28418,"activeCount":128},[],{"trials":28420,"activeCount":128},[],{"trials":28422,"activeCount":128},[],{"trials":28424,"activeCount":128},[],{"trials":28426,"activeCount":128},[28427,28434],{"nctId":28428,"briefTitle":28429,"status":104,"phases":28430,"primaryCompletion":6258,"completion":6258,"start":4464,"enrollment":28431,"conditions":28432,"interventions":28433},"NCT00620373","Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts",[94],969,[21],[28413],{"nctId":28435,"briefTitle":28436,"status":104,"phases":28437,"primaryCompletion":6365,"completion":6365,"start":1563,"enrollment":28438,"conditions":28439,"interventions":28440},"NCT01925170","Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts",[94],1638,[21],[28413],{"intervention":12067,"totalTrials":676,"cells":28442},{"EARLY_PHASE1":28443,"PHASE1":28445,"PHASE2":28447,"PHASE3":28449,"PHASE4":28451,"NA":28453},{"trials":28444,"activeCount":128},[],{"trials":28446,"activeCount":128},[],{"trials":28448,"activeCount":128},[],{"trials":28450,"activeCount":128},[],{"trials":28452,"activeCount":128},[],{"trials":28454,"activeCount":128},[28455],{"nctId":12060,"briefTitle":12061,"status":104,"phases":28456,"primaryCompletion":12063,"completion":12063,"start":4885,"enrollment":817,"conditions":28457,"interventions":28458},[],[12065],[12045,12067,12068,12069],{"intervention":12069,"totalTrials":676,"cells":28460},{"EARLY_PHASE1":28461,"PHASE1":28463,"PHASE2":28465,"PHASE3":28467,"PHASE4":28469,"NA":28471},{"trials":28462,"activeCount":128},[],{"trials":28464,"activeCount":128},[],{"trials":28466,"activeCount":128},[],{"trials":28468,"activeCount":128},[],{"trials":28470,"activeCount":128},[],{"trials":28472,"activeCount":128},[28473],{"nctId":12060,"briefTitle":12061,"status":104,"phases":28474,"primaryCompletion":12063,"completion":12063,"start":4885,"enrollment":817,"conditions":28475,"interventions":28476},[],[12065],[12045,12067,12068,12069],{"intervention":28478,"totalTrials":676,"cells":28479},"menadione topical lotion",{"EARLY_PHASE1":28480,"PHASE1":28482,"PHASE2":28484,"PHASE3":28486,"PHASE4":28488,"NA":28490},{"trials":28481,"activeCount":128},[],{"trials":28483,"activeCount":128},[],{"trials":28485,"activeCount":128},[],{"trials":28487,"activeCount":128},[],{"trials":28489,"activeCount":128},[],{"trials":28491,"activeCount":128},[28492],{"nctId":28493,"briefTitle":28494,"status":104,"phases":28495,"primaryCompletion":28496,"completion":28497,"start":28498,"enrollment":97,"conditions":28499,"interventions":28501},"NCT01393821","Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab",[94],"2013-05-11","2018-07-14","2012-01-23",[28500,24979,938],"Dermatologic Complications",[28478],{"intervention":27611,"totalTrials":676,"cells":28503},{"EARLY_PHASE1":28504,"PHASE1":28506,"PHASE2":28508,"PHASE3":28510,"PHASE4":28512,"NA":28514},{"trials":28505,"activeCount":128},[],{"trials":28507,"activeCount":128},[],{"trials":28509,"activeCount":128},[],{"trials":28511,"activeCount":128},[],{"trials":28513,"activeCount":128},[],{"trials":28515,"activeCount":128},[28516],{"nctId":27601,"briefTitle":27602,"status":1413,"phases":28517,"primaryCompletion":955,"completion":27604,"start":2936,"enrollment":128,"conditions":28518,"interventions":28519},[94],[6661,27606,27607,27608,27609],[27611,27612,5425],{"intervention":27612,"totalTrials":676,"cells":28521},{"EARLY_PHASE1":28522,"PHASE1":28524,"PHASE2":28526,"PHASE3":28528,"PHASE4":28530,"NA":28532},{"trials":28523,"activeCount":128},[],{"trials":28525,"activeCount":128},[],{"trials":28527,"activeCount":128},[],{"trials":28529,"activeCount":128},[],{"trials":28531,"activeCount":128},[],{"trials":28533,"activeCount":128},[28534],{"nctId":27601,"briefTitle":27602,"status":1413,"phases":28535,"primaryCompletion":955,"completion":27604,"start":2936,"enrollment":128,"conditions":28536,"interventions":28537},[94],[6661,27606,27607,27608,27609],[27611,27612,5425],{"intervention":28539,"totalTrials":676,"cells":28540},"2-",{"EARLY_PHASE1":28541,"PHASE1":28543,"PHASE2":28545,"PHASE3":28547,"PHASE4":28549,"NA":28551},{"trials":28542,"activeCount":128},[],{"trials":28544,"activeCount":128},[],{"trials":28546,"activeCount":128},[],{"trials":28548,"activeCount":128},[],{"trials":28550,"activeCount":128},[],{"trials":28552,"activeCount":128},[28553],{"nctId":28554,"briefTitle":28555,"status":104,"phases":28556,"primaryCompletion":6413,"completion":6413,"start":28557,"enrollment":6284,"conditions":28558,"interventions":28560},"NCT05220514","Long-term Effects of COVID-19",[],"2022-01-19",[12342,28559],"SAR-CoV-2",[28539],{"intervention":28562,"totalTrials":676,"cells":28563},"SPY Intra-operative Angiography",{"EARLY_PHASE1":28564,"PHASE1":28566,"PHASE2":28568,"PHASE3":28570,"PHASE4":28572,"NA":28574},{"trials":28565,"activeCount":128},[],{"trials":28567,"activeCount":128},[],{"trials":28569,"activeCount":128},[],{"trials":28571,"activeCount":128},[],{"trials":28573,"activeCount":128},[],{"trials":28575,"activeCount":128},[28576],{"nctId":28577,"briefTitle":28578,"status":104,"phases":28579,"primaryCompletion":28580,"completion":28580,"start":18589,"enrollment":370,"conditions":28581,"interventions":28583},"NCT03351387","Wound Necrosis in Lower Extremity Surgery",[],"2018-04-18",[28582],"Extremity Lower Wounds",[28562],{"intervention":28585,"totalTrials":676,"cells":28586},"Nivolumab 3 mg\u002Fkg IV q2 weeks",{"EARLY_PHASE1":28587,"PHASE1":28589,"PHASE2":28591,"PHASE3":28593,"PHASE4":28595,"NA":28597},{"trials":28588,"activeCount":128},[],{"trials":28590,"activeCount":128},[],{"trials":28592,"activeCount":128},[],{"trials":28594,"activeCount":128},[],{"trials":28596,"activeCount":128},[],{"trials":28598,"activeCount":128},[28599],{"nctId":28600,"briefTitle":28601,"status":134,"phases":28602,"primaryCompletion":25419,"completion":25419,"start":18984,"enrollment":6434,"conditions":28603,"interventions":28604},"NCT03539198","Study of Proton SBRT and Immunotherapy for Recurrent\u002FProgressive Locoregional or Metastatic Head and Neck Cancer",[],[4237],[28585],{"intervention":28606,"totalTrials":676,"cells":28607},"Glucagon-Like-Peptide-1\u002FRegadenoson\u002FPerflutren Lipid Microsphere",{"EARLY_PHASE1":28608,"PHASE1":28610,"PHASE2":28612,"PHASE3":28614,"PHASE4":28616,"NA":28618},{"trials":28609,"activeCount":128},[],{"trials":28611,"activeCount":128},[],{"trials":28613,"activeCount":128},[],{"trials":28615,"activeCount":128},[],{"trials":28617,"activeCount":128},[],{"trials":28619,"activeCount":128},[28620],{"nctId":28621,"briefTitle":28622,"status":104,"phases":28623,"primaryCompletion":4300,"completion":4300,"start":4032,"enrollment":31,"conditions":28624,"interventions":28626},"NCT01021865","Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes",[],[1216,28625],"Diabetes Mellitus Type 2",[28606],{"intervention":28628,"totalTrials":676,"cells":28629},"estrogen",{"EARLY_PHASE1":28630,"PHASE1":28632,"PHASE2":28634,"PHASE3":28636,"PHASE4":28638,"NA":28640},{"trials":28631,"activeCount":128},[],{"trials":28633,"activeCount":128},[],{"trials":28635,"activeCount":128},[],{"trials":28637,"activeCount":128},[],{"trials":28639,"activeCount":128},[],{"trials":28641,"activeCount":128},[28642],{"nctId":28643,"briefTitle":28644,"status":104,"phases":28645,"primaryCompletion":28646,"completion":28646,"start":28647,"enrollment":25,"conditions":28648,"interventions":28649},"NCT00443716","Determination of Adipocyte Parameters in Iliac Crest Biopsies From Post Menopausal Women",[94],"1989-04","1985-04",[27882,7721],[28628],{"intervention":28651,"totalTrials":676,"cells":28652},"Pharmacogenomics (PGx) genetic testing",{"EARLY_PHASE1":28653,"PHASE1":28655,"PHASE2":28657,"PHASE3":28659,"PHASE4":28661,"NA":28663},{"trials":28654,"activeCount":128},[],{"trials":28656,"activeCount":128},[],{"trials":28658,"activeCount":128},[],{"trials":28660,"activeCount":128},[],{"trials":28662,"activeCount":128},[],{"trials":28664,"activeCount":128},[28665],{"nctId":28666,"briefTitle":28667,"status":104,"phases":28668,"primaryCompletion":4522,"completion":4522,"start":28669,"enrollment":28670,"conditions":28671,"interventions":28672},"NCT05572593","Utility of Pharmacogenomic Testing in Patients With Gastrointestinal Disorders",[94],"2018-02-08",97,[28166],[28651],{"intervention":28674,"totalTrials":676,"cells":28675},"sulindac",{"EARLY_PHASE1":28676,"PHASE1":28678,"PHASE2":28680,"PHASE3":28682,"PHASE4":28684,"NA":28686},{"trials":28677,"activeCount":128},[],{"trials":28679,"activeCount":128},[],{"trials":28681,"activeCount":128},[],{"trials":28683,"activeCount":128},[],{"trials":28685,"activeCount":128},[],{"trials":28687,"activeCount":128},[28688],{"nctId":28689,"briefTitle":28690,"status":104,"phases":28691,"completion":933,"start":7604,"enrollment":817,"conditions":28692,"interventions":28693},"NCT00343629","Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers",[94],[4293],[28674],{"intervention":6959,"totalTrials":676,"cells":28695},{"EARLY_PHASE1":28696,"PHASE1":28698,"PHASE2":28700,"PHASE3":28702,"PHASE4":28704,"NA":28706},{"trials":28697,"activeCount":128},[],{"trials":28699,"activeCount":128},[],{"trials":28701,"activeCount":128},[],{"trials":28703,"activeCount":128},[],{"trials":28705,"activeCount":128},[],{"trials":28707,"activeCount":128},[28708],{"nctId":6952,"briefTitle":6953,"status":134,"phases":28709,"primaryCompletion":3717,"completion":6955,"start":5515,"enrollment":187,"conditions":28710,"interventions":28711},[94],[6957],[6909,6959],{"intervention":28713,"totalTrials":676,"cells":28714},"Antibiotic",{"EARLY_PHASE1":28715,"PHASE1":28717,"PHASE2":28719,"PHASE3":28721,"PHASE4":28723,"NA":28725},{"trials":28716,"activeCount":128},[],{"trials":28718,"activeCount":128},[],{"trials":28720,"activeCount":128},[],{"trials":28722,"activeCount":128},[],{"trials":28724,"activeCount":128},[],{"trials":28726,"activeCount":128},[28727],{"nctId":28728,"briefTitle":28729,"status":1413,"phases":28730,"primaryCompletion":28731,"completion":1650,"start":28732,"enrollment":128,"conditions":28733,"interventions":28737},"NCT06207786","Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery",[94],"2029-05","2024-09-01",[28734,28735,28736],"Skin Cancer","Skin Cancer Face","Malignant Cutaneous Adnexal Neoplasm",[28713],{"intervention":28739,"totalTrials":676,"cells":28740},"DNA Analysis of Blood Sample",{"EARLY_PHASE1":28741,"PHASE1":28743,"PHASE2":28745,"PHASE3":28747,"PHASE4":28749,"NA":28751},{"trials":28742,"activeCount":128},[],{"trials":28744,"activeCount":128},[],{"trials":28746,"activeCount":128},[],{"trials":28748,"activeCount":128},[],{"trials":28750,"activeCount":128},[],{"trials":28752,"activeCount":128},[28753],{"nctId":28754,"briefTitle":28755,"status":104,"phases":28756,"primaryCompletion":28757,"completion":28757,"start":2946,"enrollment":785,"conditions":28758,"interventions":28760},"NCT03266068","Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders",[],"2020-03-11",[28759,2885],"Campylobacter Infections",[28739],{"intervention":28762,"totalTrials":676,"cells":28763},"MN-166",{"EARLY_PHASE1":28764,"PHASE1":28766,"PHASE2":28768,"PHASE3":28770,"PHASE4":28772,"NA":28774},{"trials":28765,"activeCount":128},[],{"trials":28767,"activeCount":128},[],{"trials":28769,"activeCount":128},[],{"trials":28771,"activeCount":128},[],{"trials":28773,"activeCount":128},[],{"trials":28775,"activeCount":128},[28776],{"nctId":28777,"briefTitle":28778,"status":28779,"phases":28780,"conditions":28781,"interventions":28782},"NCT06743776","Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS","AVAILABLE",[],[8116],[28762],{"intervention":28784,"totalTrials":676,"cells":28785},"Paricalcitol",{"EARLY_PHASE1":28786,"PHASE1":28788,"PHASE2":28790,"PHASE3":28792,"PHASE4":28794,"NA":28796},{"trials":28787,"activeCount":128},[],{"trials":28789,"activeCount":128},[],{"trials":28791,"activeCount":128},[],{"trials":28793,"activeCount":128},[],{"trials":28795,"activeCount":128},[],{"trials":28797,"activeCount":128},[28798],{"nctId":28799,"briefTitle":28800,"status":104,"phases":28801,"primaryCompletion":3842,"completion":3842,"start":5034,"enrollment":712,"conditions":28802,"interventions":28806},"NCT00587158","Oral Paricalcitol in Kidney Transplant Recipients",[94],[28803,28804,28805],"Transplant; Failure, Kidney","Renal Disease, End Stage","Hyperparathyroidism, Secondary",[28784],{"intervention":28808,"totalTrials":676,"cells":28809},"Vascular Boot",{"EARLY_PHASE1":28810,"PHASE1":28812,"PHASE2":28814,"PHASE3":28816,"PHASE4":28818,"NA":28820},{"trials":28811,"activeCount":128},[],{"trials":28813,"activeCount":128},[],{"trials":28815,"activeCount":128},[],{"trials":28817,"activeCount":128},[],{"trials":28819,"activeCount":128},[],{"trials":28821,"activeCount":128},[28822],{"nctId":28823,"briefTitle":28824,"status":134,"phases":28825,"primaryCompletion":28826,"completion":28827,"start":28828,"enrollment":4565,"conditions":28829,"interventions":28831},"NCT03465735","Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)",[94],"2019-08-29","2020-01-03","2017-01-13",[28830],"Acute DVT of Lower Extremity",[28808,28832],"Standard of Care",{"intervention":28832,"totalTrials":676,"cells":28834},{"EARLY_PHASE1":28835,"PHASE1":28837,"PHASE2":28839,"PHASE3":28841,"PHASE4":28843,"NA":28845},{"trials":28836,"activeCount":128},[],{"trials":28838,"activeCount":128},[],{"trials":28840,"activeCount":128},[],{"trials":28842,"activeCount":128},[],{"trials":28844,"activeCount":128},[],{"trials":28846,"activeCount":128},[28847],{"nctId":28823,"briefTitle":28824,"status":134,"phases":28848,"primaryCompletion":28826,"completion":28827,"start":28828,"enrollment":4565,"conditions":28849,"interventions":28850},[94],[28830],[28808,28832],{"intervention":28852,"totalTrials":676,"cells":28853},"COVID-19 convalescent plasma",{"EARLY_PHASE1":28854,"PHASE1":28856,"PHASE2":28858,"PHASE3":28860,"PHASE4":28862,"NA":28864},{"trials":28855,"activeCount":128},[],{"trials":28857,"activeCount":128},[],{"trials":28859,"activeCount":128},[],{"trials":28861,"activeCount":128},[],{"trials":28863,"activeCount":128},[],{"trials":28865,"activeCount":128},[28866],{"nctId":28867,"briefTitle":28868,"status":28869,"phases":28870,"conditions":28871,"interventions":28873},"NCT04338360","Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19","APPROVED_FOR_MARKETING",[],[28872],"COVID19",[28852],{"intervention":28875,"totalTrials":676,"cells":28876},"SNP analysis",{"EARLY_PHASE1":28877,"PHASE1":28879,"PHASE2":28881,"PHASE3":28883,"PHASE4":28885,"NA":28887},{"trials":28878,"activeCount":128},[],{"trials":28880,"activeCount":128},[],{"trials":28882,"activeCount":128},[],{"trials":28884,"activeCount":128},[],{"trials":28886,"activeCount":128},[],{"trials":28888,"activeCount":128},[28889],{"nctId":28890,"briefTitle":28891,"status":104,"phases":28892,"primaryCompletion":2642,"completion":2642,"start":13742,"enrollment":7368,"conditions":28893,"interventions":28897},"NCT00782366","Predictive Genetic Risk Assessment Trial",[],[28894,8059,33,28895,15,21,28896,1340,14416,23238,4292],"Colon Cancer","Diabetes Type 2","Graves Disease",[28875],{"intervention":28899,"totalTrials":676,"cells":28900},"CEUS or Contrast enhanced Ultrasound",{"EARLY_PHASE1":28901,"PHASE1":28903,"PHASE2":28905,"PHASE3":28907,"PHASE4":28909,"NA":28911},{"trials":28902,"activeCount":128},[],{"trials":28904,"activeCount":128},[],{"trials":28906,"activeCount":128},[],{"trials":28908,"activeCount":128},[],{"trials":28910,"activeCount":128},[],{"trials":28912,"activeCount":128},[28913],{"nctId":28914,"briefTitle":28915,"status":104,"phases":28916,"primaryCompletion":28917,"completion":28917,"start":28918,"enrollment":2742,"conditions":28919,"interventions":28921},"NCT03357081","Utility of Real-Time Contrast Enhanced Ultrasound (CEUS) in the Evaluation of Soft Tissue Hematomas",[],"2019-09-22","2018-02-27",[28920],"Hematoma",[28899],{"intervention":2648,"totalTrials":676,"cells":28923},{"EARLY_PHASE1":28924,"PHASE1":28926,"PHASE2":28928,"PHASE3":28930,"PHASE4":28932,"NA":28934},{"trials":28925,"activeCount":128},[],{"trials":28927,"activeCount":128},[],{"trials":28929,"activeCount":128},[],{"trials":28931,"activeCount":128},[],{"trials":28933,"activeCount":128},[],{"trials":28935,"activeCount":128},[28936],{"nctId":2639,"briefTitle":2640,"status":104,"phases":28937,"primaryCompletion":2642,"completion":2642,"start":2643,"enrollment":2644,"conditions":28938,"interventions":28939},[94],[2646],[790,2648],{"intervention":28941,"totalTrials":676,"cells":28942},"Acute migraine treatment with any prescribed triptans",{"EARLY_PHASE1":28943,"PHASE1":28945,"PHASE2":28947,"PHASE3":28949,"PHASE4":28951,"NA":28953},{"trials":28944,"activeCount":128},[],{"trials":28946,"activeCount":128},[],{"trials":28948,"activeCount":128},[],{"trials":28950,"activeCount":128},[],{"trials":28952,"activeCount":128},[],{"trials":28954,"activeCount":128},[28955],{"nctId":28956,"briefTitle":28957,"status":104,"phases":28958,"primaryCompletion":28959,"completion":28959,"start":24444,"enrollment":28960,"conditions":28961,"interventions":28963},"NCT05854992","Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women",[],"2024-11-01",68419,[1938,27825,28962],"Pregnancy",[28941,28964],"Standard of care management of acute migraine without triptans",{"intervention":28964,"totalTrials":676,"cells":28966},{"EARLY_PHASE1":28967,"PHASE1":28969,"PHASE2":28971,"PHASE3":28973,"PHASE4":28975,"NA":28977},{"trials":28968,"activeCount":128},[],{"trials":28970,"activeCount":128},[],{"trials":28972,"activeCount":128},[],{"trials":28974,"activeCount":128},[],{"trials":28976,"activeCount":128},[],{"trials":28978,"activeCount":128},[28979],{"nctId":28956,"briefTitle":28957,"status":104,"phases":28980,"primaryCompletion":28959,"completion":28959,"start":24444,"enrollment":28960,"conditions":28981,"interventions":28982},[],[1938,27825,28962],[28941,28964],{"intervention":28984,"totalTrials":676,"cells":28985},"Genotyping results",{"EARLY_PHASE1":28986,"PHASE1":28988,"PHASE2":28990,"PHASE3":28992,"PHASE4":28994,"NA":28996},{"trials":28987,"activeCount":128},[],{"trials":28989,"activeCount":128},[],{"trials":28991,"activeCount":128},[],{"trials":28993,"activeCount":128},[],{"trials":28995,"activeCount":128},[],{"trials":28997,"activeCount":128},[28998],{"nctId":28999,"briefTitle":29000,"status":104,"phases":29001,"primaryCompletion":16249,"completion":2978,"start":18761,"enrollment":25,"conditions":29002,"interventions":29003},"NCT02479464","Clinical Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Therapy-based Clinical Setting",[94],[849],[28984],{"intervention":29005,"totalTrials":676,"cells":29006},"stiripentol",{"EARLY_PHASE1":29007,"PHASE1":29009,"PHASE2":29011,"PHASE3":29013,"PHASE4":29015,"NA":29017},{"trials":29008,"activeCount":128},[],{"trials":29010,"activeCount":128},[],{"trials":29012,"activeCount":128},[],{"trials":29014,"activeCount":128},[],{"trials":29016,"activeCount":128},[],{"trials":29018,"activeCount":128},[29019],{"nctId":29020,"briefTitle":29021,"status":29022,"phases":29023,"primaryCompletion":10245,"completion":10245,"start":2979,"conditions":29024,"interventions":29026},"NCT01533506","Stiripentol in Dravet Syndrome","NO_LONGER_AVAILABLE",[],[29025],"Dravet Syndrome",[29005],{"intervention":29028,"totalTrials":676,"cells":29029},"Branchamin 4%",{"EARLY_PHASE1":29030,"PHASE1":29032,"PHASE2":29034,"PHASE3":29036,"PHASE4":29038,"NA":29040},{"trials":29031,"activeCount":128},[],{"trials":29033,"activeCount":128},[],{"trials":29035,"activeCount":128},[],{"trials":29037,"activeCount":128},[],{"trials":29039,"activeCount":128},[],{"trials":29041,"activeCount":128},[29042],{"nctId":29043,"briefTitle":29044,"status":104,"phases":29045,"primaryCompletion":1297,"completion":1297,"start":7332,"enrollment":498,"conditions":29046,"interventions":29047},"NCT00170144","Effect of Branched Chain Amino Acids on Muscle",[94],[18],[29028],{"intervention":29049,"totalTrials":676,"cells":29050},"[13C]-Spirulina platensis and 99mTc sulfur colloid",{"EARLY_PHASE1":29051,"PHASE1":29053,"PHASE2":29055,"PHASE3":29057,"PHASE4":29059,"NA":29061},{"trials":29052,"activeCount":128},[],{"trials":29054,"activeCount":128},[],{"trials":29056,"activeCount":128},[],{"trials":29058,"activeCount":128},[],{"trials":29060,"activeCount":128},[],{"trials":29062,"activeCount":128},[29063],{"nctId":29064,"briefTitle":29065,"status":104,"phases":29066,"primaryCompletion":1021,"completion":1021,"start":946,"enrollment":729,"conditions":29067,"interventions":29068},"NCT01248221","Carbon-13 (13C)-Spirulina Platensis Gastric Emptying Breath Test (GEBT)",[94],[6538],[29049],{"intervention":28332,"totalTrials":676,"cells":29070},{"EARLY_PHASE1":29071,"PHASE1":29073,"PHASE2":29075,"PHASE3":29077,"PHASE4":29079,"NA":29081},{"trials":29072,"activeCount":128},[],{"trials":29074,"activeCount":128},[],{"trials":29076,"activeCount":128},[],{"trials":29078,"activeCount":128},[],{"trials":29080,"activeCount":128},[],{"trials":29082,"activeCount":128},[29083],{"nctId":28327,"briefTitle":28328,"status":134,"phases":29084,"primaryCompletion":27903,"completion":27903,"start":4784,"enrollment":15202,"conditions":29085,"interventions":29086},[],[21],[28332,2767],{"intervention":29088,"totalTrials":676,"cells":29089},"Fibrinogen",{"EARLY_PHASE1":29090,"PHASE1":29092,"PHASE2":29094,"PHASE3":29096,"PHASE4":29098,"NA":29100},{"trials":29091,"activeCount":128},[],{"trials":29093,"activeCount":128},[],{"trials":29095,"activeCount":128},[],{"trials":29097,"activeCount":128},[],{"trials":29099,"activeCount":128},[],{"trials":29101,"activeCount":128},[29102],{"nctId":29103,"briefTitle":29104,"status":134,"phases":29105,"primaryCompletion":2642,"completion":2642,"start":5351,"enrollment":558,"conditions":29106,"interventions":29109},"NCT00713596","Study Evaluating Benefit of Using Fibrin Glue in Septorhinoplasty",[94],[29107,29108],"Recovery Time","Bruising",[29088],{"intervention":2869,"totalTrials":676,"cells":29111},{"EARLY_PHASE1":29112,"PHASE1":29114,"PHASE2":29116,"PHASE3":29118,"PHASE4":29120,"NA":29122},{"trials":29113,"activeCount":128},[],{"trials":29115,"activeCount":128},[],{"trials":29117,"activeCount":128},[],{"trials":29119,"activeCount":128},[],{"trials":29121,"activeCount":128},[],{"trials":29123,"activeCount":128},[29124],{"nctId":2859,"briefTitle":2860,"status":104,"phases":29125,"primaryCompletion":2862,"completion":2862,"start":2863,"enrollment":2864,"conditions":29126,"interventions":29127},[94],[2866],[2868,2869],{"intervention":29129,"totalTrials":676,"cells":29130},"citalopram",{"EARLY_PHASE1":29131,"PHASE1":29133,"PHASE2":29135,"PHASE3":29137,"PHASE4":29139,"NA":29141},{"trials":29132,"activeCount":128},[],{"trials":29134,"activeCount":128},[],{"trials":29136,"activeCount":128},[],{"trials":29138,"activeCount":128},[],{"trials":29140,"activeCount":128},[],{"trials":29142,"activeCount":128},[29143],{"nctId":29144,"briefTitle":29145,"status":104,"phases":29146,"primaryCompletion":19035,"completion":19035,"start":2665,"enrollment":885,"conditions":29147,"interventions":29149},"NCT02330068","Microbiome of Depression & Treatment Response to Citalopram",[],[29148],"Major Depressive Disorder, Bipolar I and Bipolar II",[29129],{"intervention":2763,"totalTrials":676,"cells":29151},{"EARLY_PHASE1":29152,"PHASE1":29154,"PHASE2":29156,"PHASE3":29158,"PHASE4":29160,"NA":29162},{"trials":29153,"activeCount":128},[],{"trials":29155,"activeCount":128},[],{"trials":29157,"activeCount":128},[],{"trials":29159,"activeCount":128},[],{"trials":29161,"activeCount":128},[],{"trials":29163,"activeCount":128},[29164],{"nctId":2753,"briefTitle":2754,"status":104,"phases":29165,"primaryCompletion":2756,"completion":2757,"start":2758,"enrollment":797,"conditions":29166,"interventions":29167},[],[21,876,2760,2761],[2763,2764,2765,2766,2767,2768,2769],{"intervention":2764,"totalTrials":676,"cells":29169},{"EARLY_PHASE1":29170,"PHASE1":29172,"PHASE2":29174,"PHASE3":29176,"PHASE4":29178,"NA":29180},{"trials":29171,"activeCount":128},[],{"trials":29173,"activeCount":128},[],{"trials":29175,"activeCount":128},[],{"trials":29177,"activeCount":128},[],{"trials":29179,"activeCount":128},[],{"trials":29181,"activeCount":128},[29182],{"nctId":2753,"briefTitle":2754,"status":104,"phases":29183,"primaryCompletion":2756,"completion":2757,"start":2758,"enrollment":797,"conditions":29184,"interventions":29185},[],[21,876,2760,2761],[2763,2764,2765,2766,2767,2768,2769],{"intervention":2766,"totalTrials":676,"cells":29187},{"EARLY_PHASE1":29188,"PHASE1":29190,"PHASE2":29192,"PHASE3":29194,"PHASE4":29196,"NA":29198},{"trials":29189,"activeCount":128},[],{"trials":29191,"activeCount":128},[],{"trials":29193,"activeCount":128},[],{"trials":29195,"activeCount":128},[],{"trials":29197,"activeCount":128},[],{"trials":29199,"activeCount":128},[29200],{"nctId":2753,"briefTitle":2754,"status":104,"phases":29201,"primaryCompletion":2756,"completion":2757,"start":2758,"enrollment":797,"conditions":29202,"interventions":29203},[],[21,876,2760,2761],[2763,2764,2765,2766,2767,2768,2769],{"intervention":2769,"totalTrials":676,"cells":29205},{"EARLY_PHASE1":29206,"PHASE1":29208,"PHASE2":29210,"PHASE3":29212,"PHASE4":29214,"NA":29216},{"trials":29207,"activeCount":128},[],{"trials":29209,"activeCount":128},[],{"trials":29211,"activeCount":128},[],{"trials":29213,"activeCount":128},[],{"trials":29215,"activeCount":128},[],{"trials":29217,"activeCount":128},[29218],{"nctId":2753,"briefTitle":2754,"status":104,"phases":29219,"primaryCompletion":2756,"completion":2757,"start":2758,"enrollment":797,"conditions":29220,"interventions":29221},[],[21,876,2760,2761],[2763,2764,2765,2766,2767,2768,2769],{"intervention":29223,"totalTrials":676,"cells":29224},"Glucagon like peptide 1 receptor agonist",{"EARLY_PHASE1":29225,"PHASE1":29227,"PHASE2":29229,"PHASE3":29231,"PHASE4":29233,"NA":29235},{"trials":29226,"activeCount":128},[],{"trials":29228,"activeCount":128},[],{"trials":29230,"activeCount":128},[],{"trials":29232,"activeCount":128},[],{"trials":29234,"activeCount":128},[],{"trials":29236,"activeCount":128},[29237],{"nctId":29238,"briefTitle":29239,"status":104,"phases":29240,"primaryCompletion":29241,"completion":29242,"start":29243,"enrollment":29244,"conditions":29245,"interventions":29246},"NCT05214573","Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk",[],"2023-09-30","2025-07-22","2021-12-01",386301,[1868,19436],[29223,29247,29248,29249],"Sodium-glucose cotransporter 2 inhibitor","Dipeptidyl Peptidase 4 Inhibitor","Sulfonylurea",{"intervention":29247,"totalTrials":676,"cells":29251},{"EARLY_PHASE1":29252,"PHASE1":29254,"PHASE2":29256,"PHASE3":29258,"PHASE4":29260,"NA":29262},{"trials":29253,"activeCount":128},[],{"trials":29255,"activeCount":128},[],{"trials":29257,"activeCount":128},[],{"trials":29259,"activeCount":128},[],{"trials":29261,"activeCount":128},[],{"trials":29263,"activeCount":128},[29264],{"nctId":29238,"briefTitle":29239,"status":104,"phases":29265,"primaryCompletion":29241,"completion":29242,"start":29243,"enrollment":29244,"conditions":29266,"interventions":29267},[],[1868,19436],[29223,29247,29248,29249],{"intervention":29248,"totalTrials":676,"cells":29269},{"EARLY_PHASE1":29270,"PHASE1":29272,"PHASE2":29274,"PHASE3":29276,"PHASE4":29278,"NA":29280},{"trials":29271,"activeCount":128},[],{"trials":29273,"activeCount":128},[],{"trials":29275,"activeCount":128},[],{"trials":29277,"activeCount":128},[],{"trials":29279,"activeCount":128},[],{"trials":29281,"activeCount":128},[29282],{"nctId":29238,"briefTitle":29239,"status":104,"phases":29283,"primaryCompletion":29241,"completion":29242,"start":29243,"enrollment":29244,"conditions":29284,"interventions":29285},[],[1868,19436],[29223,29247,29248,29249],{"intervention":29249,"totalTrials":676,"cells":29287},{"EARLY_PHASE1":29288,"PHASE1":29290,"PHASE2":29292,"PHASE3":29294,"PHASE4":29296,"NA":29298},{"trials":29289,"activeCount":128},[],{"trials":29291,"activeCount":128},[],{"trials":29293,"activeCount":128},[],{"trials":29295,"activeCount":128},[],{"trials":29297,"activeCount":128},[],{"trials":29299,"activeCount":128},[29300],{"nctId":29238,"briefTitle":29239,"status":104,"phases":29301,"primaryCompletion":29241,"completion":29242,"start":29243,"enrollment":29244,"conditions":29302,"interventions":29303},[],[1868,19436],[29223,29247,29248,29249],{"intervention":27828,"totalTrials":676,"cells":29305},{"EARLY_PHASE1":29306,"PHASE1":29308,"PHASE2":29310,"PHASE3":29312,"PHASE4":29314,"NA":29316},{"trials":29307,"activeCount":128},[],{"trials":29309,"activeCount":128},[],{"trials":29311,"activeCount":128},[],{"trials":29313,"activeCount":128},[],{"trials":29315,"activeCount":128},[],{"trials":29317,"activeCount":128},[29318],{"nctId":27819,"briefTitle":27820,"status":104,"phases":29319,"primaryCompletion":4503,"completion":4503,"start":27822,"enrollment":27823,"conditions":29320,"interventions":29321},[],[27825,27826,12895],[27828,15401],{"intervention":29323,"totalTrials":676,"cells":29324},"nicotine",{"EARLY_PHASE1":29325,"PHASE1":29327,"PHASE2":29329,"PHASE3":29331,"PHASE4":29333,"NA":29335},{"trials":29326,"activeCount":128},[],{"trials":29328,"activeCount":128},[],{"trials":29330,"activeCount":128},[],{"trials":29332,"activeCount":128},[],{"trials":29334,"activeCount":128},[],{"trials":29336,"activeCount":128},[29337],{"nctId":29338,"briefTitle":29339,"status":1413,"phases":29340,"start":13617,"enrollment":128,"conditions":29341,"interventions":29343},"NCT00425906","Nicotine in Treating \"Hunger Pain\" in Patients With Malignant Bowel Obstruction Caused By Cancer",[94],[17184,29342,938,2761,4293],"Constipation, Impaction, and Bowel Obstruction",[29323],{"intervention":29345,"totalTrials":676,"cells":29346},"DHEA",{"EARLY_PHASE1":29347,"PHASE1":29349,"PHASE2":29351,"PHASE3":29353,"PHASE4":29355,"NA":29357},{"trials":29348,"activeCount":128},[],{"trials":29350,"activeCount":128},[],{"trials":29352,"activeCount":128},[],{"trials":29354,"activeCount":128},[],{"trials":29356,"activeCount":128},[],{"trials":29358,"activeCount":128},[29359],{"nctId":29360,"briefTitle":29361,"status":104,"phases":29362,"primaryCompletion":5472,"completion":5472,"start":5516,"enrollment":1225,"conditions":29363,"interventions":29364},"NCT00434915","Does DHEA Enhance the Effects of Exercise in Postmenopausal Women?",[94],[7089],[29345],{"intervention":29366,"totalTrials":676,"cells":29367},"Rate Control",{"EARLY_PHASE1":29368,"PHASE1":29370,"PHASE2":29372,"PHASE3":29374,"PHASE4":29376,"NA":29378},{"trials":29369,"activeCount":128},[],{"trials":29371,"activeCount":128},[],{"trials":29373,"activeCount":128},[],{"trials":29375,"activeCount":128},[],{"trials":29377,"activeCount":128},[],{"trials":29379,"activeCount":128},[29380],{"nctId":29381,"briefTitle":29382,"status":104,"phases":29383,"primaryCompletion":3546,"completion":6258,"start":15822,"enrollment":25,"conditions":29384,"interventions":29385},"NCT00578617","Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial",[94],[33,10450],[29366,29366,29386,29386,29386,29366,29366,29366,29387,29388,29388,29388,29388,29388],"Rate control","Rhythm Control","Rhythm control",{"intervention":29387,"totalTrials":676,"cells":29390},{"EARLY_PHASE1":29391,"PHASE1":29393,"PHASE2":29395,"PHASE3":29397,"PHASE4":29399,"NA":29401},{"trials":29392,"activeCount":128},[],{"trials":29394,"activeCount":128},[],{"trials":29396,"activeCount":128},[],{"trials":29398,"activeCount":128},[],{"trials":29400,"activeCount":128},[],{"trials":29402,"activeCount":128},[29403],{"nctId":29381,"briefTitle":29382,"status":104,"phases":29404,"primaryCompletion":3546,"completion":6258,"start":15822,"enrollment":25,"conditions":29405,"interventions":29406},[94],[33,10450],[29366,29366,29386,29386,29386,29366,29366,29366,29387,29388,29388,29388,29388,29388],{"intervention":29408,"totalTrials":676,"cells":29409},"Metformin vs Thiazolidinedione",{"EARLY_PHASE1":29410,"PHASE1":29412,"PHASE2":29414,"PHASE3":29416,"PHASE4":29418,"NA":29420},{"trials":29411,"activeCount":128},[],{"trials":29413,"activeCount":128},[],{"trials":29415,"activeCount":128},[],{"trials":29417,"activeCount":128},[],{"trials":29419,"activeCount":128},[],{"trials":29421,"activeCount":128},[29422],{"nctId":29423,"briefTitle":29424,"status":104,"phases":29425,"primaryCompletion":5280,"completion":5280,"start":12886,"enrollment":21860,"conditions":29426,"interventions":29427},"NCT00308373","Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus",[94],[15686],[29408],{"intervention":27620,"totalTrials":676,"cells":29429},{"EARLY_PHASE1":29430,"PHASE1":29432,"PHASE2":29434,"PHASE3":29436,"PHASE4":29438,"NA":29440},{"trials":29431,"activeCount":128},[],{"trials":29433,"activeCount":128},[],{"trials":29435,"activeCount":128},[],{"trials":29437,"activeCount":128},[],{"trials":29439,"activeCount":128},[],{"trials":29441,"activeCount":128},[29442],{"nctId":27614,"briefTitle":27615,"status":104,"phases":29443,"primaryCompletion":6502,"completion":6502,"start":16723,"enrollment":1320,"conditions":29444,"interventions":29445},[94],[27618],[27620,3598,27621,5425,7661],{"intervention":27621,"totalTrials":676,"cells":29447},{"EARLY_PHASE1":29448,"PHASE1":29450,"PHASE2":29452,"PHASE3":29454,"PHASE4":29456,"NA":29458},{"trials":29449,"activeCount":128},[],{"trials":29451,"activeCount":128},[],{"trials":29453,"activeCount":128},[],{"trials":29455,"activeCount":128},[],{"trials":29457,"activeCount":128},[],{"trials":29459,"activeCount":128},[29460],{"nctId":27614,"briefTitle":27615,"status":104,"phases":29461,"primaryCompletion":6502,"completion":6502,"start":16723,"enrollment":1320,"conditions":29462,"interventions":29463},[94],[27618],[27620,3598,27621,5425,7661],{"intervention":29465,"totalTrials":676,"cells":29466},"Low volume prep",{"EARLY_PHASE1":29467,"PHASE1":29469,"PHASE2":29471,"PHASE3":29473,"PHASE4":29475,"NA":29477},{"trials":29468,"activeCount":128},[],{"trials":29470,"activeCount":128},[],{"trials":29472,"activeCount":128},[],{"trials":29474,"activeCount":128},[],{"trials":29476,"activeCount":128},[],{"trials":29478,"activeCount":128},[29479],{"nctId":29480,"briefTitle":29481,"status":134,"phases":29482,"primaryCompletion":29483,"completion":29483,"start":4279,"enrollment":1225,"conditions":29484,"interventions":29486},"NCT01978509","The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies",[94],"2019-03",[29485],"Colonoscopy",[29465,29487,29488],"Moderate volume prep","High volume prep",{"intervention":29487,"totalTrials":676,"cells":29490},{"EARLY_PHASE1":29491,"PHASE1":29493,"PHASE2":29495,"PHASE3":29497,"PHASE4":29499,"NA":29501},{"trials":29492,"activeCount":128},[],{"trials":29494,"activeCount":128},[],{"trials":29496,"activeCount":128},[],{"trials":29498,"activeCount":128},[],{"trials":29500,"activeCount":128},[],{"trials":29502,"activeCount":128},[29503],{"nctId":29480,"briefTitle":29481,"status":134,"phases":29504,"primaryCompletion":29483,"completion":29483,"start":4279,"enrollment":1225,"conditions":29505,"interventions":29506},[94],[29485],[29465,29487,29488],{"intervention":29488,"totalTrials":676,"cells":29508},{"EARLY_PHASE1":29509,"PHASE1":29511,"PHASE2":29513,"PHASE3":29515,"PHASE4":29517,"NA":29519},{"trials":29510,"activeCount":128},[],{"trials":29512,"activeCount":128},[],{"trials":29514,"activeCount":128},[],{"trials":29516,"activeCount":128},[],{"trials":29518,"activeCount":128},[],{"trials":29520,"activeCount":128},[29521],{"nctId":29480,"briefTitle":29481,"status":134,"phases":29522,"primaryCompletion":29483,"completion":29483,"start":4279,"enrollment":1225,"conditions":29523,"interventions":29524},[94],[29485],[29465,29487,29488],{"intervention":29526,"totalTrials":676,"cells":29527},"Anti-seizure medication",{"EARLY_PHASE1":29528,"PHASE1":29530,"PHASE2":29532,"PHASE3":29534,"PHASE4":29536,"NA":29538},{"trials":29529,"activeCount":128},[],{"trials":29531,"activeCount":128},[],{"trials":29533,"activeCount":128},[],{"trials":29535,"activeCount":128},[],{"trials":29537,"activeCount":128},[],{"trials":29539,"activeCount":128},[29540],{"nctId":29541,"briefTitle":29542,"status":104,"phases":29543,"primaryCompletion":29544,"completion":29544,"start":29545,"enrollment":173,"conditions":29546,"interventions":29552},"NCT03138876","EEG Cap for Identification of Non-Convulsive Status Epilepticus",[94],"2018-08-16","2017-05-30",[29547,29548,29549,29550,29551],"Nonconvulsive Status Epilepticus","Subclinical Seizure","Altered Mental Status","Nonepileptic Seizures","Encephalopathy",[29526],{"intervention":29554,"totalTrials":676,"cells":29555},"Pharmacogentic Analysis",{"EARLY_PHASE1":29556,"PHASE1":29558,"PHASE2":29560,"PHASE3":29562,"PHASE4":29564,"NA":29566},{"trials":29557,"activeCount":128},[],{"trials":29559,"activeCount":128},[],{"trials":29561,"activeCount":128},[],{"trials":29563,"activeCount":128},[],{"trials":29565,"activeCount":128},[],{"trials":29567,"activeCount":128},[29568],{"nctId":29569,"briefTitle":29570,"status":104,"phases":29571,"primaryCompletion":29572,"completion":29572,"start":29573,"enrollment":2678,"conditions":29574,"interventions":29576},"NCT03748355","Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects",[94],"2020-01-02","2018-10-14",[29575],"Psychiatric Disorder",[29554],{"intervention":29578,"totalTrials":676,"cells":29579},"Multifocal Lung Adenocarcinoma",{"EARLY_PHASE1":29580,"PHASE1":29582,"PHASE2":29584,"PHASE3":29586,"PHASE4":29588,"NA":29590},{"trials":29581,"activeCount":128},[],{"trials":29583,"activeCount":128},[],{"trials":29585,"activeCount":128},[],{"trials":29587,"activeCount":128},[],{"trials":29589,"activeCount":128},[],{"trials":29591,"activeCount":128},[29592],{"nctId":29593,"briefTitle":29594,"status":134,"phases":29595,"primaryCompletion":6939,"completion":6939,"start":29596,"enrollment":712,"conditions":29597,"interventions":29600},"NCT01946100","Treatment of Multifocal Lung Adenocarcinoma",[94],"2013-11-06",[7079,29598,29599],"Carcinoma Non-small-cell Lung","Adenocarcinoma",[29578],{"intervention":29602,"totalTrials":676,"cells":29603},"Hydromorphone Hydrochloride",{"EARLY_PHASE1":29604,"PHASE1":29606,"PHASE2":29608,"PHASE3":29610,"PHASE4":29612,"NA":29614},{"trials":29605,"activeCount":128},[],{"trials":29607,"activeCount":128},[],{"trials":29609,"activeCount":128},[],{"trials":29611,"activeCount":128},[],{"trials":29613,"activeCount":128},[],{"trials":29615,"activeCount":128},[29616],{"nctId":29617,"briefTitle":29618,"status":104,"phases":29619,"primaryCompletion":29620,"completion":29620,"start":29621,"enrollment":29622,"conditions":29623,"interventions":29624},"NCT03411109","Outcomes of Intrathecal Analgesia in Colorectal Surgery",[],"2013-12-31","2012-10-01",601,[16572],[29602],{"intervention":29626,"totalTrials":676,"cells":29627},"Conjugated estrogen",{"EARLY_PHASE1":29628,"PHASE1":29630,"PHASE2":29632,"PHASE3":29634,"PHASE4":29636,"NA":29638},{"trials":29629,"activeCount":128},[],{"trials":29631,"activeCount":128},[],{"trials":29633,"activeCount":128},[],{"trials":29635,"activeCount":128},[],{"trials":29637,"activeCount":128},[],{"trials":29639,"activeCount":128},[29640],{"nctId":29641,"briefTitle":29642,"status":104,"phases":29643,"primaryCompletion":12956,"completion":12956,"start":29644,"enrollment":218,"conditions":29645,"interventions":29646},"NCT04301934","Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection",[94],"2020-06-01",[13810],[29626,29647],"Estradiol",{"intervention":29647,"totalTrials":676,"cells":29649},{"EARLY_PHASE1":29650,"PHASE1":29652,"PHASE2":29654,"PHASE3":29656,"PHASE4":29658,"NA":29660},{"trials":29651,"activeCount":128},[],{"trials":29653,"activeCount":128},[],{"trials":29655,"activeCount":128},[],{"trials":29657,"activeCount":128},[],{"trials":29659,"activeCount":128},[],{"trials":29661,"activeCount":128},[29662],{"nctId":29641,"briefTitle":29642,"status":104,"phases":29663,"primaryCompletion":12956,"completion":12956,"start":29644,"enrollment":218,"conditions":29664,"interventions":29665},[94],[13810],[29626,29647],{"intervention":29667,"totalTrials":676,"cells":29668},"Regadenoson",{"EARLY_PHASE1":29669,"PHASE1":29671,"PHASE2":29673,"PHASE3":29675,"PHASE4":29677,"NA":29679},{"trials":29670,"activeCount":128},[],{"trials":29672,"activeCount":128},[],{"trials":29674,"activeCount":128},[],{"trials":29676,"activeCount":128},[],{"trials":29678,"activeCount":128},[],{"trials":29680,"activeCount":128},[29681],{"nctId":29682,"briefTitle":29683,"status":104,"phases":29684,"primaryCompletion":2979,"completion":3509,"start":2787,"enrollment":218,"conditions":29685,"interventions":29686},"NCT01370265","Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress",[94],[1216],[29667,29687,29688],"Adenosine","N-13 ammonia",{"intervention":29687,"totalTrials":676,"cells":29690},{"EARLY_PHASE1":29691,"PHASE1":29693,"PHASE2":29695,"PHASE3":29697,"PHASE4":29699,"NA":29701},{"trials":29692,"activeCount":128},[],{"trials":29694,"activeCount":128},[],{"trials":29696,"activeCount":128},[],{"trials":29698,"activeCount":128},[],{"trials":29700,"activeCount":128},[],{"trials":29702,"activeCount":128},[29703],{"nctId":29682,"briefTitle":29683,"status":104,"phases":29704,"primaryCompletion":2979,"completion":3509,"start":2787,"enrollment":218,"conditions":29705,"interventions":29706},[94],[1216],[29667,29687,29688],{"intervention":29688,"totalTrials":676,"cells":29708},{"EARLY_PHASE1":29709,"PHASE1":29711,"PHASE2":29713,"PHASE3":29715,"PHASE4":29717,"NA":29719},{"trials":29710,"activeCount":128},[],{"trials":29712,"activeCount":128},[],{"trials":29714,"activeCount":128},[],{"trials":29716,"activeCount":128},[],{"trials":29718,"activeCount":128},[],{"trials":29720,"activeCount":128},[29721],{"nctId":29682,"briefTitle":29683,"status":104,"phases":29722,"primaryCompletion":2979,"completion":3509,"start":2787,"enrollment":218,"conditions":29723,"interventions":29724},[94],[1216],[29667,29687,29688],{"intervention":29726,"totalTrials":676,"cells":29727},"Phenylephrine 2.5%",{"EARLY_PHASE1":29728,"PHASE1":29730,"PHASE2":29732,"PHASE3":29734,"PHASE4":29736,"NA":29738},{"trials":29729,"activeCount":128},[],{"trials":29731,"activeCount":128},[],{"trials":29733,"activeCount":128},[],{"trials":29735,"activeCount":128},[],{"trials":29737,"activeCount":128},[],{"trials":29739,"activeCount":128},[29740],{"nctId":29741,"briefTitle":29742,"status":104,"phases":29743,"primaryCompletion":7706,"completion":7706,"start":1337,"enrollment":173,"conditions":29744,"interventions":29746},"NCT02965924","Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes",[94],[29745],"Assess Phenylephrine on EVP and IOP",[29726],{"intervention":4497,"totalTrials":676,"cells":29748},{"EARLY_PHASE1":29749,"PHASE1":29751,"PHASE2":29753,"PHASE3":29755,"PHASE4":29757,"NA":29759},{"trials":29750,"activeCount":128},[],{"trials":29752,"activeCount":128},[],{"trials":29754,"activeCount":128},[],{"trials":29756,"activeCount":128},[],{"trials":29758,"activeCount":128},[],{"trials":29760,"activeCount":128},[29761],{"nctId":4488,"briefTitle":4489,"status":1413,"phases":29762,"primaryCompletion":3559,"completion":3559,"start":1471,"enrollment":128,"conditions":29763,"interventions":29764},[94],[4492,4493,4494,4495],[4089,161,4497],{"intervention":29766,"totalTrials":676,"cells":29767},"response to therapy",{"EARLY_PHASE1":29768,"PHASE1":29770,"PHASE2":29772,"PHASE3":29774,"PHASE4":29776,"NA":29778},{"trials":29769,"activeCount":128},[],{"trials":29771,"activeCount":128},[],{"trials":29773,"activeCount":128},[],{"trials":29775,"activeCount":128},[],{"trials":29777,"activeCount":128},[],{"trials":29779,"activeCount":128},[29780],{"nctId":29781,"briefTitle":29782,"status":104,"phases":29783,"primaryCompletion":29544,"completion":29544,"start":3033,"enrollment":1300,"conditions":29784,"interventions":29785},"NCT01568723","Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation",[],[12032],[29766],{"intervention":29787,"totalTrials":676,"cells":29788},"GLP-1",{"EARLY_PHASE1":29789,"PHASE1":29791,"PHASE2":29793,"PHASE3":29795,"PHASE4":29797,"NA":29799},{"trials":29790,"activeCount":128},[],{"trials":29792,"activeCount":128},[],{"trials":29794,"activeCount":128},[],{"trials":29796,"activeCount":128},[],{"trials":29798,"activeCount":128},[],{"trials":29800,"activeCount":128},[29801],{"nctId":29802,"briefTitle":29803,"status":104,"phases":29804,"primaryCompletion":16249,"completion":16249,"start":2643,"enrollment":797,"conditions":29805,"interventions":29806},"NCT00588380","GLP1R Polymorphisms and Response to GLP1",[94],[1063],[29787],{"intervention":29808,"totalTrials":676,"cells":29809},"Single nucleotide polymorphism",{"EARLY_PHASE1":29810,"PHASE1":29812,"PHASE2":29814,"PHASE3":29816,"PHASE4":29818,"NA":29820},{"trials":29811,"activeCount":128},[],{"trials":29813,"activeCount":128},[],{"trials":29815,"activeCount":128},[],{"trials":29817,"activeCount":128},[],{"trials":29819,"activeCount":128},[],{"trials":29821,"activeCount":128},[29822],{"nctId":29823,"briefTitle":29824,"status":104,"phases":29825,"primaryCompletion":1357,"completion":1357,"start":1299,"enrollment":29826,"conditions":29827,"interventions":29828},"NCT00283608","Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and\u002For Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer",[],1000,[21],[29808],{"intervention":29830,"totalTrials":676,"cells":29831},"Misoprostol",{"EARLY_PHASE1":29832,"PHASE1":29834,"PHASE2":29836,"PHASE3":29838,"PHASE4":29840,"NA":29842},{"trials":29833,"activeCount":128},[],{"trials":29835,"activeCount":128},[],{"trials":29837,"activeCount":128},[],{"trials":29839,"activeCount":128},[],{"trials":29841,"activeCount":128},[],{"trials":29843,"activeCount":128},[29844],{"nctId":29845,"briefTitle":29846,"status":134,"phases":29847,"primaryCompletion":29848,"completion":29848,"start":905,"enrollment":1236,"conditions":29849,"interventions":29850},"NCT02546193","Outpatient Foley Catheter Compared to Usual Inpatient Care for Labor Induction",[94],"2017-06-08",[28962],[29830],{"intervention":29852,"totalTrials":676,"cells":29853},"Oxymetazoline 0.05%",{"EARLY_PHASE1":29854,"PHASE1":29856,"PHASE2":29858,"PHASE3":29860,"PHASE4":29862,"NA":29864},{"trials":29855,"activeCount":128},[],{"trials":29857,"activeCount":128},[],{"trials":29859,"activeCount":128},[],{"trials":29861,"activeCount":128},[],{"trials":29863,"activeCount":128},[],{"trials":29865,"activeCount":128},[29866],{"nctId":29867,"briefTitle":29868,"status":104,"phases":29869,"primaryCompletion":29870,"completion":29871,"start":5361,"enrollment":3547,"conditions":29872,"interventions":29874},"NCT02285634","The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.",[94],"2016-12-22","2017-12-22",[29873,948],"Epistaxis",[29852,29875,29876,29877],"Phenylephrine 0.25%","Lidocaine 1% plus epinephrine 1:100,000","Bacteriostatic 0.9% NaCL",{"intervention":29875,"totalTrials":676,"cells":29879},{"EARLY_PHASE1":29880,"PHASE1":29882,"PHASE2":29884,"PHASE3":29886,"PHASE4":29888,"NA":29890},{"trials":29881,"activeCount":128},[],{"trials":29883,"activeCount":128},[],{"trials":29885,"activeCount":128},[],{"trials":29887,"activeCount":128},[],{"trials":29889,"activeCount":128},[],{"trials":29891,"activeCount":128},[29892],{"nctId":29867,"briefTitle":29868,"status":104,"phases":29893,"primaryCompletion":29870,"completion":29871,"start":5361,"enrollment":3547,"conditions":29894,"interventions":29895},[94],[29873,948],[29852,29875,29876,29877],{"intervention":29876,"totalTrials":676,"cells":29897},{"EARLY_PHASE1":29898,"PHASE1":29900,"PHASE2":29902,"PHASE3":29904,"PHASE4":29906,"NA":29908},{"trials":29899,"activeCount":128},[],{"trials":29901,"activeCount":128},[],{"trials":29903,"activeCount":128},[],{"trials":29905,"activeCount":128},[],{"trials":29907,"activeCount":128},[],{"trials":29909,"activeCount":128},[29910],{"nctId":29867,"briefTitle":29868,"status":104,"phases":29911,"primaryCompletion":29870,"completion":29871,"start":5361,"enrollment":3547,"conditions":29912,"interventions":29913},[94],[29873,948],[29852,29875,29876,29877],{"intervention":29877,"totalTrials":676,"cells":29915},{"EARLY_PHASE1":29916,"PHASE1":29918,"PHASE2":29920,"PHASE3":29922,"PHASE4":29924,"NA":29926},{"trials":29917,"activeCount":128},[],{"trials":29919,"activeCount":128},[],{"trials":29921,"activeCount":128},[],{"trials":29923,"activeCount":128},[],{"trials":29925,"activeCount":128},[],{"trials":29927,"activeCount":128},[29928],{"nctId":29867,"briefTitle":29868,"status":104,"phases":29929,"primaryCompletion":29870,"completion":29871,"start":5361,"enrollment":3547,"conditions":29930,"interventions":29931},[94],[29873,948],[29852,29875,29876,29877],{"intervention":29933,"totalTrials":676,"cells":29934},"StrataXRT",{"EARLY_PHASE1":29935,"PHASE1":29937,"PHASE2":29939,"PHASE3":29941,"PHASE4":29943,"NA":29945},{"trials":29936,"activeCount":128},[],{"trials":29938,"activeCount":128},[],{"trials":29940,"activeCount":128},[],{"trials":29942,"activeCount":128},[],{"trials":29944,"activeCount":128},[],{"trials":29946,"activeCount":128},[29947],{"nctId":29948,"briefTitle":29949,"status":134,"phases":29950,"primaryCompletion":29951,"completion":29951,"start":29952,"enrollment":355,"conditions":29953,"interventions":29955},"NCT04715386","Feasibility in the Prophylaxis of Radiation Dermatitis Severity",[],"2024-01-30","2020-06-22",[29954],"Radiation Dermatitis",[29933],{"intervention":29957,"totalTrials":676,"cells":29958},"DNA Extraction",{"EARLY_PHASE1":29959,"PHASE1":29961,"PHASE2":29963,"PHASE3":29965,"PHASE4":29967,"NA":29969},{"trials":29960,"activeCount":128},[],{"trials":29962,"activeCount":128},[],{"trials":29964,"activeCount":128},[],{"trials":29966,"activeCount":128},[],{"trials":29968,"activeCount":128},[],{"trials":29970,"activeCount":128},[29971],{"nctId":29972,"briefTitle":29973,"status":134,"phases":29974,"primaryCompletion":29975,"completion":29975,"start":29976,"enrollment":3002,"conditions":29977,"interventions":29986},"NCT02549638","Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma",[],"2020-04-23","2015-04-08",[29978,29979,6668,7079,29980,29981,8059,29982,29983,29984,29985],"Carcinoma, Squamous Cell","Carcinoma, Squamous","Cancer of Lung","Cancer of the Lung","Neoplasms, Lung","Neoplasms, Pulmonary","Pulmonary Cancer","Pulmonary Neoplasms",[29957],{"intervention":29988,"totalTrials":676,"cells":29989},"Genetic Testing",{"EARLY_PHASE1":29990,"PHASE1":29992,"PHASE2":29994,"PHASE3":29996,"PHASE4":29998,"NA":30000},{"trials":29991,"activeCount":128},[],{"trials":29993,"activeCount":128},[],{"trials":29995,"activeCount":128},[],{"trials":29997,"activeCount":128},[],{"trials":29999,"activeCount":128},[],{"trials":30001,"activeCount":128},[30002],{"nctId":30003,"briefTitle":30004,"status":104,"phases":30005,"primaryCompletion":30006,"completion":30006,"start":30007,"enrollment":30008,"conditions":30009,"interventions":30011},"NCT04002986","Comprehensive Genetic Assessment, Risk and Education in a Mammography Pilot",[94],"2021-05-24","2019-08-20",116,[30010],"Women Age 35+ Qualifies if >15% Lifetime Risk of Breast Cancer as Defined by IBIS Version 8",[29988],{"intervention":30013,"totalTrials":676,"cells":30014},"Proparacaine",{"EARLY_PHASE1":30015,"PHASE1":30017,"PHASE2":30019,"PHASE3":30021,"PHASE4":30023,"NA":30025},{"trials":30016,"activeCount":128},[],{"trials":30018,"activeCount":128},[],{"trials":30020,"activeCount":128},[],{"trials":30022,"activeCount":128},[],{"trials":30024,"activeCount":128},[],{"trials":30026,"activeCount":128},[30027],{"nctId":30028,"briefTitle":30029,"status":104,"phases":30030,"primaryCompletion":30031,"completion":2606,"start":30032,"enrollment":187,"conditions":30033,"interventions":30038},"NCT02951351","Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections",[94],"2018-02-01","2016-10-12",[30034,30035,30036,30037,799],"Age-related Macular Degeneration","Diabetic Macular Edema","Injection Site","Injection Site Infection",[30013],{"intervention":30040,"totalTrials":676,"cells":30041},"Amyl nitrite inhalation",{"EARLY_PHASE1":30042,"PHASE1":30044,"PHASE2":30046,"PHASE3":30048,"PHASE4":30050,"NA":30052},{"trials":30043,"activeCount":128},[],{"trials":30045,"activeCount":128},[],{"trials":30047,"activeCount":128},[],{"trials":30049,"activeCount":128},[],{"trials":30051,"activeCount":128},[],{"trials":30053,"activeCount":128},[30054],{"nctId":30055,"briefTitle":30056,"status":1413,"phases":30057,"primaryCompletion":30058,"completion":30058,"start":27335,"enrollment":128,"conditions":30059,"interventions":30063},"NCT04905173","Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiography in Inducing Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy",[94],"2022-05",[30060,30061,30062],"Hypertrophic Cardiomyopathy","Hypertrophic Obstructive Cardiomyopathy","Cardiomyopathy, Hypertrophic",[30040],{"intervention":30065,"totalTrials":676,"cells":30066},"Multifocal Tissue Banking",{"EARLY_PHASE1":30067,"PHASE1":30069,"PHASE2":30071,"PHASE3":30073,"PHASE4":30075,"NA":30077},{"trials":30068,"activeCount":128},[],{"trials":30070,"activeCount":128},[],{"trials":30072,"activeCount":128},[],{"trials":30074,"activeCount":128},[],{"trials":30076,"activeCount":128},[],{"trials":30078,"activeCount":128},[30079],{"nctId":30080,"briefTitle":30081,"status":134,"phases":30082,"primaryCompletion":30083,"completion":30083,"start":30084,"enrollment":2563,"conditions":30085,"interventions":30086},"NCT02705404","A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing",[],"2021-11-16","2016-02-11",[7079,29598],[30065],{"intervention":28019,"totalTrials":676,"cells":30088},{"EARLY_PHASE1":30089,"PHASE1":30091,"PHASE2":30093,"PHASE3":30095,"PHASE4":30097,"NA":30099},{"trials":30090,"activeCount":128},[],{"trials":30092,"activeCount":128},[],{"trials":30094,"activeCount":128},[],{"trials":30096,"activeCount":128},[],{"trials":30098,"activeCount":128},[],{"trials":30100,"activeCount":128},[30101],{"nctId":28013,"briefTitle":28014,"status":134,"phases":30102,"primaryCompletion":3546,"completion":3546,"start":3519,"enrollment":7368,"conditions":30103,"interventions":30104},[94],[28017],[12478,28019,28020],{"intervention":28020,"totalTrials":676,"cells":30106},{"EARLY_PHASE1":30107,"PHASE1":30109,"PHASE2":30111,"PHASE3":30113,"PHASE4":30115,"NA":30117},{"trials":30108,"activeCount":128},[],{"trials":30110,"activeCount":128},[],{"trials":30112,"activeCount":128},[],{"trials":30114,"activeCount":128},[],{"trials":30116,"activeCount":128},[],{"trials":30118,"activeCount":128},[30119],{"nctId":28013,"briefTitle":28014,"status":134,"phases":30120,"primaryCompletion":3546,"completion":3546,"start":3519,"enrollment":7368,"conditions":30121,"interventions":30122},[94],[28017],[12478,28019,28020],{"intervention":959,"totalTrials":676,"cells":30124},{"EARLY_PHASE1":30125,"PHASE1":30127,"PHASE2":30129,"PHASE3":30131,"PHASE4":30133,"NA":30135},{"trials":30126,"activeCount":128},[],{"trials":30128,"activeCount":128},[],{"trials":30130,"activeCount":128},[],{"trials":30132,"activeCount":128},[],{"trials":30134,"activeCount":128},[],{"trials":30136,"activeCount":128},[30137],{"nctId":951,"briefTitle":952,"status":104,"phases":30138,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":30139,"interventions":30140},[94],[876],[839,959],{"intervention":30142,"totalTrials":676,"cells":30143},"Prolotherapy",{"EARLY_PHASE1":30144,"PHASE1":30146,"PHASE2":30148,"PHASE3":30150,"PHASE4":30152,"NA":30154},{"trials":30145,"activeCount":128},[],{"trials":30147,"activeCount":128},[],{"trials":30149,"activeCount":128},[],{"trials":30151,"activeCount":128},[],{"trials":30153,"activeCount":128},[],{"trials":30155,"activeCount":128},[30156],{"nctId":30157,"briefTitle":30158,"status":134,"phases":30159,"primaryCompletion":5246,"completion":5246,"start":5033,"enrollment":224,"conditions":30160,"interventions":30161},"NCT00685880","Prolotherapy Versus Steroids for Thumb Carpo-metacarpal Joint Arthritis",[94],[28310],[30142,30162],"Betamethasone",{"intervention":30162,"totalTrials":676,"cells":30164},{"EARLY_PHASE1":30165,"PHASE1":30167,"PHASE2":30169,"PHASE3":30171,"PHASE4":30173,"NA":30175},{"trials":30166,"activeCount":128},[],{"trials":30168,"activeCount":128},[],{"trials":30170,"activeCount":128},[],{"trials":30172,"activeCount":128},[],{"trials":30174,"activeCount":128},[],{"trials":30176,"activeCount":128},[30177],{"nctId":30157,"briefTitle":30158,"status":134,"phases":30178,"primaryCompletion":5246,"completion":5246,"start":5033,"enrollment":224,"conditions":30179,"interventions":30180},[94],[28310],[30142,30162],{"intervention":30182,"totalTrials":676,"cells":30183},"Steroid",{"EARLY_PHASE1":30184,"PHASE1":30186,"PHASE2":30188,"PHASE3":30190,"PHASE4":30192,"NA":30194},{"trials":30185,"activeCount":128},[],{"trials":30187,"activeCount":128},[],{"trials":30189,"activeCount":128},[],{"trials":30191,"activeCount":128},[],{"trials":30193,"activeCount":128},[],{"trials":30195,"activeCount":128},[30196],{"nctId":30197,"briefTitle":30198,"status":104,"phases":30199,"primaryCompletion":30200,"completion":30200,"start":874,"enrollment":30201,"conditions":30202,"interventions":30204},"NCT02219555","DUCATS Trial: Dynamic Ultrasound to Enhance Understanding of Carpal Tunnel Syndrome",[],"2020-08-15",204,[30203],"Carpal Tunnel",[30182],{"intervention":30206,"totalTrials":676,"cells":30207},"Rate or Rhythm Control Therapy",{"EARLY_PHASE1":30208,"PHASE1":30210,"PHASE2":30212,"PHASE3":30214,"PHASE4":30216,"NA":30218},{"trials":30209,"activeCount":128},[],{"trials":30211,"activeCount":128},[],{"trials":30213,"activeCount":128},[],{"trials":30215,"activeCount":128},[],{"trials":30217,"activeCount":128},[],{"trials":30219,"activeCount":128},[30220],{"nctId":30221,"briefTitle":30222,"status":104,"phases":30223,"primaryCompletion":30224,"completion":30224,"start":30225,"enrollment":30226,"conditions":30227,"interventions":30228},"NCT00911508","Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial",[94],"2017-12-31","2009-11-13",2204,[33,10450],[30206],{"intervention":30230,"totalTrials":676,"cells":30231},"T3",{"EARLY_PHASE1":30232,"PHASE1":30234,"PHASE2":30236,"PHASE3":30238,"PHASE4":30240,"NA":30242},{"trials":30233,"activeCount":128},[],{"trials":30235,"activeCount":128},[],{"trials":30237,"activeCount":128},[],{"trials":30239,"activeCount":128},[],{"trials":30241,"activeCount":128},[],{"trials":30243,"activeCount":128},[30244],{"nctId":30245,"briefTitle":30246,"status":104,"phases":30247,"primaryCompletion":4785,"completion":4785,"start":1298,"enrollment":34,"conditions":30248,"interventions":30249},"NCT01299337","Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)",[],[876],[30230],{"intervention":30251,"totalTrials":676,"cells":30252},"Randomized Midazolam",{"EARLY_PHASE1":30253,"PHASE1":30255,"PHASE2":30257,"PHASE3":30259,"PHASE4":30261,"NA":30263},{"trials":30254,"activeCount":128},[],{"trials":30256,"activeCount":128},[],{"trials":30258,"activeCount":128},[],{"trials":30260,"activeCount":128},[],{"trials":30262,"activeCount":128},[],{"trials":30264,"activeCount":128},[30265],{"nctId":30266,"briefTitle":30267,"status":104,"phases":30268,"primaryCompletion":1390,"completion":1298,"start":11897,"enrollment":668,"conditions":30269,"interventions":30270},"NCT00578214","Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery",[94],[6654,6668,28734,898],[30251,30271,30272],"Local Anesthesia","Prospective Midazolam",{"intervention":30271,"totalTrials":676,"cells":30274},{"EARLY_PHASE1":30275,"PHASE1":30277,"PHASE2":30279,"PHASE3":30281,"PHASE4":30283,"NA":30285},{"trials":30276,"activeCount":128},[],{"trials":30278,"activeCount":128},[],{"trials":30280,"activeCount":128},[],{"trials":30282,"activeCount":128},[],{"trials":30284,"activeCount":128},[],{"trials":30286,"activeCount":128},[30287],{"nctId":30266,"briefTitle":30267,"status":104,"phases":30288,"primaryCompletion":1390,"completion":1298,"start":11897,"enrollment":668,"conditions":30289,"interventions":30290},[94],[6654,6668,28734,898],[30251,30271,30272],{"intervention":30272,"totalTrials":676,"cells":30292},{"EARLY_PHASE1":30293,"PHASE1":30295,"PHASE2":30297,"PHASE3":30299,"PHASE4":30301,"NA":30303},{"trials":30294,"activeCount":128},[],{"trials":30296,"activeCount":128},[],{"trials":30298,"activeCount":128},[],{"trials":30300,"activeCount":128},[],{"trials":30302,"activeCount":128},[],{"trials":30304,"activeCount":128},[30305],{"nctId":30266,"briefTitle":30267,"status":104,"phases":30306,"primaryCompletion":1390,"completion":1298,"start":11897,"enrollment":668,"conditions":30307,"interventions":30308},[94],[6654,6668,28734,898],[30251,30271,30272],{"intervention":30310,"totalTrials":676,"cells":30311},"immune globulin",{"EARLY_PHASE1":30312,"PHASE1":30314,"PHASE2":30316,"PHASE3":30318,"PHASE4":30320,"NA":30322},{"trials":30313,"activeCount":128},[],{"trials":30315,"activeCount":128},[],{"trials":30317,"activeCount":128},[],{"trials":30319,"activeCount":128},[],{"trials":30321,"activeCount":128},[],{"trials":30323,"activeCount":128},[30324],{"nctId":30325,"briefTitle":30326,"status":134,"phases":30327,"completion":30328,"start":30329,"enrollment":668,"conditions":30330,"interventions":30332},"NCT00004407","Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic Neuropathy",[94],"2000-03","1998-02",[30331],"Diabetic Neuropathies",[30310],{"intervention":30334,"totalTrials":676,"cells":30335},"Application of oxymetazoline",{"EARLY_PHASE1":30336,"PHASE1":30338,"PHASE2":30340,"PHASE3":30342,"PHASE4":30344,"NA":30346},{"trials":30337,"activeCount":128},[],{"trials":30339,"activeCount":128},[],{"trials":30341,"activeCount":128},[],{"trials":30343,"activeCount":128},[],{"trials":30345,"activeCount":128},[],{"trials":30347,"activeCount":128},[30348],{"nctId":30349,"briefTitle":30350,"status":104,"phases":30351,"primaryCompletion":3641,"completion":3641,"start":3569,"enrollment":25,"conditions":30352,"interventions":30354},"NCT01850511","The Effect of Nasal Hair on Nasal Obstruction",[94],[30353],"Nasal Obstruction",[30334],{"intervention":28362,"totalTrials":676,"cells":30356},{"EARLY_PHASE1":30357,"PHASE1":30359,"PHASE2":30361,"PHASE3":30363,"PHASE4":30365,"NA":30367},{"trials":30358,"activeCount":128},[],{"trials":30360,"activeCount":128},[],{"trials":30362,"activeCount":128},[],{"trials":30364,"activeCount":128},[],{"trials":30366,"activeCount":128},[],{"trials":30368,"activeCount":128},[30369],{"nctId":28356,"briefTitle":28357,"status":104,"phases":30370,"primaryCompletion":935,"completion":935,"start":20999,"enrollment":1997,"conditions":30371,"interventions":30372},[94],[28360],[28362,20915]]